DrTarget’s AI-Driven Approach to Metabolic & Endocrine Disorders
DrTarget has identified 347 target proteins from PubChem screens associated with 1,324 metabolic and endocrine disorders, leveraging data from Open Targets and other public repositories. Through machine learning models and AI-powered analytics, we uncover new therapeutic targets and drug repurposing opportunities for conditions such as diabetes, obesity, thyroid disorders, and rare metabolic diseases.
Our AI-powered approach enables:
✔ Identification of key molecular targets for metabolic and endocrine diseases
✔ Drug repurposing strategies to accelerate treatment discovery
✔ Pathway and biomarker analysis for precision medicine applications
By integrating AI-driven virtual screening and multi-source validation, DrTarget supports the discovery of next-generation therapies to address metabolic imbalances and hormonal dysfunctions.
Target-disease associations for metabolic/endocrine disorders.
Check best scored target-disease associations in table:
| PubChemAssay | program | diseaseName | assayType | testedCompounds | activeCompounds | associationScore | numberOfEvidences |
|---|---|---|---|---|---|---|---|
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | metabolic syndrome | targetBased | 99314 | 335 | 0.614697417851648 | 113 |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | metabolic syndrome | targetBased | 196176 | 782 | 0.614697417851648 | 113 |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | metabolic syndrome | targetBased | 99314 | 390 | 0.614697417851648 | 113 |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | metabolic syndrome | targetBased | 196177 | 811 | 0.614697417851648 | 113 |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | metabolic syndrome | targetBased | 196176 | 670 | 0.614697417851648 | 113 |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | metabolic syndrome | targetBased | 196177 | 519 | 0.614697417851648 | 113 |
| HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity | CACNA1D_inhibitors | metabolic syndrome | targetBased | 335531 | 328 | 0.513066064153847 | 6 |
| Identification of Small Molecule Correctors of the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Delta508 Mutation Function in Human Bronchial Epithelial Cells. Measured in Cell-Based System Using Plate Reader - 7017-01_Other_SinglePoint_HTS_Activity | cftrCorrectors | pancreatitis | targetBased | 343786 | 1253 | 0.554613148487925 | 169 |
| Fluorescence Polarization with CAL-PDZ Measured in Biochemical System Using Plate Reader - 2109-02_Inhibitor_SinglePoint_HTS_Activity | cftrTrafficModulators | pancreatitis | targetBased | 296501 | 2737 | 0.554613148487925 | 169 |
| Primary cell-based high-throughput screening assay for identification of compounds that inhibit KCNQ1 potassium channels | KCNQ1 | diabetes mellitus | targetBased | 305610 | 3878 | 0.501787244287448 | 334 |
| Primary cell-based high-throughput screening assay for identification of compounds that potentiate/activate KCNQ1 potassium channels | KCNQ1 | diabetes mellitus | targetBased | 305610 | 1082 | 0.501787244287448 | 334 |
| Inhibitors of the vitamin D receptor (VDR): qHTS | VDR | diabetic nephropathy | targetBased | 394050 | 3624 | 0.567904792936959 | 90 |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | diabetic nephropathy | targetBased | 405130 | 6428 | 0.555656269282092 | 300 |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | diabetic nephropathy | targetBased | 373462 | 23 | 0.555656269282092 | 300 |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | diabetic nephropathy | targetBased | 405130 | 6428 | 0.555656269282092 | 300 |
| Identification of Small Molecule Correctors of the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Delta508 Mutation Function in Human Bronchial Epithelial Cells. Measured in Cell-Based System Using Plate Reader - 7017-01_Other_SinglePoint_HTS_Activity | cftrCorrectors | chronic pancreatitis | targetBased | 343786 | 1253 | 0.720305011735222 | 173 |
| Fluorescence Polarization with CAL-PDZ Measured in Biochemical System Using Plate Reader - 2109-02_Inhibitor_SinglePoint_HTS_Activity | cftrTrafficModulators | chronic pancreatitis | targetBased | 296501 | 2737 | 0.720305011735222 | 173 |
| Inhibitors of the vitamin D receptor (VDR): qHTS | VDR | diabetes mellitus | targetBased | 394050 | 3624 | 0.529105742384322 | 476 |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | diabetes mellitus | targetBased | 405130 | 6428 | 0.746078951984027 | 6203 |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | diabetes mellitus | targetBased | 373462 | 23 | 0.746078951984027 | 6203 |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | diabetes mellitus | targetBased | 405130 | 6428 | 0.746078951984027 | 6203 |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | diabetes mellitus | targetBased | 99314 | 335 | 0.832249916636913 | 3050 |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | diabetes mellitus | targetBased | 196176 | 782 | 0.832249916636913 | 3050 |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | diabetes mellitus | targetBased | 99314 | 390 | 0.832249916636913 | 3050 |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | diabetes mellitus | targetBased | 196177 | 811 | 0.832249916636913 | 3050 |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | diabetes mellitus | targetBased | 196176 | 670 | 0.832249916636913 | 3050 |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | diabetes mellitus | targetBased | 196177 | 519 | 0.832249916636913 | 3050 |
| HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity | CACNA1D_inhibitors | diabetes mellitus | targetBased | 335531 | 328 | 0.6503387957345 | 50 |
| qHTS Assay for Activators of Human alpha-Glucosidase as a Potential Chaperone Treatment of Pompe Disease | GAA | diabetes mellitus | targetBased | 199169 | 715 | 0.55166609042028 | 16 |
| qHTS Assay for Inhibitors and Activators of Human alpha-Glucosidase Cleavage of Glycogen | GAA_inhibitors | diabetes mellitus | targetBased | 302297 | 1165 | 0.55166609042028 | 16 |
| Thrombin 1536 HTS | F2_modulation | diabetes mellitus | targetBased | 217233 | 557 | 0.511277238254476 | 101 |
| Primary screen for compounds that activate Insulin promoter activity in TRM-6 cells | INS | diabetes mellitus | targetBased | 128695 | 1039 | 0.682345221976707 | 3901 |
| Primary screen for compounds that inhibit Insulin promoter activity in TRM-6 cells | INS | diabetes mellitus | targetBased | 127961 | 1153 | 0.682345221976707 | 3901 |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | metabolic disease | targetBased | 99314 | 335 | 0.650932856407589 | 2914 |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | metabolic disease | targetBased | 196176 | 782 | 0.650932856407589 | 2914 |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | metabolic disease | targetBased | 99314 | 390 | 0.650932856407589 | 2914 |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | metabolic disease | targetBased | 196177 | 811 | 0.650932856407589 | 2914 |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | metabolic disease | targetBased | 196176 | 670 | 0.650932856407589 | 2914 |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | metabolic disease | targetBased | 196177 | 519 | 0.650932856407589 | 2914 |
| HTS for Beta-2AR agonists via FAP method | ADRB2_activators | portal hypertension | targetBased | 339297 | 1446 | 0.579427222756886 | 14 |
| uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay | OPRK1 | obesity | targetBased | 290355 | 265 | 0.620061063972936 | 23 |
| HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors | ESR1_inhibitors | obesity | targetBased | 86095 | 1442 | 0.558027801578465 | 27 |
| HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators | ESR1_modulators | obesity | targetBased | 86095 | 1151 | 0.558027801578465 | 27 |
| Inhibitors of the vitamin D receptor (VDR): qHTS | VDR | obesity | targetBased | 394050 | 3624 | 0.61655642640449 | 21 |
| Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors | OPRM1 | obesity | targetBased | 335239 | 991 | 0.638477857428487 | 43 |
| Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors | OPRM1 | obesity | targetBased | 335239 | 695 | 0.638477857428487 | 43 |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | obesity | targetBased | 405130 | 6428 | 0.665388121938735 | 202 |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | obesity | targetBased | 373462 | 23 | 0.665388121938735 | 202 |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | obesity | targetBased | 405130 | 6428 | 0.665388121938735 | 202 |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | obesity | targetBased | 99314 | 335 | 0.693615894867754 | 71 |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | obesity | targetBased | 196176 | 782 | 0.693615894867754 | 71 |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | obesity | targetBased | 99314 | 390 | 0.693615894867754 | 71 |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | obesity | targetBased | 196177 | 811 | 0.693615894867754 | 71 |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | obesity | targetBased | 196176 | 670 | 0.693615894867754 | 71 |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | obesity | targetBased | 196177 | 519 | 0.693615894867754 | 71 |
| High Throughput Screening for Cocaine Antagonists: Primary Screen | SLC6A3 | obesity | targetBased | 108286 | 1415 | 0.658323474596516 | 83 |
| Luminescence-based cell-based primary high throughput screening assay to identify biased ligands of the melanocortin 4 receptor (MC4R): agonists of MC4R | MC4R | obesity | targetBased | 356160 | 3470 | 0.891868554414912 | 272 |
| TRFRET-based cell-based primary high throughput screening assay to identify biased ligands of the melanocortin 4 receptor (MC4R): antagonists of MC4R | MC4R | obesity | targetBased | 356160 | 1703 | 0.891868554414912 | 272 |
| HTS for Beta-2AR agonists via FAP method | ADRB2_activators | obesity | targetBased | 339297 | 1446 | 0.552014995286952 | 13 |
| Fluorescence-based primary cell-based high throughput screening assay to identify agonists of the Oxytocin Receptor (OXTR). | OXTR | obesity | targetBased | 324747 | 1043 | 0.560691974339547 | 9 |
| HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1 | TRPV1 | obesity | targetBased | 316642 | 617 | 0.5193543582675 | 9 |
| Fluorescence-based cell-based primary high throughput screening assay to identify inhibitors of TLR9-MyD88 binding. | TLR9 | obesity | targetBased | 343468 | 734 | 0.577168330395272 | 6 |
| Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors | OPRM1 | morbid obesity | targetBased | 335239 | 991 | 0.612786737888709 | 18 |
| Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors | OPRM1 | morbid obesity | targetBased | 335239 | 695 | 0.612786737888709 | 18 |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | morbid obesity | targetBased | 405130 | 6428 | 0.528103011465632 | 23 |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | morbid obesity | targetBased | 373462 | 23 | 0.528103011465632 | 23 |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | morbid obesity | targetBased | 405130 | 6428 | 0.528103011465632 | 23 |
| HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1 | TRPV1 | morbid obesity | targetBased | 316642 | 617 | 0.555158533283897 | 8 |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | liver disease | targetBased | 99314 | 335 | 0.685650937463137 | 671 |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | liver disease | targetBased | 196176 | 782 | 0.685650937463137 | 671 |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | liver disease | targetBased | 99314 | 390 | 0.685650937463137 | 671 |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | liver disease | targetBased | 196177 | 811 | 0.685650937463137 | 671 |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | liver disease | targetBased | 196176 | 670 | 0.685650937463137 | 671 |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | liver disease | targetBased | 196177 | 519 | 0.685650937463137 | 671 |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | abnormal glucose tolerance | targetBased | 99314 | 335 | 0.57280694202758 | 8 |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | abnormal glucose tolerance | targetBased | 196176 | 782 | 0.57280694202758 | 8 |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | abnormal glucose tolerance | targetBased | 99314 | 390 | 0.57280694202758 | 8 |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | abnormal glucose tolerance | targetBased | 196177 | 811 | 0.57280694202758 | 8 |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | abnormal glucose tolerance | targetBased | 196176 | 670 | 0.57280694202758 | 8 |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | abnormal glucose tolerance | targetBased | 196177 | 519 | 0.57280694202758 | 8 |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | non-alcoholic fatty liver disease | targetBased | 405130 | 6428 | 0.597702476941513 | 707 |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | non-alcoholic fatty liver disease | targetBased | 373462 | 23 | 0.597702476941513 | 707 |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | non-alcoholic fatty liver disease | targetBased | 405130 | 6428 | 0.597702476941513 | 707 |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | non-alcoholic fatty liver disease | targetBased | 99314 | 335 | 0.67440205565891 | 877 |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | non-alcoholic fatty liver disease | targetBased | 196176 | 782 | 0.67440205565891 | 877 |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | non-alcoholic fatty liver disease | targetBased | 99314 | 390 | 0.67440205565891 | 877 |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | non-alcoholic fatty liver disease | targetBased | 196177 | 811 | 0.67440205565891 | 877 |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | non-alcoholic fatty liver disease | targetBased | 196176 | 670 | 0.67440205565891 | 877 |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | non-alcoholic fatty liver disease | targetBased | 196177 | 519 | 0.67440205565891 | 877 |
| qHTS for Agonist of gsp, the Etiologic Mutation Responsible for Fibrous Dysplasia/McCune-Albright Syndrome: qHTS | GNAS | Cushing syndrome | targetBased | 334825 | 423 | 0.622867247821216 | 68 |
| qHTS for Antagonists of gsp, the Etiologic Mutation Responsible for Fibrous Dysplasia/McCune-Albright Syndrome: qHTS | GNAS | Cushing syndrome | targetBased | 337446 | 1356 | 0.622867247821216 | 68 |
| USP8 deubiquitinase inhibition: Primary qHTS | USP8 | Cushing syndrome | targetBased | 47480 | 2010 | 0.600698602908734 | 10 |
| Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | TSHR | Graves disease | targetBased | 329153 | 670 | 0.575702894356837 | 2048 |
| Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | TSHR | Graves disease | targetBased | 329153 | 670 | 0.575702894356837 | 2048 |
| qHTS Assay for Agonists of the Thyroid Stimulating Hormone Receptor | TSHR | Graves disease | targetBased | 72026 | 352 | 0.575702894356837 | 2048 |
| qHTS Assay for Agonists of the Thyroid Stimulating Hormone Receptor: Activators of Intracellular cAMP Concentrations in Parental HEK 293 | TSHR | Graves disease | targetBased | 72026 | 1794 | 0.575702894356837 | 2048 |
| Primary Cell-based High Throughput Screening assay for activators of the Retinoic Acid Receptor-related orphan receptor A (RORA) | RORA | body mass index | pathwayBased | 64908 | 979 | 0.529527129428927 | 12 |
| Primary Cell-based High Throughput Screening assay for inhibitors of the Retinoic Acid Receptor-related orphan receptor A (RORA) | RORA | body mass index | pathwayBased | 64908 | 278 | 0.529527129428927 | 12 |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | body mass index | targetBased | 99314 | 335 | 0.517791092042884 | 17 |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | body mass index | targetBased | 196176 | 782 | 0.517791092042884 | 17 |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | body mass index | targetBased | 99314 | 390 | 0.517791092042884 | 17 |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | body mass index | targetBased | 196177 | 811 | 0.517791092042884 | 17 |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | body mass index | targetBased | 196176 | 670 | 0.517791092042884 | 17 |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | body mass index | targetBased | 196177 | 519 | 0.517791092042884 | 17 |
| qHTS Assay for NPC1 Promoter Activators | NPC1 | body mass index | pathwayBased | 320682 | 7575 | 0.500783917608923 | 23 |
| Luminescence-based cell-based primary high throughput screening assay to identify biased ligands of the melanocortin 4 receptor (MC4R): agonists of MC4R | MC4R | body mass index | targetBased | 356160 | 3470 | 0.793103015324844 | 185 |
| TRFRET-based cell-based primary high throughput screening assay to identify biased ligands of the melanocortin 4 receptor (MC4R): antagonists of MC4R | MC4R | body mass index | targetBased | 356160 | 1703 | 0.793103015324844 | 185 |
| SMM ID4 Measured in Biochemical System Using Small Molecule MicroArray - 2128-01_Other_SinglePoint_HTS_Activity | ID4 | body fat distribution | targetBased | 31324 | 362 | 0.502294312755366 | 6 |
| Luminescence-based cell-based primary high throughput screening assay to identify biased ligands of the melanocortin 4 receptor (MC4R): agonists of MC4R | MC4R | body weights and measures | targetBased | 356160 | 3470 | 0.694882527663013 | 216 |
| TRFRET-based cell-based primary high throughput screening assay to identify biased ligands of the melanocortin 4 receptor (MC4R): antagonists of MC4R | MC4R | body weights and measures | targetBased | 356160 | 1703 | 0.694882527663013 | 216 |
| Luminescence-based cell-based primary high throughput screening assay to identify biased ligands of the melanocortin 4 receptor (MC4R): agonists of MC4R | MC4R | body weight | targetBased | 356160 | 3470 | 0.779946115907984 | 80 |
| TRFRET-based cell-based primary high throughput screening assay to identify biased ligands of the melanocortin 4 receptor (MC4R): antagonists of MC4R | MC4R | body weight | targetBased | 356160 | 1703 | 0.779946115907984 | 80 |
| Inhibitors of the vitamin D receptor (VDR): qHTS | VDR | gestational diabetes | targetBased | 394050 | 3624 | 0.512465339236712 | 62 |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | gestational diabetes | targetBased | 405130 | 6428 | 0.573876632832523 | 32 |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | gestational diabetes | targetBased | 373462 | 23 | 0.573876632832523 | 32 |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | gestational diabetes | targetBased | 405130 | 6428 | 0.573876632832523 | 32 |
| HTS using DiI-HDL to assay lipid transfer in ldlA[SR-BI] cells Measured in Cell-Based System Using Plate Reader - 2085-01_Inhibitor_SinglePoint_HTS_Activity | SCARB1 | triglyceride measurement | targetBased | 319204 | 3065 | 0.515570905781065 | 10 |
| HTS using DiI-HDL to assay lipid transfer in ldlA[SR-BI] cells Measured in Cell-Based System Using Plate Reader - 2085-01_Activator_SinglePoint_HTS_Activity | SCARB1 | triglyceride measurement | targetBased | 316970 | 306 | 0.515570905781065 | 10 |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | triglyceride measurement | targetBased | 99314 | 335 | 0.515247998154276 | 14 |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | triglyceride measurement | targetBased | 196176 | 782 | 0.515247998154276 | 14 |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | triglyceride measurement | targetBased | 99314 | 390 | 0.515247998154276 | 14 |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | triglyceride measurement | targetBased | 196177 | 811 | 0.515247998154276 | 14 |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | triglyceride measurement | targetBased | 196176 | 670 | 0.515247998154276 | 14 |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | triglyceride measurement | targetBased | 196177 | 519 | 0.515247998154276 | 14 |
| Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2 | THRB | triglyceride measurement | targetBased | 276265 | 806 | 0.511763821304796 | 8 |
| HTS using DiI-HDL to assay lipid transfer in ldlA[SR-BI] cells Measured in Cell-Based System Using Plate Reader - 2085-01_Inhibitor_SinglePoint_HTS_Activity | SCARB1 | low density lipoprotein cholesterol measurement | targetBased | 319204 | 3065 | 0.507078142237239 | 11 |
| HTS using DiI-HDL to assay lipid transfer in ldlA[SR-BI] cells Measured in Cell-Based System Using Plate Reader - 2085-01_Activator_SinglePoint_HTS_Activity | SCARB1 | low density lipoprotein cholesterol measurement | targetBased | 316970 | 306 | 0.507078142237239 | 11 |
| HTS using DiI-HDL to assay lipid transfer in ldlA[SR-BI] cells Measured in Cell-Based System Using Plate Reader - 2085-01_Inhibitor_SinglePoint_HTS_Activity | SCARB1 | high density lipoprotein cholesterol measurement | targetBased | 319204 | 3065 | 0.774346264551129 | 83 |
| HTS using DiI-HDL to assay lipid transfer in ldlA[SR-BI] cells Measured in Cell-Based System Using Plate Reader - 2085-01_Activator_SinglePoint_HTS_Activity | SCARB1 | high density lipoprotein cholesterol measurement | targetBased | 316970 | 306 | 0.774346264551129 | 83 |
| uHTS identification of modulators of interaction between CendR and NRP-1 using Fluorescence Polarization assay | NRP1 | high density lipoprotein cholesterol measurement | targetBased | 363840 | 3086 | 0.513255797802339 | 14 |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | high density lipoprotein cholesterol measurement | targetBased | 99314 | 335 | 0.709062972457657 | 42 |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | high density lipoprotein cholesterol measurement | targetBased | 196176 | 782 | 0.709062972457657 | 42 |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | high density lipoprotein cholesterol measurement | targetBased | 99314 | 390 | 0.709062972457657 | 42 |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | high density lipoprotein cholesterol measurement | targetBased | 196177 | 811 | 0.709062972457657 | 42 |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | high density lipoprotein cholesterol measurement | targetBased | 196176 | 670 | 0.709062972457657 | 42 |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | high density lipoprotein cholesterol measurement | targetBased | 196177 | 519 | 0.709062972457657 | 42 |
| Luminescence-based cell-based primary high throughput screening assay to identify biased ligands of the melanocortin 4 receptor (MC4R): agonists of MC4R | MC4R | high density lipoprotein cholesterol measurement | targetBased | 356160 | 3470 | 0.517829028574134 | 24 |
| TRFRET-based cell-based primary high throughput screening assay to identify biased ligands of the melanocortin 4 receptor (MC4R): antagonists of MC4R | MC4R | high density lipoprotein cholesterol measurement | targetBased | 356160 | 1703 | 0.517829028574134 | 24 |
| HTS using DiI-HDL to assay lipid transfer in ldlA[SR-BI] cells Measured in Cell-Based System Using Plate Reader - 2085-01_Inhibitor_SinglePoint_HTS_Activity | SCARB1 | total cholesterol measurement | targetBased | 319204 | 3065 | 0.720081380330332 | 28 |
| HTS using DiI-HDL to assay lipid transfer in ldlA[SR-BI] cells Measured in Cell-Based System Using Plate Reader - 2085-01_Activator_SinglePoint_HTS_Activity | SCARB1 | total cholesterol measurement | targetBased | 316970 | 306 | 0.720081380330332 | 28 |
| Primary cell-based high throughput screening assay to measure STAT1 activation | STAT1 activation | hypothyroidism | pathwayBased | 195980 | 5134 | 0.506525369873782 | 28 |
| Primary cell-based high throughput screening assay to measure STAT1 inhibition | STAT1 | hypothyroidism | targetBased | 195980 | 695 | 0.506525369873782 | 28 |
| Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2 | THRB | hypothyroidism | targetBased | 276265 | 806 | 0.676224852086246 | 502 |
| Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | TSHR | hypothyroidism | targetBased | 329153 | 670 | 0.852391824258962 | 546 |
| Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | TSHR | hypothyroidism | targetBased | 329153 | 670 | 0.852391824258962 | 546 |
| qHTS Assay for Agonists of the Thyroid Stimulating Hormone Receptor | TSHR | hypothyroidism | targetBased | 72026 | 352 | 0.852391824258962 | 546 |
| qHTS Assay for Agonists of the Thyroid Stimulating Hormone Receptor: Activators of Intracellular cAMP Concentrations in Parental HEK 293 | TSHR | hypothyroidism | targetBased | 72026 | 1794 | 0.852391824258962 | 546 |
| HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors | ESR1_inhibitors | lean body mass | targetBased | 86095 | 1442 | 0.605276599282585 | 33 |
| HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators | ESR1_modulators | lean body mass | targetBased | 86095 | 1151 | 0.605276599282585 | 33 |
| Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors | OPRM1 | lean body mass | targetBased | 335239 | 991 | 0.521145657342475 | 17 |
| Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors | OPRM1 | lean body mass | targetBased | 335239 | 695 | 0.521145657342475 | 17 |
| Primary cell-based high-throughput screening assay for identification of compounds that inhibit/block inward-rectifying potassium ion channel Kir2.1 | KCNJ2 | lean body mass | targetBased | 305610 | 2592 | 0.50328478437926 | 17 |
| Luminescence-based cell-based primary high throughput screening assay to identify biased ligands of the melanocortin 4 receptor (MC4R): agonists of MC4R | MC4R | lean body mass | targetBased | 356160 | 3470 | 0.797055288021613 | 210 |
| TRFRET-based cell-based primary high throughput screening assay to identify biased ligands of the melanocortin 4 receptor (MC4R): antagonists of MC4R | MC4R | lean body mass | targetBased | 356160 | 1703 | 0.797055288021613 | 210 |
| HTS of Smad transcription factor inhibitors | SMAD3 | lean body mass | targetBased | 88033 | 251 | 0.522966736589418 | 12 |
| SMM ID4 Measured in Biochemical System Using Small Molecule MicroArray - 2128-01_Other_SinglePoint_HTS_Activity | ID4 | lean body mass | targetBased | 31324 | 362 | 0.557680215912674 | 29 |
| HTS using DiI-HDL to assay lipid transfer in ldlA[SR-BI] cells Measured in Cell-Based System Using Plate Reader - 2085-01_Inhibitor_SinglePoint_HTS_Activity | SCARB1 | lipoprotein measurement | targetBased | 319204 | 3065 | 0.737641092943203 | 90 |
| HTS using DiI-HDL to assay lipid transfer in ldlA[SR-BI] cells Measured in Cell-Based System Using Plate Reader - 2085-01_Activator_SinglePoint_HTS_Activity | SCARB1 | lipoprotein measurement | targetBased | 316970 | 306 | 0.737641092943203 | 90 |
| HTS identification of compounds activating phosphomannose isomerase (PMI) via a fluorescence intensity assay using a near- saturating concentration of mannose 6-phosphat | MPI | congenital disorder of glycosylation type I | targetBased | 194152 | 656 | 0.582877315384715 | 260 |
| HTS identification of compounds inhibiting phosphomannose isomerase (PMI) via a fluorescence intensity assay using a high concentration of mannose 6-phosphate | MPI | congenital disorder of glycosylation type I | targetBased | 194152 | 1288 | 0.582877315384715 | 260 |
| HTS identification of compounds inhibiting phosphomannose isomerase (PMI) via a fluorescence intensity assay. | MPI | congenital disorder of glycosylation type I | targetBased | 194152 | 814 | 0.582877315384715 | 260 |
| Luminescence-based cell-based primary high throughput screening assay to identify biased ligands of the melanocortin 4 receptor (MC4R): agonists of MC4R | MC4R | fat body mass | targetBased | 356160 | 3470 | 0.792334309492539 | 188 |
| TRFRET-based cell-based primary high throughput screening assay to identify biased ligands of the melanocortin 4 receptor (MC4R): antagonists of MC4R | MC4R | fat body mass | targetBased | 356160 | 1703 | 0.792334309492539 | 188 |
| SMM ID4 Measured in Biochemical System Using Small Molecule MicroArray - 2128-01_Other_SinglePoint_HTS_Activity | ID4 | fat body mass | targetBased | 31324 | 362 | 0.521144086906474 | 11 |
| Inhibitors of the vitamin D receptor (VDR): qHTS | VDR | parathyroid disease | targetBased | 394050 | 3624 | 0.612533808842894 | 202 |
| qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Texas Red Labeled MLL-derived Mutant Peptide | Menin-MLL_inhibitors | parathyroid disease | targetBased | 263421 | 615 | 0.672577744708436 | 1855 |
| Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists | D2_agonists | hyperprolactinemia | targetBased | 359518 | 300 | 0.622566399114305 | 15 |
| HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists | D2_agonists | hyperprolactinemia | targetBased | 335652 | 1779 | 0.622566399114305 | 15 |
| Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists | D2_antagonists | hyperprolactinemia | targetBased | 362274 | 1056 | 0.622566399114305 | 15 |
| HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists | D2_antagonists | hyperprolactinemia | targetBased | 336308 | 6862 | 0.622566399114305 | 15 |
| Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators | D2_PAMs | hyperprolactinemia | targetBased | 357537 | 806 | 0.622566399114305 | 15 |
| HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators | D2_PAMs | hyperprolactinemia | targetBased | 339887 | 1178 | 0.622566399114305 | 15 |
| qHTS of D3 Dopamine Receptor Agonist: qHTS | D3_agonists | hyperprolactinemia | targetBased | 407539 | 2380 | 0.605697325591456 | 11 |
| qHTS of D3 Dopamine Receptor Antagonist: qHTS | D3_antagonists | hyperprolactinemia | targetBased | 364051 | 9106 | 0.605697325591456 | 11 |
| qHTS of D3 Dopamine Receptor Potentiators: qHTS | D3_PAMs | hyperprolactinemia | targetBased | 407539 | 2380 | 0.605697325591456 | 11 |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | body fat percentage | targetBased | 99314 | 335 | 0.576341088252982 | 45 |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | body fat percentage | targetBased | 196176 | 782 | 0.576341088252982 | 45 |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | body fat percentage | targetBased | 99314 | 390 | 0.576341088252982 | 45 |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | body fat percentage | targetBased | 196177 | 811 | 0.576341088252982 | 45 |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | body fat percentage | targetBased | 196176 | 670 | 0.576341088252982 | 45 |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | body fat percentage | targetBased | 196177 | 519 | 0.576341088252982 | 45 |
| Luminescence-based cell-based primary high throughput screening assay to identify biased ligands of the melanocortin 4 receptor (MC4R): agonists of MC4R | MC4R | body fat percentage | targetBased | 356160 | 3470 | 0.790829523756632 | 128 |
| TRFRET-based cell-based primary high throughput screening assay to identify biased ligands of the melanocortin 4 receptor (MC4R): antagonists of MC4R | MC4R | body fat percentage | targetBased | 356160 | 1703 | 0.790829523756632 | 128 |
| Cell-based high throughput primary assay to identify activators of GPR151 | GPR151 | body fat percentage | targetBased | 642701 | 6746 | 0.510129293451637 | 14 |
| Luminescence-based cell-based primary high throughput screening assay to identify biased ligands of the melanocortin 4 receptor (MC4R): agonists of MC4R | MC4R | base metabolic rate measurement | targetBased | 356160 | 3470 | 0.746509529530886 | 33 |
| TRFRET-based cell-based primary high throughput screening assay to identify biased ligands of the melanocortin 4 receptor (MC4R): antagonists of MC4R | MC4R | base metabolic rate measurement | targetBased | 356160 | 1703 | 0.746509529530886 | 33 |
| qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Texas Red Labeled MLL-derived Mutant Peptide | Menin-MLL_inhibitors | hyperparathyroidism | targetBased | 263421 | 615 | 0.832240869271689 | 1881 |
| Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | TSHR | hyperthyroidism | targetBased | 329153 | 670 | 0.603756541413275 | 1906 |
| Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | TSHR | hyperthyroidism | targetBased | 329153 | 670 | 0.603756541413275 | 1906 |
| qHTS Assay for Agonists of the Thyroid Stimulating Hormone Receptor | TSHR | hyperthyroidism | targetBased | 72026 | 352 | 0.603756541413275 | 1906 |
| qHTS Assay for Agonists of the Thyroid Stimulating Hormone Receptor: Activators of Intracellular cAMP Concentrations in Parental HEK 293 | TSHR | hyperthyroidism | targetBased | 72026 | 1794 | 0.603756541413275 | 1906 |
| HTS for Beta-2AR agonists via FAP method | ADRB2_activators | hyperthyroidism | targetBased | 339297 | 1446 | 0.523521299969412 | 12 |
| Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | TSHR | Thyrotoxicosis | targetBased | 329153 | 670 | 0.517506253480117 | 315 |
| Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | TSHR | Thyrotoxicosis | targetBased | 329153 | 670 | 0.517506253480117 | 315 |
| qHTS Assay for Agonists of the Thyroid Stimulating Hormone Receptor | TSHR | Thyrotoxicosis | targetBased | 72026 | 352 | 0.517506253480117 | 315 |
| qHTS Assay for Agonists of the Thyroid Stimulating Hormone Receptor: Activators of Intracellular cAMP Concentrations in Parental HEK 293 | TSHR | Thyrotoxicosis | targetBased | 72026 | 1794 | 0.517506253480117 | 315 |
| qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Texas Red Labeled MLL-derived Mutant Peptide | Menin-MLL_inhibitors | primary hyperparathyroidism | targetBased | 263421 | 615 | 0.731336275407759 | 1712 |
| Inhibitors of the vitamin D receptor (VDR): qHTS | VDR | hypoparathyroidism | targetBased | 394050 | 3624 | 0.641977609633434 | 58 |
| qHTS for PTHR1 Agonists: Primary Screen | PTH1R | hypoparathyroidism | targetBased | 405685 | 308 | 0.61948357909798 | 44 |
| Luminescence-based cell-based primary high throughput screening assay to identify biased ligands of the melanocortin 4 receptor (MC4R): agonists of MC4R | MC4R | whole body water mass | targetBased | 356160 | 3470 | 0.724805104839169 | 30 |
| TRFRET-based cell-based primary high throughput screening assay to identify biased ligands of the melanocortin 4 receptor (MC4R): antagonists of MC4R | MC4R | whole body water mass | targetBased | 356160 | 1703 | 0.724805104839169 | 30 |
| HTS using DiI-HDL to assay lipid transfer in ldlA[SR-BI] cells Measured in Cell-Based System Using Plate Reader - 2085-01_Inhibitor_SinglePoint_HTS_Activity | SCARB1 | cholesteryl ester measurement | targetBased | 319204 | 3065 | 0.605296400781166 | 14 |
| HTS using DiI-HDL to assay lipid transfer in ldlA[SR-BI] cells Measured in Cell-Based System Using Plate Reader - 2085-01_Activator_SinglePoint_HTS_Activity | SCARB1 | cholesteryl ester measurement | targetBased | 316970 | 306 | 0.605296400781166 | 14 |
| uHTS identification of TNAP inhibitors in the absence of phosphate acceptor performed in luminescent assay | ALPL_inhibitors | infantile hypophosphatasia | targetBased | 195560 | 517 | 0.90622530582871 | 371 |
| HTS using DiI-HDL to assay lipid transfer in ldlA[SR-BI] cells Measured in Cell-Based System Using Plate Reader - 2085-01_Inhibitor_SinglePoint_HTS_Activity | SCARB1 | concentration of large HDL particles measurement | targetBased | 319204 | 3065 | 0.589321137126282 | 11 |
| HTS using DiI-HDL to assay lipid transfer in ldlA[SR-BI] cells Measured in Cell-Based System Using Plate Reader - 2085-01_Activator_SinglePoint_HTS_Activity | SCARB1 | concentration of large HDL particles measurement | targetBased | 316970 | 306 | 0.589321137126282 | 11 |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | lipodystrophy | targetBased | 99314 | 335 | 0.538756514793434 | 170 |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | lipodystrophy | targetBased | 196176 | 782 | 0.538756514793434 | 170 |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | lipodystrophy | targetBased | 99314 | 390 | 0.538756514793434 | 170 |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | lipodystrophy | targetBased | 196177 | 811 | 0.538756514793434 | 170 |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | lipodystrophy | targetBased | 196176 | 670 | 0.538756514793434 | 170 |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | lipodystrophy | targetBased | 196177 | 519 | 0.538756514793434 | 170 |
| Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | TSHR | thyroid disease | targetBased | 329153 | 670 | 0.834278902759498 | 1999 |
| Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | TSHR | thyroid disease | targetBased | 329153 | 670 | 0.834278902759498 | 1999 |
| qHTS Assay for Agonists of the Thyroid Stimulating Hormone Receptor | TSHR | thyroid disease | targetBased | 72026 | 352 | 0.834278902759498 | 1999 |
| qHTS Assay for Agonists of the Thyroid Stimulating Hormone Receptor: Activators of Intracellular cAMP Concentrations in Parental HEK 293 | TSHR | thyroid disease | targetBased | 72026 | 1794 | 0.834278902759498 | 1999 |
| Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2 | THRB | myxedema | targetBased | 276265 | 806 | 0.577168330395272 | 6 |
| Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | TSHR | myxedema | targetBased | 329153 | 670 | 0.647247201046324 | 83 |
| Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | TSHR | myxedema | targetBased | 329153 | 670 | 0.647247201046324 | 83 |
| qHTS Assay for Agonists of the Thyroid Stimulating Hormone Receptor | TSHR | myxedema | targetBased | 72026 | 352 | 0.647247201046324 | 83 |
| qHTS Assay for Agonists of the Thyroid Stimulating Hormone Receptor: Activators of Intracellular cAMP Concentrations in Parental HEK 293 | TSHR | myxedema | targetBased | 72026 | 1794 | 0.647247201046324 | 83 |
| Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2 | THRB | nodular goiter | targetBased | 276265 | 806 | 0.514169279031916 | 7 |
| USP8 deubiquitinase inhibition: Primary qHTS | USP8 | pituitary-dependent Cushing's disease | targetBased | 47480 | 2010 | 0.551867769967705 | 8 |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | prediabetes syndrome | targetBased | 405130 | 6428 | 0.596101338955186 | 71 |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | prediabetes syndrome | targetBased | 373462 | 23 | 0.596101338955186 | 71 |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | prediabetes syndrome | targetBased | 405130 | 6428 | 0.596101338955186 | 71 |
| qHTS Assay for NPC1 Promoter Activators | NPC1 | Niemann-Pick disease | pathwayBased | 320682 | 7575 | 0.810720962981773 | 1356 |
| uHTS identification of small molecule modulators of NR3A | GRIN3A | postencephalitic Parkinson disease | targetBased | 339772 | 8480 | 0.638992421523723 | 21 |
| Inhibitors of the vitamin D receptor (VDR): qHTS | VDR | secondary hyperparathyroidism | targetBased | 394050 | 3624 | 0.6628175930313 | 274 |
| qHTS Assay to Identify Small Molecule Activators of BRCA1 Expression | BRCA1 activation | secondary Parkinson disease | pathwayBased | 376029 | 3978 | 0.567451434636309 | 6 |
| qHTS Assay for Identifying a Potential Treatment of Ataxia-Telangiectasia | ATM_modulators | secondary Parkinson disease | targetBased | 322361 | 619 | 0.585513080048089 | 14 |
| uHTS identification of small molecule modulators of NR3A | GRIN3A | secondary Parkinson disease | targetBased | 339772 | 8480 | 0.643570744246353 | 28 |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | non-alcoholic steatohepatitis | targetBased | 99314 | 335 | 0.582785079482869 | 375 |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | non-alcoholic steatohepatitis | targetBased | 196176 | 782 | 0.582785079482869 | 375 |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | non-alcoholic steatohepatitis | targetBased | 99314 | 390 | 0.582785079482869 | 375 |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | non-alcoholic steatohepatitis | targetBased | 196177 | 811 | 0.582785079482869 | 375 |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | non-alcoholic steatohepatitis | targetBased | 196176 | 670 | 0.582785079482869 | 375 |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | non-alcoholic steatohepatitis | targetBased | 196177 | 519 | 0.582785079482869 | 375 |
| Counterscreen for Oxytocin Receptor (OXTR) agonists: Fluorescence-based primary cell-based high throughput assay to identify agonists of the vasopressin 1 receptor (V1R) | AVPR1A_agonists | Central diabetes insipidus | targetBased | 324747 | 813 | 0.60466648961276 | 9 |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | Hyperglycemia | targetBased | 405130 | 6428 | 0.516596040424956 | 758 |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | Hyperglycemia | targetBased | 373462 | 23 | 0.516596040424956 | 758 |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | Hyperglycemia | targetBased | 405130 | 6428 | 0.516596040424956 | 758 |
| HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity | CACNA1D_inhibitors | Hypercholesterolemia | targetBased | 335531 | 328 | 0.575286284252107 | 9 |
| Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2 | THRB | thyroid hormone resistance syndrome | targetBased | 276265 | 806 | 0.74824198378622 | 236 |
| qHTS assay for inhibitors of human lactate dehydrogenase | lactateDehydrogenaseInhibitors | disorder of glycogen metabolism | targetBased | 476056 | 732 | 0.650586578528587 | 90 |
| qHTS Assay for Activators of Human alpha-Glucosidase as a Potential Chaperone Treatment of Pompe Disease | GAA | disorder of glycogen metabolism | targetBased | 199169 | 715 | 0.692888266555033 | 1495 |
| qHTS Assay for Inhibitors and Activators of Human alpha-Glucosidase Cleavage of Glycogen | GAA_inhibitors | disorder of glycogen metabolism | targetBased | 302297 | 1165 | 0.692888266555033 | 1495 |
| qHTS assay for re-activators of p53 using a Luc reporter | TP53 | lysosomal storage disease | pathwayBased | 321427 | 201 | 0.510748835743924 | 23 |
| qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Nonpermissive Temperature | nonSmallCellLungCarcinomaWithP53Mutations | lysosomal storage disease | targetBased | 54509 | 528 | 0.510748835743924 | 23 |
| qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Permissive Temperature | nonSmallCellLungCarcinomaWithP53Mutations | lysosomal storage disease | targetBased | 54513 | 338 | 0.510748835743924 | 23 |
| qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature | nonSmallCellLungCarcinomaWithP53Mutations | lysosomal storage disease | targetBased | 125394 | 1890 | 0.510748835743924 | 23 |
| qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature | nonSmallCellLungCarcinomaWithP53Mutations | lysosomal storage disease | targetBased | 124022 | 1156 | 0.510748835743924 | 23 |
| Fluorescence polarization assay for PLK1 inhibitors | PLK1 | lysosomal storage disease | targetBased | 97099 | 518 | 0.577168330395272 | 6 |
| qHTS for Inhibitors of PLK1-PDB (polo-like kinase 1 - polo-box domain): Primary Screen | PLK1 | lysosomal storage disease | targetBased | 364065 | 10181 | 0.577168330395272 | 6 |
| Acumen qHTS Assay for Inhibitors of the mTORC1 Signaling Pathway in MEF (Tsc2-/-, p53-/-) Cells: Sytravon | MTOR | lysosomal storage disease | pathwayBased | 43989 | 342 | 0.511744604694731 | 47 |
| Inhibitors of the vitamin D receptor (VDR): qHTS | VDR | type 1 diabetes mellitus | targetBased | 394050 | 3624 | 0.623714942338902 | 286 |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | type 1 diabetes mellitus | targetBased | 405130 | 6428 | 0.667118677384461 | 374 |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | type 1 diabetes mellitus | targetBased | 373462 | 23 | 0.667118677384461 | 374 |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | type 1 diabetes mellitus | targetBased | 405130 | 6428 | 0.667118677384461 | 374 |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | type 1 diabetes mellitus | targetBased | 99314 | 335 | 0.530795116220742 | 83 |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | type 1 diabetes mellitus | targetBased | 196176 | 782 | 0.530795116220742 | 83 |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | type 1 diabetes mellitus | targetBased | 99314 | 390 | 0.530795116220742 | 83 |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | type 1 diabetes mellitus | targetBased | 196177 | 811 | 0.530795116220742 | 83 |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | type 1 diabetes mellitus | targetBased | 196176 | 670 | 0.530795116220742 | 83 |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | type 1 diabetes mellitus | targetBased | 196177 | 519 | 0.530795116220742 | 83 |
| Primary screen for compounds that activate Insulin promoter activity in TRM-6 cells | INS | type 1 diabetes mellitus | targetBased | 128695 | 1039 | 0.756980358905614 | 1970 |
| Primary screen for compounds that inhibit Insulin promoter activity in TRM-6 cells | INS | type 1 diabetes mellitus | targetBased | 127961 | 1153 | 0.756980358905614 | 1970 |
| Primary cell-based high-throughput screening assay for identification of compounds that inhibit KCNQ1 potassium channels | KCNQ1 | type 2 diabetes mellitus | targetBased | 305610 | 3878 | 0.66637441362342 | 573 |
| Primary cell-based high-throughput screening assay for identification of compounds that potentiate/activate KCNQ1 potassium channels | KCNQ1 | type 2 diabetes mellitus | targetBased | 305610 | 1082 | 0.66637441362342 | 573 |
| Inhibitors of the vitamin D receptor (VDR): qHTS | VDR | type 2 diabetes mellitus | targetBased | 394050 | 3624 | 0.630637978861556 | 347 |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | type 2 diabetes mellitus | targetBased | 405130 | 6428 | 0.822214179786226 | 8610 |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | type 2 diabetes mellitus | targetBased | 373462 | 23 | 0.822214179786226 | 8610 |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | type 2 diabetes mellitus | targetBased | 405130 | 6428 | 0.822214179786226 | 8610 |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | type 2 diabetes mellitus | targetBased | 99314 | 335 | 0.920445028915377 | 3693 |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | type 2 diabetes mellitus | targetBased | 196176 | 782 | 0.920445028915377 | 3693 |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | type 2 diabetes mellitus | targetBased | 99314 | 390 | 0.920445028915377 | 3693 |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | type 2 diabetes mellitus | targetBased | 196177 | 811 | 0.920445028915377 | 3693 |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | type 2 diabetes mellitus | targetBased | 196176 | 670 | 0.920445028915377 | 3693 |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | type 2 diabetes mellitus | targetBased | 196177 | 519 | 0.920445028915377 | 3693 |
| Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists | D2_agonists | type 2 diabetes mellitus | targetBased | 359518 | 300 | 0.639626764279892 | 80 |
| HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists | D2_agonists | type 2 diabetes mellitus | targetBased | 335652 | 1779 | 0.639626764279892 | 80 |
| Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists | D2_antagonists | type 2 diabetes mellitus | targetBased | 362274 | 1056 | 0.639626764279892 | 80 |
| HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists | D2_antagonists | type 2 diabetes mellitus | targetBased | 336308 | 6862 | 0.639626764279892 | 80 |
| Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators | D2_PAMs | type 2 diabetes mellitus | targetBased | 357537 | 806 | 0.639626764279892 | 80 |
| HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators | D2_PAMs | type 2 diabetes mellitus | targetBased | 339887 | 1178 | 0.639626764279892 | 80 |
| qHTS of D3 Dopamine Receptor Agonist: qHTS | D3_agonists | type 2 diabetes mellitus | targetBased | 407539 | 2380 | 0.619586482443362 | 21 |
| qHTS of D3 Dopamine Receptor Antagonist: qHTS | D3_antagonists | type 2 diabetes mellitus | targetBased | 364051 | 9106 | 0.619586482443362 | 21 |
| qHTS of D3 Dopamine Receptor Potentiators: qHTS | D3_PAMs | type 2 diabetes mellitus | targetBased | 407539 | 2380 | 0.619586482443362 | 21 |
| HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity | CACNA1D_inhibitors | type 2 diabetes mellitus | targetBased | 335531 | 328 | 0.57586675548928 | 30 |
| Luminescence-based cell-based primary high throughput screening assay to identify biased ligands of the melanocortin 4 receptor (MC4R): agonists of MC4R | MC4R | type 2 diabetes mellitus | targetBased | 356160 | 3470 | 0.55611341627735 | 228 |
| TRFRET-based cell-based primary high throughput screening assay to identify biased ligands of the melanocortin 4 receptor (MC4R): antagonists of MC4R | MC4R | type 2 diabetes mellitus | targetBased | 356160 | 1703 | 0.55611341627735 | 228 |
| qHTS Assay for Activators of Human alpha-Glucosidase as a Potential Chaperone Treatment of Pompe Disease | GAA | type 2 diabetes mellitus | targetBased | 199169 | 715 | 0.633159771804883 | 32 |
| qHTS Assay for Inhibitors and Activators of Human alpha-Glucosidase Cleavage of Glycogen | GAA_inhibitors | type 2 diabetes mellitus | targetBased | 302297 | 1165 | 0.633159771804883 | 32 |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | familial partial lipodystrophy, Dunnigan type | targetBased | 99314 | 335 | 0.61433213627937 | 87 |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | familial partial lipodystrophy, Dunnigan type | targetBased | 196176 | 782 | 0.61433213627937 | 87 |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | familial partial lipodystrophy, Dunnigan type | targetBased | 99314 | 390 | 0.61433213627937 | 87 |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | familial partial lipodystrophy, Dunnigan type | targetBased | 196177 | 811 | 0.61433213627937 | 87 |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | familial partial lipodystrophy, Dunnigan type | targetBased | 196176 | 670 | 0.61433213627937 | 87 |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | familial partial lipodystrophy, Dunnigan type | targetBased | 196177 | 519 | 0.61433213627937 | 87 |
| Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2 | THRB | selective pituitary resistance to thyroid hormone | targetBased | 276265 | 806 | 0.819781482042683 | 48 |
| Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of the prolyl oligopeptidase-like enzyme (PREPL) | PREPL | cystinuria | targetBased | 324747 | 2221 | 0.610967494573669 | 95 |
| Identification of Small Molecule Correctors of the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Delta508 Mutation Function in Human Bronchial Epithelial Cells. Measured in Cell-Based System Using Plate Reader - 7017-01_Other_SinglePoint_HTS_Activity | cftrCorrectors | hereditary chronic pancreatitis | targetBased | 343786 | 1253 | 0.777489202209142 | 461 |
| Fluorescence Polarization with CAL-PDZ Measured in Biochemical System Using Plate Reader - 2109-02_Inhibitor_SinglePoint_HTS_Activity | cftrTrafficModulators | hereditary chronic pancreatitis | targetBased | 296501 | 2737 | 0.777489202209142 | 461 |
| qHTS for Inhibitors of Tau Fibril Formation, Fluorescence Polarization | MAPT | late-onset Parkinson disease | pathwayBased | 271402 | 1048 | 0.554854250374523 | 6 |
| qHTS for Inhibitors of Tau Fibril Formation, Thioflavin T Binding | MAPT | late-onset Parkinson disease | pathwayBased | 267412 | 5703 | 0.554854250374523 | 6 |
| qHTS Assay for Tau Filament Binding | MAPT | late-onset Parkinson disease | targetBased | 69668 | 1391 | 0.554854250374523 | 6 |
| Glucocerebrosidase | GBA1 | Gaucher disease-ophthalmoplegia-cardiovascular calcification syndrome | targetBased | 48118 | 549 | 0.779415318502638 | 122 |
| Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2 | THRB | generalized resistance to thyroid hormone | targetBased | 276265 | 806 | 0.770774380396017 | 44 |
| uHTS Identification of Diaphorase Inhibitors and Chemcical Oxidizers: Counter Screen for Diaphorase-based Primary Assays | DiaphoraseInhibitors | pyruvate dehydrogenase E3 deficiency | targetBased | 194152 | 1342 | 0.909058118974501 | 882 |
| uHTS Identification of Diaphorase Inhibitors and Chemcical Oxidizers: Counter Screen for Diaphorase-based Primary Assays | DiaphoraseInhibitors | maple syrup urine disease | targetBased | 194152 | 1342 | 0.726575680343748 | 1132 |
| uHTS Identification of Diaphorase Inhibitors and Chemcical Oxidizers: Counter Screen for Diaphorase-based Primary Assays | DiaphoraseInhibitors | Leigh syndrome | targetBased | 194152 | 1342 | 0.702759335081669 | 123 |
| qHTS for Agonists of the Human Mucolipin Transient Receptor Potential 1 (TRPML1) | MCOLN1 | mucolipidosis type IV | targetBased | 400814 | 482 | 0.926582257823166 | 1539 |
| Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | TSHR | hypothyroidism due to TSH receptor mutations | targetBased | 329153 | 670 | 0.876175090766287 | 206 |
| Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | TSHR | hypothyroidism due to TSH receptor mutations | targetBased | 329153 | 670 | 0.876175090766287 | 206 |
| qHTS Assay for Agonists of the Thyroid Stimulating Hormone Receptor | TSHR | hypothyroidism due to TSH receptor mutations | targetBased | 72026 | 352 | 0.876175090766287 | 206 |
| qHTS Assay for Agonists of the Thyroid Stimulating Hormone Receptor: Activators of Intracellular cAMP Concentrations in Parental HEK 293 | TSHR | hypothyroidism due to TSH receptor mutations | targetBased | 72026 | 1794 | 0.876175090766287 | 206 |
| uHTS identification of small molecule inhibitors of Artemis endonuclease activity via a fluorescence intensity assay | artemis_inhibitors | severe combined immunodeficiency due to DCLRE1C deficiency | targetBased | 30104 | 235 | 0.890628296247178 | 1470 |
| qHTS for Inhibitors of Polymerase Eta | POLH | xeroderma pigmentosum variant type | targetBased | 388717 | 4730 | 0.860919268933285 | 369 |
| HTS identification of compounds activating phosphomannose isomerase (PMI) via a fluorescence intensity assay using a near- saturating concentration of mannose 6-phosphat | MPI | MPI-congenital disorder of glycosylation | targetBased | 194152 | 656 | 0.92306803154231 | 773 |
| HTS identification of compounds inhibiting phosphomannose isomerase (PMI) via a fluorescence intensity assay using a high concentration of mannose 6-phosphate | MPI | MPI-congenital disorder of glycosylation | targetBased | 194152 | 1288 | 0.92306803154231 | 773 |
| HTS identification of compounds inhibiting phosphomannose isomerase (PMI) via a fluorescence intensity assay. | MPI | MPI-congenital disorder of glycosylation | targetBased | 194152 | 814 | 0.92306803154231 | 773 |
| qHTS for Agonist of gsp, the Etiologic Mutation Responsible for Fibrous Dysplasia/McCune-Albright Syndrome: qHTS | GNAS | pseudohypoparathyroidism type 1B | targetBased | 334825 | 423 | 0.884574613045788 | 245 |
| qHTS for Antagonists of gsp, the Etiologic Mutation Responsible for Fibrous Dysplasia/McCune-Albright Syndrome: qHTS | GNAS | pseudohypoparathyroidism type 1B | targetBased | 337446 | 1356 | 0.884574613045788 | 245 |
| Glucocerebrosidase | GBA1 | Gaucher disease perinatal lethal | targetBased | 48118 | 549 | 0.87178890644602 | 119 |
| Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of the prolyl oligopeptidase-like enzyme (PREPL) | PREPL | hypotonia-cystinuria syndrome | targetBased | 324747 | 2221 | 0.603812914945978 | 23 |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG-related familial partial lipodystrophy | targetBased | 99314 | 335 | 0.853828081057315 | 135 |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG-related familial partial lipodystrophy | targetBased | 196176 | 782 | 0.853828081057315 | 135 |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG-related familial partial lipodystrophy | targetBased | 99314 | 390 | 0.853828081057315 | 135 |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG-related familial partial lipodystrophy | targetBased | 196177 | 811 | 0.853828081057315 | 135 |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG-related familial partial lipodystrophy | targetBased | 196176 | 670 | 0.853828081057315 | 135 |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG-related familial partial lipodystrophy | targetBased | 196177 | 519 | 0.853828081057315 | 135 |
| Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | TSHR | familial hyperthyroidism due to mutations in TSH receptor | targetBased | 329153 | 670 | 0.78816112707411 | 209 |
| Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | TSHR | familial hyperthyroidism due to mutations in TSH receptor | targetBased | 329153 | 670 | 0.78816112707411 | 209 |
| qHTS Assay for Agonists of the Thyroid Stimulating Hormone Receptor | TSHR | familial hyperthyroidism due to mutations in TSH receptor | targetBased | 72026 | 352 | 0.78816112707411 | 209 |
| qHTS Assay for Agonists of the Thyroid Stimulating Hormone Receptor: Activators of Intracellular cAMP Concentrations in Parental HEK 293 | TSHR | familial hyperthyroidism due to mutations in TSH receptor | targetBased | 72026 | 1794 | 0.78816112707411 | 209 |
| qHTS Assay for Inhibitors of Tyrosyl-DNA Phosphodiesterase (TDP1) | TDP1 | spinocerebellar ataxia, autosomal recessive, with axonal neuropathy 1 | targetBased | 344442 | 978 | 0.615241893026113 | 162 |
| qHTS for Inhibitors of human tyrosyl-DNA phosphodiesterase 1 (TDP1): qHTS in cells in absence of CPT | TDP1 | spinocerebellar ataxia, autosomal recessive, with axonal neuropathy 1 | targetBased | 416824 | 63248 | 0.615241893026113 | 162 |
| qHTS for Inhibitors of human tyrosyl-DNA phosphodiesterase 1 (TDP1): qHTS in cells in presence of CPT | TDP1 | spinocerebellar ataxia, autosomal recessive, with axonal neuropathy 1 | targetBased | 416856 | 49238 | 0.615241893026113 | 162 |
| HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity | CACNA1D_inhibitors | aldosterone-producing adenoma with seizures and neurological abnormalities | targetBased | 335531 | 328 | 0.824148217889939 | 128 |
| HTS identification of compounds activating phosphomannose isomerase (PMI) via a fluorescence intensity assay using a near- saturating concentration of mannose 6-phosphat | MPI | congenital disorder of glycosylation | targetBased | 194152 | 656 | 0.735305299331021 | 997 |
| HTS identification of compounds inhibiting phosphomannose isomerase (PMI) via a fluorescence intensity assay using a high concentration of mannose 6-phosphate | MPI | congenital disorder of glycosylation | targetBased | 194152 | 1288 | 0.735305299331021 | 997 |
| HTS identification of compounds inhibiting phosphomannose isomerase (PMI) via a fluorescence intensity assay. | MPI | congenital disorder of glycosylation | targetBased | 194152 | 814 | 0.735305299331021 | 997 |
| Primary screen for compounds that activate Insulin promoter activity in TRM-6 cells | INS | neonatal diabetes mellitus | targetBased | 128695 | 1039 | 0.608360646017274 | 151 |
| Primary screen for compounds that inhibit Insulin promoter activity in TRM-6 cells | INS | neonatal diabetes mellitus | targetBased | 127961 | 1153 | 0.608360646017274 | 151 |
| uHTS identification of TNAP inhibitors in the absence of phosphate acceptor performed in luminescent assay | ALPL_inhibitors | odontohypophosphatasia | targetBased | 195560 | 517 | 0.741759323098823 | 20 |
| qHTS Assay for Activators of ClpP | Bacillus subtilis (strain 168) | Perrault syndrome | targetBased | 338378 | 6439 | 0.851666345145291 | 107 |
| uHTS identification of DNMT1 inhibitors in a Fluorescent Molecular Beacon assay | DNMT1 | hereditary sensory and autonomic neuropathy type 1 | targetBased | 359244 | 2975 | 0.678383562696946 | 2457 |
| Inhibitors of Cav3 T-type Calcium Channels: Primary Screen | CACNA1H_inhibitors | familial hyperaldosteronism | targetBased | 104728 | 4230 | 0.579874415386324 | 5432 |
| Glucocerebrosidase | GBA1 | Gaucher disease | targetBased | 48118 | 549 | 0.823552732111791 | 2711 |
| qHTS for Agonists of the Human Mucolipin Transient Receptor Potential 1 (TRPML1) | MCOLN1 | mucolipidosis | targetBased | 400814 | 482 | 0.558287279679423 | 524 |
| uHTS identification of TNAP inhibitors in the absence of phosphate acceptor performed in luminescent assay | ALPL_inhibitors | hypophosphatasia | targetBased | 195560 | 517 | 0.896956238684656 | 1435 |
| HTS for PAX8 inhibitors using PAX8 luciferase reporter gene assay in RMG-I cells Measured in Cell-Based System Using Plate Reader - 7054-01_Inhibitor_SinglePoint_HTS_Activity | PAX8 | congenital hypothyroidism | targetBased | 353950 | 4145 | 0.722405177821548 | 288 |
| Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2 | THRB | congenital hypothyroidism | targetBased | 276265 | 806 | 0.611703580698182 | 39 |
| Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | TSHR | congenital hypothyroidism | targetBased | 329153 | 670 | 0.645401662748241 | 232 |
| Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | TSHR | congenital hypothyroidism | targetBased | 329153 | 670 | 0.645401662748241 | 232 |
| qHTS Assay for Agonists of the Thyroid Stimulating Hormone Receptor | TSHR | congenital hypothyroidism | targetBased | 72026 | 352 | 0.645401662748241 | 232 |
| qHTS Assay for Agonists of the Thyroid Stimulating Hormone Receptor: Activators of Intracellular cAMP Concentrations in Parental HEK 293 | TSHR | congenital hypothyroidism | targetBased | 72026 | 1794 | 0.645401662748241 | 232 |
| Primary screen for compounds that activate Insulin promoter activity in TRM-6 cells | INS | maturity-onset diabetes of the young | targetBased | 128695 | 1039 | 0.629780097686834 | 56 |
| Primary screen for compounds that inhibit Insulin promoter activity in TRM-6 cells | INS | maturity-onset diabetes of the young | targetBased | 127961 | 1153 | 0.629780097686834 | 56 |
| Luminescence-based cell-based primary high throughput screening assay to identify biased ligands of the melanocortin 4 receptor (MC4R): agonists of MC4R | MC4R | obesity due to melanocortin 4 receptor deficiency | targetBased | 356160 | 3470 | 0.739222725453875 | 152 |
| TRFRET-based cell-based primary high throughput screening assay to identify biased ligands of the melanocortin 4 receptor (MC4R): antagonists of MC4R | MC4R | obesity due to melanocortin 4 receptor deficiency | targetBased | 356160 | 1703 | 0.739222725453875 | 152 |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | inherited obesity | targetBased | 99314 | 335 | 0.624128943995849 | 13 |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | inherited obesity | targetBased | 196176 | 782 | 0.624128943995849 | 13 |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | inherited obesity | targetBased | 99314 | 390 | 0.624128943995849 | 13 |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | inherited obesity | targetBased | 196177 | 811 | 0.624128943995849 | 13 |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | inherited obesity | targetBased | 196176 | 670 | 0.624128943995849 | 13 |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | inherited obesity | targetBased | 196177 | 519 | 0.624128943995849 | 13 |
| Luminescence-based cell-based primary high throughput screening assay to identify biased ligands of the melanocortin 4 receptor (MC4R): agonists of MC4R | MC4R | inherited obesity | targetBased | 356160 | 3470 | 0.557144807777269 | 70 |
| TRFRET-based cell-based primary high throughput screening assay to identify biased ligands of the melanocortin 4 receptor (MC4R): antagonists of MC4R | MC4R | inherited obesity | targetBased | 356160 | 1703 | 0.557144807777269 | 70 |
| qHTS Assay for NPC1 Promoter Activators | NPC1 | Niemann-Pick disease type C | pathwayBased | 320682 | 7575 | 0.875385794852707 | 3870 |
| HTS for Identification of VLA-4 Allosteric Modulators from MLPCN library | ITGA4 | retinitis pigmentosa | targetBased | 326888 | 645 | 0.512584351790701 | 68 |
| Luminescence-based cell-based high throughput primary screening assay to identify agonists of nuclear receptor subfamily 2, group E, member 3 (NR2E3) | NR2E3 | retinitis pigmentosa | targetBased | 362026 | 1281 | 0.794921236355417 | 203 |
| TR-FRET-based primary biochemical high throughput screening assay to identify agonists of nuclear receptor subfamily 2, group E, member 3 (NR2E3). | NR2E3 | retinitis pigmentosa | targetBased | 314998 | 380 | 0.794921236355417 | 203 |
| qHTS for Inhibitors of Polymerase Eta | POLH | xeroderma pigmentosum | targetBased | 388717 | 4730 | 0.633286070298763 | 248 |
| HTS for PAX8 inhibitors using PAX8 luciferase reporter gene assay in RMG-I cells Measured in Cell-Based System Using Plate Reader - 7054-01_Inhibitor_SinglePoint_HTS_Activity | PAX8 | thyroid hypoplasia | targetBased | 353950 | 4145 | 0.509848214804856 | 35 |
| Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | TSHR | thyroid hypoplasia | targetBased | 329153 | 670 | 0.511564109249492 | 41 |
| Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | TSHR | thyroid hypoplasia | targetBased | 329153 | 670 | 0.511564109249492 | 41 |
| qHTS Assay for Agonists of the Thyroid Stimulating Hormone Receptor | TSHR | thyroid hypoplasia | targetBased | 72026 | 352 | 0.511564109249492 | 41 |
| qHTS Assay for Agonists of the Thyroid Stimulating Hormone Receptor: Activators of Intracellular cAMP Concentrations in Parental HEK 293 | TSHR | thyroid hypoplasia | targetBased | 72026 | 1794 | 0.511564109249492 | 41 |
| qHTS for Agonist of gsp, the Etiologic Mutation Responsible for Fibrous Dysplasia/McCune-Albright Syndrome: qHTS | GNAS | pseudohypoparathyroidism | targetBased | 334825 | 423 | 0.734855055294246 | 573 |
| qHTS for Antagonists of gsp, the Etiologic Mutation Responsible for Fibrous Dysplasia/McCune-Albright Syndrome: qHTS | GNAS | pseudohypoparathyroidism | targetBased | 337446 | 1356 | 0.734855055294246 | 573 |
| HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity | CACNA1D_inhibitors | hyperlipidemia | targetBased | 335531 | 328 | 0.643396782824324 | 27 |
| Primary screen for compounds that activate Insulin promoter activity in TRM-6 cells | INS | diabetes mellitus, permanent neonatal 4 | targetBased | 128695 | 1039 | 0.827937679728068 | 86 |
| Primary screen for compounds that inhibit Insulin promoter activity in TRM-6 cells | INS | diabetes mellitus, permanent neonatal 4 | targetBased | 127961 | 1153 | 0.827937679728068 | 86 |
| Primary screen for compounds that activate Insulin promoter activity in TRM-6 cells | INS | permanent neonatal diabetes mellitus | targetBased | 128695 | 1039 | 0.777959509145123 | 63 |
| Primary screen for compounds that inhibit Insulin promoter activity in TRM-6 cells | INS | permanent neonatal diabetes mellitus | targetBased | 127961 | 1153 | 0.777959509145123 | 63 |
| Dicer-mediated maturation of pre-microRNA | Dicer_inhibitors | Familial multinodular goiter | targetBased | 46715 | 2829 | 0.763909243189879 | 84 |
| Primary qHTS assay for inhibitors of alpha-synuclein gene (SNCA) expression | SNCA | Young adult-onset Parkinsonism | pathwayBased | 140118 | 236 | 0.769243896644589 | 113 |
| qHTS of alpha-syn Inhibitors | SNCA | Young adult-onset Parkinsonism | pathwayBased | 368791 | 501 | 0.769243896644589 | 113 |
| Glucocerebrosidase | GBA1 | Gaucher disease - ophthalmoplegia - cardiovascular calcification | targetBased | 48118 | 549 | 0.507250879663592 | 6 |
| Glucocerebrosidase | GBA1 | Gaucher disease type 2 | targetBased | 48118 | 549 | 0.881332474439115 | 207 |
| MITF Measured in Cell-Based System Using Plate Reader - 2084-01_Inhibitor_SinglePoint_HTS_Activity | MITF | Ocular albinism with congenital sensorineural deafness | targetBased | 331360 | 2760 | 0.643378037527545 | 8 |
| AlphaScreen-based biochemical high throughput primary assay to identify inhibitors of microphthalmia-associated transcription factor (MITF) | MITF inhibitors | Ocular albinism with congenital sensorineural deafness | targetBased | 642362 | 5830 | 0.643378037527545 | 8 |
| Primary qHTS assay for inhibitors of alpha-synuclein gene (SNCA) expression | SNCA | Hereditary late-onset Parkinson disease | pathwayBased | 140118 | 236 | 0.870085087181022 | 125 |
| qHTS of alpha-syn Inhibitors | SNCA | Hereditary late-onset Parkinson disease | pathwayBased | 368791 | 501 | 0.870085087181022 | 125 |
| Glucocerebrosidase | GBA1 | Hereditary late-onset Parkinson disease | targetBased | 48118 | 549 | 0.624207386504889 | 108 |
| qHTS for Inhibitors of Tau Fibril Formation, Fluorescence Polarization | MAPT | Hereditary late-onset Parkinson disease | pathwayBased | 271402 | 1048 | 0.538121040106858 | 23 |
| qHTS for Inhibitors of Tau Fibril Formation, Thioflavin T Binding | MAPT | Hereditary late-onset Parkinson disease | pathwayBased | 267412 | 5703 | 0.538121040106858 | 23 |
| qHTS Assay for Tau Filament Binding | MAPT | Hereditary late-onset Parkinson disease | targetBased | 69668 | 1391 | 0.538121040106858 | 23 |
| Primary screen for compounds that activate Insulin promoter activity in TRM-6 cells | INS | MODY | targetBased | 128695 | 1039 | 0.801268492989806 | 168 |
| Primary screen for compounds that inhibit Insulin promoter activity in TRM-6 cells | INS | MODY | targetBased | 127961 | 1153 | 0.801268492989806 | 168 |
Some of these associations have also gone through clinical trials, as those in the graph below.
Find clinical trials details in table. Use scroll bar or search funtion to select specific drugs, molecular targets or diseases.
| BioAssay Name | program | gene | protName | diseaseName | molname | assayMode | clinicalPhase | clinicalStatus | studyStartDate | url | score | variantEffect | directionOnTrait | studyStopReason |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| High Throughput Screening for Cocaine Antagonists: Primary Screen | SLC6A3 | SLC6A3 | Sodium-dependent dopamine transporter | obesity | AMPHETAMINE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f469fb38-0380-4621-9db3-a4f429126156 | 1 | protect | ||||
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | diabetes mellitus | TROGLITAZONE | targetBased | 4 | https://www.whocc.no/atc_ddd_index/?code=A10BG01 | 1 | GoF | protect | |||
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | diabetes mellitus | TROGLITAZONE | targetBased | 4 | https://www.whocc.no/atc_ddd_index/?code=A10BG01 | 1 | GoF | protect | |||
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | diabetes mellitus | TROGLITAZONE | targetBased | 4 | https://www.whocc.no/atc_ddd_index/?code=A10BG01 | 1 | GoF | protect | |||
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | diabetes mellitus | TROGLITAZONE | targetBased | 4 | https://www.whocc.no/atc_ddd_index/?code=A10BG01 | 1 | GoF | protect | |||
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | diabetes mellitus | TROGLITAZONE | targetBased | 4 | https://www.whocc.no/atc_ddd_index/?code=A10BG01 | 1 | GoF | protect | |||
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | diabetes mellitus | TROGLITAZONE | targetBased | 4 | https://www.whocc.no/atc_ddd_index/?code=A10BG01 | 1 | GoF | protect | |||
| HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity | CACNA1D_inhibitors | CACNA1D | Voltage-dependent N-type calcium channel subunit alpha-1B | diabetes mellitus | VERAPAMIL | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=92f7adf1-cb8c-4c6e-95d1-9afd28fe5116 | 1 | LoF | protect | |||
| HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity | CACNA1D_inhibitors | CACNA1D | Voltage-dependent N-type calcium channel subunit alpha-1B | type 1 diabetes mellitus | VERAPAMIL | targetBased | 3 | Completed | 09/07/2020 | https://clinicaltrials.gov/study/NCT04233034 | 0.7 | LoF | protect | |
| HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity | CACNA1D_inhibitors | CACNA1D | Voltage-dependent N-type calcium channel subunit alpha-1B | type 2 diabetes mellitus | DILTIAZEM | targetBased | 3 | Completed | 01/09/1999 | https://clinicaltrials.gov/study/NCT00000620 | 0.7 | LoF | protect | |
| HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity | CACNA1D_inhibitors | CACNA1D | Voltage-dependent N-type calcium channel subunit alpha-1B | Hypercholesterolemia | DILTIAZEM | targetBased | 3 | Completed | 01/09/1999 | https://clinicaltrials.gov/study/NCT00000620 | 0.7 | LoF | protect | |
| HTS for Beta-2AR agonists via FAP method | ADRB2_activators | ADRB2 | Beta-2 adrenergic receptor | portal hypertension | PROPRANOLOL | targetBased | 3 | Completed | 01/01/2005 | https://clinicaltrials.gov/study/NCT01000779 | 0.7 | LoF | protect | |
| HTS for Beta-2AR agonists via FAP method | ADRB2_activators | ADRB2 | Beta-2 adrenergic receptor | hyperthyroidism | PROPRANOLOL | targetBased | 4 | Completed | 01/09/2008 | https://clinicaltrials.gov/study/NCT03393728 | 1 | LoF | protect | |
| HTS for Beta-2AR agonists via FAP method | ADRB2_activators | ADRB2 | Beta-2 adrenergic receptor | hyperthyroidism | PROPRANOLOL | targetBased | 4 | Completed | 18/07/2017 | https://clinicaltrials.gov/study/NCT03379181 | 1 | LoF | protect | |
| Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists | D2_agonists | DRD2 | Dopaminereceptor2 | metabolic syndrome | CLOZAPINE | targetBased | 4 | Completed | 01/05/2013 | https://clinicaltrials.gov/study/NCT02751307 | 1 | LoF | protect | |
| HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists | D2_agonists | DRD2 | Dopaminereceptor2 | metabolic syndrome | CLOZAPINE | targetBased | 4 | Completed | 01/05/2013 | https://clinicaltrials.gov/study/NCT02751307 | 1 | LoF | protect | |
| Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators | D2_PAMs | DRD2 | Dopaminereceptor2 | metabolic syndrome | CLOZAPINE | targetBased | 4 | Completed | 01/05/2013 | https://clinicaltrials.gov/study/NCT02751307 | 1 | LoF | protect | |
| HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators | D2_PAMs | DRD2 | Dopaminereceptor2 | metabolic syndrome | CLOZAPINE | targetBased | 4 | Completed | 01/05/2013 | https://clinicaltrials.gov/study/NCT02751307 | 1 | LoF | protect | |
| Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists | D2_antagonists | DRD2 | Dopaminereceptor2 | metabolic syndrome | CLOZAPINE | targetBased | 4 | Completed | 01/05/2013 | https://clinicaltrials.gov/study/NCT02751307 | 1 | LoF | protect | |
| HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists | D2_antagonists | DRD2 | Dopaminereceptor2 | metabolic syndrome | CLOZAPINE | targetBased | 4 | Completed | 01/05/2013 | https://clinicaltrials.gov/study/NCT02751307 | 1 | LoF | protect | |
| Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A) | HTR2A | HTR2A | 5-hydroxytryptamine receptor 2A | metabolic syndrome | CLOZAPINE | targetBased | 4 | Completed | 01/05/2013 | https://clinicaltrials.gov/study/NCT02751307 | 1 | LoF | protect | |
| ROC1-CUL1 CTD Inhibitor di-Ub FRET Primary HTS Screen | RBX1 | RBX1 | E3 ubiquitin-protein ligase RBX1 | malnutrition | THALIDOMIDE | targetBased | 4 | Withdrawn | 01/01/2007 | https://clinicaltrials.gov/study/NCT00390247 | 1 | LoF | protect | Fail of applying funding |
| Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors | OPRM1 | OPRM1 | Mu-type opioid receptor | obesity | MORPHINE | targetBased | 3 | Completed | 01/03/2016 | https://clinicaltrials.gov/study/NCT02880540 | 0.7 | GoF | protect | |
| Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors | OPRM1 | OPRM1 | Mu-type opioid receptor | obesity | MORPHINE | targetBased | 3 | Completed | 01/03/2016 | https://clinicaltrials.gov/study/NCT02880540 | 0.7 | GoF | protect | |
| Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors | OPRM1 | OPRM1 | Mu-type opioid receptor | gallstones | MORPHINE | targetBased | 4 | Completed | 01/01/2015 | https://clinicaltrials.gov/study/NCT02327923 | 1 | GoF | protect | |
| Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors | OPRM1 | OPRM1 | Mu-type opioid receptor | gallstones | MORPHINE | targetBased | 4 | Completed | 01/01/2015 | https://clinicaltrials.gov/study/NCT02327923 | 1 | GoF | protect | |
| Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors | OPRM1 | OPRM1 | Mu-type opioid receptor | morbid obesity | MORPHINE | targetBased | 4 | Unknown status | 01/11/2013 | https://clinicaltrials.gov/study/NCT02017314 | 1 | GoF | protect | |
| Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors | OPRM1 | OPRM1 | Mu-type opioid receptor | morbid obesity | MORPHINE | targetBased | 4 | Unknown status | 01/11/2013 | https://clinicaltrials.gov/study/NCT02017314 | 1 | GoF | protect | |
| Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists | D2_agonists | DRD2 | Dopaminereceptor2 | porphyria | CHLORPROMAZINE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9575c766-3758-6f33-e053-2995a90ae6b1 | 1 | LoF | protect | |||
| HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists | D2_agonists | DRD2 | Dopaminereceptor2 | porphyria | CHLORPROMAZINE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9575c766-3758-6f33-e053-2995a90ae6b1 | 1 | LoF | protect | |||
| Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators | D2_PAMs | DRD2 | Dopaminereceptor2 | porphyria | CHLORPROMAZINE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9575c766-3758-6f33-e053-2995a90ae6b1 | 1 | LoF | protect | |||
| HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators | D2_PAMs | DRD2 | Dopaminereceptor2 | porphyria | CHLORPROMAZINE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9575c766-3758-6f33-e053-2995a90ae6b1 | 1 | LoF | protect | |||
| Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists | D2_antagonists | DRD2 | Dopaminereceptor2 | porphyria | CHLORPROMAZINE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9575c766-3758-6f33-e053-2995a90ae6b1 | 1 | LoF | protect | |||
| HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists | D2_antagonists | DRD2 | Dopaminereceptor2 | porphyria | CHLORPROMAZINE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9575c766-3758-6f33-e053-2995a90ae6b1 | 1 | LoF | protect | |||
| Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A) | HTR2A | HTR2A | 5-hydroxytryptamine receptor 2A | porphyria | CHLORPROMAZINE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9575c766-3758-6f33-e053-2995a90ae6b1 | 1 | LoF | protect | |||
| qHTS of D3 Dopamine Receptor Antagonist: qHTS | D3_antagonists | DRD3 | Dopaminereceptor3 | porphyria | CHLORPROMAZINE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9575c766-3758-6f33-e053-2995a90ae6b1 | 1 | LoF | protect | |||
| qHTS of D3 Dopamine Receptor Agonist: qHTS | D3_agonists | DRD3 | Dopaminereceptor3 | porphyria | CHLORPROMAZINE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9575c766-3758-6f33-e053-2995a90ae6b1 | 1 | LoF | protect | |||
| qHTS of D3 Dopamine Receptor Potentiators: qHTS | D3_PAMs | DRD3 | Dopaminereceptor3 | porphyria | CHLORPROMAZINE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9575c766-3758-6f33-e053-2995a90ae6b1 | 1 | LoF | protect | |||
| qHTS of D3 Dopamine Receptor Antagonist: qHTS | D3_antagonists | DRD3 | Dopaminereceptor3 | hyperprolactinemia | BROMOCRIPTINE | targetBased | 4 | https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/020866s009lbl.pdf | 1 | GoF | protect | |||
| qHTS of D3 Dopamine Receptor Agonist: qHTS | D3_agonists | DRD3 | Dopaminereceptor3 | hyperprolactinemia | BROMOCRIPTINE | targetBased | 4 | https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/020866s009lbl.pdf | 1 | GoF | protect | |||
| qHTS of D3 Dopamine Receptor Potentiators: qHTS | D3_PAMs | DRD3 | Dopaminereceptor3 | hyperprolactinemia | BROMOCRIPTINE | targetBased | 4 | https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/020866s009lbl.pdf | 1 | GoF | protect | |||
| qHTS of D3 Dopamine Receptor Antagonist: qHTS | D3_antagonists | DRD3 | Dopaminereceptor3 | hyperprolactinemia | BROMOCRIPTINE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d69003ee-0b6f-47a9-834e-ba59c02f566c | 1 | GoF | protect | |||
| qHTS of D3 Dopamine Receptor Agonist: qHTS | D3_agonists | DRD3 | Dopaminereceptor3 | hyperprolactinemia | BROMOCRIPTINE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d69003ee-0b6f-47a9-834e-ba59c02f566c | 1 | GoF | protect | |||
| qHTS of D3 Dopamine Receptor Potentiators: qHTS | D3_PAMs | DRD3 | Dopaminereceptor3 | hyperprolactinemia | BROMOCRIPTINE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d69003ee-0b6f-47a9-834e-ba59c02f566c | 1 | GoF | protect | |||
| qHTS of D3 Dopamine Receptor Antagonist: qHTS | D3_antagonists | DRD3 | Dopaminereceptor3 | hyperprolactinemia | BROMOCRIPTINE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=97e7e051-ff64-4381-a869-6c1c364ad822 | 1 | GoF | protect | |||
| qHTS of D3 Dopamine Receptor Agonist: qHTS | D3_agonists | DRD3 | Dopaminereceptor3 | hyperprolactinemia | BROMOCRIPTINE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=97e7e051-ff64-4381-a869-6c1c364ad822 | 1 | GoF | protect | |||
| qHTS of D3 Dopamine Receptor Potentiators: qHTS | D3_PAMs | DRD3 | Dopaminereceptor3 | hyperprolactinemia | BROMOCRIPTINE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=97e7e051-ff64-4381-a869-6c1c364ad822 | 1 | GoF | protect | |||
| qHTS of D3 Dopamine Receptor Antagonist: qHTS | D3_antagonists | DRD3 | Dopaminereceptor3 | type 2 diabetes mellitus | BROMOCRIPTINE | targetBased | 3 | Terminated | 01/02/2005 | https://clinicaltrials.gov/study/NCT00441363 | 0.7 | GoF | protect | Failure to Recruit in a Timely manner |
| qHTS of D3 Dopamine Receptor Agonist: qHTS | D3_agonists | DRD3 | Dopaminereceptor3 | type 2 diabetes mellitus | BROMOCRIPTINE | targetBased | 3 | Terminated | 01/02/2005 | https://clinicaltrials.gov/study/NCT00441363 | 0.7 | GoF | protect | Failure to Recruit in a Timely manner |
| qHTS of D3 Dopamine Receptor Potentiators: qHTS | D3_PAMs | DRD3 | Dopaminereceptor3 | type 2 diabetes mellitus | BROMOCRIPTINE | targetBased | 3 | Terminated | 01/02/2005 | https://clinicaltrials.gov/study/NCT00441363 | 0.7 | GoF | protect | Failure to Recruit in a Timely manner |
| qHTS of D3 Dopamine Receptor Antagonist: qHTS | D3_antagonists | DRD3 | Dopaminereceptor3 | type 2 diabetes mellitus | BROMOCRIPTINE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3e719d6a-342e-428b-93d3-377d31cb15c7 | 1 | GoF | protect | |||
| qHTS of D3 Dopamine Receptor Agonist: qHTS | D3_agonists | DRD3 | Dopaminereceptor3 | type 2 diabetes mellitus | BROMOCRIPTINE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3e719d6a-342e-428b-93d3-377d31cb15c7 | 1 | GoF | protect | |||
| qHTS of D3 Dopamine Receptor Potentiators: qHTS | D3_PAMs | DRD3 | Dopaminereceptor3 | type 2 diabetes mellitus | BROMOCRIPTINE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3e719d6a-342e-428b-93d3-377d31cb15c7 | 1 | GoF | protect | |||
| qHTS of D3 Dopamine Receptor Antagonist: qHTS | D3_antagonists | DRD3 | Dopaminereceptor3 | type 2 diabetes mellitus | BROMOCRIPTINE | targetBased | 4 | Completed | 01/11/2011 | https://clinicaltrials.gov/study/NCT01474018 | 1 | GoF | protect | |
| qHTS of D3 Dopamine Receptor Agonist: qHTS | D3_agonists | DRD3 | Dopaminereceptor3 | type 2 diabetes mellitus | BROMOCRIPTINE | targetBased | 4 | Completed | 01/11/2011 | https://clinicaltrials.gov/study/NCT01474018 | 1 | GoF | protect | |
| qHTS of D3 Dopamine Receptor Potentiators: qHTS | D3_PAMs | DRD3 | Dopaminereceptor3 | type 2 diabetes mellitus | BROMOCRIPTINE | targetBased | 4 | Completed | 01/11/2011 | https://clinicaltrials.gov/study/NCT01474018 | 1 | GoF | protect | |
| qHTS of D3 Dopamine Receptor Antagonist: qHTS | D3_antagonists | DRD3 | Dopaminereceptor3 | type 2 diabetes mellitus | BROMOCRIPTINE | targetBased | 4 | Completed | 01/06/2014 | https://clinicaltrials.gov/study/NCT02299050 | 1 | GoF | protect | |
| qHTS of D3 Dopamine Receptor Agonist: qHTS | D3_agonists | DRD3 | Dopaminereceptor3 | type 2 diabetes mellitus | BROMOCRIPTINE | targetBased | 4 | Completed | 01/06/2014 | https://clinicaltrials.gov/study/NCT02299050 | 1 | GoF | protect | |
| qHTS of D3 Dopamine Receptor Potentiators: qHTS | D3_PAMs | DRD3 | Dopaminereceptor3 | type 2 diabetes mellitus | BROMOCRIPTINE | targetBased | 4 | Completed | 01/06/2014 | https://clinicaltrials.gov/study/NCT02299050 | 1 | GoF | protect | |
| qHTS of D3 Dopamine Receptor Antagonist: qHTS | D3_antagonists | DRD3 | Dopaminereceptor3 | type 2 diabetes mellitus | BROMOCRIPTINE | targetBased | 3 | Completed | 01/07/2004 | https://clinicaltrials.gov/study/NCT00377676 | 0.7 | GoF | protect | |
| qHTS of D3 Dopamine Receptor Agonist: qHTS | D3_agonists | DRD3 | Dopaminereceptor3 | type 2 diabetes mellitus | BROMOCRIPTINE | targetBased | 3 | Completed | 01/07/2004 | https://clinicaltrials.gov/study/NCT00377676 | 0.7 | GoF | protect | |
| qHTS of D3 Dopamine Receptor Potentiators: qHTS | D3_PAMs | DRD3 | Dopaminereceptor3 | type 2 diabetes mellitus | BROMOCRIPTINE | targetBased | 3 | Completed | 01/07/2004 | https://clinicaltrials.gov/study/NCT00377676 | 0.7 | GoF | protect | |
| Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists | D2_agonists | DRD2 | Dopaminereceptor2 | type 2 diabetes mellitus | BROMOCRIPTINE | targetBased | 4 | Completed | 01/06/2014 | https://clinicaltrials.gov/study/NCT02299050 | 1 | GoF | protect | |
| HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists | D2_agonists | DRD2 | Dopaminereceptor2 | type 2 diabetes mellitus | BROMOCRIPTINE | targetBased | 4 | Completed | 01/06/2014 | https://clinicaltrials.gov/study/NCT02299050 | 1 | GoF | protect | |
| Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators | D2_PAMs | DRD2 | Dopaminereceptor2 | type 2 diabetes mellitus | BROMOCRIPTINE | targetBased | 4 | Completed | 01/06/2014 | https://clinicaltrials.gov/study/NCT02299050 | 1 | GoF | protect | |
| HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators | D2_PAMs | DRD2 | Dopaminereceptor2 | type 2 diabetes mellitus | BROMOCRIPTINE | targetBased | 4 | Completed | 01/06/2014 | https://clinicaltrials.gov/study/NCT02299050 | 1 | GoF | protect | |
| Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists | D2_antagonists | DRD2 | Dopaminereceptor2 | type 2 diabetes mellitus | BROMOCRIPTINE | targetBased | 4 | Completed | 01/06/2014 | https://clinicaltrials.gov/study/NCT02299050 | 1 | GoF | protect | |
| HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists | D2_antagonists | DRD2 | Dopaminereceptor2 | type 2 diabetes mellitus | BROMOCRIPTINE | targetBased | 4 | Completed | 01/06/2014 | https://clinicaltrials.gov/study/NCT02299050 | 1 | GoF | protect | |
| Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists | D2_agonists | DRD2 | Dopaminereceptor2 | type 2 diabetes mellitus | BROMOCRIPTINE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3e719d6a-342e-428b-93d3-377d31cb15c7 | 1 | GoF | protect | |||
| HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists | D2_agonists | DRD2 | Dopaminereceptor2 | type 2 diabetes mellitus | BROMOCRIPTINE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3e719d6a-342e-428b-93d3-377d31cb15c7 | 1 | GoF | protect | |||
| Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators | D2_PAMs | DRD2 | Dopaminereceptor2 | type 2 diabetes mellitus | BROMOCRIPTINE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3e719d6a-342e-428b-93d3-377d31cb15c7 | 1 | GoF | protect | |||
| HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators | D2_PAMs | DRD2 | Dopaminereceptor2 | type 2 diabetes mellitus | BROMOCRIPTINE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3e719d6a-342e-428b-93d3-377d31cb15c7 | 1 | GoF | protect | |||
| Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists | D2_antagonists | DRD2 | Dopaminereceptor2 | type 2 diabetes mellitus | BROMOCRIPTINE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3e719d6a-342e-428b-93d3-377d31cb15c7 | 1 | GoF | protect | |||
| HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists | D2_antagonists | DRD2 | Dopaminereceptor2 | type 2 diabetes mellitus | BROMOCRIPTINE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3e719d6a-342e-428b-93d3-377d31cb15c7 | 1 | GoF | protect | |||
| Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists | D2_agonists | DRD2 | Dopaminereceptor2 | type 2 diabetes mellitus | BROMOCRIPTINE | targetBased | 3 | Terminated | 01/02/2005 | https://clinicaltrials.gov/study/NCT00441363 | 0.7 | GoF | protect | Failure to Recruit in a Timely manner |
| HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists | D2_agonists | DRD2 | Dopaminereceptor2 | type 2 diabetes mellitus | BROMOCRIPTINE | targetBased | 3 | Terminated | 01/02/2005 | https://clinicaltrials.gov/study/NCT00441363 | 0.7 | GoF | protect | Failure to Recruit in a Timely manner |
| Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators | D2_PAMs | DRD2 | Dopaminereceptor2 | type 2 diabetes mellitus | BROMOCRIPTINE | targetBased | 3 | Terminated | 01/02/2005 | https://clinicaltrials.gov/study/NCT00441363 | 0.7 | GoF | protect | Failure to Recruit in a Timely manner |
| HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators | D2_PAMs | DRD2 | Dopaminereceptor2 | type 2 diabetes mellitus | BROMOCRIPTINE | targetBased | 3 | Terminated | 01/02/2005 | https://clinicaltrials.gov/study/NCT00441363 | 0.7 | GoF | protect | Failure to Recruit in a Timely manner |
| Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists | D2_antagonists | DRD2 | Dopaminereceptor2 | type 2 diabetes mellitus | BROMOCRIPTINE | targetBased | 3 | Terminated | 01/02/2005 | https://clinicaltrials.gov/study/NCT00441363 | 0.7 | GoF | protect | Failure to Recruit in a Timely manner |
| HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists | D2_antagonists | DRD2 | Dopaminereceptor2 | type 2 diabetes mellitus | BROMOCRIPTINE | targetBased | 3 | Terminated | 01/02/2005 | https://clinicaltrials.gov/study/NCT00441363 | 0.7 | GoF | protect | Failure to Recruit in a Timely manner |
| Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists | D2_agonists | DRD2 | Dopaminereceptor2 | type 2 diabetes mellitus | BROMOCRIPTINE | targetBased | 3 | Completed | 01/07/2004 | https://clinicaltrials.gov/study/NCT00377676 | 0.7 | GoF | protect | |
| HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists | D2_agonists | DRD2 | Dopaminereceptor2 | type 2 diabetes mellitus | BROMOCRIPTINE | targetBased | 3 | Completed | 01/07/2004 | https://clinicaltrials.gov/study/NCT00377676 | 0.7 | GoF | protect | |
| Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators | D2_PAMs | DRD2 | Dopaminereceptor2 | type 2 diabetes mellitus | BROMOCRIPTINE | targetBased | 3 | Completed | 01/07/2004 | https://clinicaltrials.gov/study/NCT00377676 | 0.7 | GoF | protect | |
| HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators | D2_PAMs | DRD2 | Dopaminereceptor2 | type 2 diabetes mellitus | BROMOCRIPTINE | targetBased | 3 | Completed | 01/07/2004 | https://clinicaltrials.gov/study/NCT00377676 | 0.7 | GoF | protect | |
| Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists | D2_antagonists | DRD2 | Dopaminereceptor2 | type 2 diabetes mellitus | BROMOCRIPTINE | targetBased | 3 | Completed | 01/07/2004 | https://clinicaltrials.gov/study/NCT00377676 | 0.7 | GoF | protect | |
| HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists | D2_antagonists | DRD2 | Dopaminereceptor2 | type 2 diabetes mellitus | BROMOCRIPTINE | targetBased | 3 | Completed | 01/07/2004 | https://clinicaltrials.gov/study/NCT00377676 | 0.7 | GoF | protect | |
| Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists | D2_agonists | DRD2 | Dopaminereceptor2 | type 2 diabetes mellitus | BROMOCRIPTINE | targetBased | 4 | Completed | 01/11/2011 | https://clinicaltrials.gov/study/NCT01474018 | 1 | GoF | protect | |
| HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists | D2_agonists | DRD2 | Dopaminereceptor2 | type 2 diabetes mellitus | BROMOCRIPTINE | targetBased | 4 | Completed | 01/11/2011 | https://clinicaltrials.gov/study/NCT01474018 | 1 | GoF | protect | |
| Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators | D2_PAMs | DRD2 | Dopaminereceptor2 | type 2 diabetes mellitus | BROMOCRIPTINE | targetBased | 4 | Completed | 01/11/2011 | https://clinicaltrials.gov/study/NCT01474018 | 1 | GoF | protect | |
| HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators | D2_PAMs | DRD2 | Dopaminereceptor2 | type 2 diabetes mellitus | BROMOCRIPTINE | targetBased | 4 | Completed | 01/11/2011 | https://clinicaltrials.gov/study/NCT01474018 | 1 | GoF | protect | |
| Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists | D2_antagonists | DRD2 | Dopaminereceptor2 | type 2 diabetes mellitus | BROMOCRIPTINE | targetBased | 4 | Completed | 01/11/2011 | https://clinicaltrials.gov/study/NCT01474018 | 1 | GoF | protect | |
| HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists | D2_antagonists | DRD2 | Dopaminereceptor2 | type 2 diabetes mellitus | BROMOCRIPTINE | targetBased | 4 | Completed | 01/11/2011 | https://clinicaltrials.gov/study/NCT01474018 | 1 | GoF | protect | |
| Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists | D2_agonists | DRD2 | Dopaminereceptor2 | hyperprolactinemia | BROMOCRIPTINE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=97e7e051-ff64-4381-a869-6c1c364ad822 | 1 | GoF | protect | |||
| HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists | D2_agonists | DRD2 | Dopaminereceptor2 | hyperprolactinemia | BROMOCRIPTINE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=97e7e051-ff64-4381-a869-6c1c364ad822 | 1 | GoF | protect | |||
| Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators | D2_PAMs | DRD2 | Dopaminereceptor2 | hyperprolactinemia | BROMOCRIPTINE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=97e7e051-ff64-4381-a869-6c1c364ad822 | 1 | GoF | protect | |||
| HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators | D2_PAMs | DRD2 | Dopaminereceptor2 | hyperprolactinemia | BROMOCRIPTINE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=97e7e051-ff64-4381-a869-6c1c364ad822 | 1 | GoF | protect | |||
| Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists | D2_antagonists | DRD2 | Dopaminereceptor2 | hyperprolactinemia | BROMOCRIPTINE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=97e7e051-ff64-4381-a869-6c1c364ad822 | 1 | GoF | protect | |||
| HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists | D2_antagonists | DRD2 | Dopaminereceptor2 | hyperprolactinemia | BROMOCRIPTINE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=97e7e051-ff64-4381-a869-6c1c364ad822 | 1 | GoF | protect | |||
| Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists | D2_agonists | DRD2 | Dopaminereceptor2 | hyperprolactinemia | BROMOCRIPTINE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d69003ee-0b6f-47a9-834e-ba59c02f566c | 1 | GoF | protect | |||
| HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists | D2_agonists | DRD2 | Dopaminereceptor2 | hyperprolactinemia | BROMOCRIPTINE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d69003ee-0b6f-47a9-834e-ba59c02f566c | 1 | GoF | protect | |||
| Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators | D2_PAMs | DRD2 | Dopaminereceptor2 | hyperprolactinemia | BROMOCRIPTINE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d69003ee-0b6f-47a9-834e-ba59c02f566c | 1 | GoF | protect | |||
| HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators | D2_PAMs | DRD2 | Dopaminereceptor2 | hyperprolactinemia | BROMOCRIPTINE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d69003ee-0b6f-47a9-834e-ba59c02f566c | 1 | GoF | protect | |||
| Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists | D2_antagonists | DRD2 | Dopaminereceptor2 | hyperprolactinemia | BROMOCRIPTINE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d69003ee-0b6f-47a9-834e-ba59c02f566c | 1 | GoF | protect | |||
| HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists | D2_antagonists | DRD2 | Dopaminereceptor2 | hyperprolactinemia | BROMOCRIPTINE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d69003ee-0b6f-47a9-834e-ba59c02f566c | 1 | GoF | protect | |||
| Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists | D2_agonists | DRD2 | Dopaminereceptor2 | hyperprolactinemia | BROMOCRIPTINE | targetBased | 4 | https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/020866s009lbl.pdf | 1 | GoF | protect | |||
| HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists | D2_agonists | DRD2 | Dopaminereceptor2 | hyperprolactinemia | BROMOCRIPTINE | targetBased | 4 | https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/020866s009lbl.pdf | 1 | GoF | protect | |||
| Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators | D2_PAMs | DRD2 | Dopaminereceptor2 | hyperprolactinemia | BROMOCRIPTINE | targetBased | 4 | https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/020866s009lbl.pdf | 1 | GoF | protect | |||
| HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators | D2_PAMs | DRD2 | Dopaminereceptor2 | hyperprolactinemia | BROMOCRIPTINE | targetBased | 4 | https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/020866s009lbl.pdf | 1 | GoF | protect | |||
| Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists | D2_antagonists | DRD2 | Dopaminereceptor2 | hyperprolactinemia | BROMOCRIPTINE | targetBased | 4 | https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/020866s009lbl.pdf | 1 | GoF | protect | |||
| HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists | D2_antagonists | DRD2 | Dopaminereceptor2 | hyperprolactinemia | BROMOCRIPTINE | targetBased | 4 | https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/020866s009lbl.pdf | 1 | GoF | protect | |||
| Inhibitors of the EP2 Prostaglandin E2 Receptor - Primary Screen | PTGER2 | PTGER2 | Prostaglandin E2 receptor EP2 subtype | diabetic nephropathy | ALPROSTADIL | targetBased | 4 | Completed | 01/12/2015 | https://clinicaltrials.gov/study/NCT02628106 | 1 | GoF | protect | |
| Modulators of the EP2 prostaglandin E2 receptor - Primary Screening | PTGER2 | PTGER2 | Prostaglandin E2 receptor EP2 subtype | diabetic nephropathy | ALPROSTADIL | targetBased | 4 | Completed | 01/12/2015 | https://clinicaltrials.gov/study/NCT02628106 | 1 | GoF | protect | |
| HTS for Beta-2AR agonists via FAP method | ADRB2_activators | ADRB2 | Beta-2 adrenergic receptor | portal hypertension | TIMOLOL | targetBased | 3 | Completed | 01/08/1993 | https://clinicaltrials.gov/study/NCT00006398 | 0.7 | LoF | protect | |
| High Throughput Screening for Cocaine Antagonists: Primary Screen | SLC6A3 | SLC6A3 | Sodium-dependent dopamine transporter | obesity | AMPHETAMINE SULFATE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f469fb38-0380-4621-9db3-a4f429126156 | 1 | protect | ||||
| HCS assay for microtubule stabilizers | TUBB | TUBB | Tubulin beta chain | Cachexia | DOCETAXEL | targetBased | 3 | Completed | 01/10/2002 | https://clinicaltrials.gov/study/NCT00040885 | 0.7 | LoF | protect | |
| HCS assay for microtubule stabilizers | TUBB | TUBB | Tubulin beta chain | drug-induced liver injury | DOCETAXEL | targetBased | 4 | Unknown status | 10/02/2017 | https://clinicaltrials.gov/study/NCT03069820 | 1 | LoF | protect | |
| HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1 | TRPV1 | TRPV1 | Transient receptor potential cation channel subfamily V member 1 | obesity | ACETAMINOPHEN | targetBased | 4 | Completed | 01/02/2016 | https://clinicaltrials.gov/study/NCT02452320 | 1 | protect | ||
| HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1 | TRPV1 | TRPV1 | Transient receptor potential cation channel subfamily V member 1 | obesity | ACETAMINOPHEN | targetBased | 3 | Recruiting | 01/08/2016 | https://clinicaltrials.gov/study/NCT03192566 | 0.7 | protect | ||
| HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1 | TRPV1 | TRPV1 | Transient receptor potential cation channel subfamily V member 1 | acute pancreatitis | ACETAMINOPHEN | targetBased | 3 | Completed | 06/06/2014 | https://clinicaltrials.gov/study/NCT02126332 | 0.7 | protect | ||
| HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1 | TRPV1 | TRPV1 | Transient receptor potential cation channel subfamily V member 1 | type 2 diabetes mellitus | ACETAMINOPHEN | targetBased | 4 | Completed | 01/07/2014 | https://clinicaltrials.gov/study/NCT02180334 | 1 | protect | ||
| HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1 | TRPV1 | TRPV1 | Transient receptor potential cation channel subfamily V member 1 | gallstones | ACETAMINOPHEN | targetBased | 4 | Completed | 01/01/2015 | https://clinicaltrials.gov/study/NCT02327923 | 1 | protect | ||
| HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1 | TRPV1 | TRPV1 | Transient receptor potential cation channel subfamily V member 1 | morbid obesity | ACETAMINOPHEN | targetBased | 4 | Completed | 01/01/2016 | https://clinicaltrials.gov/study/NCT02778958 | 1 | protect | ||
| HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1 | TRPV1 | TRPV1 | Transient receptor potential cation channel subfamily V member 1 | morbid obesity | ACETAMINOPHEN | targetBased | 4 | Completed | 01/12/2012 | https://clinicaltrials.gov/study/NCT01764555 | 1 | protect | ||
| HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1 | TRPV1 | TRPV1 | Transient receptor potential cation channel subfamily V member 1 | morbid obesity | ACETAMINOPHEN | targetBased | 4 | Recruiting | 20/01/2021 | https://clinicaltrials.gov/study/NCT04240626 | 1 | protect | ||
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | insulin resistance | PIOGLITAZONE | targetBased | 3 | Not yet recruiting | 01/11/2022 | https://clinicaltrials.gov/study/NCT05591235 | 0.7 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | insulin resistance | PIOGLITAZONE | targetBased | 3 | Not yet recruiting | 01/11/2022 | https://clinicaltrials.gov/study/NCT05591235 | 0.7 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | insulin resistance | PIOGLITAZONE | targetBased | 3 | Not yet recruiting | 01/11/2022 | https://clinicaltrials.gov/study/NCT05591235 | 0.7 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | insulin resistance | PIOGLITAZONE | targetBased | 3 | Not yet recruiting | 01/11/2022 | https://clinicaltrials.gov/study/NCT05591235 | 0.7 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | insulin resistance | PIOGLITAZONE | targetBased | 3 | Not yet recruiting | 01/11/2022 | https://clinicaltrials.gov/study/NCT05591235 | 0.7 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | insulin resistance | PIOGLITAZONE | targetBased | 3 | Not yet recruiting | 01/11/2022 | https://clinicaltrials.gov/study/NCT05591235 | 0.7 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | liver disease | PIOGLITAZONE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=42e49120-6f3f-11db-9fe1-0800200c9a66 | 1 | GoF | protect | |||
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | liver disease | PIOGLITAZONE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=42e49120-6f3f-11db-9fe1-0800200c9a66 | 1 | GoF | protect | |||
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | liver disease | PIOGLITAZONE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=42e49120-6f3f-11db-9fe1-0800200c9a66 | 1 | GoF | protect | |||
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | liver disease | PIOGLITAZONE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=42e49120-6f3f-11db-9fe1-0800200c9a66 | 1 | GoF | protect | |||
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | liver disease | PIOGLITAZONE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=42e49120-6f3f-11db-9fe1-0800200c9a66 | 1 | GoF | protect | |||
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | liver disease | PIOGLITAZONE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=42e49120-6f3f-11db-9fe1-0800200c9a66 | 1 | GoF | protect | |||
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | liver disease | PIOGLITAZONE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f8b0c917-3fdd-4a28-a47d-6225b8195458 | 1 | GoF | protect | |||
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | liver disease | PIOGLITAZONE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f8b0c917-3fdd-4a28-a47d-6225b8195458 | 1 | GoF | protect | |||
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | liver disease | PIOGLITAZONE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f8b0c917-3fdd-4a28-a47d-6225b8195458 | 1 | GoF | protect | |||
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | liver disease | PIOGLITAZONE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f8b0c917-3fdd-4a28-a47d-6225b8195458 | 1 | GoF | protect | |||
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | liver disease | PIOGLITAZONE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f8b0c917-3fdd-4a28-a47d-6225b8195458 | 1 | GoF | protect | |||
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | liver disease | PIOGLITAZONE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f8b0c917-3fdd-4a28-a47d-6225b8195458 | 1 | GoF | protect | |||
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | liver disease | PIOGLITAZONE | targetBased | 3 | Completed | 01/01/2005 | https://clinicaltrials.gov/study/NCT00063622 | 0.7 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | liver disease | PIOGLITAZONE | targetBased | 3 | Completed | 01/01/2005 | https://clinicaltrials.gov/study/NCT00063622 | 0.7 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | liver disease | PIOGLITAZONE | targetBased | 3 | Completed | 01/01/2005 | https://clinicaltrials.gov/study/NCT00063622 | 0.7 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | liver disease | PIOGLITAZONE | targetBased | 3 | Completed | 01/01/2005 | https://clinicaltrials.gov/study/NCT00063622 | 0.7 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | liver disease | PIOGLITAZONE | targetBased | 3 | Completed | 01/01/2005 | https://clinicaltrials.gov/study/NCT00063622 | 0.7 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | liver disease | PIOGLITAZONE | targetBased | 3 | Completed | 01/01/2005 | https://clinicaltrials.gov/study/NCT00063622 | 0.7 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | liver disease | PIOGLITAZONE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7f6e4b4d-7480-444f-e053-2a91aa0a62ec | 1 | GoF | protect | |||
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | liver disease | PIOGLITAZONE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7f6e4b4d-7480-444f-e053-2a91aa0a62ec | 1 | GoF | protect | |||
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | liver disease | PIOGLITAZONE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7f6e4b4d-7480-444f-e053-2a91aa0a62ec | 1 | GoF | protect | |||
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | liver disease | PIOGLITAZONE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7f6e4b4d-7480-444f-e053-2a91aa0a62ec | 1 | GoF | protect | |||
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | liver disease | PIOGLITAZONE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7f6e4b4d-7480-444f-e053-2a91aa0a62ec | 1 | GoF | protect | |||
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | liver disease | PIOGLITAZONE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7f6e4b4d-7480-444f-e053-2a91aa0a62ec | 1 | GoF | protect | |||
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | non-alcoholic fatty liver disease | PIOGLITAZONE | targetBased | 3 | Not yet recruiting | 01/11/2022 | https://clinicaltrials.gov/study/NCT05605158 | 0.7 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | non-alcoholic fatty liver disease | PIOGLITAZONE | targetBased | 3 | Not yet recruiting | 01/11/2022 | https://clinicaltrials.gov/study/NCT05605158 | 0.7 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | non-alcoholic fatty liver disease | PIOGLITAZONE | targetBased | 3 | Not yet recruiting | 01/11/2022 | https://clinicaltrials.gov/study/NCT05605158 | 0.7 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | non-alcoholic fatty liver disease | PIOGLITAZONE | targetBased | 3 | Not yet recruiting | 01/11/2022 | https://clinicaltrials.gov/study/NCT05605158 | 0.7 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | non-alcoholic fatty liver disease | PIOGLITAZONE | targetBased | 3 | Not yet recruiting | 01/11/2022 | https://clinicaltrials.gov/study/NCT05605158 | 0.7 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | non-alcoholic fatty liver disease | PIOGLITAZONE | targetBased | 3 | Not yet recruiting | 01/11/2022 | https://clinicaltrials.gov/study/NCT05605158 | 0.7 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | non-alcoholic fatty liver disease | PIOGLITAZONE | targetBased | 3 | Completed | 06/06/2019 | https://clinicaltrials.gov/study/NCT05521633 | 0.7 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | non-alcoholic fatty liver disease | PIOGLITAZONE | targetBased | 3 | Completed | 06/06/2019 | https://clinicaltrials.gov/study/NCT05521633 | 0.7 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | non-alcoholic fatty liver disease | PIOGLITAZONE | targetBased | 3 | Completed | 06/06/2019 | https://clinicaltrials.gov/study/NCT05521633 | 0.7 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | non-alcoholic fatty liver disease | PIOGLITAZONE | targetBased | 3 | Completed | 06/06/2019 | https://clinicaltrials.gov/study/NCT05521633 | 0.7 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | non-alcoholic fatty liver disease | PIOGLITAZONE | targetBased | 3 | Completed | 06/06/2019 | https://clinicaltrials.gov/study/NCT05521633 | 0.7 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | non-alcoholic fatty liver disease | PIOGLITAZONE | targetBased | 3 | Completed | 06/06/2019 | https://clinicaltrials.gov/study/NCT05521633 | 0.7 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | non-alcoholic fatty liver disease | PIOGLITAZONE | targetBased | 4 | Completed | 15/02/2023 | https://clinicaltrials.gov/study/NCT05813249 | 1 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | non-alcoholic fatty liver disease | PIOGLITAZONE | targetBased | 4 | Completed | 15/02/2023 | https://clinicaltrials.gov/study/NCT05813249 | 1 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | non-alcoholic fatty liver disease | PIOGLITAZONE | targetBased | 4 | Completed | 15/02/2023 | https://clinicaltrials.gov/study/NCT05813249 | 1 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | non-alcoholic fatty liver disease | PIOGLITAZONE | targetBased | 4 | Completed | 15/02/2023 | https://clinicaltrials.gov/study/NCT05813249 | 1 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | non-alcoholic fatty liver disease | PIOGLITAZONE | targetBased | 4 | Completed | 15/02/2023 | https://clinicaltrials.gov/study/NCT05813249 | 1 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | non-alcoholic fatty liver disease | PIOGLITAZONE | targetBased | 4 | Completed | 15/02/2023 | https://clinicaltrials.gov/study/NCT05813249 | 1 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 1 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | Recruiting | 08/08/2019 | https://clinicaltrials.gov/study/NCT03878459 | 1 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 1 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | Recruiting | 08/08/2019 | https://clinicaltrials.gov/study/NCT03878459 | 1 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 1 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | Recruiting | 08/08/2019 | https://clinicaltrials.gov/study/NCT03878459 | 1 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 1 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | Recruiting | 08/08/2019 | https://clinicaltrials.gov/study/NCT03878459 | 1 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 1 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | Recruiting | 08/08/2019 | https://clinicaltrials.gov/study/NCT03878459 | 1 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 1 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | Recruiting | 08/08/2019 | https://clinicaltrials.gov/study/NCT03878459 | 1 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1f93fa66-c086-4811-a9ae-7b76bfafef2b | 1 | GoF | protect | |||
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1f93fa66-c086-4811-a9ae-7b76bfafef2b | 1 | GoF | protect | |||
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1f93fa66-c086-4811-a9ae-7b76bfafef2b | 1 | GoF | protect | |||
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1f93fa66-c086-4811-a9ae-7b76bfafef2b | 1 | GoF | protect | |||
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1f93fa66-c086-4811-a9ae-7b76bfafef2b | 1 | GoF | protect | |||
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1f93fa66-c086-4811-a9ae-7b76bfafef2b | 1 | GoF | protect | |||
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | Completed | 01/05/2008 | https://clinicaltrials.gov/study/NCT00656864 | 1 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | Completed | 01/05/2008 | https://clinicaltrials.gov/study/NCT00656864 | 1 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | Completed | 01/05/2008 | https://clinicaltrials.gov/study/NCT00656864 | 1 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | Completed | 01/05/2008 | https://clinicaltrials.gov/study/NCT00656864 | 1 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | Completed | 01/05/2008 | https://clinicaltrials.gov/study/NCT00656864 | 1 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | Completed | 01/05/2008 | https://clinicaltrials.gov/study/NCT00656864 | 1 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4c619ed9-fe3e-4158-9938-80c6c3493d55 | 1 | GoF | protect | |||
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4c619ed9-fe3e-4158-9938-80c6c3493d55 | 1 | GoF | protect | |||
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4c619ed9-fe3e-4158-9938-80c6c3493d55 | 1 | GoF | protect | |||
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4c619ed9-fe3e-4158-9938-80c6c3493d55 | 1 | GoF | protect | |||
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4c619ed9-fe3e-4158-9938-80c6c3493d55 | 1 | GoF | protect | |||
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4c619ed9-fe3e-4158-9938-80c6c3493d55 | 1 | GoF | protect | |||
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | Unknown status | 01/09/2014 | https://clinicaltrials.gov/study/NCT02315287 | 1 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | Unknown status | 01/09/2014 | https://clinicaltrials.gov/study/NCT02315287 | 1 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | Unknown status | 01/09/2014 | https://clinicaltrials.gov/study/NCT02315287 | 1 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | Unknown status | 01/09/2014 | https://clinicaltrials.gov/study/NCT02315287 | 1 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | Unknown status | 01/09/2014 | https://clinicaltrials.gov/study/NCT02315287 | 1 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | Unknown status | 01/09/2014 | https://clinicaltrials.gov/study/NCT02315287 | 1 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 3 | Completed | 01/01/2008 | https://clinicaltrials.gov/study/NCT00637273 | 0.7 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 3 | Completed | 01/01/2008 | https://clinicaltrials.gov/study/NCT00637273 | 0.7 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 3 | Completed | 01/01/2008 | https://clinicaltrials.gov/study/NCT00637273 | 0.7 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 3 | Completed | 01/01/2008 | https://clinicaltrials.gov/study/NCT00637273 | 0.7 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 3 | Completed | 01/01/2008 | https://clinicaltrials.gov/study/NCT00637273 | 0.7 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 3 | Completed | 01/01/2008 | https://clinicaltrials.gov/study/NCT00637273 | 0.7 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 3 | Completed | 06/07/2016 | https://clinicaltrials.gov/study/NCT02787551 | 0.7 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 3 | Completed | 06/07/2016 | https://clinicaltrials.gov/study/NCT02787551 | 0.7 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 3 | Completed | 06/07/2016 | https://clinicaltrials.gov/study/NCT02787551 | 0.7 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 3 | Completed | 06/07/2016 | https://clinicaltrials.gov/study/NCT02787551 | 0.7 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 3 | Completed | 06/07/2016 | https://clinicaltrials.gov/study/NCT02787551 | 0.7 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 3 | Completed | 06/07/2016 | https://clinicaltrials.gov/study/NCT02787551 | 0.7 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | Completed | 01/08/2009 | https://clinicaltrials.gov/study/NCT01223196 | 1 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | Completed | 01/08/2009 | https://clinicaltrials.gov/study/NCT01223196 | 1 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | Completed | 01/08/2009 | https://clinicaltrials.gov/study/NCT01223196 | 1 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | Completed | 01/08/2009 | https://clinicaltrials.gov/study/NCT01223196 | 1 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | Completed | 01/08/2009 | https://clinicaltrials.gov/study/NCT01223196 | 1 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | Completed | 01/08/2009 | https://clinicaltrials.gov/study/NCT01223196 | 1 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | Completed | 18/09/2020 | https://clinicaltrials.gov/study/NCT04535700 | 1 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | Completed | 18/09/2020 | https://clinicaltrials.gov/study/NCT04535700 | 1 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | Completed | 18/09/2020 | https://clinicaltrials.gov/study/NCT04535700 | 1 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | Completed | 18/09/2020 | https://clinicaltrials.gov/study/NCT04535700 | 1 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | Completed | 18/09/2020 | https://clinicaltrials.gov/study/NCT04535700 | 1 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | Completed | 18/09/2020 | https://clinicaltrials.gov/study/NCT04535700 | 1 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 3 | Completed | 03/06/2010 | https://clinicaltrials.gov/study/NCT01076075 | 0.7 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 3 | Completed | 03/06/2010 | https://clinicaltrials.gov/study/NCT01076075 | 0.7 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 3 | Completed | 03/06/2010 | https://clinicaltrials.gov/study/NCT01076075 | 0.7 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 3 | Completed | 03/06/2010 | https://clinicaltrials.gov/study/NCT01076075 | 0.7 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 3 | Completed | 03/06/2010 | https://clinicaltrials.gov/study/NCT01076075 | 0.7 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 3 | Completed | 03/06/2010 | https://clinicaltrials.gov/study/NCT01076075 | 0.7 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | Completed | 01/04/2004 | https://clinicaltrials.gov/study/NCT00609856 | 1 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | Completed | 01/04/2004 | https://clinicaltrials.gov/study/NCT00609856 | 1 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | Completed | 01/04/2004 | https://clinicaltrials.gov/study/NCT00609856 | 1 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | Completed | 01/04/2004 | https://clinicaltrials.gov/study/NCT00609856 | 1 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | Completed | 01/04/2004 | https://clinicaltrials.gov/study/NCT00609856 | 1 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | Completed | 01/04/2004 | https://clinicaltrials.gov/study/NCT00609856 | 1 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=fb49b7d6-8071-44c7-a10c-e8116d7d5b42 | 1 | GoF | protect | |||
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=fb49b7d6-8071-44c7-a10c-e8116d7d5b42 | 1 | GoF | protect | |||
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=fb49b7d6-8071-44c7-a10c-e8116d7d5b42 | 1 | GoF | protect | |||
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=fb49b7d6-8071-44c7-a10c-e8116d7d5b42 | 1 | GoF | protect | |||
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=fb49b7d6-8071-44c7-a10c-e8116d7d5b42 | 1 | GoF | protect | |||
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=fb49b7d6-8071-44c7-a10c-e8116d7d5b42 | 1 | GoF | protect | |||
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 3 | Completed | 01/08/2005 | https://clinicaltrials.gov/study/NCT00106808 | 0.7 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 3 | Completed | 01/08/2005 | https://clinicaltrials.gov/study/NCT00106808 | 0.7 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 3 | Completed | 01/08/2005 | https://clinicaltrials.gov/study/NCT00106808 | 0.7 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 3 | Completed | 01/08/2005 | https://clinicaltrials.gov/study/NCT00106808 | 0.7 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 3 | Completed | 01/08/2005 | https://clinicaltrials.gov/study/NCT00106808 | 0.7 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 3 | Completed | 01/08/2005 | https://clinicaltrials.gov/study/NCT00106808 | 0.7 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2aab19ce-1e5e-44ee-85e5-d8f125f9bb1a | 1 | GoF | protect | |||
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2aab19ce-1e5e-44ee-85e5-d8f125f9bb1a | 1 | GoF | protect | |||
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2aab19ce-1e5e-44ee-85e5-d8f125f9bb1a | 1 | GoF | protect | |||
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2aab19ce-1e5e-44ee-85e5-d8f125f9bb1a | 1 | GoF | protect | |||
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2aab19ce-1e5e-44ee-85e5-d8f125f9bb1a | 1 | GoF | protect | |||
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2aab19ce-1e5e-44ee-85e5-d8f125f9bb1a | 1 | GoF | protect | |||
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5e36173a-2b5f-4ed7-bf81-6e79d78df0c4 | 1 | GoF | protect | |||
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5e36173a-2b5f-4ed7-bf81-6e79d78df0c4 | 1 | GoF | protect | |||
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5e36173a-2b5f-4ed7-bf81-6e79d78df0c4 | 1 | GoF | protect | |||
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5e36173a-2b5f-4ed7-bf81-6e79d78df0c4 | 1 | GoF | protect | |||
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5e36173a-2b5f-4ed7-bf81-6e79d78df0c4 | 1 | GoF | protect | |||
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5e36173a-2b5f-4ed7-bf81-6e79d78df0c4 | 1 | GoF | protect | |||
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=91385f6c-ba70-4247-88f4-5f3b25ddd6b3 | 1 | GoF | protect | |||
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=91385f6c-ba70-4247-88f4-5f3b25ddd6b3 | 1 | GoF | protect | |||
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=91385f6c-ba70-4247-88f4-5f3b25ddd6b3 | 1 | GoF | protect | |||
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=91385f6c-ba70-4247-88f4-5f3b25ddd6b3 | 1 | GoF | protect | |||
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=91385f6c-ba70-4247-88f4-5f3b25ddd6b3 | 1 | GoF | protect | |||
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=91385f6c-ba70-4247-88f4-5f3b25ddd6b3 | 1 | GoF | protect | |||
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | Unknown status | 01/10/2005 | https://clinicaltrials.gov/study/NCT02142309 | 1 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | Unknown status | 01/10/2005 | https://clinicaltrials.gov/study/NCT02142309 | 1 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | Unknown status | 01/10/2005 | https://clinicaltrials.gov/study/NCT02142309 | 1 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | Unknown status | 01/10/2005 | https://clinicaltrials.gov/study/NCT02142309 | 1 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | Unknown status | 01/10/2005 | https://clinicaltrials.gov/study/NCT02142309 | 1 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | Unknown status | 01/10/2005 | https://clinicaltrials.gov/study/NCT02142309 | 1 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 3 | Recruiting | 10/04/2022 | https://clinicaltrials.gov/study/NCT05629806 | 0.7 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 3 | Recruiting | 10/04/2022 | https://clinicaltrials.gov/study/NCT05629806 | 0.7 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 3 | Recruiting | 10/04/2022 | https://clinicaltrials.gov/study/NCT05629806 | 0.7 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 3 | Recruiting | 10/04/2022 | https://clinicaltrials.gov/study/NCT05629806 | 0.7 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 3 | Recruiting | 10/04/2022 | https://clinicaltrials.gov/study/NCT05629806 | 0.7 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 3 | Recruiting | 10/04/2022 | https://clinicaltrials.gov/study/NCT05629806 | 0.7 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 3 | Completed | 01/05/2009 | https://clinicaltrials.gov/study/NCT00909597 | 0.7 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 3 | Completed | 01/05/2009 | https://clinicaltrials.gov/study/NCT00909597 | 0.7 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 3 | Completed | 01/05/2009 | https://clinicaltrials.gov/study/NCT00909597 | 0.7 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 3 | Completed | 01/05/2009 | https://clinicaltrials.gov/study/NCT00909597 | 0.7 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 3 | Completed | 01/05/2009 | https://clinicaltrials.gov/study/NCT00909597 | 0.7 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 3 | Completed | 01/05/2009 | https://clinicaltrials.gov/study/NCT00909597 | 0.7 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f986164c-51a7-41c2-8952-511b8f46d593 | 1 | GoF | protect | |||
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f986164c-51a7-41c2-8952-511b8f46d593 | 1 | GoF | protect | |||
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f986164c-51a7-41c2-8952-511b8f46d593 | 1 | GoF | protect | |||
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f986164c-51a7-41c2-8952-511b8f46d593 | 1 | GoF | protect | |||
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f986164c-51a7-41c2-8952-511b8f46d593 | 1 | GoF | protect | |||
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f986164c-51a7-41c2-8952-511b8f46d593 | 1 | GoF | protect | |||
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 3 | Completed | 06/10/2004 | https://clinicaltrials.gov/study/NCT00094757 | 0.7 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 3 | Completed | 06/10/2004 | https://clinicaltrials.gov/study/NCT00094757 | 0.7 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 3 | Completed | 06/10/2004 | https://clinicaltrials.gov/study/NCT00094757 | 0.7 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 3 | Completed | 06/10/2004 | https://clinicaltrials.gov/study/NCT00094757 | 0.7 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 3 | Completed | 06/10/2004 | https://clinicaltrials.gov/study/NCT00094757 | 0.7 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 3 | Completed | 06/10/2004 | https://clinicaltrials.gov/study/NCT00094757 | 0.7 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | https://www.ema.europa.eu/en/medicines/human/EPAR/glidipion | 1 | GoF | protect | |||
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | https://www.ema.europa.eu/en/medicines/human/EPAR/glidipion | 1 | GoF | protect | |||
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | https://www.ema.europa.eu/en/medicines/human/EPAR/glidipion | 1 | GoF | protect | |||
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | https://www.ema.europa.eu/en/medicines/human/EPAR/glidipion | 1 | GoF | protect | |||
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | https://www.ema.europa.eu/en/medicines/human/EPAR/glidipion | 1 | GoF | protect | |||
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | https://www.ema.europa.eu/en/medicines/human/EPAR/glidipion | 1 | GoF | protect | |||
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 3 | Completed | 01/05/2010 | https://clinicaltrials.gov/study/NCT01106131 | 0.7 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 3 | Completed | 01/05/2010 | https://clinicaltrials.gov/study/NCT01106131 | 0.7 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 3 | Completed | 01/05/2010 | https://clinicaltrials.gov/study/NCT01106131 | 0.7 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 3 | Completed | 01/05/2010 | https://clinicaltrials.gov/study/NCT01106131 | 0.7 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 3 | Completed | 01/05/2010 | https://clinicaltrials.gov/study/NCT01106131 | 0.7 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 3 | Completed | 01/05/2010 | https://clinicaltrials.gov/study/NCT01106131 | 0.7 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7f6e4b4d-7480-444f-e053-2a91aa0a62ec | 1 | GoF | protect | |||
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7f6e4b4d-7480-444f-e053-2a91aa0a62ec | 1 | GoF | protect | |||
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7f6e4b4d-7480-444f-e053-2a91aa0a62ec | 1 | GoF | protect | |||
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7f6e4b4d-7480-444f-e053-2a91aa0a62ec | 1 | GoF | protect | |||
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7f6e4b4d-7480-444f-e053-2a91aa0a62ec | 1 | GoF | protect | |||
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7f6e4b4d-7480-444f-e053-2a91aa0a62ec | 1 | GoF | protect | |||
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1fa2703e-fb73-44d5-aaa2-b12b1090d42c | 1 | GoF | protect | |||
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1fa2703e-fb73-44d5-aaa2-b12b1090d42c | 1 | GoF | protect | |||
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1fa2703e-fb73-44d5-aaa2-b12b1090d42c | 1 | GoF | protect | |||
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1fa2703e-fb73-44d5-aaa2-b12b1090d42c | 1 | GoF | protect | |||
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1fa2703e-fb73-44d5-aaa2-b12b1090d42c | 1 | GoF | protect | |||
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1fa2703e-fb73-44d5-aaa2-b12b1090d42c | 1 | GoF | protect | |||
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 3 | Not yet recruiting | 01/07/2024 | https://clinicaltrials.gov/study/NCT06246799 | 0.7 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 3 | Not yet recruiting | 01/07/2024 | https://clinicaltrials.gov/study/NCT06246799 | 0.7 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 3 | Not yet recruiting | 01/07/2024 | https://clinicaltrials.gov/study/NCT06246799 | 0.7 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 3 | Not yet recruiting | 01/07/2024 | https://clinicaltrials.gov/study/NCT06246799 | 0.7 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 3 | Not yet recruiting | 01/07/2024 | https://clinicaltrials.gov/study/NCT06246799 | 0.7 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 3 | Not yet recruiting | 01/07/2024 | https://clinicaltrials.gov/study/NCT06246799 | 0.7 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 3 | Completed | 23/04/2007 | https://clinicaltrials.gov/study/NCT00484198 | 0.7 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 3 | Completed | 23/04/2007 | https://clinicaltrials.gov/study/NCT00484198 | 0.7 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 3 | Completed | 23/04/2007 | https://clinicaltrials.gov/study/NCT00484198 | 0.7 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 3 | Completed | 23/04/2007 | https://clinicaltrials.gov/study/NCT00484198 | 0.7 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 3 | Completed | 23/04/2007 | https://clinicaltrials.gov/study/NCT00484198 | 0.7 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 3 | Completed | 23/04/2007 | https://clinicaltrials.gov/study/NCT00484198 | 0.7 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 3 | Completed | 15/01/2008 | https://clinicaltrials.gov/study/NCT00541450 | 0.7 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 3 | Completed | 15/01/2008 | https://clinicaltrials.gov/study/NCT00541450 | 0.7 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 3 | Completed | 15/01/2008 | https://clinicaltrials.gov/study/NCT00541450 | 0.7 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 3 | Completed | 15/01/2008 | https://clinicaltrials.gov/study/NCT00541450 | 0.7 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 3 | Completed | 15/01/2008 | https://clinicaltrials.gov/study/NCT00541450 | 0.7 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 3 | Completed | 15/01/2008 | https://clinicaltrials.gov/study/NCT00541450 | 0.7 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 3 | Completed | 01/04/2008 | https://clinicaltrials.gov/study/NCT00680745 | 0.7 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 3 | Completed | 01/04/2008 | https://clinicaltrials.gov/study/NCT00680745 | 0.7 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 3 | Completed | 01/04/2008 | https://clinicaltrials.gov/study/NCT00680745 | 0.7 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 3 | Completed | 01/04/2008 | https://clinicaltrials.gov/study/NCT00680745 | 0.7 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 3 | Completed | 01/04/2008 | https://clinicaltrials.gov/study/NCT00680745 | 0.7 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 3 | Completed | 01/04/2008 | https://clinicaltrials.gov/study/NCT00680745 | 0.7 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | Completed | 01/01/2012 | https://clinicaltrials.gov/study/NCT02099838 | 1 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | Completed | 01/01/2012 | https://clinicaltrials.gov/study/NCT02099838 | 1 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | Completed | 01/01/2012 | https://clinicaltrials.gov/study/NCT02099838 | 1 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | Completed | 01/01/2012 | https://clinicaltrials.gov/study/NCT02099838 | 1 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | Completed | 01/01/2012 | https://clinicaltrials.gov/study/NCT02099838 | 1 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | Completed | 01/01/2012 | https://clinicaltrials.gov/study/NCT02099838 | 1 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 3 | Completed | 01/02/2015 | https://clinicaltrials.gov/study/NCT03125694 | 0.7 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 3 | Completed | 01/02/2015 | https://clinicaltrials.gov/study/NCT03125694 | 0.7 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 3 | Completed | 01/02/2015 | https://clinicaltrials.gov/study/NCT03125694 | 0.7 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 3 | Completed | 01/02/2015 | https://clinicaltrials.gov/study/NCT03125694 | 0.7 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 3 | Completed | 01/02/2015 | https://clinicaltrials.gov/study/NCT03125694 | 0.7 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 3 | Completed | 01/02/2015 | https://clinicaltrials.gov/study/NCT03125694 | 0.7 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | Withdrawn | 01/01/2006 | https://clinicaltrials.gov/study/NCT00399204 | 1 | GoF | protect | lack of funding |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | Withdrawn | 01/01/2006 | https://clinicaltrials.gov/study/NCT00399204 | 1 | GoF | protect | lack of funding |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | Withdrawn | 01/01/2006 | https://clinicaltrials.gov/study/NCT00399204 | 1 | GoF | protect | lack of funding |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | Withdrawn | 01/01/2006 | https://clinicaltrials.gov/study/NCT00399204 | 1 | GoF | protect | lack of funding |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | Withdrawn | 01/01/2006 | https://clinicaltrials.gov/study/NCT00399204 | 1 | GoF | protect | lack of funding |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | Withdrawn | 01/01/2006 | https://clinicaltrials.gov/study/NCT00399204 | 1 | GoF | protect | lack of funding |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5c81c67-90cf-4e64-acb5-58b0358fa742 | 1 | GoF | protect | |||
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5c81c67-90cf-4e64-acb5-58b0358fa742 | 1 | GoF | protect | |||
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5c81c67-90cf-4e64-acb5-58b0358fa742 | 1 | GoF | protect | |||
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5c81c67-90cf-4e64-acb5-58b0358fa742 | 1 | GoF | protect | |||
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5c81c67-90cf-4e64-acb5-58b0358fa742 | 1 | GoF | protect | |||
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5c81c67-90cf-4e64-acb5-58b0358fa742 | 1 | GoF | protect | |||
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | Completed | 01/09/2013 | https://clinicaltrials.gov/study/NCT01947790 | 1 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | Completed | 01/09/2013 | https://clinicaltrials.gov/study/NCT01947790 | 1 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | Completed | 01/09/2013 | https://clinicaltrials.gov/study/NCT01947790 | 1 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | Completed | 01/09/2013 | https://clinicaltrials.gov/study/NCT01947790 | 1 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | Completed | 01/09/2013 | https://clinicaltrials.gov/study/NCT01947790 | 1 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | Completed | 01/09/2013 | https://clinicaltrials.gov/study/NCT01947790 | 1 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | Completed | 01/10/2007 | https://clinicaltrials.gov/study/NCT00815399 | 1 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | Completed | 01/10/2007 | https://clinicaltrials.gov/study/NCT00815399 | 1 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | Completed | 01/10/2007 | https://clinicaltrials.gov/study/NCT00815399 | 1 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | Completed | 01/10/2007 | https://clinicaltrials.gov/study/NCT00815399 | 1 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | Completed | 01/10/2007 | https://clinicaltrials.gov/study/NCT00815399 | 1 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | Completed | 01/10/2007 | https://clinicaltrials.gov/study/NCT00815399 | 1 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 3 | Terminated | 01/03/2005 | https://clinicaltrials.gov/study/NCT00226330 | 0.7 | GoF | protect | The development program has been terminated |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 3 | Terminated | 01/03/2005 | https://clinicaltrials.gov/study/NCT00226330 | 0.7 | GoF | protect | The development program has been terminated |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 3 | Terminated | 01/03/2005 | https://clinicaltrials.gov/study/NCT00226330 | 0.7 | GoF | protect | The development program has been terminated |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 3 | Terminated | 01/03/2005 | https://clinicaltrials.gov/study/NCT00226330 | 0.7 | GoF | protect | The development program has been terminated |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 3 | Terminated | 01/03/2005 | https://clinicaltrials.gov/study/NCT00226330 | 0.7 | GoF | protect | The development program has been terminated |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 3 | Terminated | 01/03/2005 | https://clinicaltrials.gov/study/NCT00226330 | 0.7 | GoF | protect | The development program has been terminated |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 3 | Completed | 01/10/2008 | https://clinicaltrials.gov/study/NCT00744367 | 0.7 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 3 | Completed | 01/10/2008 | https://clinicaltrials.gov/study/NCT00744367 | 0.7 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 3 | Completed | 01/10/2008 | https://clinicaltrials.gov/study/NCT00744367 | 0.7 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 3 | Completed | 01/10/2008 | https://clinicaltrials.gov/study/NCT00744367 | 0.7 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 3 | Completed | 01/10/2008 | https://clinicaltrials.gov/study/NCT00744367 | 0.7 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 3 | Completed | 01/10/2008 | https://clinicaltrials.gov/study/NCT00744367 | 0.7 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f8b0c917-3fdd-4a28-a47d-6225b8195458 | 1 | GoF | protect | |||
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f8b0c917-3fdd-4a28-a47d-6225b8195458 | 1 | GoF | protect | |||
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f8b0c917-3fdd-4a28-a47d-6225b8195458 | 1 | GoF | protect | |||
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f8b0c917-3fdd-4a28-a47d-6225b8195458 | 1 | GoF | protect | |||
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f8b0c917-3fdd-4a28-a47d-6225b8195458 | 1 | GoF | protect | |||
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f8b0c917-3fdd-4a28-a47d-6225b8195458 | 1 | GoF | protect | |||
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c7dbc36d-3c84-488e-9b72-0593b5ed53a0 | 1 | GoF | protect | |||
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c7dbc36d-3c84-488e-9b72-0593b5ed53a0 | 1 | GoF | protect | |||
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c7dbc36d-3c84-488e-9b72-0593b5ed53a0 | 1 | GoF | protect | |||
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c7dbc36d-3c84-488e-9b72-0593b5ed53a0 | 1 | GoF | protect | |||
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c7dbc36d-3c84-488e-9b72-0593b5ed53a0 | 1 | GoF | protect | |||
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c7dbc36d-3c84-488e-9b72-0593b5ed53a0 | 1 | GoF | protect | |||
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | Completed | 01/03/2003 | https://clinicaltrials.gov/study/NCT00816218 | 1 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | Completed | 01/03/2003 | https://clinicaltrials.gov/study/NCT00816218 | 1 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | Completed | 01/03/2003 | https://clinicaltrials.gov/study/NCT00816218 | 1 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | Completed | 01/03/2003 | https://clinicaltrials.gov/study/NCT00816218 | 1 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | Completed | 01/03/2003 | https://clinicaltrials.gov/study/NCT00816218 | 1 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | Completed | 01/03/2003 | https://clinicaltrials.gov/study/NCT00816218 | 1 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | Completed | 01/02/2010 | https://clinicaltrials.gov/study/NCT01040819 | 1 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | Completed | 01/02/2010 | https://clinicaltrials.gov/study/NCT01040819 | 1 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | Completed | 01/02/2010 | https://clinicaltrials.gov/study/NCT01040819 | 1 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | Completed | 01/02/2010 | https://clinicaltrials.gov/study/NCT01040819 | 1 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | Completed | 01/02/2010 | https://clinicaltrials.gov/study/NCT01040819 | 1 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | Completed | 01/02/2010 | https://clinicaltrials.gov/study/NCT01040819 | 1 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 3 | Completed | 01/06/2010 | https://clinicaltrials.gov/study/NCT01106690 | 0.7 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 3 | Completed | 01/06/2010 | https://clinicaltrials.gov/study/NCT01106690 | 0.7 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 3 | Completed | 01/06/2010 | https://clinicaltrials.gov/study/NCT01106690 | 0.7 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 3 | Completed | 01/06/2010 | https://clinicaltrials.gov/study/NCT01106690 | 0.7 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 3 | Completed | 01/06/2010 | https://clinicaltrials.gov/study/NCT01106690 | 0.7 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 3 | Completed | 01/06/2010 | https://clinicaltrials.gov/study/NCT01106690 | 0.7 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 3 | Completed | 01/06/2010 | https://clinicaltrials.gov/study/NCT01095666 | 0.7 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 3 | Completed | 01/06/2010 | https://clinicaltrials.gov/study/NCT01095666 | 0.7 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 3 | Completed | 01/06/2010 | https://clinicaltrials.gov/study/NCT01095666 | 0.7 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 3 | Completed | 01/06/2010 | https://clinicaltrials.gov/study/NCT01095666 | 0.7 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 3 | Completed | 01/06/2010 | https://clinicaltrials.gov/study/NCT01095666 | 0.7 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 3 | Completed | 01/06/2010 | https://clinicaltrials.gov/study/NCT01095666 | 0.7 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8f2d7000-37ca-4e09-98ec-07d1c0354cb3 | 1 | GoF | protect | |||
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8f2d7000-37ca-4e09-98ec-07d1c0354cb3 | 1 | GoF | protect | |||
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8f2d7000-37ca-4e09-98ec-07d1c0354cb3 | 1 | GoF | protect | |||
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8f2d7000-37ca-4e09-98ec-07d1c0354cb3 | 1 | GoF | protect | |||
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8f2d7000-37ca-4e09-98ec-07d1c0354cb3 | 1 | GoF | protect | |||
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8f2d7000-37ca-4e09-98ec-07d1c0354cb3 | 1 | GoF | protect | |||
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1f259863-21fd-4d62-b094-4eff845944df | 1 | GoF | protect | |||
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1f259863-21fd-4d62-b094-4eff845944df | 1 | GoF | protect | |||
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1f259863-21fd-4d62-b094-4eff845944df | 1 | GoF | protect | |||
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1f259863-21fd-4d62-b094-4eff845944df | 1 | GoF | protect | |||
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1f259863-21fd-4d62-b094-4eff845944df | 1 | GoF | protect | |||
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1f259863-21fd-4d62-b094-4eff845944df | 1 | GoF | protect | |||
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ccf82737-754b-472e-a9bb-961fd1a3c307 | 1 | GoF | protect | |||
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ccf82737-754b-472e-a9bb-961fd1a3c307 | 1 | GoF | protect | |||
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ccf82737-754b-472e-a9bb-961fd1a3c307 | 1 | GoF | protect | |||
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ccf82737-754b-472e-a9bb-961fd1a3c307 | 1 | GoF | protect | |||
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ccf82737-754b-472e-a9bb-961fd1a3c307 | 1 | GoF | protect | |||
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ccf82737-754b-472e-a9bb-961fd1a3c307 | 1 | GoF | protect | |||
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 3 | Completed | 01/04/2008 | https://clinicaltrials.gov/study/NCT01156597 | 0.7 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 3 | Completed | 01/04/2008 | https://clinicaltrials.gov/study/NCT01156597 | 0.7 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 3 | Completed | 01/04/2008 | https://clinicaltrials.gov/study/NCT01156597 | 0.7 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 3 | Completed | 01/04/2008 | https://clinicaltrials.gov/study/NCT01156597 | 0.7 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 3 | Completed | 01/04/2008 | https://clinicaltrials.gov/study/NCT01156597 | 0.7 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 3 | Completed | 01/04/2008 | https://clinicaltrials.gov/study/NCT01156597 | 0.7 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | Terminated | 01/02/2014 | https://clinicaltrials.gov/study/NCT02072096 | 1 | GoF | protect | The trial was terminated per protocol because of lack of feasibility. |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | Terminated | 01/02/2014 | https://clinicaltrials.gov/study/NCT02072096 | 1 | GoF | protect | The trial was terminated per protocol because of lack of feasibility. |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | Terminated | 01/02/2014 | https://clinicaltrials.gov/study/NCT02072096 | 1 | GoF | protect | The trial was terminated per protocol because of lack of feasibility. |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | Terminated | 01/02/2014 | https://clinicaltrials.gov/study/NCT02072096 | 1 | GoF | protect | The trial was terminated per protocol because of lack of feasibility. |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | Terminated | 01/02/2014 | https://clinicaltrials.gov/study/NCT02072096 | 1 | GoF | protect | The trial was terminated per protocol because of lack of feasibility. |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | Terminated | 01/02/2014 | https://clinicaltrials.gov/study/NCT02072096 | 1 | GoF | protect | The trial was terminated per protocol because of lack of feasibility. |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a3ae5cba-f495-4593-b8fc-5ada34790745 | 1 | GoF | protect | |||
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a3ae5cba-f495-4593-b8fc-5ada34790745 | 1 | GoF | protect | |||
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a3ae5cba-f495-4593-b8fc-5ada34790745 | 1 | GoF | protect | |||
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a3ae5cba-f495-4593-b8fc-5ada34790745 | 1 | GoF | protect | |||
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a3ae5cba-f495-4593-b8fc-5ada34790745 | 1 | GoF | protect | |||
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a3ae5cba-f495-4593-b8fc-5ada34790745 | 1 | GoF | protect | |||
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | Terminated | 01/05/2009 | https://clinicaltrials.gov/study/NCT00879970 | 1 | GoF | protect | FDA has placed the trial on full clinical hold. |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | Terminated | 01/05/2009 | https://clinicaltrials.gov/study/NCT00879970 | 1 | GoF | protect | FDA has placed the trial on full clinical hold. |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | Terminated | 01/05/2009 | https://clinicaltrials.gov/study/NCT00879970 | 1 | GoF | protect | FDA has placed the trial on full clinical hold. |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | Terminated | 01/05/2009 | https://clinicaltrials.gov/study/NCT00879970 | 1 | GoF | protect | FDA has placed the trial on full clinical hold. |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | Terminated | 01/05/2009 | https://clinicaltrials.gov/study/NCT00879970 | 1 | GoF | protect | FDA has placed the trial on full clinical hold. |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | Terminated | 01/05/2009 | https://clinicaltrials.gov/study/NCT00879970 | 1 | GoF | protect | FDA has placed the trial on full clinical hold. |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 3 | Not yet recruiting | 01/03/2024 | https://clinicaltrials.gov/study/NCT05028140 | 0.7 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 3 | Not yet recruiting | 01/03/2024 | https://clinicaltrials.gov/study/NCT05028140 | 0.7 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 3 | Not yet recruiting | 01/03/2024 | https://clinicaltrials.gov/study/NCT05028140 | 0.7 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 3 | Not yet recruiting | 01/03/2024 | https://clinicaltrials.gov/study/NCT05028140 | 0.7 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 3 | Not yet recruiting | 01/03/2024 | https://clinicaltrials.gov/study/NCT05028140 | 0.7 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 3 | Not yet recruiting | 01/03/2024 | https://clinicaltrials.gov/study/NCT05028140 | 0.7 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=dc314f38-26dc-0b66-d533-065d90fe7375 | 1 | GoF | protect | |||
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=dc314f38-26dc-0b66-d533-065d90fe7375 | 1 | GoF | protect | |||
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=dc314f38-26dc-0b66-d533-065d90fe7375 | 1 | GoF | protect | |||
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=dc314f38-26dc-0b66-d533-065d90fe7375 | 1 | GoF | protect | |||
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=dc314f38-26dc-0b66-d533-065d90fe7375 | 1 | GoF | protect | |||
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=dc314f38-26dc-0b66-d533-065d90fe7375 | 1 | GoF | protect | |||
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 3 | Completed | 01/09/2007 | https://clinicaltrials.gov/study/NCT01028391 | 0.7 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 3 | Completed | 01/09/2007 | https://clinicaltrials.gov/study/NCT01028391 | 0.7 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 3 | Completed | 01/09/2007 | https://clinicaltrials.gov/study/NCT01028391 | 0.7 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 3 | Completed | 01/09/2007 | https://clinicaltrials.gov/study/NCT01028391 | 0.7 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 3 | Completed | 01/09/2007 | https://clinicaltrials.gov/study/NCT01028391 | 0.7 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 3 | Completed | 01/09/2007 | https://clinicaltrials.gov/study/NCT01028391 | 0.7 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 3 | Completed | 05/09/2008 | https://clinicaltrials.gov/study/NCT00722371 | 0.7 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 3 | Completed | 05/09/2008 | https://clinicaltrials.gov/study/NCT00722371 | 0.7 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 3 | Completed | 05/09/2008 | https://clinicaltrials.gov/study/NCT00722371 | 0.7 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 3 | Completed | 05/09/2008 | https://clinicaltrials.gov/study/NCT00722371 | 0.7 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 3 | Completed | 05/09/2008 | https://clinicaltrials.gov/study/NCT00722371 | 0.7 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 3 | Completed | 05/09/2008 | https://clinicaltrials.gov/study/NCT00722371 | 0.7 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 3 | Completed | 19/12/2006 | https://clinicaltrials.gov/study/NCT00397631 | 0.7 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 3 | Completed | 19/12/2006 | https://clinicaltrials.gov/study/NCT00397631 | 0.7 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 3 | Completed | 19/12/2006 | https://clinicaltrials.gov/study/NCT00397631 | 0.7 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 3 | Completed | 19/12/2006 | https://clinicaltrials.gov/study/NCT00397631 | 0.7 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 3 | Completed | 19/12/2006 | https://clinicaltrials.gov/study/NCT00397631 | 0.7 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 3 | Completed | 19/12/2006 | https://clinicaltrials.gov/study/NCT00397631 | 0.7 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | Terminated | 18/05/2016 | https://clinicaltrials.gov/study/NCT02763007 | 1 | GoF | protect | difficulty in recruiting patients |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | Terminated | 18/05/2016 | https://clinicaltrials.gov/study/NCT02763007 | 1 | GoF | protect | difficulty in recruiting patients |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | Terminated | 18/05/2016 | https://clinicaltrials.gov/study/NCT02763007 | 1 | GoF | protect | difficulty in recruiting patients |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | Terminated | 18/05/2016 | https://clinicaltrials.gov/study/NCT02763007 | 1 | GoF | protect | difficulty in recruiting patients |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | Terminated | 18/05/2016 | https://clinicaltrials.gov/study/NCT02763007 | 1 | GoF | protect | difficulty in recruiting patients |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | Terminated | 18/05/2016 | https://clinicaltrials.gov/study/NCT02763007 | 1 | GoF | protect | difficulty in recruiting patients |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=71b48b31-5b50-4c11-91a8-d3a8cc8e6bf8 | 1 | GoF | protect | |||
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=71b48b31-5b50-4c11-91a8-d3a8cc8e6bf8 | 1 | GoF | protect | |||
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=71b48b31-5b50-4c11-91a8-d3a8cc8e6bf8 | 1 | GoF | protect | |||
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=71b48b31-5b50-4c11-91a8-d3a8cc8e6bf8 | 1 | GoF | protect | |||
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=71b48b31-5b50-4c11-91a8-d3a8cc8e6bf8 | 1 | GoF | protect | |||
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=71b48b31-5b50-4c11-91a8-d3a8cc8e6bf8 | 1 | GoF | protect | |||
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b73e5856-e6f5-4239-80d9-fda136c4748b | 1 | GoF | protect | |||
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b73e5856-e6f5-4239-80d9-fda136c4748b | 1 | GoF | protect | |||
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b73e5856-e6f5-4239-80d9-fda136c4748b | 1 | GoF | protect | |||
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b73e5856-e6f5-4239-80d9-fda136c4748b | 1 | GoF | protect | |||
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b73e5856-e6f5-4239-80d9-fda136c4748b | 1 | GoF | protect | |||
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b73e5856-e6f5-4239-80d9-fda136c4748b | 1 | GoF | protect | |||
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 3 | Completed | 01/04/2009 | https://clinicaltrials.gov/study/NCT00789750 | 0.7 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 3 | Completed | 01/04/2009 | https://clinicaltrials.gov/study/NCT00789750 | 0.7 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 3 | Completed | 01/04/2009 | https://clinicaltrials.gov/study/NCT00789750 | 0.7 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 3 | Completed | 01/04/2009 | https://clinicaltrials.gov/study/NCT00789750 | 0.7 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 3 | Completed | 01/04/2009 | https://clinicaltrials.gov/study/NCT00789750 | 0.7 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 3 | Completed | 01/04/2009 | https://clinicaltrials.gov/study/NCT00789750 | 0.7 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | Completed | 01/06/2007 | https://clinicaltrials.gov/study/NCT01432405 | 1 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | Completed | 01/06/2007 | https://clinicaltrials.gov/study/NCT01432405 | 1 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | Completed | 01/06/2007 | https://clinicaltrials.gov/study/NCT01432405 | 1 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | Completed | 01/06/2007 | https://clinicaltrials.gov/study/NCT01432405 | 1 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | Completed | 01/06/2007 | https://clinicaltrials.gov/study/NCT01432405 | 1 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | Completed | 01/06/2007 | https://clinicaltrials.gov/study/NCT01432405 | 1 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=db790f58-3c27-49c3-b7f6-58344a14400e | 1 | GoF | protect | |||
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=db790f58-3c27-49c3-b7f6-58344a14400e | 1 | GoF | protect | |||
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=db790f58-3c27-49c3-b7f6-58344a14400e | 1 | GoF | protect | |||
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=db790f58-3c27-49c3-b7f6-58344a14400e | 1 | GoF | protect | |||
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=db790f58-3c27-49c3-b7f6-58344a14400e | 1 | GoF | protect | |||
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=db790f58-3c27-49c3-b7f6-58344a14400e | 1 | GoF | protect | |||
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 3 | Completed | 01/05/2006 | https://clinicaltrials.gov/study/NCT00328627 | 0.7 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 3 | Completed | 01/05/2006 | https://clinicaltrials.gov/study/NCT00328627 | 0.7 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 3 | Completed | 01/05/2006 | https://clinicaltrials.gov/study/NCT00328627 | 0.7 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 3 | Completed | 01/05/2006 | https://clinicaltrials.gov/study/NCT00328627 | 0.7 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 3 | Completed | 01/05/2006 | https://clinicaltrials.gov/study/NCT00328627 | 0.7 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 3 | Completed | 01/05/2006 | https://clinicaltrials.gov/study/NCT00328627 | 0.7 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7547c308-3c83-429c-b761-0610d775317d | 1 | GoF | protect | |||
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7547c308-3c83-429c-b761-0610d775317d | 1 | GoF | protect | |||
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7547c308-3c83-429c-b761-0610d775317d | 1 | GoF | protect | |||
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7547c308-3c83-429c-b761-0610d775317d | 1 | GoF | protect | |||
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7547c308-3c83-429c-b761-0610d775317d | 1 | GoF | protect | |||
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7547c308-3c83-429c-b761-0610d775317d | 1 | GoF | protect | |||
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=482cef76-0623-4b4f-a0ea-f008c97b2281 | 1 | GoF | protect | |||
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=482cef76-0623-4b4f-a0ea-f008c97b2281 | 1 | GoF | protect | |||
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=482cef76-0623-4b4f-a0ea-f008c97b2281 | 1 | GoF | protect | |||
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=482cef76-0623-4b4f-a0ea-f008c97b2281 | 1 | GoF | protect | |||
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=482cef76-0623-4b4f-a0ea-f008c97b2281 | 1 | GoF | protect | |||
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=482cef76-0623-4b4f-a0ea-f008c97b2281 | 1 | GoF | protect | |||
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0478f0e7-87fb-4adb-ae9b-6624555ccbe4 | 1 | GoF | protect | |||
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0478f0e7-87fb-4adb-ae9b-6624555ccbe4 | 1 | GoF | protect | |||
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0478f0e7-87fb-4adb-ae9b-6624555ccbe4 | 1 | GoF | protect | |||
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0478f0e7-87fb-4adb-ae9b-6624555ccbe4 | 1 | GoF | protect | |||
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0478f0e7-87fb-4adb-ae9b-6624555ccbe4 | 1 | GoF | protect | |||
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0478f0e7-87fb-4adb-ae9b-6624555ccbe4 | 1 | GoF | protect | |||
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | Unknown status | 01/09/2008 | https://clinicaltrials.gov/study/NCT00749047 | 1 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | Unknown status | 01/09/2008 | https://clinicaltrials.gov/study/NCT00749047 | 1 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | Unknown status | 01/09/2008 | https://clinicaltrials.gov/study/NCT00749047 | 1 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | Unknown status | 01/09/2008 | https://clinicaltrials.gov/study/NCT00749047 | 1 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | Unknown status | 01/09/2008 | https://clinicaltrials.gov/study/NCT00749047 | 1 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | Unknown status | 01/09/2008 | https://clinicaltrials.gov/study/NCT00749047 | 1 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 3 | Completed | 01/12/2009 | https://clinicaltrials.gov/study/NCT01026194 | 0.7 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 3 | Completed | 01/12/2009 | https://clinicaltrials.gov/study/NCT01026194 | 0.7 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 3 | Completed | 01/12/2009 | https://clinicaltrials.gov/study/NCT01026194 | 0.7 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 3 | Completed | 01/12/2009 | https://clinicaltrials.gov/study/NCT01026194 | 0.7 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 3 | Completed | 01/12/2009 | https://clinicaltrials.gov/study/NCT01026194 | 0.7 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 3 | Completed | 01/12/2009 | https://clinicaltrials.gov/study/NCT01026194 | 0.7 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=51033f88-4938-4666-b2a9-147044ed00e3 | 1 | GoF | protect | |||
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=51033f88-4938-4666-b2a9-147044ed00e3 | 1 | GoF | protect | |||
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=51033f88-4938-4666-b2a9-147044ed00e3 | 1 | GoF | protect | |||
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=51033f88-4938-4666-b2a9-147044ed00e3 | 1 | GoF | protect | |||
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=51033f88-4938-4666-b2a9-147044ed00e3 | 1 | GoF | protect | |||
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=51033f88-4938-4666-b2a9-147044ed00e3 | 1 | GoF | protect | |||
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=73e92590-87c0-4087-839e-d1aff2851a06 | 1 | GoF | protect | |||
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=73e92590-87c0-4087-839e-d1aff2851a06 | 1 | GoF | protect | |||
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=73e92590-87c0-4087-839e-d1aff2851a06 | 1 | GoF | protect | |||
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=73e92590-87c0-4087-839e-d1aff2851a06 | 1 | GoF | protect | |||
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=73e92590-87c0-4087-839e-d1aff2851a06 | 1 | GoF | protect | |||
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=73e92590-87c0-4087-839e-d1aff2851a06 | 1 | GoF | protect | |||
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=171a41f7-da5a-4a55-bd0e-40a29977b2e5 | 1 | GoF | protect | |||
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=171a41f7-da5a-4a55-bd0e-40a29977b2e5 | 1 | GoF | protect | |||
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=171a41f7-da5a-4a55-bd0e-40a29977b2e5 | 1 | GoF | protect | |||
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=171a41f7-da5a-4a55-bd0e-40a29977b2e5 | 1 | GoF | protect | |||
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=171a41f7-da5a-4a55-bd0e-40a29977b2e5 | 1 | GoF | protect | |||
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=171a41f7-da5a-4a55-bd0e-40a29977b2e5 | 1 | GoF | protect | |||
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 3 | Completed | 01/11/2004 | https://clinicaltrials.gov/study/NCT00138554 | 0.7 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 3 | Completed | 01/11/2004 | https://clinicaltrials.gov/study/NCT00138554 | 0.7 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 3 | Completed | 01/11/2004 | https://clinicaltrials.gov/study/NCT00138554 | 0.7 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 3 | Completed | 01/11/2004 | https://clinicaltrials.gov/study/NCT00138554 | 0.7 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 3 | Completed | 01/11/2004 | https://clinicaltrials.gov/study/NCT00138554 | 0.7 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 3 | Completed | 01/11/2004 | https://clinicaltrials.gov/study/NCT00138554 | 0.7 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a3fcf590-64a7-4d6e-8b5a-ee637675f716 | 1 | GoF | protect | |||
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a3fcf590-64a7-4d6e-8b5a-ee637675f716 | 1 | GoF | protect | |||
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a3fcf590-64a7-4d6e-8b5a-ee637675f716 | 1 | GoF | protect | |||
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a3fcf590-64a7-4d6e-8b5a-ee637675f716 | 1 | GoF | protect | |||
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a3fcf590-64a7-4d6e-8b5a-ee637675f716 | 1 | GoF | protect | |||
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a3fcf590-64a7-4d6e-8b5a-ee637675f716 | 1 | GoF | protect | |||
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 3 | Completed | 01/03/2006 | https://clinicaltrials.gov/study/NCT00295633 | 0.7 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 3 | Completed | 01/03/2006 | https://clinicaltrials.gov/study/NCT00295633 | 0.7 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 3 | Completed | 01/03/2006 | https://clinicaltrials.gov/study/NCT00295633 | 0.7 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 3 | Completed | 01/03/2006 | https://clinicaltrials.gov/study/NCT00295633 | 0.7 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 3 | Completed | 01/03/2006 | https://clinicaltrials.gov/study/NCT00295633 | 0.7 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 3 | Completed | 01/03/2006 | https://clinicaltrials.gov/study/NCT00295633 | 0.7 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | Completed | 01/04/2011 | https://clinicaltrials.gov/study/NCT02292290 | 1 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | Completed | 01/04/2011 | https://clinicaltrials.gov/study/NCT02292290 | 1 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | Completed | 01/04/2011 | https://clinicaltrials.gov/study/NCT02292290 | 1 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | Completed | 01/04/2011 | https://clinicaltrials.gov/study/NCT02292290 | 1 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | Completed | 01/04/2011 | https://clinicaltrials.gov/study/NCT02292290 | 1 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | Completed | 01/04/2011 | https://clinicaltrials.gov/study/NCT02292290 | 1 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 3 | Terminated | 01/06/2006 | https://clinicaltrials.gov/study/NCT00376181 | 0.7 | GoF | protect | Combination formulation concerns |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 3 | Terminated | 01/06/2006 | https://clinicaltrials.gov/study/NCT00376181 | 0.7 | GoF | protect | Combination formulation concerns |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 3 | Terminated | 01/06/2006 | https://clinicaltrials.gov/study/NCT00376181 | 0.7 | GoF | protect | Combination formulation concerns |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 3 | Terminated | 01/06/2006 | https://clinicaltrials.gov/study/NCT00376181 | 0.7 | GoF | protect | Combination formulation concerns |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 3 | Terminated | 01/06/2006 | https://clinicaltrials.gov/study/NCT00376181 | 0.7 | GoF | protect | Combination formulation concerns |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 3 | Terminated | 01/06/2006 | https://clinicaltrials.gov/study/NCT00376181 | 0.7 | GoF | protect | Combination formulation concerns |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4b2ba1fe-5355-4d15-9f07-c3e6fec7181a | 1 | GoF | protect | |||
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4b2ba1fe-5355-4d15-9f07-c3e6fec7181a | 1 | GoF | protect | |||
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4b2ba1fe-5355-4d15-9f07-c3e6fec7181a | 1 | GoF | protect | |||
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4b2ba1fe-5355-4d15-9f07-c3e6fec7181a | 1 | GoF | protect | |||
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4b2ba1fe-5355-4d15-9f07-c3e6fec7181a | 1 | GoF | protect | |||
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4b2ba1fe-5355-4d15-9f07-c3e6fec7181a | 1 | GoF | protect | |||
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 3 | Completed | 21/08/2006 | https://clinicaltrials.gov/study/NCT00372060 | 0.7 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 3 | Completed | 21/08/2006 | https://clinicaltrials.gov/study/NCT00372060 | 0.7 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 3 | Completed | 21/08/2006 | https://clinicaltrials.gov/study/NCT00372060 | 0.7 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 3 | Completed | 21/08/2006 | https://clinicaltrials.gov/study/NCT00372060 | 0.7 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 3 | Completed | 21/08/2006 | https://clinicaltrials.gov/study/NCT00372060 | 0.7 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 3 | Completed | 21/08/2006 | https://clinicaltrials.gov/study/NCT00372060 | 0.7 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=237d8fa2-633c-4c29-84d3-f1b413610dc3 | 1 | GoF | protect | |||
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=237d8fa2-633c-4c29-84d3-f1b413610dc3 | 1 | GoF | protect | |||
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=237d8fa2-633c-4c29-84d3-f1b413610dc3 | 1 | GoF | protect | |||
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=237d8fa2-633c-4c29-84d3-f1b413610dc3 | 1 | GoF | protect | |||
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=237d8fa2-633c-4c29-84d3-f1b413610dc3 | 1 | GoF | protect | |||
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=237d8fa2-633c-4c29-84d3-f1b413610dc3 | 1 | GoF | protect | |||
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 3 | Completed | 01/08/2010 | https://clinicaltrials.gov/study/NCT01183013 | 0.7 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 3 | Completed | 01/08/2010 | https://clinicaltrials.gov/study/NCT01183013 | 0.7 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 3 | Completed | 01/08/2010 | https://clinicaltrials.gov/study/NCT01183013 | 0.7 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 3 | Completed | 01/08/2010 | https://clinicaltrials.gov/study/NCT01183013 | 0.7 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 3 | Completed | 01/08/2010 | https://clinicaltrials.gov/study/NCT01183013 | 0.7 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 3 | Completed | 01/08/2010 | https://clinicaltrials.gov/study/NCT01183013 | 0.7 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | Recruiting | 01/02/2024 | https://clinicaltrials.gov/study/NCT06399835 | 1 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | Recruiting | 01/02/2024 | https://clinicaltrials.gov/study/NCT06399835 | 1 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | Recruiting | 01/02/2024 | https://clinicaltrials.gov/study/NCT06399835 | 1 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | Recruiting | 01/02/2024 | https://clinicaltrials.gov/study/NCT06399835 | 1 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | Recruiting | 01/02/2024 | https://clinicaltrials.gov/study/NCT06399835 | 1 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | Recruiting | 01/02/2024 | https://clinicaltrials.gov/study/NCT06399835 | 1 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | Completed | 01/10/2007 | https://clinicaltrials.gov/study/NCT00953498 | 1 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | Completed | 01/10/2007 | https://clinicaltrials.gov/study/NCT00953498 | 1 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | Completed | 01/10/2007 | https://clinicaltrials.gov/study/NCT00953498 | 1 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | Completed | 01/10/2007 | https://clinicaltrials.gov/study/NCT00953498 | 1 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | Completed | 01/10/2007 | https://clinicaltrials.gov/study/NCT00953498 | 1 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | Completed | 01/10/2007 | https://clinicaltrials.gov/study/NCT00953498 | 1 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | Completed | 01/03/2014 | https://clinicaltrials.gov/study/NCT01919489 | 1 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | Completed | 01/03/2014 | https://clinicaltrials.gov/study/NCT01919489 | 1 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | Completed | 01/03/2014 | https://clinicaltrials.gov/study/NCT01919489 | 1 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | Completed | 01/03/2014 | https://clinicaltrials.gov/study/NCT01919489 | 1 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | Completed | 01/03/2014 | https://clinicaltrials.gov/study/NCT01919489 | 1 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | Completed | 01/03/2014 | https://clinicaltrials.gov/study/NCT01919489 | 1 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | Completed | 01/11/2008 | https://clinicaltrials.gov/study/NCT01589445 | 1 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | Completed | 01/11/2008 | https://clinicaltrials.gov/study/NCT01589445 | 1 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | Completed | 01/11/2008 | https://clinicaltrials.gov/study/NCT01589445 | 1 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | Completed | 01/11/2008 | https://clinicaltrials.gov/study/NCT01589445 | 1 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | Completed | 01/11/2008 | https://clinicaltrials.gov/study/NCT01589445 | 1 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | Completed | 01/11/2008 | https://clinicaltrials.gov/study/NCT01589445 | 1 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 3 | Completed | 01/05/2004 | https://clinicaltrials.gov/study/NCT00099853 | 0.7 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 3 | Completed | 01/05/2004 | https://clinicaltrials.gov/study/NCT00099853 | 0.7 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 3 | Completed | 01/05/2004 | https://clinicaltrials.gov/study/NCT00099853 | 0.7 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 3 | Completed | 01/05/2004 | https://clinicaltrials.gov/study/NCT00099853 | 0.7 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 3 | Completed | 01/05/2004 | https://clinicaltrials.gov/study/NCT00099853 | 0.7 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 3 | Completed | 01/05/2004 | https://clinicaltrials.gov/study/NCT00099853 | 0.7 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | Completed | 01/12/2008 | https://clinicaltrials.gov/study/NCT00780715 | 1 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | Completed | 01/12/2008 | https://clinicaltrials.gov/study/NCT00780715 | 1 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | Completed | 01/12/2008 | https://clinicaltrials.gov/study/NCT00780715 | 1 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | Completed | 01/12/2008 | https://clinicaltrials.gov/study/NCT00780715 | 1 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | Completed | 01/12/2008 | https://clinicaltrials.gov/study/NCT00780715 | 1 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | Completed | 01/12/2008 | https://clinicaltrials.gov/study/NCT00780715 | 1 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6912a5c9-309b-4641-9232-72a218240c0d | 1 | GoF | protect | |||
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6912a5c9-309b-4641-9232-72a218240c0d | 1 | GoF | protect | |||
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6912a5c9-309b-4641-9232-72a218240c0d | 1 | GoF | protect | |||
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6912a5c9-309b-4641-9232-72a218240c0d | 1 | GoF | protect | |||
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6912a5c9-309b-4641-9232-72a218240c0d | 1 | GoF | protect | |||
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6912a5c9-309b-4641-9232-72a218240c0d | 1 | GoF | protect | |||
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | Completed | 16/12/2013 | https://clinicaltrials.gov/study/NCT01972724 | 1 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | Completed | 16/12/2013 | https://clinicaltrials.gov/study/NCT01972724 | 1 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | Completed | 16/12/2013 | https://clinicaltrials.gov/study/NCT01972724 | 1 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | Completed | 16/12/2013 | https://clinicaltrials.gov/study/NCT01972724 | 1 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | Completed | 16/12/2013 | https://clinicaltrials.gov/study/NCT01972724 | 1 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | Completed | 16/12/2013 | https://clinicaltrials.gov/study/NCT01972724 | 1 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/021073s046lbl.pdf | 1 | GoF | protect | |||
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/021073s046lbl.pdf | 1 | GoF | protect | |||
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/021073s046lbl.pdf | 1 | GoF | protect | |||
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/021073s046lbl.pdf | 1 | GoF | protect | |||
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/021073s046lbl.pdf | 1 | GoF | protect | |||
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/021073s046lbl.pdf | 1 | GoF | protect | |||
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 3 | Completed | 01/08/2008 | https://clinicaltrials.gov/study/NCT00736099 | 0.7 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 3 | Completed | 01/08/2008 | https://clinicaltrials.gov/study/NCT00736099 | 0.7 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 3 | Completed | 01/08/2008 | https://clinicaltrials.gov/study/NCT00736099 | 0.7 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 3 | Completed | 01/08/2008 | https://clinicaltrials.gov/study/NCT00736099 | 0.7 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 3 | Completed | 01/08/2008 | https://clinicaltrials.gov/study/NCT00736099 | 0.7 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 3 | Completed | 01/08/2008 | https://clinicaltrials.gov/study/NCT00736099 | 0.7 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | Unknown status | 01/05/2008 | https://clinicaltrials.gov/study/NCT00991055 | 1 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | Unknown status | 01/05/2008 | https://clinicaltrials.gov/study/NCT00991055 | 1 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | Unknown status | 01/05/2008 | https://clinicaltrials.gov/study/NCT00991055 | 1 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | Unknown status | 01/05/2008 | https://clinicaltrials.gov/study/NCT00991055 | 1 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | Unknown status | 01/05/2008 | https://clinicaltrials.gov/study/NCT00991055 | 1 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | Unknown status | 01/05/2008 | https://clinicaltrials.gov/study/NCT00991055 | 1 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | Active, not recruiting | 31/12/2015 | https://clinicaltrials.gov/study/NCT04470310 | 1 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | Active, not recruiting | 31/12/2015 | https://clinicaltrials.gov/study/NCT04470310 | 1 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | Active, not recruiting | 31/12/2015 | https://clinicaltrials.gov/study/NCT04470310 | 1 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | Active, not recruiting | 31/12/2015 | https://clinicaltrials.gov/study/NCT04470310 | 1 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | Active, not recruiting | 31/12/2015 | https://clinicaltrials.gov/study/NCT04470310 | 1 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | Active, not recruiting | 31/12/2015 | https://clinicaltrials.gov/study/NCT04470310 | 1 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 3 | Completed | 15/09/2010 | https://clinicaltrials.gov/study/NCT01225081 | 0.7 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 3 | Completed | 15/09/2010 | https://clinicaltrials.gov/study/NCT01225081 | 0.7 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 3 | Completed | 15/09/2010 | https://clinicaltrials.gov/study/NCT01225081 | 0.7 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 3 | Completed | 15/09/2010 | https://clinicaltrials.gov/study/NCT01225081 | 0.7 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 3 | Completed | 15/09/2010 | https://clinicaltrials.gov/study/NCT01225081 | 0.7 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 3 | Completed | 15/09/2010 | https://clinicaltrials.gov/study/NCT01225081 | 0.7 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 3 | Terminated | 14/11/2007 | https://clinicaltrials.gov/study/NCT00571519 | 0.7 | GoF | protect | DSPD focusing on Study 301 to confirm the clinical profile before proceeding. Daiichi Sankyo Pharma Development terminated this study on 23 Apr 2008 because of changes in the clinical development plan with 94 of 2600 planned, randomized participants. |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 3 | Terminated | 14/11/2007 | https://clinicaltrials.gov/study/NCT00571519 | 0.7 | GoF | protect | DSPD focusing on Study 301 to confirm the clinical profile before proceeding. Daiichi Sankyo Pharma Development terminated this study on 23 Apr 2008 because of changes in the clinical development plan with 94 of 2600 planned, randomized participants. |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 3 | Terminated | 14/11/2007 | https://clinicaltrials.gov/study/NCT00571519 | 0.7 | GoF | protect | DSPD focusing on Study 301 to confirm the clinical profile before proceeding. Daiichi Sankyo Pharma Development terminated this study on 23 Apr 2008 because of changes in the clinical development plan with 94 of 2600 planned, randomized participants. |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 3 | Terminated | 14/11/2007 | https://clinicaltrials.gov/study/NCT00571519 | 0.7 | GoF | protect | DSPD focusing on Study 301 to confirm the clinical profile before proceeding. Daiichi Sankyo Pharma Development terminated this study on 23 Apr 2008 because of changes in the clinical development plan with 94 of 2600 planned, randomized participants. |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 3 | Terminated | 14/11/2007 | https://clinicaltrials.gov/study/NCT00571519 | 0.7 | GoF | protect | DSPD focusing on Study 301 to confirm the clinical profile before proceeding. Daiichi Sankyo Pharma Development terminated this study on 23 Apr 2008 because of changes in the clinical development plan with 94 of 2600 planned, randomized participants. |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 3 | Terminated | 14/11/2007 | https://clinicaltrials.gov/study/NCT00571519 | 0.7 | GoF | protect | DSPD focusing on Study 301 to confirm the clinical profile before proceeding. Daiichi Sankyo Pharma Development terminated this study on 23 Apr 2008 because of changes in the clinical development plan with 94 of 2600 planned, randomized participants. |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 3 | Completed | 01/03/2005 | https://clinicaltrials.gov/study/NCT00106704 | 0.7 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 3 | Completed | 01/03/2005 | https://clinicaltrials.gov/study/NCT00106704 | 0.7 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 3 | Completed | 01/03/2005 | https://clinicaltrials.gov/study/NCT00106704 | 0.7 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 3 | Completed | 01/03/2005 | https://clinicaltrials.gov/study/NCT00106704 | 0.7 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 3 | Completed | 01/03/2005 | https://clinicaltrials.gov/study/NCT00106704 | 0.7 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 3 | Completed | 01/03/2005 | https://clinicaltrials.gov/study/NCT00106704 | 0.7 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | Unknown status | 01/02/2015 | https://clinicaltrials.gov/study/NCT02426294 | 1 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | Unknown status | 01/02/2015 | https://clinicaltrials.gov/study/NCT02426294 | 1 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | Unknown status | 01/02/2015 | https://clinicaltrials.gov/study/NCT02426294 | 1 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | Unknown status | 01/02/2015 | https://clinicaltrials.gov/study/NCT02426294 | 1 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | Unknown status | 01/02/2015 | https://clinicaltrials.gov/study/NCT02426294 | 1 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | Unknown status | 01/02/2015 | https://clinicaltrials.gov/study/NCT02426294 | 1 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d2ddc491-88a9-4063-9150-443b4fa4330c | 1 | GoF | protect | |||
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d2ddc491-88a9-4063-9150-443b4fa4330c | 1 | GoF | protect | |||
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d2ddc491-88a9-4063-9150-443b4fa4330c | 1 | GoF | protect | |||
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d2ddc491-88a9-4063-9150-443b4fa4330c | 1 | GoF | protect | |||
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d2ddc491-88a9-4063-9150-443b4fa4330c | 1 | GoF | protect | |||
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d2ddc491-88a9-4063-9150-443b4fa4330c | 1 | GoF | protect | |||
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 3 | Completed | 01/03/2008 | https://clinicaltrials.gov/study/NCT00641043 | 0.7 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 3 | Completed | 01/03/2008 | https://clinicaltrials.gov/study/NCT00641043 | 0.7 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 3 | Completed | 01/03/2008 | https://clinicaltrials.gov/study/NCT00641043 | 0.7 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 3 | Completed | 01/03/2008 | https://clinicaltrials.gov/study/NCT00641043 | 0.7 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 3 | Completed | 01/03/2008 | https://clinicaltrials.gov/study/NCT00641043 | 0.7 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 3 | Completed | 01/03/2008 | https://clinicaltrials.gov/study/NCT00641043 | 0.7 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3d11a0bc-26b4-49f4-a8e7-0fad1524b3d1 | 1 | GoF | protect | |||
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3d11a0bc-26b4-49f4-a8e7-0fad1524b3d1 | 1 | GoF | protect | |||
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3d11a0bc-26b4-49f4-a8e7-0fad1524b3d1 | 1 | GoF | protect | |||
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3d11a0bc-26b4-49f4-a8e7-0fad1524b3d1 | 1 | GoF | protect | |||
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3d11a0bc-26b4-49f4-a8e7-0fad1524b3d1 | 1 | GoF | protect | |||
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3d11a0bc-26b4-49f4-a8e7-0fad1524b3d1 | 1 | GoF | protect | |||
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=586651c6-8d9d-4e96-b17b-7bb535eb3153 | 1 | GoF | protect | |||
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=586651c6-8d9d-4e96-b17b-7bb535eb3153 | 1 | GoF | protect | |||
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=586651c6-8d9d-4e96-b17b-7bb535eb3153 | 1 | GoF | protect | |||
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=586651c6-8d9d-4e96-b17b-7bb535eb3153 | 1 | GoF | protect | |||
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=586651c6-8d9d-4e96-b17b-7bb535eb3153 | 1 | GoF | protect | |||
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=586651c6-8d9d-4e96-b17b-7bb535eb3153 | 1 | GoF | protect | |||
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | Completed | 01/07/2010 | https://clinicaltrials.gov/study/NCT01087567 | 1 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | Completed | 01/07/2010 | https://clinicaltrials.gov/study/NCT01087567 | 1 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | Completed | 01/07/2010 | https://clinicaltrials.gov/study/NCT01087567 | 1 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | Completed | 01/07/2010 | https://clinicaltrials.gov/study/NCT01087567 | 1 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | Completed | 01/07/2010 | https://clinicaltrials.gov/study/NCT01087567 | 1 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | Completed | 01/07/2010 | https://clinicaltrials.gov/study/NCT01087567 | 1 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | Completed | 01/12/2000 | https://clinicaltrials.gov/study/NCT00179400 | 1 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | Completed | 01/12/2000 | https://clinicaltrials.gov/study/NCT00179400 | 1 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | Completed | 01/12/2000 | https://clinicaltrials.gov/study/NCT00179400 | 1 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | Completed | 01/12/2000 | https://clinicaltrials.gov/study/NCT00179400 | 1 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | Completed | 01/12/2000 | https://clinicaltrials.gov/study/NCT00179400 | 1 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | Completed | 01/12/2000 | https://clinicaltrials.gov/study/NCT00179400 | 1 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 3 | Completed | 01/02/2010 | https://clinicaltrials.gov/study/NCT01064687 | 0.7 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 3 | Completed | 01/02/2010 | https://clinicaltrials.gov/study/NCT01064687 | 0.7 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 3 | Completed | 01/02/2010 | https://clinicaltrials.gov/study/NCT01064687 | 0.7 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 3 | Completed | 01/02/2010 | https://clinicaltrials.gov/study/NCT01064687 | 0.7 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 3 | Completed | 01/02/2010 | https://clinicaltrials.gov/study/NCT01064687 | 0.7 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 3 | Completed | 01/02/2010 | https://clinicaltrials.gov/study/NCT01064687 | 0.7 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | Completed | 01/11/2006 | https://clinicaltrials.gov/study/NCT00402012 | 1 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | Completed | 01/11/2006 | https://clinicaltrials.gov/study/NCT00402012 | 1 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | Completed | 01/11/2006 | https://clinicaltrials.gov/study/NCT00402012 | 1 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | Completed | 01/11/2006 | https://clinicaltrials.gov/study/NCT00402012 | 1 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | Completed | 01/11/2006 | https://clinicaltrials.gov/study/NCT00402012 | 1 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | Completed | 01/11/2006 | https://clinicaltrials.gov/study/NCT00402012 | 1 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | Active, not recruiting | 11/02/2020 | https://clinicaltrials.gov/study/NCT03499704 | 1 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | Active, not recruiting | 11/02/2020 | https://clinicaltrials.gov/study/NCT03499704 | 1 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | Active, not recruiting | 11/02/2020 | https://clinicaltrials.gov/study/NCT03499704 | 1 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | Active, not recruiting | 11/02/2020 | https://clinicaltrials.gov/study/NCT03499704 | 1 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | Active, not recruiting | 11/02/2020 | https://clinicaltrials.gov/study/NCT03499704 | 1 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | Active, not recruiting | 11/02/2020 | https://clinicaltrials.gov/study/NCT03499704 | 1 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 3 | Completed | 01/08/2004 | https://clinicaltrials.gov/study/NCT00097279 | 0.7 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 3 | Completed | 01/08/2004 | https://clinicaltrials.gov/study/NCT00097279 | 0.7 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 3 | Completed | 01/08/2004 | https://clinicaltrials.gov/study/NCT00097279 | 0.7 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 3 | Completed | 01/08/2004 | https://clinicaltrials.gov/study/NCT00097279 | 0.7 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 3 | Completed | 01/08/2004 | https://clinicaltrials.gov/study/NCT00097279 | 0.7 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 3 | Completed | 01/08/2004 | https://clinicaltrials.gov/study/NCT00097279 | 0.7 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | Unknown status | 01/10/2011 | https://clinicaltrials.gov/study/NCT01471808 | 1 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | Unknown status | 01/10/2011 | https://clinicaltrials.gov/study/NCT01471808 | 1 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | Unknown status | 01/10/2011 | https://clinicaltrials.gov/study/NCT01471808 | 1 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | Unknown status | 01/10/2011 | https://clinicaltrials.gov/study/NCT01471808 | 1 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | Unknown status | 01/10/2011 | https://clinicaltrials.gov/study/NCT01471808 | 1 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | Unknown status | 01/10/2011 | https://clinicaltrials.gov/study/NCT01471808 | 1 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | Completed | 01/07/2016 | https://clinicaltrials.gov/study/NCT02694263 | 1 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | Completed | 01/07/2016 | https://clinicaltrials.gov/study/NCT02694263 | 1 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | Completed | 01/07/2016 | https://clinicaltrials.gov/study/NCT02694263 | 1 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | Completed | 01/07/2016 | https://clinicaltrials.gov/study/NCT02694263 | 1 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | Completed | 01/07/2016 | https://clinicaltrials.gov/study/NCT02694263 | 1 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | Completed | 01/07/2016 | https://clinicaltrials.gov/study/NCT02694263 | 1 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=42e49120-6f3f-11db-9fe1-0800200c9a66 | 1 | GoF | protect | |||
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=42e49120-6f3f-11db-9fe1-0800200c9a66 | 1 | GoF | protect | |||
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=42e49120-6f3f-11db-9fe1-0800200c9a66 | 1 | GoF | protect | |||
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=42e49120-6f3f-11db-9fe1-0800200c9a66 | 1 | GoF | protect | |||
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=42e49120-6f3f-11db-9fe1-0800200c9a66 | 1 | GoF | protect | |||
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=42e49120-6f3f-11db-9fe1-0800200c9a66 | 1 | GoF | protect | |||
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 3 | Completed | 01/09/2008 | https://clinicaltrials.gov/study/NCT00763815 | 0.7 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 3 | Completed | 01/09/2008 | https://clinicaltrials.gov/study/NCT00763815 | 0.7 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 3 | Completed | 01/09/2008 | https://clinicaltrials.gov/study/NCT00763815 | 0.7 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 3 | Completed | 01/09/2008 | https://clinicaltrials.gov/study/NCT00763815 | 0.7 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 3 | Completed | 01/09/2008 | https://clinicaltrials.gov/study/NCT00763815 | 0.7 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 3 | Completed | 01/09/2008 | https://clinicaltrials.gov/study/NCT00763815 | 0.7 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | Completed | 01/12/2020 | https://clinicaltrials.gov/study/NCT04657939 | 1 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | Completed | 01/12/2020 | https://clinicaltrials.gov/study/NCT04657939 | 1 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | Completed | 01/12/2020 | https://clinicaltrials.gov/study/NCT04657939 | 1 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | Completed | 01/12/2020 | https://clinicaltrials.gov/study/NCT04657939 | 1 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | Completed | 01/12/2020 | https://clinicaltrials.gov/study/NCT04657939 | 1 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | Completed | 01/12/2020 | https://clinicaltrials.gov/study/NCT04657939 | 1 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 3 | Completed | 26/01/2008 | https://clinicaltrials.gov/study/NCT00532935 | 0.7 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 3 | Completed | 26/01/2008 | https://clinicaltrials.gov/study/NCT00532935 | 0.7 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 3 | Completed | 26/01/2008 | https://clinicaltrials.gov/study/NCT00532935 | 0.7 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 3 | Completed | 26/01/2008 | https://clinicaltrials.gov/study/NCT00532935 | 0.7 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 3 | Completed | 26/01/2008 | https://clinicaltrials.gov/study/NCT00532935 | 0.7 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 3 | Completed | 26/01/2008 | https://clinicaltrials.gov/study/NCT00532935 | 0.7 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | Completed | 01/10/2009 | https://clinicaltrials.gov/study/NCT01195090 | 1 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | Completed | 01/10/2009 | https://clinicaltrials.gov/study/NCT01195090 | 1 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | Completed | 01/10/2009 | https://clinicaltrials.gov/study/NCT01195090 | 1 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | Completed | 01/10/2009 | https://clinicaltrials.gov/study/NCT01195090 | 1 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | Completed | 01/10/2009 | https://clinicaltrials.gov/study/NCT01195090 | 1 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | Completed | 01/10/2009 | https://clinicaltrials.gov/study/NCT01195090 | 1 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=730f747a-850d-4a81-89e2-200007a5db5a | 1 | GoF | protect | |||
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=730f747a-850d-4a81-89e2-200007a5db5a | 1 | GoF | protect | |||
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=730f747a-850d-4a81-89e2-200007a5db5a | 1 | GoF | protect | |||
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=730f747a-850d-4a81-89e2-200007a5db5a | 1 | GoF | protect | |||
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=730f747a-850d-4a81-89e2-200007a5db5a | 1 | GoF | protect | |||
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=730f747a-850d-4a81-89e2-200007a5db5a | 1 | GoF | protect | |||
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 3 | Completed | 01/07/2008 | https://clinicaltrials.gov/study/NCT00683878 | 0.7 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 3 | Completed | 01/07/2008 | https://clinicaltrials.gov/study/NCT00683878 | 0.7 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 3 | Completed | 01/07/2008 | https://clinicaltrials.gov/study/NCT00683878 | 0.7 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 3 | Completed | 01/07/2008 | https://clinicaltrials.gov/study/NCT00683878 | 0.7 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 3 | Completed | 01/07/2008 | https://clinicaltrials.gov/study/NCT00683878 | 0.7 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 3 | Completed | 01/07/2008 | https://clinicaltrials.gov/study/NCT00683878 | 0.7 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | Withdrawn | 01/04/2008 | https://clinicaltrials.gov/study/NCT00437970 | 1 | GoF | protect | Unable to secure supply of the study medication |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | Withdrawn | 01/04/2008 | https://clinicaltrials.gov/study/NCT00437970 | 1 | GoF | protect | Unable to secure supply of the study medication |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | Withdrawn | 01/04/2008 | https://clinicaltrials.gov/study/NCT00437970 | 1 | GoF | protect | Unable to secure supply of the study medication |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | Withdrawn | 01/04/2008 | https://clinicaltrials.gov/study/NCT00437970 | 1 | GoF | protect | Unable to secure supply of the study medication |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | Withdrawn | 01/04/2008 | https://clinicaltrials.gov/study/NCT00437970 | 1 | GoF | protect | Unable to secure supply of the study medication |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | Withdrawn | 01/04/2008 | https://clinicaltrials.gov/study/NCT00437970 | 1 | GoF | protect | Unable to secure supply of the study medication |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6c6f14bb-c964-42a6-93a6-192204ae1b99 | 1 | GoF | protect | |||
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6c6f14bb-c964-42a6-93a6-192204ae1b99 | 1 | GoF | protect | |||
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6c6f14bb-c964-42a6-93a6-192204ae1b99 | 1 | GoF | protect | |||
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6c6f14bb-c964-42a6-93a6-192204ae1b99 | 1 | GoF | protect | |||
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6c6f14bb-c964-42a6-93a6-192204ae1b99 | 1 | GoF | protect | |||
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6c6f14bb-c964-42a6-93a6-192204ae1b99 | 1 | GoF | protect | |||
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 3 | Terminated | 29/11/2006 | https://clinicaltrials.gov/study/NCT00411892 | 0.7 | GoF | protect | See termination reason in detailed description |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 3 | Terminated | 29/11/2006 | https://clinicaltrials.gov/study/NCT00411892 | 0.7 | GoF | protect | See termination reason in detailed description |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 3 | Terminated | 29/11/2006 | https://clinicaltrials.gov/study/NCT00411892 | 0.7 | GoF | protect | See termination reason in detailed description |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 3 | Terminated | 29/11/2006 | https://clinicaltrials.gov/study/NCT00411892 | 0.7 | GoF | protect | See termination reason in detailed description |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 3 | Terminated | 29/11/2006 | https://clinicaltrials.gov/study/NCT00411892 | 0.7 | GoF | protect | See termination reason in detailed description |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 3 | Terminated | 29/11/2006 | https://clinicaltrials.gov/study/NCT00411892 | 0.7 | GoF | protect | See termination reason in detailed description |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 3 | Completed | 01/02/2009 | https://clinicaltrials.gov/study/NCT00839527 | 0.7 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 3 | Completed | 01/02/2009 | https://clinicaltrials.gov/study/NCT00839527 | 0.7 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 3 | Completed | 01/02/2009 | https://clinicaltrials.gov/study/NCT00839527 | 0.7 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 3 | Completed | 01/02/2009 | https://clinicaltrials.gov/study/NCT00839527 | 0.7 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 3 | Completed | 01/02/2009 | https://clinicaltrials.gov/study/NCT00839527 | 0.7 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 3 | Completed | 01/02/2009 | https://clinicaltrials.gov/study/NCT00839527 | 0.7 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 3 | Completed | 01/06/2004 | https://clinicaltrials.gov/study/NCT00086502 | 0.7 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 3 | Completed | 01/06/2004 | https://clinicaltrials.gov/study/NCT00086502 | 0.7 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 3 | Completed | 01/06/2004 | https://clinicaltrials.gov/study/NCT00086502 | 0.7 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 3 | Completed | 01/06/2004 | https://clinicaltrials.gov/study/NCT00086502 | 0.7 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 3 | Completed | 01/06/2004 | https://clinicaltrials.gov/study/NCT00086502 | 0.7 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 3 | Completed | 01/06/2004 | https://clinicaltrials.gov/study/NCT00086502 | 0.7 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | Completed | 01/09/2014 | https://clinicaltrials.gov/study/NCT02231021 | 1 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | Completed | 01/09/2014 | https://clinicaltrials.gov/study/NCT02231021 | 1 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | Completed | 01/09/2014 | https://clinicaltrials.gov/study/NCT02231021 | 1 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | Completed | 01/09/2014 | https://clinicaltrials.gov/study/NCT02231021 | 1 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | Completed | 01/09/2014 | https://clinicaltrials.gov/study/NCT02231021 | 1 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | Completed | 01/09/2014 | https://clinicaltrials.gov/study/NCT02231021 | 1 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f5c534e8-656c-406d-b3dc-b562576ba4eb | 1 | GoF | protect | |||
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f5c534e8-656c-406d-b3dc-b562576ba4eb | 1 | GoF | protect | |||
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f5c534e8-656c-406d-b3dc-b562576ba4eb | 1 | GoF | protect | |||
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f5c534e8-656c-406d-b3dc-b562576ba4eb | 1 | GoF | protect | |||
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f5c534e8-656c-406d-b3dc-b562576ba4eb | 1 | GoF | protect | |||
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f5c534e8-656c-406d-b3dc-b562576ba4eb | 1 | GoF | protect | |||
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f4ca7537-ed49-4dee-9003-48dc001a9dc1 | 1 | GoF | protect | |||
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f4ca7537-ed49-4dee-9003-48dc001a9dc1 | 1 | GoF | protect | |||
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f4ca7537-ed49-4dee-9003-48dc001a9dc1 | 1 | GoF | protect | |||
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f4ca7537-ed49-4dee-9003-48dc001a9dc1 | 1 | GoF | protect | |||
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f4ca7537-ed49-4dee-9003-48dc001a9dc1 | 1 | GoF | protect | |||
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f4ca7537-ed49-4dee-9003-48dc001a9dc1 | 1 | GoF | protect | |||
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f22dab23-3cf6-4473-a367-5303353e9f9d | 1 | GoF | protect | |||
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f22dab23-3cf6-4473-a367-5303353e9f9d | 1 | GoF | protect | |||
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f22dab23-3cf6-4473-a367-5303353e9f9d | 1 | GoF | protect | |||
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f22dab23-3cf6-4473-a367-5303353e9f9d | 1 | GoF | protect | |||
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f22dab23-3cf6-4473-a367-5303353e9f9d | 1 | GoF | protect | |||
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f22dab23-3cf6-4473-a367-5303353e9f9d | 1 | GoF | protect | |||
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 3 | Completed | 01/11/2002 | https://clinicaltrials.gov/study/NCT00598793 | 0.7 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 3 | Completed | 01/11/2002 | https://clinicaltrials.gov/study/NCT00598793 | 0.7 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 3 | Completed | 01/11/2002 | https://clinicaltrials.gov/study/NCT00598793 | 0.7 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 3 | Completed | 01/11/2002 | https://clinicaltrials.gov/study/NCT00598793 | 0.7 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 3 | Completed | 01/11/2002 | https://clinicaltrials.gov/study/NCT00598793 | 0.7 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 3 | Completed | 01/11/2002 | https://clinicaltrials.gov/study/NCT00598793 | 0.7 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | Unknown status | 01/12/2016 | https://clinicaltrials.gov/study/NCT03196362 | 1 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | Unknown status | 01/12/2016 | https://clinicaltrials.gov/study/NCT03196362 | 1 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | Unknown status | 01/12/2016 | https://clinicaltrials.gov/study/NCT03196362 | 1 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | Unknown status | 01/12/2016 | https://clinicaltrials.gov/study/NCT03196362 | 1 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | Unknown status | 01/12/2016 | https://clinicaltrials.gov/study/NCT03196362 | 1 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | Unknown status | 01/12/2016 | https://clinicaltrials.gov/study/NCT03196362 | 1 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | Recruiting | 01/07/2020 | https://clinicaltrials.gov/study/NCT04392557 | 1 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | Recruiting | 01/07/2020 | https://clinicaltrials.gov/study/NCT04392557 | 1 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | Recruiting | 01/07/2020 | https://clinicaltrials.gov/study/NCT04392557 | 1 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | Recruiting | 01/07/2020 | https://clinicaltrials.gov/study/NCT04392557 | 1 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | Recruiting | 01/07/2020 | https://clinicaltrials.gov/study/NCT04392557 | 1 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | Recruiting | 01/07/2020 | https://clinicaltrials.gov/study/NCT04392557 | 1 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=fd156adc-3174-44da-bff7-eeaef5983f18 | 1 | GoF | protect | |||
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=fd156adc-3174-44da-bff7-eeaef5983f18 | 1 | GoF | protect | |||
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=fd156adc-3174-44da-bff7-eeaef5983f18 | 1 | GoF | protect | |||
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=fd156adc-3174-44da-bff7-eeaef5983f18 | 1 | GoF | protect | |||
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=fd156adc-3174-44da-bff7-eeaef5983f18 | 1 | GoF | protect | |||
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=fd156adc-3174-44da-bff7-eeaef5983f18 | 1 | GoF | protect | |||
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | Completed | 01/11/2016 | https://clinicaltrials.gov/study/NCT02653209 | 1 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | Completed | 01/11/2016 | https://clinicaltrials.gov/study/NCT02653209 | 1 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | Completed | 01/11/2016 | https://clinicaltrials.gov/study/NCT02653209 | 1 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | Completed | 01/11/2016 | https://clinicaltrials.gov/study/NCT02653209 | 1 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | Completed | 01/11/2016 | https://clinicaltrials.gov/study/NCT02653209 | 1 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | Completed | 01/11/2016 | https://clinicaltrials.gov/study/NCT02653209 | 1 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 3 | Completed | 01/09/1999 | https://clinicaltrials.gov/study/NCT00000620 | 0.7 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 3 | Completed | 01/09/1999 | https://clinicaltrials.gov/study/NCT00000620 | 0.7 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 3 | Completed | 01/09/1999 | https://clinicaltrials.gov/study/NCT00000620 | 0.7 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 3 | Completed | 01/09/1999 | https://clinicaltrials.gov/study/NCT00000620 | 0.7 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 3 | Completed | 01/09/1999 | https://clinicaltrials.gov/study/NCT00000620 | 0.7 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 3 | Completed | 01/09/1999 | https://clinicaltrials.gov/study/NCT00000620 | 0.7 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 3 | Completed | 15/04/2009 | https://clinicaltrials.gov/study/NCT00885352 | 0.7 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 3 | Completed | 15/04/2009 | https://clinicaltrials.gov/study/NCT00885352 | 0.7 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 3 | Completed | 15/04/2009 | https://clinicaltrials.gov/study/NCT00885352 | 0.7 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 3 | Completed | 15/04/2009 | https://clinicaltrials.gov/study/NCT00885352 | 0.7 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 3 | Completed | 15/04/2009 | https://clinicaltrials.gov/study/NCT00885352 | 0.7 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 3 | Completed | 15/04/2009 | https://clinicaltrials.gov/study/NCT00885352 | 0.7 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 3 | Completed | 30/06/2004 | https://clinicaltrials.gov/study/NCT00086515 | 0.7 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 3 | Completed | 30/06/2004 | https://clinicaltrials.gov/study/NCT00086515 | 0.7 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 3 | Completed | 30/06/2004 | https://clinicaltrials.gov/study/NCT00086515 | 0.7 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 3 | Completed | 30/06/2004 | https://clinicaltrials.gov/study/NCT00086515 | 0.7 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 3 | Completed | 30/06/2004 | https://clinicaltrials.gov/study/NCT00086515 | 0.7 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 3 | Completed | 30/06/2004 | https://clinicaltrials.gov/study/NCT00086515 | 0.7 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 3 | Completed | 01/08/2005 | https://clinicaltrials.gov/study/NCT00121667 | 0.7 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 3 | Completed | 01/08/2005 | https://clinicaltrials.gov/study/NCT00121667 | 0.7 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 3 | Completed | 01/08/2005 | https://clinicaltrials.gov/study/NCT00121667 | 0.7 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 3 | Completed | 01/08/2005 | https://clinicaltrials.gov/study/NCT00121667 | 0.7 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 3 | Completed | 01/08/2005 | https://clinicaltrials.gov/study/NCT00121667 | 0.7 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 3 | Completed | 01/08/2005 | https://clinicaltrials.gov/study/NCT00121667 | 0.7 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 3 | Completed | 01/12/2010 | https://clinicaltrials.gov/study/NCT01289119 | 0.7 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 3 | Completed | 01/12/2010 | https://clinicaltrials.gov/study/NCT01289119 | 0.7 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 3 | Completed | 01/12/2010 | https://clinicaltrials.gov/study/NCT01289119 | 0.7 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 3 | Completed | 01/12/2010 | https://clinicaltrials.gov/study/NCT01289119 | 0.7 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 3 | Completed | 01/12/2010 | https://clinicaltrials.gov/study/NCT01289119 | 0.7 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 3 | Completed | 01/12/2010 | https://clinicaltrials.gov/study/NCT01289119 | 0.7 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 3 | Terminated | 01/09/2006 | https://clinicaltrials.gov/study/NCT01124656 | 0.7 | GoF | protect | Formulation issues. |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 3 | Terminated | 01/09/2006 | https://clinicaltrials.gov/study/NCT01124656 | 0.7 | GoF | protect | Formulation issues. |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 3 | Terminated | 01/09/2006 | https://clinicaltrials.gov/study/NCT01124656 | 0.7 | GoF | protect | Formulation issues. |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 3 | Terminated | 01/09/2006 | https://clinicaltrials.gov/study/NCT01124656 | 0.7 | GoF | protect | Formulation issues. |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 3 | Terminated | 01/09/2006 | https://clinicaltrials.gov/study/NCT01124656 | 0.7 | GoF | protect | Formulation issues. |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 3 | Terminated | 01/09/2006 | https://clinicaltrials.gov/study/NCT01124656 | 0.7 | GoF | protect | Formulation issues. |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2a97ef74-b338-4655-a60b-923f86720179 | 1 | GoF | protect | |||
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2a97ef74-b338-4655-a60b-923f86720179 | 1 | GoF | protect | |||
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2a97ef74-b338-4655-a60b-923f86720179 | 1 | GoF | protect | |||
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2a97ef74-b338-4655-a60b-923f86720179 | 1 | GoF | protect | |||
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2a97ef74-b338-4655-a60b-923f86720179 | 1 | GoF | protect | |||
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2a97ef74-b338-4655-a60b-923f86720179 | 1 | GoF | protect | |||
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | Unknown status | 01/06/2013 | https://clinicaltrials.gov/study/NCT01895569 | 1 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | Unknown status | 01/06/2013 | https://clinicaltrials.gov/study/NCT01895569 | 1 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | Unknown status | 01/06/2013 | https://clinicaltrials.gov/study/NCT01895569 | 1 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | Unknown status | 01/06/2013 | https://clinicaltrials.gov/study/NCT01895569 | 1 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | Unknown status | 01/06/2013 | https://clinicaltrials.gov/study/NCT01895569 | 1 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | Unknown status | 01/06/2013 | https://clinicaltrials.gov/study/NCT01895569 | 1 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 3 | Completed | 01/11/2008 | https://clinicaltrials.gov/study/NCT00676338 | 0.7 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 3 | Completed | 01/11/2008 | https://clinicaltrials.gov/study/NCT00676338 | 0.7 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 3 | Completed | 01/11/2008 | https://clinicaltrials.gov/study/NCT00676338 | 0.7 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 3 | Completed | 01/11/2008 | https://clinicaltrials.gov/study/NCT00676338 | 0.7 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 3 | Completed | 01/11/2008 | https://clinicaltrials.gov/study/NCT00676338 | 0.7 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 3 | Completed | 01/11/2008 | https://clinicaltrials.gov/study/NCT00676338 | 0.7 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | Completed | 01/12/2009 | https://clinicaltrials.gov/study/NCT01882907 | 1 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | Completed | 01/12/2009 | https://clinicaltrials.gov/study/NCT01882907 | 1 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | Completed | 01/12/2009 | https://clinicaltrials.gov/study/NCT01882907 | 1 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | Completed | 01/12/2009 | https://clinicaltrials.gov/study/NCT01882907 | 1 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | Completed | 01/12/2009 | https://clinicaltrials.gov/study/NCT01882907 | 1 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE | targetBased | 4 | Completed | 01/12/2009 | https://clinicaltrials.gov/study/NCT01882907 | 1 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | Hypercholesterolemia | PIOGLITAZONE | targetBased | 3 | Completed | 01/09/1999 | https://clinicaltrials.gov/study/NCT00000620 | 0.7 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | Hypercholesterolemia | PIOGLITAZONE | targetBased | 3 | Completed | 01/09/1999 | https://clinicaltrials.gov/study/NCT00000620 | 0.7 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | Hypercholesterolemia | PIOGLITAZONE | targetBased | 3 | Completed | 01/09/1999 | https://clinicaltrials.gov/study/NCT00000620 | 0.7 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | Hypercholesterolemia | PIOGLITAZONE | targetBased | 3 | Completed | 01/09/1999 | https://clinicaltrials.gov/study/NCT00000620 | 0.7 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | Hypercholesterolemia | PIOGLITAZONE | targetBased | 3 | Completed | 01/09/1999 | https://clinicaltrials.gov/study/NCT00000620 | 0.7 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | Hypercholesterolemia | PIOGLITAZONE | targetBased | 3 | Completed | 01/09/1999 | https://clinicaltrials.gov/study/NCT00000620 | 0.7 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | non-alcoholic steatohepatitis | PIOGLITAZONE | targetBased | 4 | Completed | 01/10/2002 | https://clinicaltrials.gov/study/NCT00227110 | 1 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | non-alcoholic steatohepatitis | PIOGLITAZONE | targetBased | 4 | Completed | 01/10/2002 | https://clinicaltrials.gov/study/NCT00227110 | 1 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | non-alcoholic steatohepatitis | PIOGLITAZONE | targetBased | 4 | Completed | 01/10/2002 | https://clinicaltrials.gov/study/NCT00227110 | 1 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | non-alcoholic steatohepatitis | PIOGLITAZONE | targetBased | 4 | Completed | 01/10/2002 | https://clinicaltrials.gov/study/NCT00227110 | 1 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | non-alcoholic steatohepatitis | PIOGLITAZONE | targetBased | 4 | Completed | 01/10/2002 | https://clinicaltrials.gov/study/NCT00227110 | 1 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | non-alcoholic steatohepatitis | PIOGLITAZONE | targetBased | 4 | Completed | 01/10/2002 | https://clinicaltrials.gov/study/NCT00227110 | 1 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | non-alcoholic steatohepatitis | PIOGLITAZONE | targetBased | 4 | Completed | 24/06/2010 | https://clinicaltrials.gov/study/NCT01002547 | 1 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | non-alcoholic steatohepatitis | PIOGLITAZONE | targetBased | 4 | Completed | 24/06/2010 | https://clinicaltrials.gov/study/NCT01002547 | 1 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | non-alcoholic steatohepatitis | PIOGLITAZONE | targetBased | 4 | Completed | 24/06/2010 | https://clinicaltrials.gov/study/NCT01002547 | 1 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | non-alcoholic steatohepatitis | PIOGLITAZONE | targetBased | 4 | Completed | 24/06/2010 | https://clinicaltrials.gov/study/NCT01002547 | 1 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | non-alcoholic steatohepatitis | PIOGLITAZONE | targetBased | 4 | Completed | 24/06/2010 | https://clinicaltrials.gov/study/NCT01002547 | 1 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | non-alcoholic steatohepatitis | PIOGLITAZONE | targetBased | 4 | Completed | 24/06/2010 | https://clinicaltrials.gov/study/NCT01002547 | 1 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | metabolic syndrome | PIOGLITAZONE | targetBased | 4 | Completed | 01/10/2006 | https://clinicaltrials.gov/study/NCT00926341 | 1 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | metabolic syndrome | PIOGLITAZONE | targetBased | 4 | Completed | 01/10/2006 | https://clinicaltrials.gov/study/NCT00926341 | 1 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | metabolic syndrome | PIOGLITAZONE | targetBased | 4 | Completed | 01/10/2006 | https://clinicaltrials.gov/study/NCT00926341 | 1 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | metabolic syndrome | PIOGLITAZONE | targetBased | 4 | Completed | 01/10/2006 | https://clinicaltrials.gov/study/NCT00926341 | 1 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | metabolic syndrome | PIOGLITAZONE | targetBased | 4 | Completed | 01/10/2006 | https://clinicaltrials.gov/study/NCT00926341 | 1 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | metabolic syndrome | PIOGLITAZONE | targetBased | 4 | Completed | 01/10/2006 | https://clinicaltrials.gov/study/NCT00926341 | 1 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | metabolic syndrome | PIOGLITAZONE | targetBased | 4 | Completed | 01/05/2006 | https://clinicaltrials.gov/study/NCT00314561 | 1 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | metabolic syndrome | PIOGLITAZONE | targetBased | 4 | Completed | 01/05/2006 | https://clinicaltrials.gov/study/NCT00314561 | 1 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | metabolic syndrome | PIOGLITAZONE | targetBased | 4 | Completed | 01/05/2006 | https://clinicaltrials.gov/study/NCT00314561 | 1 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | metabolic syndrome | PIOGLITAZONE | targetBased | 4 | Completed | 01/05/2006 | https://clinicaltrials.gov/study/NCT00314561 | 1 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | metabolic syndrome | PIOGLITAZONE | targetBased | 4 | Completed | 01/05/2006 | https://clinicaltrials.gov/study/NCT00314561 | 1 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | metabolic syndrome | PIOGLITAZONE | targetBased | 4 | Completed | 01/05/2006 | https://clinicaltrials.gov/study/NCT00314561 | 1 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | metabolic syndrome | PIOGLITAZONE | targetBased | 3 | Unknown status | 01/11/2008 | https://clinicaltrials.gov/study/NCT00408850 | 0.7 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | metabolic syndrome | PIOGLITAZONE | targetBased | 3 | Unknown status | 01/11/2008 | https://clinicaltrials.gov/study/NCT00408850 | 0.7 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | metabolic syndrome | PIOGLITAZONE | targetBased | 3 | Unknown status | 01/11/2008 | https://clinicaltrials.gov/study/NCT00408850 | 0.7 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | metabolic syndrome | PIOGLITAZONE | targetBased | 3 | Unknown status | 01/11/2008 | https://clinicaltrials.gov/study/NCT00408850 | 0.7 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | metabolic syndrome | PIOGLITAZONE | targetBased | 3 | Unknown status | 01/11/2008 | https://clinicaltrials.gov/study/NCT00408850 | 0.7 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | metabolic syndrome | PIOGLITAZONE | targetBased | 3 | Unknown status | 01/11/2008 | https://clinicaltrials.gov/study/NCT00408850 | 0.7 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | diabetes mellitus | PIOGLITAZONE | targetBased | 3 | Completed | 01/05/2006 | https://clinicaltrials.gov/study/NCT00327015 | 0.7 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | diabetes mellitus | PIOGLITAZONE | targetBased | 3 | Completed | 01/05/2006 | https://clinicaltrials.gov/study/NCT00327015 | 0.7 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | diabetes mellitus | PIOGLITAZONE | targetBased | 3 | Completed | 01/05/2006 | https://clinicaltrials.gov/study/NCT00327015 | 0.7 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | diabetes mellitus | PIOGLITAZONE | targetBased | 3 | Completed | 01/05/2006 | https://clinicaltrials.gov/study/NCT00327015 | 0.7 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | diabetes mellitus | PIOGLITAZONE | targetBased | 3 | Completed | 01/05/2006 | https://clinicaltrials.gov/study/NCT00327015 | 0.7 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | diabetes mellitus | PIOGLITAZONE | targetBased | 3 | Completed | 01/05/2006 | https://clinicaltrials.gov/study/NCT00327015 | 0.7 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | diabetes mellitus | PIOGLITAZONE | targetBased | 3 | Completed | 01/11/2006 | https://clinicaltrials.gov/study/NCT00395512 | 0.7 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | diabetes mellitus | PIOGLITAZONE | targetBased | 3 | Completed | 01/11/2006 | https://clinicaltrials.gov/study/NCT00395512 | 0.7 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | diabetes mellitus | PIOGLITAZONE | targetBased | 3 | Completed | 01/11/2006 | https://clinicaltrials.gov/study/NCT00395512 | 0.7 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | diabetes mellitus | PIOGLITAZONE | targetBased | 3 | Completed | 01/11/2006 | https://clinicaltrials.gov/study/NCT00395512 | 0.7 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | diabetes mellitus | PIOGLITAZONE | targetBased | 3 | Completed | 01/11/2006 | https://clinicaltrials.gov/study/NCT00395512 | 0.7 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | diabetes mellitus | PIOGLITAZONE | targetBased | 3 | Completed | 01/11/2006 | https://clinicaltrials.gov/study/NCT00395512 | 0.7 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | diabetes mellitus | PIOGLITAZONE | targetBased | 3 | Completed | 01/12/2006 | https://clinicaltrials.gov/study/NCT00770952 | 0.7 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | diabetes mellitus | PIOGLITAZONE | targetBased | 3 | Completed | 01/12/2006 | https://clinicaltrials.gov/study/NCT00770952 | 0.7 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | diabetes mellitus | PIOGLITAZONE | targetBased | 3 | Completed | 01/12/2006 | https://clinicaltrials.gov/study/NCT00770952 | 0.7 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | diabetes mellitus | PIOGLITAZONE | targetBased | 3 | Completed | 01/12/2006 | https://clinicaltrials.gov/study/NCT00770952 | 0.7 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | diabetes mellitus | PIOGLITAZONE | targetBased | 3 | Completed | 01/12/2006 | https://clinicaltrials.gov/study/NCT00770952 | 0.7 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | diabetes mellitus | PIOGLITAZONE | targetBased | 3 | Completed | 01/12/2006 | https://clinicaltrials.gov/study/NCT00770952 | 0.7 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | diabetes mellitus | PIOGLITAZONE | targetBased | 3 | Completed | 01/07/2003 | https://clinicaltrials.gov/study/NCT00225277 | 0.7 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | diabetes mellitus | PIOGLITAZONE | targetBased | 3 | Completed | 01/07/2003 | https://clinicaltrials.gov/study/NCT00225277 | 0.7 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | diabetes mellitus | PIOGLITAZONE | targetBased | 3 | Completed | 01/07/2003 | https://clinicaltrials.gov/study/NCT00225277 | 0.7 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | diabetes mellitus | PIOGLITAZONE | targetBased | 3 | Completed | 01/07/2003 | https://clinicaltrials.gov/study/NCT00225277 | 0.7 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | diabetes mellitus | PIOGLITAZONE | targetBased | 3 | Completed | 01/07/2003 | https://clinicaltrials.gov/study/NCT00225277 | 0.7 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | diabetes mellitus | PIOGLITAZONE | targetBased | 3 | Completed | 01/07/2003 | https://clinicaltrials.gov/study/NCT00225277 | 0.7 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | diabetes mellitus | PIOGLITAZONE | targetBased | 3 | Completed | 01/09/2000 | https://clinicaltrials.gov/study/NCT00331487 | 0.7 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | diabetes mellitus | PIOGLITAZONE | targetBased | 3 | Completed | 01/09/2000 | https://clinicaltrials.gov/study/NCT00331487 | 0.7 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | diabetes mellitus | PIOGLITAZONE | targetBased | 3 | Completed | 01/09/2000 | https://clinicaltrials.gov/study/NCT00331487 | 0.7 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | diabetes mellitus | PIOGLITAZONE | targetBased | 3 | Completed | 01/09/2000 | https://clinicaltrials.gov/study/NCT00331487 | 0.7 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | diabetes mellitus | PIOGLITAZONE | targetBased | 3 | Completed | 01/09/2000 | https://clinicaltrials.gov/study/NCT00331487 | 0.7 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | diabetes mellitus | PIOGLITAZONE | targetBased | 3 | Completed | 01/09/2000 | https://clinicaltrials.gov/study/NCT00331487 | 0.7 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | diabetes mellitus | PIOGLITAZONE | targetBased | 3 | Completed | 01/10/2003 | https://clinicaltrials.gov/study/NCT00225264 | 0.7 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | diabetes mellitus | PIOGLITAZONE | targetBased | 3 | Completed | 01/10/2003 | https://clinicaltrials.gov/study/NCT00225264 | 0.7 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | diabetes mellitus | PIOGLITAZONE | targetBased | 3 | Completed | 01/10/2003 | https://clinicaltrials.gov/study/NCT00225264 | 0.7 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | diabetes mellitus | PIOGLITAZONE | targetBased | 3 | Completed | 01/10/2003 | https://clinicaltrials.gov/study/NCT00225264 | 0.7 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | diabetes mellitus | PIOGLITAZONE | targetBased | 3 | Completed | 01/10/2003 | https://clinicaltrials.gov/study/NCT00225264 | 0.7 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | diabetes mellitus | PIOGLITAZONE | targetBased | 3 | Completed | 01/10/2003 | https://clinicaltrials.gov/study/NCT00225264 | 0.7 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | diabetes mellitus | PIOGLITAZONE | targetBased | 3 | Completed | 01/01/2007 | https://clinicaltrials.gov/study/NCT00432276 | 0.7 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | diabetes mellitus | PIOGLITAZONE | targetBased | 3 | Completed | 01/01/2007 | https://clinicaltrials.gov/study/NCT00432276 | 0.7 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | diabetes mellitus | PIOGLITAZONE | targetBased | 3 | Completed | 01/01/2007 | https://clinicaltrials.gov/study/NCT00432276 | 0.7 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | diabetes mellitus | PIOGLITAZONE | targetBased | 3 | Completed | 01/01/2007 | https://clinicaltrials.gov/study/NCT00432276 | 0.7 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | diabetes mellitus | PIOGLITAZONE | targetBased | 3 | Completed | 01/01/2007 | https://clinicaltrials.gov/study/NCT00432276 | 0.7 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | diabetes mellitus | PIOGLITAZONE | targetBased | 3 | Completed | 01/01/2007 | https://clinicaltrials.gov/study/NCT00432276 | 0.7 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | diabetes mellitus | PIOGLITAZONE | targetBased | 4 | https://www.whocc.no/atc_ddd_index/?code=A10BG03 | 1 | GoF | protect | |||
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | diabetes mellitus | PIOGLITAZONE | targetBased | 4 | https://www.whocc.no/atc_ddd_index/?code=A10BG03 | 1 | GoF | protect | |||
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | diabetes mellitus | PIOGLITAZONE | targetBased | 4 | https://www.whocc.no/atc_ddd_index/?code=A10BG03 | 1 | GoF | protect | |||
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | diabetes mellitus | PIOGLITAZONE | targetBased | 4 | https://www.whocc.no/atc_ddd_index/?code=A10BG03 | 1 | GoF | protect | |||
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | diabetes mellitus | PIOGLITAZONE | targetBased | 4 | https://www.whocc.no/atc_ddd_index/?code=A10BG03 | 1 | GoF | protect | |||
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | diabetes mellitus | PIOGLITAZONE | targetBased | 4 | https://www.whocc.no/atc_ddd_index/?code=A10BG03 | 1 | GoF | protect | |||
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | diabetes mellitus | PIOGLITAZONE | targetBased | 4 | Completed | 01/10/2000 | https://clinicaltrials.gov/study/NCT00494312 | 1 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | diabetes mellitus | PIOGLITAZONE | targetBased | 4 | Completed | 01/10/2000 | https://clinicaltrials.gov/study/NCT00494312 | 1 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | diabetes mellitus | PIOGLITAZONE | targetBased | 4 | Completed | 01/10/2000 | https://clinicaltrials.gov/study/NCT00494312 | 1 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | diabetes mellitus | PIOGLITAZONE | targetBased | 4 | Completed | 01/10/2000 | https://clinicaltrials.gov/study/NCT00494312 | 1 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | diabetes mellitus | PIOGLITAZONE | targetBased | 4 | Completed | 01/10/2000 | https://clinicaltrials.gov/study/NCT00494312 | 1 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | diabetes mellitus | PIOGLITAZONE | targetBased | 4 | Completed | 01/10/2000 | https://clinicaltrials.gov/study/NCT00494312 | 1 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | diabetes mellitus | PIOGLITAZONE | targetBased | 4 | Completed | 01/10/2008 | https://clinicaltrials.gov/study/NCT00770367 | 1 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | diabetes mellitus | PIOGLITAZONE | targetBased | 4 | Completed | 01/10/2008 | https://clinicaltrials.gov/study/NCT00770367 | 1 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | diabetes mellitus | PIOGLITAZONE | targetBased | 4 | Completed | 01/10/2008 | https://clinicaltrials.gov/study/NCT00770367 | 1 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | diabetes mellitus | PIOGLITAZONE | targetBased | 4 | Completed | 01/10/2008 | https://clinicaltrials.gov/study/NCT00770367 | 1 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | diabetes mellitus | PIOGLITAZONE | targetBased | 4 | Completed | 01/10/2008 | https://clinicaltrials.gov/study/NCT00770367 | 1 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | diabetes mellitus | PIOGLITAZONE | targetBased | 4 | Completed | 01/10/2008 | https://clinicaltrials.gov/study/NCT00770367 | 1 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | diabetes mellitus | PIOGLITAZONE | targetBased | 3 | Completed | 01/05/2001 | https://clinicaltrials.gov/study/NCT00174993 | 0.7 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | diabetes mellitus | PIOGLITAZONE | targetBased | 3 | Completed | 01/05/2001 | https://clinicaltrials.gov/study/NCT00174993 | 0.7 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | diabetes mellitus | PIOGLITAZONE | targetBased | 3 | Completed | 01/05/2001 | https://clinicaltrials.gov/study/NCT00174993 | 0.7 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | diabetes mellitus | PIOGLITAZONE | targetBased | 3 | Completed | 01/05/2001 | https://clinicaltrials.gov/study/NCT00174993 | 0.7 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | diabetes mellitus | PIOGLITAZONE | targetBased | 3 | Completed | 01/05/2001 | https://clinicaltrials.gov/study/NCT00174993 | 0.7 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | diabetes mellitus | PIOGLITAZONE | targetBased | 3 | Completed | 01/05/2001 | https://clinicaltrials.gov/study/NCT00174993 | 0.7 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | diabetes mellitus | PIOGLITAZONE | targetBased | 3 | Completed | 01/02/2006 | https://clinicaltrials.gov/study/NCT00286494 | 0.7 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | diabetes mellitus | PIOGLITAZONE | targetBased | 3 | Completed | 01/02/2006 | https://clinicaltrials.gov/study/NCT00286494 | 0.7 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | diabetes mellitus | PIOGLITAZONE | targetBased | 3 | Completed | 01/02/2006 | https://clinicaltrials.gov/study/NCT00286494 | 0.7 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | diabetes mellitus | PIOGLITAZONE | targetBased | 3 | Completed | 01/02/2006 | https://clinicaltrials.gov/study/NCT00286494 | 0.7 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | diabetes mellitus | PIOGLITAZONE | targetBased | 3 | Completed | 01/02/2006 | https://clinicaltrials.gov/study/NCT00286494 | 0.7 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | diabetes mellitus | PIOGLITAZONE | targetBased | 3 | Completed | 01/02/2006 | https://clinicaltrials.gov/study/NCT00286494 | 0.7 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | diabetes mellitus | PIOGLITAZONE | targetBased | 3 | Completed | 28/05/2021 | https://clinicaltrials.gov/study/NCT04885712 | 0.7 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | diabetes mellitus | PIOGLITAZONE | targetBased | 3 | Completed | 28/05/2021 | https://clinicaltrials.gov/study/NCT04885712 | 0.7 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | diabetes mellitus | PIOGLITAZONE | targetBased | 3 | Completed | 28/05/2021 | https://clinicaltrials.gov/study/NCT04885712 | 0.7 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | diabetes mellitus | PIOGLITAZONE | targetBased | 3 | Completed | 28/05/2021 | https://clinicaltrials.gov/study/NCT04885712 | 0.7 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | diabetes mellitus | PIOGLITAZONE | targetBased | 3 | Completed | 28/05/2021 | https://clinicaltrials.gov/study/NCT04885712 | 0.7 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | diabetes mellitus | PIOGLITAZONE | targetBased | 3 | Completed | 28/05/2021 | https://clinicaltrials.gov/study/NCT04885712 | 0.7 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | diabetes mellitus | PIOGLITAZONE | targetBased | 4 | Completed | 01/04/2008 | https://clinicaltrials.gov/study/NCT00485056 | 1 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | diabetes mellitus | PIOGLITAZONE | targetBased | 4 | Completed | 01/04/2008 | https://clinicaltrials.gov/study/NCT00485056 | 1 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | diabetes mellitus | PIOGLITAZONE | targetBased | 4 | Completed | 01/04/2008 | https://clinicaltrials.gov/study/NCT00485056 | 1 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | diabetes mellitus | PIOGLITAZONE | targetBased | 4 | Completed | 01/04/2008 | https://clinicaltrials.gov/study/NCT00485056 | 1 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | diabetes mellitus | PIOGLITAZONE | targetBased | 4 | Completed | 01/04/2008 | https://clinicaltrials.gov/study/NCT00485056 | 1 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | diabetes mellitus | PIOGLITAZONE | targetBased | 4 | Completed | 01/04/2008 | https://clinicaltrials.gov/study/NCT00485056 | 1 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | diabetes mellitus | PIOGLITAZONE | targetBased | 4 | Recruiting | 07/08/2020 | https://clinicaltrials.gov/study/NCT04416269 | 1 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | diabetes mellitus | PIOGLITAZONE | targetBased | 4 | Recruiting | 07/08/2020 | https://clinicaltrials.gov/study/NCT04416269 | 1 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | diabetes mellitus | PIOGLITAZONE | targetBased | 4 | Recruiting | 07/08/2020 | https://clinicaltrials.gov/study/NCT04416269 | 1 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | diabetes mellitus | PIOGLITAZONE | targetBased | 4 | Recruiting | 07/08/2020 | https://clinicaltrials.gov/study/NCT04416269 | 1 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | diabetes mellitus | PIOGLITAZONE | targetBased | 4 | Recruiting | 07/08/2020 | https://clinicaltrials.gov/study/NCT04416269 | 1 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | diabetes mellitus | PIOGLITAZONE | targetBased | 4 | Recruiting | 07/08/2020 | https://clinicaltrials.gov/study/NCT04416269 | 1 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | diabetes mellitus | PIOGLITAZONE | targetBased | 4 | Unknown status | 01/07/2010 | https://clinicaltrials.gov/study/NCT01175486 | 1 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | diabetes mellitus | PIOGLITAZONE | targetBased | 4 | Unknown status | 01/07/2010 | https://clinicaltrials.gov/study/NCT01175486 | 1 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | diabetes mellitus | PIOGLITAZONE | targetBased | 4 | Unknown status | 01/07/2010 | https://clinicaltrials.gov/study/NCT01175486 | 1 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | diabetes mellitus | PIOGLITAZONE | targetBased | 4 | Unknown status | 01/07/2010 | https://clinicaltrials.gov/study/NCT01175486 | 1 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | diabetes mellitus | PIOGLITAZONE | targetBased | 4 | Unknown status | 01/07/2010 | https://clinicaltrials.gov/study/NCT01175486 | 1 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | diabetes mellitus | PIOGLITAZONE | targetBased | 4 | Unknown status | 01/07/2010 | https://clinicaltrials.gov/study/NCT01175486 | 1 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | diabetes mellitus | PIOGLITAZONE | targetBased | 4 | Completed | 01/01/2008 | https://clinicaltrials.gov/study/NCT03030300 | 1 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | diabetes mellitus | PIOGLITAZONE | targetBased | 4 | Completed | 01/01/2008 | https://clinicaltrials.gov/study/NCT03030300 | 1 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | diabetes mellitus | PIOGLITAZONE | targetBased | 4 | Completed | 01/01/2008 | https://clinicaltrials.gov/study/NCT03030300 | 1 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | diabetes mellitus | PIOGLITAZONE | targetBased | 4 | Completed | 01/01/2008 | https://clinicaltrials.gov/study/NCT03030300 | 1 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | diabetes mellitus | PIOGLITAZONE | targetBased | 4 | Completed | 01/01/2008 | https://clinicaltrials.gov/study/NCT03030300 | 1 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | diabetes mellitus | PIOGLITAZONE | targetBased | 4 | Completed | 01/01/2008 | https://clinicaltrials.gov/study/NCT03030300 | 1 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | diabetes mellitus | PIOGLITAZONE | targetBased | 3 | Completed | 01/01/2007 | https://clinicaltrials.gov/study/NCT00772174 | 0.7 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | diabetes mellitus | PIOGLITAZONE | targetBased | 3 | Completed | 01/01/2007 | https://clinicaltrials.gov/study/NCT00772174 | 0.7 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | diabetes mellitus | PIOGLITAZONE | targetBased | 3 | Completed | 01/01/2007 | https://clinicaltrials.gov/study/NCT00772174 | 0.7 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | diabetes mellitus | PIOGLITAZONE | targetBased | 3 | Completed | 01/01/2007 | https://clinicaltrials.gov/study/NCT00772174 | 0.7 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | diabetes mellitus | PIOGLITAZONE | targetBased | 3 | Completed | 01/01/2007 | https://clinicaltrials.gov/study/NCT00772174 | 0.7 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | diabetes mellitus | PIOGLITAZONE | targetBased | 3 | Completed | 01/01/2007 | https://clinicaltrials.gov/study/NCT00772174 | 0.7 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | diabetes mellitus | PIOGLITAZONE | targetBased | 4 | Completed | 01/11/2003 | https://clinicaltrials.gov/study/NCT00672919 | 1 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | diabetes mellitus | PIOGLITAZONE | targetBased | 4 | Completed | 01/11/2003 | https://clinicaltrials.gov/study/NCT00672919 | 1 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | diabetes mellitus | PIOGLITAZONE | targetBased | 4 | Completed | 01/11/2003 | https://clinicaltrials.gov/study/NCT00672919 | 1 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | diabetes mellitus | PIOGLITAZONE | targetBased | 4 | Completed | 01/11/2003 | https://clinicaltrials.gov/study/NCT00672919 | 1 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | diabetes mellitus | PIOGLITAZONE | targetBased | 4 | Completed | 01/11/2003 | https://clinicaltrials.gov/study/NCT00672919 | 1 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | diabetes mellitus | PIOGLITAZONE | targetBased | 4 | Completed | 01/11/2003 | https://clinicaltrials.gov/study/NCT00672919 | 1 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | diabetes mellitus | PIOGLITAZONE | targetBased | 3 | Completed | 01/03/2001 | https://clinicaltrials.gov/study/NCT00521742 | 0.7 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | diabetes mellitus | PIOGLITAZONE | targetBased | 3 | Completed | 01/03/2001 | https://clinicaltrials.gov/study/NCT00521742 | 0.7 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | diabetes mellitus | PIOGLITAZONE | targetBased | 3 | Completed | 01/03/2001 | https://clinicaltrials.gov/study/NCT00521742 | 0.7 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | diabetes mellitus | PIOGLITAZONE | targetBased | 3 | Completed | 01/03/2001 | https://clinicaltrials.gov/study/NCT00521742 | 0.7 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | diabetes mellitus | PIOGLITAZONE | targetBased | 3 | Completed | 01/03/2001 | https://clinicaltrials.gov/study/NCT00521742 | 0.7 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | diabetes mellitus | PIOGLITAZONE | targetBased | 3 | Completed | 01/03/2001 | https://clinicaltrials.gov/study/NCT00521742 | 0.7 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | diabetes mellitus | PIOGLITAZONE | targetBased | 4 | Completed | 01/01/2004 | https://clinicaltrials.gov/study/NCT00108615 | 1 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | diabetes mellitus | PIOGLITAZONE | targetBased | 4 | Completed | 01/01/2004 | https://clinicaltrials.gov/study/NCT00108615 | 1 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | diabetes mellitus | PIOGLITAZONE | targetBased | 4 | Completed | 01/01/2004 | https://clinicaltrials.gov/study/NCT00108615 | 1 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | diabetes mellitus | PIOGLITAZONE | targetBased | 4 | Completed | 01/01/2004 | https://clinicaltrials.gov/study/NCT00108615 | 1 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | diabetes mellitus | PIOGLITAZONE | targetBased | 4 | Completed | 01/01/2004 | https://clinicaltrials.gov/study/NCT00108615 | 1 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | diabetes mellitus | PIOGLITAZONE | targetBased | 4 | Completed | 01/01/2004 | https://clinicaltrials.gov/study/NCT00108615 | 1 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | diabetes mellitus | PIOGLITAZONE | targetBased | 3 | Completed | 01/08/2004 | https://clinicaltrials.gov/study/NCT00097279 | 0.7 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | diabetes mellitus | PIOGLITAZONE | targetBased | 3 | Completed | 01/08/2004 | https://clinicaltrials.gov/study/NCT00097279 | 0.7 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | diabetes mellitus | PIOGLITAZONE | targetBased | 3 | Completed | 01/08/2004 | https://clinicaltrials.gov/study/NCT00097279 | 0.7 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | diabetes mellitus | PIOGLITAZONE | targetBased | 3 | Completed | 01/08/2004 | https://clinicaltrials.gov/study/NCT00097279 | 0.7 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | diabetes mellitus | PIOGLITAZONE | targetBased | 3 | Completed | 01/08/2004 | https://clinicaltrials.gov/study/NCT00097279 | 0.7 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | diabetes mellitus | PIOGLITAZONE | targetBased | 3 | Completed | 01/08/2004 | https://clinicaltrials.gov/study/NCT00097279 | 0.7 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | diabetes mellitus | PIOGLITAZONE | targetBased | 4 | Completed | 01/03/2009 | https://clinicaltrials.gov/study/NCT00770835 | 1 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | diabetes mellitus | PIOGLITAZONE | targetBased | 4 | Completed | 01/03/2009 | https://clinicaltrials.gov/study/NCT00770835 | 1 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | diabetes mellitus | PIOGLITAZONE | targetBased | 4 | Completed | 01/03/2009 | https://clinicaltrials.gov/study/NCT00770835 | 1 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | diabetes mellitus | PIOGLITAZONE | targetBased | 4 | Completed | 01/03/2009 | https://clinicaltrials.gov/study/NCT00770835 | 1 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | diabetes mellitus | PIOGLITAZONE | targetBased | 4 | Completed | 01/03/2009 | https://clinicaltrials.gov/study/NCT00770835 | 1 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | diabetes mellitus | PIOGLITAZONE | targetBased | 4 | Completed | 01/03/2009 | https://clinicaltrials.gov/study/NCT00770835 | 1 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | diabetes mellitus | PIOGLITAZONE | targetBased | 3 | Completed | 01/06/2007 | https://clinicaltrials.gov/study/NCT00727857 | 0.7 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | diabetes mellitus | PIOGLITAZONE | targetBased | 3 | Completed | 01/06/2007 | https://clinicaltrials.gov/study/NCT00727857 | 0.7 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | diabetes mellitus | PIOGLITAZONE | targetBased | 3 | Completed | 01/06/2007 | https://clinicaltrials.gov/study/NCT00727857 | 0.7 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | diabetes mellitus | PIOGLITAZONE | targetBased | 3 | Completed | 01/06/2007 | https://clinicaltrials.gov/study/NCT00727857 | 0.7 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | diabetes mellitus | PIOGLITAZONE | targetBased | 3 | Completed | 01/06/2007 | https://clinicaltrials.gov/study/NCT00727857 | 0.7 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | diabetes mellitus | PIOGLITAZONE | targetBased | 3 | Completed | 01/06/2007 | https://clinicaltrials.gov/study/NCT00727857 | 0.7 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | diabetes mellitus | PIOGLITAZONE | targetBased | 3 | Terminated | 01/06/2000 | https://clinicaltrials.gov/study/NCT00521820 | 0.35 | GoF | protect | Higher incidence of hospitalization for congestive heart failure in pioglitazone-treated subjects compared to glyburide treated subjects. |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | diabetes mellitus | PIOGLITAZONE | targetBased | 3 | Terminated | 01/06/2000 | https://clinicaltrials.gov/study/NCT00521820 | 0.35 | GoF | protect | Higher incidence of hospitalization for congestive heart failure in pioglitazone-treated subjects compared to glyburide treated subjects. |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | diabetes mellitus | PIOGLITAZONE | targetBased | 3 | Terminated | 01/06/2000 | https://clinicaltrials.gov/study/NCT00521820 | 0.35 | GoF | protect | Higher incidence of hospitalization for congestive heart failure in pioglitazone-treated subjects compared to glyburide treated subjects. |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | diabetes mellitus | PIOGLITAZONE | targetBased | 3 | Terminated | 01/06/2000 | https://clinicaltrials.gov/study/NCT00521820 | 0.35 | GoF | protect | Higher incidence of hospitalization for congestive heart failure in pioglitazone-treated subjects compared to glyburide treated subjects. |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | diabetes mellitus | PIOGLITAZONE | targetBased | 3 | Terminated | 01/06/2000 | https://clinicaltrials.gov/study/NCT00521820 | 0.35 | GoF | protect | Higher incidence of hospitalization for congestive heart failure in pioglitazone-treated subjects compared to glyburide treated subjects. |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | diabetes mellitus | PIOGLITAZONE | targetBased | 3 | Terminated | 01/06/2000 | https://clinicaltrials.gov/study/NCT00521820 | 0.35 | GoF | protect | Higher incidence of hospitalization for congestive heart failure in pioglitazone-treated subjects compared to glyburide treated subjects. |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | diabetes mellitus | PIOGLITAZONE | targetBased | 4 | Completed | 01/01/2009 | https://clinicaltrials.gov/study/NCT01107717 | 1 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | diabetes mellitus | PIOGLITAZONE | targetBased | 4 | Completed | 01/01/2009 | https://clinicaltrials.gov/study/NCT01107717 | 1 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | diabetes mellitus | PIOGLITAZONE | targetBased | 4 | Completed | 01/01/2009 | https://clinicaltrials.gov/study/NCT01107717 | 1 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | diabetes mellitus | PIOGLITAZONE | targetBased | 4 | Completed | 01/01/2009 | https://clinicaltrials.gov/study/NCT01107717 | 1 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | diabetes mellitus | PIOGLITAZONE | targetBased | 4 | Completed | 01/01/2009 | https://clinicaltrials.gov/study/NCT01107717 | 1 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | diabetes mellitus | PIOGLITAZONE | targetBased | 4 | Completed | 01/01/2009 | https://clinicaltrials.gov/study/NCT01107717 | 1 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | diabetes mellitus | PIOGLITAZONE | targetBased | 3 | Completed | 01/07/2007 | https://clinicaltrials.gov/study/NCT00655863 | 0.7 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | diabetes mellitus | PIOGLITAZONE | targetBased | 3 | Completed | 01/07/2007 | https://clinicaltrials.gov/study/NCT00655863 | 0.7 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | diabetes mellitus | PIOGLITAZONE | targetBased | 3 | Completed | 01/07/2007 | https://clinicaltrials.gov/study/NCT00655863 | 0.7 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | diabetes mellitus | PIOGLITAZONE | targetBased | 3 | Completed | 01/07/2007 | https://clinicaltrials.gov/study/NCT00655863 | 0.7 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | diabetes mellitus | PIOGLITAZONE | targetBased | 3 | Completed | 01/07/2007 | https://clinicaltrials.gov/study/NCT00655863 | 0.7 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | diabetes mellitus | PIOGLITAZONE | targetBased | 3 | Completed | 01/07/2007 | https://clinicaltrials.gov/study/NCT00655863 | 0.7 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | diabetes mellitus | PIOGLITAZONE | targetBased | 4 | Completed | 01/03/2002 | https://clinicaltrials.gov/study/NCT01799850 | 1 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | diabetes mellitus | PIOGLITAZONE | targetBased | 4 | Completed | 01/03/2002 | https://clinicaltrials.gov/study/NCT01799850 | 1 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | diabetes mellitus | PIOGLITAZONE | targetBased | 4 | Completed | 01/03/2002 | https://clinicaltrials.gov/study/NCT01799850 | 1 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | diabetes mellitus | PIOGLITAZONE | targetBased | 4 | Completed | 01/03/2002 | https://clinicaltrials.gov/study/NCT01799850 | 1 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | diabetes mellitus | PIOGLITAZONE | targetBased | 4 | Completed | 01/03/2002 | https://clinicaltrials.gov/study/NCT01799850 | 1 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | diabetes mellitus | PIOGLITAZONE | targetBased | 4 | Completed | 01/03/2002 | https://clinicaltrials.gov/study/NCT01799850 | 1 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | diabetes mellitus | PIOGLITAZONE | targetBased | 4 | Not yet recruiting | 02/03/2020 | https://clinicaltrials.gov/study/NCT04287387 | 1 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | diabetes mellitus | PIOGLITAZONE | targetBased | 4 | Not yet recruiting | 02/03/2020 | https://clinicaltrials.gov/study/NCT04287387 | 1 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | diabetes mellitus | PIOGLITAZONE | targetBased | 4 | Not yet recruiting | 02/03/2020 | https://clinicaltrials.gov/study/NCT04287387 | 1 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | diabetes mellitus | PIOGLITAZONE | targetBased | 4 | Not yet recruiting | 02/03/2020 | https://clinicaltrials.gov/study/NCT04287387 | 1 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | diabetes mellitus | PIOGLITAZONE | targetBased | 4 | Not yet recruiting | 02/03/2020 | https://clinicaltrials.gov/study/NCT04287387 | 1 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | diabetes mellitus | PIOGLITAZONE | targetBased | 4 | Not yet recruiting | 02/03/2020 | https://clinicaltrials.gov/study/NCT04287387 | 1 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | diabetes mellitus | PIOGLITAZONE | targetBased | 4 | Completed | 01/07/2005 | https://clinicaltrials.gov/study/NCT00754403 | 1 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | diabetes mellitus | PIOGLITAZONE | targetBased | 4 | Completed | 01/07/2005 | https://clinicaltrials.gov/study/NCT00754403 | 1 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | diabetes mellitus | PIOGLITAZONE | targetBased | 4 | Completed | 01/07/2005 | https://clinicaltrials.gov/study/NCT00754403 | 1 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | diabetes mellitus | PIOGLITAZONE | targetBased | 4 | Completed | 01/07/2005 | https://clinicaltrials.gov/study/NCT00754403 | 1 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | diabetes mellitus | PIOGLITAZONE | targetBased | 4 | Completed | 01/07/2005 | https://clinicaltrials.gov/study/NCT00754403 | 1 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | diabetes mellitus | PIOGLITAZONE | targetBased | 4 | Completed | 01/07/2005 | https://clinicaltrials.gov/study/NCT00754403 | 1 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | diabetes mellitus | PIOGLITAZONE | targetBased | 4 | Completed | 01/05/2008 | https://clinicaltrials.gov/study/NCT00770445 | 1 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | diabetes mellitus | PIOGLITAZONE | targetBased | 4 | Completed | 01/05/2008 | https://clinicaltrials.gov/study/NCT00770445 | 1 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | diabetes mellitus | PIOGLITAZONE | targetBased | 4 | Completed | 01/05/2008 | https://clinicaltrials.gov/study/NCT00770445 | 1 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | diabetes mellitus | PIOGLITAZONE | targetBased | 4 | Completed | 01/05/2008 | https://clinicaltrials.gov/study/NCT00770445 | 1 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | diabetes mellitus | PIOGLITAZONE | targetBased | 4 | Completed | 01/05/2008 | https://clinicaltrials.gov/study/NCT00770445 | 1 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | diabetes mellitus | PIOGLITAZONE | targetBased | 4 | Completed | 01/05/2008 | https://clinicaltrials.gov/study/NCT00770445 | 1 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | diabetes mellitus | PIOGLITAZONE | targetBased | 4 | Completed | 01/09/2012 | https://clinicaltrials.gov/study/NCT01686711 | 1 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | diabetes mellitus | PIOGLITAZONE | targetBased | 4 | Completed | 01/09/2012 | https://clinicaltrials.gov/study/NCT01686711 | 1 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | diabetes mellitus | PIOGLITAZONE | targetBased | 4 | Completed | 01/09/2012 | https://clinicaltrials.gov/study/NCT01686711 | 1 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | diabetes mellitus | PIOGLITAZONE | targetBased | 4 | Completed | 01/09/2012 | https://clinicaltrials.gov/study/NCT01686711 | 1 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | diabetes mellitus | PIOGLITAZONE | targetBased | 4 | Completed | 01/09/2012 | https://clinicaltrials.gov/study/NCT01686711 | 1 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | diabetes mellitus | PIOGLITAZONE | targetBased | 4 | Completed | 01/09/2012 | https://clinicaltrials.gov/study/NCT01686711 | 1 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | metabolic disease | PIOGLITAZONE | targetBased | 4 | Withdrawn | https://clinicaltrials.gov/study/NCT00306826 | 1 | GoF | protect | financial support withdrawn | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | metabolic disease | PIOGLITAZONE | targetBased | 4 | Withdrawn | https://clinicaltrials.gov/study/NCT00306826 | 1 | GoF | protect | financial support withdrawn | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | metabolic disease | PIOGLITAZONE | targetBased | 4 | Withdrawn | https://clinicaltrials.gov/study/NCT00306826 | 1 | GoF | protect | financial support withdrawn | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | metabolic disease | PIOGLITAZONE | targetBased | 4 | Withdrawn | https://clinicaltrials.gov/study/NCT00306826 | 1 | GoF | protect | financial support withdrawn | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | metabolic disease | PIOGLITAZONE | targetBased | 4 | Withdrawn | https://clinicaltrials.gov/study/NCT00306826 | 1 | GoF | protect | financial support withdrawn | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | metabolic disease | PIOGLITAZONE | targetBased | 4 | Withdrawn | https://clinicaltrials.gov/study/NCT00306826 | 1 | GoF | protect | financial support withdrawn | |
| Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors | OPRM1 | OPRM1 | Mu-type opioid receptor | obesity | FENTANYL | targetBased | 3 | Completed | 01/03/2016 | https://clinicaltrials.gov/study/NCT02880540 | 0.7 | GoF | protect | |
| Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors | OPRM1 | OPRM1 | Mu-type opioid receptor | obesity | FENTANYL | targetBased | 3 | Completed | 01/03/2016 | https://clinicaltrials.gov/study/NCT02880540 | 0.7 | GoF | protect | |
| Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors | OPRM1 | OPRM1 | Mu-type opioid receptor | gallstones | FENTANYL | targetBased | 4 | Completed | 01/01/2015 | https://clinicaltrials.gov/study/NCT02327923 | 1 | GoF | protect | |
| Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors | OPRM1 | OPRM1 | Mu-type opioid receptor | gallstones | FENTANYL | targetBased | 4 | Completed | 01/01/2015 | https://clinicaltrials.gov/study/NCT02327923 | 1 | GoF | protect | |
| Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors | OPRM1 | OPRM1 | Mu-type opioid receptor | morbid obesity | FENTANYL | targetBased | 3 | Unknown status | 01/06/2012 | https://clinicaltrials.gov/study/NCT01724983 | 0.7 | GoF | protect | |
| Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors | OPRM1 | OPRM1 | Mu-type opioid receptor | morbid obesity | FENTANYL | targetBased | 3 | Unknown status | 01/06/2012 | https://clinicaltrials.gov/study/NCT01724983 | 0.7 | GoF | protect | |
| Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors | OPRM1 | OPRM1 | Mu-type opioid receptor | liver disease | FENTANYL | targetBased | 3 | Recruiting | 04/10/2017 | https://clinicaltrials.gov/study/NCT03214510 | 0.7 | GoF | protect | |
| Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors | OPRM1 | OPRM1 | Mu-type opioid receptor | liver disease | FENTANYL | targetBased | 3 | Recruiting | 04/10/2017 | https://clinicaltrials.gov/study/NCT03214510 | 0.7 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | insulin resistance | ROSIGLITAZONE | targetBased | 3 | Completed | 01/10/2002 | https://clinicaltrials.gov/study/NCT00197132 | 0.7 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | insulin resistance | ROSIGLITAZONE | targetBased | 3 | Completed | 01/10/2002 | https://clinicaltrials.gov/study/NCT00197132 | 0.7 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | insulin resistance | ROSIGLITAZONE | targetBased | 3 | Completed | 01/10/2002 | https://clinicaltrials.gov/study/NCT00197132 | 0.7 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | insulin resistance | ROSIGLITAZONE | targetBased | 3 | Completed | 01/10/2002 | https://clinicaltrials.gov/study/NCT00197132 | 0.7 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | insulin resistance | ROSIGLITAZONE | targetBased | 3 | Completed | 01/10/2002 | https://clinicaltrials.gov/study/NCT00197132 | 0.7 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | insulin resistance | ROSIGLITAZONE | targetBased | 3 | Completed | 01/10/2002 | https://clinicaltrials.gov/study/NCT00197132 | 0.7 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | non-alcoholic fatty liver disease | ROSIGLITAZONE | targetBased | 4 | Terminated | 01/01/2004 | https://clinicaltrials.gov/study/NCT01406704 | 1 | GoF | protect | because of withdrawal of Avandia sale due to its risks outweigh its benefits |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | non-alcoholic fatty liver disease | ROSIGLITAZONE | targetBased | 4 | Terminated | 01/01/2004 | https://clinicaltrials.gov/study/NCT01406704 | 1 | GoF | protect | because of withdrawal of Avandia sale due to its risks outweigh its benefits |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | non-alcoholic fatty liver disease | ROSIGLITAZONE | targetBased | 4 | Terminated | 01/01/2004 | https://clinicaltrials.gov/study/NCT01406704 | 1 | GoF | protect | because of withdrawal of Avandia sale due to its risks outweigh its benefits |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | non-alcoholic fatty liver disease | ROSIGLITAZONE | targetBased | 4 | Terminated | 01/01/2004 | https://clinicaltrials.gov/study/NCT01406704 | 1 | GoF | protect | because of withdrawal of Avandia sale due to its risks outweigh its benefits |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | non-alcoholic fatty liver disease | ROSIGLITAZONE | targetBased | 4 | Terminated | 01/01/2004 | https://clinicaltrials.gov/study/NCT01406704 | 1 | GoF | protect | because of withdrawal of Avandia sale due to its risks outweigh its benefits |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | non-alcoholic fatty liver disease | ROSIGLITAZONE | targetBased | 4 | Terminated | 01/01/2004 | https://clinicaltrials.gov/study/NCT01406704 | 1 | GoF | protect | because of withdrawal of Avandia sale due to its risks outweigh its benefits |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 1 diabetes mellitus | ROSIGLITAZONE | targetBased | 4 | Completed | 01/08/2003 | https://clinicaltrials.gov/study/NCT00372086 | 1 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 1 diabetes mellitus | ROSIGLITAZONE | targetBased | 4 | Completed | 01/08/2003 | https://clinicaltrials.gov/study/NCT00372086 | 1 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 1 diabetes mellitus | ROSIGLITAZONE | targetBased | 4 | Completed | 01/08/2003 | https://clinicaltrials.gov/study/NCT00372086 | 1 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 1 diabetes mellitus | ROSIGLITAZONE | targetBased | 4 | Completed | 01/08/2003 | https://clinicaltrials.gov/study/NCT00372086 | 1 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 1 diabetes mellitus | ROSIGLITAZONE | targetBased | 4 | Completed | 01/08/2003 | https://clinicaltrials.gov/study/NCT00372086 | 1 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 1 diabetes mellitus | ROSIGLITAZONE | targetBased | 4 | Completed | 01/08/2003 | https://clinicaltrials.gov/study/NCT00372086 | 1 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | Disorder of lipid metabolism | ROSIGLITAZONE | targetBased | 3 | Terminated | 01/06/2006 | https://clinicaltrials.gov/study/NCT00361868 | 0.7 | GoF | protect | The study was discontinued prematurely at the end of March 2007 due to slow enrolment. |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | Disorder of lipid metabolism | ROSIGLITAZONE | targetBased | 3 | Terminated | 01/06/2006 | https://clinicaltrials.gov/study/NCT00361868 | 0.7 | GoF | protect | The study was discontinued prematurely at the end of March 2007 due to slow enrolment. |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | Disorder of lipid metabolism | ROSIGLITAZONE | targetBased | 3 | Terminated | 01/06/2006 | https://clinicaltrials.gov/study/NCT00361868 | 0.7 | GoF | protect | The study was discontinued prematurely at the end of March 2007 due to slow enrolment. |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | Disorder of lipid metabolism | ROSIGLITAZONE | targetBased | 3 | Terminated | 01/06/2006 | https://clinicaltrials.gov/study/NCT00361868 | 0.7 | GoF | protect | The study was discontinued prematurely at the end of March 2007 due to slow enrolment. |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | Disorder of lipid metabolism | ROSIGLITAZONE | targetBased | 3 | Terminated | 01/06/2006 | https://clinicaltrials.gov/study/NCT00361868 | 0.7 | GoF | protect | The study was discontinued prematurely at the end of March 2007 due to slow enrolment. |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | Disorder of lipid metabolism | ROSIGLITAZONE | targetBased | 3 | Terminated | 01/06/2006 | https://clinicaltrials.gov/study/NCT00361868 | 0.7 | GoF | protect | The study was discontinued prematurely at the end of March 2007 due to slow enrolment. |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | ROSIGLITAZONE | targetBased | 4 | Completed | 25/06/2003 | https://clinicaltrials.gov/study/NCT00241605 | 1 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | ROSIGLITAZONE | targetBased | 4 | Completed | 25/06/2003 | https://clinicaltrials.gov/study/NCT00241605 | 1 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | ROSIGLITAZONE | targetBased | 4 | Completed | 25/06/2003 | https://clinicaltrials.gov/study/NCT00241605 | 1 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | ROSIGLITAZONE | targetBased | 4 | Completed | 25/06/2003 | https://clinicaltrials.gov/study/NCT00241605 | 1 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | ROSIGLITAZONE | targetBased | 4 | Completed | 25/06/2003 | https://clinicaltrials.gov/study/NCT00241605 | 1 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | ROSIGLITAZONE | targetBased | 4 | Completed | 25/06/2003 | https://clinicaltrials.gov/study/NCT00241605 | 1 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | ROSIGLITAZONE | targetBased | 3 | Completed | 01/04/2001 | https://clinicaltrials.gov/study/NCT00379769 | 0.7 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | ROSIGLITAZONE | targetBased | 3 | Completed | 01/04/2001 | https://clinicaltrials.gov/study/NCT00379769 | 0.7 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | ROSIGLITAZONE | targetBased | 3 | Completed | 01/04/2001 | https://clinicaltrials.gov/study/NCT00379769 | 0.7 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | ROSIGLITAZONE | targetBased | 3 | Completed | 01/04/2001 | https://clinicaltrials.gov/study/NCT00379769 | 0.7 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | ROSIGLITAZONE | targetBased | 3 | Completed | 01/04/2001 | https://clinicaltrials.gov/study/NCT00379769 | 0.7 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | ROSIGLITAZONE | targetBased | 3 | Completed | 01/04/2001 | https://clinicaltrials.gov/study/NCT00379769 | 0.7 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | ROSIGLITAZONE | targetBased | 4 | https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/200678s016lbledt.pdf | 1 | GoF | protect | |||
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | ROSIGLITAZONE | targetBased | 4 | https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/200678s016lbledt.pdf | 1 | GoF | protect | |||
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | ROSIGLITAZONE | targetBased | 4 | https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/200678s016lbledt.pdf | 1 | GoF | protect | |||
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | ROSIGLITAZONE | targetBased | 4 | https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/200678s016lbledt.pdf | 1 | GoF | protect | |||
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | ROSIGLITAZONE | targetBased | 4 | https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/200678s016lbledt.pdf | 1 | GoF | protect | |||
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | ROSIGLITAZONE | targetBased | 4 | https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/200678s016lbledt.pdf | 1 | GoF | protect | |||
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | ROSIGLITAZONE | targetBased | 3 | Completed | 03/01/2000 | https://clinicaltrials.gov/study/NCT00279045 | 0.7 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | ROSIGLITAZONE | targetBased | 3 | Completed | 03/01/2000 | https://clinicaltrials.gov/study/NCT00279045 | 0.7 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | ROSIGLITAZONE | targetBased | 3 | Completed | 03/01/2000 | https://clinicaltrials.gov/study/NCT00279045 | 0.7 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | ROSIGLITAZONE | targetBased | 3 | Completed | 03/01/2000 | https://clinicaltrials.gov/study/NCT00279045 | 0.7 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | ROSIGLITAZONE | targetBased | 3 | Completed | 03/01/2000 | https://clinicaltrials.gov/study/NCT00279045 | 0.7 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | ROSIGLITAZONE | targetBased | 3 | Completed | 03/01/2000 | https://clinicaltrials.gov/study/NCT00279045 | 0.7 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | ROSIGLITAZONE | targetBased | 3 | Completed | 01/09/2005 | https://clinicaltrials.gov/study/NCT00131664 | 0.7 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | ROSIGLITAZONE | targetBased | 3 | Completed | 01/09/2005 | https://clinicaltrials.gov/study/NCT00131664 | 0.7 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | ROSIGLITAZONE | targetBased | 3 | Completed | 01/09/2005 | https://clinicaltrials.gov/study/NCT00131664 | 0.7 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | ROSIGLITAZONE | targetBased | 3 | Completed | 01/09/2005 | https://clinicaltrials.gov/study/NCT00131664 | 0.7 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | ROSIGLITAZONE | targetBased | 3 | Completed | 01/09/2005 | https://clinicaltrials.gov/study/NCT00131664 | 0.7 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | ROSIGLITAZONE | targetBased | 3 | Completed | 01/09/2005 | https://clinicaltrials.gov/study/NCT00131664 | 0.7 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | ROSIGLITAZONE | targetBased | 3 | Completed | 01/05/2004 | https://clinicaltrials.gov/study/NCT00081328 | 0.7 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | ROSIGLITAZONE | targetBased | 3 | Completed | 01/05/2004 | https://clinicaltrials.gov/study/NCT00081328 | 0.7 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | ROSIGLITAZONE | targetBased | 3 | Completed | 01/05/2004 | https://clinicaltrials.gov/study/NCT00081328 | 0.7 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | ROSIGLITAZONE | targetBased | 3 | Completed | 01/05/2004 | https://clinicaltrials.gov/study/NCT00081328 | 0.7 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | ROSIGLITAZONE | targetBased | 3 | Completed | 01/05/2004 | https://clinicaltrials.gov/study/NCT00081328 | 0.7 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | ROSIGLITAZONE | targetBased | 3 | Completed | 01/05/2004 | https://clinicaltrials.gov/study/NCT00081328 | 0.7 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | ROSIGLITAZONE | targetBased | 4 | Completed | 01/01/2003 | https://clinicaltrials.gov/study/NCT00121966 | 1 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | ROSIGLITAZONE | targetBased | 4 | Completed | 01/01/2003 | https://clinicaltrials.gov/study/NCT00121966 | 1 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | ROSIGLITAZONE | targetBased | 4 | Completed | 01/01/2003 | https://clinicaltrials.gov/study/NCT00121966 | 1 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | ROSIGLITAZONE | targetBased | 4 | Completed | 01/01/2003 | https://clinicaltrials.gov/study/NCT00121966 | 1 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | ROSIGLITAZONE | targetBased | 4 | Completed | 01/01/2003 | https://clinicaltrials.gov/study/NCT00121966 | 1 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | ROSIGLITAZONE | targetBased | 4 | Completed | 01/01/2003 | https://clinicaltrials.gov/study/NCT00121966 | 1 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | ROSIGLITAZONE | targetBased | 4 | Completed | 01/05/2002 | https://clinicaltrials.gov/study/NCT00306644 | 1 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | ROSIGLITAZONE | targetBased | 4 | Completed | 01/05/2002 | https://clinicaltrials.gov/study/NCT00306644 | 1 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | ROSIGLITAZONE | targetBased | 4 | Completed | 01/05/2002 | https://clinicaltrials.gov/study/NCT00306644 | 1 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | ROSIGLITAZONE | targetBased | 4 | Completed | 01/05/2002 | https://clinicaltrials.gov/study/NCT00306644 | 1 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | ROSIGLITAZONE | targetBased | 4 | Completed | 01/05/2002 | https://clinicaltrials.gov/study/NCT00306644 | 1 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | ROSIGLITAZONE | targetBased | 4 | Completed | 01/05/2002 | https://clinicaltrials.gov/study/NCT00306644 | 1 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | ROSIGLITAZONE | targetBased | 3 | Terminated | 10/01/2007 | https://clinicaltrials.gov/study/NCT00427154 | 0.7 | GoF | protect | See termination reason in detailed description |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | ROSIGLITAZONE | targetBased | 3 | Terminated | 10/01/2007 | https://clinicaltrials.gov/study/NCT00427154 | 0.7 | GoF | protect | See termination reason in detailed description |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | ROSIGLITAZONE | targetBased | 3 | Terminated | 10/01/2007 | https://clinicaltrials.gov/study/NCT00427154 | 0.7 | GoF | protect | See termination reason in detailed description |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | ROSIGLITAZONE | targetBased | 3 | Terminated | 10/01/2007 | https://clinicaltrials.gov/study/NCT00427154 | 0.7 | GoF | protect | See termination reason in detailed description |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | ROSIGLITAZONE | targetBased | 3 | Terminated | 10/01/2007 | https://clinicaltrials.gov/study/NCT00427154 | 0.7 | GoF | protect | See termination reason in detailed description |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | ROSIGLITAZONE | targetBased | 3 | Terminated | 10/01/2007 | https://clinicaltrials.gov/study/NCT00427154 | 0.7 | GoF | protect | See termination reason in detailed description |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | ROSIGLITAZONE | targetBased | 4 | Suspended | 01/06/2008 | https://clinicaltrials.gov/study/NCT00948324 | 1 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | ROSIGLITAZONE | targetBased | 4 | Suspended | 01/06/2008 | https://clinicaltrials.gov/study/NCT00948324 | 1 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | ROSIGLITAZONE | targetBased | 4 | Suspended | 01/06/2008 | https://clinicaltrials.gov/study/NCT00948324 | 1 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | ROSIGLITAZONE | targetBased | 4 | Suspended | 01/06/2008 | https://clinicaltrials.gov/study/NCT00948324 | 1 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | ROSIGLITAZONE | targetBased | 4 | Suspended | 01/06/2008 | https://clinicaltrials.gov/study/NCT00948324 | 1 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | ROSIGLITAZONE | targetBased | 4 | Suspended | 01/06/2008 | https://clinicaltrials.gov/study/NCT00948324 | 1 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | ROSIGLITAZONE | targetBased | 4 | Completed | 28/07/2000 | https://clinicaltrials.gov/study/NCT00333723 | 1 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | ROSIGLITAZONE | targetBased | 4 | Completed | 28/07/2000 | https://clinicaltrials.gov/study/NCT00333723 | 1 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | ROSIGLITAZONE | targetBased | 4 | Completed | 28/07/2000 | https://clinicaltrials.gov/study/NCT00333723 | 1 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | ROSIGLITAZONE | targetBased | 4 | Completed | 28/07/2000 | https://clinicaltrials.gov/study/NCT00333723 | 1 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | ROSIGLITAZONE | targetBased | 4 | Completed | 28/07/2000 | https://clinicaltrials.gov/study/NCT00333723 | 1 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | ROSIGLITAZONE | targetBased | 4 | Completed | 28/07/2000 | https://clinicaltrials.gov/study/NCT00333723 | 1 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | ROSIGLITAZONE | targetBased | 3 | Completed | 01/04/2008 | https://clinicaltrials.gov/study/NCT00680745 | 0.7 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | ROSIGLITAZONE | targetBased | 3 | Completed | 01/04/2008 | https://clinicaltrials.gov/study/NCT00680745 | 0.7 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | ROSIGLITAZONE | targetBased | 3 | Completed | 01/04/2008 | https://clinicaltrials.gov/study/NCT00680745 | 0.7 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | ROSIGLITAZONE | targetBased | 3 | Completed | 01/04/2008 | https://clinicaltrials.gov/study/NCT00680745 | 0.7 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | ROSIGLITAZONE | targetBased | 3 | Completed | 01/04/2008 | https://clinicaltrials.gov/study/NCT00680745 | 0.7 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | ROSIGLITAZONE | targetBased | 3 | Completed | 01/04/2008 | https://clinicaltrials.gov/study/NCT00680745 | 0.7 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | ROSIGLITAZONE | targetBased | 3 | Completed | 01/09/1999 | https://clinicaltrials.gov/study/NCT00000620 | 0.7 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | ROSIGLITAZONE | targetBased | 3 | Completed | 01/09/1999 | https://clinicaltrials.gov/study/NCT00000620 | 0.7 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | ROSIGLITAZONE | targetBased | 3 | Completed | 01/09/1999 | https://clinicaltrials.gov/study/NCT00000620 | 0.7 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | ROSIGLITAZONE | targetBased | 3 | Completed | 01/09/1999 | https://clinicaltrials.gov/study/NCT00000620 | 0.7 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | ROSIGLITAZONE | targetBased | 3 | Completed | 01/09/1999 | https://clinicaltrials.gov/study/NCT00000620 | 0.7 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | ROSIGLITAZONE | targetBased | 3 | Completed | 01/09/1999 | https://clinicaltrials.gov/study/NCT00000620 | 0.7 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | ROSIGLITAZONE | targetBased | 3 | Terminated | 10/10/2006 | https://clinicaltrials.gov/study/NCT00343980 | 0.7 | GoF | protect | See termination reason in detailed description |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | ROSIGLITAZONE | targetBased | 3 | Terminated | 10/10/2006 | https://clinicaltrials.gov/study/NCT00343980 | 0.7 | GoF | protect | See termination reason in detailed description |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | ROSIGLITAZONE | targetBased | 3 | Terminated | 10/10/2006 | https://clinicaltrials.gov/study/NCT00343980 | 0.7 | GoF | protect | See termination reason in detailed description |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | ROSIGLITAZONE | targetBased | 3 | Terminated | 10/10/2006 | https://clinicaltrials.gov/study/NCT00343980 | 0.7 | GoF | protect | See termination reason in detailed description |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | ROSIGLITAZONE | targetBased | 3 | Terminated | 10/10/2006 | https://clinicaltrials.gov/study/NCT00343980 | 0.7 | GoF | protect | See termination reason in detailed description |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | ROSIGLITAZONE | targetBased | 3 | Terminated | 10/10/2006 | https://clinicaltrials.gov/study/NCT00343980 | 0.7 | GoF | protect | See termination reason in detailed description |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | ROSIGLITAZONE | targetBased | 4 | Completed | 01/10/2004 | https://clinicaltrials.gov/study/NCT00367055 | 1 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | ROSIGLITAZONE | targetBased | 4 | Completed | 01/10/2004 | https://clinicaltrials.gov/study/NCT00367055 | 1 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | ROSIGLITAZONE | targetBased | 4 | Completed | 01/10/2004 | https://clinicaltrials.gov/study/NCT00367055 | 1 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | ROSIGLITAZONE | targetBased | 4 | Completed | 01/10/2004 | https://clinicaltrials.gov/study/NCT00367055 | 1 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | ROSIGLITAZONE | targetBased | 4 | Completed | 01/10/2004 | https://clinicaltrials.gov/study/NCT00367055 | 1 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | ROSIGLITAZONE | targetBased | 4 | Completed | 01/10/2004 | https://clinicaltrials.gov/study/NCT00367055 | 1 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | ROSIGLITAZONE | targetBased | 4 | Completed | 21/04/2008 | https://clinicaltrials.gov/study/NCT00679939 | 1 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | ROSIGLITAZONE | targetBased | 4 | Completed | 21/04/2008 | https://clinicaltrials.gov/study/NCT00679939 | 1 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | ROSIGLITAZONE | targetBased | 4 | Completed | 21/04/2008 | https://clinicaltrials.gov/study/NCT00679939 | 1 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | ROSIGLITAZONE | targetBased | 4 | Completed | 21/04/2008 | https://clinicaltrials.gov/study/NCT00679939 | 1 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | ROSIGLITAZONE | targetBased | 4 | Completed | 21/04/2008 | https://clinicaltrials.gov/study/NCT00679939 | 1 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | ROSIGLITAZONE | targetBased | 4 | Completed | 21/04/2008 | https://clinicaltrials.gov/study/NCT00679939 | 1 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | ROSIGLITAZONE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ef14122b-7fff-45fa-b13b-0ea9e48bd57d | 1 | GoF | protect | |||
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | ROSIGLITAZONE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ef14122b-7fff-45fa-b13b-0ea9e48bd57d | 1 | GoF | protect | |||
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | ROSIGLITAZONE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ef14122b-7fff-45fa-b13b-0ea9e48bd57d | 1 | GoF | protect | |||
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | ROSIGLITAZONE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ef14122b-7fff-45fa-b13b-0ea9e48bd57d | 1 | GoF | protect | |||
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | ROSIGLITAZONE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ef14122b-7fff-45fa-b13b-0ea9e48bd57d | 1 | GoF | protect | |||
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | ROSIGLITAZONE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ef14122b-7fff-45fa-b13b-0ea9e48bd57d | 1 | GoF | protect | |||
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | ROSIGLITAZONE | targetBased | 3 | Completed | 01/02/2004 | https://clinicaltrials.gov/study/NCT00359112 | 0.7 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | ROSIGLITAZONE | targetBased | 3 | Completed | 01/02/2004 | https://clinicaltrials.gov/study/NCT00359112 | 0.7 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | ROSIGLITAZONE | targetBased | 3 | Completed | 01/02/2004 | https://clinicaltrials.gov/study/NCT00359112 | 0.7 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | ROSIGLITAZONE | targetBased | 3 | Completed | 01/02/2004 | https://clinicaltrials.gov/study/NCT00359112 | 0.7 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | ROSIGLITAZONE | targetBased | 3 | Completed | 01/02/2004 | https://clinicaltrials.gov/study/NCT00359112 | 0.7 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | ROSIGLITAZONE | targetBased | 3 | Completed | 01/02/2004 | https://clinicaltrials.gov/study/NCT00359112 | 0.7 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | ROSIGLITAZONE | targetBased | 3 | Completed | 08/10/2003 | https://clinicaltrials.gov/study/NCT00499707 | 0.7 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | ROSIGLITAZONE | targetBased | 3 | Completed | 08/10/2003 | https://clinicaltrials.gov/study/NCT00499707 | 0.7 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | ROSIGLITAZONE | targetBased | 3 | Completed | 08/10/2003 | https://clinicaltrials.gov/study/NCT00499707 | 0.7 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | ROSIGLITAZONE | targetBased | 3 | Completed | 08/10/2003 | https://clinicaltrials.gov/study/NCT00499707 | 0.7 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | ROSIGLITAZONE | targetBased | 3 | Completed | 08/10/2003 | https://clinicaltrials.gov/study/NCT00499707 | 0.7 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | ROSIGLITAZONE | targetBased | 3 | Completed | 08/10/2003 | https://clinicaltrials.gov/study/NCT00499707 | 0.7 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | ROSIGLITAZONE | targetBased | 4 | Completed | 01/05/2002 | https://clinicaltrials.gov/study/NCT00044460 | 1 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | ROSIGLITAZONE | targetBased | 4 | Completed | 01/05/2002 | https://clinicaltrials.gov/study/NCT00044460 | 1 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | ROSIGLITAZONE | targetBased | 4 | Completed | 01/05/2002 | https://clinicaltrials.gov/study/NCT00044460 | 1 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | ROSIGLITAZONE | targetBased | 4 | Completed | 01/05/2002 | https://clinicaltrials.gov/study/NCT00044460 | 1 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | ROSIGLITAZONE | targetBased | 4 | Completed | 01/05/2002 | https://clinicaltrials.gov/study/NCT00044460 | 1 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | ROSIGLITAZONE | targetBased | 4 | Completed | 01/05/2002 | https://clinicaltrials.gov/study/NCT00044460 | 1 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | ROSIGLITAZONE | targetBased | 4 | Completed | 01/12/2005 | https://clinicaltrials.gov/study/NCT00300911 | 1 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | ROSIGLITAZONE | targetBased | 4 | Completed | 01/12/2005 | https://clinicaltrials.gov/study/NCT00300911 | 1 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | ROSIGLITAZONE | targetBased | 4 | Completed | 01/12/2005 | https://clinicaltrials.gov/study/NCT00300911 | 1 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | ROSIGLITAZONE | targetBased | 4 | Completed | 01/12/2005 | https://clinicaltrials.gov/study/NCT00300911 | 1 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | ROSIGLITAZONE | targetBased | 4 | Completed | 01/12/2005 | https://clinicaltrials.gov/study/NCT00300911 | 1 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | ROSIGLITAZONE | targetBased | 4 | Completed | 01/12/2005 | https://clinicaltrials.gov/study/NCT00300911 | 1 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | ROSIGLITAZONE | targetBased | 3 | Terminated | 30/10/2006 | https://clinicaltrials.gov/study/NCT00348712 | 0.7 | GoF | protect | See termination reason in detailed description |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | ROSIGLITAZONE | targetBased | 3 | Terminated | 30/10/2006 | https://clinicaltrials.gov/study/NCT00348712 | 0.7 | GoF | protect | See termination reason in detailed description |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | ROSIGLITAZONE | targetBased | 3 | Terminated | 30/10/2006 | https://clinicaltrials.gov/study/NCT00348712 | 0.7 | GoF | protect | See termination reason in detailed description |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | ROSIGLITAZONE | targetBased | 3 | Terminated | 30/10/2006 | https://clinicaltrials.gov/study/NCT00348712 | 0.7 | GoF | protect | See termination reason in detailed description |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | ROSIGLITAZONE | targetBased | 3 | Terminated | 30/10/2006 | https://clinicaltrials.gov/study/NCT00348712 | 0.7 | GoF | protect | See termination reason in detailed description |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | ROSIGLITAZONE | targetBased | 3 | Terminated | 30/10/2006 | https://clinicaltrials.gov/study/NCT00348712 | 0.7 | GoF | protect | See termination reason in detailed description |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | ROSIGLITAZONE | targetBased | 3 | Completed | 01/05/2006 | https://clinicaltrials.gov/study/NCT00333151 | 0.7 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | ROSIGLITAZONE | targetBased | 3 | Completed | 01/05/2006 | https://clinicaltrials.gov/study/NCT00333151 | 0.7 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | ROSIGLITAZONE | targetBased | 3 | Completed | 01/05/2006 | https://clinicaltrials.gov/study/NCT00333151 | 0.7 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | ROSIGLITAZONE | targetBased | 3 | Completed | 01/05/2006 | https://clinicaltrials.gov/study/NCT00333151 | 0.7 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | ROSIGLITAZONE | targetBased | 3 | Completed | 01/05/2006 | https://clinicaltrials.gov/study/NCT00333151 | 0.7 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | ROSIGLITAZONE | targetBased | 3 | Completed | 01/05/2006 | https://clinicaltrials.gov/study/NCT00333151 | 0.7 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | ROSIGLITAZONE | targetBased | 3 | Completed | 01/11/2005 | https://clinicaltrials.gov/study/NCT00523913 | 0.7 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | ROSIGLITAZONE | targetBased | 3 | Completed | 01/11/2005 | https://clinicaltrials.gov/study/NCT00523913 | 0.7 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | ROSIGLITAZONE | targetBased | 3 | Completed | 01/11/2005 | https://clinicaltrials.gov/study/NCT00523913 | 0.7 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | ROSIGLITAZONE | targetBased | 3 | Completed | 01/11/2005 | https://clinicaltrials.gov/study/NCT00523913 | 0.7 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | ROSIGLITAZONE | targetBased | 3 | Completed | 01/11/2005 | https://clinicaltrials.gov/study/NCT00523913 | 0.7 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | ROSIGLITAZONE | targetBased | 3 | Completed | 01/11/2005 | https://clinicaltrials.gov/study/NCT00523913 | 0.7 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | ROSIGLITAZONE | targetBased | 3 | Completed | 01/10/2005 | https://clinicaltrials.gov/study/NCT00349427 | 0.7 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | ROSIGLITAZONE | targetBased | 3 | Completed | 01/10/2005 | https://clinicaltrials.gov/study/NCT00349427 | 0.7 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | ROSIGLITAZONE | targetBased | 3 | Completed | 01/10/2005 | https://clinicaltrials.gov/study/NCT00349427 | 0.7 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | ROSIGLITAZONE | targetBased | 3 | Completed | 01/10/2005 | https://clinicaltrials.gov/study/NCT00349427 | 0.7 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | ROSIGLITAZONE | targetBased | 3 | Completed | 01/10/2005 | https://clinicaltrials.gov/study/NCT00349427 | 0.7 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | ROSIGLITAZONE | targetBased | 3 | Completed | 01/10/2005 | https://clinicaltrials.gov/study/NCT00349427 | 0.7 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | ROSIGLITAZONE | targetBased | 4 | Completed | 05/06/2001 | https://clinicaltrials.gov/study/NCT00501020 | 1 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | ROSIGLITAZONE | targetBased | 4 | Completed | 05/06/2001 | https://clinicaltrials.gov/study/NCT00501020 | 1 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | ROSIGLITAZONE | targetBased | 4 | Completed | 05/06/2001 | https://clinicaltrials.gov/study/NCT00501020 | 1 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | ROSIGLITAZONE | targetBased | 4 | Completed | 05/06/2001 | https://clinicaltrials.gov/study/NCT00501020 | 1 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | ROSIGLITAZONE | targetBased | 4 | Completed | 05/06/2001 | https://clinicaltrials.gov/study/NCT00501020 | 1 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | ROSIGLITAZONE | targetBased | 4 | Completed | 05/06/2001 | https://clinicaltrials.gov/study/NCT00501020 | 1 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | ROSIGLITAZONE | targetBased | 3 | Completed | 01/06/2006 | https://clinicaltrials.gov/study/NCT00541775 | 0.7 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | ROSIGLITAZONE | targetBased | 3 | Completed | 01/06/2006 | https://clinicaltrials.gov/study/NCT00541775 | 0.7 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | ROSIGLITAZONE | targetBased | 3 | Completed | 01/06/2006 | https://clinicaltrials.gov/study/NCT00541775 | 0.7 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | ROSIGLITAZONE | targetBased | 3 | Completed | 01/06/2006 | https://clinicaltrials.gov/study/NCT00541775 | 0.7 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | ROSIGLITAZONE | targetBased | 3 | Completed | 01/06/2006 | https://clinicaltrials.gov/study/NCT00541775 | 0.7 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | ROSIGLITAZONE | targetBased | 3 | Completed | 01/06/2006 | https://clinicaltrials.gov/study/NCT00541775 | 0.7 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | ROSIGLITAZONE | targetBased | 3 | Terminated | 01/04/2010 | https://clinicaltrials.gov/study/NCT01453049 | 0.7 | GoF | protect | US FDA/EMA/SFDA decisions to rosiglitazone-containing medicines, ethic |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | ROSIGLITAZONE | targetBased | 3 | Terminated | 01/04/2010 | https://clinicaltrials.gov/study/NCT01453049 | 0.7 | GoF | protect | US FDA/EMA/SFDA decisions to rosiglitazone-containing medicines, ethic |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | ROSIGLITAZONE | targetBased | 3 | Terminated | 01/04/2010 | https://clinicaltrials.gov/study/NCT01453049 | 0.7 | GoF | protect | US FDA/EMA/SFDA decisions to rosiglitazone-containing medicines, ethic |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | ROSIGLITAZONE | targetBased | 3 | Terminated | 01/04/2010 | https://clinicaltrials.gov/study/NCT01453049 | 0.7 | GoF | protect | US FDA/EMA/SFDA decisions to rosiglitazone-containing medicines, ethic |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | ROSIGLITAZONE | targetBased | 3 | Terminated | 01/04/2010 | https://clinicaltrials.gov/study/NCT01453049 | 0.7 | GoF | protect | US FDA/EMA/SFDA decisions to rosiglitazone-containing medicines, ethic |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | ROSIGLITAZONE | targetBased | 3 | Terminated | 01/04/2010 | https://clinicaltrials.gov/study/NCT01453049 | 0.7 | GoF | protect | US FDA/EMA/SFDA decisions to rosiglitazone-containing medicines, ethic |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | ROSIGLITAZONE | targetBased | 3 | Completed | 12/06/2006 | https://clinicaltrials.gov/study/NCT00350779 | 0.7 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | ROSIGLITAZONE | targetBased | 3 | Completed | 12/06/2006 | https://clinicaltrials.gov/study/NCT00350779 | 0.7 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | ROSIGLITAZONE | targetBased | 3 | Completed | 12/06/2006 | https://clinicaltrials.gov/study/NCT00350779 | 0.7 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | ROSIGLITAZONE | targetBased | 3 | Completed | 12/06/2006 | https://clinicaltrials.gov/study/NCT00350779 | 0.7 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | ROSIGLITAZONE | targetBased | 3 | Completed | 12/06/2006 | https://clinicaltrials.gov/study/NCT00350779 | 0.7 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | ROSIGLITAZONE | targetBased | 3 | Completed | 12/06/2006 | https://clinicaltrials.gov/study/NCT00350779 | 0.7 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | ROSIGLITAZONE | targetBased | 3 | Completed | 01/03/2006 | https://clinicaltrials.gov/study/NCT00295633 | 0.7 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | ROSIGLITAZONE | targetBased | 3 | Completed | 01/03/2006 | https://clinicaltrials.gov/study/NCT00295633 | 0.7 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | ROSIGLITAZONE | targetBased | 3 | Completed | 01/03/2006 | https://clinicaltrials.gov/study/NCT00295633 | 0.7 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | ROSIGLITAZONE | targetBased | 3 | Completed | 01/03/2006 | https://clinicaltrials.gov/study/NCT00295633 | 0.7 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | ROSIGLITAZONE | targetBased | 3 | Completed | 01/03/2006 | https://clinicaltrials.gov/study/NCT00295633 | 0.7 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | ROSIGLITAZONE | targetBased | 3 | Completed | 01/03/2006 | https://clinicaltrials.gov/study/NCT00295633 | 0.7 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | ROSIGLITAZONE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=28c31e58-0b27-43e2-bae0-9bbb21420e9f | 1 | GoF | protect | |||
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | ROSIGLITAZONE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=28c31e58-0b27-43e2-bae0-9bbb21420e9f | 1 | GoF | protect | |||
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | ROSIGLITAZONE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=28c31e58-0b27-43e2-bae0-9bbb21420e9f | 1 | GoF | protect | |||
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | ROSIGLITAZONE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=28c31e58-0b27-43e2-bae0-9bbb21420e9f | 1 | GoF | protect | |||
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | ROSIGLITAZONE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=28c31e58-0b27-43e2-bae0-9bbb21420e9f | 1 | GoF | protect | |||
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | ROSIGLITAZONE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=28c31e58-0b27-43e2-bae0-9bbb21420e9f | 1 | GoF | protect | |||
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | ROSIGLITAZONE | targetBased | 4 | Completed | 01/01/2001 | https://clinicaltrials.gov/study/NCT00358124 | 1 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | ROSIGLITAZONE | targetBased | 4 | Completed | 01/01/2001 | https://clinicaltrials.gov/study/NCT00358124 | 1 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | ROSIGLITAZONE | targetBased | 4 | Completed | 01/01/2001 | https://clinicaltrials.gov/study/NCT00358124 | 1 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | ROSIGLITAZONE | targetBased | 4 | Completed | 01/01/2001 | https://clinicaltrials.gov/study/NCT00358124 | 1 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | ROSIGLITAZONE | targetBased | 4 | Completed | 01/01/2001 | https://clinicaltrials.gov/study/NCT00358124 | 1 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | ROSIGLITAZONE | targetBased | 4 | Completed | 01/01/2001 | https://clinicaltrials.gov/study/NCT00358124 | 1 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | ROSIGLITAZONE | targetBased | 4 | Completed | 01/11/2005 | https://clinicaltrials.gov/study/NCT00318656 | 1 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | ROSIGLITAZONE | targetBased | 4 | Completed | 01/11/2005 | https://clinicaltrials.gov/study/NCT00318656 | 1 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | ROSIGLITAZONE | targetBased | 4 | Completed | 01/11/2005 | https://clinicaltrials.gov/study/NCT00318656 | 1 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | ROSIGLITAZONE | targetBased | 4 | Completed | 01/11/2005 | https://clinicaltrials.gov/study/NCT00318656 | 1 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | ROSIGLITAZONE | targetBased | 4 | Completed | 01/11/2005 | https://clinicaltrials.gov/study/NCT00318656 | 1 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | ROSIGLITAZONE | targetBased | 4 | Completed | 01/11/2005 | https://clinicaltrials.gov/study/NCT00318656 | 1 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | ROSIGLITAZONE | targetBased | 4 | Terminated | 01/05/2009 | https://clinicaltrials.gov/study/NCT00879970 | 1 | GoF | protect | FDA has placed the trial on full clinical hold. |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | ROSIGLITAZONE | targetBased | 4 | Terminated | 01/05/2009 | https://clinicaltrials.gov/study/NCT00879970 | 1 | GoF | protect | FDA has placed the trial on full clinical hold. |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | ROSIGLITAZONE | targetBased | 4 | Terminated | 01/05/2009 | https://clinicaltrials.gov/study/NCT00879970 | 1 | GoF | protect | FDA has placed the trial on full clinical hold. |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | ROSIGLITAZONE | targetBased | 4 | Terminated | 01/05/2009 | https://clinicaltrials.gov/study/NCT00879970 | 1 | GoF | protect | FDA has placed the trial on full clinical hold. |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | ROSIGLITAZONE | targetBased | 4 | Terminated | 01/05/2009 | https://clinicaltrials.gov/study/NCT00879970 | 1 | GoF | protect | FDA has placed the trial on full clinical hold. |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | ROSIGLITAZONE | targetBased | 4 | Terminated | 01/05/2009 | https://clinicaltrials.gov/study/NCT00879970 | 1 | GoF | protect | FDA has placed the trial on full clinical hold. |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | ROSIGLITAZONE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=dd8d7ec8-79b0-4152-8789-d247c77232ce | 1 | GoF | protect | |||
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | ROSIGLITAZONE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=dd8d7ec8-79b0-4152-8789-d247c77232ce | 1 | GoF | protect | |||
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | ROSIGLITAZONE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=dd8d7ec8-79b0-4152-8789-d247c77232ce | 1 | GoF | protect | |||
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | ROSIGLITAZONE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=dd8d7ec8-79b0-4152-8789-d247c77232ce | 1 | GoF | protect | |||
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | ROSIGLITAZONE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=dd8d7ec8-79b0-4152-8789-d247c77232ce | 1 | GoF | protect | |||
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | ROSIGLITAZONE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=dd8d7ec8-79b0-4152-8789-d247c77232ce | 1 | GoF | protect | |||
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | ROSIGLITAZONE | targetBased | 4 | Completed | 01/01/2005 | https://clinicaltrials.gov/study/NCT00373178 | 1 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | ROSIGLITAZONE | targetBased | 4 | Completed | 01/01/2005 | https://clinicaltrials.gov/study/NCT00373178 | 1 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | ROSIGLITAZONE | targetBased | 4 | Completed | 01/01/2005 | https://clinicaltrials.gov/study/NCT00373178 | 1 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | ROSIGLITAZONE | targetBased | 4 | Completed | 01/01/2005 | https://clinicaltrials.gov/study/NCT00373178 | 1 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | ROSIGLITAZONE | targetBased | 4 | Completed | 01/01/2005 | https://clinicaltrials.gov/study/NCT00373178 | 1 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | ROSIGLITAZONE | targetBased | 4 | Completed | 01/01/2005 | https://clinicaltrials.gov/study/NCT00373178 | 1 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | ROSIGLITAZONE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0789dc6b-db34-44a6-8a5d-fdcc8e4ce8fd | 1 | GoF | protect | |||
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | ROSIGLITAZONE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0789dc6b-db34-44a6-8a5d-fdcc8e4ce8fd | 1 | GoF | protect | |||
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | ROSIGLITAZONE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0789dc6b-db34-44a6-8a5d-fdcc8e4ce8fd | 1 | GoF | protect | |||
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | ROSIGLITAZONE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0789dc6b-db34-44a6-8a5d-fdcc8e4ce8fd | 1 | GoF | protect | |||
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | ROSIGLITAZONE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0789dc6b-db34-44a6-8a5d-fdcc8e4ce8fd | 1 | GoF | protect | |||
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | ROSIGLITAZONE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0789dc6b-db34-44a6-8a5d-fdcc8e4ce8fd | 1 | GoF | protect | |||
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | ROSIGLITAZONE | targetBased | 3 | Completed | 01/11/2006 | https://clinicaltrials.gov/study/NCT00399711 | 0.7 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | ROSIGLITAZONE | targetBased | 3 | Completed | 01/11/2006 | https://clinicaltrials.gov/study/NCT00399711 | 0.7 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | ROSIGLITAZONE | targetBased | 3 | Completed | 01/11/2006 | https://clinicaltrials.gov/study/NCT00399711 | 0.7 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | ROSIGLITAZONE | targetBased | 3 | Completed | 01/11/2006 | https://clinicaltrials.gov/study/NCT00399711 | 0.7 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | ROSIGLITAZONE | targetBased | 3 | Completed | 01/11/2006 | https://clinicaltrials.gov/study/NCT00399711 | 0.7 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | ROSIGLITAZONE | targetBased | 3 | Completed | 01/11/2006 | https://clinicaltrials.gov/study/NCT00399711 | 0.7 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | ROSIGLITAZONE | targetBased | 3 | Completed | 01/04/2000 | https://clinicaltrials.gov/study/NCT00500955 | 0.7 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | ROSIGLITAZONE | targetBased | 3 | Completed | 01/04/2000 | https://clinicaltrials.gov/study/NCT00500955 | 0.7 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | ROSIGLITAZONE | targetBased | 3 | Completed | 01/04/2000 | https://clinicaltrials.gov/study/NCT00500955 | 0.7 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | ROSIGLITAZONE | targetBased | 3 | Completed | 01/04/2000 | https://clinicaltrials.gov/study/NCT00500955 | 0.7 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | ROSIGLITAZONE | targetBased | 3 | Completed | 01/04/2000 | https://clinicaltrials.gov/study/NCT00500955 | 0.7 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | ROSIGLITAZONE | targetBased | 3 | Completed | 01/04/2000 | https://clinicaltrials.gov/study/NCT00500955 | 0.7 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | ROSIGLITAZONE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ec682aec-e98f-41a1-9d21-eb7580ea3a8a | 1 | GoF | protect | |||
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | ROSIGLITAZONE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ec682aec-e98f-41a1-9d21-eb7580ea3a8a | 1 | GoF | protect | |||
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | ROSIGLITAZONE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ec682aec-e98f-41a1-9d21-eb7580ea3a8a | 1 | GoF | protect | |||
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | ROSIGLITAZONE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ec682aec-e98f-41a1-9d21-eb7580ea3a8a | 1 | GoF | protect | |||
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | ROSIGLITAZONE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ec682aec-e98f-41a1-9d21-eb7580ea3a8a | 1 | GoF | protect | |||
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | ROSIGLITAZONE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ec682aec-e98f-41a1-9d21-eb7580ea3a8a | 1 | GoF | protect | |||
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | ROSIGLITAZONE | targetBased | 3 | Completed | 01/05/2006 | https://clinicaltrials.gov/study/NCT00318422 | 0.7 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | ROSIGLITAZONE | targetBased | 3 | Completed | 01/05/2006 | https://clinicaltrials.gov/study/NCT00318422 | 0.7 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | ROSIGLITAZONE | targetBased | 3 | Completed | 01/05/2006 | https://clinicaltrials.gov/study/NCT00318422 | 0.7 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | ROSIGLITAZONE | targetBased | 3 | Completed | 01/05/2006 | https://clinicaltrials.gov/study/NCT00318422 | 0.7 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | ROSIGLITAZONE | targetBased | 3 | Completed | 01/05/2006 | https://clinicaltrials.gov/study/NCT00318422 | 0.7 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | ROSIGLITAZONE | targetBased | 3 | Completed | 01/05/2006 | https://clinicaltrials.gov/study/NCT00318422 | 0.7 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | ROSIGLITAZONE | targetBased | 4 | Completed | 01/02/2005 | https://clinicaltrials.gov/study/NCT00424762 | 1 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | ROSIGLITAZONE | targetBased | 4 | Completed | 01/02/2005 | https://clinicaltrials.gov/study/NCT00424762 | 1 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | ROSIGLITAZONE | targetBased | 4 | Completed | 01/02/2005 | https://clinicaltrials.gov/study/NCT00424762 | 1 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | ROSIGLITAZONE | targetBased | 4 | Completed | 01/02/2005 | https://clinicaltrials.gov/study/NCT00424762 | 1 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | ROSIGLITAZONE | targetBased | 4 | Completed | 01/02/2005 | https://clinicaltrials.gov/study/NCT00424762 | 1 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | ROSIGLITAZONE | targetBased | 4 | Completed | 01/02/2005 | https://clinicaltrials.gov/study/NCT00424762 | 1 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | ROSIGLITAZONE | targetBased | 4 | Completed | 01/01/2005 | https://clinicaltrials.gov/study/NCT00306176 | 1 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | ROSIGLITAZONE | targetBased | 4 | Completed | 01/01/2005 | https://clinicaltrials.gov/study/NCT00306176 | 1 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | ROSIGLITAZONE | targetBased | 4 | Completed | 01/01/2005 | https://clinicaltrials.gov/study/NCT00306176 | 1 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | ROSIGLITAZONE | targetBased | 4 | Completed | 01/01/2005 | https://clinicaltrials.gov/study/NCT00306176 | 1 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | ROSIGLITAZONE | targetBased | 4 | Completed | 01/01/2005 | https://clinicaltrials.gov/study/NCT00306176 | 1 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | ROSIGLITAZONE | targetBased | 4 | Completed | 01/01/2005 | https://clinicaltrials.gov/study/NCT00306176 | 1 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | ROSIGLITAZONE | targetBased | 4 | Completed | 01/09/2002 | https://clinicaltrials.gov/study/NCT00329225 | 1 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | ROSIGLITAZONE | targetBased | 4 | Completed | 01/09/2002 | https://clinicaltrials.gov/study/NCT00329225 | 1 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | ROSIGLITAZONE | targetBased | 4 | Completed | 01/09/2002 | https://clinicaltrials.gov/study/NCT00329225 | 1 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | ROSIGLITAZONE | targetBased | 4 | Completed | 01/09/2002 | https://clinicaltrials.gov/study/NCT00329225 | 1 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | ROSIGLITAZONE | targetBased | 4 | Completed | 01/09/2002 | https://clinicaltrials.gov/study/NCT00329225 | 1 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | ROSIGLITAZONE | targetBased | 4 | Completed | 01/09/2002 | https://clinicaltrials.gov/study/NCT00329225 | 1 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | ROSIGLITAZONE | targetBased | 3 | Completed | 01/10/2003 | https://clinicaltrials.gov/study/NCT00069836 | 0.7 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | ROSIGLITAZONE | targetBased | 3 | Completed | 01/10/2003 | https://clinicaltrials.gov/study/NCT00069836 | 0.7 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | ROSIGLITAZONE | targetBased | 3 | Completed | 01/10/2003 | https://clinicaltrials.gov/study/NCT00069836 | 0.7 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | ROSIGLITAZONE | targetBased | 3 | Completed | 01/10/2003 | https://clinicaltrials.gov/study/NCT00069836 | 0.7 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | ROSIGLITAZONE | targetBased | 3 | Completed | 01/10/2003 | https://clinicaltrials.gov/study/NCT00069836 | 0.7 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | ROSIGLITAZONE | targetBased | 3 | Completed | 01/10/2003 | https://clinicaltrials.gov/study/NCT00069836 | 0.7 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | ROSIGLITAZONE | targetBased | 4 | Completed | 01/05/2003 | https://clinicaltrials.gov/study/NCT00123643 | 1 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | ROSIGLITAZONE | targetBased | 4 | Completed | 01/05/2003 | https://clinicaltrials.gov/study/NCT00123643 | 1 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | ROSIGLITAZONE | targetBased | 4 | Completed | 01/05/2003 | https://clinicaltrials.gov/study/NCT00123643 | 1 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | ROSIGLITAZONE | targetBased | 4 | Completed | 01/05/2003 | https://clinicaltrials.gov/study/NCT00123643 | 1 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | ROSIGLITAZONE | targetBased | 4 | Completed | 01/05/2003 | https://clinicaltrials.gov/study/NCT00123643 | 1 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | ROSIGLITAZONE | targetBased | 4 | Completed | 01/05/2003 | https://clinicaltrials.gov/study/NCT00123643 | 1 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | ROSIGLITAZONE | targetBased | 4 | Completed | 01/10/2007 | https://clinicaltrials.gov/study/NCT00953498 | 1 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | ROSIGLITAZONE | targetBased | 4 | Completed | 01/10/2007 | https://clinicaltrials.gov/study/NCT00953498 | 1 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | ROSIGLITAZONE | targetBased | 4 | Completed | 01/10/2007 | https://clinicaltrials.gov/study/NCT00953498 | 1 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | ROSIGLITAZONE | targetBased | 4 | Completed | 01/10/2007 | https://clinicaltrials.gov/study/NCT00953498 | 1 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | ROSIGLITAZONE | targetBased | 4 | Completed | 01/10/2007 | https://clinicaltrials.gov/study/NCT00953498 | 1 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | ROSIGLITAZONE | targetBased | 4 | Completed | 01/10/2007 | https://clinicaltrials.gov/study/NCT00953498 | 1 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | ROSIGLITAZONE | targetBased | 3 | Completed | 17/10/2003 | https://clinicaltrials.gov/study/NCT00067951 | 0.7 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | ROSIGLITAZONE | targetBased | 3 | Completed | 17/10/2003 | https://clinicaltrials.gov/study/NCT00067951 | 0.7 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | ROSIGLITAZONE | targetBased | 3 | Completed | 17/10/2003 | https://clinicaltrials.gov/study/NCT00067951 | 0.7 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | ROSIGLITAZONE | targetBased | 3 | Completed | 17/10/2003 | https://clinicaltrials.gov/study/NCT00067951 | 0.7 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | ROSIGLITAZONE | targetBased | 3 | Completed | 17/10/2003 | https://clinicaltrials.gov/study/NCT00067951 | 0.7 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | ROSIGLITAZONE | targetBased | 3 | Completed | 17/10/2003 | https://clinicaltrials.gov/study/NCT00067951 | 0.7 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | ROSIGLITAZONE | targetBased | 3 | Completed | 11/01/2006 | https://clinicaltrials.gov/study/NCT00297063 | 0.7 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | ROSIGLITAZONE | targetBased | 3 | Completed | 11/01/2006 | https://clinicaltrials.gov/study/NCT00297063 | 0.7 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | ROSIGLITAZONE | targetBased | 3 | Completed | 11/01/2006 | https://clinicaltrials.gov/study/NCT00297063 | 0.7 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | ROSIGLITAZONE | targetBased | 3 | Completed | 11/01/2006 | https://clinicaltrials.gov/study/NCT00297063 | 0.7 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | ROSIGLITAZONE | targetBased | 3 | Completed | 11/01/2006 | https://clinicaltrials.gov/study/NCT00297063 | 0.7 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | ROSIGLITAZONE | targetBased | 3 | Completed | 11/01/2006 | https://clinicaltrials.gov/study/NCT00297063 | 0.7 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | ROSIGLITAZONE | targetBased | 3 | Completed | 01/10/2005 | https://clinicaltrials.gov/study/NCT00135330 | 0.7 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | ROSIGLITAZONE | targetBased | 3 | Completed | 01/10/2005 | https://clinicaltrials.gov/study/NCT00135330 | 0.7 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | ROSIGLITAZONE | targetBased | 3 | Completed | 01/10/2005 | https://clinicaltrials.gov/study/NCT00135330 | 0.7 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | ROSIGLITAZONE | targetBased | 3 | Completed | 01/10/2005 | https://clinicaltrials.gov/study/NCT00135330 | 0.7 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | ROSIGLITAZONE | targetBased | 3 | Completed | 01/10/2005 | https://clinicaltrials.gov/study/NCT00135330 | 0.7 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | ROSIGLITAZONE | targetBased | 3 | Completed | 01/10/2005 | https://clinicaltrials.gov/study/NCT00135330 | 0.7 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | ROSIGLITAZONE | targetBased | 3 | Completed | 24/05/2006 | https://clinicaltrials.gov/study/NCT00432679 | 0.7 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | ROSIGLITAZONE | targetBased | 3 | Completed | 24/05/2006 | https://clinicaltrials.gov/study/NCT00432679 | 0.7 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | ROSIGLITAZONE | targetBased | 3 | Completed | 24/05/2006 | https://clinicaltrials.gov/study/NCT00432679 | 0.7 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | ROSIGLITAZONE | targetBased | 3 | Completed | 24/05/2006 | https://clinicaltrials.gov/study/NCT00432679 | 0.7 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | ROSIGLITAZONE | targetBased | 3 | Completed | 24/05/2006 | https://clinicaltrials.gov/study/NCT00432679 | 0.7 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | ROSIGLITAZONE | targetBased | 3 | Completed | 24/05/2006 | https://clinicaltrials.gov/study/NCT00432679 | 0.7 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | ROSIGLITAZONE | targetBased | 3 | Completed | 01/09/2002 | https://clinicaltrials.gov/study/NCT00231387 | 0.7 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | ROSIGLITAZONE | targetBased | 3 | Completed | 01/09/2002 | https://clinicaltrials.gov/study/NCT00231387 | 0.7 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | ROSIGLITAZONE | targetBased | 3 | Completed | 01/09/2002 | https://clinicaltrials.gov/study/NCT00231387 | 0.7 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | ROSIGLITAZONE | targetBased | 3 | Completed | 01/09/2002 | https://clinicaltrials.gov/study/NCT00231387 | 0.7 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | ROSIGLITAZONE | targetBased | 3 | Completed | 01/09/2002 | https://clinicaltrials.gov/study/NCT00231387 | 0.7 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | ROSIGLITAZONE | targetBased | 3 | Completed | 01/09/2002 | https://clinicaltrials.gov/study/NCT00231387 | 0.7 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | ROSIGLITAZONE | targetBased | 3 | Completed | 01/12/2000 | https://clinicaltrials.gov/study/NCT00032487 | 0.7 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | ROSIGLITAZONE | targetBased | 3 | Completed | 01/12/2000 | https://clinicaltrials.gov/study/NCT00032487 | 0.7 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | ROSIGLITAZONE | targetBased | 3 | Completed | 01/12/2000 | https://clinicaltrials.gov/study/NCT00032487 | 0.7 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | ROSIGLITAZONE | targetBased | 3 | Completed | 01/12/2000 | https://clinicaltrials.gov/study/NCT00032487 | 0.7 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | ROSIGLITAZONE | targetBased | 3 | Completed | 01/12/2000 | https://clinicaltrials.gov/study/NCT00032487 | 0.7 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | ROSIGLITAZONE | targetBased | 3 | Completed | 01/12/2000 | https://clinicaltrials.gov/study/NCT00032487 | 0.7 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | ROSIGLITAZONE | targetBased | 4 | Completed | 01/10/2000 | https://clinicaltrials.gov/study/NCT02526615 | 1 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | ROSIGLITAZONE | targetBased | 4 | Completed | 01/10/2000 | https://clinicaltrials.gov/study/NCT02526615 | 1 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | ROSIGLITAZONE | targetBased | 4 | Completed | 01/10/2000 | https://clinicaltrials.gov/study/NCT02526615 | 1 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | ROSIGLITAZONE | targetBased | 4 | Completed | 01/10/2000 | https://clinicaltrials.gov/study/NCT02526615 | 1 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | ROSIGLITAZONE | targetBased | 4 | Completed | 01/10/2000 | https://clinicaltrials.gov/study/NCT02526615 | 1 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | ROSIGLITAZONE | targetBased | 4 | Completed | 01/10/2000 | https://clinicaltrials.gov/study/NCT02526615 | 1 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | ROSIGLITAZONE | targetBased | 4 | Completed | 01/03/2004 | https://clinicaltrials.gov/study/NCT00290394 | 1 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | ROSIGLITAZONE | targetBased | 4 | Completed | 01/03/2004 | https://clinicaltrials.gov/study/NCT00290394 | 1 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | ROSIGLITAZONE | targetBased | 4 | Completed | 01/03/2004 | https://clinicaltrials.gov/study/NCT00290394 | 1 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | ROSIGLITAZONE | targetBased | 4 | Completed | 01/03/2004 | https://clinicaltrials.gov/study/NCT00290394 | 1 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | ROSIGLITAZONE | targetBased | 4 | Completed | 01/03/2004 | https://clinicaltrials.gov/study/NCT00290394 | 1 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | ROSIGLITAZONE | targetBased | 4 | Completed | 01/03/2004 | https://clinicaltrials.gov/study/NCT00290394 | 1 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | ROSIGLITAZONE | targetBased | 4 | Completed | 01/10/2006 | https://clinicaltrials.gov/study/NCT00386100 | 1 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | ROSIGLITAZONE | targetBased | 4 | Completed | 01/10/2006 | https://clinicaltrials.gov/study/NCT00386100 | 1 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | ROSIGLITAZONE | targetBased | 4 | Completed | 01/10/2006 | https://clinicaltrials.gov/study/NCT00386100 | 1 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | ROSIGLITAZONE | targetBased | 4 | Completed | 01/10/2006 | https://clinicaltrials.gov/study/NCT00386100 | 1 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | ROSIGLITAZONE | targetBased | 4 | Completed | 01/10/2006 | https://clinicaltrials.gov/study/NCT00386100 | 1 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | ROSIGLITAZONE | targetBased | 4 | Completed | 01/10/2006 | https://clinicaltrials.gov/study/NCT00386100 | 1 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | abnormal glucose tolerance | ROSIGLITAZONE | targetBased | 4 | Completed | 01/01/2004 | https://clinicaltrials.gov/study/NCT00675740 | 1 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | abnormal glucose tolerance | ROSIGLITAZONE | targetBased | 4 | Completed | 01/01/2004 | https://clinicaltrials.gov/study/NCT00675740 | 1 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | abnormal glucose tolerance | ROSIGLITAZONE | targetBased | 4 | Completed | 01/01/2004 | https://clinicaltrials.gov/study/NCT00675740 | 1 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | abnormal glucose tolerance | ROSIGLITAZONE | targetBased | 4 | Completed | 01/01/2004 | https://clinicaltrials.gov/study/NCT00675740 | 1 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | abnormal glucose tolerance | ROSIGLITAZONE | targetBased | 4 | Completed | 01/01/2004 | https://clinicaltrials.gov/study/NCT00675740 | 1 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | abnormal glucose tolerance | ROSIGLITAZONE | targetBased | 4 | Completed | 01/01/2004 | https://clinicaltrials.gov/study/NCT00675740 | 1 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | abnormal glucose tolerance | ROSIGLITAZONE | targetBased | 3 | Completed | 01/07/2001 | https://clinicaltrials.gov/study/NCT00095654 | 0.7 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | abnormal glucose tolerance | ROSIGLITAZONE | targetBased | 3 | Completed | 01/07/2001 | https://clinicaltrials.gov/study/NCT00095654 | 0.7 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | abnormal glucose tolerance | ROSIGLITAZONE | targetBased | 3 | Completed | 01/07/2001 | https://clinicaltrials.gov/study/NCT00095654 | 0.7 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | abnormal glucose tolerance | ROSIGLITAZONE | targetBased | 3 | Completed | 01/07/2001 | https://clinicaltrials.gov/study/NCT00095654 | 0.7 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | abnormal glucose tolerance | ROSIGLITAZONE | targetBased | 3 | Completed | 01/07/2001 | https://clinicaltrials.gov/study/NCT00095654 | 0.7 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | abnormal glucose tolerance | ROSIGLITAZONE | targetBased | 3 | Completed | 01/07/2001 | https://clinicaltrials.gov/study/NCT00095654 | 0.7 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | abnormal glucose tolerance | ROSIGLITAZONE | targetBased | 4 | Unknown status | 01/03/2004 | https://clinicaltrials.gov/study/NCT00733174 | 1 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | abnormal glucose tolerance | ROSIGLITAZONE | targetBased | 4 | Unknown status | 01/03/2004 | https://clinicaltrials.gov/study/NCT00733174 | 1 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | abnormal glucose tolerance | ROSIGLITAZONE | targetBased | 4 | Unknown status | 01/03/2004 | https://clinicaltrials.gov/study/NCT00733174 | 1 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | abnormal glucose tolerance | ROSIGLITAZONE | targetBased | 4 | Unknown status | 01/03/2004 | https://clinicaltrials.gov/study/NCT00733174 | 1 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | abnormal glucose tolerance | ROSIGLITAZONE | targetBased | 4 | Unknown status | 01/03/2004 | https://clinicaltrials.gov/study/NCT00733174 | 1 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | abnormal glucose tolerance | ROSIGLITAZONE | targetBased | 4 | Unknown status | 01/03/2004 | https://clinicaltrials.gov/study/NCT00733174 | 1 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | abnormal glucose tolerance | ROSIGLITAZONE | targetBased | 4 | Completed | 01/02/2004 | https://clinicaltrials.gov/study/NCT00746174 | 1 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | abnormal glucose tolerance | ROSIGLITAZONE | targetBased | 4 | Completed | 01/02/2004 | https://clinicaltrials.gov/study/NCT00746174 | 1 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | abnormal glucose tolerance | ROSIGLITAZONE | targetBased | 4 | Completed | 01/02/2004 | https://clinicaltrials.gov/study/NCT00746174 | 1 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | abnormal glucose tolerance | ROSIGLITAZONE | targetBased | 4 | Completed | 01/02/2004 | https://clinicaltrials.gov/study/NCT00746174 | 1 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | abnormal glucose tolerance | ROSIGLITAZONE | targetBased | 4 | Completed | 01/02/2004 | https://clinicaltrials.gov/study/NCT00746174 | 1 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | abnormal glucose tolerance | ROSIGLITAZONE | targetBased | 4 | Completed | 01/02/2004 | https://clinicaltrials.gov/study/NCT00746174 | 1 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | Hypercholesterolemia | ROSIGLITAZONE | targetBased | 3 | Completed | 01/09/1999 | https://clinicaltrials.gov/study/NCT00000620 | 0.7 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | Hypercholesterolemia | ROSIGLITAZONE | targetBased | 3 | Completed | 01/09/1999 | https://clinicaltrials.gov/study/NCT00000620 | 0.7 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | Hypercholesterolemia | ROSIGLITAZONE | targetBased | 3 | Completed | 01/09/1999 | https://clinicaltrials.gov/study/NCT00000620 | 0.7 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | Hypercholesterolemia | ROSIGLITAZONE | targetBased | 3 | Completed | 01/09/1999 | https://clinicaltrials.gov/study/NCT00000620 | 0.7 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | Hypercholesterolemia | ROSIGLITAZONE | targetBased | 3 | Completed | 01/09/1999 | https://clinicaltrials.gov/study/NCT00000620 | 0.7 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | Hypercholesterolemia | ROSIGLITAZONE | targetBased | 3 | Completed | 01/09/1999 | https://clinicaltrials.gov/study/NCT00000620 | 0.7 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | metabolic syndrome | ROSIGLITAZONE | targetBased | 4 | Completed | 01/05/2006 | https://clinicaltrials.gov/study/NCT00314561 | 1 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | metabolic syndrome | ROSIGLITAZONE | targetBased | 4 | Completed | 01/05/2006 | https://clinicaltrials.gov/study/NCT00314561 | 1 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | metabolic syndrome | ROSIGLITAZONE | targetBased | 4 | Completed | 01/05/2006 | https://clinicaltrials.gov/study/NCT00314561 | 1 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | metabolic syndrome | ROSIGLITAZONE | targetBased | 4 | Completed | 01/05/2006 | https://clinicaltrials.gov/study/NCT00314561 | 1 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | metabolic syndrome | ROSIGLITAZONE | targetBased | 4 | Completed | 01/05/2006 | https://clinicaltrials.gov/study/NCT00314561 | 1 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | metabolic syndrome | ROSIGLITAZONE | targetBased | 4 | Completed | 01/05/2006 | https://clinicaltrials.gov/study/NCT00314561 | 1 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | metabolic syndrome | ROSIGLITAZONE | targetBased | 3 | Terminated | 01/01/2006 | https://clinicaltrials.gov/study/NCT00465296 | 0.7 | GoF | protect | Funding Discontinued |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | metabolic syndrome | ROSIGLITAZONE | targetBased | 3 | Terminated | 01/01/2006 | https://clinicaltrials.gov/study/NCT00465296 | 0.7 | GoF | protect | Funding Discontinued |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | metabolic syndrome | ROSIGLITAZONE | targetBased | 3 | Terminated | 01/01/2006 | https://clinicaltrials.gov/study/NCT00465296 | 0.7 | GoF | protect | Funding Discontinued |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | metabolic syndrome | ROSIGLITAZONE | targetBased | 3 | Terminated | 01/01/2006 | https://clinicaltrials.gov/study/NCT00465296 | 0.7 | GoF | protect | Funding Discontinued |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | metabolic syndrome | ROSIGLITAZONE | targetBased | 3 | Terminated | 01/01/2006 | https://clinicaltrials.gov/study/NCT00465296 | 0.7 | GoF | protect | Funding Discontinued |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | metabolic syndrome | ROSIGLITAZONE | targetBased | 3 | Terminated | 01/01/2006 | https://clinicaltrials.gov/study/NCT00465296 | 0.7 | GoF | protect | Funding Discontinued |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | diabetes mellitus | ROSIGLITAZONE | targetBased | 4 | https://www.whocc.no/atc_ddd_index/?code=A10BG02 | 1 | GoF | protect | |||
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | diabetes mellitus | ROSIGLITAZONE | targetBased | 4 | https://www.whocc.no/atc_ddd_index/?code=A10BG02 | 1 | GoF | protect | |||
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | diabetes mellitus | ROSIGLITAZONE | targetBased | 4 | https://www.whocc.no/atc_ddd_index/?code=A10BG02 | 1 | GoF | protect | |||
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | diabetes mellitus | ROSIGLITAZONE | targetBased | 4 | https://www.whocc.no/atc_ddd_index/?code=A10BG02 | 1 | GoF | protect | |||
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | diabetes mellitus | ROSIGLITAZONE | targetBased | 4 | https://www.whocc.no/atc_ddd_index/?code=A10BG02 | 1 | GoF | protect | |||
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | diabetes mellitus | ROSIGLITAZONE | targetBased | 4 | https://www.whocc.no/atc_ddd_index/?code=A10BG02 | 1 | GoF | protect | |||
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | diabetes mellitus | ROSIGLITAZONE | targetBased | 3 | Terminated | 10/10/2006 | https://clinicaltrials.gov/study/NCT00343980 | 0.7 | GoF | protect | See termination reason in detailed description |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | diabetes mellitus | ROSIGLITAZONE | targetBased | 3 | Terminated | 10/10/2006 | https://clinicaltrials.gov/study/NCT00343980 | 0.7 | GoF | protect | See termination reason in detailed description |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | diabetes mellitus | ROSIGLITAZONE | targetBased | 3 | Terminated | 10/10/2006 | https://clinicaltrials.gov/study/NCT00343980 | 0.7 | GoF | protect | See termination reason in detailed description |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | diabetes mellitus | ROSIGLITAZONE | targetBased | 3 | Terminated | 10/10/2006 | https://clinicaltrials.gov/study/NCT00343980 | 0.7 | GoF | protect | See termination reason in detailed description |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | diabetes mellitus | ROSIGLITAZONE | targetBased | 3 | Terminated | 10/10/2006 | https://clinicaltrials.gov/study/NCT00343980 | 0.7 | GoF | protect | See termination reason in detailed description |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | diabetes mellitus | ROSIGLITAZONE | targetBased | 3 | Terminated | 10/10/2006 | https://clinicaltrials.gov/study/NCT00343980 | 0.7 | GoF | protect | See termination reason in detailed description |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | diabetes mellitus | ROSIGLITAZONE | targetBased | 3 | Terminated | 01/09/2003 | https://clinicaltrials.gov/study/NCT00203632 | 0.35 | GoF | protect | Terminated at 50% enrollment due to recent concerns about rosiglitazone |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | diabetes mellitus | ROSIGLITAZONE | targetBased | 3 | Terminated | 01/09/2003 | https://clinicaltrials.gov/study/NCT00203632 | 0.35 | GoF | protect | Terminated at 50% enrollment due to recent concerns about rosiglitazone |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | diabetes mellitus | ROSIGLITAZONE | targetBased | 3 | Terminated | 01/09/2003 | https://clinicaltrials.gov/study/NCT00203632 | 0.35 | GoF | protect | Terminated at 50% enrollment due to recent concerns about rosiglitazone |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | diabetes mellitus | ROSIGLITAZONE | targetBased | 3 | Terminated | 01/09/2003 | https://clinicaltrials.gov/study/NCT00203632 | 0.35 | GoF | protect | Terminated at 50% enrollment due to recent concerns about rosiglitazone |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | diabetes mellitus | ROSIGLITAZONE | targetBased | 3 | Terminated | 01/09/2003 | https://clinicaltrials.gov/study/NCT00203632 | 0.35 | GoF | protect | Terminated at 50% enrollment due to recent concerns about rosiglitazone |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | diabetes mellitus | ROSIGLITAZONE | targetBased | 3 | Terminated | 01/09/2003 | https://clinicaltrials.gov/study/NCT00203632 | 0.35 | GoF | protect | Terminated at 50% enrollment due to recent concerns about rosiglitazone |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | diabetes mellitus | ROSIGLITAZONE | targetBased | 3 | Terminated | 10/01/2007 | https://clinicaltrials.gov/study/NCT00427154 | 0.7 | GoF | protect | See termination reason in detailed description |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | diabetes mellitus | ROSIGLITAZONE | targetBased | 3 | Terminated | 10/01/2007 | https://clinicaltrials.gov/study/NCT00427154 | 0.7 | GoF | protect | See termination reason in detailed description |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | diabetes mellitus | ROSIGLITAZONE | targetBased | 3 | Terminated | 10/01/2007 | https://clinicaltrials.gov/study/NCT00427154 | 0.7 | GoF | protect | See termination reason in detailed description |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | diabetes mellitus | ROSIGLITAZONE | targetBased | 3 | Terminated | 10/01/2007 | https://clinicaltrials.gov/study/NCT00427154 | 0.7 | GoF | protect | See termination reason in detailed description |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | diabetes mellitus | ROSIGLITAZONE | targetBased | 3 | Terminated | 10/01/2007 | https://clinicaltrials.gov/study/NCT00427154 | 0.7 | GoF | protect | See termination reason in detailed description |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | diabetes mellitus | ROSIGLITAZONE | targetBased | 3 | Terminated | 10/01/2007 | https://clinicaltrials.gov/study/NCT00427154 | 0.7 | GoF | protect | See termination reason in detailed description |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | diabetes mellitus | ROSIGLITAZONE | targetBased | 3 | Completed | 01/09/2000 | https://clinicaltrials.gov/study/NCT00331487 | 0.7 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | diabetes mellitus | ROSIGLITAZONE | targetBased | 3 | Completed | 01/09/2000 | https://clinicaltrials.gov/study/NCT00331487 | 0.7 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | diabetes mellitus | ROSIGLITAZONE | targetBased | 3 | Completed | 01/09/2000 | https://clinicaltrials.gov/study/NCT00331487 | 0.7 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | diabetes mellitus | ROSIGLITAZONE | targetBased | 3 | Completed | 01/09/2000 | https://clinicaltrials.gov/study/NCT00331487 | 0.7 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | diabetes mellitus | ROSIGLITAZONE | targetBased | 3 | Completed | 01/09/2000 | https://clinicaltrials.gov/study/NCT00331487 | 0.7 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | diabetes mellitus | ROSIGLITAZONE | targetBased | 3 | Completed | 01/09/2000 | https://clinicaltrials.gov/study/NCT00331487 | 0.7 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | diabetes mellitus | ROSIGLITAZONE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b019bfc3-5a3b-4b8f-9962-d885447639db | 1 | GoF | protect | |||
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | diabetes mellitus | ROSIGLITAZONE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b019bfc3-5a3b-4b8f-9962-d885447639db | 1 | GoF | protect | |||
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | diabetes mellitus | ROSIGLITAZONE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b019bfc3-5a3b-4b8f-9962-d885447639db | 1 | GoF | protect | |||
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | diabetes mellitus | ROSIGLITAZONE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b019bfc3-5a3b-4b8f-9962-d885447639db | 1 | GoF | protect | |||
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | diabetes mellitus | ROSIGLITAZONE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b019bfc3-5a3b-4b8f-9962-d885447639db | 1 | GoF | protect | |||
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | diabetes mellitus | ROSIGLITAZONE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b019bfc3-5a3b-4b8f-9962-d885447639db | 1 | GoF | protect | |||
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | diabetes mellitus | ROSIGLITAZONE | targetBased | 3 | Completed | 01/06/2003 | https://clinicaltrials.gov/study/NCT00169832 | 0.7 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | diabetes mellitus | ROSIGLITAZONE | targetBased | 3 | Completed | 01/06/2003 | https://clinicaltrials.gov/study/NCT00169832 | 0.7 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | diabetes mellitus | ROSIGLITAZONE | targetBased | 3 | Completed | 01/06/2003 | https://clinicaltrials.gov/study/NCT00169832 | 0.7 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | diabetes mellitus | ROSIGLITAZONE | targetBased | 3 | Completed | 01/06/2003 | https://clinicaltrials.gov/study/NCT00169832 | 0.7 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | diabetes mellitus | ROSIGLITAZONE | targetBased | 3 | Completed | 01/06/2003 | https://clinicaltrials.gov/study/NCT00169832 | 0.7 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | diabetes mellitus | ROSIGLITAZONE | targetBased | 3 | Completed | 01/06/2003 | https://clinicaltrials.gov/study/NCT00169832 | 0.7 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | diabetes mellitus | ROSIGLITAZONE | targetBased | 4 | Completed | 01/10/2002 | https://clinicaltrials.gov/study/NCT00306696 | 1 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | diabetes mellitus | ROSIGLITAZONE | targetBased | 4 | Completed | 01/10/2002 | https://clinicaltrials.gov/study/NCT00306696 | 1 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | diabetes mellitus | ROSIGLITAZONE | targetBased | 4 | Completed | 01/10/2002 | https://clinicaltrials.gov/study/NCT00306696 | 1 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | diabetes mellitus | ROSIGLITAZONE | targetBased | 4 | Completed | 01/10/2002 | https://clinicaltrials.gov/study/NCT00306696 | 1 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | diabetes mellitus | ROSIGLITAZONE | targetBased | 4 | Completed | 01/10/2002 | https://clinicaltrials.gov/study/NCT00306696 | 1 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | diabetes mellitus | ROSIGLITAZONE | targetBased | 4 | Completed | 01/10/2002 | https://clinicaltrials.gov/study/NCT00306696 | 1 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | metabolic disease | ROSIGLITAZONE | targetBased | 3 | Completed | 01/07/2001 | https://clinicaltrials.gov/study/NCT00095654 | 0.7 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | metabolic disease | ROSIGLITAZONE | targetBased | 3 | Completed | 01/07/2001 | https://clinicaltrials.gov/study/NCT00095654 | 0.7 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | metabolic disease | ROSIGLITAZONE | targetBased | 3 | Completed | 01/07/2001 | https://clinicaltrials.gov/study/NCT00095654 | 0.7 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | metabolic disease | ROSIGLITAZONE | targetBased | 3 | Completed | 01/07/2001 | https://clinicaltrials.gov/study/NCT00095654 | 0.7 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | metabolic disease | ROSIGLITAZONE | targetBased | 3 | Completed | 01/07/2001 | https://clinicaltrials.gov/study/NCT00095654 | 0.7 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | metabolic disease | ROSIGLITAZONE | targetBased | 3 | Completed | 01/07/2001 | https://clinicaltrials.gov/study/NCT00095654 | 0.7 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | Glucose intolerance | ROSIGLITAZONE | targetBased | 3 | Unknown status | 01/04/2005 | https://clinicaltrials.gov/study/NCT00240604 | 0.7 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | Glucose intolerance | ROSIGLITAZONE | targetBased | 3 | Unknown status | 01/04/2005 | https://clinicaltrials.gov/study/NCT00240604 | 0.7 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | Glucose intolerance | ROSIGLITAZONE | targetBased | 3 | Unknown status | 01/04/2005 | https://clinicaltrials.gov/study/NCT00240604 | 0.7 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | Glucose intolerance | ROSIGLITAZONE | targetBased | 3 | Unknown status | 01/04/2005 | https://clinicaltrials.gov/study/NCT00240604 | 0.7 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | Glucose intolerance | ROSIGLITAZONE | targetBased | 3 | Unknown status | 01/04/2005 | https://clinicaltrials.gov/study/NCT00240604 | 0.7 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | Glucose intolerance | ROSIGLITAZONE | targetBased | 3 | Unknown status | 01/04/2005 | https://clinicaltrials.gov/study/NCT00240604 | 0.7 | GoF | protect | |
| uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay | OPRK1 | OPRK1 | Kappa-type opioid receptor | obesity | NALTREXONE | targetBased | 4 | Withdrawn | 01/11/2020 | https://clinicaltrials.gov/study/NCT04399395 | 1 | LoF | protect | Covid-pandemic |
| uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay | OPRK1 | OPRK1 | Kappa-type opioid receptor | obesity | NALTREXONE | targetBased | 3 | Completed | 01/03/2007 | https://clinicaltrials.gov/study/NCT00456521 | 0.7 | LoF | protect | |
| uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay | OPRK1 | OPRK1 | Kappa-type opioid receptor | obesity | NALTREXONE | targetBased | 4 | Recruiting | 08/06/2023 | https://clinicaltrials.gov/study/NCT05919797 | 1 | LoF | protect | |
| uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay | OPRK1 | OPRK1 | Kappa-type opioid receptor | obesity | NALTREXONE | targetBased | 4 | Unknown status | 01/11/2009 | https://clinicaltrials.gov/study/NCT01623440 | 1 | LoF | protect | |
| uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay | OPRK1 | OPRK1 | Kappa-type opioid receptor | obesity | NALTREXONE | targetBased | 3 | Completed | 11/12/2017 | https://clinicaltrials.gov/study/NCT03374956 | 0.7 | LoF | protect | |
| uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay | OPRK1 | OPRK1 | Kappa-type opioid receptor | obesity | NALTREXONE | targetBased | 3 | Completed | 01/10/2007 | https://clinicaltrials.gov/study/NCT00532779 | 0.7 | LoF | protect | |
| uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay | OPRK1 | OPRK1 | Kappa-type opioid receptor | obesity | NALTREXONE | targetBased | 3 | Completed | 01/12/2007 | https://clinicaltrials.gov/study/NCT00567255 | 0.7 | LoF | protect | |
| uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay | OPRK1 | OPRK1 | Kappa-type opioid receptor | obesity | NALTREXONE | targetBased | 4 | Recruiting | 08/09/2020 | https://clinicaltrials.gov/study/NCT04575194 | 1 | LoF | protect | |
| uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay | OPRK1 | OPRK1 | Kappa-type opioid receptor | obesity | NALTREXONE | targetBased | 4 | Active, not recruiting | 19/01/2023 | https://clinicaltrials.gov/study/NCT05579249 | 1 | LoF | protect | |
| Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors | OPRM1 | OPRM1 | Mu-type opioid receptor | obesity | NALTREXONE | targetBased | 4 | Active, not recruiting | 19/01/2023 | https://clinicaltrials.gov/study/NCT05579249 | 1 | LoF | protect | |
| Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors | OPRM1 | OPRM1 | Mu-type opioid receptor | obesity | NALTREXONE | targetBased | 4 | Active, not recruiting | 19/01/2023 | https://clinicaltrials.gov/study/NCT05579249 | 1 | LoF | protect | |
| Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors | OPRM1 | OPRM1 | Mu-type opioid receptor | obesity | NALTREXONE | targetBased | 3 | Completed | 11/12/2017 | https://clinicaltrials.gov/study/NCT03374956 | 0.7 | LoF | protect | |
| Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors | OPRM1 | OPRM1 | Mu-type opioid receptor | obesity | NALTREXONE | targetBased | 3 | Completed | 11/12/2017 | https://clinicaltrials.gov/study/NCT03374956 | 0.7 | LoF | protect | |
| Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors | OPRM1 | OPRM1 | Mu-type opioid receptor | obesity | NALTREXONE | targetBased | 3 | Completed | 01/03/2007 | https://clinicaltrials.gov/study/NCT00456521 | 0.7 | LoF | protect | |
| Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors | OPRM1 | OPRM1 | Mu-type opioid receptor | obesity | NALTREXONE | targetBased | 3 | Completed | 01/03/2007 | https://clinicaltrials.gov/study/NCT00456521 | 0.7 | LoF | protect | |
| Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors | OPRM1 | OPRM1 | Mu-type opioid receptor | obesity | NALTREXONE | targetBased | 3 | Completed | 01/10/2007 | https://clinicaltrials.gov/study/NCT00532779 | 0.7 | LoF | protect | |
| Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors | OPRM1 | OPRM1 | Mu-type opioid receptor | obesity | NALTREXONE | targetBased | 3 | Completed | 01/10/2007 | https://clinicaltrials.gov/study/NCT00532779 | 0.7 | LoF | protect | |
| Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors | OPRM1 | OPRM1 | Mu-type opioid receptor | obesity | NALTREXONE | targetBased | 3 | Completed | 01/12/2007 | https://clinicaltrials.gov/study/NCT00567255 | 0.7 | LoF | protect | |
| Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors | OPRM1 | OPRM1 | Mu-type opioid receptor | obesity | NALTREXONE | targetBased | 3 | Completed | 01/12/2007 | https://clinicaltrials.gov/study/NCT00567255 | 0.7 | LoF | protect | |
| Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors | OPRM1 | OPRM1 | Mu-type opioid receptor | obesity | NALTREXONE | targetBased | 4 | Unknown status | 01/11/2009 | https://clinicaltrials.gov/study/NCT01623440 | 1 | LoF | protect | |
| Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors | OPRM1 | OPRM1 | Mu-type opioid receptor | obesity | NALTREXONE | targetBased | 4 | Unknown status | 01/11/2009 | https://clinicaltrials.gov/study/NCT01623440 | 1 | LoF | protect | |
| Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors | OPRM1 | OPRM1 | Mu-type opioid receptor | obesity | NALTREXONE | targetBased | 4 | Withdrawn | 01/11/2020 | https://clinicaltrials.gov/study/NCT04399395 | 1 | LoF | protect | Covid-pandemic |
| Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors | OPRM1 | OPRM1 | Mu-type opioid receptor | obesity | NALTREXONE | targetBased | 4 | Withdrawn | 01/11/2020 | https://clinicaltrials.gov/study/NCT04399395 | 1 | LoF | protect | Covid-pandemic |
| Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors | OPRM1 | OPRM1 | Mu-type opioid receptor | obesity | NALTREXONE | targetBased | 4 | Recruiting | 08/06/2023 | https://clinicaltrials.gov/study/NCT05919797 | 1 | LoF | protect | |
| Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors | OPRM1 | OPRM1 | Mu-type opioid receptor | obesity | NALTREXONE | targetBased | 4 | Recruiting | 08/06/2023 | https://clinicaltrials.gov/study/NCT05919797 | 1 | LoF | protect | |
| Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors | OPRM1 | OPRM1 | Mu-type opioid receptor | obesity | NALTREXONE | targetBased | 4 | Recruiting | 08/09/2020 | https://clinicaltrials.gov/study/NCT04575194 | 1 | LoF | protect | |
| Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors | OPRM1 | OPRM1 | Mu-type opioid receptor | obesity | NALTREXONE | targetBased | 4 | Recruiting | 08/09/2020 | https://clinicaltrials.gov/study/NCT04575194 | 1 | LoF | protect | |
| Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors | OPRM1 | OPRM1 | Mu-type opioid receptor | morbid obesity | NALTREXONE | targetBased | 4 | Recruiting | 21/03/2023 | https://clinicaltrials.gov/study/NCT04902625 | 1 | LoF | protect | |
| Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors | OPRM1 | OPRM1 | Mu-type opioid receptor | morbid obesity | NALTREXONE | targetBased | 4 | Recruiting | 21/03/2023 | https://clinicaltrials.gov/study/NCT04902625 | 1 | LoF | protect | |
| uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay | OPRK1 | OPRK1 | Kappa-type opioid receptor | morbid obesity | NALTREXONE | targetBased | 4 | Recruiting | 21/03/2023 | https://clinicaltrials.gov/study/NCT04902625 | 1 | LoF | protect | |
| Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors | OPRM1 | OPRM1 | Mu-type opioid receptor | gallbladder disease | MEPERIDINE | targetBased | 4 | Completed | 01/06/2010 | https://clinicaltrials.gov/study/NCT01709422 | 1 | GoF | protect | |
| Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors | OPRM1 | OPRM1 | Mu-type opioid receptor | gallbladder disease | MEPERIDINE | targetBased | 4 | Completed | 01/06/2010 | https://clinicaltrials.gov/study/NCT01709422 | 1 | GoF | protect | |
| Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors | OPRM1 | OPRM1 | Mu-type opioid receptor | cholelithiasis | ALFENTANIL | targetBased | 4 | Completed | 01/06/2009 | https://clinicaltrials.gov/study/NCT01350037 | 1 | GoF | protect | |
| Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors | OPRM1 | OPRM1 | Mu-type opioid receptor | cholelithiasis | ALFENTANIL | targetBased | 4 | Completed | 01/06/2009 | https://clinicaltrials.gov/study/NCT01350037 | 1 | GoF | protect | |
| HTS for Beta-2AR agonists via FAP method | ADRB2_activators | ADRB2 | Beta-2 adrenergic receptor | metabolic syndrome | NEBIVOLOL | targetBased | 4 | Completed | 01/10/2008 | https://clinicaltrials.gov/study/NCT00775671 | 1 | LoF | protect | |
| Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors | OPRM1 | OPRM1 | Mu-type opioid receptor | morbid obesity | OXYCODONE | targetBased | 4 | Recruiting | 20/01/2021 | https://clinicaltrials.gov/study/NCT04240626 | 1 | GoF | protect | |
| Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors | OPRM1 | OPRM1 | Mu-type opioid receptor | morbid obesity | OXYCODONE | targetBased | 4 | Recruiting | 20/01/2021 | https://clinicaltrials.gov/study/NCT04240626 | 1 | GoF | protect | |
| HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors | ESR1_inhibitors | ESR1 | Estrogen receptor, Estrogen receptor | non-alcoholic steatohepatitis | ESTRADIOL | targetBased | 3 | Recruiting | 02/12/2021 | https://clinicaltrials.gov/study/NCT04833140 | 0.7 | GoF | protect | |
| HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators | ESR1_modulators | ESR1 | Estrogen receptor, Estrogen receptor | non-alcoholic steatohepatitis | ESTRADIOL | targetBased | 3 | Recruiting | 02/12/2021 | https://clinicaltrials.gov/study/NCT04833140 | 0.7 | GoF | protect | |
| HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors | ESR1_inhibitors | ESR1 | Estrogen receptor, Estrogen receptor | obesity | ESTRADIOL | targetBased | 3 | Completed | 01/05/2008 | https://clinicaltrials.gov/study/NCT00687739 | 0.7 | GoF | protect | |
| HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators | ESR1_modulators | ESR1 | Estrogen receptor, Estrogen receptor | obesity | ESTRADIOL | targetBased | 3 | Completed | 01/05/2008 | https://clinicaltrials.gov/study/NCT00687739 | 0.7 | GoF | protect | |
| Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors | OPRM1 | OPRM1 | Mu-type opioid receptor | acute pancreatitis | SUFENTANIL | targetBased | 3 | Completed | 06/06/2014 | https://clinicaltrials.gov/study/NCT02126332 | 0.7 | GoF | protect | |
| Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors | OPRM1 | OPRM1 | Mu-type opioid receptor | acute pancreatitis | SUFENTANIL | targetBased | 3 | Completed | 06/06/2014 | https://clinicaltrials.gov/study/NCT02126332 | 0.7 | GoF | protect | |
| uHTS identification of small molecule modulators of NR3A | GRIN3A | GRIN3A | secondary Parkinson disease | AMANTADINE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e3ea1dbc-47cc-462d-a360-a3944f80b14c | 1 | LoF | protect | ||||
| uHTS identification of small molecule modulators of NR3A | GRIN3A | GRIN3A | secondary Parkinson disease | AMANTADINE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14452da8-3b48-497d-9017-bdfb967b7f56 | 1 | LoF | protect | ||||
| uHTS identification of small molecule modulators of NR3A | GRIN3A | GRIN3A | secondary Parkinson disease | AMANTADINE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=13602c1d-d1c9-496b-baa6-8dee92519d67 | 1 | LoF | protect | ||||
| uHTS identification of small molecule modulators of NR3A | GRIN3A | GRIN3A | secondary Parkinson disease | AMANTADINE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=87db36f3-c831-4a84-a3c5-e9d6cc7191af | 1 | LoF | protect | ||||
| uHTS identification of small molecule modulators of NR3A | GRIN3A | GRIN3A | secondary Parkinson disease | AMANTADINE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=17f205dd-0feb-4c49-a0e1-2d0c362c6bd7 | 1 | LoF | protect | ||||
| uHTS identification of small molecule modulators of NR3A | GRIN3A | GRIN3A | secondary Parkinson disease | AMANTADINE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=461e6444-189e-62ed-6c61-1c36a04459c6 | 1 | LoF | protect | ||||
| uHTS identification of small molecule modulators of NR3A | GRIN3A | GRIN3A | secondary Parkinson disease | AMANTADINE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=bfd129ae-8b0a-f118-b7d0-45d106290b63 | 1 | LoF | protect | ||||
| uHTS identification of small molecule modulators of NR3A | GRIN3A | GRIN3A | postencephalitic Parkinson disease | AMANTADINE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=87db36f3-c831-4a84-a3c5-e9d6cc7191af | 1 | LoF | protect | ||||
| uHTS identification of small molecule modulators of NR3A | GRIN3A | GRIN3A | postencephalitic Parkinson disease | AMANTADINE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=bfd129ae-8b0a-f118-b7d0-45d106290b63 | 1 | LoF | protect | ||||
| uHTS identification of small molecule modulators of NR3A | GRIN3A | GRIN3A | postencephalitic Parkinson disease | AMANTADINE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e3ea1dbc-47cc-462d-a360-a3944f80b14c | 1 | LoF | protect | ||||
| uHTS identification of small molecule modulators of NR3A | GRIN3A | GRIN3A | postencephalitic Parkinson disease | AMANTADINE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14452da8-3b48-497d-9017-bdfb967b7f56 | 1 | LoF | protect | ||||
| uHTS identification of small molecule modulators of NR3A | GRIN3A | GRIN3A | postencephalitic Parkinson disease | AMANTADINE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=13602c1d-d1c9-496b-baa6-8dee92519d67 | 1 | LoF | protect | ||||
| uHTS identification of small molecule modulators of NR3A | GRIN3A | GRIN3A | postencephalitic Parkinson disease | AMANTADINE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=461e6444-189e-62ed-6c61-1c36a04459c6 | 1 | LoF | protect | ||||
| uHTS identification of small molecule modulators of NR3A | GRIN3A | GRIN3A | postencephalitic Parkinson disease | AMANTADINE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=17f205dd-0feb-4c49-a0e1-2d0c362c6bd7 | 1 | LoF | protect | ||||
| Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A) | HTR2A | HTR2A | 5-hydroxytryptamine receptor 2A | morbid obesity | CYCLOBENZAPRINE | targetBased | 4 | Recruiting | 20/01/2021 | https://clinicaltrials.gov/study/NCT04240626 | 1 | LoF | protect | |
| HTS for Beta-2AR agonists via FAP method | ADRB2_activators | ADRB2 | Beta-2 adrenergic receptor | acute pancreatitis | EPINEPHRINE | targetBased | 4 | Unknown status | 01/07/2016 | https://clinicaltrials.gov/study/NCT02839356 | 1 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | TESAGLITAZAR | targetBased | 3 | Terminated | 01/07/2004 | https://clinicaltrials.gov/study/NCT00251953 | 0.7 | GoF | protect | The development program has been terminated |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | TESAGLITAZAR | targetBased | 3 | Terminated | 01/07/2004 | https://clinicaltrials.gov/study/NCT00251953 | 0.7 | GoF | protect | The development program has been terminated |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | TESAGLITAZAR | targetBased | 3 | Terminated | 01/07/2004 | https://clinicaltrials.gov/study/NCT00251953 | 0.7 | GoF | protect | The development program has been terminated |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | TESAGLITAZAR | targetBased | 3 | Terminated | 01/07/2004 | https://clinicaltrials.gov/study/NCT00251953 | 0.7 | GoF | protect | The development program has been terminated |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | TESAGLITAZAR | targetBased | 3 | Terminated | 01/07/2004 | https://clinicaltrials.gov/study/NCT00251953 | 0.7 | GoF | protect | The development program has been terminated |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | TESAGLITAZAR | targetBased | 3 | Terminated | 01/07/2004 | https://clinicaltrials.gov/study/NCT00251953 | 0.7 | GoF | protect | The development program has been terminated |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | TESAGLITAZAR | targetBased | 3 | Terminated | 01/08/2004 | https://clinicaltrials.gov/study/NCT00242372 | 0.7 | GoF | protect | The development program has been terminated |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | TESAGLITAZAR | targetBased | 3 | Terminated | 01/08/2004 | https://clinicaltrials.gov/study/NCT00242372 | 0.7 | GoF | protect | The development program has been terminated |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | TESAGLITAZAR | targetBased | 3 | Terminated | 01/08/2004 | https://clinicaltrials.gov/study/NCT00242372 | 0.7 | GoF | protect | The development program has been terminated |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | TESAGLITAZAR | targetBased | 3 | Terminated | 01/08/2004 | https://clinicaltrials.gov/study/NCT00242372 | 0.7 | GoF | protect | The development program has been terminated |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | TESAGLITAZAR | targetBased | 3 | Terminated | 01/08/2004 | https://clinicaltrials.gov/study/NCT00242372 | 0.7 | GoF | protect | The development program has been terminated |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | TESAGLITAZAR | targetBased | 3 | Terminated | 01/08/2004 | https://clinicaltrials.gov/study/NCT00242372 | 0.7 | GoF | protect | The development program has been terminated |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | TESAGLITAZAR | targetBased | 3 | Terminated | 01/07/2004 | https://clinicaltrials.gov/study/NCT00251940 | 0.7 | GoF | protect | The development program has been terminated |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | TESAGLITAZAR | targetBased | 3 | Terminated | 01/07/2004 | https://clinicaltrials.gov/study/NCT00251940 | 0.7 | GoF | protect | The development program has been terminated |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | TESAGLITAZAR | targetBased | 3 | Terminated | 01/07/2004 | https://clinicaltrials.gov/study/NCT00251940 | 0.7 | GoF | protect | The development program has been terminated |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | TESAGLITAZAR | targetBased | 3 | Terminated | 01/07/2004 | https://clinicaltrials.gov/study/NCT00251940 | 0.7 | GoF | protect | The development program has been terminated |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | TESAGLITAZAR | targetBased | 3 | Terminated | 01/07/2004 | https://clinicaltrials.gov/study/NCT00251940 | 0.7 | GoF | protect | The development program has been terminated |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | TESAGLITAZAR | targetBased | 3 | Terminated | 01/07/2004 | https://clinicaltrials.gov/study/NCT00251940 | 0.7 | GoF | protect | The development program has been terminated |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | TESAGLITAZAR | targetBased | 3 | Terminated | 01/04/2005 | https://clinicaltrials.gov/study/NCT00252837 | 0.7 | GoF | protect | The development program has been terminated |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | TESAGLITAZAR | targetBased | 3 | Terminated | 01/04/2005 | https://clinicaltrials.gov/study/NCT00252837 | 0.7 | GoF | protect | The development program has been terminated |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | TESAGLITAZAR | targetBased | 3 | Terminated | 01/04/2005 | https://clinicaltrials.gov/study/NCT00252837 | 0.7 | GoF | protect | The development program has been terminated |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | TESAGLITAZAR | targetBased | 3 | Terminated | 01/04/2005 | https://clinicaltrials.gov/study/NCT00252837 | 0.7 | GoF | protect | The development program has been terminated |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | TESAGLITAZAR | targetBased | 3 | Terminated | 01/04/2005 | https://clinicaltrials.gov/study/NCT00252837 | 0.7 | GoF | protect | The development program has been terminated |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | TESAGLITAZAR | targetBased | 3 | Terminated | 01/04/2005 | https://clinicaltrials.gov/study/NCT00252837 | 0.7 | GoF | protect | The development program has been terminated |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | TESAGLITAZAR | targetBased | 3 | Terminated | 01/03/2005 | https://clinicaltrials.gov/study/NCT00252876 | 0.7 | GoF | protect | The development program has been terminated |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | TESAGLITAZAR | targetBased | 3 | Terminated | 01/03/2005 | https://clinicaltrials.gov/study/NCT00252876 | 0.7 | GoF | protect | The development program has been terminated |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | TESAGLITAZAR | targetBased | 3 | Terminated | 01/03/2005 | https://clinicaltrials.gov/study/NCT00252876 | 0.7 | GoF | protect | The development program has been terminated |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | TESAGLITAZAR | targetBased | 3 | Terminated | 01/03/2005 | https://clinicaltrials.gov/study/NCT00252876 | 0.7 | GoF | protect | The development program has been terminated |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | TESAGLITAZAR | targetBased | 3 | Terminated | 01/03/2005 | https://clinicaltrials.gov/study/NCT00252876 | 0.7 | GoF | protect | The development program has been terminated |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | TESAGLITAZAR | targetBased | 3 | Terminated | 01/03/2005 | https://clinicaltrials.gov/study/NCT00252876 | 0.7 | GoF | protect | The development program has been terminated |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | TESAGLITAZAR | targetBased | 3 | Terminated | 01/09/2004 | https://clinicaltrials.gov/study/NCT00255541 | 0.7 | GoF | protect | The development program has been terminated |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | TESAGLITAZAR | targetBased | 3 | Terminated | 01/09/2004 | https://clinicaltrials.gov/study/NCT00255541 | 0.7 | GoF | protect | The development program has been terminated |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | TESAGLITAZAR | targetBased | 3 | Terminated | 01/09/2004 | https://clinicaltrials.gov/study/NCT00255541 | 0.7 | GoF | protect | The development program has been terminated |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | TESAGLITAZAR | targetBased | 3 | Terminated | 01/09/2004 | https://clinicaltrials.gov/study/NCT00255541 | 0.7 | GoF | protect | The development program has been terminated |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | TESAGLITAZAR | targetBased | 3 | Terminated | 01/09/2004 | https://clinicaltrials.gov/study/NCT00255541 | 0.7 | GoF | protect | The development program has been terminated |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | TESAGLITAZAR | targetBased | 3 | Terminated | 01/09/2004 | https://clinicaltrials.gov/study/NCT00255541 | 0.7 | GoF | protect | The development program has been terminated |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | TESAGLITAZAR | targetBased | 3 | Terminated | 01/10/2005 | https://clinicaltrials.gov/study/NCT00300105 | 0.7 | GoF | protect | The development program has been terminated |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | TESAGLITAZAR | targetBased | 3 | Terminated | 01/10/2005 | https://clinicaltrials.gov/study/NCT00300105 | 0.7 | GoF | protect | The development program has been terminated |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | TESAGLITAZAR | targetBased | 3 | Terminated | 01/10/2005 | https://clinicaltrials.gov/study/NCT00300105 | 0.7 | GoF | protect | The development program has been terminated |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | TESAGLITAZAR | targetBased | 3 | Terminated | 01/10/2005 | https://clinicaltrials.gov/study/NCT00300105 | 0.7 | GoF | protect | The development program has been terminated |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | TESAGLITAZAR | targetBased | 3 | Terminated | 01/10/2005 | https://clinicaltrials.gov/study/NCT00300105 | 0.7 | GoF | protect | The development program has been terminated |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | TESAGLITAZAR | targetBased | 3 | Terminated | 01/10/2005 | https://clinicaltrials.gov/study/NCT00300105 | 0.7 | GoF | protect | The development program has been terminated |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | TESAGLITAZAR | targetBased | 3 | Terminated | 01/08/2004 | https://clinicaltrials.gov/study/NCT00214591 | 0.7 | GoF | protect | The development program has been terminated |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | TESAGLITAZAR | targetBased | 3 | Terminated | 01/08/2004 | https://clinicaltrials.gov/study/NCT00214591 | 0.7 | GoF | protect | The development program has been terminated |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | TESAGLITAZAR | targetBased | 3 | Terminated | 01/08/2004 | https://clinicaltrials.gov/study/NCT00214591 | 0.7 | GoF | protect | The development program has been terminated |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | TESAGLITAZAR | targetBased | 3 | Terminated | 01/08/2004 | https://clinicaltrials.gov/study/NCT00214591 | 0.7 | GoF | protect | The development program has been terminated |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | TESAGLITAZAR | targetBased | 3 | Terminated | 01/08/2004 | https://clinicaltrials.gov/study/NCT00214591 | 0.7 | GoF | protect | The development program has been terminated |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | TESAGLITAZAR | targetBased | 3 | Terminated | 01/08/2004 | https://clinicaltrials.gov/study/NCT00214591 | 0.7 | GoF | protect | The development program has been terminated |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | TESAGLITAZAR | targetBased | 3 | Terminated | 01/03/2005 | https://clinicaltrials.gov/study/NCT00226330 | 0.7 | GoF | protect | The development program has been terminated |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | TESAGLITAZAR | targetBased | 3 | Terminated | 01/03/2005 | https://clinicaltrials.gov/study/NCT00226330 | 0.7 | GoF | protect | The development program has been terminated |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | TESAGLITAZAR | targetBased | 3 | Terminated | 01/03/2005 | https://clinicaltrials.gov/study/NCT00226330 | 0.7 | GoF | protect | The development program has been terminated |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | TESAGLITAZAR | targetBased | 3 | Terminated | 01/03/2005 | https://clinicaltrials.gov/study/NCT00226330 | 0.7 | GoF | protect | The development program has been terminated |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | TESAGLITAZAR | targetBased | 3 | Terminated | 01/03/2005 | https://clinicaltrials.gov/study/NCT00226330 | 0.7 | GoF | protect | The development program has been terminated |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | TESAGLITAZAR | targetBased | 3 | Terminated | 01/03/2005 | https://clinicaltrials.gov/study/NCT00226330 | 0.7 | GoF | protect | The development program has been terminated |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | TESAGLITAZAR | targetBased | 3 | Terminated | 01/09/2004 | https://clinicaltrials.gov/study/NCT00252772 | 0.7 | GoF | protect | The development program has been terminated |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | TESAGLITAZAR | targetBased | 3 | Terminated | 01/09/2004 | https://clinicaltrials.gov/study/NCT00252772 | 0.7 | GoF | protect | The development program has been terminated |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | TESAGLITAZAR | targetBased | 3 | Terminated | 01/09/2004 | https://clinicaltrials.gov/study/NCT00252772 | 0.7 | GoF | protect | The development program has been terminated |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | TESAGLITAZAR | targetBased | 3 | Terminated | 01/09/2004 | https://clinicaltrials.gov/study/NCT00252772 | 0.7 | GoF | protect | The development program has been terminated |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | TESAGLITAZAR | targetBased | 3 | Terminated | 01/09/2004 | https://clinicaltrials.gov/study/NCT00252772 | 0.7 | GoF | protect | The development program has been terminated |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | TESAGLITAZAR | targetBased | 3 | Terminated | 01/09/2004 | https://clinicaltrials.gov/study/NCT00252772 | 0.7 | GoF | protect | The development program has been terminated |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | TESAGLITAZAR | targetBased | 3 | Terminated | 01/02/2005 | https://clinicaltrials.gov/study/NCT00229710 | 0.7 | GoF | protect | The development program has been terminated |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | TESAGLITAZAR | targetBased | 3 | Terminated | 01/02/2005 | https://clinicaltrials.gov/study/NCT00229710 | 0.7 | GoF | protect | The development program has been terminated |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | TESAGLITAZAR | targetBased | 3 | Terminated | 01/02/2005 | https://clinicaltrials.gov/study/NCT00229710 | 0.7 | GoF | protect | The development program has been terminated |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | TESAGLITAZAR | targetBased | 3 | Terminated | 01/02/2005 | https://clinicaltrials.gov/study/NCT00229710 | 0.7 | GoF | protect | The development program has been terminated |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | TESAGLITAZAR | targetBased | 3 | Terminated | 01/02/2005 | https://clinicaltrials.gov/study/NCT00229710 | 0.7 | GoF | protect | The development program has been terminated |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | TESAGLITAZAR | targetBased | 3 | Terminated | 01/02/2005 | https://clinicaltrials.gov/study/NCT00229710 | 0.7 | GoF | protect | The development program has been terminated |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | TESAGLITAZAR | targetBased | 3 | Terminated | 01/08/2004 | https://clinicaltrials.gov/study/NCT00214565 | 0.7 | GoF | protect | The development program has been terminated |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | TESAGLITAZAR | targetBased | 3 | Terminated | 01/08/2004 | https://clinicaltrials.gov/study/NCT00214565 | 0.7 | GoF | protect | The development program has been terminated |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | TESAGLITAZAR | targetBased | 3 | Terminated | 01/08/2004 | https://clinicaltrials.gov/study/NCT00214565 | 0.7 | GoF | protect | The development program has been terminated |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | TESAGLITAZAR | targetBased | 3 | Terminated | 01/08/2004 | https://clinicaltrials.gov/study/NCT00214565 | 0.7 | GoF | protect | The development program has been terminated |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | TESAGLITAZAR | targetBased | 3 | Terminated | 01/08/2004 | https://clinicaltrials.gov/study/NCT00214565 | 0.7 | GoF | protect | The development program has been terminated |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | TESAGLITAZAR | targetBased | 3 | Terminated | 01/08/2004 | https://clinicaltrials.gov/study/NCT00214565 | 0.7 | GoF | protect | The development program has been terminated |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | TESAGLITAZAR | targetBased | 3 | Terminated | 01/03/2005 | https://clinicaltrials.gov/study/NCT00261352 | 0.7 | GoF | protect | The development program has been terminated |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | TESAGLITAZAR | targetBased | 3 | Terminated | 01/03/2005 | https://clinicaltrials.gov/study/NCT00261352 | 0.7 | GoF | protect | The development program has been terminated |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | TESAGLITAZAR | targetBased | 3 | Terminated | 01/03/2005 | https://clinicaltrials.gov/study/NCT00261352 | 0.7 | GoF | protect | The development program has been terminated |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | TESAGLITAZAR | targetBased | 3 | Terminated | 01/03/2005 | https://clinicaltrials.gov/study/NCT00261352 | 0.7 | GoF | protect | The development program has been terminated |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | TESAGLITAZAR | targetBased | 3 | Terminated | 01/03/2005 | https://clinicaltrials.gov/study/NCT00261352 | 0.7 | GoF | protect | The development program has been terminated |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | TESAGLITAZAR | targetBased | 3 | Terminated | 01/03/2005 | https://clinicaltrials.gov/study/NCT00261352 | 0.7 | GoF | protect | The development program has been terminated |
| qHTS of D3 Dopamine Receptor Antagonist: qHTS | D3_antagonists | DRD3 | Dopaminereceptor3 | body weight gain | OLANZAPINE | targetBased | 4 | Completed | 01/03/2003 | https://clinicaltrials.gov/study/NCT00191828 | 1 | LoF | protect | |
| qHTS of D3 Dopamine Receptor Agonist: qHTS | D3_agonists | DRD3 | Dopaminereceptor3 | body weight gain | OLANZAPINE | targetBased | 4 | Completed | 01/03/2003 | https://clinicaltrials.gov/study/NCT00191828 | 1 | LoF | protect | |
| qHTS of D3 Dopamine Receptor Potentiators: qHTS | D3_PAMs | DRD3 | Dopaminereceptor3 | body weight gain | OLANZAPINE | targetBased | 4 | Completed | 01/03/2003 | https://clinicaltrials.gov/study/NCT00191828 | 1 | LoF | protect | |
| qHTS of D3 Dopamine Receptor Antagonist: qHTS | D3_antagonists | DRD3 | Dopaminereceptor3 | body weight gain | OLANZAPINE | targetBased | 3 | Completed | 01/01/2008 | https://clinicaltrials.gov/study/NCT00363376 | 0.7 | LoF | protect | |
| qHTS of D3 Dopamine Receptor Agonist: qHTS | D3_agonists | DRD3 | Dopaminereceptor3 | body weight gain | OLANZAPINE | targetBased | 3 | Completed | 01/01/2008 | https://clinicaltrials.gov/study/NCT00363376 | 0.7 | LoF | protect | |
| qHTS of D3 Dopamine Receptor Potentiators: qHTS | D3_PAMs | DRD3 | Dopaminereceptor3 | body weight gain | OLANZAPINE | targetBased | 3 | Completed | 01/01/2008 | https://clinicaltrials.gov/study/NCT00363376 | 0.7 | LoF | protect | |
| Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A) | HTR2A | HTR2A | 5-hydroxytryptamine receptor 2A | body weight gain | OLANZAPINE | targetBased | 3 | Completed | 01/01/2008 | https://clinicaltrials.gov/study/NCT00363376 | 0.7 | LoF | protect | |
| Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A) | HTR2A | HTR2A | 5-hydroxytryptamine receptor 2A | body weight gain | OLANZAPINE | targetBased | 4 | Completed | 01/03/2003 | https://clinicaltrials.gov/study/NCT00191828 | 1 | LoF | protect | |
| Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists | D2_agonists | DRD2 | Dopaminereceptor2 | body weight gain | OLANZAPINE | targetBased | 4 | Completed | 01/03/2003 | https://clinicaltrials.gov/study/NCT00191828 | 1 | LoF | protect | |
| HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists | D2_agonists | DRD2 | Dopaminereceptor2 | body weight gain | OLANZAPINE | targetBased | 4 | Completed | 01/03/2003 | https://clinicaltrials.gov/study/NCT00191828 | 1 | LoF | protect | |
| Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators | D2_PAMs | DRD2 | Dopaminereceptor2 | body weight gain | OLANZAPINE | targetBased | 4 | Completed | 01/03/2003 | https://clinicaltrials.gov/study/NCT00191828 | 1 | LoF | protect | |
| HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators | D2_PAMs | DRD2 | Dopaminereceptor2 | body weight gain | OLANZAPINE | targetBased | 4 | Completed | 01/03/2003 | https://clinicaltrials.gov/study/NCT00191828 | 1 | LoF | protect | |
| Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists | D2_antagonists | DRD2 | Dopaminereceptor2 | body weight gain | OLANZAPINE | targetBased | 4 | Completed | 01/03/2003 | https://clinicaltrials.gov/study/NCT00191828 | 1 | LoF | protect | |
| HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists | D2_antagonists | DRD2 | Dopaminereceptor2 | body weight gain | OLANZAPINE | targetBased | 4 | Completed | 01/03/2003 | https://clinicaltrials.gov/study/NCT00191828 | 1 | LoF | protect | |
| Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists | D2_agonists | DRD2 | Dopaminereceptor2 | body weight gain | OLANZAPINE | targetBased | 3 | Completed | 01/01/2008 | https://clinicaltrials.gov/study/NCT00363376 | 0.7 | LoF | protect | |
| HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists | D2_agonists | DRD2 | Dopaminereceptor2 | body weight gain | OLANZAPINE | targetBased | 3 | Completed | 01/01/2008 | https://clinicaltrials.gov/study/NCT00363376 | 0.7 | LoF | protect | |
| Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators | D2_PAMs | DRD2 | Dopaminereceptor2 | body weight gain | OLANZAPINE | targetBased | 3 | Completed | 01/01/2008 | https://clinicaltrials.gov/study/NCT00363376 | 0.7 | LoF | protect | |
| HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators | D2_PAMs | DRD2 | Dopaminereceptor2 | body weight gain | OLANZAPINE | targetBased | 3 | Completed | 01/01/2008 | https://clinicaltrials.gov/study/NCT00363376 | 0.7 | LoF | protect | |
| Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists | D2_antagonists | DRD2 | Dopaminereceptor2 | body weight gain | OLANZAPINE | targetBased | 3 | Completed | 01/01/2008 | https://clinicaltrials.gov/study/NCT00363376 | 0.7 | LoF | protect | |
| HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists | D2_antagonists | DRD2 | Dopaminereceptor2 | body weight gain | OLANZAPINE | targetBased | 3 | Completed | 01/01/2008 | https://clinicaltrials.gov/study/NCT00363376 | 0.7 | LoF | protect | |
| HTS for Beta-2AR agonists via FAP method | ADRB2_activators | ADRB2 | Beta-2 adrenergic receptor | portal hypertension | CARVEDILOL | targetBased | 3 | Unknown status | 01/12/2014 | https://clinicaltrials.gov/study/NCT02975323 | 0.7 | LoF | protect | |
| HTS for Beta-2AR agonists via FAP method | ADRB2_activators | ADRB2 | Beta-2 adrenergic receptor | portal hypertension | CARVEDILOL | targetBased | 4 | Unknown status | 01/06/2002 | https://clinicaltrials.gov/study/NCT01070641 | 1 | LoF | protect | |
| HTS for Beta-2AR agonists via FAP method | ADRB2_activators | ADRB2 | Beta-2 adrenergic receptor | portal hypertension | CARVEDILOL | targetBased | 4 | Unknown status | 05/04/2018 | https://clinicaltrials.gov/study/NCT02945982 | 1 | LoF | protect | |
| HTS for Beta-2AR agonists via FAP method | ADRB2_activators | ADRB2 | Beta-2 adrenergic receptor | type 2 diabetes mellitus | CARVEDILOL | targetBased | 3 | Completed | 01/09/1999 | https://clinicaltrials.gov/study/NCT00000620 | 0.7 | LoF | protect | |
| HTS for Beta-2AR agonists via FAP method | ADRB2_activators | ADRB2 | Beta-2 adrenergic receptor | diabetes mellitus | CARVEDILOL | targetBased | 4 | Completed | 01/01/2004 | https://clinicaltrials.gov/study/NCT00642434 | 1 | LoF | protect | |
| HTS for Beta-2AR agonists via FAP method | ADRB2_activators | ADRB2 | Beta-2 adrenergic receptor | obesity | CARVEDILOL | targetBased | 4 | Enrolling by invitation | 01/06/2019 | https://clinicaltrials.gov/study/NCT04049786 | 1 | LoF | protect | |
| HTS for Beta-2AR agonists via FAP method | ADRB2_activators | ADRB2 | Beta-2 adrenergic receptor | Hypercholesterolemia | CARVEDILOL | targetBased | 3 | Completed | 01/09/1999 | https://clinicaltrials.gov/study/NCT00000620 | 0.7 | LoF | protect | |
| uHTS identification of small molecule modulators of NR3A | GRIN3A | GRIN3A | morbid obesity | KETAMINE | targetBased | 3 | Unknown status | 01/06/2012 | https://clinicaltrials.gov/study/NCT01724983 | 0.7 | LoF | protect | ||
| uHTS identification of small molecule modulators of NR3A | GRIN3A | GRIN3A | morbid obesity | KETAMINE | targetBased | 3 | Active, not recruiting | 20/04/2021 | https://clinicaltrials.gov/study/NCT04576975 | 0.7 | LoF | protect | ||
| HTS for Beta-2AR agonists via FAP method | ADRB2_activators | ADRB2 | Beta-2 adrenergic receptor | gallstones | ESMOLOL | targetBased | 4 | Completed | 01/01/2015 | https://clinicaltrials.gov/study/NCT02327923 | 1 | LoF | protect | |
| High Throughput Screening for Cocaine Antagonists: Primary Screen | SLC6A3 | SLC6A3 | Sodium-dependent dopamine transporter | obesity | MAZINDOL | targetBased | 4 | https://www.whocc.no/atc_ddd_index/?code=A08AA05 | 1 | LoF | protect | |||
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | sclerosing cholangitis | BEZAFIBRATE | targetBased | 3 | Unknown status | 01/02/2016 | https://clinicaltrials.gov/study/NCT02701166 | 0.7 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | sclerosing cholangitis | BEZAFIBRATE | targetBased | 3 | Unknown status | 01/02/2016 | https://clinicaltrials.gov/study/NCT02701166 | 0.7 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | sclerosing cholangitis | BEZAFIBRATE | targetBased | 3 | Unknown status | 01/02/2016 | https://clinicaltrials.gov/study/NCT02701166 | 0.7 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | sclerosing cholangitis | BEZAFIBRATE | targetBased | 3 | Unknown status | 01/02/2016 | https://clinicaltrials.gov/study/NCT02701166 | 0.7 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | sclerosing cholangitis | BEZAFIBRATE | targetBased | 3 | Unknown status | 01/02/2016 | https://clinicaltrials.gov/study/NCT02701166 | 0.7 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | sclerosing cholangitis | BEZAFIBRATE | targetBased | 3 | Unknown status | 01/02/2016 | https://clinicaltrials.gov/study/NCT02701166 | 0.7 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | Combined hyperlipidemia | BEZAFIBRATE | targetBased | 3 | Completed | 01/04/2013 | https://clinicaltrials.gov/study/NCT02548832 | 0.7 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | Combined hyperlipidemia | BEZAFIBRATE | targetBased | 3 | Completed | 01/04/2013 | https://clinicaltrials.gov/study/NCT02548832 | 0.7 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | Combined hyperlipidemia | BEZAFIBRATE | targetBased | 3 | Completed | 01/04/2013 | https://clinicaltrials.gov/study/NCT02548832 | 0.7 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | Combined hyperlipidemia | BEZAFIBRATE | targetBased | 3 | Completed | 01/04/2013 | https://clinicaltrials.gov/study/NCT02548832 | 0.7 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | Combined hyperlipidemia | BEZAFIBRATE | targetBased | 3 | Completed | 01/04/2013 | https://clinicaltrials.gov/study/NCT02548832 | 0.7 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | Combined hyperlipidemia | BEZAFIBRATE | targetBased | 3 | Completed | 01/04/2013 | https://clinicaltrials.gov/study/NCT02548832 | 0.7 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | insulin resistance | ROSIGLITAZONE MALEATE | targetBased | 3 | Completed | 01/10/2002 | https://clinicaltrials.gov/study/NCT00197132 | 0.7 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | insulin resistance | ROSIGLITAZONE MALEATE | targetBased | 3 | Completed | 01/10/2002 | https://clinicaltrials.gov/study/NCT00197132 | 0.7 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | insulin resistance | ROSIGLITAZONE MALEATE | targetBased | 3 | Completed | 01/10/2002 | https://clinicaltrials.gov/study/NCT00197132 | 0.7 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | insulin resistance | ROSIGLITAZONE MALEATE | targetBased | 3 | Completed | 01/10/2002 | https://clinicaltrials.gov/study/NCT00197132 | 0.7 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | insulin resistance | ROSIGLITAZONE MALEATE | targetBased | 3 | Completed | 01/10/2002 | https://clinicaltrials.gov/study/NCT00197132 | 0.7 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | insulin resistance | ROSIGLITAZONE MALEATE | targetBased | 3 | Completed | 01/10/2002 | https://clinicaltrials.gov/study/NCT00197132 | 0.7 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | ROSIGLITAZONE MALEATE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ec682aec-e98f-41a1-9d21-eb7580ea3a8a | 1 | GoF | protect | |||
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | ROSIGLITAZONE MALEATE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ec682aec-e98f-41a1-9d21-eb7580ea3a8a | 1 | GoF | protect | |||
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | ROSIGLITAZONE MALEATE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ec682aec-e98f-41a1-9d21-eb7580ea3a8a | 1 | GoF | protect | |||
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | ROSIGLITAZONE MALEATE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ec682aec-e98f-41a1-9d21-eb7580ea3a8a | 1 | GoF | protect | |||
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | ROSIGLITAZONE MALEATE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ec682aec-e98f-41a1-9d21-eb7580ea3a8a | 1 | GoF | protect | |||
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | ROSIGLITAZONE MALEATE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ec682aec-e98f-41a1-9d21-eb7580ea3a8a | 1 | GoF | protect | |||
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | ROSIGLITAZONE MALEATE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=dd8d7ec8-79b0-4152-8789-d247c77232ce | 1 | GoF | protect | |||
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | ROSIGLITAZONE MALEATE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=dd8d7ec8-79b0-4152-8789-d247c77232ce | 1 | GoF | protect | |||
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | ROSIGLITAZONE MALEATE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=dd8d7ec8-79b0-4152-8789-d247c77232ce | 1 | GoF | protect | |||
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | ROSIGLITAZONE MALEATE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=dd8d7ec8-79b0-4152-8789-d247c77232ce | 1 | GoF | protect | |||
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | ROSIGLITAZONE MALEATE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=dd8d7ec8-79b0-4152-8789-d247c77232ce | 1 | GoF | protect | |||
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | ROSIGLITAZONE MALEATE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=dd8d7ec8-79b0-4152-8789-d247c77232ce | 1 | GoF | protect | |||
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | ROSIGLITAZONE MALEATE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ef14122b-7fff-45fa-b13b-0ea9e48bd57d | 1 | GoF | protect | |||
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | ROSIGLITAZONE MALEATE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ef14122b-7fff-45fa-b13b-0ea9e48bd57d | 1 | GoF | protect | |||
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | ROSIGLITAZONE MALEATE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ef14122b-7fff-45fa-b13b-0ea9e48bd57d | 1 | GoF | protect | |||
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | ROSIGLITAZONE MALEATE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ef14122b-7fff-45fa-b13b-0ea9e48bd57d | 1 | GoF | protect | |||
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | ROSIGLITAZONE MALEATE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ef14122b-7fff-45fa-b13b-0ea9e48bd57d | 1 | GoF | protect | |||
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | ROSIGLITAZONE MALEATE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ef14122b-7fff-45fa-b13b-0ea9e48bd57d | 1 | GoF | protect | |||
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | ROSIGLITAZONE MALEATE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=28c31e58-0b27-43e2-bae0-9bbb21420e9f | 1 | GoF | protect | |||
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | ROSIGLITAZONE MALEATE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=28c31e58-0b27-43e2-bae0-9bbb21420e9f | 1 | GoF | protect | |||
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | ROSIGLITAZONE MALEATE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=28c31e58-0b27-43e2-bae0-9bbb21420e9f | 1 | GoF | protect | |||
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | ROSIGLITAZONE MALEATE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=28c31e58-0b27-43e2-bae0-9bbb21420e9f | 1 | GoF | protect | |||
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | ROSIGLITAZONE MALEATE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=28c31e58-0b27-43e2-bae0-9bbb21420e9f | 1 | GoF | protect | |||
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | ROSIGLITAZONE MALEATE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=28c31e58-0b27-43e2-bae0-9bbb21420e9f | 1 | GoF | protect | |||
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | ROSIGLITAZONE MALEATE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0789dc6b-db34-44a6-8a5d-fdcc8e4ce8fd | 1 | GoF | protect | |||
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | ROSIGLITAZONE MALEATE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0789dc6b-db34-44a6-8a5d-fdcc8e4ce8fd | 1 | GoF | protect | |||
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | ROSIGLITAZONE MALEATE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0789dc6b-db34-44a6-8a5d-fdcc8e4ce8fd | 1 | GoF | protect | |||
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | ROSIGLITAZONE MALEATE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0789dc6b-db34-44a6-8a5d-fdcc8e4ce8fd | 1 | GoF | protect | |||
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | ROSIGLITAZONE MALEATE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0789dc6b-db34-44a6-8a5d-fdcc8e4ce8fd | 1 | GoF | protect | |||
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | ROSIGLITAZONE MALEATE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0789dc6b-db34-44a6-8a5d-fdcc8e4ce8fd | 1 | GoF | protect | |||
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | ROSIGLITAZONE MALEATE | targetBased | 3 | Completed | 08/10/2003 | https://clinicaltrials.gov/study/NCT00499707 | 0.7 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | ROSIGLITAZONE MALEATE | targetBased | 3 | Completed | 08/10/2003 | https://clinicaltrials.gov/study/NCT00499707 | 0.7 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | ROSIGLITAZONE MALEATE | targetBased | 3 | Completed | 08/10/2003 | https://clinicaltrials.gov/study/NCT00499707 | 0.7 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | ROSIGLITAZONE MALEATE | targetBased | 3 | Completed | 08/10/2003 | https://clinicaltrials.gov/study/NCT00499707 | 0.7 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | ROSIGLITAZONE MALEATE | targetBased | 3 | Completed | 08/10/2003 | https://clinicaltrials.gov/study/NCT00499707 | 0.7 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | ROSIGLITAZONE MALEATE | targetBased | 3 | Completed | 08/10/2003 | https://clinicaltrials.gov/study/NCT00499707 | 0.7 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | ROSIGLITAZONE MALEATE | targetBased | 4 | https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/200678s016lbledt.pdf | 1 | GoF | protect | |||
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | ROSIGLITAZONE MALEATE | targetBased | 4 | https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/200678s016lbledt.pdf | 1 | GoF | protect | |||
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | ROSIGLITAZONE MALEATE | targetBased | 4 | https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/200678s016lbledt.pdf | 1 | GoF | protect | |||
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | ROSIGLITAZONE MALEATE | targetBased | 4 | https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/200678s016lbledt.pdf | 1 | GoF | protect | |||
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | ROSIGLITAZONE MALEATE | targetBased | 4 | https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/200678s016lbledt.pdf | 1 | GoF | protect | |||
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | ROSIGLITAZONE MALEATE | targetBased | 4 | https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/200678s016lbledt.pdf | 1 | GoF | protect | |||
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | diabetes mellitus | ROSIGLITAZONE MALEATE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b019bfc3-5a3b-4b8f-9962-d885447639db | 1 | GoF | protect | |||
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | diabetes mellitus | ROSIGLITAZONE MALEATE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b019bfc3-5a3b-4b8f-9962-d885447639db | 1 | GoF | protect | |||
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | diabetes mellitus | ROSIGLITAZONE MALEATE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b019bfc3-5a3b-4b8f-9962-d885447639db | 1 | GoF | protect | |||
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | diabetes mellitus | ROSIGLITAZONE MALEATE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b019bfc3-5a3b-4b8f-9962-d885447639db | 1 | GoF | protect | |||
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | diabetes mellitus | ROSIGLITAZONE MALEATE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b019bfc3-5a3b-4b8f-9962-d885447639db | 1 | GoF | protect | |||
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | diabetes mellitus | ROSIGLITAZONE MALEATE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b019bfc3-5a3b-4b8f-9962-d885447639db | 1 | GoF | protect | |||
| Inhibitors of the vitamin D receptor (VDR): qHTS | VDR | VDR | Vitamin D3 receptor | hypoparathyroidism | CALCITRIOL | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1b2aa7df-0f38-460e-b1f1-d7473be4ab3c | 1 | GoF | protect | |||
| Inhibitors of the vitamin D receptor (VDR): qHTS | VDR | VDR | Vitamin D3 receptor | hypoparathyroidism | CALCITRIOL | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=66a69351-5b09-4368-a9fa-acf81b5ad882 | 1 | GoF | protect | |||
| Inhibitors of the vitamin D receptor (VDR): qHTS | VDR | VDR | Vitamin D3 receptor | hypoparathyroidism | CALCITRIOL | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2d755a21-9f42-4d36-aaec-962495ab2f2b | 1 | GoF | protect | |||
| Inhibitors of the vitamin D receptor (VDR): qHTS | VDR | VDR | Vitamin D3 receptor | hypoparathyroidism | CALCITRIOL | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=aaf62f0f-bd93-43f1-96f2-e4f001ea7328 | 1 | GoF | protect | |||
| Inhibitors of the vitamin D receptor (VDR): qHTS | VDR | VDR | Vitamin D3 receptor | hypoparathyroidism | CALCITRIOL | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=bebefb2a-7365-48e2-9681-83ed4b41e26e | 1 | GoF | protect | |||
| Inhibitors of the vitamin D receptor (VDR): qHTS | VDR | VDR | Vitamin D3 receptor | hypoparathyroidism | CALCITRIOL | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d1013494-bf62-4e68-9f0c-e6571137f20f | 1 | GoF | protect | |||
| Inhibitors of the vitamin D receptor (VDR): qHTS | VDR | VDR | Vitamin D3 receptor | hypoparathyroidism | CALCITRIOL | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=84262b69-df29-41d0-9e97-6e1188096aeb | 1 | GoF | protect | |||
| Inhibitors of the vitamin D receptor (VDR): qHTS | VDR | VDR | Vitamin D3 receptor | hypoparathyroidism | CALCITRIOL | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c64778c6-3be6-44f5-8387-ebcd82e3eae5 | 1 | GoF | protect | |||
| Inhibitors of the vitamin D receptor (VDR): qHTS | VDR | VDR | Vitamin D3 receptor | secondary hyperparathyroidism | CALCITRIOL | targetBased | 4 | Completed | 01/10/2010 | https://clinicaltrials.gov/study/NCT01181531 | 1 | GoF | protect | |
| Inhibitors of the vitamin D receptor (VDR): qHTS | VDR | VDR | Vitamin D3 receptor | secondary hyperparathyroidism | CALCITRIOL | targetBased | 4 | Completed | 01/08/2008 | https://clinicaltrials.gov/study/NCT01115543 | 1 | GoF | protect | |
| Inhibitors of the vitamin D receptor (VDR): qHTS | VDR | VDR | Vitamin D3 receptor | secondary hyperparathyroidism | CALCITRIOL | targetBased | 4 | Terminated | 01/01/2009 | https://clinicaltrials.gov/study/NCT00664430 | 1 | GoF | protect | Low enrollment rate |
| Inhibitors of the vitamin D receptor (VDR): qHTS | VDR | VDR | Vitamin D3 receptor | diabetic nephropathy | CALCITRIOL | targetBased | 3 | Unknown status | 10/05/2017 | https://clinicaltrials.gov/study/NCT03216564 | 0.7 | GoF | protect | |
| Inhibitors of the vitamin D receptor (VDR): qHTS | VDR | VDR | Vitamin D3 receptor | diabetic nephropathy | CALCITRIOL | targetBased | 4 | Unknown status | 01/10/2012 | https://clinicaltrials.gov/study/NCT01673204 | 1 | GoF | protect | |
| ROC1-CUL1 CTD Inhibitor di-Ub FRET Primary HTS Screen | RBX1 | RBX1 | E3 ubiquitin-protein ligase RBX1 | amyloidosis | LENALIDOMIDE | targetBased | 3 | Completed | 20/02/2019 | https://clinicaltrials.gov/study/NCT04298372 | 0.7 | LoF | protect | |
| HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors | ESR1_inhibitors | ESR1 | Estrogen receptor, Estrogen receptor | obesity | BAZEDOXIFENE | targetBased | 4 | Completed | 01/12/2014 | https://clinicaltrials.gov/study/NCT02237079 | 1 | protect | ||
| HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators | ESR1_modulators | ESR1 | Estrogen receptor, Estrogen receptor | obesity | BAZEDOXIFENE | targetBased | 4 | Completed | 01/12/2014 | https://clinicaltrials.gov/study/NCT02237079 | 1 | protect | ||
| HTS for Estrogen Receptor-beta Coactivator Binding inhibitors | ESR2_inhibitors | ESR2 | Estrogen receptor beta | obesity | BAZEDOXIFENE | targetBased | 4 | Completed | 01/12/2014 | https://clinicaltrials.gov/study/NCT02237079 | 1 | protect | ||
| Thrombin 1536 HTS | F2_modulation | F2 | Prothrombin | diabetes mellitus | DABIGATRAN | targetBased | 4 | Completed | 01/09/2015 | https://clinicaltrials.gov/study/NCT02935855 | 1 | LoF | protect | |
| High Throughput Screening for Cocaine Antagonists: Primary Screen | SLC6A3 | SLC6A3 | Sodium-dependent dopamine transporter | morbid obesity | BUPROPION | targetBased | 4 | Recruiting | 21/03/2023 | https://clinicaltrials.gov/study/NCT04902625 | 1 | LoF | protect | |
| High Throughput Screening for Cocaine Antagonists: Primary Screen | SLC6A3 | SLC6A3 | Sodium-dependent dopamine transporter | obesity | BUPROPION | targetBased | 4 | Active, not recruiting | 19/01/2023 | https://clinicaltrials.gov/study/NCT05579249 | 1 | LoF | protect | |
| High Throughput Screening for Cocaine Antagonists: Primary Screen | SLC6A3 | SLC6A3 | Sodium-dependent dopamine transporter | obesity | BUPROPION | targetBased | 3 | Completed | 01/12/2007 | https://clinicaltrials.gov/study/NCT00567255 | 0.7 | LoF | protect | |
| High Throughput Screening for Cocaine Antagonists: Primary Screen | SLC6A3 | SLC6A3 | Sodium-dependent dopamine transporter | obesity | BUPROPION | targetBased | 3 | Completed | 11/12/2017 | https://clinicaltrials.gov/study/NCT03374956 | 0.7 | LoF | protect | |
| High Throughput Screening for Cocaine Antagonists: Primary Screen | SLC6A3 | SLC6A3 | Sodium-dependent dopamine transporter | obesity | BUPROPION | targetBased | 3 | Completed | 01/03/2007 | https://clinicaltrials.gov/study/NCT00456521 | 0.7 | LoF | protect | |
| High Throughput Screening for Cocaine Antagonists: Primary Screen | SLC6A3 | SLC6A3 | Sodium-dependent dopamine transporter | obesity | BUPROPION | targetBased | 4 | Withdrawn | 01/11/2020 | https://clinicaltrials.gov/study/NCT04399395 | 1 | LoF | protect | Covid-pandemic |
| High Throughput Screening for Cocaine Antagonists: Primary Screen | SLC6A3 | SLC6A3 | Sodium-dependent dopamine transporter | obesity | BUPROPION | targetBased | 4 | Recruiting | 08/09/2020 | https://clinicaltrials.gov/study/NCT04575194 | 1 | LoF | protect | |
| High Throughput Screening for Cocaine Antagonists: Primary Screen | SLC6A3 | SLC6A3 | Sodium-dependent dopamine transporter | obesity | BUPROPION | targetBased | 3 | Completed | 01/10/2007 | https://clinicaltrials.gov/study/NCT00532779 | 0.7 | LoF | protect | |
| High Throughput Screening for Cocaine Antagonists: Primary Screen | SLC6A3 | SLC6A3 | Sodium-dependent dopamine transporter | obesity | BUPROPION | targetBased | 4 | Recruiting | 08/06/2023 | https://clinicaltrials.gov/study/NCT05919797 | 1 | LoF | protect | |
| Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A) | HTR2A | HTR2A | 5-hydroxytryptamine receptor 2A | diabetic nephropathy | SARPOGRELATE | targetBased | 4 | Completed | 01/02/2013 | https://clinicaltrials.gov/study/NCT01869881 | 1 | LoF | protect | |
| Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors | OPRM1 | OPRM1 | Mu-type opioid receptor | nodular goiter | REMIFENTANIL | targetBased | 4 | Unknown status | 01/12/2012 | https://clinicaltrials.gov/study/NCT01761149 | 1 | GoF | protect | |
| Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors | OPRM1 | OPRM1 | Mu-type opioid receptor | nodular goiter | REMIFENTANIL | targetBased | 4 | Unknown status | 01/12/2012 | https://clinicaltrials.gov/study/NCT01761149 | 1 | GoF | protect | |
| Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors | OPRM1 | OPRM1 | Mu-type opioid receptor | obesity | REMIFENTANIL | targetBased | 4 | Completed | 13/01/2022 | https://clinicaltrials.gov/study/NCT05026125 | 1 | GoF | protect | |
| Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors | OPRM1 | OPRM1 | Mu-type opioid receptor | obesity | REMIFENTANIL | targetBased | 4 | Completed | 13/01/2022 | https://clinicaltrials.gov/study/NCT05026125 | 1 | GoF | protect | |
| Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors | OPRM1 | OPRM1 | Mu-type opioid receptor | cholelithiasis | REMIFENTANIL | targetBased | 4 | Completed | 01/06/2009 | https://clinicaltrials.gov/study/NCT01350037 | 1 | GoF | protect | |
| Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors | OPRM1 | OPRM1 | Mu-type opioid receptor | cholelithiasis | REMIFENTANIL | targetBased | 4 | Completed | 01/06/2009 | https://clinicaltrials.gov/study/NCT01350037 | 1 | GoF | protect | |
| Inhibitors of the vitamin D receptor (VDR): qHTS | VDR | VDR | Vitamin D3 receptor | secondary hyperparathyroidism | CALCIFEDIOL | targetBased | 4 | Completed | 01/01/2014 | https://clinicaltrials.gov/study/NCT01939977 | 1 | GoF | protect | |
| Inhibitors of the vitamin D receptor (VDR): qHTS | VDR | VDR | Vitamin D3 receptor | secondary hyperparathyroidism | CALCIFEDIOL | targetBased | 4 | https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/208010s000lbl.pdf | 1 | GoF | protect | |||
| Inhibitors of the vitamin D receptor (VDR): qHTS | VDR | VDR | Vitamin D3 receptor | parathyroid disease | CALCIFEDIOL | targetBased | 4 | https://www.whocc.no/atc_ddd_index/?code=H05BX05 | 1 | GoF | protect | |||
| Inhibitors of the vitamin D receptor (VDR): qHTS | VDR | VDR | Vitamin D3 receptor | diabetes mellitus | CHOLECALCIFEROL | targetBased | 4 | Completed | 01/12/2011 | https://clinicaltrials.gov/study/NCT01854463 | 1 | GoF | protect | |
| Inhibitors of the vitamin D receptor (VDR): qHTS | VDR | VDR | Vitamin D3 receptor | secondary hyperparathyroidism | CHOLECALCIFEROL | targetBased | 4 | Unknown status | 01/01/2015 | https://clinicaltrials.gov/study/NCT02338934 | 1 | GoF | protect | |
| Inhibitors of the vitamin D receptor (VDR): qHTS | VDR | VDR | Vitamin D3 receptor | secondary hyperparathyroidism | CHOLECALCIFEROL | targetBased | 3 | Completed | 01/05/2000 | https://clinicaltrials.gov/study/NCT00352170 | 0.7 | GoF | protect | |
| Inhibitors of the vitamin D receptor (VDR): qHTS | VDR | VDR | Vitamin D3 receptor | metabolic syndrome | CHOLECALCIFEROL | targetBased | 4 | Unknown status | 01/10/2010 | https://clinicaltrials.gov/study/NCT01237769 | 1 | GoF | protect | |
| Inhibitors of the vitamin D receptor (VDR): qHTS | VDR | VDR | Vitamin D3 receptor | non-alcoholic fatty liver disease | CHOLECALCIFEROL | targetBased | 3 | Recruiting | 31/10/2022 | https://clinicaltrials.gov/study/NCT05613192 | 0.7 | GoF | protect | |
| Inhibitors of the vitamin D receptor (VDR): qHTS | VDR | VDR | Vitamin D3 receptor | non-alcoholic fatty liver disease | CHOLECALCIFEROL | targetBased | 3 | Completed | 01/01/2014 | https://clinicaltrials.gov/study/NCT02098317 | 0.7 | GoF | protect | |
| Inhibitors of the vitamin D receptor (VDR): qHTS | VDR | VDR | Vitamin D3 receptor | type 1 diabetes mellitus | CHOLECALCIFEROL | targetBased | 3 | Not yet recruiting | 01/06/2022 | https://clinicaltrials.gov/study/NCT05270343 | 0.7 | GoF | protect | |
| Inhibitors of the vitamin D receptor (VDR): qHTS | VDR | VDR | Vitamin D3 receptor | type 1 diabetes mellitus | CHOLECALCIFEROL | targetBased | 4 | Completed | 01/11/2010 | https://clinicaltrials.gov/study/NCT01390480 | 1 | GoF | protect | |
| Inhibitors of the vitamin D receptor (VDR): qHTS | VDR | VDR | Vitamin D3 receptor | type 1 diabetes mellitus | CHOLECALCIFEROL | targetBased | 3 | Recruiting | 19/05/2022 | https://clinicaltrials.gov/study/NCT05018585 | 0.7 | GoF | protect | |
| Inhibitors of the vitamin D receptor (VDR): qHTS | VDR | VDR | Vitamin D3 receptor | type 1 diabetes mellitus | CHOLECALCIFEROL | targetBased | 4 | Completed | 01/03/2015 | https://clinicaltrials.gov/study/NCT02407899 | 1 | GoF | protect | |
| Inhibitors of the vitamin D receptor (VDR): qHTS | VDR | VDR | Vitamin D3 receptor | type 1 diabetes mellitus | CHOLECALCIFEROL | targetBased | 4 | Completed | 01/01/2011 | https://clinicaltrials.gov/study/NCT01277913 | 1 | GoF | protect | |
| Inhibitors of the vitamin D receptor (VDR): qHTS | VDR | VDR | Vitamin D3 receptor | Disorder of lipid metabolism | CHOLECALCIFEROL | targetBased | 3 | Unknown status | 01/04/2017 | https://clinicaltrials.gov/study/NCT03133975 | 0.7 | GoF | protect | |
| Inhibitors of the vitamin D receptor (VDR): qHTS | VDR | VDR | Vitamin D3 receptor | magnesium deficiency | CHOLECALCIFEROL | targetBased | 4 | Completed | 01/05/2012 | https://clinicaltrials.gov/study/NCT01593501 | 1 | GoF | protect | |
| Inhibitors of the vitamin D receptor (VDR): qHTS | VDR | VDR | Vitamin D3 receptor | type 2 diabetes mellitus | CHOLECALCIFEROL | targetBased | 3 | Terminated | 01/12/2011 | https://clinicaltrials.gov/study/NCT01170468 | 0.7 | GoF | protect | inadequate enrollement |
| Inhibitors of the vitamin D receptor (VDR): qHTS | VDR | VDR | Vitamin D3 receptor | type 2 diabetes mellitus | CHOLECALCIFEROL | targetBased | 3 | Completed | 01/01/2009 | https://clinicaltrials.gov/study/NCT01585051 | 0.7 | GoF | protect | |
| Inhibitors of the vitamin D receptor (VDR): qHTS | VDR | VDR | Vitamin D3 receptor | type 2 diabetes mellitus | CHOLECALCIFEROL | targetBased | 3 | Not yet recruiting | 01/11/2013 | https://clinicaltrials.gov/study/NCT02015052 | 0.7 | GoF | protect | |
| Inhibitors of the vitamin D receptor (VDR): qHTS | VDR | VDR | Vitamin D3 receptor | chronic pancreatitis | CHOLECALCIFEROL | targetBased | 4 | Completed | 01/07/2009 | https://clinicaltrials.gov/study/NCT00956839 | 1 | GoF | protect | |
| Inhibitors of the vitamin D receptor (VDR): qHTS | VDR | VDR | Vitamin D3 receptor | gestational diabetes | CHOLECALCIFEROL | targetBased | 3 | Unknown status | 01/09/2019 | https://clinicaltrials.gov/study/NCT03645109 | 0.7 | GoF | protect | |
| Inhibitors of the vitamin D receptor (VDR): qHTS | VDR | VDR | Vitamin D3 receptor | obesity | CHOLECALCIFEROL | targetBased | 3 | Not yet recruiting | 01/01/2023 | https://clinicaltrials.gov/study/NCT03516968 | 0.7 | GoF | protect | |
| Inhibitors of the vitamin D receptor (VDR): qHTS | VDR | VDR | Vitamin D3 receptor | obesity | CHOLECALCIFEROL | targetBased | 4 | Completed | 30/03/2015 | https://clinicaltrials.gov/study/NCT02400151 | 1 | GoF | protect | |
| Inhibitors of the vitamin D receptor (VDR): qHTS | VDR | VDR | Vitamin D3 receptor | obesity | CHOLECALCIFEROL | targetBased | 4 | Completed | 01/06/2009 | https://clinicaltrials.gov/study/NCT00877123 | 1 | GoF | protect | |
| Inhibitors of the vitamin D receptor (VDR): qHTS | VDR | VDR | Vitamin D3 receptor | obesity | CHOLECALCIFEROL | targetBased | 4 | Recruiting | 07/01/2019 | https://clinicaltrials.gov/study/NCT04151823 | 1 | GoF | protect | |
| Inhibitors of the vitamin D receptor (VDR): qHTS | VDR | VDR | Vitamin D3 receptor | hyperparathyroidism | CHOLECALCIFEROL | targetBased | 3 | Completed | 01/07/2010 | https://clinicaltrials.gov/study/NCT01138475 | 0.7 | GoF | protect | |
| Primary Cell-Based Assay to Identify Agonists of the Sphingosine 1-Phosphate Receptor 4 (S1P4) | S1PR4 | S1PR4 | Sphingosine 1-phosphate receptor 4 | type 2 diabetes mellitus | FINGOLIMOD | targetBased | 4 | Recruiting | 15/03/2022 | https://clinicaltrials.gov/study/NCT05307731 | 1 | GoF | protect | |
| Primary Cell-Based Assay to Identify Antagonists of the Sphingosine 1-Phosphate Receptor 4 (S1P4) | S1PR4 | S1PR4 | Sphingosine 1-phosphate receptor 4 | type 2 diabetes mellitus | FINGOLIMOD | targetBased | 4 | Recruiting | 15/03/2022 | https://clinicaltrials.gov/study/NCT05307731 | 1 | GoF | protect | |
| Primary HTS and Confirmation Assays for S1P1 Agonists and Agonism Potentiators | S1PR1 | S1PR1 | Sphingosine 1-phosphate receptor 1 | type 2 diabetes mellitus | FINGOLIMOD | targetBased | 4 | Recruiting | 15/03/2022 | https://clinicaltrials.gov/study/NCT05307731 | 1 | GoF | protect | |
| Primary HTS Assay for S1P3 Antagonists | S1PR3 | S1PR3 | Sphingosine 1-phosphate receptor 3 | type 2 diabetes mellitus | FINGOLIMOD | targetBased | 4 | Recruiting | 15/03/2022 | https://clinicaltrials.gov/study/NCT05307731 | 1 | GoF | protect | |
| Primary Cell-Based High-Throughput Screening to Identify Agonists of the Sphingosine 1-phosphate receptor 2 (S1P2) | S1PR2 | S1PR2 | Sphingosine 1-phosphate receptor 2 | type 2 diabetes mellitus | FINGOLIMOD | targetBased | 4 | Recruiting | 15/03/2022 | https://clinicaltrials.gov/study/NCT05307731 | 1 | GoF | protect | |
| Primary Cell-Based High-Throughput Screening to Identify Antagonists of the Sphingosine 1-phosphate receptor 2 (S1P2) | S1PR2 | S1PR2 | Sphingosine 1-phosphate receptor 2 | type 2 diabetes mellitus | FINGOLIMOD | targetBased | 4 | Recruiting | 15/03/2022 | https://clinicaltrials.gov/study/NCT05307731 | 1 | GoF | protect | |
| Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists | D2_agonists | DRD2 | Dopaminereceptor2 | cholecystolithiasis | DROPERIDOL | targetBased | 4 | Unknown status | 01/10/2005 | https://clinicaltrials.gov/study/NCT00209885 | 1 | LoF | protect | |
| HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists | D2_agonists | DRD2 | Dopaminereceptor2 | cholecystolithiasis | DROPERIDOL | targetBased | 4 | Unknown status | 01/10/2005 | https://clinicaltrials.gov/study/NCT00209885 | 1 | LoF | protect | |
| Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators | D2_PAMs | DRD2 | Dopaminereceptor2 | cholecystolithiasis | DROPERIDOL | targetBased | 4 | Unknown status | 01/10/2005 | https://clinicaltrials.gov/study/NCT00209885 | 1 | LoF | protect | |
| HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators | D2_PAMs | DRD2 | Dopaminereceptor2 | cholecystolithiasis | DROPERIDOL | targetBased | 4 | Unknown status | 01/10/2005 | https://clinicaltrials.gov/study/NCT00209885 | 1 | LoF | protect | |
| Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists | D2_antagonists | DRD2 | Dopaminereceptor2 | cholecystolithiasis | DROPERIDOL | targetBased | 4 | Unknown status | 01/10/2005 | https://clinicaltrials.gov/study/NCT00209885 | 1 | LoF | protect | |
| HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists | D2_antagonists | DRD2 | Dopaminereceptor2 | cholecystolithiasis | DROPERIDOL | targetBased | 4 | Unknown status | 01/10/2005 | https://clinicaltrials.gov/study/NCT00209885 | 1 | LoF | protect | |
| qHTS of D3 Dopamine Receptor Antagonist: qHTS | D3_antagonists | DRD3 | Dopaminereceptor3 | cholecystolithiasis | DROPERIDOL | targetBased | 4 | Unknown status | 01/10/2005 | https://clinicaltrials.gov/study/NCT00209885 | 1 | LoF | protect | |
| qHTS of D3 Dopamine Receptor Agonist: qHTS | D3_agonists | DRD3 | Dopaminereceptor3 | cholecystolithiasis | DROPERIDOL | targetBased | 4 | Unknown status | 01/10/2005 | https://clinicaltrials.gov/study/NCT00209885 | 1 | LoF | protect | |
| qHTS of D3 Dopamine Receptor Potentiators: qHTS | D3_PAMs | DRD3 | Dopaminereceptor3 | cholecystolithiasis | DROPERIDOL | targetBased | 4 | Unknown status | 01/10/2005 | https://clinicaltrials.gov/study/NCT00209885 | 1 | LoF | protect | |
| Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A) | HTR2A | HTR2A | 5-hydroxytryptamine receptor 2A | cholecystolithiasis | DROPERIDOL | targetBased | 4 | Unknown status | 01/10/2005 | https://clinicaltrials.gov/study/NCT00209885 | 1 | LoF | protect | |
| Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A) | HTR2A | HTR2A | 5-hydroxytryptamine receptor 2A | body weight gain | ARIPIPRAZOLE | targetBased | 4 | Completed | 01/08/2016 | https://clinicaltrials.gov/study/NCT02949752 | 1 | LoF | protect | |
| Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A) | HTR2A | HTR2A | 5-hydroxytryptamine receptor 2A | hyperprolactinemia | ARIPIPRAZOLE | targetBased | 4 | Completed | 01/04/2010 | https://clinicaltrials.gov/study/NCT01085383 | 1 | LoF | protect | |
| Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) agonists | HTR1A | HTR1A | 5-hydroxytryptamine receptor 1A | hyperprolactinemia | ARIPIPRAZOLE | targetBased | 4 | Completed | 01/04/2010 | https://clinicaltrials.gov/study/NCT01085383 | 1 | GoF | protect | |
| Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) antagonists | HTR1A | HTR1A | 5-hydroxytryptamine receptor 1A | hyperprolactinemia | ARIPIPRAZOLE | targetBased | 4 | Completed | 01/04/2010 | https://clinicaltrials.gov/study/NCT01085383 | 1 | GoF | protect | |
| Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists | D2_agonists | DRD2 | Dopaminereceptor2 | hyperprolactinemia | ARIPIPRAZOLE | targetBased | 4 | Completed | 01/04/2010 | https://clinicaltrials.gov/study/NCT01085383 | 1 | GoF | protect | |
| HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists | D2_agonists | DRD2 | Dopaminereceptor2 | hyperprolactinemia | ARIPIPRAZOLE | targetBased | 4 | Completed | 01/04/2010 | https://clinicaltrials.gov/study/NCT01085383 | 1 | GoF | protect | |
| Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators | D2_PAMs | DRD2 | Dopaminereceptor2 | hyperprolactinemia | ARIPIPRAZOLE | targetBased | 4 | Completed | 01/04/2010 | https://clinicaltrials.gov/study/NCT01085383 | 1 | GoF | protect | |
| HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators | D2_PAMs | DRD2 | Dopaminereceptor2 | hyperprolactinemia | ARIPIPRAZOLE | targetBased | 4 | Completed | 01/04/2010 | https://clinicaltrials.gov/study/NCT01085383 | 1 | GoF | protect | |
| Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists | D2_antagonists | DRD2 | Dopaminereceptor2 | hyperprolactinemia | ARIPIPRAZOLE | targetBased | 4 | Completed | 01/04/2010 | https://clinicaltrials.gov/study/NCT01085383 | 1 | GoF | protect | |
| HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists | D2_antagonists | DRD2 | Dopaminereceptor2 | hyperprolactinemia | ARIPIPRAZOLE | targetBased | 4 | Completed | 01/04/2010 | https://clinicaltrials.gov/study/NCT01085383 | 1 | GoF | protect | |
| Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) agonists | HTR1A | HTR1A | 5-hydroxytryptamine receptor 1A | body weight gain | ARIPIPRAZOLE | targetBased | 4 | Completed | 01/08/2016 | https://clinicaltrials.gov/study/NCT02949752 | 1 | GoF | protect | |
| Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) antagonists | HTR1A | HTR1A | 5-hydroxytryptamine receptor 1A | body weight gain | ARIPIPRAZOLE | targetBased | 4 | Completed | 01/08/2016 | https://clinicaltrials.gov/study/NCT02949752 | 1 | GoF | protect | |
| Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists | D2_agonists | DRD2 | Dopaminereceptor2 | body weight gain | ARIPIPRAZOLE | targetBased | 4 | Completed | 01/08/2016 | https://clinicaltrials.gov/study/NCT02949752 | 1 | GoF | protect | |
| HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists | D2_agonists | DRD2 | Dopaminereceptor2 | body weight gain | ARIPIPRAZOLE | targetBased | 4 | Completed | 01/08/2016 | https://clinicaltrials.gov/study/NCT02949752 | 1 | GoF | protect | |
| Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators | D2_PAMs | DRD2 | Dopaminereceptor2 | body weight gain | ARIPIPRAZOLE | targetBased | 4 | Completed | 01/08/2016 | https://clinicaltrials.gov/study/NCT02949752 | 1 | GoF | protect | |
| HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators | D2_PAMs | DRD2 | Dopaminereceptor2 | body weight gain | ARIPIPRAZOLE | targetBased | 4 | Completed | 01/08/2016 | https://clinicaltrials.gov/study/NCT02949752 | 1 | GoF | protect | |
| Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists | D2_antagonists | DRD2 | Dopaminereceptor2 | body weight gain | ARIPIPRAZOLE | targetBased | 4 | Completed | 01/08/2016 | https://clinicaltrials.gov/study/NCT02949752 | 1 | GoF | protect | |
| HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists | D2_antagonists | DRD2 | Dopaminereceptor2 | body weight gain | ARIPIPRAZOLE | targetBased | 4 | Completed | 01/08/2016 | https://clinicaltrials.gov/study/NCT02949752 | 1 | GoF | protect | |
| HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity | CACNA1D_inhibitors | CACNA1D | Voltage-dependent N-type calcium channel subunit alpha-1B | diabetes mellitus | VERAPAMIL HYDROCHLORIDE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=92f7adf1-cb8c-4c6e-95d1-9afd28fe5116 | 1 | LoF | protect | |||
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | MURAGLITAZAR | targetBased | 3 | Completed | 01/10/2003 | https://clinicaltrials.gov/study/NCT00240370 | 0.7 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | MURAGLITAZAR | targetBased | 3 | Completed | 01/10/2003 | https://clinicaltrials.gov/study/NCT00240370 | 0.7 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | MURAGLITAZAR | targetBased | 3 | Completed | 01/10/2003 | https://clinicaltrials.gov/study/NCT00240370 | 0.7 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | MURAGLITAZAR | targetBased | 3 | Completed | 01/10/2003 | https://clinicaltrials.gov/study/NCT00240370 | 0.7 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | MURAGLITAZAR | targetBased | 3 | Completed | 01/10/2003 | https://clinicaltrials.gov/study/NCT00240370 | 0.7 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | MURAGLITAZAR | targetBased | 3 | Completed | 01/10/2003 | https://clinicaltrials.gov/study/NCT00240370 | 0.7 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | MURAGLITAZAR | targetBased | 3 | Completed | 01/06/2003 | https://clinicaltrials.gov/study/NCT00246987 | 0.7 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | MURAGLITAZAR | targetBased | 3 | Completed | 01/06/2003 | https://clinicaltrials.gov/study/NCT00246987 | 0.7 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | MURAGLITAZAR | targetBased | 3 | Completed | 01/06/2003 | https://clinicaltrials.gov/study/NCT00246987 | 0.7 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | MURAGLITAZAR | targetBased | 3 | Completed | 01/06/2003 | https://clinicaltrials.gov/study/NCT00246987 | 0.7 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | MURAGLITAZAR | targetBased | 3 | Completed | 01/06/2003 | https://clinicaltrials.gov/study/NCT00246987 | 0.7 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | MURAGLITAZAR | targetBased | 3 | Completed | 01/06/2003 | https://clinicaltrials.gov/study/NCT00246987 | 0.7 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | MURAGLITAZAR | targetBased | 3 | Completed | 01/02/2004 | https://clinicaltrials.gov/study/NCT00095030 | 0.7 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | MURAGLITAZAR | targetBased | 3 | Completed | 01/02/2004 | https://clinicaltrials.gov/study/NCT00095030 | 0.7 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | MURAGLITAZAR | targetBased | 3 | Completed | 01/02/2004 | https://clinicaltrials.gov/study/NCT00095030 | 0.7 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | MURAGLITAZAR | targetBased | 3 | Completed | 01/02/2004 | https://clinicaltrials.gov/study/NCT00095030 | 0.7 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | MURAGLITAZAR | targetBased | 3 | Completed | 01/02/2004 | https://clinicaltrials.gov/study/NCT00095030 | 0.7 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | MURAGLITAZAR | targetBased | 3 | Completed | 01/02/2004 | https://clinicaltrials.gov/study/NCT00095030 | 0.7 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | MURAGLITAZAR | targetBased | 3 | Completed | 01/05/2004 | https://clinicaltrials.gov/study/NCT00094991 | 0.7 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | MURAGLITAZAR | targetBased | 3 | Completed | 01/05/2004 | https://clinicaltrials.gov/study/NCT00094991 | 0.7 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | MURAGLITAZAR | targetBased | 3 | Completed | 01/05/2004 | https://clinicaltrials.gov/study/NCT00094991 | 0.7 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | MURAGLITAZAR | targetBased | 3 | Completed | 01/05/2004 | https://clinicaltrials.gov/study/NCT00094991 | 0.7 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | MURAGLITAZAR | targetBased | 3 | Completed | 01/05/2004 | https://clinicaltrials.gov/study/NCT00094991 | 0.7 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | MURAGLITAZAR | targetBased | 3 | Completed | 01/05/2004 | https://clinicaltrials.gov/study/NCT00094991 | 0.7 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | MURAGLITAZAR | targetBased | 3 | Terminated | 01/09/2005 | https://clinicaltrials.gov/study/NCT00130806 | 0.7 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | MURAGLITAZAR | targetBased | 3 | Terminated | 01/09/2005 | https://clinicaltrials.gov/study/NCT00130806 | 0.7 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | MURAGLITAZAR | targetBased | 3 | Terminated | 01/09/2005 | https://clinicaltrials.gov/study/NCT00130806 | 0.7 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | MURAGLITAZAR | targetBased | 3 | Terminated | 01/09/2005 | https://clinicaltrials.gov/study/NCT00130806 | 0.7 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | MURAGLITAZAR | targetBased | 3 | Terminated | 01/09/2005 | https://clinicaltrials.gov/study/NCT00130806 | 0.7 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | MURAGLITAZAR | targetBased | 3 | Terminated | 01/09/2005 | https://clinicaltrials.gov/study/NCT00130806 | 0.7 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | MURAGLITAZAR | targetBased | 3 | Completed | 01/08/2005 | https://clinicaltrials.gov/study/NCT00106808 | 0.7 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | MURAGLITAZAR | targetBased | 3 | Completed | 01/08/2005 | https://clinicaltrials.gov/study/NCT00106808 | 0.7 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | MURAGLITAZAR | targetBased | 3 | Completed | 01/08/2005 | https://clinicaltrials.gov/study/NCT00106808 | 0.7 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | MURAGLITAZAR | targetBased | 3 | Completed | 01/08/2005 | https://clinicaltrials.gov/study/NCT00106808 | 0.7 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | MURAGLITAZAR | targetBased | 3 | Completed | 01/08/2005 | https://clinicaltrials.gov/study/NCT00106808 | 0.7 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | MURAGLITAZAR | targetBased | 3 | Completed | 01/08/2005 | https://clinicaltrials.gov/study/NCT00106808 | 0.7 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | diabetes mellitus | MURAGLITAZAR | targetBased | 3 | Completed | 01/07/2003 | https://clinicaltrials.gov/study/NCT00162175 | 0.7 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | diabetes mellitus | MURAGLITAZAR | targetBased | 3 | Completed | 01/07/2003 | https://clinicaltrials.gov/study/NCT00162175 | 0.7 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | diabetes mellitus | MURAGLITAZAR | targetBased | 3 | Completed | 01/07/2003 | https://clinicaltrials.gov/study/NCT00162175 | 0.7 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | diabetes mellitus | MURAGLITAZAR | targetBased | 3 | Completed | 01/07/2003 | https://clinicaltrials.gov/study/NCT00162175 | 0.7 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | diabetes mellitus | MURAGLITAZAR | targetBased | 3 | Completed | 01/07/2003 | https://clinicaltrials.gov/study/NCT00162175 | 0.7 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | diabetes mellitus | MURAGLITAZAR | targetBased | 3 | Completed | 01/07/2003 | https://clinicaltrials.gov/study/NCT00162175 | 0.7 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | diabetes mellitus | MURAGLITAZAR | targetBased | 3 | Completed | 01/06/2003 | https://clinicaltrials.gov/study/NCT00162240 | 0.7 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | diabetes mellitus | MURAGLITAZAR | targetBased | 3 | Completed | 01/06/2003 | https://clinicaltrials.gov/study/NCT00162240 | 0.7 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | diabetes mellitus | MURAGLITAZAR | targetBased | 3 | Completed | 01/06/2003 | https://clinicaltrials.gov/study/NCT00162240 | 0.7 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | diabetes mellitus | MURAGLITAZAR | targetBased | 3 | Completed | 01/06/2003 | https://clinicaltrials.gov/study/NCT00162240 | 0.7 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | diabetes mellitus | MURAGLITAZAR | targetBased | 3 | Completed | 01/06/2003 | https://clinicaltrials.gov/study/NCT00162240 | 0.7 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | diabetes mellitus | MURAGLITAZAR | targetBased | 3 | Completed | 01/06/2003 | https://clinicaltrials.gov/study/NCT00162240 | 0.7 | GoF | protect | |
| HTS for Beta-2AR agonists via FAP method | ADRB2_activators | ADRB2 | Beta-2 adrenergic receptor | gallstones | EPHEDRINE | targetBased | 4 | Completed | 01/01/2015 | https://clinicaltrials.gov/study/NCT02327923 | 1 | GoF | protect | |
| HTS for Beta-2AR agonists via FAP method | ADRB2_activators | ADRB2 | Beta-2 adrenergic receptor | obesity | EPHEDRINE | targetBased | 3 | Completed | 01/02/2000 | https://clinicaltrials.gov/study/NCT02048215 | 0.7 | GoF | protect | |
| HTS for Beta-2AR agonists via FAP method | ADRB2_activators | ADRB2 | Beta-2 adrenergic receptor | obesity | EPHEDRINE | targetBased | 4 | https://www.whocc.no/atc_ddd_index/?code=A08AA56 | 1 | GoF | protect | |||
| High Throughput Screening for Cocaine Antagonists: Primary Screen | SLC6A3 | SLC6A3 | Sodium-dependent dopamine transporter | obesity | SIBUTRAMINE | targetBased | 3 | Completed | 01/07/2004 | https://clinicaltrials.gov/study/NCT00165685 | 0.7 | LoF | protect | |
| High Throughput Screening for Cocaine Antagonists: Primary Screen | SLC6A3 | SLC6A3 | Sodium-dependent dopamine transporter | obesity | SIBUTRAMINE | targetBased | 4 | Completed | 01/07/2006 | https://clinicaltrials.gov/study/NCT00433641 | 1 | LoF | protect | |
| High Throughput Screening for Cocaine Antagonists: Primary Screen | SLC6A3 | SLC6A3 | Sodium-dependent dopamine transporter | obesity | SIBUTRAMINE | targetBased | 3 | Unknown status | 01/11/2008 | https://clinicaltrials.gov/study/NCT00941382 | 0.7 | LoF | protect | |
| High Throughput Screening for Cocaine Antagonists: Primary Screen | SLC6A3 | SLC6A3 | Sodium-dependent dopamine transporter | obesity | SIBUTRAMINE | targetBased | 4 | Terminated | 01/07/2005 | https://clinicaltrials.gov/study/NCT00115063 | 0.5 | LoF | protect | ethical issues of continuing control group without treatment |
| High Throughput Screening for Cocaine Antagonists: Primary Screen | SLC6A3 | SLC6A3 | Sodium-dependent dopamine transporter | obesity | SIBUTRAMINE | targetBased | 3 | Completed | 01/01/2003 | https://clinicaltrials.gov/study/NCT00234832 | 0.7 | LoF | protect | |
| High Throughput Screening for Cocaine Antagonists: Primary Screen | SLC6A3 | SLC6A3 | Sodium-dependent dopamine transporter | obesity | SIBUTRAMINE | targetBased | 3 | Completed | 01/07/2000 | https://clinicaltrials.gov/study/NCT00261911 | 0.7 | LoF | protect | |
| High Throughput Screening for Cocaine Antagonists: Primary Screen | SLC6A3 | SLC6A3 | Sodium-dependent dopamine transporter | obesity | SIBUTRAMINE | targetBased | 4 | Completed | 01/06/2004 | https://clinicaltrials.gov/study/NCT00234988 | 1 | LoF | protect | |
| High Throughput Screening for Cocaine Antagonists: Primary Screen | SLC6A3 | SLC6A3 | Sodium-dependent dopamine transporter | obesity | SIBUTRAMINE | targetBased | 4 | Completed | 03/07/2020 | https://clinicaltrials.gov/study/NCT05821543 | 1 | LoF | protect | |
| High Throughput Screening for Cocaine Antagonists: Primary Screen | SLC6A3 | SLC6A3 | Sodium-dependent dopamine transporter | obesity | SIBUTRAMINE | targetBased | 4 | https://www.whocc.no/atc_ddd_index/?code=A08AA10 | 1 | LoF | protect | |||
| High Throughput Screening for Cocaine Antagonists: Primary Screen | SLC6A3 | SLC6A3 | Sodium-dependent dopamine transporter | obesity | SIBUTRAMINE | targetBased | 4 | Terminated | 01/02/2009 | https://clinicaltrials.gov/study/NCT01170364 | 1 | LoF | protect | Terminated due to sibutramine being withdrawn from the market. |
| High Throughput Screening for Cocaine Antagonists: Primary Screen | SLC6A3 | SLC6A3 | Sodium-dependent dopamine transporter | obesity | SIBUTRAMINE | targetBased | 3 | Completed | 01/12/2002 | https://clinicaltrials.gov/study/NCT00677391 | 0.7 | LoF | protect | |
| Counterscreen for Oxytocin Receptor (OXTR) agonists: Fluorescence-based primary cell-based high throughput assay to identify agonists of the vasopressin 1 receptor (V1R) | AVPR1A_agonists | AVPR1A | Vasopressin V1a receptor | Central diabetes insipidus | DESMOPRESSIN | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d9d8442a-4722-4b41-9faa-1ee853a4cc3b | 1 | GoF | protect | |||
| Counterscreen for Oxytocin Receptor (OXTR) agonists: Fluorescence-based primary cell-based high throughput assay to identify agonists of the vasopressin 1 receptor (V1R) | AVPR1A_agonists | AVPR1A | Vasopressin V1a receptor | Central diabetes insipidus | DESMOPRESSIN | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6d55baa9-2b62-469c-93ae-3909ab249332 | 1 | GoF | protect | |||
| Counterscreen for Oxytocin Receptor (OXTR) agonists: Fluorescence-based primary cell-based high throughput assay to identify agonists of the vasopressin 1 receptor (V1R) | AVPR1A_agonists | AVPR1A | Vasopressin V1a receptor | Central diabetes insipidus | DESMOPRESSIN | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=86f040d0-a073-4fa5-8997-b2fecc4a3205 | 1 | GoF | protect | |||
| uHTS identification of small molecule modulators of NR3A | GRIN3A | GRIN3A | cholecystolithiasis | ESKETAMINE | targetBased | 4 | Unknown status | 01/10/2005 | https://clinicaltrials.gov/study/NCT00209885 | 1 | LoF | protect | ||
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | EXENATIDE | targetBased | 3 | Completed | 01/06/2003 | https://clinicaltrials.gov/study/NCT00082381 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | EXENATIDE | targetBased | 3 | Completed | 01/06/2003 | https://clinicaltrials.gov/study/NCT00082381 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | EXENATIDE | targetBased | 3 | Completed | 01/06/2003 | https://clinicaltrials.gov/study/NCT00082381 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | EXENATIDE | targetBased | 3 | Completed | 01/07/2009 | https://clinicaltrials.gov/study/NCT00935532 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | EXENATIDE | targetBased | 3 | Completed | 01/07/2009 | https://clinicaltrials.gov/study/NCT00935532 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | EXENATIDE | targetBased | 3 | Completed | 01/07/2009 | https://clinicaltrials.gov/study/NCT00935532 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | EXENATIDE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a1c8ee2a-6a76-435e-ad38-8a9c99046ad9 | 1 | GoF | protect | |||
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | EXENATIDE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a1c8ee2a-6a76-435e-ad38-8a9c99046ad9 | 1 | GoF | protect | |||
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | EXENATIDE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a1c8ee2a-6a76-435e-ad38-8a9c99046ad9 | 1 | GoF | protect | |||
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | EXENATIDE | targetBased | 3 | Completed | 01/05/2004 | https://clinicaltrials.gov/study/NCT00099320 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | EXENATIDE | targetBased | 3 | Completed | 01/05/2004 | https://clinicaltrials.gov/study/NCT00099320 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | EXENATIDE | targetBased | 3 | Completed | 01/05/2004 | https://clinicaltrials.gov/study/NCT00099320 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | EXENATIDE | targetBased | 4 | Withdrawn | 01/06/2016 | https://clinicaltrials.gov/study/NCT02811484 | 1 | GoF | protect | Inability to enroll due to the widespread use of both classes of drugs in patients with T2DM, including those on concomitant insulin therapy. |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | EXENATIDE | targetBased | 4 | Withdrawn | 01/06/2016 | https://clinicaltrials.gov/study/NCT02811484 | 1 | GoF | protect | Inability to enroll due to the widespread use of both classes of drugs in patients with T2DM, including those on concomitant insulin therapy. |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | EXENATIDE | targetBased | 4 | Withdrawn | 01/06/2016 | https://clinicaltrials.gov/study/NCT02811484 | 1 | GoF | protect | Inability to enroll due to the widespread use of both classes of drugs in patients with T2DM, including those on concomitant insulin therapy. |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | EXENATIDE | targetBased | 3 | Completed | 02/12/2013 | https://clinicaltrials.gov/study/NCT01885208 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | EXENATIDE | targetBased | 3 | Completed | 02/12/2013 | https://clinicaltrials.gov/study/NCT01885208 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | EXENATIDE | targetBased | 3 | Completed | 02/12/2013 | https://clinicaltrials.gov/study/NCT01885208 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | EXENATIDE | targetBased | 4 | Unknown status | 01/02/2014 | https://clinicaltrials.gov/study/NCT02129985 | 1 | GoF | protect | |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | EXENATIDE | targetBased | 4 | Unknown status | 01/02/2014 | https://clinicaltrials.gov/study/NCT02129985 | 1 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | EXENATIDE | targetBased | 4 | Unknown status | 01/02/2014 | https://clinicaltrials.gov/study/NCT02129985 | 1 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | EXENATIDE | targetBased | 4 | https://www.ema.europa.eu/en/medicines/human/EPAR/bydureon | 1 | GoF | protect | |||
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | EXENATIDE | targetBased | 4 | https://www.ema.europa.eu/en/medicines/human/EPAR/bydureon | 1 | GoF | protect | |||
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | EXENATIDE | targetBased | 4 | https://www.ema.europa.eu/en/medicines/human/EPAR/bydureon | 1 | GoF | protect | |||
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | EXENATIDE | targetBased | 4 | Completed | 01/07/2008 | https://clinicaltrials.gov/study/NCT00948168 | 1 | GoF | protect | |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | EXENATIDE | targetBased | 4 | Completed | 01/07/2008 | https://clinicaltrials.gov/study/NCT00948168 | 1 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | EXENATIDE | targetBased | 4 | Completed | 01/07/2008 | https://clinicaltrials.gov/study/NCT00948168 | 1 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | EXENATIDE | targetBased | 3 | Completed | 01/09/2006 | https://clinicaltrials.gov/study/NCT00359762 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | EXENATIDE | targetBased | 3 | Completed | 01/09/2006 | https://clinicaltrials.gov/study/NCT00359762 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | EXENATIDE | targetBased | 3 | Completed | 01/09/2006 | https://clinicaltrials.gov/study/NCT00359762 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | EXENATIDE | targetBased | 3 | Completed | 01/03/2002 | https://clinicaltrials.gov/study/NCT00039013 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | EXENATIDE | targetBased | 3 | Completed | 01/03/2002 | https://clinicaltrials.gov/study/NCT00039013 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | EXENATIDE | targetBased | 3 | Completed | 01/03/2002 | https://clinicaltrials.gov/study/NCT00039013 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | EXENATIDE | targetBased | 3 | Completed | 01/11/2008 | https://clinicaltrials.gov/study/NCT00676338 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | EXENATIDE | targetBased | 3 | Completed | 01/11/2008 | https://clinicaltrials.gov/study/NCT00676338 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | EXENATIDE | targetBased | 3 | Completed | 01/11/2008 | https://clinicaltrials.gov/study/NCT00676338 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | EXENATIDE | targetBased | 4 | Completed | 01/06/2007 | https://clinicaltrials.gov/study/NCT01432405 | 1 | GoF | protect | |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | EXENATIDE | targetBased | 4 | Completed | 01/06/2007 | https://clinicaltrials.gov/study/NCT01432405 | 1 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | EXENATIDE | targetBased | 4 | Completed | 01/06/2007 | https://clinicaltrials.gov/study/NCT01432405 | 1 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | EXENATIDE | targetBased | 4 | Completed | 28/02/2018 | https://clinicaltrials.gov/study/NCT03331289 | 1 | GoF | protect | |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | EXENATIDE | targetBased | 4 | Completed | 28/02/2018 | https://clinicaltrials.gov/study/NCT03331289 | 1 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | EXENATIDE | targetBased | 4 | Completed | 28/02/2018 | https://clinicaltrials.gov/study/NCT03331289 | 1 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | EXENATIDE | targetBased | 4 | Completed | 01/03/2007 | https://clinicaltrials.gov/study/NCT00667732 | 1 | GoF | protect | |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | EXENATIDE | targetBased | 4 | Completed | 01/03/2007 | https://clinicaltrials.gov/study/NCT00667732 | 1 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | EXENATIDE | targetBased | 4 | Completed | 01/03/2007 | https://clinicaltrials.gov/study/NCT00667732 | 1 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | EXENATIDE | targetBased | 4 | Terminated | 26/09/2016 | https://clinicaltrials.gov/study/NCT02793154 | 1 | GoF | protect | Early termination due to insufficient enrollment. |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | EXENATIDE | targetBased | 4 | Terminated | 26/09/2016 | https://clinicaltrials.gov/study/NCT02793154 | 1 | GoF | protect | Early termination due to insufficient enrollment. |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | EXENATIDE | targetBased | 4 | Terminated | 26/09/2016 | https://clinicaltrials.gov/study/NCT02793154 | 1 | GoF | protect | Early termination due to insufficient enrollment. |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | EXENATIDE | targetBased | 3 | Not yet recruiting | 01/03/2024 | https://clinicaltrials.gov/study/NCT06254014 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | EXENATIDE | targetBased | 3 | Not yet recruiting | 01/03/2024 | https://clinicaltrials.gov/study/NCT06254014 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | EXENATIDE | targetBased | 3 | Not yet recruiting | 01/03/2024 | https://clinicaltrials.gov/study/NCT06254014 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | EXENATIDE | targetBased | 3 | Completed | 01/09/2007 | https://clinicaltrials.gov/study/NCT00516074 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | EXENATIDE | targetBased | 3 | Completed | 01/09/2007 | https://clinicaltrials.gov/study/NCT00516074 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | EXENATIDE | targetBased | 3 | Completed | 01/09/2007 | https://clinicaltrials.gov/study/NCT00516074 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | EXENATIDE | targetBased | 3 | Completed | 01/10/2008 | https://clinicaltrials.gov/study/NCT00765817 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | EXENATIDE | targetBased | 3 | Completed | 01/10/2008 | https://clinicaltrials.gov/study/NCT00765817 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | EXENATIDE | targetBased | 3 | Completed | 01/10/2008 | https://clinicaltrials.gov/study/NCT00765817 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | EXENATIDE | targetBased | 3 | Completed | 01/09/2009 | https://clinicaltrials.gov/study/NCT00960661 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | EXENATIDE | targetBased | 3 | Completed | 01/09/2009 | https://clinicaltrials.gov/study/NCT00960661 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | EXENATIDE | targetBased | 3 | Completed | 01/09/2009 | https://clinicaltrials.gov/study/NCT00960661 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | EXENATIDE | targetBased | 3 | Completed | 01/07/2008 | https://clinicaltrials.gov/study/NCT00717457 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | EXENATIDE | targetBased | 3 | Completed | 01/07/2008 | https://clinicaltrials.gov/study/NCT00717457 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | EXENATIDE | targetBased | 3 | Completed | 01/07/2008 | https://clinicaltrials.gov/study/NCT00717457 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | EXENATIDE | targetBased | 4 | Completed | 01/01/2015 | https://clinicaltrials.gov/study/NCT02380521 | 1 | GoF | protect | |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | EXENATIDE | targetBased | 4 | Completed | 01/01/2015 | https://clinicaltrials.gov/study/NCT02380521 | 1 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | EXENATIDE | targetBased | 4 | Completed | 01/01/2015 | https://clinicaltrials.gov/study/NCT02380521 | 1 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | EXENATIDE | targetBased | 3 | Completed | 01/02/2007 | https://clinicaltrials.gov/study/NCT00434954 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | EXENATIDE | targetBased | 3 | Completed | 01/02/2007 | https://clinicaltrials.gov/study/NCT00434954 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | EXENATIDE | targetBased | 3 | Completed | 01/02/2007 | https://clinicaltrials.gov/study/NCT00434954 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | EXENATIDE | targetBased | 3 | Completed | 01/01/2008 | https://clinicaltrials.gov/study/NCT00577824 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | EXENATIDE | targetBased | 3 | Completed | 01/01/2008 | https://clinicaltrials.gov/study/NCT00577824 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | EXENATIDE | targetBased | 3 | Completed | 01/01/2008 | https://clinicaltrials.gov/study/NCT00577824 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | EXENATIDE | targetBased | 3 | Completed | 01/09/2004 | https://clinicaltrials.gov/study/NCT00099619 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | EXENATIDE | targetBased | 3 | Completed | 01/09/2004 | https://clinicaltrials.gov/study/NCT00099619 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | EXENATIDE | targetBased | 3 | Completed | 01/09/2004 | https://clinicaltrials.gov/study/NCT00099619 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | EXENATIDE | targetBased | 4 | Completed | 15/12/2017 | https://clinicaltrials.gov/study/NCT02981069 | 1 | GoF | protect | |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | EXENATIDE | targetBased | 4 | Completed | 15/12/2017 | https://clinicaltrials.gov/study/NCT02981069 | 1 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | EXENATIDE | targetBased | 4 | Completed | 15/12/2017 | https://clinicaltrials.gov/study/NCT02981069 | 1 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | EXENATIDE | targetBased | 4 | Recruiting | 17/11/2017 | https://clinicaltrials.gov/study/NCT03444142 | 1 | GoF | protect | |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | EXENATIDE | targetBased | 4 | Recruiting | 17/11/2017 | https://clinicaltrials.gov/study/NCT03444142 | 1 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | EXENATIDE | targetBased | 4 | Recruiting | 17/11/2017 | https://clinicaltrials.gov/study/NCT03444142 | 1 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | EXENATIDE | targetBased | 3 | Completed | 01/09/2014 | https://clinicaltrials.gov/study/NCT02194595 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | EXENATIDE | targetBased | 3 | Completed | 01/09/2014 | https://clinicaltrials.gov/study/NCT02194595 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | EXENATIDE | targetBased | 3 | Completed | 01/09/2014 | https://clinicaltrials.gov/study/NCT02194595 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | EXENATIDE | targetBased | 4 | Completed | 01/05/2007 | https://clinicaltrials.gov/study/NCT00477581 | 1 | GoF | protect | |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | EXENATIDE | targetBased | 4 | Completed | 01/05/2007 | https://clinicaltrials.gov/study/NCT00477581 | 1 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | EXENATIDE | targetBased | 4 | Completed | 01/05/2007 | https://clinicaltrials.gov/study/NCT00477581 | 1 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | EXENATIDE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c621d002-b7bf-4f3a-af68-4f70fd298d05 | 1 | GoF | protect | |||
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | EXENATIDE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c621d002-b7bf-4f3a-af68-4f70fd298d05 | 1 | GoF | protect | |||
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | EXENATIDE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c621d002-b7bf-4f3a-af68-4f70fd298d05 | 1 | GoF | protect | |||
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | EXENATIDE | targetBased | 3 | Completed | 01/10/2008 | https://clinicaltrials.gov/study/NCT00753896 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | EXENATIDE | targetBased | 3 | Completed | 01/10/2008 | https://clinicaltrials.gov/study/NCT00753896 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | EXENATIDE | targetBased | 3 | Completed | 01/10/2008 | https://clinicaltrials.gov/study/NCT00753896 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | EXENATIDE | targetBased | 4 | Completed | 01/08/2008 | https://clinicaltrials.gov/study/NCT00729326 | 1 | GoF | protect | |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | EXENATIDE | targetBased | 4 | Completed | 01/08/2008 | https://clinicaltrials.gov/study/NCT00729326 | 1 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | EXENATIDE | targetBased | 4 | Completed | 01/08/2008 | https://clinicaltrials.gov/study/NCT00729326 | 1 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | EXENATIDE | targetBased | 3 | Completed | 01/09/2006 | https://clinicaltrials.gov/study/NCT00359879 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | EXENATIDE | targetBased | 3 | Completed | 01/09/2006 | https://clinicaltrials.gov/study/NCT00359879 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | EXENATIDE | targetBased | 3 | Completed | 01/09/2006 | https://clinicaltrials.gov/study/NCT00359879 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | EXENATIDE | targetBased | 4 | Completed | 01/08/2006 | https://clinicaltrials.gov/study/NCT00353834 | 1 | GoF | protect | |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | EXENATIDE | targetBased | 4 | Completed | 01/08/2006 | https://clinicaltrials.gov/study/NCT00353834 | 1 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | EXENATIDE | targetBased | 4 | Completed | 01/08/2006 | https://clinicaltrials.gov/study/NCT00353834 | 1 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | EXENATIDE | targetBased | 3 | Completed | 01/01/2008 | https://clinicaltrials.gov/study/NCT00603239 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | EXENATIDE | targetBased | 3 | Completed | 01/01/2008 | https://clinicaltrials.gov/study/NCT00603239 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | EXENATIDE | targetBased | 3 | Completed | 01/01/2008 | https://clinicaltrials.gov/study/NCT00603239 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | EXENATIDE | targetBased | 3 | Completed | 01/02/2002 | https://clinicaltrials.gov/study/NCT00039026 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | EXENATIDE | targetBased | 3 | Completed | 01/02/2002 | https://clinicaltrials.gov/study/NCT00039026 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | EXENATIDE | targetBased | 3 | Completed | 01/02/2002 | https://clinicaltrials.gov/study/NCT00039026 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | EXENATIDE | targetBased | 4 | Completed | 01/11/2015 | https://clinicaltrials.gov/study/NCT02449603 | 1 | GoF | protect | |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | EXENATIDE | targetBased | 4 | Completed | 01/11/2015 | https://clinicaltrials.gov/study/NCT02449603 | 1 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | EXENATIDE | targetBased | 4 | Completed | 01/11/2015 | https://clinicaltrials.gov/study/NCT02449603 | 1 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | EXENATIDE | targetBased | 3 | Completed | 01/04/2006 | https://clinicaltrials.gov/study/NCT00308139 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | EXENATIDE | targetBased | 3 | Completed | 01/04/2006 | https://clinicaltrials.gov/study/NCT00308139 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | EXENATIDE | targetBased | 3 | Completed | 01/04/2006 | https://clinicaltrials.gov/study/NCT00308139 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | EXENATIDE | targetBased | 3 | Completed | 01/06/2006 | https://clinicaltrials.gov/study/NCT00360334 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | EXENATIDE | targetBased | 3 | Completed | 01/06/2006 | https://clinicaltrials.gov/study/NCT00360334 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | EXENATIDE | targetBased | 3 | Completed | 01/06/2006 | https://clinicaltrials.gov/study/NCT00360334 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | EXENATIDE | targetBased | 3 | Completed | 01/01/2013 | https://clinicaltrials.gov/study/NCT01652716 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | EXENATIDE | targetBased | 3 | Completed | 01/01/2013 | https://clinicaltrials.gov/study/NCT01652716 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | EXENATIDE | targetBased | 3 | Completed | 01/01/2013 | https://clinicaltrials.gov/study/NCT01652716 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | EXENATIDE | targetBased | 4 | Completed | 01/09/2015 | https://clinicaltrials.gov/study/NCT02455076 | 1 | GoF | protect | |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | EXENATIDE | targetBased | 4 | Completed | 01/09/2015 | https://clinicaltrials.gov/study/NCT02455076 | 1 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | EXENATIDE | targetBased | 4 | Completed | 01/09/2015 | https://clinicaltrials.gov/study/NCT02455076 | 1 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | EXENATIDE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2d18cfc4-e0de-4814-a712-c1b7c504bff5 | 1 | GoF | protect | |||
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | EXENATIDE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2d18cfc4-e0de-4814-a712-c1b7c504bff5 | 1 | GoF | protect | |||
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | EXENATIDE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2d18cfc4-e0de-4814-a712-c1b7c504bff5 | 1 | GoF | protect | |||
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | EXENATIDE | targetBased | 3 | Completed | 01/04/2006 | https://clinicaltrials.gov/study/NCT00313001 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | EXENATIDE | targetBased | 3 | Completed | 01/04/2006 | https://clinicaltrials.gov/study/NCT00313001 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | EXENATIDE | targetBased | 3 | Completed | 01/04/2006 | https://clinicaltrials.gov/study/NCT00313001 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | EXENATIDE | targetBased | 3 | Completed | 01/06/2008 | https://clinicaltrials.gov/study/NCT00707031 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | EXENATIDE | targetBased | 3 | Completed | 01/06/2008 | https://clinicaltrials.gov/study/NCT00707031 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | EXENATIDE | targetBased | 3 | Completed | 01/06/2008 | https://clinicaltrials.gov/study/NCT00707031 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | EXENATIDE | targetBased | 3 | Completed | 01/12/2003 | https://clinicaltrials.gov/study/NCT01876849 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | EXENATIDE | targetBased | 3 | Completed | 01/12/2003 | https://clinicaltrials.gov/study/NCT01876849 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | EXENATIDE | targetBased | 3 | Completed | 01/12/2003 | https://clinicaltrials.gov/study/NCT01876849 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | EXENATIDE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=53d03c03-ebf7-418d-88a8-533eabd2ee4f | 1 | GoF | protect | |||
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | EXENATIDE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=53d03c03-ebf7-418d-88a8-533eabd2ee4f | 1 | GoF | protect | |||
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | EXENATIDE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=53d03c03-ebf7-418d-88a8-533eabd2ee4f | 1 | GoF | protect | |||
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | EXENATIDE | targetBased | 3 | Completed | 01/08/2007 | https://clinicaltrials.gov/study/NCT00518882 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | EXENATIDE | targetBased | 3 | Completed | 01/08/2007 | https://clinicaltrials.gov/study/NCT00518882 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | EXENATIDE | targetBased | 3 | Completed | 01/08/2007 | https://clinicaltrials.gov/study/NCT00518882 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | EXENATIDE | targetBased | 3 | Completed | 01/11/2003 | https://clinicaltrials.gov/study/NCT00082407 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | EXENATIDE | targetBased | 3 | Completed | 01/11/2003 | https://clinicaltrials.gov/study/NCT00082407 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | EXENATIDE | targetBased | 3 | Completed | 01/11/2003 | https://clinicaltrials.gov/study/NCT00082407 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | EXENATIDE | targetBased | 4 | Completed | 28/01/2016 | https://clinicaltrials.gov/study/NCT02533453 | 1 | GoF | protect | |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | EXENATIDE | targetBased | 4 | Completed | 28/01/2016 | https://clinicaltrials.gov/study/NCT02533453 | 1 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | EXENATIDE | targetBased | 4 | Completed | 28/01/2016 | https://clinicaltrials.gov/study/NCT02533453 | 1 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | EXENATIDE | targetBased | 3 | Completed | 01/10/2005 | https://clinicaltrials.gov/study/NCT00135330 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | EXENATIDE | targetBased | 3 | Completed | 01/10/2005 | https://clinicaltrials.gov/study/NCT00135330 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | EXENATIDE | targetBased | 3 | Completed | 01/10/2005 | https://clinicaltrials.gov/study/NCT00135330 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | EXENATIDE | targetBased | 3 | Completed | 01/01/2010 | https://clinicaltrials.gov/study/NCT01029886 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | EXENATIDE | targetBased | 3 | Completed | 01/01/2010 | https://clinicaltrials.gov/study/NCT01029886 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | EXENATIDE | targetBased | 3 | Completed | 01/01/2010 | https://clinicaltrials.gov/study/NCT01029886 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | EXENATIDE | targetBased | 3 | Completed | 06/07/2016 | https://clinicaltrials.gov/study/NCT02787551 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | EXENATIDE | targetBased | 3 | Completed | 06/07/2016 | https://clinicaltrials.gov/study/NCT02787551 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | EXENATIDE | targetBased | 3 | Completed | 06/07/2016 | https://clinicaltrials.gov/study/NCT02787551 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | EXENATIDE | targetBased | 3 | Completed | 01/09/2002 | https://clinicaltrials.gov/study/NCT01789957 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | EXENATIDE | targetBased | 3 | Completed | 01/09/2002 | https://clinicaltrials.gov/study/NCT01789957 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | EXENATIDE | targetBased | 3 | Completed | 01/09/2002 | https://clinicaltrials.gov/study/NCT01789957 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | EXENATIDE | targetBased | 3 | Completed | 01/09/2006 | https://clinicaltrials.gov/study/NCT00375492 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | EXENATIDE | targetBased | 3 | Completed | 01/09/2006 | https://clinicaltrials.gov/study/NCT00375492 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | EXENATIDE | targetBased | 3 | Completed | 01/09/2006 | https://clinicaltrials.gov/study/NCT00375492 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | EXENATIDE | targetBased | 4 | Completed | 01/03/2009 | https://clinicaltrials.gov/study/NCT00870194 | 1 | GoF | protect | |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | EXENATIDE | targetBased | 4 | Completed | 01/03/2009 | https://clinicaltrials.gov/study/NCT00870194 | 1 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | EXENATIDE | targetBased | 4 | Completed | 01/03/2009 | https://clinicaltrials.gov/study/NCT00870194 | 1 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | EXENATIDE | targetBased | 4 | Completed | 01/08/2010 | https://clinicaltrials.gov/study/NCT01181986 | 1 | GoF | protect | |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | EXENATIDE | targetBased | 4 | Completed | 01/08/2010 | https://clinicaltrials.gov/study/NCT01181986 | 1 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | EXENATIDE | targetBased | 4 | Completed | 01/08/2010 | https://clinicaltrials.gov/study/NCT01181986 | 1 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | EXENATIDE | targetBased | 3 | Completed | 18/06/2010 | https://clinicaltrials.gov/study/NCT01144338 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | EXENATIDE | targetBased | 3 | Completed | 18/06/2010 | https://clinicaltrials.gov/study/NCT01144338 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | EXENATIDE | targetBased | 3 | Completed | 18/06/2010 | https://clinicaltrials.gov/study/NCT01144338 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | EXENATIDE | targetBased | 4 | Terminated | 01/02/2011 | https://clinicaltrials.gov/study/NCT01381926 | 1 | GoF | protect | unavailability of study drug and matching placebo |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | EXENATIDE | targetBased | 4 | Terminated | 01/02/2011 | https://clinicaltrials.gov/study/NCT01381926 | 1 | GoF | protect | unavailability of study drug and matching placebo |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | EXENATIDE | targetBased | 4 | Terminated | 01/02/2011 | https://clinicaltrials.gov/study/NCT01381926 | 1 | GoF | protect | unavailability of study drug and matching placebo |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | EXENATIDE | targetBased | 3 | Completed | 01/01/2008 | https://clinicaltrials.gov/study/NCT00637273 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | EXENATIDE | targetBased | 3 | Completed | 01/01/2008 | https://clinicaltrials.gov/study/NCT00637273 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | EXENATIDE | targetBased | 3 | Completed | 01/01/2008 | https://clinicaltrials.gov/study/NCT00637273 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | EXENATIDE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=71fe88be-b4e6-4c2d-9cc3-8b1864467776 | 1 | GoF | protect | |||
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | EXENATIDE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=71fe88be-b4e6-4c2d-9cc3-8b1864467776 | 1 | GoF | protect | |||
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | EXENATIDE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=71fe88be-b4e6-4c2d-9cc3-8b1864467776 | 1 | GoF | protect | |||
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | EXENATIDE | targetBased | 4 | Completed | 01/10/2013 | https://clinicaltrials.gov/study/NCT02092597 | 1 | GoF | protect | |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | EXENATIDE | targetBased | 4 | Completed | 01/10/2013 | https://clinicaltrials.gov/study/NCT02092597 | 1 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | EXENATIDE | targetBased | 4 | Completed | 01/10/2013 | https://clinicaltrials.gov/study/NCT02092597 | 1 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | EXENATIDE | targetBased | 3 | Completed | 01/01/2006 | https://clinicaltrials.gov/study/NCT00324363 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | EXENATIDE | targetBased | 3 | Completed | 01/01/2006 | https://clinicaltrials.gov/study/NCT00324363 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | EXENATIDE | targetBased | 3 | Completed | 01/01/2006 | https://clinicaltrials.gov/study/NCT00324363 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | EXENATIDE | targetBased | 3 | Completed | 01/04/2008 | https://clinicaltrials.gov/study/NCT00641056 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | EXENATIDE | targetBased | 3 | Completed | 01/04/2008 | https://clinicaltrials.gov/study/NCT00641056 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | EXENATIDE | targetBased | 3 | Completed | 01/04/2008 | https://clinicaltrials.gov/study/NCT00641056 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | EXENATIDE | targetBased | 3 | Completed | 01/05/2002 | https://clinicaltrials.gov/study/NCT00035984 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | EXENATIDE | targetBased | 3 | Completed | 01/05/2002 | https://clinicaltrials.gov/study/NCT00035984 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | EXENATIDE | targetBased | 3 | Completed | 01/05/2002 | https://clinicaltrials.gov/study/NCT00035984 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | EXENATIDE | targetBased | 4 | Completed | 01/07/2009 | https://clinicaltrials.gov/study/NCT00950677 | 1 | GoF | protect | |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | EXENATIDE | targetBased | 4 | Completed | 01/07/2009 | https://clinicaltrials.gov/study/NCT00950677 | 1 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | EXENATIDE | targetBased | 4 | Completed | 01/07/2009 | https://clinicaltrials.gov/study/NCT00950677 | 1 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | EXENATIDE | targetBased | 3 | Completed | 01/08/2007 | https://clinicaltrials.gov/study/NCT00516048 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | EXENATIDE | targetBased | 3 | Completed | 01/08/2007 | https://clinicaltrials.gov/study/NCT00516048 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | EXENATIDE | targetBased | 3 | Completed | 01/08/2007 | https://clinicaltrials.gov/study/NCT00516048 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | EXENATIDE | targetBased | 4 | Unknown status | 01/06/2014 | https://clinicaltrials.gov/study/NCT02162550 | 1 | GoF | protect | |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | EXENATIDE | targetBased | 4 | Unknown status | 01/06/2014 | https://clinicaltrials.gov/study/NCT02162550 | 1 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | EXENATIDE | targetBased | 4 | Unknown status | 01/06/2014 | https://clinicaltrials.gov/study/NCT02162550 | 1 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | EXENATIDE | targetBased | 3 | Completed | 01/07/2009 | https://clinicaltrials.gov/study/NCT00917267 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | EXENATIDE | targetBased | 3 | Completed | 01/07/2009 | https://clinicaltrials.gov/study/NCT00917267 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | EXENATIDE | targetBased | 3 | Completed | 01/07/2009 | https://clinicaltrials.gov/study/NCT00917267 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | EXENATIDE | targetBased | 3 | Completed | 01/08/2002 | https://clinicaltrials.gov/study/NCT00044668 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | EXENATIDE | targetBased | 3 | Completed | 01/08/2002 | https://clinicaltrials.gov/study/NCT00044668 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | EXENATIDE | targetBased | 3 | Completed | 01/08/2002 | https://clinicaltrials.gov/study/NCT00044668 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | EXENATIDE | targetBased | 4 | Terminated | 01/02/2014 | https://clinicaltrials.gov/study/NCT02072096 | 1 | GoF | protect | The trial was terminated per protocol because of lack of feasibility. |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | EXENATIDE | targetBased | 4 | Terminated | 01/02/2014 | https://clinicaltrials.gov/study/NCT02072096 | 1 | GoF | protect | The trial was terminated per protocol because of lack of feasibility. |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | EXENATIDE | targetBased | 4 | Terminated | 01/02/2014 | https://clinicaltrials.gov/study/NCT02072096 | 1 | GoF | protect | The trial was terminated per protocol because of lack of feasibility. |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | EXENATIDE | targetBased | 3 | Completed | 02/12/2011 | https://clinicaltrials.gov/study/NCT01554618 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | EXENATIDE | targetBased | 3 | Completed | 02/12/2011 | https://clinicaltrials.gov/study/NCT01554618 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | EXENATIDE | targetBased | 3 | Completed | 02/12/2011 | https://clinicaltrials.gov/study/NCT01554618 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | EXENATIDE | targetBased | 4 | Completed | 01/04/2013 | https://clinicaltrials.gov/study/NCT01744236 | 1 | GoF | protect | |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | EXENATIDE | targetBased | 4 | Completed | 01/04/2013 | https://clinicaltrials.gov/study/NCT01744236 | 1 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | EXENATIDE | targetBased | 4 | Completed | 01/04/2013 | https://clinicaltrials.gov/study/NCT01744236 | 1 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | EXENATIDE | targetBased | 3 | Terminated | 01/05/2013 | https://clinicaltrials.gov/study/NCT01785771 | 0.7 | GoF | protect | Decision by Sponsor |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | EXENATIDE | targetBased | 3 | Terminated | 01/05/2013 | https://clinicaltrials.gov/study/NCT01785771 | 0.7 | GoF | protect | Decision by Sponsor |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | EXENATIDE | targetBased | 3 | Terminated | 01/05/2013 | https://clinicaltrials.gov/study/NCT01785771 | 0.7 | GoF | protect | Decision by Sponsor |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | EXENATIDE | targetBased | 4 | Unknown status | 01/02/2008 | https://clinicaltrials.gov/study/NCT01435980 | 1 | GoF | protect | |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | EXENATIDE | targetBased | 4 | Unknown status | 01/02/2008 | https://clinicaltrials.gov/study/NCT01435980 | 1 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | EXENATIDE | targetBased | 4 | Unknown status | 01/02/2008 | https://clinicaltrials.gov/study/NCT01435980 | 1 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | EXENATIDE | targetBased | 4 | Unknown status | 01/02/2017 | https://clinicaltrials.gov/study/NCT03018665 | 1 | GoF | protect | |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | EXENATIDE | targetBased | 4 | Unknown status | 01/02/2017 | https://clinicaltrials.gov/study/NCT03018665 | 1 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | EXENATIDE | targetBased | 4 | Unknown status | 01/02/2017 | https://clinicaltrials.gov/study/NCT03018665 | 1 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | EXENATIDE | targetBased | 3 | Completed | 01/11/2002 | https://clinicaltrials.gov/study/NCT00111540 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | EXENATIDE | targetBased | 3 | Completed | 01/11/2002 | https://clinicaltrials.gov/study/NCT00111540 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | EXENATIDE | targetBased | 3 | Completed | 01/11/2002 | https://clinicaltrials.gov/study/NCT00111540 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | EXENATIDE | targetBased | 3 | Completed | 01/09/2006 | https://clinicaltrials.gov/study/NCT00381342 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | EXENATIDE | targetBased | 3 | Completed | 01/09/2006 | https://clinicaltrials.gov/study/NCT00381342 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | EXENATIDE | targetBased | 3 | Completed | 01/09/2006 | https://clinicaltrials.gov/study/NCT00381342 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | EXENATIDE | targetBased | 3 | Completed | 01/02/2010 | https://clinicaltrials.gov/study/NCT01064687 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | EXENATIDE | targetBased | 3 | Completed | 01/02/2010 | https://clinicaltrials.gov/study/NCT01064687 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | EXENATIDE | targetBased | 3 | Completed | 01/02/2010 | https://clinicaltrials.gov/study/NCT01064687 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | EXENATIDE | targetBased | 3 | Completed | 01/09/2004 | https://clinicaltrials.gov/study/NCT00097500 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | EXENATIDE | targetBased | 3 | Completed | 01/09/2004 | https://clinicaltrials.gov/study/NCT00097500 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | EXENATIDE | targetBased | 3 | Completed | 01/09/2004 | https://clinicaltrials.gov/study/NCT00097500 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | EXENATIDE | targetBased | 4 | Completed | 01/08/2012 | https://clinicaltrials.gov/study/NCT01524705 | 1 | GoF | protect | |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | EXENATIDE | targetBased | 4 | Completed | 01/08/2012 | https://clinicaltrials.gov/study/NCT01524705 | 1 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | EXENATIDE | targetBased | 4 | Completed | 01/08/2012 | https://clinicaltrials.gov/study/NCT01524705 | 1 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | EXENATIDE | targetBased | 4 | Completed | 01/08/2012 | https://clinicaltrials.gov/study/NCT01776788 | 1 | GoF | protect | |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | EXENATIDE | targetBased | 4 | Completed | 01/08/2012 | https://clinicaltrials.gov/study/NCT01776788 | 1 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | EXENATIDE | targetBased | 4 | Completed | 01/08/2012 | https://clinicaltrials.gov/study/NCT01776788 | 1 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | EXENATIDE | targetBased | 4 | Completed | 01/12/2014 | https://clinicaltrials.gov/study/NCT02288273 | 1 | GoF | protect | |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | EXENATIDE | targetBased | 4 | Completed | 01/12/2014 | https://clinicaltrials.gov/study/NCT02288273 | 1 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | EXENATIDE | targetBased | 4 | Completed | 01/12/2014 | https://clinicaltrials.gov/study/NCT02288273 | 1 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | EXENATIDE | targetBased | 3 | Completed | 01/10/2009 | https://clinicaltrials.gov/study/NCT01003184 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | EXENATIDE | targetBased | 3 | Completed | 01/10/2009 | https://clinicaltrials.gov/study/NCT01003184 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | EXENATIDE | targetBased | 3 | Completed | 01/10/2009 | https://clinicaltrials.gov/study/NCT01003184 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | EXENATIDE | targetBased | 3 | Completed | 01/03/2009 | https://clinicaltrials.gov/study/NCT00877890 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | EXENATIDE | targetBased | 3 | Completed | 01/03/2009 | https://clinicaltrials.gov/study/NCT00877890 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | EXENATIDE | targetBased | 3 | Completed | 01/03/2009 | https://clinicaltrials.gov/study/NCT00877890 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | EXENATIDE | targetBased | 4 | Completed | 01/04/2010 | https://clinicaltrials.gov/study/NCT01951651 | 1 | GoF | protect | |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | EXENATIDE | targetBased | 4 | Completed | 01/04/2010 | https://clinicaltrials.gov/study/NCT01951651 | 1 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | EXENATIDE | targetBased | 4 | Completed | 01/04/2010 | https://clinicaltrials.gov/study/NCT01951651 | 1 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | EXENATIDE | targetBased | 3 | Completed | 30/05/2008 | https://clinicaltrials.gov/study/NCT00658021 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | EXENATIDE | targetBased | 3 | Completed | 30/05/2008 | https://clinicaltrials.gov/study/NCT00658021 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | EXENATIDE | targetBased | 3 | Completed | 30/05/2008 | https://clinicaltrials.gov/study/NCT00658021 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | EXENATIDE | targetBased | 4 | Completed | 01/01/2015 | https://clinicaltrials.gov/study/NCT02325960 | 1 | GoF | protect | |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | EXENATIDE | targetBased | 4 | Completed | 01/01/2015 | https://clinicaltrials.gov/study/NCT02325960 | 1 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | EXENATIDE | targetBased | 4 | Completed | 01/01/2015 | https://clinicaltrials.gov/study/NCT02325960 | 1 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | EXENATIDE | targetBased | 4 | Unknown status | 01/11/2010 | https://clinicaltrials.gov/study/NCT01270191 | 1 | GoF | protect | |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | EXENATIDE | targetBased | 4 | Unknown status | 01/11/2010 | https://clinicaltrials.gov/study/NCT01270191 | 1 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | EXENATIDE | targetBased | 4 | Unknown status | 01/11/2010 | https://clinicaltrials.gov/study/NCT01270191 | 1 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | EXENATIDE | targetBased | 3 | Completed | 29/08/2012 | https://clinicaltrials.gov/study/NCT01676116 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | EXENATIDE | targetBased | 3 | Completed | 29/08/2012 | https://clinicaltrials.gov/study/NCT01676116 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | EXENATIDE | targetBased | 3 | Completed | 29/08/2012 | https://clinicaltrials.gov/study/NCT01676116 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | abnormal glucose tolerance | EXENATIDE | targetBased | 4 | Completed | 01/10/2007 | https://clinicaltrials.gov/study/NCT00546728 | 1 | GoF | protect | |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | abnormal glucose tolerance | EXENATIDE | targetBased | 4 | Completed | 01/10/2007 | https://clinicaltrials.gov/study/NCT00546728 | 1 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | abnormal glucose tolerance | EXENATIDE | targetBased | 4 | Completed | 01/10/2007 | https://clinicaltrials.gov/study/NCT00546728 | 1 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | diabetes mellitus | EXENATIDE | targetBased | 3 | Completed | 01/08/2007 | https://clinicaltrials.gov/study/NCT00518882 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | diabetes mellitus | EXENATIDE | targetBased | 3 | Completed | 01/08/2007 | https://clinicaltrials.gov/study/NCT00518882 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | diabetes mellitus | EXENATIDE | targetBased | 3 | Completed | 01/08/2007 | https://clinicaltrials.gov/study/NCT00518882 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | diabetes mellitus | EXENATIDE | targetBased | 3 | Completed | 06/09/2014 | https://clinicaltrials.gov/study/NCT02229383 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | diabetes mellitus | EXENATIDE | targetBased | 3 | Completed | 06/09/2014 | https://clinicaltrials.gov/study/NCT02229383 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | diabetes mellitus | EXENATIDE | targetBased | 3 | Completed | 06/09/2014 | https://clinicaltrials.gov/study/NCT02229383 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | diabetes mellitus | EXENATIDE | targetBased | 4 | https://www.whocc.no/atc_ddd_index/?code=A10BJ01 | 1 | GoF | protect | |||
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | diabetes mellitus | EXENATIDE | targetBased | 4 | https://www.whocc.no/atc_ddd_index/?code=A10BJ01 | 1 | GoF | protect | |||
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | diabetes mellitus | EXENATIDE | targetBased | 4 | https://www.whocc.no/atc_ddd_index/?code=A10BJ01 | 1 | GoF | protect | |||
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | diabetes mellitus | EXENATIDE | targetBased | 3 | Completed | 01/02/2013 | https://clinicaltrials.gov/study/NCT01652729 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | diabetes mellitus | EXENATIDE | targetBased | 3 | Completed | 01/02/2013 | https://clinicaltrials.gov/study/NCT01652729 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | diabetes mellitus | EXENATIDE | targetBased | 3 | Completed | 01/02/2013 | https://clinicaltrials.gov/study/NCT01652729 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | diabetes mellitus | EXENATIDE | targetBased | 3 | Completed | 29/08/2012 | https://clinicaltrials.gov/study/NCT01676116 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | diabetes mellitus | EXENATIDE | targetBased | 3 | Completed | 29/08/2012 | https://clinicaltrials.gov/study/NCT01676116 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | diabetes mellitus | EXENATIDE | targetBased | 3 | Completed | 29/08/2012 | https://clinicaltrials.gov/study/NCT01676116 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | diabetes mellitus | EXENATIDE | targetBased | 4 | Completed | 01/04/2008 | https://clinicaltrials.gov/study/NCT01076842 | 1 | GoF | protect | |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | diabetes mellitus | EXENATIDE | targetBased | 4 | Completed | 01/04/2008 | https://clinicaltrials.gov/study/NCT01076842 | 1 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | diabetes mellitus | EXENATIDE | targetBased | 4 | Completed | 01/04/2008 | https://clinicaltrials.gov/study/NCT01076842 | 1 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | diabetes mellitus | EXENATIDE | targetBased | 3 | Completed | 01/01/2011 | https://clinicaltrials.gov/study/NCT02042664 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | diabetes mellitus | EXENATIDE | targetBased | 3 | Completed | 01/01/2011 | https://clinicaltrials.gov/study/NCT02042664 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | diabetes mellitus | EXENATIDE | targetBased | 3 | Completed | 01/01/2011 | https://clinicaltrials.gov/study/NCT02042664 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | diabetes mellitus | EXENATIDE | targetBased | 3 | Not yet recruiting | 01/03/2024 | https://clinicaltrials.gov/study/NCT06257966 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | diabetes mellitus | EXENATIDE | targetBased | 3 | Not yet recruiting | 01/03/2024 | https://clinicaltrials.gov/study/NCT06257966 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | diabetes mellitus | EXENATIDE | targetBased | 3 | Not yet recruiting | 01/03/2024 | https://clinicaltrials.gov/study/NCT06257966 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | diabetes mellitus | EXENATIDE | targetBased | 4 | Terminated | 20/09/2016 | https://clinicaltrials.gov/study/NCT02802514 | 1 | GoF | protect | |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | diabetes mellitus | EXENATIDE | targetBased | 4 | Terminated | 20/09/2016 | https://clinicaltrials.gov/study/NCT02802514 | 1 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | diabetes mellitus | EXENATIDE | targetBased | 4 | Terminated | 20/09/2016 | https://clinicaltrials.gov/study/NCT02802514 | 1 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | diabetes mellitus | EXENATIDE | targetBased | 4 | Completed | 01/01/2009 | https://clinicaltrials.gov/study/NCT01107717 | 1 | GoF | protect | |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | diabetes mellitus | EXENATIDE | targetBased | 4 | Completed | 01/01/2009 | https://clinicaltrials.gov/study/NCT01107717 | 1 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | diabetes mellitus | EXENATIDE | targetBased | 4 | Completed | 01/01/2009 | https://clinicaltrials.gov/study/NCT01107717 | 1 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | diabetes mellitus | EXENATIDE | targetBased | 4 | Completed | 01/01/2013 | https://clinicaltrials.gov/study/NCT03297879 | 1 | GoF | protect | |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | diabetes mellitus | EXENATIDE | targetBased | 4 | Completed | 01/01/2013 | https://clinicaltrials.gov/study/NCT03297879 | 1 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | diabetes mellitus | EXENATIDE | targetBased | 4 | Completed | 01/01/2013 | https://clinicaltrials.gov/study/NCT03297879 | 1 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | non-alcoholic fatty liver disease | EXENATIDE | targetBased | 4 | Completed | 01/07/2008 | https://clinicaltrials.gov/study/NCT01208649 | 1 | GoF | protect | |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | non-alcoholic fatty liver disease | EXENATIDE | targetBased | 4 | Completed | 01/07/2008 | https://clinicaltrials.gov/study/NCT01208649 | 1 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | non-alcoholic fatty liver disease | EXENATIDE | targetBased | 4 | Completed | 01/07/2008 | https://clinicaltrials.gov/study/NCT01208649 | 1 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | diabetic nephropathy | EXENATIDE | targetBased | 4 | Completed | 08/04/2016 | https://clinicaltrials.gov/study/NCT02690883 | 1 | GoF | protect | |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | diabetic nephropathy | EXENATIDE | targetBased | 4 | Completed | 08/04/2016 | https://clinicaltrials.gov/study/NCT02690883 | 1 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | diabetic nephropathy | EXENATIDE | targetBased | 4 | Completed | 08/04/2016 | https://clinicaltrials.gov/study/NCT02690883 | 1 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 1 diabetes mellitus | EXENATIDE | targetBased | 4 | Completed | 01/12/2010 | https://clinicaltrials.gov/study/NCT01269034 | 1 | GoF | protect | |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 1 diabetes mellitus | EXENATIDE | targetBased | 4 | Completed | 01/12/2010 | https://clinicaltrials.gov/study/NCT01269034 | 1 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 1 diabetes mellitus | EXENATIDE | targetBased | 4 | Completed | 01/12/2010 | https://clinicaltrials.gov/study/NCT01269034 | 1 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 1 diabetes mellitus | EXENATIDE | targetBased | 4 | Completed | 01/11/2010 | https://clinicaltrials.gov/study/NCT01235819 | 1 | GoF | protect | |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 1 diabetes mellitus | EXENATIDE | targetBased | 4 | Completed | 01/11/2010 | https://clinicaltrials.gov/study/NCT01235819 | 1 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 1 diabetes mellitus | EXENATIDE | targetBased | 4 | Completed | 01/11/2010 | https://clinicaltrials.gov/study/NCT01235819 | 1 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 1 diabetes mellitus | EXENATIDE | targetBased | 3 | Enrolling by invitation | 01/08/2009 | https://clinicaltrials.gov/study/NCT00923715 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 1 diabetes mellitus | EXENATIDE | targetBased | 3 | Enrolling by invitation | 01/08/2009 | https://clinicaltrials.gov/study/NCT00923715 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 1 diabetes mellitus | EXENATIDE | targetBased | 3 | Enrolling by invitation | 01/08/2009 | https://clinicaltrials.gov/study/NCT00923715 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 1 diabetes mellitus | EXENATIDE | targetBased | 4 | Completed | 01/08/2009 | https://clinicaltrials.gov/study/NCT01269047 | 1 | GoF | protect | |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 1 diabetes mellitus | EXENATIDE | targetBased | 4 | Completed | 01/08/2009 | https://clinicaltrials.gov/study/NCT01269047 | 1 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 1 diabetes mellitus | EXENATIDE | targetBased | 4 | Completed | 01/08/2009 | https://clinicaltrials.gov/study/NCT01269047 | 1 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | gestational diabetes | EXENATIDE | targetBased | 4 | Withdrawn | 01/08/2013 | https://clinicaltrials.gov/study/NCT00572689 | 1 | GoF | protect | |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | gestational diabetes | EXENATIDE | targetBased | 4 | Withdrawn | 01/08/2013 | https://clinicaltrials.gov/study/NCT00572689 | 1 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | gestational diabetes | EXENATIDE | targetBased | 4 | Withdrawn | 01/08/2013 | https://clinicaltrials.gov/study/NCT00572689 | 1 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | gestational diabetes | EXENATIDE | targetBased | 4 | Recruiting | 12/04/2023 | https://clinicaltrials.gov/study/NCT05482789 | 1 | GoF | protect | |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | gestational diabetes | EXENATIDE | targetBased | 4 | Recruiting | 12/04/2023 | https://clinicaltrials.gov/study/NCT05482789 | 1 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | gestational diabetes | EXENATIDE | targetBased | 4 | Recruiting | 12/04/2023 | https://clinicaltrials.gov/study/NCT05482789 | 1 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | obesity | EXENATIDE | targetBased | 3 | Recruiting | 01/09/2018 | https://clinicaltrials.gov/study/NCT03671733 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | obesity | EXENATIDE | targetBased | 3 | Recruiting | 01/09/2018 | https://clinicaltrials.gov/study/NCT03671733 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | obesity | EXENATIDE | targetBased | 3 | Recruiting | 01/09/2018 | https://clinicaltrials.gov/study/NCT03671733 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | obesity | EXENATIDE | targetBased | 3 | Completed | 03/03/2009 | https://clinicaltrials.gov/study/NCT00856609 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | obesity | EXENATIDE | targetBased | 3 | Completed | 03/03/2009 | https://clinicaltrials.gov/study/NCT00856609 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | obesity | EXENATIDE | targetBased | 3 | Completed | 03/03/2009 | https://clinicaltrials.gov/study/NCT00856609 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | obesity | EXENATIDE | targetBased | 3 | Completed | 01/03/2016 | https://clinicaltrials.gov/study/NCT02664441 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | obesity | EXENATIDE | targetBased | 3 | Completed | 01/03/2016 | https://clinicaltrials.gov/study/NCT02664441 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | obesity | EXENATIDE | targetBased | 3 | Completed | 01/03/2016 | https://clinicaltrials.gov/study/NCT02664441 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | obesity | EXENATIDE | targetBased | 4 | Completed | 01/06/2014 | https://clinicaltrials.gov/study/NCT02160990 | 1 | GoF | protect | |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | obesity | EXENATIDE | targetBased | 4 | Completed | 01/06/2014 | https://clinicaltrials.gov/study/NCT02160990 | 1 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | obesity | EXENATIDE | targetBased | 4 | Completed | 01/06/2014 | https://clinicaltrials.gov/study/NCT02160990 | 1 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | obesity | EXENATIDE | targetBased | 4 | Completed | 01/03/2012 | https://clinicaltrials.gov/study/NCT01590433 | 1 | GoF | protect | |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | obesity | EXENATIDE | targetBased | 4 | Completed | 01/03/2012 | https://clinicaltrials.gov/study/NCT01590433 | 1 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | obesity | EXENATIDE | targetBased | 4 | Completed | 01/03/2012 | https://clinicaltrials.gov/study/NCT01590433 | 1 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | obesity | EXENATIDE | targetBased | 4 | Unknown status | 01/08/2016 | https://clinicaltrials.gov/study/NCT03002675 | 1 | GoF | protect | |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | obesity | EXENATIDE | targetBased | 4 | Unknown status | 01/08/2016 | https://clinicaltrials.gov/study/NCT03002675 | 1 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | obesity | EXENATIDE | targetBased | 4 | Unknown status | 01/08/2016 | https://clinicaltrials.gov/study/NCT03002675 | 1 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | obesity | EXENATIDE | targetBased | 3 | Active, not recruiting | 28/01/2021 | https://clinicaltrials.gov/study/NCT04520490 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | obesity | EXENATIDE | targetBased | 3 | Active, not recruiting | 28/01/2021 | https://clinicaltrials.gov/study/NCT04520490 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | obesity | EXENATIDE | targetBased | 3 | Active, not recruiting | 28/01/2021 | https://clinicaltrials.gov/study/NCT04520490 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | obesity | EXENATIDE | targetBased | 4 | Completed | 01/06/2014 | https://clinicaltrials.gov/study/NCT02170324 | 1 | GoF | protect | |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | obesity | EXENATIDE | targetBased | 4 | Completed | 01/06/2014 | https://clinicaltrials.gov/study/NCT02170324 | 1 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | obesity | EXENATIDE | targetBased | 4 | Completed | 01/06/2014 | https://clinicaltrials.gov/study/NCT02170324 | 1 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | body weight gain | EXENATIDE | targetBased | 4 | Completed | 01/12/2008 | https://clinicaltrials.gov/study/NCT00845507 | 1 | GoF | protect | |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | body weight gain | EXENATIDE | targetBased | 4 | Completed | 01/12/2008 | https://clinicaltrials.gov/study/NCT00845507 | 1 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | body weight gain | EXENATIDE | targetBased | 4 | Completed | 01/12/2008 | https://clinicaltrials.gov/study/NCT00845507 | 1 | GoF | protect | |
| Fluorescence-based primary cell-based high throughput screening assay to identify agonists of the Oxytocin Receptor (OXTR). | OXTR | OXTR | Oxytocin receptor | obesity | OXYTOCIN | targetBased | 4 | Recruiting | 02/10/2021 | https://clinicaltrials.gov/study/NCT04760496 | 1 | GoF | protect | |
| Fluorescence-based primary cell-based high throughput screening assay to identify agonists of the Oxytocin Receptor (OXTR). | OXTR | OXTR | Oxytocin receptor | obesity | OXYTOCIN | targetBased | 4 | Completed | 05/06/2017 | https://clinicaltrials.gov/study/NCT03140488 | 1 | GoF | protect | |
| Fluorescence-based primary cell-based high throughput screening assay to identify agonists of the Oxytocin Receptor (OXTR). | OXTR | OXTR | Oxytocin receptor | obesity | OXYTOCIN | targetBased | 4 | Completed | 06/04/2022 | https://clinicaltrials.gov/study/NCT05289869 | 1 | GoF | protect | |
| HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity | CACNA1D_inhibitors | CACNA1D | Voltage-dependent N-type calcium channel subunit alpha-1B | type 2 diabetes mellitus | FELODIPINE | targetBased | 3 | Completed | 01/09/1999 | https://clinicaltrials.gov/study/NCT00000620 | 0.7 | LoF | protect | |
| HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity | CACNA1D_inhibitors | CACNA1D | Voltage-dependent N-type calcium channel subunit alpha-1B | diabetes mellitus | FELODIPINE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=103d9fb6-8433-4386-9f2e-d07f4c560aea | 1 | LoF | protect | |||
| HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity | CACNA1D_inhibitors | CACNA1D | Voltage-dependent N-type calcium channel subunit alpha-1B | Hypercholesterolemia | FELODIPINE | targetBased | 3 | Completed | 01/09/1999 | https://clinicaltrials.gov/study/NCT00000620 | 0.7 | LoF | protect | |
| HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity | CACNA1D_inhibitors | CACNA1D | Voltage-dependent N-type calcium channel subunit alpha-1B | diabetic nephropathy | AMLODIPINE | targetBased | 4 | Completed | 01/10/2005 | https://clinicaltrials.gov/study/NCT00535925 | 1 | LoF | protect | |
| HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity | CACNA1D_inhibitors | CACNA1D | Voltage-dependent N-type calcium channel subunit alpha-1B | familial hypercholesterolemia | AMLODIPINE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=909fad96-a941-443a-a39f-4f93607410fb | 1 | LoF | protect | |||
| HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity | CACNA1D_inhibitors | CACNA1D | Voltage-dependent N-type calcium channel subunit alpha-1B | type 2 diabetes mellitus | AMLODIPINE | targetBased | 3 | Completed | 01/09/1999 | https://clinicaltrials.gov/study/NCT00000620 | 0.7 | LoF | protect | |
| HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity | CACNA1D_inhibitors | CACNA1D | Voltage-dependent N-type calcium channel subunit alpha-1B | type 2 diabetes mellitus | AMLODIPINE | targetBased | 4 | Completed | 01/02/2008 | https://clinicaltrials.gov/study/NCT01738945 | 1 | LoF | protect | |
| HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity | CACNA1D_inhibitors | CACNA1D | Voltage-dependent N-type calcium channel subunit alpha-1B | type 2 diabetes mellitus | AMLODIPINE | targetBased | 4 | Withdrawn | 01/09/2021 | https://clinicaltrials.gov/study/NCT04978649 | 1 | LoF | protect | Cooperation plan has been changed |
| HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity | CACNA1D_inhibitors | CACNA1D | Voltage-dependent N-type calcium channel subunit alpha-1B | non-alcoholic fatty liver disease | AMLODIPINE | targetBased | 4 | Unknown status | 01/08/2014 | https://clinicaltrials.gov/study/NCT02213224 | 1 | LoF | protect | |
| HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity | CACNA1D_inhibitors | CACNA1D | Voltage-dependent N-type calcium channel subunit alpha-1B | diabetes mellitus | AMLODIPINE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b18686fa-be94-472e-8404-c69e6869ed10 | 1 | LoF | protect | |||
| HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity | CACNA1D_inhibitors | CACNA1D | Voltage-dependent N-type calcium channel subunit alpha-1B | diabetes mellitus | AMLODIPINE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5562b3f5-8757-11de-8a39-0800200c9a66 | 1 | LoF | protect | |||
| HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity | CACNA1D_inhibitors | CACNA1D | Voltage-dependent N-type calcium channel subunit alpha-1B | diabetes mellitus | AMLODIPINE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d0caec89-96ec-411d-a933-63eda74a6da7 | 1 | LoF | protect | |||
| HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity | CACNA1D_inhibitors | CACNA1D | Voltage-dependent N-type calcium channel subunit alpha-1B | diabetes mellitus | AMLODIPINE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=18d7820d-471f-4ee2-9ec6-25d8d27c77de | 1 | LoF | protect | |||
| HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity | CACNA1D_inhibitors | CACNA1D | Voltage-dependent N-type calcium channel subunit alpha-1B | diabetes mellitus | AMLODIPINE | targetBased | 3 | Completed | 01/08/1993 | https://clinicaltrials.gov/study/NCT00000542 | 0.7 | LoF | protect | |
| HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity | CACNA1D_inhibitors | CACNA1D | Voltage-dependent N-type calcium channel subunit alpha-1B | diabetes mellitus | AMLODIPINE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f48911e0-705f-11dc-afc9-0002a5d5c51b | 1 | LoF | protect | |||
| HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity | CACNA1D_inhibitors | CACNA1D | Voltage-dependent N-type calcium channel subunit alpha-1B | diabetes mellitus | AMLODIPINE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=01139e81-a4fa-4e13-acdf-c75c79a1aa9c | 1 | LoF | protect | |||
| HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity | CACNA1D_inhibitors | CACNA1D | Voltage-dependent N-type calcium channel subunit alpha-1B | hyperlipidemia | AMLODIPINE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6 | 1 | LoF | protect | |||
| HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity | CACNA1D_inhibitors | CACNA1D | Voltage-dependent N-type calcium channel subunit alpha-1B | hyperlipidemia | AMLODIPINE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=062bf1a0-9a29-4dee-a8cb-f0d051f4c0b1 | 1 | LoF | protect | |||
| HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity | CACNA1D_inhibitors | CACNA1D | Voltage-dependent N-type calcium channel subunit alpha-1B | hyperlipidemia | AMLODIPINE | targetBased | 4 | Completed | 05/07/2018 | https://clinicaltrials.gov/study/NCT03847506 | 1 | LoF | protect | |
| HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity | CACNA1D_inhibitors | CACNA1D | Voltage-dependent N-type calcium channel subunit alpha-1B | hyperlipidemia | AMLODIPINE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4be76756-4114-4d50-a36c-fd410f6c773d | 1 | LoF | protect | |||
| HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity | CACNA1D_inhibitors | CACNA1D | Voltage-dependent N-type calcium channel subunit alpha-1B | hyperlipidemia | AMLODIPINE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=909fad96-a941-443a-a39f-4f93607410fb | 1 | LoF | protect | |||
| HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity | CACNA1D_inhibitors | CACNA1D | Voltage-dependent N-type calcium channel subunit alpha-1B | hyperlipidemia | AMLODIPINE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2f568859-64e6-454f-801b-c0a0a647dc3d | 1 | LoF | protect | |||
| HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity | CACNA1D_inhibitors | CACNA1D | Voltage-dependent N-type calcium channel subunit alpha-1B | hyperlipidemia | AMLODIPINE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d2d28679-a01b-4e63-90e2-d5c23b393c94 | 1 | LoF | protect | |||
| HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity | CACNA1D_inhibitors | CACNA1D | Voltage-dependent N-type calcium channel subunit alpha-1B | hyperlipidemia | AMLODIPINE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=abee4a34-89cc-d886-192c-32582ab8f024 | 1 | LoF | protect | |||
| HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity | CACNA1D_inhibitors | CACNA1D | Voltage-dependent N-type calcium channel subunit alpha-1B | Hypercholesterolemia | AMLODIPINE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=909fad96-a941-443a-a39f-4f93607410fb | 1 | LoF | protect | |||
| HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity | CACNA1D_inhibitors | CACNA1D | Voltage-dependent N-type calcium channel subunit alpha-1B | Hypercholesterolemia | AMLODIPINE | targetBased | 3 | Completed | 01/09/1999 | https://clinicaltrials.gov/study/NCT00000620 | 0.7 | LoF | protect | |
| HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity | CACNA1D_inhibitors | CACNA1D | Voltage-dependent N-type calcium channel subunit alpha-1B | Hypercholesterolemia | AMLODIPINE | targetBased | 3 | Completed | 01/08/1993 | https://clinicaltrials.gov/study/NCT00000542 | 0.7 | LoF | protect | |
| HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity | CACNA1D_inhibitors | CACNA1D | Voltage-dependent N-type calcium channel subunit alpha-1B | metabolic syndrome | AMLODIPINE | targetBased | 4 | Terminated | 01/03/2008 | https://clinicaltrials.gov/study/NCT00542269 | 1 | LoF | protect | Early termination of the study due to slow recruitment. |
| HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity | CACNA1D_inhibitors | CACNA1D | Voltage-dependent N-type calcium channel subunit alpha-1B | metabolic syndrome | AMLODIPINE | targetBased | 4 | Completed | 01/10/2013 | https://clinicaltrials.gov/study/NCT02034435 | 1 | LoF | protect | |
| Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors | OPRM1 | OPRM1 | Mu-type opioid receptor | morbid obesity | HYDROMORPHONE | targetBased | 4 | Recruiting | 20/01/2021 | https://clinicaltrials.gov/study/NCT04240626 | 1 | GoF | protect | |
| Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors | OPRM1 | OPRM1 | Mu-type opioid receptor | morbid obesity | HYDROMORPHONE | targetBased | 4 | Recruiting | 20/01/2021 | https://clinicaltrials.gov/study/NCT04240626 | 1 | GoF | protect | |
| Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors | OPRM1 | OPRM1 | Mu-type opioid receptor | liver disease | HYDROMORPHONE | targetBased | 3 | Recruiting | 04/10/2017 | https://clinicaltrials.gov/study/NCT03214510 | 0.7 | GoF | protect | |
| Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors | OPRM1 | OPRM1 | Mu-type opioid receptor | liver disease | HYDROMORPHONE | targetBased | 3 | Recruiting | 04/10/2017 | https://clinicaltrials.gov/study/NCT03214510 | 0.7 | GoF | protect | |
| HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity | CACNA1D_inhibitors | CACNA1D | Voltage-dependent N-type calcium channel subunit alpha-1B | diabetic nephropathy | NIFEDIPINE | targetBased | 3 | Completed | 01/08/1993 | https://clinicaltrials.gov/study/NCT00004266 | 0.7 | LoF | protect | |
| Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) agonists | HTR1A | HTR1A | 5-hydroxytryptamine receptor 1A | obesity | DEXFENFLURAMINE | targetBased | 4 | https://www.whocc.no/atc_ddd_index/?code=A08AA04 | 1 | GoF | protect | |||
| Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) antagonists | HTR1A | HTR1A | 5-hydroxytryptamine receptor 1A | obesity | DEXFENFLURAMINE | targetBased | 4 | https://www.whocc.no/atc_ddd_index/?code=A08AA04 | 1 | GoF | protect | |||
| Primary Cell Based High Throughput Screening Assay for Agonists of the 5-Hydroxytryptamine Receptor Subtype 1E (5HT1E) | HTR1E | HTR1E | 5-hydroxytryptamine receptor 1E | obesity | DEXFENFLURAMINE | targetBased | 4 | https://www.whocc.no/atc_ddd_index/?code=A08AA04 | 1 | GoF | protect | |||
| Primary Cell Based High Throughput Screening Assay for Antagonists of the 5-Hydroxytryptamine Receptor Subtype 1E (5HT1E) | HTR1E | HTR1E | 5-hydroxytryptamine receptor 1E | obesity | DEXFENFLURAMINE | targetBased | 4 | https://www.whocc.no/atc_ddd_index/?code=A08AA04 | 1 | GoF | protect | |||
| Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A) | HTR2A | HTR2A | 5-hydroxytryptamine receptor 2A | obesity | DEXFENFLURAMINE | targetBased | 4 | https://www.whocc.no/atc_ddd_index/?code=A08AA04 | 1 | GoF | protect | |||
| Counterscreen for agonists of OPRM1-OPRD1 heterodimerization: luminescence-based cell-based full-deck high throughput screening assay to identify agonists of 5-hydroxytryptamine (serotonin) 5A receptor (HTR5A) | HTR5A | HTR5A | 5-hydroxytryptamine receptor 5A | obesity | DEXFENFLURAMINE | targetBased | 4 | https://www.whocc.no/atc_ddd_index/?code=A08AA04 | 1 | GoF | protect | |||
| Counterscreen for inverse agonists of OPRM1-OPRD1 heterodimerization: luminescence-based cell-based full-deck high throughput screening assay to identify inverse agonists of 5-hydroxytryptamine (serotonin) 5A receptor (HTR5A) | HTR5A | HTR5A | 5-hydroxytryptamine receptor 5A | obesity | DEXFENFLURAMINE | targetBased | 4 | https://www.whocc.no/atc_ddd_index/?code=A08AA04 | 1 | GoF | protect | |||
| Fluorescence-based cell-based primary high throughput screening assay to identify inhibitors of TLR9-MyD88 binding. | TLR9 | TLR9 | Toll-like receptor 9 | prediabetes syndrome | HYDROXYCHLOROQUINE | targetBased | 4 | Completed | 01/03/2011 | https://clinicaltrials.gov/study/NCT01326533 | 1 | LoF | protect | |
| Fluorescence-based cell-based primary high throughput screening assay to identify inhibitors of TLR9-MyD88 binding. | TLR9 | TLR9 | Toll-like receptor 9 | obesity | HYDROXYCHLOROQUINE | targetBased | 4 | Not yet recruiting | 01/08/2019 | https://clinicaltrials.gov/study/NCT04005768 | 1 | LoF | protect | |
| Fluorescence-based cell-based primary high throughput screening assay to identify inhibitors of TLR9-MyD88 binding. | TLR9 | TLR9 | Toll-like receptor 9 | obesity | HYDROXYCHLOROQUINE | targetBased | 4 | Not yet recruiting | 01/10/2019 | https://clinicaltrials.gov/study/NCT04005781 | 1 | LoF | protect | |
| Fluorescence-based cell-based primary high throughput screening assay to identify inhibitors of TLR9-MyD88 binding. | TLR9 | TLR9 | Toll-like receptor 9 | autoimmune polyendocrinopathy | HYDROXYCHLOROQUINE | targetBased | 3 | Terminated | 01/02/2013 | https://clinicaltrials.gov/study/NCT01784523 | 0.7 | LoF | protect | low recruitment rate exacerbated by manufacturing shortage and price increase of hydroxychloroquine. |
| Inhibitors of the vitamin D receptor (VDR): qHTS | VDR | VDR | Vitamin D3 receptor | Gaucher disease | ERGOCALCIFEROL | targetBased | 4 | Completed | 29/06/2016 | https://clinicaltrials.gov/study/NCT02574286 | 1 | GoF | protect | |
| Inhibitors of the vitamin D receptor (VDR): qHTS | VDR | VDR | Vitamin D3 receptor | hypoparathyroidism | ERGOCALCIFEROL | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=acb61678-d23d-405d-8c14-1a16cfd3a776 | 1 | GoF | protect | |||
| Inhibitors of the vitamin D receptor (VDR): qHTS | VDR | VDR | Vitamin D3 receptor | hypoparathyroidism | ERGOCALCIFEROL | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=84647b52-3c4c-31bb-e053-2991aa0a8a7e | 1 | GoF | protect | |||
| Inhibitors of the vitamin D receptor (VDR): qHTS | VDR | VDR | Vitamin D3 receptor | hypoparathyroidism | ERGOCALCIFEROL | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=00c063ce-5a2c-4ccb-87df-6ec3df0c9fa6 | 1 | GoF | protect | |||
| Inhibitors of the vitamin D receptor (VDR): qHTS | VDR | VDR | Vitamin D3 receptor | secondary hyperparathyroidism | ERGOCALCIFEROL | targetBased | 4 | Completed | 01/02/2009 | https://clinicaltrials.gov/study/NCT00803712 | 1 | GoF | protect | |
| Inhibitors of the vitamin D receptor (VDR): qHTS | VDR | VDR | Vitamin D3 receptor | secondary hyperparathyroidism | ERGOCALCIFEROL | targetBased | 4 | Completed | 01/08/2005 | https://clinicaltrials.gov/study/NCT00135304 | 1 | GoF | protect | |
| Inhibitors of the vitamin D receptor (VDR): qHTS | VDR | VDR | Vitamin D3 receptor | secondary hyperparathyroidism | ERGOCALCIFEROL | targetBased | 4 | Completed | 01/07/2009 | https://clinicaltrials.gov/study/NCT00958451 | 1 | GoF | protect | |
| Inhibitors of the vitamin D receptor (VDR): qHTS | VDR | VDR | Vitamin D3 receptor | hyperprolactinemia | ERGOCALCIFEROL | targetBased | 3 | Completed | 01/11/2008 | https://clinicaltrials.gov/study/NCT00799383 | 0.7 | GoF | protect | |
| Inhibitors of the vitamin D receptor (VDR): qHTS | VDR | VDR | Vitamin D3 receptor | non-alcoholic fatty liver disease | ERGOCALCIFEROL | targetBased | 3 | Unknown status | 01/09/2012 | https://clinicaltrials.gov/study/NCT01623024 | 0.7 | GoF | protect | |
| Inhibitors of the vitamin D receptor (VDR): qHTS | VDR | VDR | Vitamin D3 receptor | type 1 diabetes mellitus | ERGOCALCIFEROL | targetBased | 3 | Completed | 01/11/2009 | https://clinicaltrials.gov/study/NCT01029392 | 0.7 | GoF | protect | |
| Inhibitors of the vitamin D receptor (VDR): qHTS | VDR | VDR | Vitamin D3 receptor | Disorder of lipid metabolism | ERGOCALCIFEROL | targetBased | 3 | Completed | 01/12/2013 | https://clinicaltrials.gov/study/NCT02030041 | 0.7 | GoF | protect | |
| Inhibitors of the vitamin D receptor (VDR): qHTS | VDR | VDR | Vitamin D3 receptor | type 2 diabetes mellitus | ERGOCALCIFEROL | targetBased | 4 | Unknown status | 01/08/2012 | https://clinicaltrials.gov/study/NCT01876563 | 1 | GoF | protect | |
| Inhibitors of the vitamin D receptor (VDR): qHTS | VDR | VDR | Vitamin D3 receptor | type 2 diabetes mellitus | ERGOCALCIFEROL | targetBased | 4 | Completed | 01/05/2014 | https://clinicaltrials.gov/study/NCT02112721 | 1 | GoF | protect | |
| Inhibitors of the vitamin D receptor (VDR): qHTS | VDR | VDR | Vitamin D3 receptor | type 2 diabetes mellitus | ERGOCALCIFEROL | targetBased | 3 | Completed | 01/01/2009 | https://clinicaltrials.gov/study/NCT01585051 | 0.7 | GoF | protect | |
| Inhibitors of the vitamin D receptor (VDR): qHTS | VDR | VDR | Vitamin D3 receptor | type 2 diabetes mellitus | ERGOCALCIFEROL | targetBased | 4 | Terminated | 01/05/2009 | https://clinicaltrials.gov/study/NCT00879970 | 1 | GoF | protect | FDA has placed the trial on full clinical hold. |
| Inhibitors of the vitamin D receptor (VDR): qHTS | VDR | VDR | Vitamin D3 receptor | gestational diabetes | ERGOCALCIFEROL | targetBased | 4 | Unknown status | 01/11/2016 | https://clinicaltrials.gov/study/NCT03138616 | 1 | GoF | protect | |
| Inhibitors of the vitamin D receptor (VDR): qHTS | VDR | VDR | Vitamin D3 receptor | obesity | ERGOCALCIFEROL | targetBased | 3 | Completed | 01/10/2009 | https://clinicaltrials.gov/study/NCT01344161 | 0.7 | GoF | protect | |
| Inhibitors of the vitamin D receptor (VDR): qHTS | VDR | VDR | Vitamin D3 receptor | obesity | ERGOCALCIFEROL | targetBased | 4 | Completed | 01/01/2003 | https://clinicaltrials.gov/study/NCT00353054 | 1 | GoF | protect | |
| Inhibitors of the vitamin D receptor (VDR): qHTS | VDR | VDR | Vitamin D3 receptor | obesity | ERGOCALCIFEROL | targetBased | 3 | Completed | 01/03/2011 | https://clinicaltrials.gov/study/NCT01320722 | 0.7 | GoF | protect | |
| Inhibitors of the vitamin D receptor (VDR): qHTS | VDR | VDR | Vitamin D3 receptor | obesity | ERGOCALCIFEROL | targetBased | 4 | Completed | 01/01/2006 | https://clinicaltrials.gov/study/NCT00493012 | 1 | GoF | protect | |
| Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2 | THRB | THRB | Thyroid hormone receptor beta | hypothyroidism | LIOTHYRONINE | targetBased | 3 | Recruiting | 07/10/2022 | https://clinicaltrials.gov/study/NCT05682482 | 0.7 | GoF | protect | |
| Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2 | THRB | THRB | Thyroid hormone receptor beta | hypothyroidism | LIOTHYRONINE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=51452b31-ff68-4e0c-b982-c15502ebf1d3 | 1 | GoF | protect | |||
| Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2 | THRB | THRB | Thyroid hormone receptor beta | hypothyroidism | LIOTHYRONINE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5ccacb47-6348-6143-e053-2991aa0ac066 | 1 | GoF | protect | |||
| Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2 | THRB | THRB | Thyroid hormone receptor beta | myxedema | LIOTHYRONINE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5ccacb47-6348-6143-e053-2991aa0ac066 | 1 | GoF | protect | |||
| Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2 | THRB | THRB | Thyroid hormone receptor beta | myxedema | LIOTHYRONINE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a8b39730-de19-497d-bde8-6594aa528403 | 1 | GoF | protect | |||
| Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1) | CHRM1_agonists | CHRM1 | Muscarinic acetylcholine receptor M1 | gallstones | ATROPINE | targetBased | 4 | Completed | 01/01/2015 | https://clinicaltrials.gov/study/NCT02327923 | 1 | LoF | protect | |
| Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen | CHRM1_allosteric_activators | CHRM1 | Muscarinic acetylcholine receptor M1 | gallstones | ATROPINE | targetBased | 4 | Completed | 01/01/2015 | https://clinicaltrials.gov/study/NCT02327923 | 1 | LoF | protect | |
| Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1). | CHRM1_PAMs | CHRM1 | Muscarinic acetylcholine receptor M1 | gallstones | ATROPINE | targetBased | 4 | Completed | 01/01/2015 | https://clinicaltrials.gov/study/NCT02327923 | 1 | LoF | protect | |
| Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen | CHRM1_allosteric_antagonists | CHRM1 | Muscarinic acetylcholine receptor M1 | gallstones | ATROPINE | targetBased | 4 | Completed | 01/01/2015 | https://clinicaltrials.gov/study/NCT02327923 | 1 | LoF | protect | |
| Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1) | CHRM1_antgonists | CHRM1 | Muscarinic acetylcholine receptor M1 | gallstones | ATROPINE | targetBased | 4 | Completed | 01/01/2015 | https://clinicaltrials.gov/study/NCT02327923 | 1 | LoF | protect | |
| Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1) | CHRM1_agonists | CHRM1 | Muscarinic acetylcholine receptor M1 | pituitary dwarfism | ATROPINE | targetBased | 3 | Completed | 01/06/2003 | https://clinicaltrials.gov/study/NCT00476385 | 0.7 | LoF | protect | |
| Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen | CHRM1_allosteric_activators | CHRM1 | Muscarinic acetylcholine receptor M1 | pituitary dwarfism | ATROPINE | targetBased | 3 | Completed | 01/06/2003 | https://clinicaltrials.gov/study/NCT00476385 | 0.7 | LoF | protect | |
| Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1). | CHRM1_PAMs | CHRM1 | Muscarinic acetylcholine receptor M1 | pituitary dwarfism | ATROPINE | targetBased | 3 | Completed | 01/06/2003 | https://clinicaltrials.gov/study/NCT00476385 | 0.7 | LoF | protect | |
| Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen | CHRM1_allosteric_antagonists | CHRM1 | Muscarinic acetylcholine receptor M1 | pituitary dwarfism | ATROPINE | targetBased | 3 | Completed | 01/06/2003 | https://clinicaltrials.gov/study/NCT00476385 | 0.7 | LoF | protect | |
| Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1) | CHRM1_antgonists | CHRM1 | Muscarinic acetylcholine receptor M1 | pituitary dwarfism | ATROPINE | targetBased | 3 | Completed | 01/06/2003 | https://clinicaltrials.gov/study/NCT00476385 | 0.7 | LoF | protect | |
| qHTS Assay for Activators of Human alpha-Glucosidase as a Potential Chaperone Treatment of Pompe Disease | GAA | GAA | Lysosomal alpha-glucosidase | type 2 diabetes mellitus | MIGLITOL | targetBased | 3 | Completed | https://clinicaltrials.gov/study/NCT00334399 | 0.7 | LoF | protect | ||
| qHTS Assay for Inhibitors and Activators of Human alpha-Glucosidase Cleavage of Glycogen | GAA_inhibitors | GAA | Lysosomal alpha-glucosidase | type 2 diabetes mellitus | MIGLITOL | targetBased | 3 | Completed | https://clinicaltrials.gov/study/NCT00334399 | 0.7 | LoF | protect | ||
| qHTS Assay for Activators of Human alpha-Glucosidase as a Potential Chaperone Treatment of Pompe Disease | GAA | GAA | Lysosomal alpha-glucosidase | type 2 diabetes mellitus | MIGLITOL | targetBased | 3 | Completed | https://clinicaltrials.gov/study/NCT00213070 | 0.7 | LoF | protect | ||
| qHTS Assay for Inhibitors and Activators of Human alpha-Glucosidase Cleavage of Glycogen | GAA_inhibitors | GAA | Lysosomal alpha-glucosidase | type 2 diabetes mellitus | MIGLITOL | targetBased | 3 | Completed | https://clinicaltrials.gov/study/NCT00213070 | 0.7 | LoF | protect | ||
| qHTS Assay for Activators of Human alpha-Glucosidase as a Potential Chaperone Treatment of Pompe Disease | GAA | GAA | Lysosomal alpha-glucosidase | type 2 diabetes mellitus | MIGLITOL | targetBased | 3 | Completed | https://clinicaltrials.gov/study/NCT00213122 | 0.7 | LoF | protect | ||
| qHTS Assay for Inhibitors and Activators of Human alpha-Glucosidase Cleavage of Glycogen | GAA_inhibitors | GAA | Lysosomal alpha-glucosidase | type 2 diabetes mellitus | MIGLITOL | targetBased | 3 | Completed | https://clinicaltrials.gov/study/NCT00213122 | 0.7 | LoF | protect | ||
| qHTS Assay for Activators of Human alpha-Glucosidase as a Potential Chaperone Treatment of Pompe Disease | GAA | GAA | Lysosomal alpha-glucosidase | type 2 diabetes mellitus | MIGLITOL | targetBased | 3 | Completed | https://clinicaltrials.gov/study/NCT00334503 | 0.7 | LoF | protect | ||
| qHTS Assay for Inhibitors and Activators of Human alpha-Glucosidase Cleavage of Glycogen | GAA_inhibitors | GAA | Lysosomal alpha-glucosidase | type 2 diabetes mellitus | MIGLITOL | targetBased | 3 | Completed | https://clinicaltrials.gov/study/NCT00334503 | 0.7 | LoF | protect | ||
| qHTS Assay for Activators of Human alpha-Glucosidase as a Potential Chaperone Treatment of Pompe Disease | GAA | GAA | Lysosomal alpha-glucosidase | type 2 diabetes mellitus | MIGLITOL | targetBased | 3 | Completed | https://clinicaltrials.gov/study/NCT00380822 | 0.7 | LoF | protect | ||
| qHTS Assay for Inhibitors and Activators of Human alpha-Glucosidase Cleavage of Glycogen | GAA_inhibitors | GAA | Lysosomal alpha-glucosidase | type 2 diabetes mellitus | MIGLITOL | targetBased | 3 | Completed | https://clinicaltrials.gov/study/NCT00380822 | 0.7 | LoF | protect | ||
| qHTS Assay for Activators of Human alpha-Glucosidase as a Potential Chaperone Treatment of Pompe Disease | GAA | GAA | Lysosomal alpha-glucosidase | type 2 diabetes mellitus | MIGLITOL | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=75711d16-2d27-476e-a312-d5af448a0e25 | 1 | LoF | protect | |||
| qHTS Assay for Inhibitors and Activators of Human alpha-Glucosidase Cleavage of Glycogen | GAA_inhibitors | GAA | Lysosomal alpha-glucosidase | type 2 diabetes mellitus | MIGLITOL | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=75711d16-2d27-476e-a312-d5af448a0e25 | 1 | LoF | protect | |||
| qHTS Assay for Activators of Human alpha-Glucosidase as a Potential Chaperone Treatment of Pompe Disease | GAA | GAA | Lysosomal alpha-glucosidase | type 1 diabetes mellitus | MIGLITOL | targetBased | 3 | Completed | https://clinicaltrials.gov/study/NCT00213109 | 0.7 | LoF | protect | ||
| qHTS Assay for Inhibitors and Activators of Human alpha-Glucosidase Cleavage of Glycogen | GAA_inhibitors | GAA | Lysosomal alpha-glucosidase | type 1 diabetes mellitus | MIGLITOL | targetBased | 3 | Completed | https://clinicaltrials.gov/study/NCT00213109 | 0.7 | LoF | protect | ||
| qHTS Assay for Activators of Human alpha-Glucosidase as a Potential Chaperone Treatment of Pompe Disease | GAA | GAA | Lysosomal alpha-glucosidase | diabetes mellitus | MIGLITOL | targetBased | 4 | https://www.whocc.no/atc_ddd_index/?code=A10BF02 | 1 | LoF | protect | |||
| qHTS Assay for Inhibitors and Activators of Human alpha-Glucosidase Cleavage of Glycogen | GAA_inhibitors | GAA | Lysosomal alpha-glucosidase | diabetes mellitus | MIGLITOL | targetBased | 4 | https://www.whocc.no/atc_ddd_index/?code=A10BF02 | 1 | LoF | protect | |||
| uHTS identification of small molecule modulators of NR3A | GRIN3A | GRIN3A | secondary Parkinson disease | AMANTADINE HYDROCHLORIDE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e3ea1dbc-47cc-462d-a360-a3944f80b14c | 1 | LoF | protect | ||||
| uHTS identification of small molecule modulators of NR3A | GRIN3A | GRIN3A | secondary Parkinson disease | AMANTADINE HYDROCHLORIDE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=bfd129ae-8b0a-f118-b7d0-45d106290b63 | 1 | LoF | protect | ||||
| uHTS identification of small molecule modulators of NR3A | GRIN3A | GRIN3A | secondary Parkinson disease | AMANTADINE HYDROCHLORIDE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=17f205dd-0feb-4c49-a0e1-2d0c362c6bd7 | 1 | LoF | protect | ||||
| uHTS identification of small molecule modulators of NR3A | GRIN3A | GRIN3A | secondary Parkinson disease | AMANTADINE HYDROCHLORIDE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=13602c1d-d1c9-496b-baa6-8dee92519d67 | 1 | LoF | protect | ||||
| uHTS identification of small molecule modulators of NR3A | GRIN3A | GRIN3A | secondary Parkinson disease | AMANTADINE HYDROCHLORIDE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=461e6444-189e-62ed-6c61-1c36a04459c6 | 1 | LoF | protect | ||||
| uHTS identification of small molecule modulators of NR3A | GRIN3A | GRIN3A | secondary Parkinson disease | AMANTADINE HYDROCHLORIDE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=87db36f3-c831-4a84-a3c5-e9d6cc7191af | 1 | LoF | protect | ||||
| uHTS identification of small molecule modulators of NR3A | GRIN3A | GRIN3A | secondary Parkinson disease | AMANTADINE HYDROCHLORIDE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14452da8-3b48-497d-9017-bdfb967b7f56 | 1 | LoF | protect | ||||
| uHTS identification of small molecule modulators of NR3A | GRIN3A | GRIN3A | postencephalitic Parkinson disease | AMANTADINE HYDROCHLORIDE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=13602c1d-d1c9-496b-baa6-8dee92519d67 | 1 | LoF | protect | ||||
| uHTS identification of small molecule modulators of NR3A | GRIN3A | GRIN3A | postencephalitic Parkinson disease | AMANTADINE HYDROCHLORIDE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14452da8-3b48-497d-9017-bdfb967b7f56 | 1 | LoF | protect | ||||
| uHTS identification of small molecule modulators of NR3A | GRIN3A | GRIN3A | postencephalitic Parkinson disease | AMANTADINE HYDROCHLORIDE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=87db36f3-c831-4a84-a3c5-e9d6cc7191af | 1 | LoF | protect | ||||
| uHTS identification of small molecule modulators of NR3A | GRIN3A | GRIN3A | postencephalitic Parkinson disease | AMANTADINE HYDROCHLORIDE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=461e6444-189e-62ed-6c61-1c36a04459c6 | 1 | LoF | protect | ||||
| uHTS identification of small molecule modulators of NR3A | GRIN3A | GRIN3A | postencephalitic Parkinson disease | AMANTADINE HYDROCHLORIDE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=17f205dd-0feb-4c49-a0e1-2d0c362c6bd7 | 1 | LoF | protect | ||||
| uHTS identification of small molecule modulators of NR3A | GRIN3A | GRIN3A | postencephalitic Parkinson disease | AMANTADINE HYDROCHLORIDE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e3ea1dbc-47cc-462d-a360-a3944f80b14c | 1 | LoF | protect | ||||
| uHTS identification of small molecule modulators of NR3A | GRIN3A | GRIN3A | postencephalitic Parkinson disease | AMANTADINE HYDROCHLORIDE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=bfd129ae-8b0a-f118-b7d0-45d106290b63 | 1 | LoF | protect | ||||
| Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2 | THRB | THRB | Thyroid hormone receptor beta | hypothyroidism | LEVOTHYROXINE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b722a6c8-c44b-4ec7-9402-02dc7e965753 | 1 | GoF | protect | |||
| Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2 | THRB | THRB | Thyroid hormone receptor beta | hypothyroidism | LEVOTHYROXINE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9562b54c-7ccd-411f-8e84-0c9de897cfea | 1 | GoF | protect | |||
| Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2 | THRB | THRB | Thyroid hormone receptor beta | hypothyroidism | LEVOTHYROXINE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=69de922e-931e-4723-a91f-0cd774f008d1 | 1 | GoF | protect | |||
| Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2 | THRB | THRB | Thyroid hormone receptor beta | hypothyroidism | LEVOTHYROXINE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5e1d8d43-193d-443d-9304-9f4f59620151 | 1 | GoF | protect | |||
| Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2 | THRB | THRB | Thyroid hormone receptor beta | hypothyroidism | LEVOTHYROXINE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=eed5fdf6-2861-45a2-ae10-d8031137ed03 | 1 | GoF | protect | |||
| Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2 | THRB | THRB | Thyroid hormone receptor beta | hypothyroidism | LEVOTHYROXINE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f347f490-7199-4de6-bca2-0d44a74979af | 1 | GoF | protect | |||
| Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2 | THRB | THRB | Thyroid hormone receptor beta | hypothyroidism | LEVOTHYROXINE | targetBased | 4 | Completed | 30/07/2018 | https://clinicaltrials.gov/study/NCT03094416 | 1 | GoF | protect | |
| Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2 | THRB | THRB | Thyroid hormone receptor beta | hypothyroidism | LEVOTHYROXINE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=44a290d4-18f3-4077-89ae-ddb7db914ae7 | 1 | GoF | protect | |||
| Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2 | THRB | THRB | Thyroid hormone receptor beta | hypothyroidism | LEVOTHYROXINE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=52b448ca-30fa-464c-b79d-2835779357cb | 1 | GoF | protect | |||
| Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2 | THRB | THRB | Thyroid hormone receptor beta | hypothyroidism | LEVOTHYROXINE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=bc695a1b-b510-4376-a9a0-bcbd7c63906f | 1 | GoF | protect | |||
| Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2 | THRB | THRB | Thyroid hormone receptor beta | hypothyroidism | LEVOTHYROXINE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=26cc174c-197c-448e-b9f6-50df4926f4f4 | 1 | GoF | protect | |||
| Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2 | THRB | THRB | Thyroid hormone receptor beta | hypothyroidism | LEVOTHYROXINE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3802ed01-e081-4c07-ac66-1bc0a3dc8737 | 1 | GoF | protect | |||
| Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2 | THRB | THRB | Thyroid hormone receptor beta | hypothyroidism | LEVOTHYROXINE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=bd1ce5e4-9dd5-4bd5-ae5e-c88822c04f98 | 1 | GoF | protect | |||
| Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2 | THRB | THRB | Thyroid hormone receptor beta | hypothyroidism | LEVOTHYROXINE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=21a12ab0-43ac-4f9e-877d-a81d7463de17 | 1 | GoF | protect | |||
| Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2 | THRB | THRB | Thyroid hormone receptor beta | hypothyroidism | LEVOTHYROXINE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1ad32038-f484-4469-93fe-d3da81d8b9ea | 1 | GoF | protect | |||
| Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2 | THRB | THRB | Thyroid hormone receptor beta | hypothyroidism | LEVOTHYROXINE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=70df9c08-665f-4b12-9b11-e5521ebca3ea | 1 | GoF | protect | |||
| Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2 | THRB | THRB | Thyroid hormone receptor beta | hypothyroidism | LEVOTHYROXINE | targetBased | 4 | Completed | 01/08/2012 | https://clinicaltrials.gov/study/NCT01647750 | 1 | GoF | protect | |
| Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2 | THRB | THRB | Thyroid hormone receptor beta | hypothyroidism | LEVOTHYROXINE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=82549679-2e3b-48e8-95d7-7fdb902f9215 | 1 | GoF | protect | |||
| Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2 | THRB | THRB | Thyroid hormone receptor beta | hypothyroidism | LEVOTHYROXINE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=efe4d28c-8399-48b9-96f6-d9302e25de6d | 1 | GoF | protect | |||
| Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2 | THRB | THRB | Thyroid hormone receptor beta | hypothyroidism | LEVOTHYROXINE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3d2820e6-5bb4-4c71-9fb0-422a5c1ebaf0 | 1 | GoF | protect | |||
| Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2 | THRB | THRB | Thyroid hormone receptor beta | hypothyroidism | LEVOTHYROXINE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ca9cc882-1ae9-4260-989a-2fa7d6613470 | 1 | GoF | protect | |||
| Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2 | THRB | THRB | Thyroid hormone receptor beta | hypothyroidism | LEVOTHYROXINE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=16eb7d1c-77c4-4709-970a-1e1bdb29eb76 | 1 | GoF | protect | |||
| Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2 | THRB | THRB | Thyroid hormone receptor beta | hypothyroidism | LEVOTHYROXINE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a3b269b2-6c33-4e5e-8880-5cc8f825f60c | 1 | GoF | protect | |||
| Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2 | THRB | THRB | Thyroid hormone receptor beta | hypothyroidism | LEVOTHYROXINE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=49205c04-076b-4a6d-97aa-f0b4d3eaac46 | 1 | GoF | protect | |||
| Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2 | THRB | THRB | Thyroid hormone receptor beta | hypothyroidism | LEVOTHYROXINE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0bf2cfc3-b564-44ed-9268-1a5409a89eeb | 1 | GoF | protect | |||
| Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2 | THRB | THRB | Thyroid hormone receptor beta | hypothyroidism | LEVOTHYROXINE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e7fd03db-72cd-4dc3-ae94-e11cb67126a8 | 1 | GoF | protect | |||
| Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2 | THRB | THRB | Thyroid hormone receptor beta | hypothyroidism | LEVOTHYROXINE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=02dbb433-dc86-4967-8cd0-0424d7836b7a | 1 | GoF | protect | |||
| Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2 | THRB | THRB | Thyroid hormone receptor beta | hypothyroidism | LEVOTHYROXINE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e44f82cc-4a34-40fc-bc31-42e06ca5e8b8 | 1 | GoF | protect | |||
| Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2 | THRB | THRB | Thyroid hormone receptor beta | hypothyroidism | LEVOTHYROXINE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f887a801-744c-43c2-81d6-6433b1089667 | 1 | GoF | protect | |||
| Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2 | THRB | THRB | Thyroid hormone receptor beta | hypothyroidism | LEVOTHYROXINE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a3845f91-e0fe-42aa-8043-aeaac43f8eef | 1 | GoF | protect | |||
| Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2 | THRB | THRB | Thyroid hormone receptor beta | hypothyroidism | LEVOTHYROXINE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=32723719-5d99-4ef1-a991-b65767327c1d | 1 | GoF | protect | |||
| Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2 | THRB | THRB | Thyroid hormone receptor beta | hypothyroidism | LEVOTHYROXINE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a4e39e5c-59ee-4ba2-bf7f-62b5eae3afbc | 1 | GoF | protect | |||
| Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2 | THRB | THRB | Thyroid hormone receptor beta | hypothyroidism | LEVOTHYROXINE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=bd11d40c-67f6-4149-a705-dcf281c913a9 | 1 | GoF | protect | |||
| Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2 | THRB | THRB | Thyroid hormone receptor beta | hypothyroidism | LEVOTHYROXINE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=dd073a5a-d344-4c1a-9957-e501ff14f4ba | 1 | GoF | protect | |||
| Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2 | THRB | THRB | Thyroid hormone receptor beta | hypothyroidism | LEVOTHYROXINE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7a9ecaf3-0a05-4233-a402-ecfc512c693f | 1 | GoF | protect | |||
| Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2 | THRB | THRB | Thyroid hormone receptor beta | hypothyroidism | LEVOTHYROXINE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=94690757-d8ca-424c-acea-eece9c342712 | 1 | GoF | protect | |||
| Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2 | THRB | THRB | Thyroid hormone receptor beta | hypothyroidism | LEVOTHYROXINE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=02ca8555-a726-4dd3-afee-4435ae3e0ae1 | 1 | GoF | protect | |||
| Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2 | THRB | THRB | Thyroid hormone receptor beta | hypothyroidism | LEVOTHYROXINE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=71139e30-10c8-4474-b7a3-b575c3fd32f9 | 1 | GoF | protect | |||
| Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2 | THRB | THRB | Thyroid hormone receptor beta | hypothyroidism | LEVOTHYROXINE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7a9d4020-09d3-4a3f-a919-c16d994c65be | 1 | GoF | protect | |||
| Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2 | THRB | THRB | Thyroid hormone receptor beta | hypothyroidism | LEVOTHYROXINE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=abea9e57-11b6-4c31-b41a-3d305e57e022 | 1 | GoF | protect | |||
| Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2 | THRB | THRB | Thyroid hormone receptor beta | hypothyroidism | LEVOTHYROXINE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=cadf4802-b53f-419c-a775-82af525887e4 | 1 | GoF | protect | |||
| Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2 | THRB | THRB | Thyroid hormone receptor beta | hypothyroidism | LEVOTHYROXINE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=63bea240-a32d-4c12-85d1-b7edeca76b67 | 1 | GoF | protect | |||
| Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2 | THRB | THRB | Thyroid hormone receptor beta | hypothyroidism | LEVOTHYROXINE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=847fed05-7256-4d0e-a743-716784abc5f9 | 1 | GoF | protect | |||
| Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2 | THRB | THRB | Thyroid hormone receptor beta | hypothyroidism | LEVOTHYROXINE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=82212ab9-776f-4838-ba16-83e87c33d479 | 1 | GoF | protect | |||
| Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2 | THRB | THRB | Thyroid hormone receptor beta | hypothyroidism | LEVOTHYROXINE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=fce4372d-8bba-4995-b809-fb4e256ee798 | 1 | GoF | protect | |||
| Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2 | THRB | THRB | Thyroid hormone receptor beta | hypothyroidism | LEVOTHYROXINE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0213903b-9662-465e-a668-f228cedf5e9e | 1 | GoF | protect | |||
| Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2 | THRB | THRB | Thyroid hormone receptor beta | hypothyroidism | LEVOTHYROXINE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f8eaf67a-72e6-4ecd-bbf6-7ec8d34df2a2 | 1 | GoF | protect | |||
| Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2 | THRB | THRB | Thyroid hormone receptor beta | hypothyroidism | LEVOTHYROXINE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0f11c856-af9a-409a-9c0f-e7a10bbfe5a6 | 1 | GoF | protect | |||
| Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2 | THRB | THRB | Thyroid hormone receptor beta | hypothyroidism | LEVOTHYROXINE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9f87f620-e576-4a51-91d3-9a9e6819c638 | 1 | GoF | protect | |||
| Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2 | THRB | THRB | Thyroid hormone receptor beta | hypothyroidism | LEVOTHYROXINE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4f6a74de-bbc3-46ef-a21f-6a45aa75ccb5 | 1 | GoF | protect | |||
| Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2 | THRB | THRB | Thyroid hormone receptor beta | hypothyroidism | LEVOTHYROXINE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=34c775d0-8982-45c4-9c10-d5a52d8dad63 | 1 | GoF | protect | |||
| Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2 | THRB | THRB | Thyroid hormone receptor beta | hypothyroidism | LEVOTHYROXINE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ac81bf65-080b-450e-b1ff-6758a1733e0c | 1 | GoF | protect | |||
| Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2 | THRB | THRB | Thyroid hormone receptor beta | hypothyroidism | LEVOTHYROXINE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5644d405-8dea-48f7-8be7-828de94742b1 | 1 | GoF | protect | |||
| Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2 | THRB | THRB | Thyroid hormone receptor beta | hypothyroidism | LEVOTHYROXINE | targetBased | 4 | Active, not recruiting | 01/02/2017 | https://clinicaltrials.gov/study/NCT02467244 | 1 | GoF | protect | |
| Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2 | THRB | THRB | Thyroid hormone receptor beta | hypothyroidism | LEVOTHYROXINE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7a5a9e87-383a-4450-bf79-1f4f68655ace | 1 | GoF | protect | |||
| Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2 | THRB | THRB | Thyroid hormone receptor beta | hypothyroidism | LEVOTHYROXINE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=68eb8ab6-c018-4112-affb-71c0db88f8de | 1 | GoF | protect | |||
| Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2 | THRB | THRB | Thyroid hormone receptor beta | hypothyroidism | LEVOTHYROXINE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3218d7d0-08c8-4e96-a717-94a8cbad2092 | 1 | GoF | protect | |||
| Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2 | THRB | THRB | Thyroid hormone receptor beta | hypothyroidism | LEVOTHYROXINE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6977f0ea-3343-4f99-bcc6-85acfeb69710 | 1 | GoF | protect | |||
| Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2 | THRB | THRB | Thyroid hormone receptor beta | hypothyroidism | LEVOTHYROXINE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4220ded0-36b2-4e48-8280-aecfce89ebe2 | 1 | GoF | protect | |||
| Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2 | THRB | THRB | Thyroid hormone receptor beta | hypothyroidism | LEVOTHYROXINE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ba633224-8f70-4533-a5fc-4dfd2df703d6 | 1 | GoF | protect | |||
| Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2 | THRB | THRB | Thyroid hormone receptor beta | hypothyroidism | LEVOTHYROXINE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ee5e8470-131f-4b3d-b99b-3528853689fa | 1 | GoF | protect | |||
| Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2 | THRB | THRB | Thyroid hormone receptor beta | hypothyroidism | LEVOTHYROXINE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=600c2d08-e92f-46fa-a835-c225cc759dd1 | 1 | GoF | protect | |||
| Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2 | THRB | THRB | Thyroid hormone receptor beta | hypothyroidism | LEVOTHYROXINE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0f547137-d471-15f6-e054-00144ff8d46c | 1 | GoF | protect | |||
| Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2 | THRB | THRB | Thyroid hormone receptor beta | hypothyroidism | LEVOTHYROXINE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4c9642fa-9d53-4c16-85a7-0b3c9cadb1dd | 1 | GoF | protect | |||
| Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2 | THRB | THRB | Thyroid hormone receptor beta | hypothyroidism | LEVOTHYROXINE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=707fb53f-f27d-4169-86ff-62d02014e9c4 | 1 | GoF | protect | |||
| Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2 | THRB | THRB | Thyroid hormone receptor beta | hypothyroidism | LEVOTHYROXINE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=48428150-629d-4745-9238-18c52cb2adf8 | 1 | GoF | protect | |||
| Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2 | THRB | THRB | Thyroid hormone receptor beta | hypothyroidism | LEVOTHYROXINE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=07562e72-7eaa-4ce6-94f0-e08814787e50 | 1 | GoF | protect | |||
| Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2 | THRB | THRB | Thyroid hormone receptor beta | hypothyroidism | LEVOTHYROXINE | targetBased | 4 | Completed | 01/05/2014 | https://clinicaltrials.gov/study/NCT01660126 | 1 | GoF | protect | |
| Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2 | THRB | THRB | Thyroid hormone receptor beta | hypothyroidism | LEVOTHYROXINE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c202834e-0aba-4a06-838c-cf076681e6e4 | 1 | GoF | protect | |||
| Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2 | THRB | THRB | Thyroid hormone receptor beta | hypothyroidism | LEVOTHYROXINE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c91d4f5b-dc9a-44aa-82e5-809831c260f6 | 1 | GoF | protect | |||
| Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2 | THRB | THRB | Thyroid hormone receptor beta | hypothyroidism | LEVOTHYROXINE | targetBased | 4 | Terminated | 01/02/2017 | https://clinicaltrials.gov/study/NCT02946918 | 1 | GoF | protect | Terminating study as sponsor has sold the drug to another company |
| Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2 | THRB | THRB | Thyroid hormone receptor beta | hypothyroidism | LEVOTHYROXINE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0af3f268-7e5d-4ce5-af2b-35ae6c362dab | 1 | GoF | protect | |||
| Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2 | THRB | THRB | Thyroid hormone receptor beta | hypothyroidism | LEVOTHYROXINE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b6ced930-2630-441d-926c-7c6d2188b27d | 1 | GoF | protect | |||
| Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2 | THRB | THRB | Thyroid hormone receptor beta | hypothyroidism | LEVOTHYROXINE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3aa52a8d-0bdb-4ae4-8acb-4ea8c29fa480 | 1 | GoF | protect | |||
| Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2 | THRB | THRB | Thyroid hormone receptor beta | hypothyroidism | LEVOTHYROXINE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=dac99035-9098-4710-bf55-c46889ffc282 | 1 | GoF | protect | |||
| Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2 | THRB | THRB | Thyroid hormone receptor beta | hypothyroidism | LEVOTHYROXINE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=58d8f240-2c83-406c-bf44-3931e40103e1 | 1 | GoF | protect | |||
| Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2 | THRB | THRB | Thyroid hormone receptor beta | hypothyroidism | LEVOTHYROXINE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=dcbb33d6-9bb6-420a-9ee9-4527320d3d5c | 1 | GoF | protect | |||
| Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2 | THRB | THRB | Thyroid hormone receptor beta | hypothyroidism | LEVOTHYROXINE | targetBased | 4 | Completed | 24/03/2021 | https://clinicaltrials.gov/study/NCT04288115 | 1 | GoF | protect | |
| Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2 | THRB | THRB | Thyroid hormone receptor beta | hypothyroidism | LEVOTHYROXINE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=cadf57e5-7682-425b-8f0c-a7998114f375 | 1 | GoF | protect | |||
| Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2 | THRB | THRB | Thyroid hormone receptor beta | hypothyroidism | LEVOTHYROXINE | targetBased | 4 | Terminated | 05/05/2021 | https://clinicaltrials.gov/study/NCT04878614 | 1 | GoF | protect | Sponsor terminated study low accrual numbers |
| Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2 | THRB | THRB | Thyroid hormone receptor beta | hypothyroidism | LEVOTHYROXINE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=02786c40-5745-4bd9-b429-53948e9ce262 | 1 | GoF | protect | |||
| Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2 | THRB | THRB | Thyroid hormone receptor beta | hypothyroidism | LEVOTHYROXINE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=cc47cc71-5bdf-40fa-bb0f-12d77366ad01 | 1 | GoF | protect | |||
| Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2 | THRB | THRB | Thyroid hormone receptor beta | hypothyroidism | LEVOTHYROXINE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d3ce9a73-5f3a-4c1b-a4b7-06f45316d61a | 1 | GoF | protect | |||
| Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2 | THRB | THRB | Thyroid hormone receptor beta | hypothyroidism | LEVOTHYROXINE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ac83ac72-b447-47df-b6ad-94537305b7b8 | 1 | GoF | protect | |||
| Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2 | THRB | THRB | Thyroid hormone receptor beta | hypothyroidism | LEVOTHYROXINE | targetBased | 4 | Recruiting | 31/01/2024 | https://clinicaltrials.gov/study/NCT06073665 | 1 | GoF | protect | |
| Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2 | THRB | THRB | Thyroid hormone receptor beta | hypothyroidism | LEVOTHYROXINE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=eaf78aff-a6d2-4fb5-b4e5-8b2cb60de0de | 1 | GoF | protect | |||
| Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2 | THRB | THRB | Thyroid hormone receptor beta | hypothyroidism | LEVOTHYROXINE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=95bf72d9-3d2d-435d-8543-a9a7bb4a3bca | 1 | GoF | protect | |||
| Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2 | THRB | THRB | Thyroid hormone receptor beta | hypothyroidism | LEVOTHYROXINE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=67032026-6b2a-4f2b-aafe-cdcf3febb6eb | 1 | GoF | protect | |||
| Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2 | THRB | THRB | Thyroid hormone receptor beta | hypothyroidism | LEVOTHYROXINE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8553a519-571b-4b9e-a638-06fc523ac373 | 1 | GoF | protect | |||
| Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2 | THRB | THRB | Thyroid hormone receptor beta | hypothyroidism | LEVOTHYROXINE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3e5544bb-142b-4cfb-89a0-b97cb521e1db | 1 | GoF | protect | |||
| Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2 | THRB | THRB | Thyroid hormone receptor beta | hypothyroidism | LEVOTHYROXINE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7f8fda21-ed5b-4db1-ada0-627cf3e1c248 | 1 | GoF | protect | |||
| Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2 | THRB | THRB | Thyroid hormone receptor beta | hypothyroidism | LEVOTHYROXINE | targetBased | 4 | Unknown status | 01/04/2013 | https://clinicaltrials.gov/study/NCT01831869 | 1 | GoF | protect | |
| Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2 | THRB | THRB | Thyroid hormone receptor beta | hypothyroidism | LEVOTHYROXINE | targetBased | 4 | Completed | 01/08/2008 | https://clinicaltrials.gov/study/NCT00565864 | 1 | GoF | protect | |
| Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2 | THRB | THRB | Thyroid hormone receptor beta | hypothyroidism | LEVOTHYROXINE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ff852ce9-44ce-4d7c-b756-c164adda3796 | 1 | GoF | protect | |||
| Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2 | THRB | THRB | Thyroid hormone receptor beta | hypothyroidism | LEVOTHYROXINE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=dddad621-c42a-45a1-b6af-8f0503f67474 | 1 | GoF | protect | |||
| Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2 | THRB | THRB | Thyroid hormone receptor beta | hypothyroidism | LEVOTHYROXINE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a432460c-85b3-4d51-b945-bd62340a29bd | 1 | GoF | protect | |||
| Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2 | THRB | THRB | Thyroid hormone receptor beta | hypothyroidism | LEVOTHYROXINE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=99aebc74-0e34-4ab3-bb59-d9fb2b9a4444 | 1 | GoF | protect | |||
| Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2 | THRB | THRB | Thyroid hormone receptor beta | hypothyroidism | LEVOTHYROXINE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=00a4fc0b-7162-455e-8ed3-56efdbbe182e | 1 | GoF | protect | |||
| Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2 | THRB | THRB | Thyroid hormone receptor beta | hypothyroidism | LEVOTHYROXINE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=82a99646-c6a2-4fe1-a0e8-32cd521283c3 | 1 | GoF | protect | |||
| Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2 | THRB | THRB | Thyroid hormone receptor beta | hypothyroidism | LEVOTHYROXINE | targetBased | 4 | Completed | 01/01/2012 | https://clinicaltrials.gov/study/NCT01536678 | 1 | GoF | protect | |
| Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2 | THRB | THRB | Thyroid hormone receptor beta | hypothyroidism | LEVOTHYROXINE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f4d851f6-6bf5-4ed5-8d3a-1646773c4d40 | 1 | GoF | protect | |||
| Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2 | THRB | THRB | Thyroid hormone receptor beta | hypothyroidism | LEVOTHYROXINE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=dec03393-0e77-4716-8db8-2ff996dd3f74 | 1 | GoF | protect | |||
| Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2 | THRB | THRB | Thyroid hormone receptor beta | hypothyroidism | LEVOTHYROXINE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9fde935e-f927-46aa-ba7b-e8874f4e190d | 1 | GoF | protect | |||
| Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2 | THRB | THRB | Thyroid hormone receptor beta | hypothyroidism | LEVOTHYROXINE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e9060459-ec1b-4eb5-a34a-d777f1544f3d | 1 | GoF | protect | |||
| Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2 | THRB | THRB | Thyroid hormone receptor beta | hypothyroidism | LEVOTHYROXINE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3177aea1-c0c6-4ae1-b20e-3ca66a949e2c | 1 | GoF | protect | |||
| Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2 | THRB | THRB | Thyroid hormone receptor beta | hypothyroidism | LEVOTHYROXINE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=04c2e322-151f-4a95-b34a-622183c506fe | 1 | GoF | protect | |||
| Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2 | THRB | THRB | Thyroid hormone receptor beta | hypothyroidism | LEVOTHYROXINE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=22985313-7619-4e82-88a9-ad2c71ade0d7 | 1 | GoF | protect | |||
| Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2 | THRB | THRB | Thyroid hormone receptor beta | hypothyroidism | LEVOTHYROXINE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5680bf94-524d-45ee-b1dd-d2e81e48a312 | 1 | GoF | protect | |||
| Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2 | THRB | THRB | Thyroid hormone receptor beta | hypothyroidism | LEVOTHYROXINE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d336bf7d-6c91-4285-a877-9521c659ff99 | 1 | GoF | protect | |||
| Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2 | THRB | THRB | Thyroid hormone receptor beta | hypothyroidism | LEVOTHYROXINE | targetBased | 4 | Unknown status | 01/05/2016 | https://clinicaltrials.gov/study/NCT02917863 | 1 | GoF | protect | |
| Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2 | THRB | THRB | Thyroid hormone receptor beta | hypothyroidism | LEVOTHYROXINE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f924199f-fcac-445e-a7b9-4f57d4062be1 | 1 | GoF | protect | |||
| Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2 | THRB | THRB | Thyroid hormone receptor beta | hypothyroidism | LEVOTHYROXINE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5cf37653-c6a1-4360-b073-5f116bd16b9d | 1 | GoF | protect | |||
| Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2 | THRB | THRB | Thyroid hormone receptor beta | hypothyroidism | LEVOTHYROXINE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=574d2da2-9440-43d5-ac8e-c46017ec4bd3 | 1 | GoF | protect | |||
| Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2 | THRB | THRB | Thyroid hormone receptor beta | hypothyroidism | LEVOTHYROXINE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e0dcc021-0831-41dd-9750-251c2f71a614 | 1 | GoF | protect | |||
| Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2 | THRB | THRB | Thyroid hormone receptor beta | hypothyroidism | LEVOTHYROXINE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=05897f7a-4d31-497f-aa9e-52708b361640 | 1 | GoF | protect | |||
| Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2 | THRB | THRB | Thyroid hormone receptor beta | hypothyroidism | LEVOTHYROXINE | targetBased | 4 | Active, not recruiting | 01/07/2013 | https://clinicaltrials.gov/study/NCT01848171 | 1 | GoF | protect | |
| Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2 | THRB | THRB | Thyroid hormone receptor beta | hypothyroidism | LEVOTHYROXINE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6182a0e9-ea40-41fc-be24-822b165af1bb | 1 | GoF | protect | |||
| Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2 | THRB | THRB | Thyroid hormone receptor beta | hypothyroidism | LEVOTHYROXINE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d804fd47-a37b-41c6-ab34-c311abf14d71 | 1 | GoF | protect | |||
| Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2 | THRB | THRB | Thyroid hormone receptor beta | hypothyroidism | LEVOTHYROXINE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0986e998-ad13-4546-867d-95ed3db314ed | 1 | GoF | protect | |||
| Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2 | THRB | THRB | Thyroid hormone receptor beta | hypothyroidism | LEVOTHYROXINE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=853ff15d-bbb1-40a1-b551-db2cfcdd0bd3 | 1 | GoF | protect | |||
| Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2 | THRB | THRB | Thyroid hormone receptor beta | hypothyroidism | LEVOTHYROXINE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5ada7c99-cb63-4b68-8dd2-e0f4fafdf4f6 | 1 | GoF | protect | |||
| Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2 | THRB | THRB | Thyroid hormone receptor beta | hypothyroidism | LEVOTHYROXINE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d3ce7029-9e12-4de6-8f59-145bc91369a8 | 1 | GoF | protect | |||
| Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2 | THRB | THRB | Thyroid hormone receptor beta | hypothyroidism | LEVOTHYROXINE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8dda27c0-8368-47b7-b502-8fcaa1066e9f | 1 | GoF | protect | |||
| Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2 | THRB | THRB | Thyroid hormone receptor beta | hypothyroidism | LEVOTHYROXINE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d71ff261-ffd5-47a8-840f-40e464612bf6 | 1 | GoF | protect | |||
| Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2 | THRB | THRB | Thyroid hormone receptor beta | hypothyroidism | LEVOTHYROXINE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=46a9e4e6-af7f-4f60-a888-c6d3afce8113 | 1 | GoF | protect | |||
| Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2 | THRB | THRB | Thyroid hormone receptor beta | hypothyroidism | LEVOTHYROXINE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8bea42cb-5e06-4be7-983d-cae573ceaba6 | 1 | GoF | protect | |||
| Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2 | THRB | THRB | Thyroid hormone receptor beta | hypothyroidism | LEVOTHYROXINE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e29d7f37-212b-4caa-a1da-171c828e2d52 | 1 | GoF | protect | |||
| Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2 | THRB | THRB | Thyroid hormone receptor beta | hypothyroidism | LEVOTHYROXINE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6a3aa7ea-4a9d-4be2-a6d9-5fbf21673835 | 1 | GoF | protect | |||
| Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2 | THRB | THRB | Thyroid hormone receptor beta | hypothyroidism | LEVOTHYROXINE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=13caa583-2238-4c2c-bc32-d88e7725a02e | 1 | GoF | protect | |||
| Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2 | THRB | THRB | Thyroid hormone receptor beta | hypothyroidism | LEVOTHYROXINE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=53ee103c-52d2-4f8a-8e24-54d1f1551b8e | 1 | GoF | protect | |||
| Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2 | THRB | THRB | Thyroid hormone receptor beta | hypothyroidism | LEVOTHYROXINE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1221646b-ea75-1ce9-e054-00144ff8d46c | 1 | GoF | protect | |||
| Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2 | THRB | THRB | Thyroid hormone receptor beta | hypothyroidism | LEVOTHYROXINE | targetBased | 3 | Completed | 01/11/2006 | https://clinicaltrials.gov/study/NCT00403390 | 0.7 | GoF | protect | |
| Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2 | THRB | THRB | Thyroid hormone receptor beta | hypothyroidism | LEVOTHYROXINE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3f7bf9a8-fcfa-47fc-826d-c36174abbca0 | 1 | GoF | protect | |||
| Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2 | THRB | THRB | Thyroid hormone receptor beta | hypothyroidism | LEVOTHYROXINE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=784e246c-058d-44f0-a0a0-d96539d8888d | 1 | GoF | protect | |||
| Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2 | THRB | THRB | Thyroid hormone receptor beta | hypothyroidism | LEVOTHYROXINE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7ab991f3-3984-4925-88fa-f11027ac7a36 | 1 | GoF | protect | |||
| Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2 | THRB | THRB | Thyroid hormone receptor beta | hypothyroidism | LEVOTHYROXINE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2eabc9b4-2d5c-44b2-bf05-eb6c3260c1bd | 1 | GoF | protect | |||
| Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2 | THRB | THRB | Thyroid hormone receptor beta | hypothyroidism | LEVOTHYROXINE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ba302d90-1555-47f1-9d75-9a6bde299f98 | 1 | GoF | protect | |||
| Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2 | THRB | THRB | Thyroid hormone receptor beta | hypothyroidism | LEVOTHYROXINE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7d8e9ae0-2299-4d96-b925-bbceecf2c5d9 | 1 | GoF | protect | |||
| Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2 | THRB | THRB | Thyroid hormone receptor beta | hypothyroidism | LEVOTHYROXINE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ea2463ca-26fc-4c37-9cde-a8730c60a9e6 | 1 | GoF | protect | |||
| Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2 | THRB | THRB | Thyroid hormone receptor beta | hypothyroidism | LEVOTHYROXINE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b37ec531-9a69-4919-ba54-ffb674848a96 | 1 | GoF | protect | |||
| Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2 | THRB | THRB | Thyroid hormone receptor beta | hypothyroidism | LEVOTHYROXINE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5915b2bb-ae53-4781-91ed-ff90188fe1d8 | 1 | GoF | protect | |||
| Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2 | THRB | THRB | Thyroid hormone receptor beta | hypothyroidism | LEVOTHYROXINE | targetBased | 4 | Withdrawn | 01/10/2015 | https://clinicaltrials.gov/study/NCT02577367 | 1 | GoF | protect | Lost interest in current study |
| Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2 | THRB | THRB | Thyroid hormone receptor beta | hypothyroidism | LEVOTHYROXINE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0aad8c43-6a19-4420-8987-97a3d95c52cf | 1 | GoF | protect | |||
| Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2 | THRB | THRB | Thyroid hormone receptor beta | hypothyroidism | LEVOTHYROXINE | targetBased | 3 | Recruiting | 13/12/2021 | https://clinicaltrials.gov/study/NCT05316922 | 0.7 | GoF | protect | |
| Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2 | THRB | THRB | Thyroid hormone receptor beta | hypothyroidism | LEVOTHYROXINE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c697292b-e67f-4753-abba-c06f98b7ce90 | 1 | GoF | protect | |||
| Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2 | THRB | THRB | Thyroid hormone receptor beta | goiter | LEVOTHYROXINE | targetBased | 4 | Withdrawn | 01/05/2015 | https://clinicaltrials.gov/study/NCT02329379 | 1 | GoF | protect | No participants enrolled |
| Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2 | THRB | THRB | Thyroid hormone receptor beta | euthyroid sick syndrome | LEVOTHYROXINE | targetBased | 4 | Completed | 01/01/2012 | https://clinicaltrials.gov/study/NCT01631305 | 1 | GoF | protect | |
| Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2 | THRB | THRB | Thyroid hormone receptor beta | congenital hypothyroidism | LEVOTHYROXINE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f4d851f6-6bf5-4ed5-8d3a-1646773c4d40 | 1 | GoF | protect | |||
| Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2 | THRB | THRB | Thyroid hormone receptor beta | congenital hypothyroidism | LEVOTHYROXINE | targetBased | 4 | Completed | 01/05/2011 | https://clinicaltrials.gov/study/NCT05371262 | 1 | GoF | protect | |
| Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2 | THRB | THRB | Thyroid hormone receptor beta | congenital hypothyroidism | LEVOTHYROXINE | targetBased | 3 | Completed | 01/11/2006 | https://clinicaltrials.gov/study/NCT00403390 | 0.7 | GoF | protect | |
| Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2 | THRB | THRB | Thyroid hormone receptor beta | congenital hypothyroidism | LEVOTHYROXINE | targetBased | 4 | Active, not recruiting | 21/01/2022 | https://clinicaltrials.gov/study/NCT05228184 | 1 | GoF | protect | |
| Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2 | THRB | THRB | Thyroid hormone receptor beta | Disorder of lipid metabolism | LEVOTHYROXINE | targetBased | 3 | Unknown status | 01/10/2011 | https://clinicaltrials.gov/study/NCT01486667 | 0.7 | GoF | protect | |
| Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2 | THRB | THRB | Thyroid hormone receptor beta | nodular goiter | LEVOTHYROXINE | targetBased | 4 | Completed | 01/05/2004 | https://clinicaltrials.gov/study/NCT00277589 | 1 | GoF | protect | |
| qHTS Assay for Activators of Human alpha-Glucosidase as a Potential Chaperone Treatment of Pompe Disease | GAA | GAA | Lysosomal alpha-glucosidase | type 2 diabetes mellitus | VOGLIBOSE | targetBased | 3 | Completed | 01/04/2008 | https://clinicaltrials.gov/study/NCT00654381 | 0.7 | LoF | protect | |
| qHTS Assay for Inhibitors and Activators of Human alpha-Glucosidase Cleavage of Glycogen | GAA_inhibitors | GAA | Lysosomal alpha-glucosidase | type 2 diabetes mellitus | VOGLIBOSE | targetBased | 3 | Completed | 01/04/2008 | https://clinicaltrials.gov/study/NCT00654381 | 0.7 | LoF | protect | |
| qHTS Assay for Activators of Human alpha-Glucosidase as a Potential Chaperone Treatment of Pompe Disease | GAA | GAA | Lysosomal alpha-glucosidase | type 2 diabetes mellitus | VOGLIBOSE | targetBased | 3 | Completed | 05/02/2009 | https://clinicaltrials.gov/study/NCT00837577 | 0.7 | LoF | protect | |
| qHTS Assay for Inhibitors and Activators of Human alpha-Glucosidase Cleavage of Glycogen | GAA_inhibitors | GAA | Lysosomal alpha-glucosidase | type 2 diabetes mellitus | VOGLIBOSE | targetBased | 3 | Completed | 05/02/2009 | https://clinicaltrials.gov/study/NCT00837577 | 0.7 | LoF | protect | |
| qHTS Assay for Activators of Human alpha-Glucosidase as a Potential Chaperone Treatment of Pompe Disease | GAA | GAA | Lysosomal alpha-glucosidase | type 2 diabetes mellitus | VOGLIBOSE | targetBased | 4 | Unknown status | 01/12/2013 | https://clinicaltrials.gov/study/NCT02097342 | 1 | LoF | protect | |
| qHTS Assay for Inhibitors and Activators of Human alpha-Glucosidase Cleavage of Glycogen | GAA_inhibitors | GAA | Lysosomal alpha-glucosidase | type 2 diabetes mellitus | VOGLIBOSE | targetBased | 4 | Unknown status | 01/12/2013 | https://clinicaltrials.gov/study/NCT02097342 | 1 | LoF | protect | |
| qHTS Assay for Activators of Human alpha-Glucosidase as a Potential Chaperone Treatment of Pompe Disease | GAA | GAA | Lysosomal alpha-glucosidase | type 2 diabetes mellitus | VOGLIBOSE | targetBased | 4 | Completed | 01/02/2008 | https://clinicaltrials.gov/study/NCT00663884 | 1 | LoF | protect | |
| qHTS Assay for Inhibitors and Activators of Human alpha-Glucosidase Cleavage of Glycogen | GAA_inhibitors | GAA | Lysosomal alpha-glucosidase | type 2 diabetes mellitus | VOGLIBOSE | targetBased | 4 | Completed | 01/02/2008 | https://clinicaltrials.gov/study/NCT00663884 | 1 | LoF | protect | |
| qHTS Assay for Activators of Human alpha-Glucosidase as a Potential Chaperone Treatment of Pompe Disease | GAA | GAA | Lysosomal alpha-glucosidase | type 2 diabetes mellitus | VOGLIBOSE | targetBased | 4 | Completed | 01/11/2009 | https://clinicaltrials.gov/study/NCT00970528 | 1 | LoF | protect | |
| qHTS Assay for Inhibitors and Activators of Human alpha-Glucosidase Cleavage of Glycogen | GAA_inhibitors | GAA | Lysosomal alpha-glucosidase | type 2 diabetes mellitus | VOGLIBOSE | targetBased | 4 | Completed | 01/11/2009 | https://clinicaltrials.gov/study/NCT00970528 | 1 | LoF | protect | |
| qHTS Assay for Activators of Human alpha-Glucosidase as a Potential Chaperone Treatment of Pompe Disease | GAA | GAA | Lysosomal alpha-glucosidase | type 2 diabetes mellitus | VOGLIBOSE | targetBased | 3 | Not yet recruiting | 01/08/2023 | https://clinicaltrials.gov/study/NCT05688332 | 0.7 | LoF | protect | |
| qHTS Assay for Inhibitors and Activators of Human alpha-Glucosidase Cleavage of Glycogen | GAA_inhibitors | GAA | Lysosomal alpha-glucosidase | type 2 diabetes mellitus | VOGLIBOSE | targetBased | 3 | Not yet recruiting | 01/08/2023 | https://clinicaltrials.gov/study/NCT05688332 | 0.7 | LoF | protect | |
| qHTS Assay for Activators of Human alpha-Glucosidase as a Potential Chaperone Treatment of Pompe Disease | GAA | GAA | Lysosomal alpha-glucosidase | type 2 diabetes mellitus | VOGLIBOSE | targetBased | 4 | Completed | 09/05/2014 | https://clinicaltrials.gov/study/NCT02049814 | 1 | LoF | protect | |
| qHTS Assay for Inhibitors and Activators of Human alpha-Glucosidase Cleavage of Glycogen | GAA_inhibitors | GAA | Lysosomal alpha-glucosidase | type 2 diabetes mellitus | VOGLIBOSE | targetBased | 4 | Completed | 09/05/2014 | https://clinicaltrials.gov/study/NCT02049814 | 1 | LoF | protect | |
| qHTS Assay for Activators of Human alpha-Glucosidase as a Potential Chaperone Treatment of Pompe Disease | GAA | GAA | Lysosomal alpha-glucosidase | type 2 diabetes mellitus | VOGLIBOSE | targetBased | 3 | Completed | 01/01/2007 | https://clinicaltrials.gov/study/NCT00411554 | 0.7 | LoF | protect | |
| qHTS Assay for Inhibitors and Activators of Human alpha-Glucosidase Cleavage of Glycogen | GAA_inhibitors | GAA | Lysosomal alpha-glucosidase | type 2 diabetes mellitus | VOGLIBOSE | targetBased | 3 | Completed | 01/01/2007 | https://clinicaltrials.gov/study/NCT00411554 | 0.7 | LoF | protect | |
| qHTS Assay for Activators of Human alpha-Glucosidase as a Potential Chaperone Treatment of Pompe Disease | GAA | GAA | Lysosomal alpha-glucosidase | type 2 diabetes mellitus | VOGLIBOSE | targetBased | 4 | Completed | 01/02/2011 | https://clinicaltrials.gov/study/NCT01309698 | 1 | LoF | protect | |
| qHTS Assay for Inhibitors and Activators of Human alpha-Glucosidase Cleavage of Glycogen | GAA_inhibitors | GAA | Lysosomal alpha-glucosidase | type 2 diabetes mellitus | VOGLIBOSE | targetBased | 4 | Completed | 01/02/2011 | https://clinicaltrials.gov/study/NCT01309698 | 1 | LoF | protect | |
| qHTS Assay for Activators of Human alpha-Glucosidase as a Potential Chaperone Treatment of Pompe Disease | GAA | GAA | Lysosomal alpha-glucosidase | abnormal glucose tolerance | VOGLIBOSE | targetBased | 4 | Completed | 01/03/2010 | https://clinicaltrials.gov/study/NCT02287402 | 1 | LoF | protect | |
| qHTS Assay for Inhibitors and Activators of Human alpha-Glucosidase Cleavage of Glycogen | GAA_inhibitors | GAA | Lysosomal alpha-glucosidase | abnormal glucose tolerance | VOGLIBOSE | targetBased | 4 | Completed | 01/03/2010 | https://clinicaltrials.gov/study/NCT02287402 | 1 | LoF | protect | |
| qHTS Assay for Activators of Human alpha-Glucosidase as a Potential Chaperone Treatment of Pompe Disease | GAA | GAA | Lysosomal alpha-glucosidase | diabetes mellitus | VOGLIBOSE | targetBased | 4 | https://www.whocc.no/atc_ddd_index/?code=A10BF03 | 1 | LoF | protect | |||
| qHTS Assay for Inhibitors and Activators of Human alpha-Glucosidase Cleavage of Glycogen | GAA_inhibitors | GAA | Lysosomal alpha-glucosidase | diabetes mellitus | VOGLIBOSE | targetBased | 4 | https://www.whocc.no/atc_ddd_index/?code=A10BF03 | 1 | LoF | protect | |||
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | ALEGLITAZAR | targetBased | 3 | Completed | 01/12/2012 | https://clinicaltrials.gov/study/NCT01691989 | 0.7 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | ALEGLITAZAR | targetBased | 3 | Completed | 01/12/2012 | https://clinicaltrials.gov/study/NCT01691989 | 0.7 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | ALEGLITAZAR | targetBased | 3 | Completed | 01/12/2012 | https://clinicaltrials.gov/study/NCT01691989 | 0.7 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | ALEGLITAZAR | targetBased | 3 | Completed | 01/12/2012 | https://clinicaltrials.gov/study/NCT01691989 | 0.7 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | ALEGLITAZAR | targetBased | 3 | Completed | 01/12/2012 | https://clinicaltrials.gov/study/NCT01691989 | 0.7 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | ALEGLITAZAR | targetBased | 3 | Completed | 01/12/2012 | https://clinicaltrials.gov/study/NCT01691989 | 0.7 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | ALEGLITAZAR | targetBased | 3 | Completed | 01/11/2012 | https://clinicaltrials.gov/study/NCT01691755 | 0.7 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | ALEGLITAZAR | targetBased | 3 | Completed | 01/11/2012 | https://clinicaltrials.gov/study/NCT01691755 | 0.7 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | ALEGLITAZAR | targetBased | 3 | Completed | 01/11/2012 | https://clinicaltrials.gov/study/NCT01691755 | 0.7 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | ALEGLITAZAR | targetBased | 3 | Completed | 01/11/2012 | https://clinicaltrials.gov/study/NCT01691755 | 0.7 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | ALEGLITAZAR | targetBased | 3 | Completed | 01/11/2012 | https://clinicaltrials.gov/study/NCT01691755 | 0.7 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | ALEGLITAZAR | targetBased | 3 | Completed | 01/11/2012 | https://clinicaltrials.gov/study/NCT01691755 | 0.7 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | ALEGLITAZAR | targetBased | 3 | Completed | 01/06/2013 | https://clinicaltrials.gov/study/NCT01871428 | 0.7 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | ALEGLITAZAR | targetBased | 3 | Completed | 01/06/2013 | https://clinicaltrials.gov/study/NCT01871428 | 0.7 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | ALEGLITAZAR | targetBased | 3 | Completed | 01/06/2013 | https://clinicaltrials.gov/study/NCT01871428 | 0.7 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | ALEGLITAZAR | targetBased | 3 | Completed | 01/06/2013 | https://clinicaltrials.gov/study/NCT01871428 | 0.7 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | ALEGLITAZAR | targetBased | 3 | Completed | 01/06/2013 | https://clinicaltrials.gov/study/NCT01871428 | 0.7 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | ALEGLITAZAR | targetBased | 3 | Completed | 01/06/2013 | https://clinicaltrials.gov/study/NCT01871428 | 0.7 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | ALEGLITAZAR | targetBased | 3 | Completed | 01/05/2013 | https://clinicaltrials.gov/study/NCT01871415 | 0.7 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | ALEGLITAZAR | targetBased | 3 | Completed | 01/05/2013 | https://clinicaltrials.gov/study/NCT01871415 | 0.7 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | ALEGLITAZAR | targetBased | 3 | Completed | 01/05/2013 | https://clinicaltrials.gov/study/NCT01871415 | 0.7 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | ALEGLITAZAR | targetBased | 3 | Completed | 01/05/2013 | https://clinicaltrials.gov/study/NCT01871415 | 0.7 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | ALEGLITAZAR | targetBased | 3 | Completed | 01/05/2013 | https://clinicaltrials.gov/study/NCT01871415 | 0.7 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | ALEGLITAZAR | targetBased | 3 | Completed | 01/05/2013 | https://clinicaltrials.gov/study/NCT01871415 | 0.7 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | ALEGLITAZAR | targetBased | 3 | Completed | 01/02/2010 | https://clinicaltrials.gov/study/NCT01042769 | 0.7 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | ALEGLITAZAR | targetBased | 3 | Completed | 01/02/2010 | https://clinicaltrials.gov/study/NCT01042769 | 0.7 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | ALEGLITAZAR | targetBased | 3 | Completed | 01/02/2010 | https://clinicaltrials.gov/study/NCT01042769 | 0.7 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | ALEGLITAZAR | targetBased | 3 | Completed | 01/02/2010 | https://clinicaltrials.gov/study/NCT01042769 | 0.7 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | ALEGLITAZAR | targetBased | 3 | Completed | 01/02/2010 | https://clinicaltrials.gov/study/NCT01042769 | 0.7 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | ALEGLITAZAR | targetBased | 3 | Completed | 01/02/2010 | https://clinicaltrials.gov/study/NCT01042769 | 0.7 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | ALEGLITAZAR | targetBased | 3 | Completed | 01/10/2012 | https://clinicaltrials.gov/study/NCT01691846 | 0.7 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | ALEGLITAZAR | targetBased | 3 | Completed | 01/10/2012 | https://clinicaltrials.gov/study/NCT01691846 | 0.7 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | ALEGLITAZAR | targetBased | 3 | Completed | 01/10/2012 | https://clinicaltrials.gov/study/NCT01691846 | 0.7 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | ALEGLITAZAR | targetBased | 3 | Completed | 01/10/2012 | https://clinicaltrials.gov/study/NCT01691846 | 0.7 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | ALEGLITAZAR | targetBased | 3 | Completed | 01/10/2012 | https://clinicaltrials.gov/study/NCT01691846 | 0.7 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | ALEGLITAZAR | targetBased | 3 | Completed | 01/10/2012 | https://clinicaltrials.gov/study/NCT01691846 | 0.7 | GoF | protect | |
| Fluorescence-based cell-based primary high throughput screening assay to identify inhibitors of TLR9-MyD88 binding. | TLR9 | TLR9 | Toll-like receptor 9 | obesity | HYDROXYCHLOROQUINE SULFATE | targetBased | 4 | Not yet recruiting | 01/08/2019 | https://clinicaltrials.gov/study/NCT04005768 | 1 | LoF | protect | |
| Fluorescence-based cell-based primary high throughput screening assay to identify inhibitors of TLR9-MyD88 binding. | TLR9 | TLR9 | Toll-like receptor 9 | obesity | HYDROXYCHLOROQUINE SULFATE | targetBased | 4 | Not yet recruiting | 01/10/2019 | https://clinicaltrials.gov/study/NCT04005781 | 1 | LoF | protect | |
| High Throughput Screening for Cocaine Antagonists: Primary Screen | SLC6A3 | SLC6A3 | Sodium-dependent dopamine transporter | obesity | DIETHYLPROPION HYDROCHLORIDE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3ecb7bd7-e04c-47fe-859a-8ba8a54f9aff | 1 | LoF | protect | |||
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | liver disease | PIOGLITAZONE HYDROCHLORIDE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=42e49120-6f3f-11db-9fe1-0800200c9a66 | 1 | GoF | protect | |||
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | liver disease | PIOGLITAZONE HYDROCHLORIDE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=42e49120-6f3f-11db-9fe1-0800200c9a66 | 1 | GoF | protect | |||
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | liver disease | PIOGLITAZONE HYDROCHLORIDE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=42e49120-6f3f-11db-9fe1-0800200c9a66 | 1 | GoF | protect | |||
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | liver disease | PIOGLITAZONE HYDROCHLORIDE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=42e49120-6f3f-11db-9fe1-0800200c9a66 | 1 | GoF | protect | |||
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | liver disease | PIOGLITAZONE HYDROCHLORIDE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=42e49120-6f3f-11db-9fe1-0800200c9a66 | 1 | GoF | protect | |||
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | liver disease | PIOGLITAZONE HYDROCHLORIDE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=42e49120-6f3f-11db-9fe1-0800200c9a66 | 1 | GoF | protect | |||
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | liver disease | PIOGLITAZONE HYDROCHLORIDE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7f6e4b4d-7480-444f-e053-2a91aa0a62ec | 1 | GoF | protect | |||
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | liver disease | PIOGLITAZONE HYDROCHLORIDE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7f6e4b4d-7480-444f-e053-2a91aa0a62ec | 1 | GoF | protect | |||
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | liver disease | PIOGLITAZONE HYDROCHLORIDE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7f6e4b4d-7480-444f-e053-2a91aa0a62ec | 1 | GoF | protect | |||
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | liver disease | PIOGLITAZONE HYDROCHLORIDE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7f6e4b4d-7480-444f-e053-2a91aa0a62ec | 1 | GoF | protect | |||
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | liver disease | PIOGLITAZONE HYDROCHLORIDE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7f6e4b4d-7480-444f-e053-2a91aa0a62ec | 1 | GoF | protect | |||
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | liver disease | PIOGLITAZONE HYDROCHLORIDE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7f6e4b4d-7480-444f-e053-2a91aa0a62ec | 1 | GoF | protect | |||
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | liver disease | PIOGLITAZONE HYDROCHLORIDE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f8b0c917-3fdd-4a28-a47d-6225b8195458 | 1 | GoF | protect | |||
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | liver disease | PIOGLITAZONE HYDROCHLORIDE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f8b0c917-3fdd-4a28-a47d-6225b8195458 | 1 | GoF | protect | |||
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | liver disease | PIOGLITAZONE HYDROCHLORIDE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f8b0c917-3fdd-4a28-a47d-6225b8195458 | 1 | GoF | protect | |||
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | liver disease | PIOGLITAZONE HYDROCHLORIDE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f8b0c917-3fdd-4a28-a47d-6225b8195458 | 1 | GoF | protect | |||
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | liver disease | PIOGLITAZONE HYDROCHLORIDE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f8b0c917-3fdd-4a28-a47d-6225b8195458 | 1 | GoF | protect | |||
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | liver disease | PIOGLITAZONE HYDROCHLORIDE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f8b0c917-3fdd-4a28-a47d-6225b8195458 | 1 | GoF | protect | |||
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | non-alcoholic fatty liver disease | PIOGLITAZONE HYDROCHLORIDE | targetBased | 4 | Completed | 15/02/2023 | https://clinicaltrials.gov/study/NCT05813249 | 1 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | non-alcoholic fatty liver disease | PIOGLITAZONE HYDROCHLORIDE | targetBased | 4 | Completed | 15/02/2023 | https://clinicaltrials.gov/study/NCT05813249 | 1 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | non-alcoholic fatty liver disease | PIOGLITAZONE HYDROCHLORIDE | targetBased | 4 | Completed | 15/02/2023 | https://clinicaltrials.gov/study/NCT05813249 | 1 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | non-alcoholic fatty liver disease | PIOGLITAZONE HYDROCHLORIDE | targetBased | 4 | Completed | 15/02/2023 | https://clinicaltrials.gov/study/NCT05813249 | 1 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | non-alcoholic fatty liver disease | PIOGLITAZONE HYDROCHLORIDE | targetBased | 4 | Completed | 15/02/2023 | https://clinicaltrials.gov/study/NCT05813249 | 1 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | non-alcoholic fatty liver disease | PIOGLITAZONE HYDROCHLORIDE | targetBased | 4 | Completed | 15/02/2023 | https://clinicaltrials.gov/study/NCT05813249 | 1 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE HYDROCHLORIDE | targetBased | 3 | Completed | 01/04/2008 | https://clinicaltrials.gov/study/NCT00680745 | 0.7 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE HYDROCHLORIDE | targetBased | 3 | Completed | 01/04/2008 | https://clinicaltrials.gov/study/NCT00680745 | 0.7 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE HYDROCHLORIDE | targetBased | 3 | Completed | 01/04/2008 | https://clinicaltrials.gov/study/NCT00680745 | 0.7 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE HYDROCHLORIDE | targetBased | 3 | Completed | 01/04/2008 | https://clinicaltrials.gov/study/NCT00680745 | 0.7 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE HYDROCHLORIDE | targetBased | 3 | Completed | 01/04/2008 | https://clinicaltrials.gov/study/NCT00680745 | 0.7 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE HYDROCHLORIDE | targetBased | 3 | Completed | 01/04/2008 | https://clinicaltrials.gov/study/NCT00680745 | 0.7 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE HYDROCHLORIDE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3d11a0bc-26b4-49f4-a8e7-0fad1524b3d1 | 1 | GoF | protect | |||
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE HYDROCHLORIDE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3d11a0bc-26b4-49f4-a8e7-0fad1524b3d1 | 1 | GoF | protect | |||
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE HYDROCHLORIDE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3d11a0bc-26b4-49f4-a8e7-0fad1524b3d1 | 1 | GoF | protect | |||
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE HYDROCHLORIDE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3d11a0bc-26b4-49f4-a8e7-0fad1524b3d1 | 1 | GoF | protect | |||
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE HYDROCHLORIDE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3d11a0bc-26b4-49f4-a8e7-0fad1524b3d1 | 1 | GoF | protect | |||
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE HYDROCHLORIDE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3d11a0bc-26b4-49f4-a8e7-0fad1524b3d1 | 1 | GoF | protect | |||
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE HYDROCHLORIDE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=db790f58-3c27-49c3-b7f6-58344a14400e | 1 | GoF | protect | |||
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE HYDROCHLORIDE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=db790f58-3c27-49c3-b7f6-58344a14400e | 1 | GoF | protect | |||
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE HYDROCHLORIDE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=db790f58-3c27-49c3-b7f6-58344a14400e | 1 | GoF | protect | |||
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE HYDROCHLORIDE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=db790f58-3c27-49c3-b7f6-58344a14400e | 1 | GoF | protect | |||
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE HYDROCHLORIDE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=db790f58-3c27-49c3-b7f6-58344a14400e | 1 | GoF | protect | |||
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE HYDROCHLORIDE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=db790f58-3c27-49c3-b7f6-58344a14400e | 1 | GoF | protect | |||
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE HYDROCHLORIDE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2a97ef74-b338-4655-a60b-923f86720179 | 1 | GoF | protect | |||
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE HYDROCHLORIDE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2a97ef74-b338-4655-a60b-923f86720179 | 1 | GoF | protect | |||
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE HYDROCHLORIDE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2a97ef74-b338-4655-a60b-923f86720179 | 1 | GoF | protect | |||
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE HYDROCHLORIDE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2a97ef74-b338-4655-a60b-923f86720179 | 1 | GoF | protect | |||
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE HYDROCHLORIDE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2a97ef74-b338-4655-a60b-923f86720179 | 1 | GoF | protect | |||
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE HYDROCHLORIDE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2a97ef74-b338-4655-a60b-923f86720179 | 1 | GoF | protect | |||
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE HYDROCHLORIDE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=586651c6-8d9d-4e96-b17b-7bb535eb3153 | 1 | GoF | protect | |||
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE HYDROCHLORIDE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=586651c6-8d9d-4e96-b17b-7bb535eb3153 | 1 | GoF | protect | |||
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE HYDROCHLORIDE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=586651c6-8d9d-4e96-b17b-7bb535eb3153 | 1 | GoF | protect | |||
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE HYDROCHLORIDE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=586651c6-8d9d-4e96-b17b-7bb535eb3153 | 1 | GoF | protect | |||
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE HYDROCHLORIDE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=586651c6-8d9d-4e96-b17b-7bb535eb3153 | 1 | GoF | protect | |||
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE HYDROCHLORIDE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=586651c6-8d9d-4e96-b17b-7bb535eb3153 | 1 | GoF | protect | |||
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE HYDROCHLORIDE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f5c534e8-656c-406d-b3dc-b562576ba4eb | 1 | GoF | protect | |||
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE HYDROCHLORIDE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f5c534e8-656c-406d-b3dc-b562576ba4eb | 1 | GoF | protect | |||
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE HYDROCHLORIDE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f5c534e8-656c-406d-b3dc-b562576ba4eb | 1 | GoF | protect | |||
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE HYDROCHLORIDE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f5c534e8-656c-406d-b3dc-b562576ba4eb | 1 | GoF | protect | |||
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE HYDROCHLORIDE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f5c534e8-656c-406d-b3dc-b562576ba4eb | 1 | GoF | protect | |||
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE HYDROCHLORIDE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f5c534e8-656c-406d-b3dc-b562576ba4eb | 1 | GoF | protect | |||
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE HYDROCHLORIDE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0478f0e7-87fb-4adb-ae9b-6624555ccbe4 | 1 | GoF | protect | |||
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE HYDROCHLORIDE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0478f0e7-87fb-4adb-ae9b-6624555ccbe4 | 1 | GoF | protect | |||
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE HYDROCHLORIDE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0478f0e7-87fb-4adb-ae9b-6624555ccbe4 | 1 | GoF | protect | |||
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE HYDROCHLORIDE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0478f0e7-87fb-4adb-ae9b-6624555ccbe4 | 1 | GoF | protect | |||
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE HYDROCHLORIDE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0478f0e7-87fb-4adb-ae9b-6624555ccbe4 | 1 | GoF | protect | |||
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE HYDROCHLORIDE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0478f0e7-87fb-4adb-ae9b-6624555ccbe4 | 1 | GoF | protect | |||
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE HYDROCHLORIDE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=71b48b31-5b50-4c11-91a8-d3a8cc8e6bf8 | 1 | GoF | protect | |||
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE HYDROCHLORIDE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=71b48b31-5b50-4c11-91a8-d3a8cc8e6bf8 | 1 | GoF | protect | |||
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE HYDROCHLORIDE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=71b48b31-5b50-4c11-91a8-d3a8cc8e6bf8 | 1 | GoF | protect | |||
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE HYDROCHLORIDE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=71b48b31-5b50-4c11-91a8-d3a8cc8e6bf8 | 1 | GoF | protect | |||
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE HYDROCHLORIDE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=71b48b31-5b50-4c11-91a8-d3a8cc8e6bf8 | 1 | GoF | protect | |||
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE HYDROCHLORIDE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=71b48b31-5b50-4c11-91a8-d3a8cc8e6bf8 | 1 | GoF | protect | |||
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE HYDROCHLORIDE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=fb49b7d6-8071-44c7-a10c-e8116d7d5b42 | 1 | GoF | protect | |||
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE HYDROCHLORIDE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=fb49b7d6-8071-44c7-a10c-e8116d7d5b42 | 1 | GoF | protect | |||
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE HYDROCHLORIDE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=fb49b7d6-8071-44c7-a10c-e8116d7d5b42 | 1 | GoF | protect | |||
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE HYDROCHLORIDE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=fb49b7d6-8071-44c7-a10c-e8116d7d5b42 | 1 | GoF | protect | |||
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE HYDROCHLORIDE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=fb49b7d6-8071-44c7-a10c-e8116d7d5b42 | 1 | GoF | protect | |||
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE HYDROCHLORIDE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=fb49b7d6-8071-44c7-a10c-e8116d7d5b42 | 1 | GoF | protect | |||
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE HYDROCHLORIDE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f22dab23-3cf6-4473-a367-5303353e9f9d | 1 | GoF | protect | |||
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE HYDROCHLORIDE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f22dab23-3cf6-4473-a367-5303353e9f9d | 1 | GoF | protect | |||
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE HYDROCHLORIDE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f22dab23-3cf6-4473-a367-5303353e9f9d | 1 | GoF | protect | |||
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE HYDROCHLORIDE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f22dab23-3cf6-4473-a367-5303353e9f9d | 1 | GoF | protect | |||
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE HYDROCHLORIDE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f22dab23-3cf6-4473-a367-5303353e9f9d | 1 | GoF | protect | |||
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE HYDROCHLORIDE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f22dab23-3cf6-4473-a367-5303353e9f9d | 1 | GoF | protect | |||
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE HYDROCHLORIDE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=91385f6c-ba70-4247-88f4-5f3b25ddd6b3 | 1 | GoF | protect | |||
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE HYDROCHLORIDE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=91385f6c-ba70-4247-88f4-5f3b25ddd6b3 | 1 | GoF | protect | |||
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE HYDROCHLORIDE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=91385f6c-ba70-4247-88f4-5f3b25ddd6b3 | 1 | GoF | protect | |||
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE HYDROCHLORIDE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=91385f6c-ba70-4247-88f4-5f3b25ddd6b3 | 1 | GoF | protect | |||
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE HYDROCHLORIDE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=91385f6c-ba70-4247-88f4-5f3b25ddd6b3 | 1 | GoF | protect | |||
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE HYDROCHLORIDE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=91385f6c-ba70-4247-88f4-5f3b25ddd6b3 | 1 | GoF | protect | |||
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE HYDROCHLORIDE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6c6f14bb-c964-42a6-93a6-192204ae1b99 | 1 | GoF | protect | |||
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE HYDROCHLORIDE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6c6f14bb-c964-42a6-93a6-192204ae1b99 | 1 | GoF | protect | |||
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE HYDROCHLORIDE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6c6f14bb-c964-42a6-93a6-192204ae1b99 | 1 | GoF | protect | |||
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE HYDROCHLORIDE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6c6f14bb-c964-42a6-93a6-192204ae1b99 | 1 | GoF | protect | |||
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE HYDROCHLORIDE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6c6f14bb-c964-42a6-93a6-192204ae1b99 | 1 | GoF | protect | |||
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE HYDROCHLORIDE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6c6f14bb-c964-42a6-93a6-192204ae1b99 | 1 | GoF | protect | |||
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE HYDROCHLORIDE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=51033f88-4938-4666-b2a9-147044ed00e3 | 1 | GoF | protect | |||
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE HYDROCHLORIDE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=51033f88-4938-4666-b2a9-147044ed00e3 | 1 | GoF | protect | |||
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE HYDROCHLORIDE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=51033f88-4938-4666-b2a9-147044ed00e3 | 1 | GoF | protect | |||
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE HYDROCHLORIDE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=51033f88-4938-4666-b2a9-147044ed00e3 | 1 | GoF | protect | |||
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE HYDROCHLORIDE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=51033f88-4938-4666-b2a9-147044ed00e3 | 1 | GoF | protect | |||
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE HYDROCHLORIDE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=51033f88-4938-4666-b2a9-147044ed00e3 | 1 | GoF | protect | |||
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE HYDROCHLORIDE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6912a5c9-309b-4641-9232-72a218240c0d | 1 | GoF | protect | |||
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE HYDROCHLORIDE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6912a5c9-309b-4641-9232-72a218240c0d | 1 | GoF | protect | |||
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE HYDROCHLORIDE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6912a5c9-309b-4641-9232-72a218240c0d | 1 | GoF | protect | |||
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE HYDROCHLORIDE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6912a5c9-309b-4641-9232-72a218240c0d | 1 | GoF | protect | |||
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE HYDROCHLORIDE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6912a5c9-309b-4641-9232-72a218240c0d | 1 | GoF | protect | |||
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE HYDROCHLORIDE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6912a5c9-309b-4641-9232-72a218240c0d | 1 | GoF | protect | |||
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE HYDROCHLORIDE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=171a41f7-da5a-4a55-bd0e-40a29977b2e5 | 1 | GoF | protect | |||
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE HYDROCHLORIDE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=171a41f7-da5a-4a55-bd0e-40a29977b2e5 | 1 | GoF | protect | |||
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE HYDROCHLORIDE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=171a41f7-da5a-4a55-bd0e-40a29977b2e5 | 1 | GoF | protect | |||
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE HYDROCHLORIDE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=171a41f7-da5a-4a55-bd0e-40a29977b2e5 | 1 | GoF | protect | |||
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE HYDROCHLORIDE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=171a41f7-da5a-4a55-bd0e-40a29977b2e5 | 1 | GoF | protect | |||
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE HYDROCHLORIDE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=171a41f7-da5a-4a55-bd0e-40a29977b2e5 | 1 | GoF | protect | |||
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE HYDROCHLORIDE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f986164c-51a7-41c2-8952-511b8f46d593 | 1 | GoF | protect | |||
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE HYDROCHLORIDE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f986164c-51a7-41c2-8952-511b8f46d593 | 1 | GoF | protect | |||
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE HYDROCHLORIDE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f986164c-51a7-41c2-8952-511b8f46d593 | 1 | GoF | protect | |||
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE HYDROCHLORIDE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f986164c-51a7-41c2-8952-511b8f46d593 | 1 | GoF | protect | |||
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE HYDROCHLORIDE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f986164c-51a7-41c2-8952-511b8f46d593 | 1 | GoF | protect | |||
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE HYDROCHLORIDE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f986164c-51a7-41c2-8952-511b8f46d593 | 1 | GoF | protect | |||
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE HYDROCHLORIDE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=dc314f38-26dc-0b66-d533-065d90fe7375 | 1 | GoF | protect | |||
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE HYDROCHLORIDE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=dc314f38-26dc-0b66-d533-065d90fe7375 | 1 | GoF | protect | |||
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE HYDROCHLORIDE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=dc314f38-26dc-0b66-d533-065d90fe7375 | 1 | GoF | protect | |||
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE HYDROCHLORIDE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=dc314f38-26dc-0b66-d533-065d90fe7375 | 1 | GoF | protect | |||
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE HYDROCHLORIDE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=dc314f38-26dc-0b66-d533-065d90fe7375 | 1 | GoF | protect | |||
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE HYDROCHLORIDE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=dc314f38-26dc-0b66-d533-065d90fe7375 | 1 | GoF | protect | |||
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE HYDROCHLORIDE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ccf82737-754b-472e-a9bb-961fd1a3c307 | 1 | GoF | protect | |||
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE HYDROCHLORIDE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ccf82737-754b-472e-a9bb-961fd1a3c307 | 1 | GoF | protect | |||
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE HYDROCHLORIDE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ccf82737-754b-472e-a9bb-961fd1a3c307 | 1 | GoF | protect | |||
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE HYDROCHLORIDE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ccf82737-754b-472e-a9bb-961fd1a3c307 | 1 | GoF | protect | |||
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE HYDROCHLORIDE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ccf82737-754b-472e-a9bb-961fd1a3c307 | 1 | GoF | protect | |||
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE HYDROCHLORIDE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ccf82737-754b-472e-a9bb-961fd1a3c307 | 1 | GoF | protect | |||
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE HYDROCHLORIDE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d2ddc491-88a9-4063-9150-443b4fa4330c | 1 | GoF | protect | |||
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE HYDROCHLORIDE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d2ddc491-88a9-4063-9150-443b4fa4330c | 1 | GoF | protect | |||
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE HYDROCHLORIDE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d2ddc491-88a9-4063-9150-443b4fa4330c | 1 | GoF | protect | |||
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE HYDROCHLORIDE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d2ddc491-88a9-4063-9150-443b4fa4330c | 1 | GoF | protect | |||
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE HYDROCHLORIDE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d2ddc491-88a9-4063-9150-443b4fa4330c | 1 | GoF | protect | |||
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE HYDROCHLORIDE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d2ddc491-88a9-4063-9150-443b4fa4330c | 1 | GoF | protect | |||
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE HYDROCHLORIDE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=482cef76-0623-4b4f-a0ea-f008c97b2281 | 1 | GoF | protect | |||
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE HYDROCHLORIDE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=482cef76-0623-4b4f-a0ea-f008c97b2281 | 1 | GoF | protect | |||
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE HYDROCHLORIDE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=482cef76-0623-4b4f-a0ea-f008c97b2281 | 1 | GoF | protect | |||
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE HYDROCHLORIDE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=482cef76-0623-4b4f-a0ea-f008c97b2281 | 1 | GoF | protect | |||
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE HYDROCHLORIDE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=482cef76-0623-4b4f-a0ea-f008c97b2281 | 1 | GoF | protect | |||
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE HYDROCHLORIDE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=482cef76-0623-4b4f-a0ea-f008c97b2281 | 1 | GoF | protect | |||
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE HYDROCHLORIDE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1f93fa66-c086-4811-a9ae-7b76bfafef2b | 1 | GoF | protect | |||
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE HYDROCHLORIDE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1f93fa66-c086-4811-a9ae-7b76bfafef2b | 1 | GoF | protect | |||
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE HYDROCHLORIDE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1f93fa66-c086-4811-a9ae-7b76bfafef2b | 1 | GoF | protect | |||
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE HYDROCHLORIDE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1f93fa66-c086-4811-a9ae-7b76bfafef2b | 1 | GoF | protect | |||
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE HYDROCHLORIDE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1f93fa66-c086-4811-a9ae-7b76bfafef2b | 1 | GoF | protect | |||
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE HYDROCHLORIDE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1f93fa66-c086-4811-a9ae-7b76bfafef2b | 1 | GoF | protect | |||
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE HYDROCHLORIDE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=730f747a-850d-4a81-89e2-200007a5db5a | 1 | GoF | protect | |||
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE HYDROCHLORIDE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=730f747a-850d-4a81-89e2-200007a5db5a | 1 | GoF | protect | |||
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE HYDROCHLORIDE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=730f747a-850d-4a81-89e2-200007a5db5a | 1 | GoF | protect | |||
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE HYDROCHLORIDE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=730f747a-850d-4a81-89e2-200007a5db5a | 1 | GoF | protect | |||
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE HYDROCHLORIDE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=730f747a-850d-4a81-89e2-200007a5db5a | 1 | GoF | protect | |||
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE HYDROCHLORIDE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=730f747a-850d-4a81-89e2-200007a5db5a | 1 | GoF | protect | |||
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE HYDROCHLORIDE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7547c308-3c83-429c-b761-0610d775317d | 1 | GoF | protect | |||
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE HYDROCHLORIDE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7547c308-3c83-429c-b761-0610d775317d | 1 | GoF | protect | |||
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE HYDROCHLORIDE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7547c308-3c83-429c-b761-0610d775317d | 1 | GoF | protect | |||
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE HYDROCHLORIDE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7547c308-3c83-429c-b761-0610d775317d | 1 | GoF | protect | |||
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE HYDROCHLORIDE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7547c308-3c83-429c-b761-0610d775317d | 1 | GoF | protect | |||
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE HYDROCHLORIDE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7547c308-3c83-429c-b761-0610d775317d | 1 | GoF | protect | |||
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE HYDROCHLORIDE | targetBased | 4 | https://www.ema.europa.eu/en/medicines/human/EPAR/glidipion | 1 | GoF | protect | |||
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE HYDROCHLORIDE | targetBased | 4 | https://www.ema.europa.eu/en/medicines/human/EPAR/glidipion | 1 | GoF | protect | |||
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE HYDROCHLORIDE | targetBased | 4 | https://www.ema.europa.eu/en/medicines/human/EPAR/glidipion | 1 | GoF | protect | |||
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE HYDROCHLORIDE | targetBased | 4 | https://www.ema.europa.eu/en/medicines/human/EPAR/glidipion | 1 | GoF | protect | |||
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE HYDROCHLORIDE | targetBased | 4 | https://www.ema.europa.eu/en/medicines/human/EPAR/glidipion | 1 | GoF | protect | |||
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE HYDROCHLORIDE | targetBased | 4 | https://www.ema.europa.eu/en/medicines/human/EPAR/glidipion | 1 | GoF | protect | |||
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE HYDROCHLORIDE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a3ae5cba-f495-4593-b8fc-5ada34790745 | 1 | GoF | protect | |||
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE HYDROCHLORIDE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a3ae5cba-f495-4593-b8fc-5ada34790745 | 1 | GoF | protect | |||
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE HYDROCHLORIDE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a3ae5cba-f495-4593-b8fc-5ada34790745 | 1 | GoF | protect | |||
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE HYDROCHLORIDE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a3ae5cba-f495-4593-b8fc-5ada34790745 | 1 | GoF | protect | |||
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE HYDROCHLORIDE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a3ae5cba-f495-4593-b8fc-5ada34790745 | 1 | GoF | protect | |||
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE HYDROCHLORIDE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a3ae5cba-f495-4593-b8fc-5ada34790745 | 1 | GoF | protect | |||
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE HYDROCHLORIDE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1fa2703e-fb73-44d5-aaa2-b12b1090d42c | 1 | GoF | protect | |||
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE HYDROCHLORIDE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1fa2703e-fb73-44d5-aaa2-b12b1090d42c | 1 | GoF | protect | |||
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE HYDROCHLORIDE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1fa2703e-fb73-44d5-aaa2-b12b1090d42c | 1 | GoF | protect | |||
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE HYDROCHLORIDE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1fa2703e-fb73-44d5-aaa2-b12b1090d42c | 1 | GoF | protect | |||
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE HYDROCHLORIDE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1fa2703e-fb73-44d5-aaa2-b12b1090d42c | 1 | GoF | protect | |||
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE HYDROCHLORIDE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1fa2703e-fb73-44d5-aaa2-b12b1090d42c | 1 | GoF | protect | |||
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE HYDROCHLORIDE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f4ca7537-ed49-4dee-9003-48dc001a9dc1 | 1 | GoF | protect | |||
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE HYDROCHLORIDE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f4ca7537-ed49-4dee-9003-48dc001a9dc1 | 1 | GoF | protect | |||
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE HYDROCHLORIDE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f4ca7537-ed49-4dee-9003-48dc001a9dc1 | 1 | GoF | protect | |||
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE HYDROCHLORIDE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f4ca7537-ed49-4dee-9003-48dc001a9dc1 | 1 | GoF | protect | |||
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE HYDROCHLORIDE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f4ca7537-ed49-4dee-9003-48dc001a9dc1 | 1 | GoF | protect | |||
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE HYDROCHLORIDE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f4ca7537-ed49-4dee-9003-48dc001a9dc1 | 1 | GoF | protect | |||
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE HYDROCHLORIDE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f8b0c917-3fdd-4a28-a47d-6225b8195458 | 1 | GoF | protect | |||
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE HYDROCHLORIDE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f8b0c917-3fdd-4a28-a47d-6225b8195458 | 1 | GoF | protect | |||
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE HYDROCHLORIDE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f8b0c917-3fdd-4a28-a47d-6225b8195458 | 1 | GoF | protect | |||
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE HYDROCHLORIDE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f8b0c917-3fdd-4a28-a47d-6225b8195458 | 1 | GoF | protect | |||
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE HYDROCHLORIDE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f8b0c917-3fdd-4a28-a47d-6225b8195458 | 1 | GoF | protect | |||
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE HYDROCHLORIDE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f8b0c917-3fdd-4a28-a47d-6225b8195458 | 1 | GoF | protect | |||
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE HYDROCHLORIDE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2aab19ce-1e5e-44ee-85e5-d8f125f9bb1a | 1 | GoF | protect | |||
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE HYDROCHLORIDE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2aab19ce-1e5e-44ee-85e5-d8f125f9bb1a | 1 | GoF | protect | |||
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE HYDROCHLORIDE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2aab19ce-1e5e-44ee-85e5-d8f125f9bb1a | 1 | GoF | protect | |||
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE HYDROCHLORIDE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2aab19ce-1e5e-44ee-85e5-d8f125f9bb1a | 1 | GoF | protect | |||
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE HYDROCHLORIDE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2aab19ce-1e5e-44ee-85e5-d8f125f9bb1a | 1 | GoF | protect | |||
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE HYDROCHLORIDE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2aab19ce-1e5e-44ee-85e5-d8f125f9bb1a | 1 | GoF | protect | |||
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE HYDROCHLORIDE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5c81c67-90cf-4e64-acb5-58b0358fa742 | 1 | GoF | protect | |||
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE HYDROCHLORIDE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5c81c67-90cf-4e64-acb5-58b0358fa742 | 1 | GoF | protect | |||
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE HYDROCHLORIDE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5c81c67-90cf-4e64-acb5-58b0358fa742 | 1 | GoF | protect | |||
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE HYDROCHLORIDE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5c81c67-90cf-4e64-acb5-58b0358fa742 | 1 | GoF | protect | |||
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE HYDROCHLORIDE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5c81c67-90cf-4e64-acb5-58b0358fa742 | 1 | GoF | protect | |||
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE HYDROCHLORIDE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5c81c67-90cf-4e64-acb5-58b0358fa742 | 1 | GoF | protect | |||
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE HYDROCHLORIDE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a3fcf590-64a7-4d6e-8b5a-ee637675f716 | 1 | GoF | protect | |||
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE HYDROCHLORIDE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a3fcf590-64a7-4d6e-8b5a-ee637675f716 | 1 | GoF | protect | |||
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE HYDROCHLORIDE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a3fcf590-64a7-4d6e-8b5a-ee637675f716 | 1 | GoF | protect | |||
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE HYDROCHLORIDE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a3fcf590-64a7-4d6e-8b5a-ee637675f716 | 1 | GoF | protect | |||
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE HYDROCHLORIDE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a3fcf590-64a7-4d6e-8b5a-ee637675f716 | 1 | GoF | protect | |||
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE HYDROCHLORIDE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a3fcf590-64a7-4d6e-8b5a-ee637675f716 | 1 | GoF | protect | |||
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE HYDROCHLORIDE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c7dbc36d-3c84-488e-9b72-0593b5ed53a0 | 1 | GoF | protect | |||
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE HYDROCHLORIDE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c7dbc36d-3c84-488e-9b72-0593b5ed53a0 | 1 | GoF | protect | |||
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE HYDROCHLORIDE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c7dbc36d-3c84-488e-9b72-0593b5ed53a0 | 1 | GoF | protect | |||
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE HYDROCHLORIDE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c7dbc36d-3c84-488e-9b72-0593b5ed53a0 | 1 | GoF | protect | |||
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE HYDROCHLORIDE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c7dbc36d-3c84-488e-9b72-0593b5ed53a0 | 1 | GoF | protect | |||
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE HYDROCHLORIDE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c7dbc36d-3c84-488e-9b72-0593b5ed53a0 | 1 | GoF | protect | |||
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE HYDROCHLORIDE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4c619ed9-fe3e-4158-9938-80c6c3493d55 | 1 | GoF | protect | |||
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE HYDROCHLORIDE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4c619ed9-fe3e-4158-9938-80c6c3493d55 | 1 | GoF | protect | |||
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE HYDROCHLORIDE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4c619ed9-fe3e-4158-9938-80c6c3493d55 | 1 | GoF | protect | |||
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE HYDROCHLORIDE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4c619ed9-fe3e-4158-9938-80c6c3493d55 | 1 | GoF | protect | |||
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE HYDROCHLORIDE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4c619ed9-fe3e-4158-9938-80c6c3493d55 | 1 | GoF | protect | |||
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE HYDROCHLORIDE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4c619ed9-fe3e-4158-9938-80c6c3493d55 | 1 | GoF | protect | |||
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE HYDROCHLORIDE | targetBased | 3 | Terminated | 14/11/2007 | https://clinicaltrials.gov/study/NCT00571519 | 0.7 | GoF | protect | DSPD focusing on Study 301 to confirm the clinical profile before proceeding. Daiichi Sankyo Pharma Development terminated this study on 23 Apr 2008 because of changes in the clinical development plan with 94 of 2600 planned, randomized participants. |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE HYDROCHLORIDE | targetBased | 3 | Terminated | 14/11/2007 | https://clinicaltrials.gov/study/NCT00571519 | 0.7 | GoF | protect | DSPD focusing on Study 301 to confirm the clinical profile before proceeding. Daiichi Sankyo Pharma Development terminated this study on 23 Apr 2008 because of changes in the clinical development plan with 94 of 2600 planned, randomized participants. |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE HYDROCHLORIDE | targetBased | 3 | Terminated | 14/11/2007 | https://clinicaltrials.gov/study/NCT00571519 | 0.7 | GoF | protect | DSPD focusing on Study 301 to confirm the clinical profile before proceeding. Daiichi Sankyo Pharma Development terminated this study on 23 Apr 2008 because of changes in the clinical development plan with 94 of 2600 planned, randomized participants. |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE HYDROCHLORIDE | targetBased | 3 | Terminated | 14/11/2007 | https://clinicaltrials.gov/study/NCT00571519 | 0.7 | GoF | protect | DSPD focusing on Study 301 to confirm the clinical profile before proceeding. Daiichi Sankyo Pharma Development terminated this study on 23 Apr 2008 because of changes in the clinical development plan with 94 of 2600 planned, randomized participants. |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE HYDROCHLORIDE | targetBased | 3 | Terminated | 14/11/2007 | https://clinicaltrials.gov/study/NCT00571519 | 0.7 | GoF | protect | DSPD focusing on Study 301 to confirm the clinical profile before proceeding. Daiichi Sankyo Pharma Development terminated this study on 23 Apr 2008 because of changes in the clinical development plan with 94 of 2600 planned, randomized participants. |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE HYDROCHLORIDE | targetBased | 3 | Terminated | 14/11/2007 | https://clinicaltrials.gov/study/NCT00571519 | 0.7 | GoF | protect | DSPD focusing on Study 301 to confirm the clinical profile before proceeding. Daiichi Sankyo Pharma Development terminated this study on 23 Apr 2008 because of changes in the clinical development plan with 94 of 2600 planned, randomized participants. |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE HYDROCHLORIDE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=fd156adc-3174-44da-bff7-eeaef5983f18 | 1 | GoF | protect | |||
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE HYDROCHLORIDE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=fd156adc-3174-44da-bff7-eeaef5983f18 | 1 | GoF | protect | |||
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE HYDROCHLORIDE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=fd156adc-3174-44da-bff7-eeaef5983f18 | 1 | GoF | protect | |||
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE HYDROCHLORIDE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=fd156adc-3174-44da-bff7-eeaef5983f18 | 1 | GoF | protect | |||
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE HYDROCHLORIDE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=fd156adc-3174-44da-bff7-eeaef5983f18 | 1 | GoF | protect | |||
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE HYDROCHLORIDE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=fd156adc-3174-44da-bff7-eeaef5983f18 | 1 | GoF | protect | |||
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE HYDROCHLORIDE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=73e92590-87c0-4087-839e-d1aff2851a06 | 1 | GoF | protect | |||
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE HYDROCHLORIDE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=73e92590-87c0-4087-839e-d1aff2851a06 | 1 | GoF | protect | |||
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE HYDROCHLORIDE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=73e92590-87c0-4087-839e-d1aff2851a06 | 1 | GoF | protect | |||
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE HYDROCHLORIDE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=73e92590-87c0-4087-839e-d1aff2851a06 | 1 | GoF | protect | |||
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE HYDROCHLORIDE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=73e92590-87c0-4087-839e-d1aff2851a06 | 1 | GoF | protect | |||
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE HYDROCHLORIDE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=73e92590-87c0-4087-839e-d1aff2851a06 | 1 | GoF | protect | |||
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE HYDROCHLORIDE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b73e5856-e6f5-4239-80d9-fda136c4748b | 1 | GoF | protect | |||
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE HYDROCHLORIDE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b73e5856-e6f5-4239-80d9-fda136c4748b | 1 | GoF | protect | |||
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE HYDROCHLORIDE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b73e5856-e6f5-4239-80d9-fda136c4748b | 1 | GoF | protect | |||
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE HYDROCHLORIDE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b73e5856-e6f5-4239-80d9-fda136c4748b | 1 | GoF | protect | |||
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE HYDROCHLORIDE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b73e5856-e6f5-4239-80d9-fda136c4748b | 1 | GoF | protect | |||
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE HYDROCHLORIDE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b73e5856-e6f5-4239-80d9-fda136c4748b | 1 | GoF | protect | |||
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE HYDROCHLORIDE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=42e49120-6f3f-11db-9fe1-0800200c9a66 | 1 | GoF | protect | |||
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE HYDROCHLORIDE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=42e49120-6f3f-11db-9fe1-0800200c9a66 | 1 | GoF | protect | |||
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE HYDROCHLORIDE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=42e49120-6f3f-11db-9fe1-0800200c9a66 | 1 | GoF | protect | |||
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE HYDROCHLORIDE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=42e49120-6f3f-11db-9fe1-0800200c9a66 | 1 | GoF | protect | |||
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE HYDROCHLORIDE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=42e49120-6f3f-11db-9fe1-0800200c9a66 | 1 | GoF | protect | |||
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE HYDROCHLORIDE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=42e49120-6f3f-11db-9fe1-0800200c9a66 | 1 | GoF | protect | |||
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE HYDROCHLORIDE | targetBased | 3 | Completed | 05/09/2008 | https://clinicaltrials.gov/study/NCT00722371 | 0.7 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE HYDROCHLORIDE | targetBased | 3 | Completed | 05/09/2008 | https://clinicaltrials.gov/study/NCT00722371 | 0.7 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE HYDROCHLORIDE | targetBased | 3 | Completed | 05/09/2008 | https://clinicaltrials.gov/study/NCT00722371 | 0.7 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE HYDROCHLORIDE | targetBased | 3 | Completed | 05/09/2008 | https://clinicaltrials.gov/study/NCT00722371 | 0.7 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE HYDROCHLORIDE | targetBased | 3 | Completed | 05/09/2008 | https://clinicaltrials.gov/study/NCT00722371 | 0.7 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE HYDROCHLORIDE | targetBased | 3 | Completed | 05/09/2008 | https://clinicaltrials.gov/study/NCT00722371 | 0.7 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE HYDROCHLORIDE | targetBased | 4 | Completed | 01/11/2008 | https://clinicaltrials.gov/study/NCT01589445 | 1 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE HYDROCHLORIDE | targetBased | 4 | Completed | 01/11/2008 | https://clinicaltrials.gov/study/NCT01589445 | 1 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE HYDROCHLORIDE | targetBased | 4 | Completed | 01/11/2008 | https://clinicaltrials.gov/study/NCT01589445 | 1 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE HYDROCHLORIDE | targetBased | 4 | Completed | 01/11/2008 | https://clinicaltrials.gov/study/NCT01589445 | 1 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE HYDROCHLORIDE | targetBased | 4 | Completed | 01/11/2008 | https://clinicaltrials.gov/study/NCT01589445 | 1 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE HYDROCHLORIDE | targetBased | 4 | Completed | 01/11/2008 | https://clinicaltrials.gov/study/NCT01589445 | 1 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE HYDROCHLORIDE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7f6e4b4d-7480-444f-e053-2a91aa0a62ec | 1 | GoF | protect | |||
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE HYDROCHLORIDE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7f6e4b4d-7480-444f-e053-2a91aa0a62ec | 1 | GoF | protect | |||
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE HYDROCHLORIDE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7f6e4b4d-7480-444f-e053-2a91aa0a62ec | 1 | GoF | protect | |||
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE HYDROCHLORIDE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7f6e4b4d-7480-444f-e053-2a91aa0a62ec | 1 | GoF | protect | |||
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE HYDROCHLORIDE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7f6e4b4d-7480-444f-e053-2a91aa0a62ec | 1 | GoF | protect | |||
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE HYDROCHLORIDE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7f6e4b4d-7480-444f-e053-2a91aa0a62ec | 1 | GoF | protect | |||
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE HYDROCHLORIDE | targetBased | 4 | Completed | 01/03/2014 | https://clinicaltrials.gov/study/NCT01919489 | 1 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE HYDROCHLORIDE | targetBased | 4 | Completed | 01/03/2014 | https://clinicaltrials.gov/study/NCT01919489 | 1 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE HYDROCHLORIDE | targetBased | 4 | Completed | 01/03/2014 | https://clinicaltrials.gov/study/NCT01919489 | 1 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE HYDROCHLORIDE | targetBased | 4 | Completed | 01/03/2014 | https://clinicaltrials.gov/study/NCT01919489 | 1 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE HYDROCHLORIDE | targetBased | 4 | Completed | 01/03/2014 | https://clinicaltrials.gov/study/NCT01919489 | 1 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE HYDROCHLORIDE | targetBased | 4 | Completed | 01/03/2014 | https://clinicaltrials.gov/study/NCT01919489 | 1 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE HYDROCHLORIDE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5e36173a-2b5f-4ed7-bf81-6e79d78df0c4 | 1 | GoF | protect | |||
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE HYDROCHLORIDE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5e36173a-2b5f-4ed7-bf81-6e79d78df0c4 | 1 | GoF | protect | |||
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE HYDROCHLORIDE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5e36173a-2b5f-4ed7-bf81-6e79d78df0c4 | 1 | GoF | protect | |||
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE HYDROCHLORIDE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5e36173a-2b5f-4ed7-bf81-6e79d78df0c4 | 1 | GoF | protect | |||
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE HYDROCHLORIDE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5e36173a-2b5f-4ed7-bf81-6e79d78df0c4 | 1 | GoF | protect | |||
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE HYDROCHLORIDE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5e36173a-2b5f-4ed7-bf81-6e79d78df0c4 | 1 | GoF | protect | |||
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE HYDROCHLORIDE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=237d8fa2-633c-4c29-84d3-f1b413610dc3 | 1 | GoF | protect | |||
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE HYDROCHLORIDE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=237d8fa2-633c-4c29-84d3-f1b413610dc3 | 1 | GoF | protect | |||
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE HYDROCHLORIDE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=237d8fa2-633c-4c29-84d3-f1b413610dc3 | 1 | GoF | protect | |||
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE HYDROCHLORIDE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=237d8fa2-633c-4c29-84d3-f1b413610dc3 | 1 | GoF | protect | |||
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE HYDROCHLORIDE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=237d8fa2-633c-4c29-84d3-f1b413610dc3 | 1 | GoF | protect | |||
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE HYDROCHLORIDE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=237d8fa2-633c-4c29-84d3-f1b413610dc3 | 1 | GoF | protect | |||
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE HYDROCHLORIDE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8f2d7000-37ca-4e09-98ec-07d1c0354cb3 | 1 | GoF | protect | |||
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE HYDROCHLORIDE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8f2d7000-37ca-4e09-98ec-07d1c0354cb3 | 1 | GoF | protect | |||
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE HYDROCHLORIDE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8f2d7000-37ca-4e09-98ec-07d1c0354cb3 | 1 | GoF | protect | |||
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE HYDROCHLORIDE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8f2d7000-37ca-4e09-98ec-07d1c0354cb3 | 1 | GoF | protect | |||
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE HYDROCHLORIDE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8f2d7000-37ca-4e09-98ec-07d1c0354cb3 | 1 | GoF | protect | |||
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE HYDROCHLORIDE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8f2d7000-37ca-4e09-98ec-07d1c0354cb3 | 1 | GoF | protect | |||
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE HYDROCHLORIDE | targetBased | 4 | https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/021073s046lbl.pdf | 1 | GoF | protect | |||
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE HYDROCHLORIDE | targetBased | 4 | https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/021073s046lbl.pdf | 1 | GoF | protect | |||
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE HYDROCHLORIDE | targetBased | 4 | https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/021073s046lbl.pdf | 1 | GoF | protect | |||
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE HYDROCHLORIDE | targetBased | 4 | https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/021073s046lbl.pdf | 1 | GoF | protect | |||
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE HYDROCHLORIDE | targetBased | 4 | https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/021073s046lbl.pdf | 1 | GoF | protect | |||
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE HYDROCHLORIDE | targetBased | 4 | https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/021073s046lbl.pdf | 1 | GoF | protect | |||
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE HYDROCHLORIDE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1f259863-21fd-4d62-b094-4eff845944df | 1 | GoF | protect | |||
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE HYDROCHLORIDE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1f259863-21fd-4d62-b094-4eff845944df | 1 | GoF | protect | |||
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE HYDROCHLORIDE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1f259863-21fd-4d62-b094-4eff845944df | 1 | GoF | protect | |||
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE HYDROCHLORIDE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1f259863-21fd-4d62-b094-4eff845944df | 1 | GoF | protect | |||
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE HYDROCHLORIDE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1f259863-21fd-4d62-b094-4eff845944df | 1 | GoF | protect | |||
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE HYDROCHLORIDE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1f259863-21fd-4d62-b094-4eff845944df | 1 | GoF | protect | |||
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE HYDROCHLORIDE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4b2ba1fe-5355-4d15-9f07-c3e6fec7181a | 1 | GoF | protect | |||
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE HYDROCHLORIDE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4b2ba1fe-5355-4d15-9f07-c3e6fec7181a | 1 | GoF | protect | |||
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE HYDROCHLORIDE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4b2ba1fe-5355-4d15-9f07-c3e6fec7181a | 1 | GoF | protect | |||
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE HYDROCHLORIDE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4b2ba1fe-5355-4d15-9f07-c3e6fec7181a | 1 | GoF | protect | |||
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE HYDROCHLORIDE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4b2ba1fe-5355-4d15-9f07-c3e6fec7181a | 1 | GoF | protect | |||
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | PIOGLITAZONE HYDROCHLORIDE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4b2ba1fe-5355-4d15-9f07-c3e6fec7181a | 1 | GoF | protect | |||
| HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity | CACNA1D_inhibitors | CACNA1D | Voltage-dependent N-type calcium channel subunit alpha-1B | diabetic nephropathy | NISOLDIPINE | targetBased | 4 | Completed | 01/03/1993 | https://clinicaltrials.gov/study/NCT00311870 | 1 | LoF | protect | |
| Thrombin 1536 HTS | F2_modulation | F2 | Prothrombin | diabetes mellitus | DABIGATRAN ETEXILATE | targetBased | 4 | Recruiting | 05/03/2023 | https://clinicaltrials.gov/study/NCT06273215 | 1 | LoF | protect | |
| Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1) | CHRM1_agonists | CHRM1 | Muscarinic acetylcholine receptor M1 | morbid obesity | SCOPOLAMINE | targetBased | 4 | Recruiting | 20/01/2021 | https://clinicaltrials.gov/study/NCT04240626 | 1 | LoF | protect | |
| Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen | CHRM1_allosteric_activators | CHRM1 | Muscarinic acetylcholine receptor M1 | morbid obesity | SCOPOLAMINE | targetBased | 4 | Recruiting | 20/01/2021 | https://clinicaltrials.gov/study/NCT04240626 | 1 | LoF | protect | |
| Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1). | CHRM1_PAMs | CHRM1 | Muscarinic acetylcholine receptor M1 | morbid obesity | SCOPOLAMINE | targetBased | 4 | Recruiting | 20/01/2021 | https://clinicaltrials.gov/study/NCT04240626 | 1 | LoF | protect | |
| Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen | CHRM1_allosteric_antagonists | CHRM1 | Muscarinic acetylcholine receptor M1 | morbid obesity | SCOPOLAMINE | targetBased | 4 | Recruiting | 20/01/2021 | https://clinicaltrials.gov/study/NCT04240626 | 1 | LoF | protect | |
| Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1) | CHRM1_antgonists | CHRM1 | Muscarinic acetylcholine receptor M1 | morbid obesity | SCOPOLAMINE | targetBased | 4 | Recruiting | 20/01/2021 | https://clinicaltrials.gov/study/NCT04240626 | 1 | LoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | diabetes mellitus | IMIGLITAZAR | targetBased | 3 | Completed | 01/11/2003 | https://clinicaltrials.gov/study/NCT00763022 | 0.7 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | diabetes mellitus | IMIGLITAZAR | targetBased | 3 | Completed | 01/11/2003 | https://clinicaltrials.gov/study/NCT00763022 | 0.7 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | diabetes mellitus | IMIGLITAZAR | targetBased | 3 | Completed | 01/11/2003 | https://clinicaltrials.gov/study/NCT00763022 | 0.7 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | diabetes mellitus | IMIGLITAZAR | targetBased | 3 | Completed | 01/11/2003 | https://clinicaltrials.gov/study/NCT00763022 | 0.7 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | diabetes mellitus | IMIGLITAZAR | targetBased | 3 | Completed | 01/11/2003 | https://clinicaltrials.gov/study/NCT00763022 | 0.7 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | diabetes mellitus | IMIGLITAZAR | targetBased | 3 | Completed | 01/11/2003 | https://clinicaltrials.gov/study/NCT00763022 | 0.7 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | diabetes mellitus | IMIGLITAZAR | targetBased | 3 | Terminated | 01/11/2004 | https://clinicaltrials.gov/study/NCT00762684 | 0.35 | GoF | protect | Hepatic safety signal identified. |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | diabetes mellitus | IMIGLITAZAR | targetBased | 3 | Terminated | 01/11/2004 | https://clinicaltrials.gov/study/NCT00762684 | 0.35 | GoF | protect | Hepatic safety signal identified. |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | diabetes mellitus | IMIGLITAZAR | targetBased | 3 | Terminated | 01/11/2004 | https://clinicaltrials.gov/study/NCT00762684 | 0.35 | GoF | protect | Hepatic safety signal identified. |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | diabetes mellitus | IMIGLITAZAR | targetBased | 3 | Terminated | 01/11/2004 | https://clinicaltrials.gov/study/NCT00762684 | 0.35 | GoF | protect | Hepatic safety signal identified. |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | diabetes mellitus | IMIGLITAZAR | targetBased | 3 | Terminated | 01/11/2004 | https://clinicaltrials.gov/study/NCT00762684 | 0.35 | GoF | protect | Hepatic safety signal identified. |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | diabetes mellitus | IMIGLITAZAR | targetBased | 3 | Terminated | 01/11/2004 | https://clinicaltrials.gov/study/NCT00762684 | 0.35 | GoF | protect | Hepatic safety signal identified. |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | diabetes mellitus | IMIGLITAZAR | targetBased | 3 | Terminated | 01/11/2003 | https://clinicaltrials.gov/study/NCT00762112 | 0.35 | GoF | protect | Hepatic safety signal identified. |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | diabetes mellitus | IMIGLITAZAR | targetBased | 3 | Terminated | 01/11/2003 | https://clinicaltrials.gov/study/NCT00762112 | 0.35 | GoF | protect | Hepatic safety signal identified. |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | diabetes mellitus | IMIGLITAZAR | targetBased | 3 | Terminated | 01/11/2003 | https://clinicaltrials.gov/study/NCT00762112 | 0.35 | GoF | protect | Hepatic safety signal identified. |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | diabetes mellitus | IMIGLITAZAR | targetBased | 3 | Terminated | 01/11/2003 | https://clinicaltrials.gov/study/NCT00762112 | 0.35 | GoF | protect | Hepatic safety signal identified. |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | diabetes mellitus | IMIGLITAZAR | targetBased | 3 | Terminated | 01/11/2003 | https://clinicaltrials.gov/study/NCT00762112 | 0.35 | GoF | protect | Hepatic safety signal identified. |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | diabetes mellitus | IMIGLITAZAR | targetBased | 3 | Terminated | 01/11/2003 | https://clinicaltrials.gov/study/NCT00762112 | 0.35 | GoF | protect | Hepatic safety signal identified. |
| High Throughput Screening for Cocaine Antagonists: Primary Screen | SLC6A3 | SLC6A3 | Sodium-dependent dopamine transporter | obesity | DIETHYLPROPION | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3ecb7bd7-e04c-47fe-859a-8ba8a54f9aff | 1 | LoF | protect | |||
| High Throughput Screening for Cocaine Antagonists: Primary Screen | SLC6A3 | SLC6A3 | Sodium-dependent dopamine transporter | obesity | DIETHYLPROPION | targetBased | 4 | https://www.whocc.no/atc_ddd_index/?code=A08AA03 | 1 | LoF | protect | |||
| High Throughput Screening for Cocaine Antagonists: Primary Screen | SLC6A3 | SLC6A3 | Sodium-dependent dopamine transporter | obesity | DIETHYLPROPION | targetBased | 4 | Terminated | 01/07/2005 | https://clinicaltrials.gov/study/NCT00115063 | 0.5 | LoF | protect | ethical issues of continuing control group without treatment |
| HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity | CACNA1D_inhibitors | CACNA1D | Voltage-dependent N-type calcium channel subunit alpha-1B | familial hypercholesterolemia | AMLODIPINE BESYLATE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=909fad96-a941-443a-a39f-4f93607410fb | 1 | LoF | protect | |||
| HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity | CACNA1D_inhibitors | CACNA1D | Voltage-dependent N-type calcium channel subunit alpha-1B | diabetes mellitus | AMLODIPINE BESYLATE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=01139e81-a4fa-4e13-acdf-c75c79a1aa9c | 1 | LoF | protect | |||
| HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity | CACNA1D_inhibitors | CACNA1D | Voltage-dependent N-type calcium channel subunit alpha-1B | diabetes mellitus | AMLODIPINE BESYLATE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d0caec89-96ec-411d-a933-63eda74a6da7 | 1 | LoF | protect | |||
| HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity | CACNA1D_inhibitors | CACNA1D | Voltage-dependent N-type calcium channel subunit alpha-1B | diabetes mellitus | AMLODIPINE BESYLATE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5562b3f5-8757-11de-8a39-0800200c9a66 | 1 | LoF | protect | |||
| HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity | CACNA1D_inhibitors | CACNA1D | Voltage-dependent N-type calcium channel subunit alpha-1B | diabetes mellitus | AMLODIPINE BESYLATE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f48911e0-705f-11dc-afc9-0002a5d5c51b | 1 | LoF | protect | |||
| HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity | CACNA1D_inhibitors | CACNA1D | Voltage-dependent N-type calcium channel subunit alpha-1B | diabetes mellitus | AMLODIPINE BESYLATE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b18686fa-be94-472e-8404-c69e6869ed10 | 1 | LoF | protect | |||
| HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity | CACNA1D_inhibitors | CACNA1D | Voltage-dependent N-type calcium channel subunit alpha-1B | diabetes mellitus | AMLODIPINE BESYLATE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=18d7820d-471f-4ee2-9ec6-25d8d27c77de | 1 | LoF | protect | |||
| HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity | CACNA1D_inhibitors | CACNA1D | Voltage-dependent N-type calcium channel subunit alpha-1B | hyperlipidemia | AMLODIPINE BESYLATE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6f1a9bd8-ee30-4c7d-932f-3fa8c4e087b6 | 1 | LoF | protect | |||
| HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity | CACNA1D_inhibitors | CACNA1D | Voltage-dependent N-type calcium channel subunit alpha-1B | hyperlipidemia | AMLODIPINE BESYLATE | targetBased | 4 | Completed | 05/07/2018 | https://clinicaltrials.gov/study/NCT03847506 | 1 | LoF | protect | |
| HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity | CACNA1D_inhibitors | CACNA1D | Voltage-dependent N-type calcium channel subunit alpha-1B | hyperlipidemia | AMLODIPINE BESYLATE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=909fad96-a941-443a-a39f-4f93607410fb | 1 | LoF | protect | |||
| HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity | CACNA1D_inhibitors | CACNA1D | Voltage-dependent N-type calcium channel subunit alpha-1B | hyperlipidemia | AMLODIPINE BESYLATE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=062bf1a0-9a29-4dee-a8cb-f0d051f4c0b1 | 1 | LoF | protect | |||
| HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity | CACNA1D_inhibitors | CACNA1D | Voltage-dependent N-type calcium channel subunit alpha-1B | hyperlipidemia | AMLODIPINE BESYLATE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2f568859-64e6-454f-801b-c0a0a647dc3d | 1 | LoF | protect | |||
| HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity | CACNA1D_inhibitors | CACNA1D | Voltage-dependent N-type calcium channel subunit alpha-1B | hyperlipidemia | AMLODIPINE BESYLATE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=abee4a34-89cc-d886-192c-32582ab8f024 | 1 | LoF | protect | |||
| HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity | CACNA1D_inhibitors | CACNA1D | Voltage-dependent N-type calcium channel subunit alpha-1B | hyperlipidemia | AMLODIPINE BESYLATE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4be76756-4114-4d50-a36c-fd410f6c773d | 1 | LoF | protect | |||
| HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity | CACNA1D_inhibitors | CACNA1D | Voltage-dependent N-type calcium channel subunit alpha-1B | hyperlipidemia | AMLODIPINE BESYLATE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d2d28679-a01b-4e63-90e2-d5c23b393c94 | 1 | LoF | protect | |||
| HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity | CACNA1D_inhibitors | CACNA1D | Voltage-dependent N-type calcium channel subunit alpha-1B | Hypercholesterolemia | AMLODIPINE BESYLATE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=909fad96-a941-443a-a39f-4f93607410fb | 1 | LoF | protect | |||
| qHTS of D3 Dopamine Receptor Antagonist: qHTS | D3_antagonists | DRD3 | Dopaminereceptor3 | hyperprolactinemia | BROMOCRIPTINE MESYLATE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d69003ee-0b6f-47a9-834e-ba59c02f566c | 1 | GoF | protect | |||
| qHTS of D3 Dopamine Receptor Agonist: qHTS | D3_agonists | DRD3 | Dopaminereceptor3 | hyperprolactinemia | BROMOCRIPTINE MESYLATE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d69003ee-0b6f-47a9-834e-ba59c02f566c | 1 | GoF | protect | |||
| qHTS of D3 Dopamine Receptor Potentiators: qHTS | D3_PAMs | DRD3 | Dopaminereceptor3 | hyperprolactinemia | BROMOCRIPTINE MESYLATE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d69003ee-0b6f-47a9-834e-ba59c02f566c | 1 | GoF | protect | |||
| qHTS of D3 Dopamine Receptor Antagonist: qHTS | D3_antagonists | DRD3 | Dopaminereceptor3 | hyperprolactinemia | BROMOCRIPTINE MESYLATE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=97e7e051-ff64-4381-a869-6c1c364ad822 | 1 | GoF | protect | |||
| qHTS of D3 Dopamine Receptor Agonist: qHTS | D3_agonists | DRD3 | Dopaminereceptor3 | hyperprolactinemia | BROMOCRIPTINE MESYLATE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=97e7e051-ff64-4381-a869-6c1c364ad822 | 1 | GoF | protect | |||
| qHTS of D3 Dopamine Receptor Potentiators: qHTS | D3_PAMs | DRD3 | Dopaminereceptor3 | hyperprolactinemia | BROMOCRIPTINE MESYLATE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=97e7e051-ff64-4381-a869-6c1c364ad822 | 1 | GoF | protect | |||
| qHTS of D3 Dopamine Receptor Antagonist: qHTS | D3_antagonists | DRD3 | Dopaminereceptor3 | hyperprolactinemia | BROMOCRIPTINE MESYLATE | targetBased | 4 | https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/020866s009lbl.pdf | 1 | GoF | protect | |||
| qHTS of D3 Dopamine Receptor Agonist: qHTS | D3_agonists | DRD3 | Dopaminereceptor3 | hyperprolactinemia | BROMOCRIPTINE MESYLATE | targetBased | 4 | https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/020866s009lbl.pdf | 1 | GoF | protect | |||
| qHTS of D3 Dopamine Receptor Potentiators: qHTS | D3_PAMs | DRD3 | Dopaminereceptor3 | hyperprolactinemia | BROMOCRIPTINE MESYLATE | targetBased | 4 | https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/020866s009lbl.pdf | 1 | GoF | protect | |||
| qHTS of D3 Dopamine Receptor Antagonist: qHTS | D3_antagonists | DRD3 | Dopaminereceptor3 | type 2 diabetes mellitus | BROMOCRIPTINE MESYLATE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3e719d6a-342e-428b-93d3-377d31cb15c7 | 1 | GoF | protect | |||
| qHTS of D3 Dopamine Receptor Agonist: qHTS | D3_agonists | DRD3 | Dopaminereceptor3 | type 2 diabetes mellitus | BROMOCRIPTINE MESYLATE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3e719d6a-342e-428b-93d3-377d31cb15c7 | 1 | GoF | protect | |||
| qHTS of D3 Dopamine Receptor Potentiators: qHTS | D3_PAMs | DRD3 | Dopaminereceptor3 | type 2 diabetes mellitus | BROMOCRIPTINE MESYLATE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3e719d6a-342e-428b-93d3-377d31cb15c7 | 1 | GoF | protect | |||
| qHTS of D3 Dopamine Receptor Antagonist: qHTS | D3_antagonists | DRD3 | Dopaminereceptor3 | type 2 diabetes mellitus | BROMOCRIPTINE MESYLATE | targetBased | 4 | Completed | 01/06/2014 | https://clinicaltrials.gov/study/NCT02299050 | 1 | GoF | protect | |
| qHTS of D3 Dopamine Receptor Agonist: qHTS | D3_agonists | DRD3 | Dopaminereceptor3 | type 2 diabetes mellitus | BROMOCRIPTINE MESYLATE | targetBased | 4 | Completed | 01/06/2014 | https://clinicaltrials.gov/study/NCT02299050 | 1 | GoF | protect | |
| qHTS of D3 Dopamine Receptor Potentiators: qHTS | D3_PAMs | DRD3 | Dopaminereceptor3 | type 2 diabetes mellitus | BROMOCRIPTINE MESYLATE | targetBased | 4 | Completed | 01/06/2014 | https://clinicaltrials.gov/study/NCT02299050 | 1 | GoF | protect | |
| qHTS of D3 Dopamine Receptor Antagonist: qHTS | D3_antagonists | DRD3 | Dopaminereceptor3 | type 2 diabetes mellitus | BROMOCRIPTINE MESYLATE | targetBased | 3 | Completed | 01/07/2004 | https://clinicaltrials.gov/study/NCT00377676 | 0.7 | GoF | protect | |
| qHTS of D3 Dopamine Receptor Agonist: qHTS | D3_agonists | DRD3 | Dopaminereceptor3 | type 2 diabetes mellitus | BROMOCRIPTINE MESYLATE | targetBased | 3 | Completed | 01/07/2004 | https://clinicaltrials.gov/study/NCT00377676 | 0.7 | GoF | protect | |
| qHTS of D3 Dopamine Receptor Potentiators: qHTS | D3_PAMs | DRD3 | Dopaminereceptor3 | type 2 diabetes mellitus | BROMOCRIPTINE MESYLATE | targetBased | 3 | Completed | 01/07/2004 | https://clinicaltrials.gov/study/NCT00377676 | 0.7 | GoF | protect | |
| qHTS of D3 Dopamine Receptor Antagonist: qHTS | D3_antagonists | DRD3 | Dopaminereceptor3 | type 2 diabetes mellitus | BROMOCRIPTINE MESYLATE | targetBased | 3 | Terminated | 01/02/2005 | https://clinicaltrials.gov/study/NCT00441363 | 0.7 | GoF | protect | Failure to Recruit in a Timely manner |
| qHTS of D3 Dopamine Receptor Agonist: qHTS | D3_agonists | DRD3 | Dopaminereceptor3 | type 2 diabetes mellitus | BROMOCRIPTINE MESYLATE | targetBased | 3 | Terminated | 01/02/2005 | https://clinicaltrials.gov/study/NCT00441363 | 0.7 | GoF | protect | Failure to Recruit in a Timely manner |
| qHTS of D3 Dopamine Receptor Potentiators: qHTS | D3_PAMs | DRD3 | Dopaminereceptor3 | type 2 diabetes mellitus | BROMOCRIPTINE MESYLATE | targetBased | 3 | Terminated | 01/02/2005 | https://clinicaltrials.gov/study/NCT00441363 | 0.7 | GoF | protect | Failure to Recruit in a Timely manner |
| Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists | D2_agonists | DRD2 | Dopaminereceptor2 | type 2 diabetes mellitus | BROMOCRIPTINE MESYLATE | targetBased | 3 | Terminated | 01/02/2005 | https://clinicaltrials.gov/study/NCT00441363 | 0.7 | GoF | protect | Failure to Recruit in a Timely manner |
| HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists | D2_agonists | DRD2 | Dopaminereceptor2 | type 2 diabetes mellitus | BROMOCRIPTINE MESYLATE | targetBased | 3 | Terminated | 01/02/2005 | https://clinicaltrials.gov/study/NCT00441363 | 0.7 | GoF | protect | Failure to Recruit in a Timely manner |
| Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators | D2_PAMs | DRD2 | Dopaminereceptor2 | type 2 diabetes mellitus | BROMOCRIPTINE MESYLATE | targetBased | 3 | Terminated | 01/02/2005 | https://clinicaltrials.gov/study/NCT00441363 | 0.7 | GoF | protect | Failure to Recruit in a Timely manner |
| HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators | D2_PAMs | DRD2 | Dopaminereceptor2 | type 2 diabetes mellitus | BROMOCRIPTINE MESYLATE | targetBased | 3 | Terminated | 01/02/2005 | https://clinicaltrials.gov/study/NCT00441363 | 0.7 | GoF | protect | Failure to Recruit in a Timely manner |
| Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists | D2_antagonists | DRD2 | Dopaminereceptor2 | type 2 diabetes mellitus | BROMOCRIPTINE MESYLATE | targetBased | 3 | Terminated | 01/02/2005 | https://clinicaltrials.gov/study/NCT00441363 | 0.7 | GoF | protect | Failure to Recruit in a Timely manner |
| HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists | D2_antagonists | DRD2 | Dopaminereceptor2 | type 2 diabetes mellitus | BROMOCRIPTINE MESYLATE | targetBased | 3 | Terminated | 01/02/2005 | https://clinicaltrials.gov/study/NCT00441363 | 0.7 | GoF | protect | Failure to Recruit in a Timely manner |
| Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists | D2_agonists | DRD2 | Dopaminereceptor2 | type 2 diabetes mellitus | BROMOCRIPTINE MESYLATE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3e719d6a-342e-428b-93d3-377d31cb15c7 | 1 | GoF | protect | |||
| HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists | D2_agonists | DRD2 | Dopaminereceptor2 | type 2 diabetes mellitus | BROMOCRIPTINE MESYLATE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3e719d6a-342e-428b-93d3-377d31cb15c7 | 1 | GoF | protect | |||
| Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators | D2_PAMs | DRD2 | Dopaminereceptor2 | type 2 diabetes mellitus | BROMOCRIPTINE MESYLATE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3e719d6a-342e-428b-93d3-377d31cb15c7 | 1 | GoF | protect | |||
| HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators | D2_PAMs | DRD2 | Dopaminereceptor2 | type 2 diabetes mellitus | BROMOCRIPTINE MESYLATE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3e719d6a-342e-428b-93d3-377d31cb15c7 | 1 | GoF | protect | |||
| Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists | D2_antagonists | DRD2 | Dopaminereceptor2 | type 2 diabetes mellitus | BROMOCRIPTINE MESYLATE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3e719d6a-342e-428b-93d3-377d31cb15c7 | 1 | GoF | protect | |||
| HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists | D2_antagonists | DRD2 | Dopaminereceptor2 | type 2 diabetes mellitus | BROMOCRIPTINE MESYLATE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3e719d6a-342e-428b-93d3-377d31cb15c7 | 1 | GoF | protect | |||
| Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists | D2_agonists | DRD2 | Dopaminereceptor2 | type 2 diabetes mellitus | BROMOCRIPTINE MESYLATE | targetBased | 3 | Completed | 01/07/2004 | https://clinicaltrials.gov/study/NCT00377676 | 0.7 | GoF | protect | |
| HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists | D2_agonists | DRD2 | Dopaminereceptor2 | type 2 diabetes mellitus | BROMOCRIPTINE MESYLATE | targetBased | 3 | Completed | 01/07/2004 | https://clinicaltrials.gov/study/NCT00377676 | 0.7 | GoF | protect | |
| Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators | D2_PAMs | DRD2 | Dopaminereceptor2 | type 2 diabetes mellitus | BROMOCRIPTINE MESYLATE | targetBased | 3 | Completed | 01/07/2004 | https://clinicaltrials.gov/study/NCT00377676 | 0.7 | GoF | protect | |
| HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators | D2_PAMs | DRD2 | Dopaminereceptor2 | type 2 diabetes mellitus | BROMOCRIPTINE MESYLATE | targetBased | 3 | Completed | 01/07/2004 | https://clinicaltrials.gov/study/NCT00377676 | 0.7 | GoF | protect | |
| Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists | D2_antagonists | DRD2 | Dopaminereceptor2 | type 2 diabetes mellitus | BROMOCRIPTINE MESYLATE | targetBased | 3 | Completed | 01/07/2004 | https://clinicaltrials.gov/study/NCT00377676 | 0.7 | GoF | protect | |
| HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists | D2_antagonists | DRD2 | Dopaminereceptor2 | type 2 diabetes mellitus | BROMOCRIPTINE MESYLATE | targetBased | 3 | Completed | 01/07/2004 | https://clinicaltrials.gov/study/NCT00377676 | 0.7 | GoF | protect | |
| Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists | D2_agonists | DRD2 | Dopaminereceptor2 | type 2 diabetes mellitus | BROMOCRIPTINE MESYLATE | targetBased | 4 | Completed | 01/06/2014 | https://clinicaltrials.gov/study/NCT02299050 | 1 | GoF | protect | |
| HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists | D2_agonists | DRD2 | Dopaminereceptor2 | type 2 diabetes mellitus | BROMOCRIPTINE MESYLATE | targetBased | 4 | Completed | 01/06/2014 | https://clinicaltrials.gov/study/NCT02299050 | 1 | GoF | protect | |
| Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators | D2_PAMs | DRD2 | Dopaminereceptor2 | type 2 diabetes mellitus | BROMOCRIPTINE MESYLATE | targetBased | 4 | Completed | 01/06/2014 | https://clinicaltrials.gov/study/NCT02299050 | 1 | GoF | protect | |
| HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators | D2_PAMs | DRD2 | Dopaminereceptor2 | type 2 diabetes mellitus | BROMOCRIPTINE MESYLATE | targetBased | 4 | Completed | 01/06/2014 | https://clinicaltrials.gov/study/NCT02299050 | 1 | GoF | protect | |
| Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists | D2_antagonists | DRD2 | Dopaminereceptor2 | type 2 diabetes mellitus | BROMOCRIPTINE MESYLATE | targetBased | 4 | Completed | 01/06/2014 | https://clinicaltrials.gov/study/NCT02299050 | 1 | GoF | protect | |
| HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists | D2_antagonists | DRD2 | Dopaminereceptor2 | type 2 diabetes mellitus | BROMOCRIPTINE MESYLATE | targetBased | 4 | Completed | 01/06/2014 | https://clinicaltrials.gov/study/NCT02299050 | 1 | GoF | protect | |
| Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists | D2_agonists | DRD2 | Dopaminereceptor2 | hyperprolactinemia | BROMOCRIPTINE MESYLATE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=97e7e051-ff64-4381-a869-6c1c364ad822 | 1 | GoF | protect | |||
| HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists | D2_agonists | DRD2 | Dopaminereceptor2 | hyperprolactinemia | BROMOCRIPTINE MESYLATE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=97e7e051-ff64-4381-a869-6c1c364ad822 | 1 | GoF | protect | |||
| Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators | D2_PAMs | DRD2 | Dopaminereceptor2 | hyperprolactinemia | BROMOCRIPTINE MESYLATE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=97e7e051-ff64-4381-a869-6c1c364ad822 | 1 | GoF | protect | |||
| HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators | D2_PAMs | DRD2 | Dopaminereceptor2 | hyperprolactinemia | BROMOCRIPTINE MESYLATE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=97e7e051-ff64-4381-a869-6c1c364ad822 | 1 | GoF | protect | |||
| Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists | D2_antagonists | DRD2 | Dopaminereceptor2 | hyperprolactinemia | BROMOCRIPTINE MESYLATE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=97e7e051-ff64-4381-a869-6c1c364ad822 | 1 | GoF | protect | |||
| HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists | D2_antagonists | DRD2 | Dopaminereceptor2 | hyperprolactinemia | BROMOCRIPTINE MESYLATE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=97e7e051-ff64-4381-a869-6c1c364ad822 | 1 | GoF | protect | |||
| Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists | D2_agonists | DRD2 | Dopaminereceptor2 | hyperprolactinemia | BROMOCRIPTINE MESYLATE | targetBased | 4 | https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/020866s009lbl.pdf | 1 | GoF | protect | |||
| HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists | D2_agonists | DRD2 | Dopaminereceptor2 | hyperprolactinemia | BROMOCRIPTINE MESYLATE | targetBased | 4 | https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/020866s009lbl.pdf | 1 | GoF | protect | |||
| Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators | D2_PAMs | DRD2 | Dopaminereceptor2 | hyperprolactinemia | BROMOCRIPTINE MESYLATE | targetBased | 4 | https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/020866s009lbl.pdf | 1 | GoF | protect | |||
| HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators | D2_PAMs | DRD2 | Dopaminereceptor2 | hyperprolactinemia | BROMOCRIPTINE MESYLATE | targetBased | 4 | https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/020866s009lbl.pdf | 1 | GoF | protect | |||
| Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists | D2_antagonists | DRD2 | Dopaminereceptor2 | hyperprolactinemia | BROMOCRIPTINE MESYLATE | targetBased | 4 | https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/020866s009lbl.pdf | 1 | GoF | protect | |||
| HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists | D2_antagonists | DRD2 | Dopaminereceptor2 | hyperprolactinemia | BROMOCRIPTINE MESYLATE | targetBased | 4 | https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/020866s009lbl.pdf | 1 | GoF | protect | |||
| Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists | D2_agonists | DRD2 | Dopaminereceptor2 | hyperprolactinemia | BROMOCRIPTINE MESYLATE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d69003ee-0b6f-47a9-834e-ba59c02f566c | 1 | GoF | protect | |||
| HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists | D2_agonists | DRD2 | Dopaminereceptor2 | hyperprolactinemia | BROMOCRIPTINE MESYLATE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d69003ee-0b6f-47a9-834e-ba59c02f566c | 1 | GoF | protect | |||
| Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators | D2_PAMs | DRD2 | Dopaminereceptor2 | hyperprolactinemia | BROMOCRIPTINE MESYLATE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d69003ee-0b6f-47a9-834e-ba59c02f566c | 1 | GoF | protect | |||
| HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators | D2_PAMs | DRD2 | Dopaminereceptor2 | hyperprolactinemia | BROMOCRIPTINE MESYLATE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d69003ee-0b6f-47a9-834e-ba59c02f566c | 1 | GoF | protect | |||
| Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists | D2_antagonists | DRD2 | Dopaminereceptor2 | hyperprolactinemia | BROMOCRIPTINE MESYLATE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d69003ee-0b6f-47a9-834e-ba59c02f566c | 1 | GoF | protect | |||
| HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists | D2_antagonists | DRD2 | Dopaminereceptor2 | hyperprolactinemia | BROMOCRIPTINE MESYLATE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d69003ee-0b6f-47a9-834e-ba59c02f566c | 1 | GoF | protect | |||
| Counterscreen for Oxytocin Receptor (OXTR) agonists: Fluorescence-based primary cell-based high throughput assay to identify agonists of the vasopressin 1 receptor (V1R) | AVPR1A_agonists | AVPR1A | Vasopressin V1a receptor | Central diabetes insipidus | DESMOPRESSIN ACETATE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=86f040d0-a073-4fa5-8997-b2fecc4a3205 | 1 | GoF | protect | |||
| Counterscreen for Oxytocin Receptor (OXTR) agonists: Fluorescence-based primary cell-based high throughput assay to identify agonists of the vasopressin 1 receptor (V1R) | AVPR1A_agonists | AVPR1A | Vasopressin V1a receptor | Central diabetes insipidus | DESMOPRESSIN ACETATE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d9d8442a-4722-4b41-9faa-1ee853a4cc3b | 1 | GoF | protect | |||
| Counterscreen for Oxytocin Receptor (OXTR) agonists: Fluorescence-based primary cell-based high throughput assay to identify agonists of the vasopressin 1 receptor (V1R) | AVPR1A_agonists | AVPR1A | Vasopressin V1a receptor | Central diabetes insipidus | DESMOPRESSIN ACETATE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6d55baa9-2b62-469c-93ae-3909ab249332 | 1 | GoF | protect | |||
| Inhibitors of the vitamin D receptor (VDR): qHTS | VDR | VDR | Vitamin D3 receptor | secondary hyperparathyroidism | PARICALCITOL | targetBased | 4 | Completed | 01/09/2007 | https://clinicaltrials.gov/study/NCT00537979 | 1 | GoF | protect | |
| Inhibitors of the vitamin D receptor (VDR): qHTS | VDR | VDR | Vitamin D3 receptor | secondary hyperparathyroidism | PARICALCITOL | targetBased | 4 | Completed | 01/02/2005 | https://clinicaltrials.gov/study/NCT00307840 | 1 | GoF | protect | |
| Inhibitors of the vitamin D receptor (VDR): qHTS | VDR | VDR | Vitamin D3 receptor | secondary hyperparathyroidism | PARICALCITOL | targetBased | 4 | Completed | 01/07/2009 | https://clinicaltrials.gov/study/NCT00958451 | 1 | GoF | protect | |
| Inhibitors of the vitamin D receptor (VDR): qHTS | VDR | VDR | Vitamin D3 receptor | secondary hyperparathyroidism | PARICALCITOL | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0fbaff52-f08f-42b7-8e46-c7214112901a | 1 | GoF | protect | |||
| Inhibitors of the vitamin D receptor (VDR): qHTS | VDR | VDR | Vitamin D3 receptor | secondary hyperparathyroidism | PARICALCITOL | targetBased | 4 | Completed | 01/10/2010 | https://clinicaltrials.gov/study/NCT01181531 | 1 | GoF | protect | |
| Inhibitors of the vitamin D receptor (VDR): qHTS | VDR | VDR | Vitamin D3 receptor | secondary hyperparathyroidism | PARICALCITOL | targetBased | 4 | Completed | 01/02/2007 | https://clinicaltrials.gov/study/NCT00454350 | 1 | GoF | protect | |
| Inhibitors of the vitamin D receptor (VDR): qHTS | VDR | VDR | Vitamin D3 receptor | secondary hyperparathyroidism | PARICALCITOL | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2b7c7587-2042-0d9c-e054-00144ff88e88 | 1 | GoF | protect | |||
| Inhibitors of the vitamin D receptor (VDR): qHTS | VDR | VDR | Vitamin D3 receptor | secondary hyperparathyroidism | PARICALCITOL | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4db985c4-3ba2-4967-898b-35af77f150de | 1 | GoF | protect | |||
| Inhibitors of the vitamin D receptor (VDR): qHTS | VDR | VDR | Vitamin D3 receptor | secondary hyperparathyroidism | PARICALCITOL | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7259652f-81bc-4ad1-bba5-d01f9fac1b80 | 1 | GoF | protect | |||
| Inhibitors of the vitamin D receptor (VDR): qHTS | VDR | VDR | Vitamin D3 receptor | secondary hyperparathyroidism | PARICALCITOL | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=18d7da0b-d715-4257-bdb3-d35fd9d02a74 | 1 | GoF | protect | |||
| Inhibitors of the vitamin D receptor (VDR): qHTS | VDR | VDR | Vitamin D3 receptor | secondary hyperparathyroidism | PARICALCITOL | targetBased | 3 | Not yet recruiting | 01/02/2022 | https://clinicaltrials.gov/study/NCT04994080 | 0.7 | GoF | protect | |
| Inhibitors of the vitamin D receptor (VDR): qHTS | VDR | VDR | Vitamin D3 receptor | secondary hyperparathyroidism | PARICALCITOL | targetBased | 4 | Completed | 01/01/2014 | https://clinicaltrials.gov/study/NCT01939977 | 1 | GoF | protect | |
| Inhibitors of the vitamin D receptor (VDR): qHTS | VDR | VDR | Vitamin D3 receptor | secondary hyperparathyroidism | PARICALCITOL | targetBased | 4 | Terminated | 01/01/2009 | https://clinicaltrials.gov/study/NCT00664430 | 1 | GoF | protect | Low enrollment rate |
| Inhibitors of the vitamin D receptor (VDR): qHTS | VDR | VDR | Vitamin D3 receptor | secondary hyperparathyroidism | PARICALCITOL | targetBased | 3 | Completed | 01/05/2011 | https://clinicaltrials.gov/study/NCT01341782 | 0.7 | GoF | protect | |
| Inhibitors of the vitamin D receptor (VDR): qHTS | VDR | VDR | Vitamin D3 receptor | secondary hyperparathyroidism | PARICALCITOL | targetBased | 4 | Completed | 01/04/2007 | https://clinicaltrials.gov/study/NCT00463021 | 1 | GoF | protect | |
| Inhibitors of the vitamin D receptor (VDR): qHTS | VDR | VDR | Vitamin D3 receptor | parathyroid disease | PARICALCITOL | targetBased | 4 | https://www.whocc.no/atc_ddd_index/?code=H05BX02 | 1 | GoF | protect | |||
| Inhibitors of the vitamin D receptor (VDR): qHTS | VDR | VDR | Vitamin D3 receptor | hyperparathyroidism | PARICALCITOL | targetBased | 3 | Completed | 01/01/2007 | https://clinicaltrials.gov/study/NCT00417612 | 0.7 | GoF | protect | |
| Inhibitors of the vitamin D receptor (VDR): qHTS | VDR | VDR | Vitamin D3 receptor | hyperparathyroidism | PARICALCITOL | targetBased | 3 | Completed | 01/07/2010 | https://clinicaltrials.gov/study/NCT01138475 | 0.7 | GoF | protect | |
| Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A) | HTR2A | HTR2A | 5-hydroxytryptamine receptor 2A | morbid obesity | CYCLOBENZAPRINE HYDROCHLORIDE | targetBased | 4 | Recruiting | 20/01/2021 | https://clinicaltrials.gov/study/NCT04240626 | 1 | LoF | protect | |
| Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK9 | KCNK9_blockers | KCNK9 | two-pore domain potassium channel | obesity | DESFLURANE | targetBased | 4 | Completed | 01/01/2015 | https://clinicaltrials.gov/study/NCT03417518 | 1 | protect | ||
| Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK9 | KCNK9_blockers | KCNK9 | two-pore domain potassium channel | chronic liver failure | DESFLURANE | targetBased | 4 | Completed | 01/06/2014 | https://clinicaltrials.gov/study/NCT02504138 | 1 | protect | ||
| Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK3 | KCNK3 | KCNK3 | Potassium channel subfamily K member 3 | chronic liver failure | DESFLURANE | targetBased | 4 | Completed | 01/06/2014 | https://clinicaltrials.gov/study/NCT02504138 | 1 | protect | ||
| Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK3 | KCNK3 | KCNK3 | Potassium channel subfamily K member 3 | obesity | DESFLURANE | targetBased | 4 | Completed | 01/01/2015 | https://clinicaltrials.gov/study/NCT03417518 | 1 | protect | ||
| Inhibitors of the vitamin D receptor (VDR): qHTS | VDR | VDR | Vitamin D3 receptor | secondary hyperparathyroidism | DOXERCALCIFEROL | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a43afaad-1862-4885-9b47-ddc2302160a3 | 1 | GoF | protect | |||
| Inhibitors of the vitamin D receptor (VDR): qHTS | VDR | VDR | Vitamin D3 receptor | secondary hyperparathyroidism | DOXERCALCIFEROL | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1bb3ce2f-c77a-436f-980f-a02668f99fed | 1 | GoF | protect | |||
| Inhibitors of the vitamin D receptor (VDR): qHTS | VDR | VDR | Vitamin D3 receptor | secondary hyperparathyroidism | DOXERCALCIFEROL | targetBased | 4 | Completed | 01/02/2007 | https://clinicaltrials.gov/study/NCT00454350 | 1 | GoF | protect | |
| Inhibitors of the vitamin D receptor (VDR): qHTS | VDR | VDR | Vitamin D3 receptor | secondary hyperparathyroidism | DOXERCALCIFEROL | targetBased | 4 | Completed | 01/11/2006 | https://clinicaltrials.gov/study/NCT00418600 | 1 | GoF | protect | |
| Inhibitors of the vitamin D receptor (VDR): qHTS | VDR | VDR | Vitamin D3 receptor | secondary hyperparathyroidism | DOXERCALCIFEROL | targetBased | 4 | Completed | 01/04/2007 | https://clinicaltrials.gov/study/NCT00463021 | 1 | GoF | protect | |
| Inhibitors of the vitamin D receptor (VDR): qHTS | VDR | VDR | Vitamin D3 receptor | secondary hyperparathyroidism | DOXERCALCIFEROL | targetBased | 4 | Terminated | 01/04/2008 | https://clinicaltrials.gov/study/NCT00646282 | 1 | GoF | protect | slow enrollment and discontinued once original principal investigator left Emory |
| Inhibitors of the vitamin D receptor (VDR): qHTS | VDR | VDR | Vitamin D3 receptor | secondary hyperparathyroidism | DOXERCALCIFEROL | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=253367e2-ae31-4196-9571-71f560283cf3 | 1 | GoF | protect | |||
| Inhibitors of the vitamin D receptor (VDR): qHTS | VDR | VDR | Vitamin D3 receptor | secondary hyperparathyroidism | DOXERCALCIFEROL | targetBased | 4 | Completed | 01/10/2010 | https://clinicaltrials.gov/study/NCT01181531 | 1 | GoF | protect | |
| Inhibitors of the vitamin D receptor (VDR): qHTS | VDR | VDR | Vitamin D3 receptor | parathyroid disease | DOXERCALCIFEROL | targetBased | 4 | https://www.whocc.no/atc_ddd_index/?code=H05BX03 | 1 | GoF | protect | |||
| HTS for Beta-2AR agonists via FAP method | ADRB2_activators | ADRB2 | Beta-2 adrenergic receptor | portal hypertension | TIMOLOL MALEATE | targetBased | 3 | Completed | 01/08/1993 | https://clinicaltrials.gov/study/NCT00006398 | 0.7 | LoF | protect | |
| Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors | OPRM1 | OPRM1 | Mu-type opioid receptor | morbid obesity | OXYCODONE HYDROCHLORIDE | targetBased | 4 | Recruiting | 20/01/2021 | https://clinicaltrials.gov/study/NCT04240626 | 1 | GoF | protect | |
| Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors | OPRM1 | OPRM1 | Mu-type opioid receptor | morbid obesity | OXYCODONE HYDROCHLORIDE | targetBased | 4 | Recruiting | 20/01/2021 | https://clinicaltrials.gov/study/NCT04240626 | 1 | GoF | protect | |
| Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1) | CHRM1_agonists | CHRM1 | Muscarinic acetylcholine receptor M1 | gallstones | GLYCOPYRROLATE | targetBased | 4 | Completed | 01/01/2015 | https://clinicaltrials.gov/study/NCT02327923 | 1 | LoF | protect | |
| Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen | CHRM1_allosteric_activators | CHRM1 | Muscarinic acetylcholine receptor M1 | gallstones | GLYCOPYRROLATE | targetBased | 4 | Completed | 01/01/2015 | https://clinicaltrials.gov/study/NCT02327923 | 1 | LoF | protect | |
| Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1). | CHRM1_PAMs | CHRM1 | Muscarinic acetylcholine receptor M1 | gallstones | GLYCOPYRROLATE | targetBased | 4 | Completed | 01/01/2015 | https://clinicaltrials.gov/study/NCT02327923 | 1 | LoF | protect | |
| Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen | CHRM1_allosteric_antagonists | CHRM1 | Muscarinic acetylcholine receptor M1 | gallstones | GLYCOPYRROLATE | targetBased | 4 | Completed | 01/01/2015 | https://clinicaltrials.gov/study/NCT02327923 | 1 | LoF | protect | |
| Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1) | CHRM1_antgonists | CHRM1 | Muscarinic acetylcholine receptor M1 | gallstones | GLYCOPYRROLATE | targetBased | 4 | Completed | 01/01/2015 | https://clinicaltrials.gov/study/NCT02327923 | 1 | LoF | protect | |
| Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists | D2_agonists | DRD2 | Dopaminereceptor2 | diabetes mellitus | CABERGOLINE | targetBased | 3 | Unknown status | 14/10/2017 | https://clinicaltrials.gov/study/NCT03313661 | 0.7 | GoF | protect | |
| HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists | D2_agonists | DRD2 | Dopaminereceptor2 | diabetes mellitus | CABERGOLINE | targetBased | 3 | Unknown status | 14/10/2017 | https://clinicaltrials.gov/study/NCT03313661 | 0.7 | GoF | protect | |
| Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators | D2_PAMs | DRD2 | Dopaminereceptor2 | diabetes mellitus | CABERGOLINE | targetBased | 3 | Unknown status | 14/10/2017 | https://clinicaltrials.gov/study/NCT03313661 | 0.7 | GoF | protect | |
| HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators | D2_PAMs | DRD2 | Dopaminereceptor2 | diabetes mellitus | CABERGOLINE | targetBased | 3 | Unknown status | 14/10/2017 | https://clinicaltrials.gov/study/NCT03313661 | 0.7 | GoF | protect | |
| Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists | D2_antagonists | DRD2 | Dopaminereceptor2 | diabetes mellitus | CABERGOLINE | targetBased | 3 | Unknown status | 14/10/2017 | https://clinicaltrials.gov/study/NCT03313661 | 0.7 | GoF | protect | |
| HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists | D2_antagonists | DRD2 | Dopaminereceptor2 | diabetes mellitus | CABERGOLINE | targetBased | 3 | Unknown status | 14/10/2017 | https://clinicaltrials.gov/study/NCT03313661 | 0.7 | GoF | protect | |
| Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2 | THRB | THRB | Thyroid hormone receptor beta | hypothyroidism | LIOTHYRONINE SODIUM | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5ccacb47-6348-6143-e053-2991aa0ac066 | 1 | GoF | protect | |||
| Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2 | THRB | THRB | Thyroid hormone receptor beta | hypothyroidism | LIOTHYRONINE SODIUM | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=51452b31-ff68-4e0c-b982-c15502ebf1d3 | 1 | GoF | protect | |||
| Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2 | THRB | THRB | Thyroid hormone receptor beta | myxedema | LIOTHYRONINE SODIUM | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5ccacb47-6348-6143-e053-2991aa0ac066 | 1 | GoF | protect | |||
| Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2 | THRB | THRB | Thyroid hormone receptor beta | myxedema | LIOTHYRONINE SODIUM | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a8b39730-de19-497d-bde8-6594aa528403 | 1 | GoF | protect | |||
| High Throughput Screening for Cocaine Antagonists: Primary Screen | SLC6A3 | SLC6A3 | Sodium-dependent dopamine transporter | obesity | ARMODAFINIL | targetBased | 3 | Completed | 01/08/2011 | https://clinicaltrials.gov/study/NCT02478580 | 0.7 | LoF | protect | |
| Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1) | CHRM1_agonists | CHRM1 | Muscarinic acetylcholine receptor M1 | gallstones | GLYCOPYRRONIUM | targetBased | 4 | Completed | 01/01/2015 | https://clinicaltrials.gov/study/NCT02327923 | 1 | LoF | protect | |
| Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen | CHRM1_allosteric_activators | CHRM1 | Muscarinic acetylcholine receptor M1 | gallstones | GLYCOPYRRONIUM | targetBased | 4 | Completed | 01/01/2015 | https://clinicaltrials.gov/study/NCT02327923 | 1 | LoF | protect | |
| Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1). | CHRM1_PAMs | CHRM1 | Muscarinic acetylcholine receptor M1 | gallstones | GLYCOPYRRONIUM | targetBased | 4 | Completed | 01/01/2015 | https://clinicaltrials.gov/study/NCT02327923 | 1 | LoF | protect | |
| Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen | CHRM1_allosteric_antagonists | CHRM1 | Muscarinic acetylcholine receptor M1 | gallstones | GLYCOPYRRONIUM | targetBased | 4 | Completed | 01/01/2015 | https://clinicaltrials.gov/study/NCT02327923 | 1 | LoF | protect | |
| Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1) | CHRM1_antgonists | CHRM1 | Muscarinic acetylcholine receptor M1 | gallstones | GLYCOPYRRONIUM | targetBased | 4 | Completed | 01/01/2015 | https://clinicaltrials.gov/study/NCT02327923 | 1 | LoF | protect | |
| Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 5 (CHRM5) | CHRM5 | CHRM5 | Muscarinic acetylcholine receptor M5 | gallstones | GLYCOPYRRONIUM | targetBased | 4 | Completed | 01/01/2015 | https://clinicaltrials.gov/study/NCT02327923 | 1 | LoF | protect | |
| Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human cholinergic receptor, muscarinic 5 (CHRM5) | CHRM5 | CHRM5 | Muscarinic acetylcholine receptor M5 | gallstones | GLYCOPYRRONIUM | targetBased | 4 | Completed | 01/01/2015 | https://clinicaltrials.gov/study/NCT02327923 | 1 | LoF | protect | |
| Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human cholinergic receptor, muscarinic 5 (CHRM5) | CHRM5 | CHRM5 | Muscarinic acetylcholine receptor M5 | gallstones | GLYCOPYRRONIUM | targetBased | 4 | Completed | 01/01/2015 | https://clinicaltrials.gov/study/NCT02327923 | 1 | LoF | protect | |
| Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human cholinergic receptor, muscarinic 4 (CHRM4) | CHRM4_PAMs | CHRM4 | Muscarinic acetylcholine receptor M4 | gallstones | GLYCOPYRRONIUM | targetBased | 4 | Completed | 01/01/2015 | https://clinicaltrials.gov/study/NCT02327923 | 1 | LoF | protect | |
| Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human cholinergic receptor, muscarinic 4 (CHRM4) | CHRM4_antgonists | CHRM4 | Muscarinic acetylcholine receptor M4 | gallstones | GLYCOPYRRONIUM | targetBased | 4 | Completed | 01/01/2015 | https://clinicaltrials.gov/study/NCT02327923 | 1 | LoF | protect | |
| Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 4 (CHRM4) | CHRM4_agonists | CHRM4 | Muscarinic acetylcholine receptor M4 | gallstones | GLYCOPYRRONIUM | targetBased | 4 | Completed | 01/01/2015 | https://clinicaltrials.gov/study/NCT02327923 | 1 | LoF | protect | |
| qHTS for PTHR1 Agonists: Primary Screen | PTH1R | PTH1R | Parathyroid hormone/parathyroid hormone-related peptide receptor | hypoparathyroidism | TERIPARATIDE ACETATE | targetBased | 3 | Terminated | 30/10/2006 | https://clinicaltrials.gov/study/NCT00395538 | 0.7 | GoF | protect | Pharmacy temporarily suspended by FDA |
| Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | TSHR | TSHR | Thyrotropin receptor | hypothyroidism | THYROTROPIN ALFA | targetBased | 4 | Completed | 01/12/1997 | https://clinicaltrials.gov/study/NCT00001730 | 1 | GoF | protect | |
| Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | TSHR | TSHR | Thyrotropin receptor | hypothyroidism | THYROTROPIN ALFA | targetBased | 4 | Completed | 01/12/1997 | https://clinicaltrials.gov/study/NCT00001730 | 1 | GoF | protect | |
| qHTS Assay for Agonists of the Thyroid Stimulating Hormone Receptor | TSHR | TSHR | Thyrotropin receptor | hypothyroidism | THYROTROPIN ALFA | targetBased | 4 | Completed | 01/12/1997 | https://clinicaltrials.gov/study/NCT00001730 | 1 | GoF | protect | |
| qHTS Assay for Agonists of the Thyroid Stimulating Hormone Receptor: Activators of Intracellular cAMP Concentrations in Parental HEK 293 | TSHR | TSHR | Thyrotropin receptor | hypothyroidism | THYROTROPIN ALFA | targetBased | 4 | Completed | 01/12/1997 | https://clinicaltrials.gov/study/NCT00001730 | 1 | GoF | protect | |
| HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors | ESR1_inhibitors | ESR1 | Estrogen receptor, Estrogen receptor | Hypercholesterolemia | ESTROGENS, CONJUGATED | targetBased | 3 | Completed | 01/09/1987 | https://clinicaltrials.gov/study/NCT00000466 | 0.7 | GoF | protect | |
| HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators | ESR1_modulators | ESR1 | Estrogen receptor, Estrogen receptor | Hypercholesterolemia | ESTROGENS, CONJUGATED | targetBased | 3 | Completed | 01/09/1987 | https://clinicaltrials.gov/study/NCT00000466 | 0.7 | GoF | protect | |
| HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors | ESR1_inhibitors | ESR1 | Estrogen receptor, Estrogen receptor | obesity | ESTROGENS, CONJUGATED | targetBased | 4 | Completed | 01/12/2014 | https://clinicaltrials.gov/study/NCT02237079 | 1 | GoF | protect | |
| HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators | ESR1_modulators | ESR1 | Estrogen receptor, Estrogen receptor | obesity | ESTROGENS, CONJUGATED | targetBased | 4 | Completed | 01/12/2014 | https://clinicaltrials.gov/study/NCT02237079 | 1 | GoF | protect | |
| HTS for Estrogen Receptor-beta Coactivator Binding inhibitors | ESR2_inhibitors | ESR2 | Estrogen receptor beta | obesity | ESTROGENS, CONJUGATED | targetBased | 4 | Completed | 01/12/2014 | https://clinicaltrials.gov/study/NCT02237079 | 1 | GoF | protect | |
| HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors | ESR1_inhibitors | ESR1 | Estrogen receptor, Estrogen receptor | diabetes mellitus | ESTROGENS, CONJUGATED | targetBased | 3 | Completed | 01/09/1987 | https://clinicaltrials.gov/study/NCT00000466 | 0.7 | GoF | protect | |
| HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators | ESR1_modulators | ESR1 | Estrogen receptor, Estrogen receptor | diabetes mellitus | ESTROGENS, CONJUGATED | targetBased | 3 | Completed | 01/09/1987 | https://clinicaltrials.gov/study/NCT00000466 | 0.7 | GoF | protect | |
| HTS for Estrogen Receptor-beta Coactivator Binding inhibitors | ESR2_inhibitors | ESR2 | Estrogen receptor beta | diabetes mellitus | ESTROGENS, CONJUGATED | targetBased | 3 | Completed | 01/09/1987 | https://clinicaltrials.gov/study/NCT00000466 | 0.7 | GoF | protect | |
| HTS for Estrogen Receptor-beta Coactivator Binding inhibitors | ESR2_inhibitors | ESR2 | Estrogen receptor beta | Hypercholesterolemia | ESTROGENS, CONJUGATED | targetBased | 3 | Completed | 01/09/1987 | https://clinicaltrials.gov/study/NCT00000466 | 0.7 | GoF | protect | |
| qHTS for Inhibitors of Inflammasome Signaling: IL-1-beta AlphaLISA Primary Screen | IL-1b Inflammasome | IL1B | Interleukin-1 beta | Hypoglycemia | CANAKINUMAB | pathwayBased | 3 | Recruiting | 17/04/2023 | https://clinicaltrials.gov/study/NCT05401578 | 0.7 | LoF | protect | |
| Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors | OPRM1 | OPRM1 | Mu-type opioid receptor | acute pancreatitis | TRAMADOL | targetBased | 3 | Completed | 06/06/2014 | https://clinicaltrials.gov/study/NCT02126332 | 0.7 | GoF | protect | |
| Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors | OPRM1 | OPRM1 | Mu-type opioid receptor | acute pancreatitis | TRAMADOL | targetBased | 3 | Completed | 06/06/2014 | https://clinicaltrials.gov/study/NCT02126332 | 0.7 | GoF | protect | |
| Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors | OPRM1 | OPRM1 | Mu-type opioid receptor | gallstones | TRAMADOL | targetBased | 4 | Completed | 01/01/2015 | https://clinicaltrials.gov/study/NCT02327923 | 1 | GoF | protect | |
| Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors | OPRM1 | OPRM1 | Mu-type opioid receptor | gallstones | TRAMADOL | targetBased | 4 | Completed | 01/01/2015 | https://clinicaltrials.gov/study/NCT02327923 | 1 | GoF | protect | |
| Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors | OPRM1 | OPRM1 | Mu-type opioid receptor | morbid obesity | HYDROMORPHONE HYDROCHLORIDE | targetBased | 4 | Recruiting | 20/01/2021 | https://clinicaltrials.gov/study/NCT04240626 | 1 | GoF | protect | |
| Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors | OPRM1 | OPRM1 | Mu-type opioid receptor | morbid obesity | HYDROMORPHONE HYDROCHLORIDE | targetBased | 4 | Recruiting | 20/01/2021 | https://clinicaltrials.gov/study/NCT04240626 | 1 | GoF | protect | |
| Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors | OPRM1 | OPRM1 | Mu-type opioid receptor | liver disease | HYDROMORPHONE HYDROCHLORIDE | targetBased | 3 | Recruiting | 04/10/2017 | https://clinicaltrials.gov/study/NCT03214510 | 0.7 | GoF | protect | |
| Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors | OPRM1 | OPRM1 | Mu-type opioid receptor | liver disease | HYDROMORPHONE HYDROCHLORIDE | targetBased | 3 | Recruiting | 04/10/2017 | https://clinicaltrials.gov/study/NCT03214510 | 0.7 | GoF | protect | |
| Inhibitors of the vitamin D receptor (VDR): qHTS | VDR | VDR | Vitamin D3 receptor | secondary hyperparathyroidism | ALFACALCIDOL | targetBased | 4 | Completed | 01/08/2008 | https://clinicaltrials.gov/study/NCT01115543 | 1 | GoF | protect | |
| Inhibitors of the vitamin D receptor (VDR): qHTS | VDR | VDR | Vitamin D3 receptor | diabetic nephropathy | ALFACALCIDOL | targetBased | 4 | Completed | 28/07/2016 | https://clinicaltrials.gov/study/NCT03147677 | 1 | GoF | protect | |
| High Throughput Screening for Cocaine Antagonists: Primary Screen | SLC6A3 | SLC6A3 | Sodium-dependent dopamine transporter | obesity | PHENDIMETRAZINE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=49b13acc-c7a9-4f7c-bcc2-2c73fcedab52 | 1 | LoF | protect | |||
| High Throughput Screening for Cocaine Antagonists: Primary Screen | SLC6A3 | SLC6A3 | Sodium-dependent dopamine transporter | obesity | PHENDIMETRAZINE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4a64fde2-1db7-5878-e054-00144ff8d46c | 1 | LoF | protect | |||
| High Throughput Screening for Cocaine Antagonists: Primary Screen | SLC6A3 | SLC6A3 | Sodium-dependent dopamine transporter | obesity | PHENDIMETRAZINE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1dd8c9bd-e4c2-40f4-879f-f55fc03e3fde | 1 | LoF | protect | |||
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | diabetic nephropathy | BARDOXOLONE METHYL | targetBased | 3 | Terminated | 30/05/2018 | https://clinicaltrials.gov/study/NCT03550443 | 0.7 | LoF | protect | Based on results of double-blind parts, it was determined that it would be difficult to submit a marketing authorization application for RTA 402 for diabetic kidney disease. |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | diabetic nephropathy | BARDOXOLONE METHYL | targetBased | 3 | Terminated | 30/05/2018 | https://clinicaltrials.gov/study/NCT03550443 | 0.7 | LoF | protect | Based on results of double-blind parts, it was determined that it would be difficult to submit a marketing authorization application for RTA 402 for diabetic kidney disease. |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | diabetic nephropathy | BARDOXOLONE METHYL | targetBased | 3 | Terminated | 30/05/2018 | https://clinicaltrials.gov/study/NCT03550443 | 0.7 | LoF | protect | Based on results of double-blind parts, it was determined that it would be difficult to submit a marketing authorization application for RTA 402 for diabetic kidney disease. |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | diabetic nephropathy | BARDOXOLONE METHYL | targetBased | 3 | Terminated | 30/05/2018 | https://clinicaltrials.gov/study/NCT03550443 | 0.7 | LoF | protect | Based on results of double-blind parts, it was determined that it would be difficult to submit a marketing authorization application for RTA 402 for diabetic kidney disease. |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | diabetic nephropathy | BARDOXOLONE METHYL | targetBased | 3 | Terminated | 30/05/2018 | https://clinicaltrials.gov/study/NCT03550443 | 0.7 | LoF | protect | Based on results of double-blind parts, it was determined that it would be difficult to submit a marketing authorization application for RTA 402 for diabetic kidney disease. |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | diabetic nephropathy | BARDOXOLONE METHYL | targetBased | 3 | Terminated | 30/05/2018 | https://clinicaltrials.gov/study/NCT03550443 | 0.7 | LoF | protect | Based on results of double-blind parts, it was determined that it would be difficult to submit a marketing authorization application for RTA 402 for diabetic kidney disease. |
| Nrf2 qHTS screen for inhibitors | nrf2Inhibitors | NFE2L2 | Nuclear factor erythroid 2-related factor 2 | diabetic nephropathy | BARDOXOLONE METHYL | targetBased | 3 | Terminated | 30/05/2018 | https://clinicaltrials.gov/study/NCT03550443 | 0.7 | LoF | protect | Based on results of double-blind parts, it was determined that it would be difficult to submit a marketing authorization application for RTA 402 for diabetic kidney disease. |
| qHTS of Nrf2 Activators | Nrf2 activators | NFE2L2 | NFE2 like bZIP transcription factor 2, Nuclear factor erythroid 2-related factor 2 | diabetic nephropathy | BARDOXOLONE METHYL | pathwayBased | 3 | Terminated | 30/05/2018 | https://clinicaltrials.gov/study/NCT03550443 | 0.7 | LoF | protect | Based on results of double-blind parts, it was determined that it would be difficult to submit a marketing authorization application for RTA 402 for diabetic kidney disease. |
| Fluorescence polarization to screen for inhibitors that disrupt the protein-protein interaction between Keap1 and Nrf2 Measured in Biochemical System Using Plate Reader - 2119-01_Inhibitor_SinglePoint_HTS_Activity | KEAP1 | KEAP1 | Kelch-like ECH-associated protein 1 | diabetic nephropathy | BARDOXOLONE METHYL | targetBased | 3 | Terminated | 30/05/2018 | https://clinicaltrials.gov/study/NCT03550443 | 0.7 | LoF | protect | Based on results of double-blind parts, it was determined that it would be difficult to submit a marketing authorization application for RTA 402 for diabetic kidney disease. |
| Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2 | THRB | THRB | Thyroid hormone receptor beta | familial hypercholesterolemia | EPROTIROME | targetBased | 3 | Terminated | 01/10/2011 | https://clinicaltrials.gov/study/NCT01410383 | 0.7 | GoF | protect | |
| High Throughput Screening for Cocaine Antagonists: Primary Screen | SLC6A3 | SLC6A3 | Sodium-dependent dopamine transporter | obesity | PHENDIMETRAZINE TARTRATE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1dd8c9bd-e4c2-40f4-879f-f55fc03e3fde | 1 | LoF | protect | |||
| High Throughput Screening for Cocaine Antagonists: Primary Screen | SLC6A3 | SLC6A3 | Sodium-dependent dopamine transporter | obesity | PHENDIMETRAZINE TARTRATE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4a64fde2-1db7-5878-e054-00144ff8d46c | 1 | LoF | protect | |||
| High Throughput Screening for Cocaine Antagonists: Primary Screen | SLC6A3 | SLC6A3 | Sodium-dependent dopamine transporter | obesity | PHENDIMETRAZINE TARTRATE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=49b13acc-c7a9-4f7c-bcc2-2c73fcedab52 | 1 | LoF | protect | |||
| Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2 | THRB | THRB | Thyroid hormone receptor beta | hypothyroidism | LEVOTHYROXINE SODIUM | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=49205c04-076b-4a6d-97aa-f0b4d3eaac46 | 1 | GoF | protect | |||
| Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2 | THRB | THRB | Thyroid hormone receptor beta | hypothyroidism | LEVOTHYROXINE SODIUM | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=707fb53f-f27d-4169-86ff-62d02014e9c4 | 1 | GoF | protect | |||
| Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2 | THRB | THRB | Thyroid hormone receptor beta | hypothyroidism | LEVOTHYROXINE SODIUM | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=bd1ce5e4-9dd5-4bd5-ae5e-c88822c04f98 | 1 | GoF | protect | |||
| Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2 | THRB | THRB | Thyroid hormone receptor beta | hypothyroidism | LEVOTHYROXINE SODIUM | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0986e998-ad13-4546-867d-95ed3db314ed | 1 | GoF | protect | |||
| Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2 | THRB | THRB | Thyroid hormone receptor beta | hypothyroidism | LEVOTHYROXINE SODIUM | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e9060459-ec1b-4eb5-a34a-d777f1544f3d | 1 | GoF | protect | |||
| Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2 | THRB | THRB | Thyroid hormone receptor beta | hypothyroidism | LEVOTHYROXINE SODIUM | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=600c2d08-e92f-46fa-a835-c225cc759dd1 | 1 | GoF | protect | |||
| Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2 | THRB | THRB | Thyroid hormone receptor beta | hypothyroidism | LEVOTHYROXINE SODIUM | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=dac99035-9098-4710-bf55-c46889ffc282 | 1 | GoF | protect | |||
| Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2 | THRB | THRB | Thyroid hormone receptor beta | hypothyroidism | LEVOTHYROXINE SODIUM | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3d2820e6-5bb4-4c71-9fb0-422a5c1ebaf0 | 1 | GoF | protect | |||
| Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2 | THRB | THRB | Thyroid hormone receptor beta | hypothyroidism | LEVOTHYROXINE SODIUM | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3f7bf9a8-fcfa-47fc-826d-c36174abbca0 | 1 | GoF | protect | |||
| Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2 | THRB | THRB | Thyroid hormone receptor beta | hypothyroidism | LEVOTHYROXINE SODIUM | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=63bea240-a32d-4c12-85d1-b7edeca76b67 | 1 | GoF | protect | |||
| Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2 | THRB | THRB | Thyroid hormone receptor beta | hypothyroidism | LEVOTHYROXINE SODIUM | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5680bf94-524d-45ee-b1dd-d2e81e48a312 | 1 | GoF | protect | |||
| Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2 | THRB | THRB | Thyroid hormone receptor beta | hypothyroidism | LEVOTHYROXINE SODIUM | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=eed5fdf6-2861-45a2-ae10-d8031137ed03 | 1 | GoF | protect | |||
| Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2 | THRB | THRB | Thyroid hormone receptor beta | hypothyroidism | LEVOTHYROXINE SODIUM | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=02ca8555-a726-4dd3-afee-4435ae3e0ae1 | 1 | GoF | protect | |||
| Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2 | THRB | THRB | Thyroid hormone receptor beta | hypothyroidism | LEVOTHYROXINE SODIUM | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=dddad621-c42a-45a1-b6af-8f0503f67474 | 1 | GoF | protect | |||
| Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2 | THRB | THRB | Thyroid hormone receptor beta | hypothyroidism | LEVOTHYROXINE SODIUM | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=68eb8ab6-c018-4112-affb-71c0db88f8de | 1 | GoF | protect | |||
| Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2 | THRB | THRB | Thyroid hormone receptor beta | hypothyroidism | LEVOTHYROXINE SODIUM | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0f11c856-af9a-409a-9c0f-e7a10bbfe5a6 | 1 | GoF | protect | |||
| Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2 | THRB | THRB | Thyroid hormone receptor beta | hypothyroidism | LEVOTHYROXINE SODIUM | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=16eb7d1c-77c4-4709-970a-1e1bdb29eb76 | 1 | GoF | protect | |||
| Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2 | THRB | THRB | Thyroid hormone receptor beta | hypothyroidism | LEVOTHYROXINE SODIUM | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5e1d8d43-193d-443d-9304-9f4f59620151 | 1 | GoF | protect | |||
| Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2 | THRB | THRB | Thyroid hormone receptor beta | hypothyroidism | LEVOTHYROXINE SODIUM | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=bc695a1b-b510-4376-a9a0-bcbd7c63906f | 1 | GoF | protect | |||
| Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2 | THRB | THRB | Thyroid hormone receptor beta | hypothyroidism | LEVOTHYROXINE SODIUM | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b37ec531-9a69-4919-ba54-ffb674848a96 | 1 | GoF | protect | |||
| Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2 | THRB | THRB | Thyroid hormone receptor beta | hypothyroidism | LEVOTHYROXINE SODIUM | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d804fd47-a37b-41c6-ab34-c311abf14d71 | 1 | GoF | protect | |||
| Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2 | THRB | THRB | Thyroid hormone receptor beta | hypothyroidism | LEVOTHYROXINE SODIUM | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3177aea1-c0c6-4ae1-b20e-3ca66a949e2c | 1 | GoF | protect | |||
| Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2 | THRB | THRB | Thyroid hormone receptor beta | hypothyroidism | LEVOTHYROXINE SODIUM | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=58d8f240-2c83-406c-bf44-3931e40103e1 | 1 | GoF | protect | |||
| Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2 | THRB | THRB | Thyroid hormone receptor beta | hypothyroidism | LEVOTHYROXINE SODIUM | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a3b269b2-6c33-4e5e-8880-5cc8f825f60c | 1 | GoF | protect | |||
| Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2 | THRB | THRB | Thyroid hormone receptor beta | hypothyroidism | LEVOTHYROXINE SODIUM | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=26cc174c-197c-448e-b9f6-50df4926f4f4 | 1 | GoF | protect | |||
| Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2 | THRB | THRB | Thyroid hormone receptor beta | hypothyroidism | LEVOTHYROXINE SODIUM | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0bf2cfc3-b564-44ed-9268-1a5409a89eeb | 1 | GoF | protect | |||
| Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2 | THRB | THRB | Thyroid hormone receptor beta | hypothyroidism | LEVOTHYROXINE SODIUM | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c697292b-e67f-4753-abba-c06f98b7ce90 | 1 | GoF | protect | |||
| Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2 | THRB | THRB | Thyroid hormone receptor beta | hypothyroidism | LEVOTHYROXINE SODIUM | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3aa52a8d-0bdb-4ae4-8acb-4ea8c29fa480 | 1 | GoF | protect | |||
| Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2 | THRB | THRB | Thyroid hormone receptor beta | hypothyroidism | LEVOTHYROXINE SODIUM | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=13caa583-2238-4c2c-bc32-d88e7725a02e | 1 | GoF | protect | |||
| Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2 | THRB | THRB | Thyroid hormone receptor beta | hypothyroidism | LEVOTHYROXINE SODIUM | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7d8e9ae0-2299-4d96-b925-bbceecf2c5d9 | 1 | GoF | protect | |||
| Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2 | THRB | THRB | Thyroid hormone receptor beta | hypothyroidism | LEVOTHYROXINE SODIUM | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=efe4d28c-8399-48b9-96f6-d9302e25de6d | 1 | GoF | protect | |||
| Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2 | THRB | THRB | Thyroid hormone receptor beta | hypothyroidism | LEVOTHYROXINE SODIUM | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a4e39e5c-59ee-4ba2-bf7f-62b5eae3afbc | 1 | GoF | protect | |||
| Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2 | THRB | THRB | Thyroid hormone receptor beta | hypothyroidism | LEVOTHYROXINE SODIUM | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3218d7d0-08c8-4e96-a717-94a8cbad2092 | 1 | GoF | protect | |||
| Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2 | THRB | THRB | Thyroid hormone receptor beta | hypothyroidism | LEVOTHYROXINE SODIUM | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=99aebc74-0e34-4ab3-bb59-d9fb2b9a4444 | 1 | GoF | protect | |||
| Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2 | THRB | THRB | Thyroid hormone receptor beta | hypothyroidism | LEVOTHYROXINE SODIUM | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8553a519-571b-4b9e-a638-06fc523ac373 | 1 | GoF | protect | |||
| Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2 | THRB | THRB | Thyroid hormone receptor beta | hypothyroidism | LEVOTHYROXINE SODIUM | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=32723719-5d99-4ef1-a991-b65767327c1d | 1 | GoF | protect | |||
| Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2 | THRB | THRB | Thyroid hormone receptor beta | hypothyroidism | LEVOTHYROXINE SODIUM | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=bd11d40c-67f6-4149-a705-dcf281c913a9 | 1 | GoF | protect | |||
| Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2 | THRB | THRB | Thyroid hormone receptor beta | hypothyroidism | LEVOTHYROXINE SODIUM | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f924199f-fcac-445e-a7b9-4f57d4062be1 | 1 | GoF | protect | |||
| Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2 | THRB | THRB | Thyroid hormone receptor beta | hypothyroidism | LEVOTHYROXINE SODIUM | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=fce4372d-8bba-4995-b809-fb4e256ee798 | 1 | GoF | protect | |||
| Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2 | THRB | THRB | Thyroid hormone receptor beta | hypothyroidism | LEVOTHYROXINE SODIUM | targetBased | 4 | Completed | 30/07/2018 | https://clinicaltrials.gov/study/NCT03094416 | 1 | GoF | protect | |
| Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2 | THRB | THRB | Thyroid hormone receptor beta | hypothyroidism | LEVOTHYROXINE SODIUM | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7a5a9e87-383a-4450-bf79-1f4f68655ace | 1 | GoF | protect | |||
| Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2 | THRB | THRB | Thyroid hormone receptor beta | hypothyroidism | LEVOTHYROXINE SODIUM | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ba302d90-1555-47f1-9d75-9a6bde299f98 | 1 | GoF | protect | |||
| Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2 | THRB | THRB | Thyroid hormone receptor beta | hypothyroidism | LEVOTHYROXINE SODIUM | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5915b2bb-ae53-4781-91ed-ff90188fe1d8 | 1 | GoF | protect | |||
| Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2 | THRB | THRB | Thyroid hormone receptor beta | hypothyroidism | LEVOTHYROXINE SODIUM | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=dec03393-0e77-4716-8db8-2ff996dd3f74 | 1 | GoF | protect | |||
| Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2 | THRB | THRB | Thyroid hormone receptor beta | hypothyroidism | LEVOTHYROXINE SODIUM | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0af3f268-7e5d-4ce5-af2b-35ae6c362dab | 1 | GoF | protect | |||
| Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2 | THRB | THRB | Thyroid hormone receptor beta | hypothyroidism | LEVOTHYROXINE SODIUM | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=82212ab9-776f-4838-ba16-83e87c33d479 | 1 | GoF | protect | |||
| Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2 | THRB | THRB | Thyroid hormone receptor beta | hypothyroidism | LEVOTHYROXINE SODIUM | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0f547137-d471-15f6-e054-00144ff8d46c | 1 | GoF | protect | |||
| Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2 | THRB | THRB | Thyroid hormone receptor beta | hypothyroidism | LEVOTHYROXINE SODIUM | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6977f0ea-3343-4f99-bcc6-85acfeb69710 | 1 | GoF | protect | |||
| Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2 | THRB | THRB | Thyroid hormone receptor beta | hypothyroidism | LEVOTHYROXINE SODIUM | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a3845f91-e0fe-42aa-8043-aeaac43f8eef | 1 | GoF | protect | |||
| Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2 | THRB | THRB | Thyroid hormone receptor beta | hypothyroidism | LEVOTHYROXINE SODIUM | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=22985313-7619-4e82-88a9-ad2c71ade0d7 | 1 | GoF | protect | |||
| Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2 | THRB | THRB | Thyroid hormone receptor beta | hypothyroidism | LEVOTHYROXINE SODIUM | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f8eaf67a-72e6-4ecd-bbf6-7ec8d34df2a2 | 1 | GoF | protect | |||
| Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2 | THRB | THRB | Thyroid hormone receptor beta | hypothyroidism | LEVOTHYROXINE SODIUM | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=94690757-d8ca-424c-acea-eece9c342712 | 1 | GoF | protect | |||
| Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2 | THRB | THRB | Thyroid hormone receptor beta | hypothyroidism | LEVOTHYROXINE SODIUM | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e7fd03db-72cd-4dc3-ae94-e11cb67126a8 | 1 | GoF | protect | |||
| Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2 | THRB | THRB | Thyroid hormone receptor beta | hypothyroidism | LEVOTHYROXINE SODIUM | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5ada7c99-cb63-4b68-8dd2-e0f4fafdf4f6 | 1 | GoF | protect | |||
| Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2 | THRB | THRB | Thyroid hormone receptor beta | hypothyroidism | LEVOTHYROXINE SODIUM | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ca9cc882-1ae9-4260-989a-2fa7d6613470 | 1 | GoF | protect | |||
| Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2 | THRB | THRB | Thyroid hormone receptor beta | hypothyroidism | LEVOTHYROXINE SODIUM | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1221646b-ea75-1ce9-e054-00144ff8d46c | 1 | GoF | protect | |||
| Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2 | THRB | THRB | Thyroid hormone receptor beta | hypothyroidism | LEVOTHYROXINE SODIUM | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1ad32038-f484-4469-93fe-d3da81d8b9ea | 1 | GoF | protect | |||
| Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2 | THRB | THRB | Thyroid hormone receptor beta | hypothyroidism | LEVOTHYROXINE SODIUM | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d71ff261-ffd5-47a8-840f-40e464612bf6 | 1 | GoF | protect | |||
| Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2 | THRB | THRB | Thyroid hormone receptor beta | hypothyroidism | LEVOTHYROXINE SODIUM | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=82549679-2e3b-48e8-95d7-7fdb902f9215 | 1 | GoF | protect | |||
| Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2 | THRB | THRB | Thyroid hormone receptor beta | hypothyroidism | LEVOTHYROXINE SODIUM | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=67032026-6b2a-4f2b-aafe-cdcf3febb6eb | 1 | GoF | protect | |||
| Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2 | THRB | THRB | Thyroid hormone receptor beta | hypothyroidism | LEVOTHYROXINE SODIUM | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8dda27c0-8368-47b7-b502-8fcaa1066e9f | 1 | GoF | protect | |||
| Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2 | THRB | THRB | Thyroid hormone receptor beta | hypothyroidism | LEVOTHYROXINE SODIUM | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=21a12ab0-43ac-4f9e-877d-a81d7463de17 | 1 | GoF | protect | |||
| Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2 | THRB | THRB | Thyroid hormone receptor beta | hypothyroidism | LEVOTHYROXINE SODIUM | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7a9d4020-09d3-4a3f-a919-c16d994c65be | 1 | GoF | protect | |||
| Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2 | THRB | THRB | Thyroid hormone receptor beta | hypothyroidism | LEVOTHYROXINE SODIUM | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ee5e8470-131f-4b3d-b99b-3528853689fa | 1 | GoF | protect | |||
| Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2 | THRB | THRB | Thyroid hormone receptor beta | hypothyroidism | LEVOTHYROXINE SODIUM | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c202834e-0aba-4a06-838c-cf076681e6e4 | 1 | GoF | protect | |||
| Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2 | THRB | THRB | Thyroid hormone receptor beta | hypothyroidism | LEVOTHYROXINE SODIUM | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e29d7f37-212b-4caa-a1da-171c828e2d52 | 1 | GoF | protect | |||
| Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2 | THRB | THRB | Thyroid hormone receptor beta | hypothyroidism | LEVOTHYROXINE SODIUM | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f887a801-744c-43c2-81d6-6433b1089667 | 1 | GoF | protect | |||
| Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2 | THRB | THRB | Thyroid hormone receptor beta | hypothyroidism | LEVOTHYROXINE SODIUM | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d3ce9a73-5f3a-4c1b-a4b7-06f45316d61a | 1 | GoF | protect | |||
| Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2 | THRB | THRB | Thyroid hormone receptor beta | hypothyroidism | LEVOTHYROXINE SODIUM | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6a3aa7ea-4a9d-4be2-a6d9-5fbf21673835 | 1 | GoF | protect | |||
| Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2 | THRB | THRB | Thyroid hormone receptor beta | hypothyroidism | LEVOTHYROXINE SODIUM | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9562b54c-7ccd-411f-8e84-0c9de897cfea | 1 | GoF | protect | |||
| Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2 | THRB | THRB | Thyroid hormone receptor beta | hypothyroidism | LEVOTHYROXINE SODIUM | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=34c775d0-8982-45c4-9c10-d5a52d8dad63 | 1 | GoF | protect | |||
| Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2 | THRB | THRB | Thyroid hormone receptor beta | hypothyroidism | LEVOTHYROXINE SODIUM | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5cf37653-c6a1-4360-b073-5f116bd16b9d | 1 | GoF | protect | |||
| Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2 | THRB | THRB | Thyroid hormone receptor beta | hypothyroidism | LEVOTHYROXINE SODIUM | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=853ff15d-bbb1-40a1-b551-db2cfcdd0bd3 | 1 | GoF | protect | |||
| Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2 | THRB | THRB | Thyroid hormone receptor beta | hypothyroidism | LEVOTHYROXINE SODIUM | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3802ed01-e081-4c07-ac66-1bc0a3dc8737 | 1 | GoF | protect | |||
| Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2 | THRB | THRB | Thyroid hormone receptor beta | hypothyroidism | LEVOTHYROXINE SODIUM | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a432460c-85b3-4d51-b945-bd62340a29bd | 1 | GoF | protect | |||
| Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2 | THRB | THRB | Thyroid hormone receptor beta | hypothyroidism | LEVOTHYROXINE SODIUM | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9fde935e-f927-46aa-ba7b-e8874f4e190d | 1 | GoF | protect | |||
| Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2 | THRB | THRB | Thyroid hormone receptor beta | hypothyroidism | LEVOTHYROXINE SODIUM | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6182a0e9-ea40-41fc-be24-822b165af1bb | 1 | GoF | protect | |||
| Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2 | THRB | THRB | Thyroid hormone receptor beta | hypothyroidism | LEVOTHYROXINE SODIUM | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=eaf78aff-a6d2-4fb5-b4e5-8b2cb60de0de | 1 | GoF | protect | |||
| Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2 | THRB | THRB | Thyroid hormone receptor beta | hypothyroidism | LEVOTHYROXINE SODIUM | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7ab991f3-3984-4925-88fa-f11027ac7a36 | 1 | GoF | protect | |||
| Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2 | THRB | THRB | Thyroid hormone receptor beta | hypothyroidism | LEVOTHYROXINE SODIUM | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5644d405-8dea-48f7-8be7-828de94742b1 | 1 | GoF | protect | |||
| Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2 | THRB | THRB | Thyroid hormone receptor beta | hypothyroidism | LEVOTHYROXINE SODIUM | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ff852ce9-44ce-4d7c-b756-c164adda3796 | 1 | GoF | protect | |||
| Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2 | THRB | THRB | Thyroid hormone receptor beta | hypothyroidism | LEVOTHYROXINE SODIUM | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9f87f620-e576-4a51-91d3-9a9e6819c638 | 1 | GoF | protect | |||
| Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2 | THRB | THRB | Thyroid hormone receptor beta | hypothyroidism | LEVOTHYROXINE SODIUM | targetBased | 4 | Terminated | 05/05/2021 | https://clinicaltrials.gov/study/NCT04878614 | 1 | GoF | protect | Sponsor terminated study low accrual numbers |
| Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2 | THRB | THRB | Thyroid hormone receptor beta | hypothyroidism | LEVOTHYROXINE SODIUM | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ba633224-8f70-4533-a5fc-4dfd2df703d6 | 1 | GoF | protect | |||
| Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2 | THRB | THRB | Thyroid hormone receptor beta | hypothyroidism | LEVOTHYROXINE SODIUM | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=82a99646-c6a2-4fe1-a0e8-32cd521283c3 | 1 | GoF | protect | |||
| Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2 | THRB | THRB | Thyroid hormone receptor beta | hypothyroidism | LEVOTHYROXINE SODIUM | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=04c2e322-151f-4a95-b34a-622183c506fe | 1 | GoF | protect | |||
| Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2 | THRB | THRB | Thyroid hormone receptor beta | hypothyroidism | LEVOTHYROXINE SODIUM | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d336bf7d-6c91-4285-a877-9521c659ff99 | 1 | GoF | protect | |||
| Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2 | THRB | THRB | Thyroid hormone receptor beta | hypothyroidism | LEVOTHYROXINE SODIUM | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4f6a74de-bbc3-46ef-a21f-6a45aa75ccb5 | 1 | GoF | protect | |||
| Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2 | THRB | THRB | Thyroid hormone receptor beta | hypothyroidism | LEVOTHYROXINE SODIUM | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f347f490-7199-4de6-bca2-0d44a74979af | 1 | GoF | protect | |||
| Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2 | THRB | THRB | Thyroid hormone receptor beta | hypothyroidism | LEVOTHYROXINE SODIUM | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=52b448ca-30fa-464c-b79d-2835779357cb | 1 | GoF | protect | |||
| Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2 | THRB | THRB | Thyroid hormone receptor beta | hypothyroidism | LEVOTHYROXINE SODIUM | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7a9ecaf3-0a05-4233-a402-ecfc512c693f | 1 | GoF | protect | |||
| Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2 | THRB | THRB | Thyroid hormone receptor beta | hypothyroidism | LEVOTHYROXINE SODIUM | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e44f82cc-4a34-40fc-bc31-42e06ca5e8b8 | 1 | GoF | protect | |||
| Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2 | THRB | THRB | Thyroid hormone receptor beta | hypothyroidism | LEVOTHYROXINE SODIUM | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=69de922e-931e-4723-a91f-0cd774f008d1 | 1 | GoF | protect | |||
| Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2 | THRB | THRB | Thyroid hormone receptor beta | hypothyroidism | LEVOTHYROXINE SODIUM | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=dcbb33d6-9bb6-420a-9ee9-4527320d3d5c | 1 | GoF | protect | |||
| Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2 | THRB | THRB | Thyroid hormone receptor beta | hypothyroidism | LEVOTHYROXINE SODIUM | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=574d2da2-9440-43d5-ac8e-c46017ec4bd3 | 1 | GoF | protect | |||
| Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2 | THRB | THRB | Thyroid hormone receptor beta | hypothyroidism | LEVOTHYROXINE SODIUM | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=44a290d4-18f3-4077-89ae-ddb7db914ae7 | 1 | GoF | protect | |||
| Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2 | THRB | THRB | Thyroid hormone receptor beta | hypothyroidism | LEVOTHYROXINE SODIUM | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=847fed05-7256-4d0e-a743-716784abc5f9 | 1 | GoF | protect | |||
| Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2 | THRB | THRB | Thyroid hormone receptor beta | hypothyroidism | LEVOTHYROXINE SODIUM | targetBased | 4 | Recruiting | 31/01/2024 | https://clinicaltrials.gov/study/NCT06073665 | 1 | GoF | protect | |
| Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2 | THRB | THRB | Thyroid hormone receptor beta | hypothyroidism | LEVOTHYROXINE SODIUM | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4220ded0-36b2-4e48-8280-aecfce89ebe2 | 1 | GoF | protect | |||
| Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2 | THRB | THRB | Thyroid hormone receptor beta | hypothyroidism | LEVOTHYROXINE SODIUM | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4c9642fa-9d53-4c16-85a7-0b3c9cadb1dd | 1 | GoF | protect | |||
| Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2 | THRB | THRB | Thyroid hormone receptor beta | hypothyroidism | LEVOTHYROXINE SODIUM | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0213903b-9662-465e-a668-f228cedf5e9e | 1 | GoF | protect | |||
| Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2 | THRB | THRB | Thyroid hormone receptor beta | hypothyroidism | LEVOTHYROXINE SODIUM | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7f8fda21-ed5b-4db1-ada0-627cf3e1c248 | 1 | GoF | protect | |||
| Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2 | THRB | THRB | Thyroid hormone receptor beta | hypothyroidism | LEVOTHYROXINE SODIUM | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8bea42cb-5e06-4be7-983d-cae573ceaba6 | 1 | GoF | protect | |||
| Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2 | THRB | THRB | Thyroid hormone receptor beta | hypothyroidism | LEVOTHYROXINE SODIUM | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=53ee103c-52d2-4f8a-8e24-54d1f1551b8e | 1 | GoF | protect | |||
| Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2 | THRB | THRB | Thyroid hormone receptor beta | hypothyroidism | LEVOTHYROXINE SODIUM | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=abea9e57-11b6-4c31-b41a-3d305e57e022 | 1 | GoF | protect | |||
| Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2 | THRB | THRB | Thyroid hormone receptor beta | hypothyroidism | LEVOTHYROXINE SODIUM | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=784e246c-058d-44f0-a0a0-d96539d8888d | 1 | GoF | protect | |||
| Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2 | THRB | THRB | Thyroid hormone receptor beta | hypothyroidism | LEVOTHYROXINE SODIUM | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ac81bf65-080b-450e-b1ff-6758a1733e0c | 1 | GoF | protect | |||
| Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2 | THRB | THRB | Thyroid hormone receptor beta | hypothyroidism | LEVOTHYROXINE SODIUM | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=48428150-629d-4745-9238-18c52cb2adf8 | 1 | GoF | protect | |||
| Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2 | THRB | THRB | Thyroid hormone receptor beta | hypothyroidism | LEVOTHYROXINE SODIUM | targetBased | 4 | Unknown status | 01/05/2016 | https://clinicaltrials.gov/study/NCT02917863 | 1 | GoF | protect | |
| Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2 | THRB | THRB | Thyroid hormone receptor beta | hypothyroidism | LEVOTHYROXINE SODIUM | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=05897f7a-4d31-497f-aa9e-52708b361640 | 1 | GoF | protect | |||
| Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2 | THRB | THRB | Thyroid hormone receptor beta | hypothyroidism | LEVOTHYROXINE SODIUM | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2eabc9b4-2d5c-44b2-bf05-eb6c3260c1bd | 1 | GoF | protect | |||
| Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2 | THRB | THRB | Thyroid hormone receptor beta | hypothyroidism | LEVOTHYROXINE SODIUM | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=71139e30-10c8-4474-b7a3-b575c3fd32f9 | 1 | GoF | protect | |||
| Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2 | THRB | THRB | Thyroid hormone receptor beta | hypothyroidism | LEVOTHYROXINE SODIUM | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=cadf4802-b53f-419c-a775-82af525887e4 | 1 | GoF | protect | |||
| Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2 | THRB | THRB | Thyroid hormone receptor beta | hypothyroidism | LEVOTHYROXINE SODIUM | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3e5544bb-142b-4cfb-89a0-b97cb521e1db | 1 | GoF | protect | |||
| Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2 | THRB | THRB | Thyroid hormone receptor beta | hypothyroidism | LEVOTHYROXINE SODIUM | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b722a6c8-c44b-4ec7-9402-02dc7e965753 | 1 | GoF | protect | |||
| Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2 | THRB | THRB | Thyroid hormone receptor beta | hypothyroidism | LEVOTHYROXINE SODIUM | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b6ced930-2630-441d-926c-7c6d2188b27d | 1 | GoF | protect | |||
| Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2 | THRB | THRB | Thyroid hormone receptor beta | hypothyroidism | LEVOTHYROXINE SODIUM | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=46a9e4e6-af7f-4f60-a888-c6d3afce8113 | 1 | GoF | protect | |||
| Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2 | THRB | THRB | Thyroid hormone receptor beta | hypothyroidism | LEVOTHYROXINE SODIUM | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=02dbb433-dc86-4967-8cd0-0424d7836b7a | 1 | GoF | protect | |||
| Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2 | THRB | THRB | Thyroid hormone receptor beta | hypothyroidism | LEVOTHYROXINE SODIUM | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=cc47cc71-5bdf-40fa-bb0f-12d77366ad01 | 1 | GoF | protect | |||
| Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2 | THRB | THRB | Thyroid hormone receptor beta | hypothyroidism | LEVOTHYROXINE SODIUM | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=cadf57e5-7682-425b-8f0c-a7998114f375 | 1 | GoF | protect | |||
| Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2 | THRB | THRB | Thyroid hormone receptor beta | hypothyroidism | LEVOTHYROXINE SODIUM | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=95bf72d9-3d2d-435d-8543-a9a7bb4a3bca | 1 | GoF | protect | |||
| Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2 | THRB | THRB | Thyroid hormone receptor beta | hypothyroidism | LEVOTHYROXINE SODIUM | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=07562e72-7eaa-4ce6-94f0-e08814787e50 | 1 | GoF | protect | |||
| Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2 | THRB | THRB | Thyroid hormone receptor beta | hypothyroidism | LEVOTHYROXINE SODIUM | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0aad8c43-6a19-4420-8987-97a3d95c52cf | 1 | GoF | protect | |||
| Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2 | THRB | THRB | Thyroid hormone receptor beta | hypothyroidism | LEVOTHYROXINE SODIUM | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d3ce7029-9e12-4de6-8f59-145bc91369a8 | 1 | GoF | protect | |||
| Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2 | THRB | THRB | Thyroid hormone receptor beta | hypothyroidism | LEVOTHYROXINE SODIUM | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=70df9c08-665f-4b12-9b11-e5521ebca3ea | 1 | GoF | protect | |||
| Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2 | THRB | THRB | Thyroid hormone receptor beta | hypothyroidism | LEVOTHYROXINE SODIUM | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=dd073a5a-d344-4c1a-9957-e501ff14f4ba | 1 | GoF | protect | |||
| Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2 | THRB | THRB | Thyroid hormone receptor beta | hypothyroidism | LEVOTHYROXINE SODIUM | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f4d851f6-6bf5-4ed5-8d3a-1646773c4d40 | 1 | GoF | protect | |||
| Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2 | THRB | THRB | Thyroid hormone receptor beta | hypothyroidism | LEVOTHYROXINE SODIUM | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ea2463ca-26fc-4c37-9cde-a8730c60a9e6 | 1 | GoF | protect | |||
| Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2 | THRB | THRB | Thyroid hormone receptor beta | hypothyroidism | LEVOTHYROXINE SODIUM | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e0dcc021-0831-41dd-9750-251c2f71a614 | 1 | GoF | protect | |||
| Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2 | THRB | THRB | Thyroid hormone receptor beta | hypothyroidism | LEVOTHYROXINE SODIUM | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ac83ac72-b447-47df-b6ad-94537305b7b8 | 1 | GoF | protect | |||
| Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2 | THRB | THRB | Thyroid hormone receptor beta | hypothyroidism | LEVOTHYROXINE SODIUM | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c91d4f5b-dc9a-44aa-82e5-809831c260f6 | 1 | GoF | protect | |||
| Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2 | THRB | THRB | Thyroid hormone receptor beta | hypothyroidism | LEVOTHYROXINE SODIUM | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=02786c40-5745-4bd9-b429-53948e9ce262 | 1 | GoF | protect | |||
| Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2 | THRB | THRB | Thyroid hormone receptor beta | hypothyroidism | LEVOTHYROXINE SODIUM | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=00a4fc0b-7162-455e-8ed3-56efdbbe182e | 1 | GoF | protect | |||
| Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2 | THRB | THRB | Thyroid hormone receptor beta | congenital hypothyroidism | LEVOTHYROXINE SODIUM | targetBased | 4 | Active, not recruiting | 21/01/2022 | https://clinicaltrials.gov/study/NCT05228184 | 1 | GoF | protect | |
| Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2 | THRB | THRB | Thyroid hormone receptor beta | congenital hypothyroidism | LEVOTHYROXINE SODIUM | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f4d851f6-6bf5-4ed5-8d3a-1646773c4d40 | 1 | GoF | protect | |||
| Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2 | THRB | THRB | Thyroid hormone receptor beta | nodular goiter | LEVOTHYROXINE SODIUM | targetBased | 4 | Completed | 01/05/2004 | https://clinicaltrials.gov/study/NCT00277589 | 1 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | BALAGLITAZONE | targetBased | 3 | Completed | 01/07/2007 | https://clinicaltrials.gov/study/NCT00515632 | 0.7 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | BALAGLITAZONE | targetBased | 3 | Completed | 01/07/2007 | https://clinicaltrials.gov/study/NCT00515632 | 0.7 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | BALAGLITAZONE | targetBased | 3 | Completed | 01/07/2007 | https://clinicaltrials.gov/study/NCT00515632 | 0.7 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | BALAGLITAZONE | targetBased | 3 | Completed | 01/07/2007 | https://clinicaltrials.gov/study/NCT00515632 | 0.7 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | BALAGLITAZONE | targetBased | 3 | Completed | 01/07/2007 | https://clinicaltrials.gov/study/NCT00515632 | 0.7 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | BALAGLITAZONE | targetBased | 3 | Completed | 01/07/2007 | https://clinicaltrials.gov/study/NCT00515632 | 0.7 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | RIVOGLITAZONE | targetBased | 3 | Terminated | 14/11/2007 | https://clinicaltrials.gov/study/NCT00571519 | 0.7 | GoF | protect | DSPD focusing on Study 301 to confirm the clinical profile before proceeding. Daiichi Sankyo Pharma Development terminated this study on 23 Apr 2008 because of changes in the clinical development plan with 94 of 2600 planned, randomized participants. |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | RIVOGLITAZONE | targetBased | 3 | Terminated | 14/11/2007 | https://clinicaltrials.gov/study/NCT00571519 | 0.7 | GoF | protect | DSPD focusing on Study 301 to confirm the clinical profile before proceeding. Daiichi Sankyo Pharma Development terminated this study on 23 Apr 2008 because of changes in the clinical development plan with 94 of 2600 planned, randomized participants. |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | RIVOGLITAZONE | targetBased | 3 | Terminated | 14/11/2007 | https://clinicaltrials.gov/study/NCT00571519 | 0.7 | GoF | protect | DSPD focusing on Study 301 to confirm the clinical profile before proceeding. Daiichi Sankyo Pharma Development terminated this study on 23 Apr 2008 because of changes in the clinical development plan with 94 of 2600 planned, randomized participants. |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | RIVOGLITAZONE | targetBased | 3 | Terminated | 14/11/2007 | https://clinicaltrials.gov/study/NCT00571519 | 0.7 | GoF | protect | DSPD focusing on Study 301 to confirm the clinical profile before proceeding. Daiichi Sankyo Pharma Development terminated this study on 23 Apr 2008 because of changes in the clinical development plan with 94 of 2600 planned, randomized participants. |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | RIVOGLITAZONE | targetBased | 3 | Terminated | 14/11/2007 | https://clinicaltrials.gov/study/NCT00571519 | 0.7 | GoF | protect | DSPD focusing on Study 301 to confirm the clinical profile before proceeding. Daiichi Sankyo Pharma Development terminated this study on 23 Apr 2008 because of changes in the clinical development plan with 94 of 2600 planned, randomized participants. |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | RIVOGLITAZONE | targetBased | 3 | Terminated | 14/11/2007 | https://clinicaltrials.gov/study/NCT00571519 | 0.7 | GoF | protect | DSPD focusing on Study 301 to confirm the clinical profile before proceeding. Daiichi Sankyo Pharma Development terminated this study on 23 Apr 2008 because of changes in the clinical development plan with 94 of 2600 planned, randomized participants. |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | RIVOGLITAZONE | targetBased | 3 | Completed | 23/04/2007 | https://clinicaltrials.gov/study/NCT00484198 | 0.7 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | RIVOGLITAZONE | targetBased | 3 | Completed | 23/04/2007 | https://clinicaltrials.gov/study/NCT00484198 | 0.7 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | RIVOGLITAZONE | targetBased | 3 | Completed | 23/04/2007 | https://clinicaltrials.gov/study/NCT00484198 | 0.7 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | RIVOGLITAZONE | targetBased | 3 | Completed | 23/04/2007 | https://clinicaltrials.gov/study/NCT00484198 | 0.7 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | RIVOGLITAZONE | targetBased | 3 | Completed | 23/04/2007 | https://clinicaltrials.gov/study/NCT00484198 | 0.7 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | RIVOGLITAZONE | targetBased | 3 | Completed | 23/04/2007 | https://clinicaltrials.gov/study/NCT00484198 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | ALBIGLUTIDE | targetBased | 3 | Completed | 06/07/2016 | https://clinicaltrials.gov/study/NCT02787551 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | ALBIGLUTIDE | targetBased | 3 | Completed | 06/07/2016 | https://clinicaltrials.gov/study/NCT02787551 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | ALBIGLUTIDE | targetBased | 3 | Completed | 06/07/2016 | https://clinicaltrials.gov/study/NCT02787551 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | ALBIGLUTIDE | targetBased | 4 | Terminated | 26/09/2016 | https://clinicaltrials.gov/study/NCT02793154 | 1 | GoF | protect | Early termination due to insufficient enrollment. |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | ALBIGLUTIDE | targetBased | 4 | Terminated | 26/09/2016 | https://clinicaltrials.gov/study/NCT02793154 | 1 | GoF | protect | Early termination due to insufficient enrollment. |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | ALBIGLUTIDE | targetBased | 4 | Terminated | 26/09/2016 | https://clinicaltrials.gov/study/NCT02793154 | 1 | GoF | protect | Early termination due to insufficient enrollment. |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | ALBIGLUTIDE | targetBased | 3 | Withdrawn | 01/08/2015 | https://clinicaltrials.gov/study/NCT02229240 | 0.7 | GoF | protect | Study was cancelled prior to enrolling any patients |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | ALBIGLUTIDE | targetBased | 3 | Withdrawn | 01/08/2015 | https://clinicaltrials.gov/study/NCT02229240 | 0.7 | GoF | protect | Study was cancelled prior to enrolling any patients |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | ALBIGLUTIDE | targetBased | 3 | Withdrawn | 01/08/2015 | https://clinicaltrials.gov/study/NCT02229240 | 0.7 | GoF | protect | Study was cancelled prior to enrolling any patients |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | ALBIGLUTIDE | targetBased | 3 | Completed | 01/02/2013 | https://clinicaltrials.gov/study/NCT01733758 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | ALBIGLUTIDE | targetBased | 3 | Completed | 01/02/2013 | https://clinicaltrials.gov/study/NCT01733758 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | ALBIGLUTIDE | targetBased | 3 | Completed | 01/02/2013 | https://clinicaltrials.gov/study/NCT01733758 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | ALBIGLUTIDE | targetBased | 3 | Completed | 01/02/2009 | https://clinicaltrials.gov/study/NCT00838903 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | ALBIGLUTIDE | targetBased | 3 | Completed | 01/02/2009 | https://clinicaltrials.gov/study/NCT00838903 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | ALBIGLUTIDE | targetBased | 3 | Completed | 01/02/2009 | https://clinicaltrials.gov/study/NCT00838903 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | ALBIGLUTIDE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5fcad939-76e7-49cf-af94-4e6aef17901f | 1 | GoF | protect | |||
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | ALBIGLUTIDE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5fcad939-76e7-49cf-af94-4e6aef17901f | 1 | GoF | protect | |||
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | ALBIGLUTIDE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5fcad939-76e7-49cf-af94-4e6aef17901f | 1 | GoF | protect | |||
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | ALBIGLUTIDE | targetBased | 3 | Completed | 21/11/2014 | https://clinicaltrials.gov/study/NCT02229227 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | ALBIGLUTIDE | targetBased | 3 | Completed | 21/11/2014 | https://clinicaltrials.gov/study/NCT02229227 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | ALBIGLUTIDE | targetBased | 3 | Completed | 21/11/2014 | https://clinicaltrials.gov/study/NCT02229227 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | ALBIGLUTIDE | targetBased | 3 | Completed | 16/03/2016 | https://clinicaltrials.gov/study/NCT02683746 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | ALBIGLUTIDE | targetBased | 3 | Completed | 16/03/2016 | https://clinicaltrials.gov/study/NCT02683746 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | ALBIGLUTIDE | targetBased | 3 | Completed | 16/03/2016 | https://clinicaltrials.gov/study/NCT02683746 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | ALBIGLUTIDE | targetBased | 3 | Completed | 01/05/2010 | https://clinicaltrials.gov/study/NCT01098539 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | ALBIGLUTIDE | targetBased | 3 | Completed | 01/05/2010 | https://clinicaltrials.gov/study/NCT01098539 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | ALBIGLUTIDE | targetBased | 3 | Completed | 01/05/2010 | https://clinicaltrials.gov/study/NCT01098539 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | ALBIGLUTIDE | targetBased | 3 | Completed | 01/02/2009 | https://clinicaltrials.gov/study/NCT00839527 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | ALBIGLUTIDE | targetBased | 3 | Completed | 01/02/2009 | https://clinicaltrials.gov/study/NCT00839527 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | ALBIGLUTIDE | targetBased | 3 | Completed | 01/02/2009 | https://clinicaltrials.gov/study/NCT00839527 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | ALBIGLUTIDE | targetBased | 4 | Completed | 11/06/2015 | https://clinicaltrials.gov/study/NCT02496221 | 1 | GoF | protect | |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | ALBIGLUTIDE | targetBased | 4 | Completed | 11/06/2015 | https://clinicaltrials.gov/study/NCT02496221 | 1 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | ALBIGLUTIDE | targetBased | 4 | Completed | 11/06/2015 | https://clinicaltrials.gov/study/NCT02496221 | 1 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | ALBIGLUTIDE | targetBased | 4 | Terminated | 07/10/2016 | https://clinicaltrials.gov/study/NCT02750930 | 1 | GoF | protect | The termination was result of GSK business considerations and not due to quality, safety or efficacy concerns with any albiglutide formulations or study conduct |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | ALBIGLUTIDE | targetBased | 4 | Terminated | 07/10/2016 | https://clinicaltrials.gov/study/NCT02750930 | 1 | GoF | protect | The termination was result of GSK business considerations and not due to quality, safety or efficacy concerns with any albiglutide formulations or study conduct |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | ALBIGLUTIDE | targetBased | 4 | Terminated | 07/10/2016 | https://clinicaltrials.gov/study/NCT02750930 | 1 | GoF | protect | The termination was result of GSK business considerations and not due to quality, safety or efficacy concerns with any albiglutide formulations or study conduct |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | ALBIGLUTIDE | targetBased | 3 | Completed | 01/02/2009 | https://clinicaltrials.gov/study/NCT00838916 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | ALBIGLUTIDE | targetBased | 3 | Completed | 01/02/2009 | https://clinicaltrials.gov/study/NCT00838916 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | ALBIGLUTIDE | targetBased | 3 | Completed | 01/02/2009 | https://clinicaltrials.gov/study/NCT00838916 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | ALBIGLUTIDE | targetBased | 3 | Completed | 01/01/2009 | https://clinicaltrials.gov/study/NCT00849056 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | ALBIGLUTIDE | targetBased | 3 | Completed | 01/01/2009 | https://clinicaltrials.gov/study/NCT00849056 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | ALBIGLUTIDE | targetBased | 3 | Completed | 01/01/2009 | https://clinicaltrials.gov/study/NCT00849056 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | ALBIGLUTIDE | targetBased | 3 | Completed | 01/05/2010 | https://clinicaltrials.gov/study/NCT01128894 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | ALBIGLUTIDE | targetBased | 3 | Completed | 01/05/2010 | https://clinicaltrials.gov/study/NCT01128894 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | ALBIGLUTIDE | targetBased | 3 | Completed | 01/05/2010 | https://clinicaltrials.gov/study/NCT01128894 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | ALBIGLUTIDE | targetBased | 3 | Withdrawn | 14/08/2017 | https://clinicaltrials.gov/study/NCT03015519 | 0.7 | GoF | protect | The study did not start recruiting as albiglutide would have been withdrawn from the market prior to study end. |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | ALBIGLUTIDE | targetBased | 3 | Withdrawn | 14/08/2017 | https://clinicaltrials.gov/study/NCT03015519 | 0.7 | GoF | protect | The study did not start recruiting as albiglutide would have been withdrawn from the market prior to study end. |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | ALBIGLUTIDE | targetBased | 3 | Withdrawn | 14/08/2017 | https://clinicaltrials.gov/study/NCT03015519 | 0.7 | GoF | protect | The study did not start recruiting as albiglutide would have been withdrawn from the market prior to study end. |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | ALBIGLUTIDE | targetBased | 3 | Completed | 01/01/2009 | https://clinicaltrials.gov/study/NCT00849017 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | ALBIGLUTIDE | targetBased | 3 | Completed | 01/01/2009 | https://clinicaltrials.gov/study/NCT00849017 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | ALBIGLUTIDE | targetBased | 3 | Completed | 01/01/2009 | https://clinicaltrials.gov/study/NCT00849017 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | ALBIGLUTIDE | targetBased | 4 | https://www.ema.europa.eu/en/medicines/human/EPAR/eperzan | 1 | GoF | protect | |||
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | ALBIGLUTIDE | targetBased | 4 | https://www.ema.europa.eu/en/medicines/human/EPAR/eperzan | 1 | GoF | protect | |||
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | ALBIGLUTIDE | targetBased | 4 | https://www.ema.europa.eu/en/medicines/human/EPAR/eperzan | 1 | GoF | protect | |||
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | diabetes mellitus | ALBIGLUTIDE | targetBased | 4 | Terminated | 20/09/2016 | https://clinicaltrials.gov/study/NCT02802514 | 1 | GoF | protect | |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | diabetes mellitus | ALBIGLUTIDE | targetBased | 4 | Terminated | 20/09/2016 | https://clinicaltrials.gov/study/NCT02802514 | 1 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | diabetes mellitus | ALBIGLUTIDE | targetBased | 4 | Terminated | 20/09/2016 | https://clinicaltrials.gov/study/NCT02802514 | 1 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | diabetes mellitus | ALBIGLUTIDE | targetBased | 4 | Completed | 01/07/2015 | https://clinicaltrials.gov/study/NCT02465515 | 1 | GoF | protect | |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | diabetes mellitus | ALBIGLUTIDE | targetBased | 4 | Completed | 01/07/2015 | https://clinicaltrials.gov/study/NCT02465515 | 1 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | diabetes mellitus | ALBIGLUTIDE | targetBased | 4 | Completed | 01/07/2015 | https://clinicaltrials.gov/study/NCT02465515 | 1 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | diabetes mellitus | ALBIGLUTIDE | targetBased | 4 | https://www.whocc.no/atc_ddd_index/?code=A10BJ04 | 1 | GoF | protect | |||
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | diabetes mellitus | ALBIGLUTIDE | targetBased | 4 | https://www.whocc.no/atc_ddd_index/?code=A10BJ04 | 1 | GoF | protect | |||
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | diabetes mellitus | ALBIGLUTIDE | targetBased | 4 | https://www.whocc.no/atc_ddd_index/?code=A10BJ04 | 1 | GoF | protect | |||
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | diabetes mellitus | ALBIGLUTIDE | targetBased | 3 | Completed | 23/02/2013 | https://clinicaltrials.gov/study/NCT01777282 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | diabetes mellitus | ALBIGLUTIDE | targetBased | 3 | Completed | 23/02/2013 | https://clinicaltrials.gov/study/NCT01777282 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | diabetes mellitus | ALBIGLUTIDE | targetBased | 3 | Completed | 23/02/2013 | https://clinicaltrials.gov/study/NCT01777282 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | TASPOGLUTIDE | targetBased | 3 | Completed | 01/10/2008 | https://clinicaltrials.gov/study/NCT00744367 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | TASPOGLUTIDE | targetBased | 3 | Completed | 01/10/2008 | https://clinicaltrials.gov/study/NCT00744367 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | TASPOGLUTIDE | targetBased | 3 | Completed | 01/10/2008 | https://clinicaltrials.gov/study/NCT00744367 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | TASPOGLUTIDE | targetBased | 3 | Completed | 01/12/2008 | https://clinicaltrials.gov/study/NCT00809705 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | TASPOGLUTIDE | targetBased | 3 | Completed | 01/12/2008 | https://clinicaltrials.gov/study/NCT00809705 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | TASPOGLUTIDE | targetBased | 3 | Completed | 01/12/2008 | https://clinicaltrials.gov/study/NCT00809705 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | TASPOGLUTIDE | targetBased | 3 | Completed | 01/01/2009 | https://clinicaltrials.gov/study/NCT00823992 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | TASPOGLUTIDE | targetBased | 3 | Completed | 01/01/2009 | https://clinicaltrials.gov/study/NCT00823992 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | TASPOGLUTIDE | targetBased | 3 | Completed | 01/01/2009 | https://clinicaltrials.gov/study/NCT00823992 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | TASPOGLUTIDE | targetBased | 3 | Completed | 01/11/2008 | https://clinicaltrials.gov/study/NCT00755287 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | TASPOGLUTIDE | targetBased | 3 | Completed | 01/11/2008 | https://clinicaltrials.gov/study/NCT00755287 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | TASPOGLUTIDE | targetBased | 3 | Completed | 01/11/2008 | https://clinicaltrials.gov/study/NCT00755287 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | TASPOGLUTIDE | targetBased | 3 | Completed | 01/10/2008 | https://clinicaltrials.gov/study/NCT00754988 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | TASPOGLUTIDE | targetBased | 3 | Completed | 01/10/2008 | https://clinicaltrials.gov/study/NCT00754988 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | TASPOGLUTIDE | targetBased | 3 | Completed | 01/10/2008 | https://clinicaltrials.gov/study/NCT00754988 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | TASPOGLUTIDE | targetBased | 3 | Completed | 01/08/2008 | https://clinicaltrials.gov/study/NCT00744926 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | TASPOGLUTIDE | targetBased | 3 | Completed | 01/08/2008 | https://clinicaltrials.gov/study/NCT00744926 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | TASPOGLUTIDE | targetBased | 3 | Completed | 01/08/2008 | https://clinicaltrials.gov/study/NCT00744926 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | TASPOGLUTIDE | targetBased | 3 | Completed | 01/05/2009 | https://clinicaltrials.gov/study/NCT00909597 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | TASPOGLUTIDE | targetBased | 3 | Completed | 01/05/2009 | https://clinicaltrials.gov/study/NCT00909597 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | TASPOGLUTIDE | targetBased | 3 | Completed | 01/05/2009 | https://clinicaltrials.gov/study/NCT00909597 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | TASPOGLUTIDE | targetBased | 3 | Completed | 01/07/2008 | https://clinicaltrials.gov/study/NCT00717457 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | TASPOGLUTIDE | targetBased | 3 | Completed | 01/07/2008 | https://clinicaltrials.gov/study/NCT00717457 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | TASPOGLUTIDE | targetBased | 3 | Completed | 01/07/2008 | https://clinicaltrials.gov/study/NCT00717457 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | TASPOGLUTIDE | targetBased | 3 | Completed | 01/01/2010 | https://clinicaltrials.gov/study/NCT01018173 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | TASPOGLUTIDE | targetBased | 3 | Completed | 01/01/2010 | https://clinicaltrials.gov/study/NCT01018173 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | TASPOGLUTIDE | targetBased | 3 | Completed | 01/01/2010 | https://clinicaltrials.gov/study/NCT01018173 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | TASPOGLUTIDE | targetBased | 3 | Terminated | 01/01/2010 | https://clinicaltrials.gov/study/NCT01051011 | 0.35 | GoF | protect | high discontinuation rates mainly due to GI tolerability and implementation of risk mitigation plan to address hypersensitivity reactions |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | TASPOGLUTIDE | targetBased | 3 | Terminated | 01/01/2010 | https://clinicaltrials.gov/study/NCT01051011 | 0.35 | GoF | protect | high discontinuation rates mainly due to GI tolerability and implementation of risk mitigation plan to address hypersensitivity reactions |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | TASPOGLUTIDE | targetBased | 3 | Terminated | 01/01/2010 | https://clinicaltrials.gov/study/NCT01051011 | 0.35 | GoF | protect | high discontinuation rates mainly due to GI tolerability and implementation of risk mitigation plan to address hypersensitivity reactions |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | DULAGLUTIDE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=463050bd-2b1c-40f5-b3c3-0a04bb433309 | 1 | GoF | protect | |||
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | DULAGLUTIDE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=463050bd-2b1c-40f5-b3c3-0a04bb433309 | 1 | GoF | protect | |||
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | DULAGLUTIDE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=463050bd-2b1c-40f5-b3c3-0a04bb433309 | 1 | GoF | protect | |||
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | DULAGLUTIDE | targetBased | 3 | Completed | 01/06/2012 | https://clinicaltrials.gov/study/NCT01624259 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | DULAGLUTIDE | targetBased | 3 | Completed | 01/06/2012 | https://clinicaltrials.gov/study/NCT01624259 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | DULAGLUTIDE | targetBased | 3 | Completed | 01/06/2012 | https://clinicaltrials.gov/study/NCT01624259 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | DULAGLUTIDE | targetBased | 3 | Active, not recruiting | 06/01/2023 | https://clinicaltrials.gov/study/NCT05606913 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | DULAGLUTIDE | targetBased | 3 | Active, not recruiting | 06/01/2023 | https://clinicaltrials.gov/study/NCT05606913 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | DULAGLUTIDE | targetBased | 3 | Active, not recruiting | 06/01/2023 | https://clinicaltrials.gov/study/NCT05606913 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | DULAGLUTIDE | targetBased | 3 | Completed | 01/05/2014 | https://clinicaltrials.gov/study/NCT02152371 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | DULAGLUTIDE | targetBased | 3 | Completed | 01/05/2014 | https://clinicaltrials.gov/study/NCT02152371 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | DULAGLUTIDE | targetBased | 3 | Completed | 01/05/2014 | https://clinicaltrials.gov/study/NCT02152371 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | DULAGLUTIDE | targetBased | 3 | Completed | 29/12/2016 | https://clinicaltrials.gov/study/NCT02963766 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | DULAGLUTIDE | targetBased | 3 | Completed | 29/12/2016 | https://clinicaltrials.gov/study/NCT02963766 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | DULAGLUTIDE | targetBased | 3 | Completed | 29/12/2016 | https://clinicaltrials.gov/study/NCT02963766 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | DULAGLUTIDE | targetBased | 3 | Completed | 01/11/2015 | https://clinicaltrials.gov/study/NCT02597049 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | DULAGLUTIDE | targetBased | 3 | Completed | 01/11/2015 | https://clinicaltrials.gov/study/NCT02597049 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | DULAGLUTIDE | targetBased | 3 | Completed | 01/11/2015 | https://clinicaltrials.gov/study/NCT02597049 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | DULAGLUTIDE | targetBased | 4 | Completed | 29/12/2022 | https://clinicaltrials.gov/study/NCT05659537 | 1 | GoF | protect | |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | DULAGLUTIDE | targetBased | 4 | Completed | 29/12/2022 | https://clinicaltrials.gov/study/NCT05659537 | 1 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | DULAGLUTIDE | targetBased | 4 | Completed | 29/12/2022 | https://clinicaltrials.gov/study/NCT05659537 | 1 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | DULAGLUTIDE | targetBased | 3 | Active, not recruiting | 29/05/2020 | https://clinicaltrials.gov/study/NCT04255433 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | DULAGLUTIDE | targetBased | 3 | Active, not recruiting | 29/05/2020 | https://clinicaltrials.gov/study/NCT04255433 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | DULAGLUTIDE | targetBased | 3 | Active, not recruiting | 29/05/2020 | https://clinicaltrials.gov/study/NCT04255433 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | DULAGLUTIDE | targetBased | 3 | Completed | 01/07/2012 | https://clinicaltrials.gov/study/NCT01648582 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | DULAGLUTIDE | targetBased | 3 | Completed | 01/07/2012 | https://clinicaltrials.gov/study/NCT01648582 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | DULAGLUTIDE | targetBased | 3 | Completed | 01/07/2012 | https://clinicaltrials.gov/study/NCT01648582 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | DULAGLUTIDE | targetBased | 3 | Terminated | 26/09/2018 | https://clinicaltrials.gov/study/NCT03684642 | 0.7 | GoF | protect | Sponsor decision to cancel TRIAL, not related to safety concern. |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | DULAGLUTIDE | targetBased | 3 | Terminated | 26/09/2018 | https://clinicaltrials.gov/study/NCT03684642 | 0.7 | GoF | protect | Sponsor decision to cancel TRIAL, not related to safety concern. |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | DULAGLUTIDE | targetBased | 3 | Terminated | 26/09/2018 | https://clinicaltrials.gov/study/NCT03684642 | 0.7 | GoF | protect | Sponsor decision to cancel TRIAL, not related to safety concern. |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | DULAGLUTIDE | targetBased | 4 | Active, not recruiting | 26/05/2020 | https://clinicaltrials.gov/study/NCT04893148 | 1 | GoF | protect | |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | DULAGLUTIDE | targetBased | 4 | Active, not recruiting | 26/05/2020 | https://clinicaltrials.gov/study/NCT04893148 | 1 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | DULAGLUTIDE | targetBased | 4 | Active, not recruiting | 26/05/2020 | https://clinicaltrials.gov/study/NCT04893148 | 1 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | DULAGLUTIDE | targetBased | 3 | Completed | 13/04/2021 | https://clinicaltrials.gov/study/NCT04809220 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | DULAGLUTIDE | targetBased | 3 | Completed | 13/04/2021 | https://clinicaltrials.gov/study/NCT04809220 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | DULAGLUTIDE | targetBased | 3 | Completed | 13/04/2021 | https://clinicaltrials.gov/study/NCT04809220 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | DULAGLUTIDE | targetBased | 3 | Completed | 01/03/2012 | https://clinicaltrials.gov/study/NCT01558271 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | DULAGLUTIDE | targetBased | 3 | Completed | 01/03/2012 | https://clinicaltrials.gov/study/NCT01558271 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | DULAGLUTIDE | targetBased | 3 | Completed | 01/03/2012 | https://clinicaltrials.gov/study/NCT01558271 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | DULAGLUTIDE | targetBased | 4 | https://www.ema.europa.eu/en/medicines/human/EPAR/trulicity | 1 | GoF | protect | |||
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | DULAGLUTIDE | targetBased | 4 | https://www.ema.europa.eu/en/medicines/human/EPAR/trulicity | 1 | GoF | protect | |||
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | DULAGLUTIDE | targetBased | 4 | https://www.ema.europa.eu/en/medicines/human/EPAR/trulicity | 1 | GoF | protect | |||
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | DULAGLUTIDE | targetBased | 3 | Completed | 01/02/2010 | https://clinicaltrials.gov/study/NCT01064687 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | DULAGLUTIDE | targetBased | 3 | Completed | 01/02/2010 | https://clinicaltrials.gov/study/NCT01064687 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | DULAGLUTIDE | targetBased | 3 | Completed | 01/02/2010 | https://clinicaltrials.gov/study/NCT01064687 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | DULAGLUTIDE | targetBased | 3 | Active, not recruiting | 10/01/2023 | https://clinicaltrials.gov/study/NCT05680129 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | DULAGLUTIDE | targetBased | 3 | Active, not recruiting | 10/01/2023 | https://clinicaltrials.gov/study/NCT05680129 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | DULAGLUTIDE | targetBased | 3 | Active, not recruiting | 10/01/2023 | https://clinicaltrials.gov/study/NCT05680129 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | DULAGLUTIDE | targetBased | 3 | Completed | 06/07/2016 | https://clinicaltrials.gov/study/NCT02787551 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | DULAGLUTIDE | targetBased | 3 | Completed | 06/07/2016 | https://clinicaltrials.gov/study/NCT02787551 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | DULAGLUTIDE | targetBased | 3 | Completed | 06/07/2016 | https://clinicaltrials.gov/study/NCT02787551 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | DULAGLUTIDE | targetBased | 3 | Completed | 05/04/2018 | https://clinicaltrials.gov/study/NCT03495102 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | DULAGLUTIDE | targetBased | 3 | Completed | 05/04/2018 | https://clinicaltrials.gov/study/NCT03495102 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | DULAGLUTIDE | targetBased | 3 | Completed | 05/04/2018 | https://clinicaltrials.gov/study/NCT03495102 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | DULAGLUTIDE | targetBased | 3 | Completed | 01/05/2010 | https://clinicaltrials.gov/study/NCT01126580 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | DULAGLUTIDE | targetBased | 3 | Completed | 01/05/2010 | https://clinicaltrials.gov/study/NCT01126580 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | DULAGLUTIDE | targetBased | 3 | Completed | 01/05/2010 | https://clinicaltrials.gov/study/NCT01126580 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | DULAGLUTIDE | targetBased | 3 | Not yet recruiting | 01/03/2024 | https://clinicaltrials.gov/study/NCT06235086 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | DULAGLUTIDE | targetBased | 3 | Not yet recruiting | 01/03/2024 | https://clinicaltrials.gov/study/NCT06235086 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | DULAGLUTIDE | targetBased | 3 | Not yet recruiting | 01/03/2024 | https://clinicaltrials.gov/study/NCT06235086 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | DULAGLUTIDE | targetBased | 3 | Completed | 01/02/2010 | https://clinicaltrials.gov/study/NCT01075282 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | DULAGLUTIDE | targetBased | 3 | Completed | 01/02/2010 | https://clinicaltrials.gov/study/NCT01075282 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | DULAGLUTIDE | targetBased | 3 | Completed | 01/02/2010 | https://clinicaltrials.gov/study/NCT01075282 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | DULAGLUTIDE | targetBased | 3 | Completed | 01/11/2010 | https://clinicaltrials.gov/study/NCT01191268 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | DULAGLUTIDE | targetBased | 3 | Completed | 01/11/2010 | https://clinicaltrials.gov/study/NCT01191268 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | DULAGLUTIDE | targetBased | 3 | Completed | 01/11/2010 | https://clinicaltrials.gov/study/NCT01191268 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | DULAGLUTIDE | targetBased | 3 | Completed | 01/07/2012 | https://clinicaltrials.gov/study/NCT01644500 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | DULAGLUTIDE | targetBased | 3 | Completed | 01/07/2012 | https://clinicaltrials.gov/study/NCT01644500 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | DULAGLUTIDE | targetBased | 3 | Completed | 01/07/2012 | https://clinicaltrials.gov/study/NCT01644500 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | DULAGLUTIDE | targetBased | 4 | Completed | 01/08/2016 | https://clinicaltrials.gov/study/NCT02750410 | 1 | GoF | protect | |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | DULAGLUTIDE | targetBased | 4 | Completed | 01/08/2016 | https://clinicaltrials.gov/study/NCT02750410 | 1 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | DULAGLUTIDE | targetBased | 4 | Completed | 01/08/2016 | https://clinicaltrials.gov/study/NCT02750410 | 1 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | DULAGLUTIDE | targetBased | 3 | Completed | 01/11/2011 | https://clinicaltrials.gov/study/NCT01468181 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | DULAGLUTIDE | targetBased | 3 | Completed | 01/11/2011 | https://clinicaltrials.gov/study/NCT01468181 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | DULAGLUTIDE | targetBased | 3 | Completed | 01/11/2011 | https://clinicaltrials.gov/study/NCT01468181 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | DULAGLUTIDE | targetBased | 3 | Completed | 10/01/2017 | https://clinicaltrials.gov/study/NCT03015220 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | DULAGLUTIDE | targetBased | 3 | Completed | 10/01/2017 | https://clinicaltrials.gov/study/NCT03015220 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | DULAGLUTIDE | targetBased | 3 | Completed | 10/01/2017 | https://clinicaltrials.gov/study/NCT03015220 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | DULAGLUTIDE | targetBased | 4 | Active, not recruiting | 30/11/2022 | https://clinicaltrials.gov/study/NCT05564039 | 1 | GoF | protect | |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | DULAGLUTIDE | targetBased | 4 | Active, not recruiting | 30/11/2022 | https://clinicaltrials.gov/study/NCT05564039 | 1 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | DULAGLUTIDE | targetBased | 4 | Active, not recruiting | 30/11/2022 | https://clinicaltrials.gov/study/NCT05564039 | 1 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | DULAGLUTIDE | targetBased | 3 | Completed | 06/01/2016 | https://clinicaltrials.gov/study/NCT02648204 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | DULAGLUTIDE | targetBased | 3 | Completed | 06/01/2016 | https://clinicaltrials.gov/study/NCT02648204 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | DULAGLUTIDE | targetBased | 3 | Completed | 06/01/2016 | https://clinicaltrials.gov/study/NCT02648204 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | DULAGLUTIDE | targetBased | 3 | Completed | 07/05/2019 | https://clinicaltrials.gov/study/NCT03861052 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | DULAGLUTIDE | targetBased | 3 | Completed | 07/05/2019 | https://clinicaltrials.gov/study/NCT03861052 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | DULAGLUTIDE | targetBased | 3 | Completed | 07/05/2019 | https://clinicaltrials.gov/study/NCT03861052 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | DULAGLUTIDE | targetBased | 4 | Recruiting | 17/11/2017 | https://clinicaltrials.gov/study/NCT03444142 | 1 | GoF | protect | |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | DULAGLUTIDE | targetBased | 4 | Recruiting | 17/11/2017 | https://clinicaltrials.gov/study/NCT03444142 | 1 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | DULAGLUTIDE | targetBased | 4 | Recruiting | 17/11/2017 | https://clinicaltrials.gov/study/NCT03444142 | 1 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | DULAGLUTIDE | targetBased | 3 | Completed | 07/12/2020 | https://clinicaltrials.gov/study/NCT04591626 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | DULAGLUTIDE | targetBased | 3 | Completed | 07/12/2020 | https://clinicaltrials.gov/study/NCT04591626 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | DULAGLUTIDE | targetBased | 3 | Completed | 07/12/2020 | https://clinicaltrials.gov/study/NCT04591626 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | DULAGLUTIDE | targetBased | 3 | Completed | 01/04/2012 | https://clinicaltrials.gov/study/NCT01584232 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | DULAGLUTIDE | targetBased | 3 | Completed | 01/04/2012 | https://clinicaltrials.gov/study/NCT01584232 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | DULAGLUTIDE | targetBased | 3 | Completed | 01/04/2012 | https://clinicaltrials.gov/study/NCT01584232 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | DULAGLUTIDE | targetBased | 4 | Completed | 28/10/2017 | https://clinicaltrials.gov/study/NCT03315780 | 1 | GoF | protect | |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | DULAGLUTIDE | targetBased | 4 | Completed | 28/10/2017 | https://clinicaltrials.gov/study/NCT03315780 | 1 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | DULAGLUTIDE | targetBased | 4 | Completed | 28/10/2017 | https://clinicaltrials.gov/study/NCT03315780 | 1 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | DULAGLUTIDE | targetBased | 3 | Completed | 01/01/2013 | https://clinicaltrials.gov/study/NCT01769378 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | DULAGLUTIDE | targetBased | 3 | Completed | 01/01/2013 | https://clinicaltrials.gov/study/NCT01769378 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | DULAGLUTIDE | targetBased | 3 | Completed | 01/01/2013 | https://clinicaltrials.gov/study/NCT01769378 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | diabetes mellitus | DULAGLUTIDE | targetBased | 4 | https://www.whocc.no/atc_ddd_index/?code=A10BJ05 | 1 | GoF | protect | |||
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | diabetes mellitus | DULAGLUTIDE | targetBased | 4 | https://www.whocc.no/atc_ddd_index/?code=A10BJ05 | 1 | GoF | protect | |||
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | diabetes mellitus | DULAGLUTIDE | targetBased | 4 | https://www.whocc.no/atc_ddd_index/?code=A10BJ05 | 1 | GoF | protect | |||
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | diabetes mellitus | DULAGLUTIDE | targetBased | 3 | Not yet recruiting | 01/03/2024 | https://clinicaltrials.gov/study/NCT06257966 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | diabetes mellitus | DULAGLUTIDE | targetBased | 3 | Not yet recruiting | 01/03/2024 | https://clinicaltrials.gov/study/NCT06257966 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | diabetes mellitus | DULAGLUTIDE | targetBased | 3 | Not yet recruiting | 01/03/2024 | https://clinicaltrials.gov/study/NCT06257966 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | diabetes mellitus | DULAGLUTIDE | targetBased | 4 | Completed | 01/04/2017 | https://clinicaltrials.gov/study/NCT03824002 | 1 | GoF | protect | |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | diabetes mellitus | DULAGLUTIDE | targetBased | 4 | Completed | 01/04/2017 | https://clinicaltrials.gov/study/NCT03824002 | 1 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | diabetes mellitus | DULAGLUTIDE | targetBased | 4 | Completed | 01/04/2017 | https://clinicaltrials.gov/study/NCT03824002 | 1 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | Hyperglycemia | DULAGLUTIDE | targetBased | 4 | Terminated | 08/03/2019 | https://clinicaltrials.gov/study/NCT03743025 | 0.5 | GoF | protect | The study was terminated following the Data and Safety Monitoring Board (DSMB) review due to concerns with perioperative use of the study drug. |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | Hyperglycemia | DULAGLUTIDE | targetBased | 4 | Terminated | 08/03/2019 | https://clinicaltrials.gov/study/NCT03743025 | 0.5 | GoF | protect | The study was terminated following the Data and Safety Monitoring Board (DSMB) review due to concerns with perioperative use of the study drug. |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | Hyperglycemia | DULAGLUTIDE | targetBased | 4 | Terminated | 08/03/2019 | https://clinicaltrials.gov/study/NCT03743025 | 0.5 | GoF | protect | The study was terminated following the Data and Safety Monitoring Board (DSMB) review due to concerns with perioperative use of the study drug. |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | Hyperglycemia | DULAGLUTIDE | targetBased | 4 | Recruiting | 29/07/2021 | https://clinicaltrials.gov/study/NCT04862234 | 1 | GoF | protect | |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | Hyperglycemia | DULAGLUTIDE | targetBased | 4 | Recruiting | 29/07/2021 | https://clinicaltrials.gov/study/NCT04862234 | 1 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | Hyperglycemia | DULAGLUTIDE | targetBased | 4 | Recruiting | 29/07/2021 | https://clinicaltrials.gov/study/NCT04862234 | 1 | GoF | protect | |
| qHTS for PTHR1 Agonists: Primary Screen | PTH1R | PTH1R | Parathyroid hormone/parathyroid hormone-related peptide receptor | hypoparathyroidism | PARATHYROID HORMONE | targetBased | 3 | Completed | 19/08/2011 | https://clinicaltrials.gov/study/NCT01455181 | 0.7 | GoF | protect | |
| qHTS for PTHR1 Agonists: Primary Screen | PTH1R | PTH1R | Parathyroid hormone/parathyroid hormone-related peptide receptor | hypoparathyroidism | PARATHYROID HORMONE | targetBased | 3 | Completed | 18/12/2008 | https://clinicaltrials.gov/study/NCT00732615 | 0.7 | GoF | protect | |
| qHTS for PTHR1 Agonists: Primary Screen | PTH1R | PTH1R | Parathyroid hormone/parathyroid hormone-related peptide receptor | hypoparathyroidism | PARATHYROID HORMONE | targetBased | 4 | https://www.ema.europa.eu/en/medicines/human/EPAR/natpar | 1 | GoF | protect | |||
| qHTS for PTHR1 Agonists: Primary Screen | PTH1R | PTH1R | Parathyroid hormone/parathyroid hormone-related peptide receptor | hypoparathyroidism | PARATHYROID HORMONE | targetBased | 3 | Unknown status | 01/12/2009 | https://clinicaltrials.gov/study/NCT01199614 | 0.7 | GoF | protect | |
| qHTS for PTHR1 Agonists: Primary Screen | PTH1R | PTH1R | Parathyroid hormone/parathyroid hormone-related peptide receptor | hypoparathyroidism | PARATHYROID HORMONE | targetBased | 3 | Completed | 06/04/2011 | https://clinicaltrials.gov/study/NCT01297309 | 0.7 | GoF | protect | |
| qHTS for PTHR1 Agonists: Primary Screen | PTH1R | PTH1R | Parathyroid hormone/parathyroid hormone-related peptide receptor | hypoparathyroidism | PARATHYROID HORMONE | targetBased | 3 | Completed | 09/02/2011 | https://clinicaltrials.gov/study/NCT01268098 | 0.7 | GoF | protect | |
| qHTS for PTHR1 Agonists: Primary Screen | PTH1R | PTH1R | Parathyroid hormone/parathyroid hormone-related peptide receptor | hypoparathyroidism | PARATHYROID HORMONE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d11fba31-0a6c-11e3-8ffd-0800200c9a66 | 1 | GoF | protect | |||
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | LIXISENATIDE | targetBased | 3 | Completed | 01/07/2010 | https://clinicaltrials.gov/study/NCT01169779 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | LIXISENATIDE | targetBased | 3 | Completed | 01/07/2010 | https://clinicaltrials.gov/study/NCT01169779 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | LIXISENATIDE | targetBased | 3 | Completed | 01/07/2010 | https://clinicaltrials.gov/study/NCT01169779 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | LIXISENATIDE | targetBased | 3 | Completed | 01/03/2009 | https://clinicaltrials.gov/study/NCT00866658 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | LIXISENATIDE | targetBased | 3 | Completed | 01/03/2009 | https://clinicaltrials.gov/study/NCT00866658 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | LIXISENATIDE | targetBased | 3 | Completed | 01/03/2009 | https://clinicaltrials.gov/study/NCT00866658 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | LIXISENATIDE | targetBased | 4 | Completed | 02/10/2018 | https://clinicaltrials.gov/study/NCT03819790 | 1 | GoF | protect | |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | LIXISENATIDE | targetBased | 4 | Completed | 02/10/2018 | https://clinicaltrials.gov/study/NCT03819790 | 1 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | LIXISENATIDE | targetBased | 4 | Completed | 02/10/2018 | https://clinicaltrials.gov/study/NCT03819790 | 1 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | LIXISENATIDE | targetBased | 3 | Completed | 09/05/2016 | https://clinicaltrials.gov/study/NCT02749890 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | LIXISENATIDE | targetBased | 3 | Completed | 09/05/2016 | https://clinicaltrials.gov/study/NCT02749890 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | LIXISENATIDE | targetBased | 3 | Completed | 09/05/2016 | https://clinicaltrials.gov/study/NCT02749890 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | LIXISENATIDE | targetBased | 3 | Completed | 01/08/2009 | https://clinicaltrials.gov/study/NCT00976937 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | LIXISENATIDE | targetBased | 3 | Completed | 01/08/2009 | https://clinicaltrials.gov/study/NCT00976937 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | LIXISENATIDE | targetBased | 3 | Completed | 01/08/2009 | https://clinicaltrials.gov/study/NCT00976937 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | LIXISENATIDE | targetBased | 3 | Completed | 01/05/2008 | https://clinicaltrials.gov/study/NCT00688701 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | LIXISENATIDE | targetBased | 3 | Completed | 01/05/2008 | https://clinicaltrials.gov/study/NCT00688701 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | LIXISENATIDE | targetBased | 3 | Completed | 01/05/2008 | https://clinicaltrials.gov/study/NCT00688701 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | LIXISENATIDE | targetBased | 4 | https://www.ema.europa.eu/en/medicines/human/EPAR/lyxumia | 1 | GoF | protect | |||
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | LIXISENATIDE | targetBased | 4 | https://www.ema.europa.eu/en/medicines/human/EPAR/lyxumia | 1 | GoF | protect | |||
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | LIXISENATIDE | targetBased | 4 | https://www.ema.europa.eu/en/medicines/human/EPAR/lyxumia | 1 | GoF | protect | |||
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | LIXISENATIDE | targetBased | 4 | Completed | 01/01/2014 | https://clinicaltrials.gov/study/NCT02049034 | 1 | GoF | protect | |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | LIXISENATIDE | targetBased | 4 | Completed | 01/01/2014 | https://clinicaltrials.gov/study/NCT02049034 | 1 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | LIXISENATIDE | targetBased | 4 | Completed | 01/01/2014 | https://clinicaltrials.gov/study/NCT02049034 | 1 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | LIXISENATIDE | targetBased | 3 | Completed | 01/07/2008 | https://clinicaltrials.gov/study/NCT00713830 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | LIXISENATIDE | targetBased | 3 | Completed | 01/07/2008 | https://clinicaltrials.gov/study/NCT00713830 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | LIXISENATIDE | targetBased | 3 | Completed | 01/07/2008 | https://clinicaltrials.gov/study/NCT00713830 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | LIXISENATIDE | targetBased | 4 | Completed | 01/08/2014 | https://clinicaltrials.gov/study/NCT02200991 | 1 | GoF | protect | |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | LIXISENATIDE | targetBased | 4 | Completed | 01/08/2014 | https://clinicaltrials.gov/study/NCT02200991 | 1 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | LIXISENATIDE | targetBased | 4 | Completed | 01/08/2014 | https://clinicaltrials.gov/study/NCT02200991 | 1 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | LIXISENATIDE | targetBased | 3 | Completed | 01/06/2008 | https://clinicaltrials.gov/study/NCT00707031 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | LIXISENATIDE | targetBased | 3 | Completed | 01/06/2008 | https://clinicaltrials.gov/study/NCT00707031 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | LIXISENATIDE | targetBased | 3 | Completed | 01/06/2008 | https://clinicaltrials.gov/study/NCT00707031 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | LIXISENATIDE | targetBased | 3 | Completed | 01/11/2014 | https://clinicaltrials.gov/study/NCT02168491 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | LIXISENATIDE | targetBased | 3 | Completed | 01/11/2014 | https://clinicaltrials.gov/study/NCT02168491 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | LIXISENATIDE | targetBased | 3 | Completed | 01/11/2014 | https://clinicaltrials.gov/study/NCT02168491 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | LIXISENATIDE | targetBased | 3 | Completed | 06/07/2016 | https://clinicaltrials.gov/study/NCT02787551 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | LIXISENATIDE | targetBased | 3 | Completed | 06/07/2016 | https://clinicaltrials.gov/study/NCT02787551 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | LIXISENATIDE | targetBased | 3 | Completed | 06/07/2016 | https://clinicaltrials.gov/study/NCT02787551 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | LIXISENATIDE | targetBased | 3 | Completed | 01/09/2008 | https://clinicaltrials.gov/study/NCT00763815 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | LIXISENATIDE | targetBased | 3 | Completed | 01/09/2008 | https://clinicaltrials.gov/study/NCT00763815 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | LIXISENATIDE | targetBased | 3 | Completed | 01/09/2008 | https://clinicaltrials.gov/study/NCT00763815 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | LIXISENATIDE | targetBased | 3 | Completed | 01/10/2012 | https://clinicaltrials.gov/study/NCT01632163 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | LIXISENATIDE | targetBased | 3 | Completed | 01/10/2012 | https://clinicaltrials.gov/study/NCT01632163 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | LIXISENATIDE | targetBased | 3 | Completed | 01/10/2012 | https://clinicaltrials.gov/study/NCT01632163 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | LIXISENATIDE | targetBased | 4 | Terminated | 12/07/2016 | https://clinicaltrials.gov/study/NCT02767596 | 1 | GoF | protect | Insufficient recruitment rate |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | LIXISENATIDE | targetBased | 4 | Terminated | 12/07/2016 | https://clinicaltrials.gov/study/NCT02767596 | 1 | GoF | protect | Insufficient recruitment rate |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | LIXISENATIDE | targetBased | 4 | Terminated | 12/07/2016 | https://clinicaltrials.gov/study/NCT02767596 | 1 | GoF | protect | Insufficient recruitment rate |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | LIXISENATIDE | targetBased | 3 | Completed | 01/02/2014 | https://clinicaltrials.gov/study/NCT02058147 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | LIXISENATIDE | targetBased | 3 | Completed | 01/02/2014 | https://clinicaltrials.gov/study/NCT02058147 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | LIXISENATIDE | targetBased | 3 | Completed | 01/02/2014 | https://clinicaltrials.gov/study/NCT02058147 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | LIXISENATIDE | targetBased | 4 | Completed | 27/01/2022 | https://clinicaltrials.gov/study/NCT05114590 | 1 | GoF | protect | |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | LIXISENATIDE | targetBased | 4 | Completed | 27/01/2022 | https://clinicaltrials.gov/study/NCT05114590 | 1 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | LIXISENATIDE | targetBased | 4 | Completed | 27/01/2022 | https://clinicaltrials.gov/study/NCT05114590 | 1 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | LIXISENATIDE | targetBased | 3 | Completed | 01/05/2009 | https://clinicaltrials.gov/study/NCT00905255 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | LIXISENATIDE | targetBased | 3 | Completed | 01/05/2009 | https://clinicaltrials.gov/study/NCT00905255 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | LIXISENATIDE | targetBased | 3 | Completed | 01/05/2009 | https://clinicaltrials.gov/study/NCT00905255 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | LIXISENATIDE | targetBased | 4 | Completed | 01/12/2013 | https://clinicaltrials.gov/study/NCT02020629 | 1 | GoF | protect | |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | LIXISENATIDE | targetBased | 4 | Completed | 01/12/2013 | https://clinicaltrials.gov/study/NCT02020629 | 1 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | LIXISENATIDE | targetBased | 4 | Completed | 01/12/2013 | https://clinicaltrials.gov/study/NCT02020629 | 1 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | LIXISENATIDE | targetBased | 3 | Completed | 01/06/2008 | https://clinicaltrials.gov/study/NCT00712673 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | LIXISENATIDE | targetBased | 3 | Completed | 01/06/2008 | https://clinicaltrials.gov/study/NCT00712673 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | LIXISENATIDE | targetBased | 3 | Completed | 01/06/2008 | https://clinicaltrials.gov/study/NCT00712673 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | LIXISENATIDE | targetBased | 3 | Completed | 01/07/2008 | https://clinicaltrials.gov/study/NCT00715624 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | LIXISENATIDE | targetBased | 3 | Completed | 01/07/2008 | https://clinicaltrials.gov/study/NCT00715624 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | LIXISENATIDE | targetBased | 3 | Completed | 01/07/2008 | https://clinicaltrials.gov/study/NCT00715624 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | LIXISENATIDE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1727cc16-4f86-4f13-b8b5-804d4984fa8c | 1 | GoF | protect | |||
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | LIXISENATIDE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1727cc16-4f86-4f13-b8b5-804d4984fa8c | 1 | GoF | protect | |||
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | LIXISENATIDE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1727cc16-4f86-4f13-b8b5-804d4984fa8c | 1 | GoF | protect | |||
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | LIXISENATIDE | targetBased | 3 | Completed | 01/02/2012 | https://clinicaltrials.gov/study/NCT01517412 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | LIXISENATIDE | targetBased | 3 | Completed | 01/02/2012 | https://clinicaltrials.gov/study/NCT01517412 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | LIXISENATIDE | targetBased | 3 | Completed | 01/02/2012 | https://clinicaltrials.gov/study/NCT01517412 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | LIXISENATIDE | targetBased | 3 | Completed | 01/06/2013 | https://clinicaltrials.gov/study/NCT01798706 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | LIXISENATIDE | targetBased | 3 | Completed | 01/06/2013 | https://clinicaltrials.gov/study/NCT01798706 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | LIXISENATIDE | targetBased | 3 | Completed | 01/06/2013 | https://clinicaltrials.gov/study/NCT01798706 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | LIXISENATIDE | targetBased | 3 | Completed | 01/09/2008 | https://clinicaltrials.gov/study/NCT00763451 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | LIXISENATIDE | targetBased | 3 | Completed | 01/09/2008 | https://clinicaltrials.gov/study/NCT00763451 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | LIXISENATIDE | targetBased | 3 | Completed | 01/09/2008 | https://clinicaltrials.gov/study/NCT00763451 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | LIXISENATIDE | targetBased | 3 | Completed | 07/07/2022 | https://clinicaltrials.gov/study/NCT05413369 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | LIXISENATIDE | targetBased | 3 | Completed | 07/07/2022 | https://clinicaltrials.gov/study/NCT05413369 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | LIXISENATIDE | targetBased | 3 | Completed | 07/07/2022 | https://clinicaltrials.gov/study/NCT05413369 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | LIXISENATIDE | targetBased | 3 | Terminated | 20/02/2018 | https://clinicaltrials.gov/study/NCT03434119 | 0.7 | GoF | protect | ("Trial terminated (recruitment delays)") |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | LIXISENATIDE | targetBased | 3 | Terminated | 20/02/2018 | https://clinicaltrials.gov/study/NCT03434119 | 0.7 | GoF | protect | ("Trial terminated (recruitment delays)") |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | LIXISENATIDE | targetBased | 3 | Terminated | 20/02/2018 | https://clinicaltrials.gov/study/NCT03434119 | 0.7 | GoF | protect | ("Trial terminated (recruitment delays)") |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | LIXISENATIDE | targetBased | 4 | Completed | 01/10/2013 | https://clinicaltrials.gov/study/NCT01973231 | 1 | GoF | protect | |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | LIXISENATIDE | targetBased | 4 | Completed | 01/10/2013 | https://clinicaltrials.gov/study/NCT01973231 | 1 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | LIXISENATIDE | targetBased | 4 | Completed | 01/10/2013 | https://clinicaltrials.gov/study/NCT01973231 | 1 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | LIXISENATIDE | targetBased | 3 | Completed | 01/01/2013 | https://clinicaltrials.gov/study/NCT01768559 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | LIXISENATIDE | targetBased | 3 | Completed | 01/01/2013 | https://clinicaltrials.gov/study/NCT01768559 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | LIXISENATIDE | targetBased | 3 | Completed | 01/01/2013 | https://clinicaltrials.gov/study/NCT01768559 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | LIXISENATIDE | targetBased | 3 | Completed | 11/03/2019 | https://clinicaltrials.gov/study/NCT03767543 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | LIXISENATIDE | targetBased | 3 | Completed | 11/03/2019 | https://clinicaltrials.gov/study/NCT03767543 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | LIXISENATIDE | targetBased | 3 | Completed | 11/03/2019 | https://clinicaltrials.gov/study/NCT03767543 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | LIXISENATIDE | targetBased | 3 | Completed | 15/02/2019 | https://clinicaltrials.gov/study/NCT03798054 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | LIXISENATIDE | targetBased | 3 | Completed | 15/02/2019 | https://clinicaltrials.gov/study/NCT03798054 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | LIXISENATIDE | targetBased | 3 | Completed | 15/02/2019 | https://clinicaltrials.gov/study/NCT03798054 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | LIXISENATIDE | targetBased | 4 | https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/208471Orig1s000lbl.pdf | 1 | GoF | protect | |||
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | LIXISENATIDE | targetBased | 4 | https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/208471Orig1s000lbl.pdf | 1 | GoF | protect | |||
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | LIXISENATIDE | targetBased | 4 | https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/208471Orig1s000lbl.pdf | 1 | GoF | protect | |||
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | LIXISENATIDE | targetBased | 3 | Completed | 01/09/2013 | https://clinicaltrials.gov/study/NCT01940965 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | LIXISENATIDE | targetBased | 3 | Completed | 01/09/2013 | https://clinicaltrials.gov/study/NCT01940965 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | LIXISENATIDE | targetBased | 3 | Completed | 01/09/2013 | https://clinicaltrials.gov/study/NCT01940965 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | LIXISENATIDE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4bba538b-cf7c-4310-ae8f-cb711ed21bcc | 1 | GoF | protect | |||
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | LIXISENATIDE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4bba538b-cf7c-4310-ae8f-cb711ed21bcc | 1 | GoF | protect | |||
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | LIXISENATIDE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4bba538b-cf7c-4310-ae8f-cb711ed21bcc | 1 | GoF | protect | |||
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | LIXISENATIDE | targetBased | 3 | Completed | 01/11/2013 | https://clinicaltrials.gov/study/NCT01960179 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | LIXISENATIDE | targetBased | 3 | Completed | 01/11/2013 | https://clinicaltrials.gov/study/NCT01960179 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | LIXISENATIDE | targetBased | 3 | Completed | 01/11/2013 | https://clinicaltrials.gov/study/NCT01960179 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | LIXISENATIDE | targetBased | 3 | Completed | 01/10/2009 | https://clinicaltrials.gov/study/NCT00975286 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | LIXISENATIDE | targetBased | 3 | Completed | 01/10/2009 | https://clinicaltrials.gov/study/NCT00975286 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | LIXISENATIDE | targetBased | 3 | Completed | 01/10/2009 | https://clinicaltrials.gov/study/NCT00975286 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | LIXISENATIDE | targetBased | 4 | Completed | 23/02/2017 | https://clinicaltrials.gov/study/NCT02941367 | 1 | GoF | protect | |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | LIXISENATIDE | targetBased | 4 | Completed | 23/02/2017 | https://clinicaltrials.gov/study/NCT02941367 | 1 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | LIXISENATIDE | targetBased | 4 | Completed | 23/02/2017 | https://clinicaltrials.gov/study/NCT02941367 | 1 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | diabetes mellitus | LIXISENATIDE | targetBased | 4 | https://www.whocc.no/atc_ddd_index/?code=A10BJ03 | 1 | GoF | protect | |||
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | diabetes mellitus | LIXISENATIDE | targetBased | 4 | https://www.whocc.no/atc_ddd_index/?code=A10BJ03 | 1 | GoF | protect | |||
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | diabetes mellitus | LIXISENATIDE | targetBased | 4 | https://www.whocc.no/atc_ddd_index/?code=A10BJ03 | 1 | GoF | protect | |||
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | SEMAGLUTIDE | targetBased | 3 | Completed | 15/02/2016 | https://clinicaltrials.gov/study/NCT02607865 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | SEMAGLUTIDE | targetBased | 3 | Completed | 15/02/2016 | https://clinicaltrials.gov/study/NCT02607865 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | SEMAGLUTIDE | targetBased | 3 | Completed | 15/02/2016 | https://clinicaltrials.gov/study/NCT02607865 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | SEMAGLUTIDE | targetBased | 3 | Completed | 10/01/2017 | https://clinicaltrials.gov/study/NCT03018028 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | SEMAGLUTIDE | targetBased | 3 | Completed | 10/01/2017 | https://clinicaltrials.gov/study/NCT03018028 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | SEMAGLUTIDE | targetBased | 3 | Completed | 10/01/2017 | https://clinicaltrials.gov/study/NCT03018028 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | SEMAGLUTIDE | targetBased | 3 | Completed | 19/06/2019 | https://clinicaltrials.gov/study/NCT03989232 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | SEMAGLUTIDE | targetBased | 3 | Completed | 19/06/2019 | https://clinicaltrials.gov/study/NCT03989232 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | SEMAGLUTIDE | targetBased | 3 | Completed | 19/06/2019 | https://clinicaltrials.gov/study/NCT03989232 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | SEMAGLUTIDE | targetBased | 4 | Completed | 29/03/2022 | https://clinicaltrials.gov/study/NCT05533632 | 1 | GoF | protect | |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | SEMAGLUTIDE | targetBased | 4 | Completed | 29/03/2022 | https://clinicaltrials.gov/study/NCT05533632 | 1 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | SEMAGLUTIDE | targetBased | 4 | Completed | 29/03/2022 | https://clinicaltrials.gov/study/NCT05533632 | 1 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | SEMAGLUTIDE | targetBased | 3 | Completed | 30/07/2019 | https://clinicaltrials.gov/study/NCT03987919 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | SEMAGLUTIDE | targetBased | 3 | Completed | 30/07/2019 | https://clinicaltrials.gov/study/NCT03987919 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | SEMAGLUTIDE | targetBased | 3 | Completed | 30/07/2019 | https://clinicaltrials.gov/study/NCT03987919 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | SEMAGLUTIDE | targetBased | 3 | Completed | 01/10/2018 | https://clinicaltrials.gov/study/NCT03689374 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | SEMAGLUTIDE | targetBased | 3 | Completed | 01/10/2018 | https://clinicaltrials.gov/study/NCT03689374 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | SEMAGLUTIDE | targetBased | 3 | Completed | 01/10/2018 | https://clinicaltrials.gov/study/NCT03689374 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | SEMAGLUTIDE | targetBased | 3 | Not yet recruiting | 01/04/2024 | https://clinicaltrials.gov/study/NCT06339086 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | SEMAGLUTIDE | targetBased | 3 | Not yet recruiting | 01/04/2024 | https://clinicaltrials.gov/study/NCT06339086 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | SEMAGLUTIDE | targetBased | 3 | Not yet recruiting | 01/04/2024 | https://clinicaltrials.gov/study/NCT06339086 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | SEMAGLUTIDE | targetBased | 4 | Completed | 18/10/2018 | https://clinicaltrials.gov/study/NCT03724981 | 1 | GoF | protect | |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | SEMAGLUTIDE | targetBased | 4 | Completed | 18/10/2018 | https://clinicaltrials.gov/study/NCT03724981 | 1 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | SEMAGLUTIDE | targetBased | 4 | Completed | 18/10/2018 | https://clinicaltrials.gov/study/NCT03724981 | 1 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | SEMAGLUTIDE | targetBased | 3 | Completed | 27/06/2017 | https://clinicaltrials.gov/study/NCT03191396 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | SEMAGLUTIDE | targetBased | 3 | Completed | 27/06/2017 | https://clinicaltrials.gov/study/NCT03191396 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | SEMAGLUTIDE | targetBased | 3 | Completed | 27/06/2017 | https://clinicaltrials.gov/study/NCT03191396 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | SEMAGLUTIDE | targetBased | 4 | https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/209637lbl.pdf | 1 | GoF | protect | |||
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | SEMAGLUTIDE | targetBased | 4 | https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/209637lbl.pdf | 1 | GoF | protect | |||
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | SEMAGLUTIDE | targetBased | 4 | https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/209637lbl.pdf | 1 | GoF | protect | |||
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | SEMAGLUTIDE | targetBased | 3 | Completed | 15/01/2021 | https://clinicaltrials.gov/study/NCT04707469 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | SEMAGLUTIDE | targetBased | 3 | Completed | 15/01/2021 | https://clinicaltrials.gov/study/NCT04707469 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | SEMAGLUTIDE | targetBased | 3 | Completed | 15/01/2021 | https://clinicaltrials.gov/study/NCT04707469 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | SEMAGLUTIDE | targetBased | 3 | Completed | 01/10/2019 | https://clinicaltrials.gov/study/NCT04109547 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | SEMAGLUTIDE | targetBased | 3 | Completed | 01/10/2019 | https://clinicaltrials.gov/study/NCT04109547 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | SEMAGLUTIDE | targetBased | 3 | Completed | 01/10/2019 | https://clinicaltrials.gov/study/NCT04109547 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | SEMAGLUTIDE | targetBased | 4 | Completed | 01/08/2019 | https://clinicaltrials.gov/study/NCT04126603 | 1 | GoF | protect | |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | SEMAGLUTIDE | targetBased | 4 | Completed | 01/08/2019 | https://clinicaltrials.gov/study/NCT04126603 | 1 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | SEMAGLUTIDE | targetBased | 4 | Completed | 01/08/2019 | https://clinicaltrials.gov/study/NCT04126603 | 1 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | SEMAGLUTIDE | targetBased | 3 | Withdrawn | 09/03/2020 | https://clinicaltrials.gov/study/NCT04287179 | 0.7 | GoF | protect | COVID19 impact on this trial was evaluated and a delay of at least 6-9 months was expected. In parallel, the development of a new type of pen injector, which was an important part of the trial, was ceased and thus this trial was cancelled. |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | SEMAGLUTIDE | targetBased | 3 | Withdrawn | 09/03/2020 | https://clinicaltrials.gov/study/NCT04287179 | 0.7 | GoF | protect | COVID19 impact on this trial was evaluated and a delay of at least 6-9 months was expected. In parallel, the development of a new type of pen injector, which was an important part of the trial, was ceased and thus this trial was cancelled. |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | SEMAGLUTIDE | targetBased | 3 | Withdrawn | 09/03/2020 | https://clinicaltrials.gov/study/NCT04287179 | 0.7 | GoF | protect | COVID19 impact on this trial was evaluated and a delay of at least 6-9 months was expected. In parallel, the development of a new type of pen injector, which was an important part of the trial, was ceased and thus this trial was cancelled. |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | SEMAGLUTIDE | targetBased | 3 | Completed | 20/09/2016 | https://clinicaltrials.gov/study/NCT02827708 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | SEMAGLUTIDE | targetBased | 3 | Completed | 20/09/2016 | https://clinicaltrials.gov/study/NCT02827708 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | SEMAGLUTIDE | targetBased | 3 | Completed | 20/09/2016 | https://clinicaltrials.gov/study/NCT02827708 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | SEMAGLUTIDE | targetBased | 3 | Recruiting | 02/11/2020 | https://clinicaltrials.gov/study/NCT04596631 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | SEMAGLUTIDE | targetBased | 3 | Recruiting | 02/11/2020 | https://clinicaltrials.gov/study/NCT04596631 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | SEMAGLUTIDE | targetBased | 3 | Recruiting | 02/11/2020 | https://clinicaltrials.gov/study/NCT04596631 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | SEMAGLUTIDE | targetBased | 3 | Active, not recruiting | 17/06/2019 | https://clinicaltrials.gov/study/NCT03819153 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | SEMAGLUTIDE | targetBased | 3 | Active, not recruiting | 17/06/2019 | https://clinicaltrials.gov/study/NCT03819153 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | SEMAGLUTIDE | targetBased | 3 | Active, not recruiting | 17/06/2019 | https://clinicaltrials.gov/study/NCT03819153 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | SEMAGLUTIDE | targetBased | 4 | Terminated | 29/01/2022 | https://clinicaltrials.gov/study/NCT04938388 | 1 | GoF | protect | Principal Investigator no longer at study site. |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | SEMAGLUTIDE | targetBased | 4 | Terminated | 29/01/2022 | https://clinicaltrials.gov/study/NCT04938388 | 1 | GoF | protect | Principal Investigator no longer at study site. |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | SEMAGLUTIDE | targetBased | 4 | Terminated | 29/01/2022 | https://clinicaltrials.gov/study/NCT04938388 | 1 | GoF | protect | Principal Investigator no longer at study site. |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | SEMAGLUTIDE | targetBased | 3 | Completed | 20/09/2016 | https://clinicaltrials.gov/study/NCT02906930 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | SEMAGLUTIDE | targetBased | 3 | Completed | 20/09/2016 | https://clinicaltrials.gov/study/NCT02906930 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | SEMAGLUTIDE | targetBased | 3 | Completed | 20/09/2016 | https://clinicaltrials.gov/study/NCT02906930 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | SEMAGLUTIDE | targetBased | 3 | Completed | 28/08/2017 | https://clinicaltrials.gov/study/NCT03061214 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | SEMAGLUTIDE | targetBased | 3 | Completed | 28/08/2017 | https://clinicaltrials.gov/study/NCT03061214 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | SEMAGLUTIDE | targetBased | 3 | Completed | 28/08/2017 | https://clinicaltrials.gov/study/NCT03061214 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | SEMAGLUTIDE | targetBased | 3 | Completed | 29/07/2019 | https://clinicaltrials.gov/study/NCT04017832 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | SEMAGLUTIDE | targetBased | 3 | Completed | 29/07/2019 | https://clinicaltrials.gov/study/NCT04017832 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | SEMAGLUTIDE | targetBased | 3 | Completed | 29/07/2019 | https://clinicaltrials.gov/study/NCT04017832 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | SEMAGLUTIDE | targetBased | 3 | Not yet recruiting | 10/07/2023 | https://clinicaltrials.gov/study/NCT05950516 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | SEMAGLUTIDE | targetBased | 3 | Not yet recruiting | 10/07/2023 | https://clinicaltrials.gov/study/NCT05950516 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | SEMAGLUTIDE | targetBased | 3 | Not yet recruiting | 10/07/2023 | https://clinicaltrials.gov/study/NCT05950516 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | SEMAGLUTIDE | targetBased | 3 | Completed | 06/01/2016 | https://clinicaltrials.gov/study/NCT02648204 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | SEMAGLUTIDE | targetBased | 3 | Completed | 06/01/2016 | https://clinicaltrials.gov/study/NCT02648204 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | SEMAGLUTIDE | targetBased | 3 | Completed | 06/01/2016 | https://clinicaltrials.gov/study/NCT02648204 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | SEMAGLUTIDE | targetBased | 3 | Completed | 02/10/2014 | https://clinicaltrials.gov/study/NCT02254291 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | SEMAGLUTIDE | targetBased | 3 | Completed | 02/10/2014 | https://clinicaltrials.gov/study/NCT02254291 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | SEMAGLUTIDE | targetBased | 3 | Completed | 02/10/2014 | https://clinicaltrials.gov/study/NCT02254291 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | SEMAGLUTIDE | targetBased | 3 | Completed | 10/08/2016 | https://clinicaltrials.gov/study/NCT02863328 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | SEMAGLUTIDE | targetBased | 3 | Completed | 10/08/2016 | https://clinicaltrials.gov/study/NCT02863328 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | SEMAGLUTIDE | targetBased | 3 | Completed | 10/08/2016 | https://clinicaltrials.gov/study/NCT02863328 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | SEMAGLUTIDE | targetBased | 3 | Recruiting | 27/09/2023 | https://clinicaltrials.gov/study/NCT06065540 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | SEMAGLUTIDE | targetBased | 3 | Recruiting | 27/09/2023 | https://clinicaltrials.gov/study/NCT06065540 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | SEMAGLUTIDE | targetBased | 3 | Recruiting | 27/09/2023 | https://clinicaltrials.gov/study/NCT06065540 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | SEMAGLUTIDE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=27f15fac-7d98-4114-a2ec-92494a91da98 | 1 | GoF | protect | |||
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | SEMAGLUTIDE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=27f15fac-7d98-4114-a2ec-92494a91da98 | 1 | GoF | protect | |||
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | SEMAGLUTIDE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=27f15fac-7d98-4114-a2ec-92494a91da98 | 1 | GoF | protect | |||
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | SEMAGLUTIDE | targetBased | 3 | Recruiting | 22/09/2023 | https://clinicaltrials.gov/study/NCT06045221 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | SEMAGLUTIDE | targetBased | 3 | Recruiting | 22/09/2023 | https://clinicaltrials.gov/study/NCT06045221 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | SEMAGLUTIDE | targetBased | 3 | Recruiting | 22/09/2023 | https://clinicaltrials.gov/study/NCT06045221 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | SEMAGLUTIDE | targetBased | 3 | Completed | 03/08/2022 | https://clinicaltrials.gov/study/NCT05478252 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | SEMAGLUTIDE | targetBased | 3 | Completed | 03/08/2022 | https://clinicaltrials.gov/study/NCT05478252 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | SEMAGLUTIDE | targetBased | 3 | Completed | 03/08/2022 | https://clinicaltrials.gov/study/NCT05478252 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | SEMAGLUTIDE | targetBased | 3 | Completed | 02/12/2013 | https://clinicaltrials.gov/study/NCT01930188 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | SEMAGLUTIDE | targetBased | 3 | Completed | 02/12/2013 | https://clinicaltrials.gov/study/NCT01930188 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | SEMAGLUTIDE | targetBased | 3 | Completed | 02/12/2013 | https://clinicaltrials.gov/study/NCT01930188 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | SEMAGLUTIDE | targetBased | 3 | Completed | 04/08/2014 | https://clinicaltrials.gov/study/NCT02128932 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | SEMAGLUTIDE | targetBased | 3 | Completed | 04/08/2014 | https://clinicaltrials.gov/study/NCT02128932 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | SEMAGLUTIDE | targetBased | 3 | Completed | 04/08/2014 | https://clinicaltrials.gov/study/NCT02128932 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | SEMAGLUTIDE | targetBased | 4 | Active, not recruiting | 01/09/2021 | https://clinicaltrials.gov/study/NCT05035082 | 1 | GoF | protect | |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | SEMAGLUTIDE | targetBased | 4 | Active, not recruiting | 01/09/2021 | https://clinicaltrials.gov/study/NCT05035082 | 1 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | SEMAGLUTIDE | targetBased | 4 | Active, not recruiting | 01/09/2021 | https://clinicaltrials.gov/study/NCT05035082 | 1 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | SEMAGLUTIDE | targetBased | 3 | Recruiting | 19/03/2024 | https://clinicaltrials.gov/study/NCT06323174 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | SEMAGLUTIDE | targetBased | 3 | Recruiting | 19/03/2024 | https://clinicaltrials.gov/study/NCT06323174 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | SEMAGLUTIDE | targetBased | 3 | Recruiting | 19/03/2024 | https://clinicaltrials.gov/study/NCT06323174 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | SEMAGLUTIDE | targetBased | 3 | Completed | 02/02/2017 | https://clinicaltrials.gov/study/NCT03021187 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | SEMAGLUTIDE | targetBased | 3 | Completed | 02/02/2017 | https://clinicaltrials.gov/study/NCT03021187 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | SEMAGLUTIDE | targetBased | 3 | Completed | 02/02/2017 | https://clinicaltrials.gov/study/NCT03021187 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | SEMAGLUTIDE | targetBased | 4 | Completed | 18/01/2021 | https://clinicaltrials.gov/study/NCT04538352 | 1 | GoF | protect | |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | SEMAGLUTIDE | targetBased | 4 | Completed | 18/01/2021 | https://clinicaltrials.gov/study/NCT04538352 | 1 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | SEMAGLUTIDE | targetBased | 4 | Completed | 18/01/2021 | https://clinicaltrials.gov/study/NCT04538352 | 1 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | SEMAGLUTIDE | targetBased | 3 | Completed | 15/03/2017 | https://clinicaltrials.gov/study/NCT03086330 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | SEMAGLUTIDE | targetBased | 3 | Completed | 15/03/2017 | https://clinicaltrials.gov/study/NCT03086330 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | SEMAGLUTIDE | targetBased | 3 | Completed | 15/03/2017 | https://clinicaltrials.gov/study/NCT03086330 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | SEMAGLUTIDE | targetBased | 3 | Recruiting | 16/01/2024 | https://clinicaltrials.gov/study/NCT06221969 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | SEMAGLUTIDE | targetBased | 3 | Recruiting | 16/01/2024 | https://clinicaltrials.gov/study/NCT06221969 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | SEMAGLUTIDE | targetBased | 3 | Recruiting | 16/01/2024 | https://clinicaltrials.gov/study/NCT06221969 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | SEMAGLUTIDE | targetBased | 4 | Recruiting | 13/03/2023 | https://clinicaltrials.gov/study/NCT05441267 | 1 | GoF | protect | |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | SEMAGLUTIDE | targetBased | 4 | Recruiting | 13/03/2023 | https://clinicaltrials.gov/study/NCT05441267 | 1 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | SEMAGLUTIDE | targetBased | 4 | Recruiting | 13/03/2023 | https://clinicaltrials.gov/study/NCT05441267 | 1 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | SEMAGLUTIDE | targetBased | 3 | Active, not recruiting | 08/05/2019 | https://clinicaltrials.gov/study/NCT03811561 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | SEMAGLUTIDE | targetBased | 3 | Active, not recruiting | 08/05/2019 | https://clinicaltrials.gov/study/NCT03811561 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | SEMAGLUTIDE | targetBased | 3 | Active, not recruiting | 08/05/2019 | https://clinicaltrials.gov/study/NCT03811561 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | SEMAGLUTIDE | targetBased | 3 | Withdrawn | 26/01/2024 | https://clinicaltrials.gov/study/NCT06083675 | 0.7 | GoF | protect | Due to internal reprioritization, trial was cancelled. |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | SEMAGLUTIDE | targetBased | 3 | Withdrawn | 26/01/2024 | https://clinicaltrials.gov/study/NCT06083675 | 0.7 | GoF | protect | Due to internal reprioritization, trial was cancelled. |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | SEMAGLUTIDE | targetBased | 3 | Withdrawn | 26/01/2024 | https://clinicaltrials.gov/study/NCT06083675 | 0.7 | GoF | protect | Due to internal reprioritization, trial was cancelled. |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | SEMAGLUTIDE | targetBased | 4 | Terminated | 25/08/2021 | https://clinicaltrials.gov/study/NCT04624672 | 1 | GoF | protect | Poor enrollment |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | SEMAGLUTIDE | targetBased | 4 | Terminated | 25/08/2021 | https://clinicaltrials.gov/study/NCT04624672 | 1 | GoF | protect | Poor enrollment |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | SEMAGLUTIDE | targetBased | 4 | Terminated | 25/08/2021 | https://clinicaltrials.gov/study/NCT04624672 | 1 | GoF | protect | Poor enrollment |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | SEMAGLUTIDE | targetBased | 3 | Completed | 10/01/2017 | https://clinicaltrials.gov/study/NCT03015220 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | SEMAGLUTIDE | targetBased | 3 | Completed | 10/01/2017 | https://clinicaltrials.gov/study/NCT03015220 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | SEMAGLUTIDE | targetBased | 3 | Completed | 10/01/2017 | https://clinicaltrials.gov/study/NCT03015220 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | SEMAGLUTIDE | targetBased | 3 | Recruiting | 26/03/2024 | https://clinicaltrials.gov/study/NCT06323161 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | SEMAGLUTIDE | targetBased | 3 | Recruiting | 26/03/2024 | https://clinicaltrials.gov/study/NCT06323161 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | SEMAGLUTIDE | targetBased | 3 | Recruiting | 26/03/2024 | https://clinicaltrials.gov/study/NCT06323161 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | SEMAGLUTIDE | targetBased | 3 | Completed | 01/12/2014 | https://clinicaltrials.gov/study/NCT02305381 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | SEMAGLUTIDE | targetBased | 3 | Completed | 01/12/2014 | https://clinicaltrials.gov/study/NCT02305381 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | SEMAGLUTIDE | targetBased | 3 | Completed | 01/12/2014 | https://clinicaltrials.gov/study/NCT02305381 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | SEMAGLUTIDE | targetBased | 3 | Active, not recruiting | 17/06/2019 | https://clinicaltrials.gov/study/NCT03914326 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | SEMAGLUTIDE | targetBased | 3 | Active, not recruiting | 17/06/2019 | https://clinicaltrials.gov/study/NCT03914326 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | SEMAGLUTIDE | targetBased | 3 | Active, not recruiting | 17/06/2019 | https://clinicaltrials.gov/study/NCT03914326 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | SEMAGLUTIDE | targetBased | 4 | Recruiting | 03/03/2022 | https://clinicaltrials.gov/study/NCT05303857 | 1 | GoF | protect | |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | SEMAGLUTIDE | targetBased | 4 | Recruiting | 03/03/2022 | https://clinicaltrials.gov/study/NCT05303857 | 1 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | SEMAGLUTIDE | targetBased | 4 | Recruiting | 03/03/2022 | https://clinicaltrials.gov/study/NCT05303857 | 1 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | SEMAGLUTIDE | targetBased | 4 | Completed | 13/07/2018 | https://clinicaltrials.gov/study/NCT03596450 | 1 | GoF | protect | |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | SEMAGLUTIDE | targetBased | 4 | Completed | 13/07/2018 | https://clinicaltrials.gov/study/NCT03596450 | 1 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | SEMAGLUTIDE | targetBased | 4 | Completed | 13/07/2018 | https://clinicaltrials.gov/study/NCT03596450 | 1 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | SEMAGLUTIDE | targetBased | 3 | Completed | 15/03/2017 | https://clinicaltrials.gov/study/NCT03136484 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | SEMAGLUTIDE | targetBased | 3 | Completed | 15/03/2017 | https://clinicaltrials.gov/study/NCT03136484 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | SEMAGLUTIDE | targetBased | 3 | Completed | 15/03/2017 | https://clinicaltrials.gov/study/NCT03136484 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | SEMAGLUTIDE | targetBased | 3 | Withdrawn | 06/10/2022 | https://clinicaltrials.gov/study/NCT05444153 | 0.7 | GoF | protect | Sponsor decision |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | SEMAGLUTIDE | targetBased | 3 | Withdrawn | 06/10/2022 | https://clinicaltrials.gov/study/NCT05444153 | 0.7 | GoF | protect | Sponsor decision |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | SEMAGLUTIDE | targetBased | 3 | Withdrawn | 06/10/2022 | https://clinicaltrials.gov/study/NCT05444153 | 0.7 | GoF | protect | Sponsor decision |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | SEMAGLUTIDE | targetBased | 3 | Completed | 17/01/2017 | https://clinicaltrials.gov/study/NCT02692716 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | SEMAGLUTIDE | targetBased | 3 | Completed | 17/01/2017 | https://clinicaltrials.gov/study/NCT02692716 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | SEMAGLUTIDE | targetBased | 3 | Completed | 17/01/2017 | https://clinicaltrials.gov/study/NCT02692716 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | SEMAGLUTIDE | targetBased | 3 | Completed | 10/08/2016 | https://clinicaltrials.gov/study/NCT02863419 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | SEMAGLUTIDE | targetBased | 3 | Completed | 10/08/2016 | https://clinicaltrials.gov/study/NCT02863419 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | SEMAGLUTIDE | targetBased | 3 | Completed | 10/08/2016 | https://clinicaltrials.gov/study/NCT02863419 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | SEMAGLUTIDE | targetBased | 3 | Recruiting | 22/09/2023 | https://clinicaltrials.gov/study/NCT05813912 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | SEMAGLUTIDE | targetBased | 3 | Recruiting | 22/09/2023 | https://clinicaltrials.gov/study/NCT05813912 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | SEMAGLUTIDE | targetBased | 3 | Recruiting | 22/09/2023 | https://clinicaltrials.gov/study/NCT05813912 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | SEMAGLUTIDE | targetBased | 3 | Completed | 25/07/2022 | https://clinicaltrials.gov/study/NCT05816057 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | SEMAGLUTIDE | targetBased | 3 | Completed | 25/07/2022 | https://clinicaltrials.gov/study/NCT05816057 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | SEMAGLUTIDE | targetBased | 3 | Completed | 25/07/2022 | https://clinicaltrials.gov/study/NCT05816057 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | SEMAGLUTIDE | targetBased | 3 | Completed | 02/12/2013 | https://clinicaltrials.gov/study/NCT01885208 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | SEMAGLUTIDE | targetBased | 3 | Completed | 02/12/2013 | https://clinicaltrials.gov/study/NCT01885208 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | SEMAGLUTIDE | targetBased | 3 | Completed | 02/12/2013 | https://clinicaltrials.gov/study/NCT01885208 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | SEMAGLUTIDE | targetBased | 3 | Completed | 04/08/2014 | https://clinicaltrials.gov/study/NCT02207374 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | SEMAGLUTIDE | targetBased | 3 | Completed | 04/08/2014 | https://clinicaltrials.gov/study/NCT02207374 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | SEMAGLUTIDE | targetBased | 3 | Completed | 04/08/2014 | https://clinicaltrials.gov/study/NCT02207374 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | SEMAGLUTIDE | targetBased | 3 | Recruiting | 21/02/2024 | https://clinicaltrials.gov/study/NCT06260722 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | SEMAGLUTIDE | targetBased | 3 | Recruiting | 21/02/2024 | https://clinicaltrials.gov/study/NCT06260722 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | SEMAGLUTIDE | targetBased | 3 | Recruiting | 21/02/2024 | https://clinicaltrials.gov/study/NCT06260722 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | SEMAGLUTIDE | targetBased | 4 | Recruiting | 01/01/2023 | https://clinicaltrials.gov/study/NCT05597202 | 1 | GoF | protect | |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | SEMAGLUTIDE | targetBased | 4 | Recruiting | 01/01/2023 | https://clinicaltrials.gov/study/NCT05597202 | 1 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | SEMAGLUTIDE | targetBased | 4 | Recruiting | 01/01/2023 | https://clinicaltrials.gov/study/NCT05597202 | 1 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | SEMAGLUTIDE | targetBased | 3 | Completed | 21/02/2013 | https://clinicaltrials.gov/study/NCT01720446 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | SEMAGLUTIDE | targetBased | 3 | Completed | 21/02/2013 | https://clinicaltrials.gov/study/NCT01720446 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | SEMAGLUTIDE | targetBased | 3 | Completed | 21/02/2013 | https://clinicaltrials.gov/study/NCT01720446 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | SEMAGLUTIDE | targetBased | 3 | Completed | 20/09/2016 | https://clinicaltrials.gov/study/NCT02849080 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | SEMAGLUTIDE | targetBased | 3 | Completed | 20/09/2016 | https://clinicaltrials.gov/study/NCT02849080 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | SEMAGLUTIDE | targetBased | 3 | Completed | 20/09/2016 | https://clinicaltrials.gov/study/NCT02849080 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | SEMAGLUTIDE | targetBased | 3 | Completed | 11/04/2022 | https://clinicaltrials.gov/study/NCT05259033 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | SEMAGLUTIDE | targetBased | 3 | Completed | 11/04/2022 | https://clinicaltrials.gov/study/NCT05259033 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | SEMAGLUTIDE | targetBased | 3 | Completed | 11/04/2022 | https://clinicaltrials.gov/study/NCT05259033 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | SEMAGLUTIDE | targetBased | 3 | Completed | 03/02/2014 | https://clinicaltrials.gov/study/NCT02054897 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | SEMAGLUTIDE | targetBased | 3 | Completed | 03/02/2014 | https://clinicaltrials.gov/study/NCT02054897 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | SEMAGLUTIDE | targetBased | 3 | Completed | 03/02/2014 | https://clinicaltrials.gov/study/NCT02054897 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | SEMAGLUTIDE | targetBased | 3 | Recruiting | 23/02/2024 | https://clinicaltrials.gov/study/NCT06161844 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | SEMAGLUTIDE | targetBased | 3 | Recruiting | 23/02/2024 | https://clinicaltrials.gov/study/NCT06161844 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | SEMAGLUTIDE | targetBased | 3 | Recruiting | 23/02/2024 | https://clinicaltrials.gov/study/NCT06161844 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | SEMAGLUTIDE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b5399d16-01c1-4315-af3c-7619fee86621 | 1 | GoF | protect | |||
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | SEMAGLUTIDE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b5399d16-01c1-4315-af3c-7619fee86621 | 1 | GoF | protect | |||
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | SEMAGLUTIDE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b5399d16-01c1-4315-af3c-7619fee86621 | 1 | GoF | protect | |||
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | diabetes mellitus | SEMAGLUTIDE | targetBased | 3 | Completed | 02/12/2013 | https://clinicaltrials.gov/study/NCT01930188 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | diabetes mellitus | SEMAGLUTIDE | targetBased | 3 | Completed | 02/12/2013 | https://clinicaltrials.gov/study/NCT01930188 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | diabetes mellitus | SEMAGLUTIDE | targetBased | 3 | Completed | 02/12/2013 | https://clinicaltrials.gov/study/NCT01930188 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | diabetes mellitus | SEMAGLUTIDE | targetBased | 4 | https://www.ema.europa.eu/en/medicines/human/EPAR/ozempic | 1 | GoF | protect | |||
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | diabetes mellitus | SEMAGLUTIDE | targetBased | 4 | https://www.ema.europa.eu/en/medicines/human/EPAR/ozempic | 1 | GoF | protect | |||
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | diabetes mellitus | SEMAGLUTIDE | targetBased | 4 | https://www.ema.europa.eu/en/medicines/human/EPAR/ozempic | 1 | GoF | protect | |||
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | diabetes mellitus | SEMAGLUTIDE | targetBased | 3 | Completed | 20/09/2016 | https://clinicaltrials.gov/study/NCT02827708 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | diabetes mellitus | SEMAGLUTIDE | targetBased | 3 | Completed | 20/09/2016 | https://clinicaltrials.gov/study/NCT02827708 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | diabetes mellitus | SEMAGLUTIDE | targetBased | 3 | Completed | 20/09/2016 | https://clinicaltrials.gov/study/NCT02827708 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | diabetes mellitus | SEMAGLUTIDE | targetBased | 3 | Active, not recruiting | 12/07/2022 | https://clinicaltrials.gov/study/NCT05305794 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | diabetes mellitus | SEMAGLUTIDE | targetBased | 3 | Active, not recruiting | 12/07/2022 | https://clinicaltrials.gov/study/NCT05305794 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | diabetes mellitus | SEMAGLUTIDE | targetBased | 3 | Active, not recruiting | 12/07/2022 | https://clinicaltrials.gov/study/NCT05305794 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | diabetes mellitus | SEMAGLUTIDE | targetBased | 3 | Completed | 20/09/2016 | https://clinicaltrials.gov/study/NCT02849080 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | diabetes mellitus | SEMAGLUTIDE | targetBased | 3 | Completed | 20/09/2016 | https://clinicaltrials.gov/study/NCT02849080 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | diabetes mellitus | SEMAGLUTIDE | targetBased | 3 | Completed | 20/09/2016 | https://clinicaltrials.gov/study/NCT02849080 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | diabetes mellitus | SEMAGLUTIDE | targetBased | 3 | Completed | 21/02/2013 | https://clinicaltrials.gov/study/NCT01720446 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | diabetes mellitus | SEMAGLUTIDE | targetBased | 3 | Completed | 21/02/2013 | https://clinicaltrials.gov/study/NCT01720446 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | diabetes mellitus | SEMAGLUTIDE | targetBased | 3 | Completed | 21/02/2013 | https://clinicaltrials.gov/study/NCT01720446 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | diabetes mellitus | SEMAGLUTIDE | targetBased | 4 | Recruiting | 17/02/2022 | https://clinicaltrials.gov/study/NCT04854083 | 1 | GoF | protect | |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | diabetes mellitus | SEMAGLUTIDE | targetBased | 4 | Recruiting | 17/02/2022 | https://clinicaltrials.gov/study/NCT04854083 | 1 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | diabetes mellitus | SEMAGLUTIDE | targetBased | 4 | Recruiting | 17/02/2022 | https://clinicaltrials.gov/study/NCT04854083 | 1 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | diabetes mellitus | SEMAGLUTIDE | targetBased | 3 | Completed | 10/08/2016 | https://clinicaltrials.gov/study/NCT02863419 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | diabetes mellitus | SEMAGLUTIDE | targetBased | 3 | Completed | 10/08/2016 | https://clinicaltrials.gov/study/NCT02863419 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | diabetes mellitus | SEMAGLUTIDE | targetBased | 3 | Completed | 10/08/2016 | https://clinicaltrials.gov/study/NCT02863419 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | diabetes mellitus | SEMAGLUTIDE | targetBased | 3 | Completed | 15/02/2016 | https://clinicaltrials.gov/study/NCT02607865 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | diabetes mellitus | SEMAGLUTIDE | targetBased | 3 | Completed | 15/02/2016 | https://clinicaltrials.gov/study/NCT02607865 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | diabetes mellitus | SEMAGLUTIDE | targetBased | 3 | Completed | 15/02/2016 | https://clinicaltrials.gov/study/NCT02607865 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | diabetes mellitus | SEMAGLUTIDE | targetBased | 3 | Completed | 28/08/2017 | https://clinicaltrials.gov/study/NCT03061214 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | diabetes mellitus | SEMAGLUTIDE | targetBased | 3 | Completed | 28/08/2017 | https://clinicaltrials.gov/study/NCT03061214 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | diabetes mellitus | SEMAGLUTIDE | targetBased | 3 | Completed | 28/08/2017 | https://clinicaltrials.gov/study/NCT03061214 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | diabetes mellitus | SEMAGLUTIDE | targetBased | 4 | https://www.whocc.no/atc_ddd_index/?code=A10BJ06 | 1 | GoF | protect | |||
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | diabetes mellitus | SEMAGLUTIDE | targetBased | 4 | https://www.whocc.no/atc_ddd_index/?code=A10BJ06 | 1 | GoF | protect | |||
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | diabetes mellitus | SEMAGLUTIDE | targetBased | 4 | https://www.whocc.no/atc_ddd_index/?code=A10BJ06 | 1 | GoF | protect | |||
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | non-alcoholic fatty liver disease | SEMAGLUTIDE | targetBased | 4 | Completed | 15/02/2023 | https://clinicaltrials.gov/study/NCT05813249 | 1 | GoF | protect | |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | non-alcoholic fatty liver disease | SEMAGLUTIDE | targetBased | 4 | Completed | 15/02/2023 | https://clinicaltrials.gov/study/NCT05813249 | 1 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | non-alcoholic fatty liver disease | SEMAGLUTIDE | targetBased | 4 | Completed | 15/02/2023 | https://clinicaltrials.gov/study/NCT05813249 | 1 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | nutritional disorder | SEMAGLUTIDE | targetBased | 3 | Completed | 04/06/2018 | https://clinicaltrials.gov/study/NCT03548987 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | nutritional disorder | SEMAGLUTIDE | targetBased | 3 | Completed | 04/06/2018 | https://clinicaltrials.gov/study/NCT03548987 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | nutritional disorder | SEMAGLUTIDE | targetBased | 3 | Completed | 04/06/2018 | https://clinicaltrials.gov/study/NCT03548987 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 1 diabetes mellitus | SEMAGLUTIDE | targetBased | 3 | Recruiting | 21/06/2023 | https://clinicaltrials.gov/study/NCT05819138 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 1 diabetes mellitus | SEMAGLUTIDE | targetBased | 3 | Recruiting | 21/06/2023 | https://clinicaltrials.gov/study/NCT05819138 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 1 diabetes mellitus | SEMAGLUTIDE | targetBased | 3 | Recruiting | 21/06/2023 | https://clinicaltrials.gov/study/NCT05819138 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | prediabetes syndrome | SEMAGLUTIDE | targetBased | 4 | Recruiting | 13/01/2022 | https://clinicaltrials.gov/study/NCT04873050 | 1 | GoF | protect | |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | prediabetes syndrome | SEMAGLUTIDE | targetBased | 4 | Recruiting | 13/01/2022 | https://clinicaltrials.gov/study/NCT04873050 | 1 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | prediabetes syndrome | SEMAGLUTIDE | targetBased | 4 | Recruiting | 13/01/2022 | https://clinicaltrials.gov/study/NCT04873050 | 1 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | prediabetes syndrome | SEMAGLUTIDE | targetBased | 4 | Recruiting | 22/11/2021 | https://clinicaltrials.gov/study/NCT05119179 | 1 | GoF | protect | |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | prediabetes syndrome | SEMAGLUTIDE | targetBased | 4 | Recruiting | 22/11/2021 | https://clinicaltrials.gov/study/NCT05119179 | 1 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | prediabetes syndrome | SEMAGLUTIDE | targetBased | 4 | Recruiting | 22/11/2021 | https://clinicaltrials.gov/study/NCT05119179 | 1 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | non-alcoholic steatohepatitis | SEMAGLUTIDE | targetBased | 3 | Recruiting | 01/04/2021 | https://clinicaltrials.gov/study/NCT04822181 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | non-alcoholic steatohepatitis | SEMAGLUTIDE | targetBased | 3 | Recruiting | 01/04/2021 | https://clinicaltrials.gov/study/NCT04822181 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | non-alcoholic steatohepatitis | SEMAGLUTIDE | targetBased | 3 | Recruiting | 01/04/2021 | https://clinicaltrials.gov/study/NCT04822181 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | obesity | SEMAGLUTIDE | targetBased | 3 | Completed | 01/08/2018 | https://clinicaltrials.gov/study/NCT03611582 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | obesity | SEMAGLUTIDE | targetBased | 3 | Completed | 01/08/2018 | https://clinicaltrials.gov/study/NCT03611582 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | obesity | SEMAGLUTIDE | targetBased | 3 | Completed | 01/08/2018 | https://clinicaltrials.gov/study/NCT03611582 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | obesity | SEMAGLUTIDE | targetBased | 3 | Completed | 24/10/2018 | https://clinicaltrials.gov/study/NCT03574597 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | obesity | SEMAGLUTIDE | targetBased | 3 | Completed | 24/10/2018 | https://clinicaltrials.gov/study/NCT03574597 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | obesity | SEMAGLUTIDE | targetBased | 3 | Completed | 24/10/2018 | https://clinicaltrials.gov/study/NCT03574597 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | obesity | SEMAGLUTIDE | targetBased | 4 | Active, not recruiting | 19/01/2023 | https://clinicaltrials.gov/study/NCT05579249 | 1 | GoF | protect | |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | obesity | SEMAGLUTIDE | targetBased | 4 | Active, not recruiting | 19/01/2023 | https://clinicaltrials.gov/study/NCT05579249 | 1 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | obesity | SEMAGLUTIDE | targetBased | 4 | Active, not recruiting | 19/01/2023 | https://clinicaltrials.gov/study/NCT05579249 | 1 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | obesity | SEMAGLUTIDE | targetBased | 3 | Recruiting | 03/04/2023 | https://clinicaltrials.gov/study/NCT05813925 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | obesity | SEMAGLUTIDE | targetBased | 3 | Recruiting | 03/04/2023 | https://clinicaltrials.gov/study/NCT05813925 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | obesity | SEMAGLUTIDE | targetBased | 3 | Recruiting | 03/04/2023 | https://clinicaltrials.gov/study/NCT05813925 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | obesity | SEMAGLUTIDE | targetBased | 3 | Completed | 04/06/2018 | https://clinicaltrials.gov/study/NCT03548987 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | obesity | SEMAGLUTIDE | targetBased | 3 | Completed | 04/06/2018 | https://clinicaltrials.gov/study/NCT03548987 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | obesity | SEMAGLUTIDE | targetBased | 3 | Completed | 04/06/2018 | https://clinicaltrials.gov/study/NCT03548987 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | obesity | SEMAGLUTIDE | targetBased | 3 | Completed | 15/08/2022 | https://clinicaltrials.gov/study/NCT04998136 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | obesity | SEMAGLUTIDE | targetBased | 3 | Completed | 15/08/2022 | https://clinicaltrials.gov/study/NCT04998136 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | obesity | SEMAGLUTIDE | targetBased | 3 | Completed | 15/08/2022 | https://clinicaltrials.gov/study/NCT04998136 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | obesity | SEMAGLUTIDE | targetBased | 4 | Recruiting | 01/06/2022 | https://clinicaltrials.gov/study/NCT05574439 | 1 | GoF | protect | |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | obesity | SEMAGLUTIDE | targetBased | 4 | Recruiting | 01/06/2022 | https://clinicaltrials.gov/study/NCT05574439 | 1 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | obesity | SEMAGLUTIDE | targetBased | 4 | Recruiting | 01/06/2022 | https://clinicaltrials.gov/study/NCT05574439 | 1 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | obesity | SEMAGLUTIDE | targetBased | 3 | Completed | 07/10/2019 | https://clinicaltrials.gov/study/NCT04102189 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | obesity | SEMAGLUTIDE | targetBased | 3 | Completed | 07/10/2019 | https://clinicaltrials.gov/study/NCT04102189 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | obesity | SEMAGLUTIDE | targetBased | 3 | Completed | 07/10/2019 | https://clinicaltrials.gov/study/NCT04102189 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | obesity | SEMAGLUTIDE | targetBased | 4 | Active, not recruiting | 26/07/2022 | https://clinicaltrials.gov/study/NCT05548647 | 1 | GoF | protect | |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | obesity | SEMAGLUTIDE | targetBased | 4 | Active, not recruiting | 26/07/2022 | https://clinicaltrials.gov/study/NCT05548647 | 1 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | obesity | SEMAGLUTIDE | targetBased | 4 | Active, not recruiting | 26/07/2022 | https://clinicaltrials.gov/study/NCT05548647 | 1 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | obesity | SEMAGLUTIDE | targetBased | 3 | Completed | 06/09/2021 | https://clinicaltrials.gov/study/NCT05040971 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | obesity | SEMAGLUTIDE | targetBased | 3 | Completed | 06/09/2021 | https://clinicaltrials.gov/study/NCT05040971 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | obesity | SEMAGLUTIDE | targetBased | 3 | Completed | 06/09/2021 | https://clinicaltrials.gov/study/NCT05040971 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | obesity | SEMAGLUTIDE | targetBased | 3 | Completed | 16/03/2021 | https://clinicaltrials.gov/study/NCT04788511 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | obesity | SEMAGLUTIDE | targetBased | 3 | Completed | 16/03/2021 | https://clinicaltrials.gov/study/NCT04788511 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | obesity | SEMAGLUTIDE | targetBased | 3 | Completed | 16/03/2021 | https://clinicaltrials.gov/study/NCT04788511 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | obesity | SEMAGLUTIDE | targetBased | 3 | Recruiting | 15/08/2023 | https://clinicaltrials.gov/study/NCT05996848 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | obesity | SEMAGLUTIDE | targetBased | 3 | Recruiting | 15/08/2023 | https://clinicaltrials.gov/study/NCT05996848 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | obesity | SEMAGLUTIDE | targetBased | 3 | Recruiting | 15/08/2023 | https://clinicaltrials.gov/study/NCT05996848 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | obesity | SEMAGLUTIDE | targetBased | 3 | Completed | 01/10/2021 | https://clinicaltrials.gov/study/NCT05064735 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | obesity | SEMAGLUTIDE | targetBased | 3 | Completed | 01/10/2021 | https://clinicaltrials.gov/study/NCT05064735 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | obesity | SEMAGLUTIDE | targetBased | 3 | Completed | 01/10/2021 | https://clinicaltrials.gov/study/NCT05064735 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | obesity | SEMAGLUTIDE | targetBased | 3 | Completed | 11/09/2019 | https://clinicaltrials.gov/study/NCT04074161 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | obesity | SEMAGLUTIDE | targetBased | 3 | Completed | 11/09/2019 | https://clinicaltrials.gov/study/NCT04074161 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | obesity | SEMAGLUTIDE | targetBased | 3 | Completed | 11/09/2019 | https://clinicaltrials.gov/study/NCT04074161 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | obesity | SEMAGLUTIDE | targetBased | 3 | Completed | 13/09/2021 | https://clinicaltrials.gov/study/NCT05035095 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | obesity | SEMAGLUTIDE | targetBased | 3 | Completed | 13/09/2021 | https://clinicaltrials.gov/study/NCT05035095 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | obesity | SEMAGLUTIDE | targetBased | 3 | Completed | 13/09/2021 | https://clinicaltrials.gov/study/NCT05035095 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | obesity | SEMAGLUTIDE | targetBased | 3 | Completed | 04/06/2018 | https://clinicaltrials.gov/study/NCT03552757 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | obesity | SEMAGLUTIDE | targetBased | 3 | Completed | 04/06/2018 | https://clinicaltrials.gov/study/NCT03552757 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | obesity | SEMAGLUTIDE | targetBased | 3 | Completed | 04/06/2018 | https://clinicaltrials.gov/study/NCT03552757 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | obesity | SEMAGLUTIDE | targetBased | 3 | Completed | 04/06/2018 | https://clinicaltrials.gov/study/NCT03548935 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | obesity | SEMAGLUTIDE | targetBased | 3 | Completed | 04/06/2018 | https://clinicaltrials.gov/study/NCT03548935 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | obesity | SEMAGLUTIDE | targetBased | 3 | Completed | 04/06/2018 | https://clinicaltrials.gov/study/NCT03548935 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | obesity | SEMAGLUTIDE | targetBased | 3 | Completed | 05/10/2018 | https://clinicaltrials.gov/study/NCT03693430 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | obesity | SEMAGLUTIDE | targetBased | 3 | Completed | 05/10/2018 | https://clinicaltrials.gov/study/NCT03693430 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | obesity | SEMAGLUTIDE | targetBased | 3 | Completed | 05/10/2018 | https://clinicaltrials.gov/study/NCT03693430 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | obesity | SEMAGLUTIDE | targetBased | 3 | Completed | 21/01/2019 | https://clinicaltrials.gov/study/NCT03811574 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | obesity | SEMAGLUTIDE | targetBased | 3 | Completed | 21/01/2019 | https://clinicaltrials.gov/study/NCT03811574 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | obesity | SEMAGLUTIDE | targetBased | 3 | Completed | 21/01/2019 | https://clinicaltrials.gov/study/NCT03811574 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | obesity | SEMAGLUTIDE | targetBased | 3 | Completed | 16/11/2021 | https://clinicaltrials.gov/study/NCT05132088 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | obesity | SEMAGLUTIDE | targetBased | 3 | Completed | 16/11/2021 | https://clinicaltrials.gov/study/NCT05132088 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | obesity | SEMAGLUTIDE | targetBased | 3 | Completed | 16/11/2021 | https://clinicaltrials.gov/study/NCT05132088 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | obesity | SEMAGLUTIDE | targetBased | 3 | Recruiting | 30/05/2023 | https://clinicaltrials.gov/study/NCT05890976 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | obesity | SEMAGLUTIDE | targetBased | 3 | Recruiting | 30/05/2023 | https://clinicaltrials.gov/study/NCT05890976 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | obesity | SEMAGLUTIDE | targetBased | 3 | Recruiting | 30/05/2023 | https://clinicaltrials.gov/study/NCT05890976 | 0.7 | GoF | protect | |
| Fluorescence polarization-based biochemical primary high throughput screening assay to identify inhibitors that disrupt the binding of a cyclic peptide (Tn6) to the fibrin proteolytic product D-Dimer and fragment E complex [DD(E )] | FGB_inhibitors | FGB | Fibrinogen beta chain [Cleaved into: Fibrinopeptide B; Fibrinogen beta chain] | liver disease | FIBRINOGEN, HUMAN | targetBased | 3 | Completed | 01/10/2005 | https://clinicaltrials.gov/study/NCT00365248 | 0.7 | protect | ||
| Fluorescence polarization-based biochemical primary high throughput screening assay to identify inhibitors that disrupt the binding of a cyclic peptide (Tn7) to the fibrin proteolytic product D-Dimer and fragment E complex [DD(E )] | FGB_inhibitors | FGB | Fibrinogen beta chain [Cleaved into: Fibrinopeptide B; Fibrinogen beta chain] | liver disease | FIBRINOGEN, HUMAN | targetBased | 3 | Completed | 01/10/2005 | https://clinicaltrials.gov/study/NCT00365248 | 0.7 | protect | ||
| Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2 | THRB | THRB | Thyroid hormone receptor beta | non-alcoholic fatty liver disease | RESMETIROM | targetBased | 3 | Completed | 16/12/2019 | https://clinicaltrials.gov/study/NCT04197479 | 0.7 | GoF | protect | |
| Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2 | THRB | THRB | Thyroid hormone receptor beta | non-alcoholic fatty liver disease | RESMETIROM | targetBased | 3 | Recruiting | 09/07/2021 | https://clinicaltrials.gov/study/NCT04951219 | 0.7 | GoF | protect | |
| Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2 | THRB | THRB | Thyroid hormone receptor beta | non-alcoholic steatohepatitis | RESMETIROM | targetBased | 3 | Active, not recruiting | 28/03/2019 | https://clinicaltrials.gov/study/NCT03900429 | 0.7 | GoF | protect | |
| Luminescence-based cell-based primary high throughput screening assay to identify biased ligands of the melanocortin 4 receptor (MC4R): agonists of MC4R | MC4R | MC4R | Melanocortin receptor 4 | obesity | SETMELANOTIDE | targetBased | 3 | Enrolling by invitation | 26/04/2023 | https://clinicaltrials.gov/study/NCT05774756 | 0.7 | GoF | protect | |
| TRFRET-based cell-based primary high throughput screening assay to identify biased ligands of the melanocortin 4 receptor (MC4R): antagonists of MC4R | MC4R | MC4R | Melanocortin receptor 4 | obesity | SETMELANOTIDE | targetBased | 3 | Enrolling by invitation | 26/04/2023 | https://clinicaltrials.gov/study/NCT05774756 | 0.7 | GoF | protect | |
| Luminescence-based cell-based primary high throughput screening assay to identify biased ligands of the melanocortin 4 receptor (MC4R): agonists of MC4R | MC4R | MC4R | Melanocortin receptor 4 | obesity | SETMELANOTIDE | targetBased | 4 | https://www.whocc.no/atc_ddd_index/?code=A08AA12 | 1 | GoF | protect | |||
| TRFRET-based cell-based primary high throughput screening assay to identify biased ligands of the melanocortin 4 receptor (MC4R): antagonists of MC4R | MC4R | MC4R | Melanocortin receptor 4 | obesity | SETMELANOTIDE | targetBased | 4 | https://www.whocc.no/atc_ddd_index/?code=A08AA12 | 1 | GoF | protect | |||
| Luminescence-based cell-based primary high throughput screening assay to identify biased ligands of the melanocortin 4 receptor (MC4R): agonists of MC4R | MC4R | MC4R | Melanocortin receptor 4 | obesity | SETMELANOTIDE | targetBased | 4 | https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213793Orig1s000RPLlbl.pdf | 1 | GoF | protect | |||
| TRFRET-based cell-based primary high throughput screening assay to identify biased ligands of the melanocortin 4 receptor (MC4R): antagonists of MC4R | MC4R | MC4R | Melanocortin receptor 4 | obesity | SETMELANOTIDE | targetBased | 4 | https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213793Orig1s000RPLlbl.pdf | 1 | GoF | protect | |||
| Luminescence-based cell-based primary high throughput screening assay to identify biased ligands of the melanocortin 4 receptor (MC4R): agonists of MC4R | MC4R | MC4R | Melanocortin receptor 4 | obesity | SETMELANOTIDE | targetBased | 3 | Completed | 30/01/2018 | https://clinicaltrials.gov/study/NCT03287960 | 0.7 | GoF | protect | |
| TRFRET-based cell-based primary high throughput screening assay to identify biased ligands of the melanocortin 4 receptor (MC4R): antagonists of MC4R | MC4R | MC4R | Melanocortin receptor 4 | obesity | SETMELANOTIDE | targetBased | 3 | Completed | 30/01/2018 | https://clinicaltrials.gov/study/NCT03287960 | 0.7 | GoF | protect | |
| Luminescence-based cell-based primary high throughput screening assay to identify biased ligands of the melanocortin 4 receptor (MC4R): agonists of MC4R | MC4R | MC4R | Melanocortin receptor 4 | obesity | SETMELANOTIDE | targetBased | 3 | Completed | 14/02/2017 | https://clinicaltrials.gov/study/NCT02896192 | 0.7 | GoF | protect | |
| TRFRET-based cell-based primary high throughput screening assay to identify biased ligands of the melanocortin 4 receptor (MC4R): antagonists of MC4R | MC4R | MC4R | Melanocortin receptor 4 | obesity | SETMELANOTIDE | targetBased | 3 | Completed | 14/02/2017 | https://clinicaltrials.gov/study/NCT02896192 | 0.7 | GoF | protect | |
| Luminescence-based cell-based primary high throughput screening assay to identify biased ligands of the melanocortin 4 receptor (MC4R): agonists of MC4R | MC4R | MC4R | Melanocortin receptor 4 | obesity | SETMELANOTIDE | targetBased | 4 | https://www.ema.europa.eu/en/medicines/human/EPAR/imcivree | 1 | GoF | protect | |||
| TRFRET-based cell-based primary high throughput screening assay to identify biased ligands of the melanocortin 4 receptor (MC4R): antagonists of MC4R | MC4R | MC4R | Melanocortin receptor 4 | obesity | SETMELANOTIDE | targetBased | 4 | https://www.ema.europa.eu/en/medicines/human/EPAR/imcivree | 1 | GoF | protect | |||
| Luminescence-based cell-based primary high throughput screening assay to identify biased ligands of the melanocortin 4 receptor (MC4R): agonists of MC4R | MC4R | MC4R | Melanocortin receptor 4 | obesity | SETMELANOTIDE | targetBased | 3 | Recruiting | 10/12/2021 | https://clinicaltrials.gov/study/NCT05093634 | 0.7 | GoF | protect | |
| TRFRET-based cell-based primary high throughput screening assay to identify biased ligands of the melanocortin 4 receptor (MC4R): antagonists of MC4R | MC4R | MC4R | Melanocortin receptor 4 | obesity | SETMELANOTIDE | targetBased | 3 | Recruiting | 10/12/2021 | https://clinicaltrials.gov/study/NCT05093634 | 0.7 | GoF | protect | |
| Luminescence-based cell-based primary high throughput screening assay to identify biased ligands of the melanocortin 4 receptor (MC4R): agonists of MC4R | MC4R | MC4R | Melanocortin receptor 4 | Genetic obesity | SETMELANOTIDE | targetBased | 3 | Recruiting | 10/12/2021 | https://clinicaltrials.gov/study/NCT05093634 | 0.7 | GoF | protect | |
| TRFRET-based cell-based primary high throughput screening assay to identify biased ligands of the melanocortin 4 receptor (MC4R): antagonists of MC4R | MC4R | MC4R | Melanocortin receptor 4 | Genetic obesity | SETMELANOTIDE | targetBased | 3 | Recruiting | 10/12/2021 | https://clinicaltrials.gov/study/NCT05093634 | 0.7 | GoF | protect | |
| Fluorescence-based primary cell-based high throughput screening assay to identify agonists of the Oxytocin Receptor (OXTR). | OXTR | OXTR | Oxytocin receptor | Prader-Willi syndrome | CARBETOCIN | targetBased | 3 | Completed | 20/11/2018 | https://clinicaltrials.gov/study/NCT03649477 | 0.7 | GoF | protect | |
| High Throughput Screening for Cocaine Antagonists: Primary Screen | SLC6A3 | SLC6A3 | Sodium-dependent dopamine transporter | obesity | SIBUTRAMINE HYDROCHLORIDE | targetBased | 3 | Completed | 01/01/2003 | https://clinicaltrials.gov/study/NCT00234832 | 0.7 | LoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | LIRAGLUTIDE | targetBased | 3 | Completed | 01/08/2007 | https://clinicaltrials.gov/study/NCT00518882 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | LIRAGLUTIDE | targetBased | 3 | Completed | 01/08/2007 | https://clinicaltrials.gov/study/NCT00518882 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | LIRAGLUTIDE | targetBased | 3 | Completed | 01/08/2007 | https://clinicaltrials.gov/study/NCT00518882 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | LIRAGLUTIDE | targetBased | 3 | Completed | 01/10/2006 | https://clinicaltrials.gov/study/NCT00395746 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | LIRAGLUTIDE | targetBased | 3 | Completed | 01/10/2006 | https://clinicaltrials.gov/study/NCT00395746 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | LIRAGLUTIDE | targetBased | 3 | Completed | 01/10/2006 | https://clinicaltrials.gov/study/NCT00395746 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | LIRAGLUTIDE | targetBased | 4 | Completed | 26/10/2017 | https://clinicaltrials.gov/study/NCT03449654 | 1 | GoF | protect | |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | LIRAGLUTIDE | targetBased | 4 | Completed | 26/10/2017 | https://clinicaltrials.gov/study/NCT03449654 | 1 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | LIRAGLUTIDE | targetBased | 4 | Completed | 26/10/2017 | https://clinicaltrials.gov/study/NCT03449654 | 1 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | LIRAGLUTIDE | targetBased | 4 | Terminated | 01/02/2014 | https://clinicaltrials.gov/study/NCT02072096 | 1 | GoF | protect | The trial was terminated per protocol because of lack of feasibility. |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | LIRAGLUTIDE | targetBased | 4 | Terminated | 01/02/2014 | https://clinicaltrials.gov/study/NCT02072096 | 1 | GoF | protect | The trial was terminated per protocol because of lack of feasibility. |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | LIRAGLUTIDE | targetBased | 4 | Terminated | 01/02/2014 | https://clinicaltrials.gov/study/NCT02072096 | 1 | GoF | protect | The trial was terminated per protocol because of lack of feasibility. |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | LIRAGLUTIDE | targetBased | 4 | Completed | 01/05/2013 | https://clinicaltrials.gov/study/NCT01931982 | 1 | GoF | protect | |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | LIRAGLUTIDE | targetBased | 4 | Completed | 01/05/2013 | https://clinicaltrials.gov/study/NCT01931982 | 1 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | LIRAGLUTIDE | targetBased | 4 | Completed | 01/05/2013 | https://clinicaltrials.gov/study/NCT01931982 | 1 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | LIRAGLUTIDE | targetBased | 3 | Completed | 01/11/2006 | https://clinicaltrials.gov/study/NCT00393718 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | LIRAGLUTIDE | targetBased | 3 | Completed | 01/11/2006 | https://clinicaltrials.gov/study/NCT00393718 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | LIRAGLUTIDE | targetBased | 3 | Completed | 01/11/2006 | https://clinicaltrials.gov/study/NCT00393718 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | LIRAGLUTIDE | targetBased | 4 | Recruiting | 01/05/2020 | https://clinicaltrials.gov/study/NCT04146155 | 1 | GoF | protect | |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | LIRAGLUTIDE | targetBased | 4 | Recruiting | 01/05/2020 | https://clinicaltrials.gov/study/NCT04146155 | 1 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | LIRAGLUTIDE | targetBased | 4 | Recruiting | 01/05/2020 | https://clinicaltrials.gov/study/NCT04146155 | 1 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | LIRAGLUTIDE | targetBased | 3 | Not yet recruiting | 01/05/2020 | https://clinicaltrials.gov/study/NCT04373967 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | LIRAGLUTIDE | targetBased | 3 | Not yet recruiting | 01/05/2020 | https://clinicaltrials.gov/study/NCT04373967 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | LIRAGLUTIDE | targetBased | 3 | Not yet recruiting | 01/05/2020 | https://clinicaltrials.gov/study/NCT04373967 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | LIRAGLUTIDE | targetBased | 3 | Completed | 01/02/2008 | https://clinicaltrials.gov/study/NCT00620282 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | LIRAGLUTIDE | targetBased | 3 | Completed | 01/02/2008 | https://clinicaltrials.gov/study/NCT00620282 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | LIRAGLUTIDE | targetBased | 3 | Completed | 01/02/2008 | https://clinicaltrials.gov/study/NCT00620282 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | LIRAGLUTIDE | targetBased | 3 | Completed | 01/03/2009 | https://clinicaltrials.gov/study/NCT00856986 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | LIRAGLUTIDE | targetBased | 3 | Completed | 01/03/2009 | https://clinicaltrials.gov/study/NCT00856986 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | LIRAGLUTIDE | targetBased | 3 | Completed | 01/03/2009 | https://clinicaltrials.gov/study/NCT00856986 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | LIRAGLUTIDE | targetBased | 3 | Completed | 10/08/2016 | https://clinicaltrials.gov/study/NCT02863419 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | LIRAGLUTIDE | targetBased | 3 | Completed | 10/08/2016 | https://clinicaltrials.gov/study/NCT02863419 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | LIRAGLUTIDE | targetBased | 3 | Completed | 10/08/2016 | https://clinicaltrials.gov/study/NCT02863419 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | LIRAGLUTIDE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=21335fe4-d395-4501-ac2a-2f20d7520da9 | 1 | GoF | protect | |||
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | LIRAGLUTIDE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=21335fe4-d395-4501-ac2a-2f20d7520da9 | 1 | GoF | protect | |||
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | LIRAGLUTIDE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=21335fe4-d395-4501-ac2a-2f20d7520da9 | 1 | GoF | protect | |||
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | LIRAGLUTIDE | targetBased | 3 | Completed | 31/08/2010 | https://clinicaltrials.gov/study/NCT01179048 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | LIRAGLUTIDE | targetBased | 3 | Completed | 31/08/2010 | https://clinicaltrials.gov/study/NCT01179048 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | LIRAGLUTIDE | targetBased | 3 | Completed | 31/08/2010 | https://clinicaltrials.gov/study/NCT01179048 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | LIRAGLUTIDE | targetBased | 3 | Completed | 21/07/2015 | https://clinicaltrials.gov/study/NCT02505334 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | LIRAGLUTIDE | targetBased | 3 | Completed | 21/07/2015 | https://clinicaltrials.gov/study/NCT02505334 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | LIRAGLUTIDE | targetBased | 3 | Completed | 21/07/2015 | https://clinicaltrials.gov/study/NCT02505334 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | LIRAGLUTIDE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3946d389-0926-4f77-a708-0acb8153b143 | 1 | GoF | protect | |||
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | LIRAGLUTIDE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3946d389-0926-4f77-a708-0acb8153b143 | 1 | GoF | protect | |||
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | LIRAGLUTIDE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3946d389-0926-4f77-a708-0acb8153b143 | 1 | GoF | protect | |||
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | LIRAGLUTIDE | targetBased | 4 | Completed | 01/10/2013 | https://clinicaltrials.gov/study/NCT01973231 | 1 | GoF | protect | |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | LIRAGLUTIDE | targetBased | 4 | Completed | 01/10/2013 | https://clinicaltrials.gov/study/NCT01973231 | 1 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | LIRAGLUTIDE | targetBased | 4 | Completed | 01/10/2013 | https://clinicaltrials.gov/study/NCT01973231 | 1 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | LIRAGLUTIDE | targetBased | 4 | Completed | 01/04/2011 | https://clinicaltrials.gov/study/NCT02292290 | 1 | GoF | protect | |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | LIRAGLUTIDE | targetBased | 4 | Completed | 01/04/2011 | https://clinicaltrials.gov/study/NCT02292290 | 1 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | LIRAGLUTIDE | targetBased | 4 | Completed | 01/04/2011 | https://clinicaltrials.gov/study/NCT02292290 | 1 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | LIRAGLUTIDE | targetBased | 3 | Completed | 23/05/2011 | https://clinicaltrials.gov/study/NCT01336023 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | LIRAGLUTIDE | targetBased | 3 | Completed | 23/05/2011 | https://clinicaltrials.gov/study/NCT01336023 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | LIRAGLUTIDE | targetBased | 3 | Completed | 23/05/2011 | https://clinicaltrials.gov/study/NCT01336023 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | LIRAGLUTIDE | targetBased | 4 | Completed | 01/12/2011 | https://clinicaltrials.gov/study/NCT01654120 | 1 | GoF | protect | |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | LIRAGLUTIDE | targetBased | 4 | Completed | 01/12/2011 | https://clinicaltrials.gov/study/NCT01654120 | 1 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | LIRAGLUTIDE | targetBased | 4 | Completed | 01/12/2011 | https://clinicaltrials.gov/study/NCT01654120 | 1 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | LIRAGLUTIDE | targetBased | 3 | Terminated | 01/02/2006 | https://clinicaltrials.gov/study/NCT00294723 | 0.7 | GoF | protect | The trial was terminated at week 195 due to an insufficient number of subjects remaining to obtain reasonable statistical power |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | LIRAGLUTIDE | targetBased | 3 | Terminated | 01/02/2006 | https://clinicaltrials.gov/study/NCT00294723 | 0.7 | GoF | protect | The trial was terminated at week 195 due to an insufficient number of subjects remaining to obtain reasonable statistical power |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | LIRAGLUTIDE | targetBased | 3 | Terminated | 01/02/2006 | https://clinicaltrials.gov/study/NCT00294723 | 0.7 | GoF | protect | The trial was terminated at week 195 due to an insufficient number of subjects remaining to obtain reasonable statistical power |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | LIRAGLUTIDE | targetBased | 4 | Withdrawn | 01/05/2012 | https://clinicaltrials.gov/study/NCT01593137 | 1 | GoF | protect | Lack of patients with the criteria established in the protocol. |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | LIRAGLUTIDE | targetBased | 4 | Withdrawn | 01/05/2012 | https://clinicaltrials.gov/study/NCT01593137 | 1 | GoF | protect | Lack of patients with the criteria established in the protocol. |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | LIRAGLUTIDE | targetBased | 4 | Withdrawn | 01/05/2012 | https://clinicaltrials.gov/study/NCT01593137 | 1 | GoF | protect | Lack of patients with the criteria established in the protocol. |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | LIRAGLUTIDE | targetBased | 3 | Completed | 01/01/2010 | https://clinicaltrials.gov/study/NCT01029886 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | LIRAGLUTIDE | targetBased | 3 | Completed | 01/01/2010 | https://clinicaltrials.gov/study/NCT01029886 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | LIRAGLUTIDE | targetBased | 3 | Completed | 01/01/2010 | https://clinicaltrials.gov/study/NCT01029886 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | LIRAGLUTIDE | targetBased | 3 | Completed | 27/06/2017 | https://clinicaltrials.gov/study/NCT03191396 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | LIRAGLUTIDE | targetBased | 3 | Completed | 27/06/2017 | https://clinicaltrials.gov/study/NCT03191396 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | LIRAGLUTIDE | targetBased | 3 | Completed | 27/06/2017 | https://clinicaltrials.gov/study/NCT03191396 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | LIRAGLUTIDE | targetBased | 3 | Completed | 26/05/2017 | https://clinicaltrials.gov/study/NCT03175120 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | LIRAGLUTIDE | targetBased | 3 | Completed | 26/05/2017 | https://clinicaltrials.gov/study/NCT03175120 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | LIRAGLUTIDE | targetBased | 3 | Completed | 26/05/2017 | https://clinicaltrials.gov/study/NCT03175120 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | LIRAGLUTIDE | targetBased | 3 | Completed | 26/05/2017 | https://clinicaltrials.gov/study/NCT03172494 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | LIRAGLUTIDE | targetBased | 3 | Completed | 26/05/2017 | https://clinicaltrials.gov/study/NCT03172494 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | LIRAGLUTIDE | targetBased | 3 | Completed | 26/05/2017 | https://clinicaltrials.gov/study/NCT03172494 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | LIRAGLUTIDE | targetBased | 3 | Completed | 14/06/2012 | https://clinicaltrials.gov/study/NCT01620489 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | LIRAGLUTIDE | targetBased | 3 | Completed | 14/06/2012 | https://clinicaltrials.gov/study/NCT01620489 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | LIRAGLUTIDE | targetBased | 3 | Completed | 14/06/2012 | https://clinicaltrials.gov/study/NCT01620489 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | LIRAGLUTIDE | targetBased | 3 | Completed | 01/09/2012 | https://clinicaltrials.gov/study/NCT01617434 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | LIRAGLUTIDE | targetBased | 3 | Completed | 01/09/2012 | https://clinicaltrials.gov/study/NCT01617434 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | LIRAGLUTIDE | targetBased | 3 | Completed | 01/09/2012 | https://clinicaltrials.gov/study/NCT01617434 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | LIRAGLUTIDE | targetBased | 3 | Terminated | 01/08/2012 | https://clinicaltrials.gov/study/NCT01628445 | 0.7 | GoF | protect | Error made by local pharmacy caused mixed randomization of 20 participants |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | LIRAGLUTIDE | targetBased | 3 | Terminated | 01/08/2012 | https://clinicaltrials.gov/study/NCT01628445 | 0.7 | GoF | protect | Error made by local pharmacy caused mixed randomization of 20 participants |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | LIRAGLUTIDE | targetBased | 3 | Terminated | 01/08/2012 | https://clinicaltrials.gov/study/NCT01628445 | 0.7 | GoF | protect | Error made by local pharmacy caused mixed randomization of 20 participants |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | LIRAGLUTIDE | targetBased | 4 | Unknown status | 01/02/2013 | https://clinicaltrials.gov/study/NCT01790308 | 1 | GoF | protect | |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | LIRAGLUTIDE | targetBased | 4 | Unknown status | 01/02/2013 | https://clinicaltrials.gov/study/NCT01790308 | 1 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | LIRAGLUTIDE | targetBased | 4 | Unknown status | 01/02/2013 | https://clinicaltrials.gov/study/NCT01790308 | 1 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | LIRAGLUTIDE | targetBased | 4 | Completed | 01/02/2015 | https://clinicaltrials.gov/study/NCT02765399 | 1 | GoF | protect | |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | LIRAGLUTIDE | targetBased | 4 | Completed | 01/02/2015 | https://clinicaltrials.gov/study/NCT02765399 | 1 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | LIRAGLUTIDE | targetBased | 4 | Completed | 01/02/2015 | https://clinicaltrials.gov/study/NCT02765399 | 1 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | LIRAGLUTIDE | targetBased | 3 | Completed | 20/09/2013 | https://clinicaltrials.gov/study/NCT01952145 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | LIRAGLUTIDE | targetBased | 3 | Completed | 20/09/2013 | https://clinicaltrials.gov/study/NCT01952145 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | LIRAGLUTIDE | targetBased | 3 | Completed | 20/09/2013 | https://clinicaltrials.gov/study/NCT01952145 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | LIRAGLUTIDE | targetBased | 4 | Completed | 01/04/2013 | https://clinicaltrials.gov/study/NCT01744236 | 1 | GoF | protect | |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | LIRAGLUTIDE | targetBased | 4 | Completed | 01/04/2013 | https://clinicaltrials.gov/study/NCT01744236 | 1 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | LIRAGLUTIDE | targetBased | 4 | Completed | 01/04/2013 | https://clinicaltrials.gov/study/NCT01744236 | 1 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | LIRAGLUTIDE | targetBased | 3 | Completed | 01/12/2015 | https://clinicaltrials.gov/study/NCT02638805 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | LIRAGLUTIDE | targetBased | 3 | Completed | 01/12/2015 | https://clinicaltrials.gov/study/NCT02638805 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | LIRAGLUTIDE | targetBased | 3 | Completed | 01/12/2015 | https://clinicaltrials.gov/study/NCT02638805 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | LIRAGLUTIDE | targetBased | 4 | Completed | 09/01/2014 | https://clinicaltrials.gov/study/NCT01917656 | 1 | GoF | protect | |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | LIRAGLUTIDE | targetBased | 4 | Completed | 09/01/2014 | https://clinicaltrials.gov/study/NCT01917656 | 1 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | LIRAGLUTIDE | targetBased | 4 | Completed | 09/01/2014 | https://clinicaltrials.gov/study/NCT01917656 | 1 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | LIRAGLUTIDE | targetBased | 3 | Completed | 01/08/2013 | https://clinicaltrials.gov/study/NCT01937598 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | LIRAGLUTIDE | targetBased | 3 | Completed | 01/08/2013 | https://clinicaltrials.gov/study/NCT01937598 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | LIRAGLUTIDE | targetBased | 3 | Completed | 01/08/2013 | https://clinicaltrials.gov/study/NCT01937598 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | LIRAGLUTIDE | targetBased | 4 | Completed | 01/03/2014 | https://clinicaltrials.gov/study/NCT01919489 | 1 | GoF | protect | |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | LIRAGLUTIDE | targetBased | 4 | Completed | 01/03/2014 | https://clinicaltrials.gov/study/NCT01919489 | 1 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | LIRAGLUTIDE | targetBased | 4 | Completed | 01/03/2014 | https://clinicaltrials.gov/study/NCT01919489 | 1 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | LIRAGLUTIDE | targetBased | 3 | Completed | 01/05/2006 | https://clinicaltrials.gov/study/NCT00331851 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | LIRAGLUTIDE | targetBased | 3 | Completed | 01/05/2006 | https://clinicaltrials.gov/study/NCT00331851 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | LIRAGLUTIDE | targetBased | 3 | Completed | 01/05/2006 | https://clinicaltrials.gov/study/NCT00331851 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | LIRAGLUTIDE | targetBased | 3 | Unknown status | 20/06/2019 | https://clinicaltrials.gov/study/NCT03421119 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | LIRAGLUTIDE | targetBased | 3 | Unknown status | 20/06/2019 | https://clinicaltrials.gov/study/NCT03421119 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | LIRAGLUTIDE | targetBased | 3 | Unknown status | 20/06/2019 | https://clinicaltrials.gov/study/NCT03421119 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | LIRAGLUTIDE | targetBased | 3 | Completed | 03/03/2017 | https://clinicaltrials.gov/study/NCT02964247 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | LIRAGLUTIDE | targetBased | 3 | Completed | 03/03/2017 | https://clinicaltrials.gov/study/NCT02964247 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | LIRAGLUTIDE | targetBased | 3 | Completed | 03/03/2017 | https://clinicaltrials.gov/study/NCT02964247 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | LIRAGLUTIDE | targetBased | 3 | Completed | 05/04/2012 | https://clinicaltrials.gov/study/NCT01572740 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | LIRAGLUTIDE | targetBased | 3 | Completed | 05/04/2012 | https://clinicaltrials.gov/study/NCT01572740 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | LIRAGLUTIDE | targetBased | 3 | Completed | 05/04/2012 | https://clinicaltrials.gov/study/NCT01572740 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | LIRAGLUTIDE | targetBased | 4 | Terminated | 10/07/2012 | https://clinicaltrials.gov/study/NCT02721888 | 1 | GoF | protect | Failure of inclusion |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | LIRAGLUTIDE | targetBased | 4 | Terminated | 10/07/2012 | https://clinicaltrials.gov/study/NCT02721888 | 1 | GoF | protect | Failure of inclusion |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | LIRAGLUTIDE | targetBased | 4 | Terminated | 10/07/2012 | https://clinicaltrials.gov/study/NCT02721888 | 1 | GoF | protect | Failure of inclusion |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | LIRAGLUTIDE | targetBased | 3 | Completed | 23/05/2016 | https://clinicaltrials.gov/study/NCT02773368 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | LIRAGLUTIDE | targetBased | 3 | Completed | 23/05/2016 | https://clinicaltrials.gov/study/NCT02773368 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | LIRAGLUTIDE | targetBased | 3 | Completed | 23/05/2016 | https://clinicaltrials.gov/study/NCT02773368 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | LIRAGLUTIDE | targetBased | 4 | Withdrawn | 01/12/2019 | https://clinicaltrials.gov/study/NCT02198209 | 1 | GoF | protect | Investigator decided not to move forward with study prior to study start date |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | LIRAGLUTIDE | targetBased | 4 | Withdrawn | 01/12/2019 | https://clinicaltrials.gov/study/NCT02198209 | 1 | GoF | protect | Investigator decided not to move forward with study prior to study start date |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | LIRAGLUTIDE | targetBased | 4 | Withdrawn | 01/12/2019 | https://clinicaltrials.gov/study/NCT02198209 | 1 | GoF | protect | Investigator decided not to move forward with study prior to study start date |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | LIRAGLUTIDE | targetBased | 4 | Completed | 01/11/2014 | https://clinicaltrials.gov/study/NCT01966978 | 1 | GoF | protect | |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | LIRAGLUTIDE | targetBased | 4 | Completed | 01/11/2014 | https://clinicaltrials.gov/study/NCT01966978 | 1 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | LIRAGLUTIDE | targetBased | 4 | Completed | 01/11/2014 | https://clinicaltrials.gov/study/NCT01966978 | 1 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | LIRAGLUTIDE | targetBased | 4 | Completed | 18/05/2016 | https://clinicaltrials.gov/study/NCT02686177 | 1 | GoF | protect | |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | LIRAGLUTIDE | targetBased | 4 | Completed | 18/05/2016 | https://clinicaltrials.gov/study/NCT02686177 | 1 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | LIRAGLUTIDE | targetBased | 4 | Completed | 18/05/2016 | https://clinicaltrials.gov/study/NCT02686177 | 1 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | LIRAGLUTIDE | targetBased | 4 | Completed | 01/03/2013 | https://clinicaltrials.gov/study/NCT01785043 | 1 | GoF | protect | |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | LIRAGLUTIDE | targetBased | 4 | Completed | 01/03/2013 | https://clinicaltrials.gov/study/NCT01785043 | 1 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | LIRAGLUTIDE | targetBased | 4 | Completed | 01/03/2013 | https://clinicaltrials.gov/study/NCT01785043 | 1 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | LIRAGLUTIDE | targetBased | 4 | Terminated | 01/06/2012 | https://clinicaltrials.gov/study/NCT01597531 | 1 | GoF | protect | Difficulty recruiting patients |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | LIRAGLUTIDE | targetBased | 4 | Terminated | 01/06/2012 | https://clinicaltrials.gov/study/NCT01597531 | 1 | GoF | protect | Difficulty recruiting patients |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | LIRAGLUTIDE | targetBased | 4 | Terminated | 01/06/2012 | https://clinicaltrials.gov/study/NCT01597531 | 1 | GoF | protect | Difficulty recruiting patients |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | LIRAGLUTIDE | targetBased | 4 | Completed | 01/12/2013 | https://clinicaltrials.gov/study/NCT02008682 | 1 | GoF | protect | |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | LIRAGLUTIDE | targetBased | 4 | Completed | 01/12/2013 | https://clinicaltrials.gov/study/NCT02008682 | 1 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | LIRAGLUTIDE | targetBased | 4 | Completed | 01/12/2013 | https://clinicaltrials.gov/study/NCT02008682 | 1 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | LIRAGLUTIDE | targetBased | 3 | Completed | 01/05/2010 | https://clinicaltrials.gov/study/NCT01128894 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | LIRAGLUTIDE | targetBased | 3 | Completed | 01/05/2010 | https://clinicaltrials.gov/study/NCT01128894 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | LIRAGLUTIDE | targetBased | 3 | Completed | 01/05/2010 | https://clinicaltrials.gov/study/NCT01128894 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | LIRAGLUTIDE | targetBased | 3 | Completed | 29/08/2012 | https://clinicaltrials.gov/study/NCT01618162 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | LIRAGLUTIDE | targetBased | 3 | Completed | 29/08/2012 | https://clinicaltrials.gov/study/NCT01618162 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | LIRAGLUTIDE | targetBased | 3 | Completed | 29/08/2012 | https://clinicaltrials.gov/study/NCT01618162 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | LIRAGLUTIDE | targetBased | 4 | Unknown status | 01/10/2014 | https://clinicaltrials.gov/study/NCT02501850 | 1 | GoF | protect | |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | LIRAGLUTIDE | targetBased | 4 | Unknown status | 01/10/2014 | https://clinicaltrials.gov/study/NCT02501850 | 1 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | LIRAGLUTIDE | targetBased | 4 | Unknown status | 01/10/2014 | https://clinicaltrials.gov/study/NCT02501850 | 1 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | LIRAGLUTIDE | targetBased | 4 | Completed | 01/01/2016 | https://clinicaltrials.gov/study/NCT02832999 | 1 | GoF | protect | |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | LIRAGLUTIDE | targetBased | 4 | Completed | 01/01/2016 | https://clinicaltrials.gov/study/NCT02832999 | 1 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | LIRAGLUTIDE | targetBased | 4 | Completed | 01/01/2016 | https://clinicaltrials.gov/study/NCT02832999 | 1 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | LIRAGLUTIDE | targetBased | 3 | Completed | 04/10/2016 | https://clinicaltrials.gov/study/NCT02889510 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | LIRAGLUTIDE | targetBased | 3 | Completed | 04/10/2016 | https://clinicaltrials.gov/study/NCT02889510 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | LIRAGLUTIDE | targetBased | 3 | Completed | 04/10/2016 | https://clinicaltrials.gov/study/NCT02889510 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | LIRAGLUTIDE | targetBased | 3 | Completed | 11/03/2011 | https://clinicaltrials.gov/study/NCT01296412 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | LIRAGLUTIDE | targetBased | 3 | Completed | 11/03/2011 | https://clinicaltrials.gov/study/NCT01296412 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | LIRAGLUTIDE | targetBased | 3 | Completed | 11/03/2011 | https://clinicaltrials.gov/study/NCT01296412 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | LIRAGLUTIDE | targetBased | 3 | Completed | 31/01/2016 | https://clinicaltrials.gov/study/NCT02501161 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | LIRAGLUTIDE | targetBased | 3 | Completed | 31/01/2016 | https://clinicaltrials.gov/study/NCT02501161 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | LIRAGLUTIDE | targetBased | 3 | Completed | 31/01/2016 | https://clinicaltrials.gov/study/NCT02501161 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | LIRAGLUTIDE | targetBased | 3 | Completed | 28/11/2011 | https://clinicaltrials.gov/study/NCT01392573 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | LIRAGLUTIDE | targetBased | 3 | Completed | 28/11/2011 | https://clinicaltrials.gov/study/NCT01392573 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | LIRAGLUTIDE | targetBased | 3 | Completed | 28/11/2011 | https://clinicaltrials.gov/study/NCT01392573 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | LIRAGLUTIDE | targetBased | 3 | Completed | 21/11/2014 | https://clinicaltrials.gov/study/NCT02298192 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | LIRAGLUTIDE | targetBased | 3 | Completed | 21/11/2014 | https://clinicaltrials.gov/study/NCT02298192 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | LIRAGLUTIDE | targetBased | 3 | Completed | 21/11/2014 | https://clinicaltrials.gov/study/NCT02298192 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | LIRAGLUTIDE | targetBased | 4 | Unknown status | 01/05/2014 | https://clinicaltrials.gov/study/NCT02344186 | 1 | GoF | protect | |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | LIRAGLUTIDE | targetBased | 4 | Unknown status | 01/05/2014 | https://clinicaltrials.gov/study/NCT02344186 | 1 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | LIRAGLUTIDE | targetBased | 4 | Unknown status | 01/05/2014 | https://clinicaltrials.gov/study/NCT02344186 | 1 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | LIRAGLUTIDE | targetBased | 4 | Completed | 02/12/2013 | https://clinicaltrials.gov/study/NCT01907854 | 1 | GoF | protect | |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | LIRAGLUTIDE | targetBased | 4 | Completed | 02/12/2013 | https://clinicaltrials.gov/study/NCT01907854 | 1 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | LIRAGLUTIDE | targetBased | 4 | Completed | 02/12/2013 | https://clinicaltrials.gov/study/NCT01907854 | 1 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | LIRAGLUTIDE | targetBased | 3 | Completed | 06/07/2016 | https://clinicaltrials.gov/study/NCT02787551 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | LIRAGLUTIDE | targetBased | 3 | Completed | 06/07/2016 | https://clinicaltrials.gov/study/NCT02787551 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | LIRAGLUTIDE | targetBased | 3 | Completed | 06/07/2016 | https://clinicaltrials.gov/study/NCT02787551 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | LIRAGLUTIDE | targetBased | 4 | Completed | 01/04/2010 | https://clinicaltrials.gov/study/NCT01208012 | 1 | GoF | protect | |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | LIRAGLUTIDE | targetBased | 4 | Completed | 01/04/2010 | https://clinicaltrials.gov/study/NCT01208012 | 1 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | LIRAGLUTIDE | targetBased | 4 | Completed | 01/04/2010 | https://clinicaltrials.gov/study/NCT01208012 | 1 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | LIRAGLUTIDE | targetBased | 4 | Completed | 01/10/2011 | https://clinicaltrials.gov/study/NCT01455441 | 1 | GoF | protect | |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | LIRAGLUTIDE | targetBased | 4 | Completed | 01/10/2011 | https://clinicaltrials.gov/study/NCT01455441 | 1 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | LIRAGLUTIDE | targetBased | 4 | Completed | 01/10/2011 | https://clinicaltrials.gov/study/NCT01455441 | 1 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | LIRAGLUTIDE | targetBased | 3 | Completed | 10/01/2012 | https://clinicaltrials.gov/study/NCT01512108 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | LIRAGLUTIDE | targetBased | 3 | Completed | 10/01/2012 | https://clinicaltrials.gov/study/NCT01512108 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | LIRAGLUTIDE | targetBased | 3 | Completed | 10/01/2012 | https://clinicaltrials.gov/study/NCT01512108 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | LIRAGLUTIDE | targetBased | 3 | Completed | 01/06/2012 | https://clinicaltrials.gov/study/NCT01624259 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | LIRAGLUTIDE | targetBased | 3 | Completed | 01/06/2012 | https://clinicaltrials.gov/study/NCT01624259 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | LIRAGLUTIDE | targetBased | 3 | Completed | 01/06/2012 | https://clinicaltrials.gov/study/NCT01624259 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | LIRAGLUTIDE | targetBased | 4 | Completed | 01/08/2012 | https://clinicaltrials.gov/study/NCT01499108 | 1 | GoF | protect | |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | LIRAGLUTIDE | targetBased | 4 | Completed | 01/08/2012 | https://clinicaltrials.gov/study/NCT01499108 | 1 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | LIRAGLUTIDE | targetBased | 4 | Completed | 01/08/2012 | https://clinicaltrials.gov/study/NCT01499108 | 1 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | LIRAGLUTIDE | targetBased | 3 | Completed | 01/03/2012 | https://clinicaltrials.gov/study/NCT01558271 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | LIRAGLUTIDE | targetBased | 3 | Completed | 01/03/2012 | https://clinicaltrials.gov/study/NCT01558271 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | LIRAGLUTIDE | targetBased | 3 | Completed | 01/03/2012 | https://clinicaltrials.gov/study/NCT01558271 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | LIRAGLUTIDE | targetBased | 3 | Completed | 01/05/2006 | https://clinicaltrials.gov/study/NCT00333151 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | LIRAGLUTIDE | targetBased | 3 | Completed | 01/05/2006 | https://clinicaltrials.gov/study/NCT00333151 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | LIRAGLUTIDE | targetBased | 3 | Completed | 01/05/2006 | https://clinicaltrials.gov/study/NCT00333151 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | LIRAGLUTIDE | targetBased | 3 | Recruiting | 01/12/2022 | https://clinicaltrials.gov/study/NCT05767255 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | LIRAGLUTIDE | targetBased | 3 | Recruiting | 01/12/2022 | https://clinicaltrials.gov/study/NCT05767255 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | LIRAGLUTIDE | targetBased | 3 | Recruiting | 01/12/2022 | https://clinicaltrials.gov/study/NCT05767255 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | LIRAGLUTIDE | targetBased | 3 | Completed | 29/08/2012 | https://clinicaltrials.gov/study/NCT01676116 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | LIRAGLUTIDE | targetBased | 3 | Completed | 29/08/2012 | https://clinicaltrials.gov/study/NCT01676116 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | LIRAGLUTIDE | targetBased | 3 | Completed | 29/08/2012 | https://clinicaltrials.gov/study/NCT01676116 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | LIRAGLUTIDE | targetBased | 3 | Completed | 01/02/2013 | https://clinicaltrials.gov/study/NCT01733758 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | LIRAGLUTIDE | targetBased | 3 | Completed | 01/02/2013 | https://clinicaltrials.gov/study/NCT01733758 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | LIRAGLUTIDE | targetBased | 3 | Completed | 01/02/2013 | https://clinicaltrials.gov/study/NCT01733758 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | LIRAGLUTIDE | targetBased | 3 | Completed | 26/07/2015 | https://clinicaltrials.gov/study/NCT02420262 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | LIRAGLUTIDE | targetBased | 3 | Completed | 26/07/2015 | https://clinicaltrials.gov/study/NCT02420262 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | LIRAGLUTIDE | targetBased | 3 | Completed | 26/07/2015 | https://clinicaltrials.gov/study/NCT02420262 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | LIRAGLUTIDE | targetBased | 3 | Completed | 01/01/2008 | https://clinicaltrials.gov/study/NCT00614120 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | LIRAGLUTIDE | targetBased | 3 | Completed | 01/01/2008 | https://clinicaltrials.gov/study/NCT00614120 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | LIRAGLUTIDE | targetBased | 3 | Completed | 01/01/2008 | https://clinicaltrials.gov/study/NCT00614120 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | LIRAGLUTIDE | targetBased | 3 | Completed | 01/05/2013 | https://clinicaltrials.gov/study/NCT01794143 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | LIRAGLUTIDE | targetBased | 3 | Completed | 01/05/2013 | https://clinicaltrials.gov/study/NCT01794143 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | LIRAGLUTIDE | targetBased | 3 | Completed | 01/05/2013 | https://clinicaltrials.gov/study/NCT01794143 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | LIRAGLUTIDE | targetBased | 3 | Completed | 01/10/2018 | https://clinicaltrials.gov/study/NCT03707171 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | LIRAGLUTIDE | targetBased | 3 | Completed | 01/10/2018 | https://clinicaltrials.gov/study/NCT03707171 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | LIRAGLUTIDE | targetBased | 3 | Completed | 01/10/2018 | https://clinicaltrials.gov/study/NCT03707171 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | LIRAGLUTIDE | targetBased | 3 | Completed | 01/10/2012 | https://clinicaltrials.gov/study/NCT01664247 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | LIRAGLUTIDE | targetBased | 3 | Completed | 01/10/2012 | https://clinicaltrials.gov/study/NCT01664247 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | LIRAGLUTIDE | targetBased | 3 | Completed | 01/10/2012 | https://clinicaltrials.gov/study/NCT01664247 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | LIRAGLUTIDE | targetBased | 3 | Completed | 01/04/2013 | https://clinicaltrials.gov/study/NCT01779362 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | LIRAGLUTIDE | targetBased | 3 | Completed | 01/04/2013 | https://clinicaltrials.gov/study/NCT01779362 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | LIRAGLUTIDE | targetBased | 3 | Completed | 01/04/2013 | https://clinicaltrials.gov/study/NCT01779362 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | LIRAGLUTIDE | targetBased | 3 | Completed | 01/05/2006 | https://clinicaltrials.gov/study/NCT00318422 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | LIRAGLUTIDE | targetBased | 3 | Completed | 01/05/2006 | https://clinicaltrials.gov/study/NCT00318422 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | LIRAGLUTIDE | targetBased | 3 | Completed | 01/05/2006 | https://clinicaltrials.gov/study/NCT00318422 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | LIRAGLUTIDE | targetBased | 3 | Completed | 18/11/2015 | https://clinicaltrials.gov/study/NCT02607306 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | LIRAGLUTIDE | targetBased | 3 | Completed | 18/11/2015 | https://clinicaltrials.gov/study/NCT02607306 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | LIRAGLUTIDE | targetBased | 3 | Completed | 18/11/2015 | https://clinicaltrials.gov/study/NCT02607306 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | LIRAGLUTIDE | targetBased | 4 | Terminated | 01/10/2012 | https://clinicaltrials.gov/study/NCT01638260 | 1 | GoF | protect | Terminated because of insufficient number of subjects included. |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | LIRAGLUTIDE | targetBased | 4 | Terminated | 01/10/2012 | https://clinicaltrials.gov/study/NCT01638260 | 1 | GoF | protect | Terminated because of insufficient number of subjects included. |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | LIRAGLUTIDE | targetBased | 4 | Terminated | 01/10/2012 | https://clinicaltrials.gov/study/NCT01638260 | 1 | GoF | protect | Terminated because of insufficient number of subjects included. |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | LIRAGLUTIDE | targetBased | 3 | Completed | 13/11/2012 | https://clinicaltrials.gov/study/NCT01541215 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | LIRAGLUTIDE | targetBased | 3 | Completed | 13/11/2012 | https://clinicaltrials.gov/study/NCT01541215 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | LIRAGLUTIDE | targetBased | 3 | Completed | 13/11/2012 | https://clinicaltrials.gov/study/NCT01541215 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | LIRAGLUTIDE | targetBased | 4 | Completed | 01/12/2012 | https://clinicaltrials.gov/study/NCT01664676 | 1 | GoF | protect | |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | LIRAGLUTIDE | targetBased | 4 | Completed | 01/12/2012 | https://clinicaltrials.gov/study/NCT01664676 | 1 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | LIRAGLUTIDE | targetBased | 4 | Completed | 01/12/2012 | https://clinicaltrials.gov/study/NCT01664676 | 1 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | LIRAGLUTIDE | targetBased | 3 | Completed | 01/05/2006 | https://clinicaltrials.gov/study/NCT00318461 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | LIRAGLUTIDE | targetBased | 3 | Completed | 01/05/2006 | https://clinicaltrials.gov/study/NCT00318461 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | LIRAGLUTIDE | targetBased | 3 | Completed | 01/05/2006 | https://clinicaltrials.gov/study/NCT00318461 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | LIRAGLUTIDE | targetBased | 3 | Completed | 21/09/2016 | https://clinicaltrials.gov/study/NCT02911948 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | LIRAGLUTIDE | targetBased | 3 | Completed | 21/09/2016 | https://clinicaltrials.gov/study/NCT02911948 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | LIRAGLUTIDE | targetBased | 3 | Completed | 21/09/2016 | https://clinicaltrials.gov/study/NCT02911948 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | LIRAGLUTIDE | targetBased | 3 | Completed | 10/01/2017 | https://clinicaltrials.gov/study/NCT03018028 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | LIRAGLUTIDE | targetBased | 3 | Completed | 10/01/2017 | https://clinicaltrials.gov/study/NCT03018028 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | LIRAGLUTIDE | targetBased | 3 | Completed | 10/01/2017 | https://clinicaltrials.gov/study/NCT03018028 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | LIRAGLUTIDE | targetBased | 3 | Completed | 01/04/2014 | https://clinicaltrials.gov/study/NCT02100475 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | LIRAGLUTIDE | targetBased | 3 | Completed | 01/04/2014 | https://clinicaltrials.gov/study/NCT02100475 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | LIRAGLUTIDE | targetBased | 3 | Completed | 01/04/2014 | https://clinicaltrials.gov/study/NCT02100475 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | LIRAGLUTIDE | targetBased | 4 | Completed | 28/03/2016 | https://clinicaltrials.gov/study/NCT02730377 | 1 | GoF | protect | |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | LIRAGLUTIDE | targetBased | 4 | Completed | 28/03/2016 | https://clinicaltrials.gov/study/NCT02730377 | 1 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | LIRAGLUTIDE | targetBased | 4 | Completed | 28/03/2016 | https://clinicaltrials.gov/study/NCT02730377 | 1 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | LIRAGLUTIDE | targetBased | 4 | Completed | 01/01/2012 | https://clinicaltrials.gov/study/NCT01518101 | 1 | GoF | protect | |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | LIRAGLUTIDE | targetBased | 4 | Completed | 01/01/2012 | https://clinicaltrials.gov/study/NCT01518101 | 1 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | LIRAGLUTIDE | targetBased | 4 | Completed | 01/01/2012 | https://clinicaltrials.gov/study/NCT01518101 | 1 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | LIRAGLUTIDE | targetBased | 3 | Completed | 20/01/2021 | https://clinicaltrials.gov/study/NCT05360147 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | LIRAGLUTIDE | targetBased | 3 | Completed | 20/01/2021 | https://clinicaltrials.gov/study/NCT05360147 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | LIRAGLUTIDE | targetBased | 3 | Completed | 20/01/2021 | https://clinicaltrials.gov/study/NCT05360147 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | LIRAGLUTIDE | targetBased | 3 | Completed | 01/09/2011 | https://clinicaltrials.gov/study/NCT01388361 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | LIRAGLUTIDE | targetBased | 3 | Completed | 01/09/2011 | https://clinicaltrials.gov/study/NCT01388361 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | LIRAGLUTIDE | targetBased | 3 | Completed | 01/09/2011 | https://clinicaltrials.gov/study/NCT01388361 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | LIRAGLUTIDE | targetBased | 3 | Completed | 01/06/2008 | https://clinicaltrials.gov/study/NCT00700817 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | LIRAGLUTIDE | targetBased | 3 | Completed | 01/06/2008 | https://clinicaltrials.gov/study/NCT00700817 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | LIRAGLUTIDE | targetBased | 3 | Completed | 01/06/2008 | https://clinicaltrials.gov/study/NCT00700817 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | LIRAGLUTIDE | targetBased | 4 | Completed | 01/12/2020 | https://clinicaltrials.gov/study/NCT04657939 | 1 | GoF | protect | |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | LIRAGLUTIDE | targetBased | 4 | Completed | 01/12/2020 | https://clinicaltrials.gov/study/NCT04657939 | 1 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | LIRAGLUTIDE | targetBased | 4 | Completed | 01/12/2020 | https://clinicaltrials.gov/study/NCT04657939 | 1 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | LIRAGLUTIDE | targetBased | 4 | Completed | 01/07/2010 | https://clinicaltrials.gov/study/NCT01117350 | 1 | GoF | protect | |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | LIRAGLUTIDE | targetBased | 4 | Completed | 01/07/2010 | https://clinicaltrials.gov/study/NCT01117350 | 1 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | LIRAGLUTIDE | targetBased | 4 | Completed | 01/07/2010 | https://clinicaltrials.gov/study/NCT01117350 | 1 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | LIRAGLUTIDE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5a9ef4ea-c76a-4d34-a604-27c5b505f5a4 | 1 | GoF | protect | |||
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | LIRAGLUTIDE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5a9ef4ea-c76a-4d34-a604-27c5b505f5a4 | 1 | GoF | protect | |||
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | LIRAGLUTIDE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5a9ef4ea-c76a-4d34-a604-27c5b505f5a4 | 1 | GoF | protect | |||
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | LIRAGLUTIDE | targetBased | 3 | Completed | 01/01/2011 | https://clinicaltrials.gov/study/NCT01270789 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | LIRAGLUTIDE | targetBased | 3 | Completed | 01/01/2011 | https://clinicaltrials.gov/study/NCT01270789 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | LIRAGLUTIDE | targetBased | 3 | Completed | 01/01/2011 | https://clinicaltrials.gov/study/NCT01270789 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | LIRAGLUTIDE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7b11f6ac-4c27-4748-9e65-22d4cf3adfb4 | 1 | GoF | protect | |||
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | LIRAGLUTIDE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7b11f6ac-4c27-4748-9e65-22d4cf3adfb4 | 1 | GoF | protect | |||
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | LIRAGLUTIDE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7b11f6ac-4c27-4748-9e65-22d4cf3adfb4 | 1 | GoF | protect | |||
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | abnormal glucose tolerance | LIRAGLUTIDE | targetBased | 3 | Completed | 11/08/2011 | https://clinicaltrials.gov/study/NCT01234649 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | abnormal glucose tolerance | LIRAGLUTIDE | targetBased | 3 | Completed | 11/08/2011 | https://clinicaltrials.gov/study/NCT01234649 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | abnormal glucose tolerance | LIRAGLUTIDE | targetBased | 3 | Completed | 11/08/2011 | https://clinicaltrials.gov/study/NCT01234649 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | pituitary dwarfism | LIRAGLUTIDE | targetBased | 4 | Recruiting | 01/05/2023 | https://clinicaltrials.gov/study/NCT05681299 | 1 | GoF | protect | |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | pituitary dwarfism | LIRAGLUTIDE | targetBased | 4 | Recruiting | 01/05/2023 | https://clinicaltrials.gov/study/NCT05681299 | 1 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | pituitary dwarfism | LIRAGLUTIDE | targetBased | 4 | Recruiting | 01/05/2023 | https://clinicaltrials.gov/study/NCT05681299 | 1 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | diabetes mellitus | LIRAGLUTIDE | targetBased | 3 | Completed | 26/05/2017 | https://clinicaltrials.gov/study/NCT03175120 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | diabetes mellitus | LIRAGLUTIDE | targetBased | 3 | Completed | 26/05/2017 | https://clinicaltrials.gov/study/NCT03175120 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | diabetes mellitus | LIRAGLUTIDE | targetBased | 3 | Completed | 26/05/2017 | https://clinicaltrials.gov/study/NCT03175120 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | diabetes mellitus | LIRAGLUTIDE | targetBased | 3 | Completed | 31/08/2010 | https://clinicaltrials.gov/study/NCT01179048 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | diabetes mellitus | LIRAGLUTIDE | targetBased | 3 | Completed | 31/08/2010 | https://clinicaltrials.gov/study/NCT01179048 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | diabetes mellitus | LIRAGLUTIDE | targetBased | 3 | Completed | 31/08/2010 | https://clinicaltrials.gov/study/NCT01179048 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | diabetes mellitus | LIRAGLUTIDE | targetBased | 3 | Completed | 21/11/2014 | https://clinicaltrials.gov/study/NCT02298192 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | diabetes mellitus | LIRAGLUTIDE | targetBased | 3 | Completed | 21/11/2014 | https://clinicaltrials.gov/study/NCT02298192 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | diabetes mellitus | LIRAGLUTIDE | targetBased | 3 | Completed | 21/11/2014 | https://clinicaltrials.gov/study/NCT02298192 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | diabetes mellitus | LIRAGLUTIDE | targetBased | 3 | Completed | 23/05/2011 | https://clinicaltrials.gov/study/NCT01336023 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | diabetes mellitus | LIRAGLUTIDE | targetBased | 3 | Completed | 23/05/2011 | https://clinicaltrials.gov/study/NCT01336023 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | diabetes mellitus | LIRAGLUTIDE | targetBased | 3 | Completed | 23/05/2011 | https://clinicaltrials.gov/study/NCT01336023 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | diabetes mellitus | LIRAGLUTIDE | targetBased | 3 | Completed | 01/10/2006 | https://clinicaltrials.gov/study/NCT00395746 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | diabetes mellitus | LIRAGLUTIDE | targetBased | 3 | Completed | 01/10/2006 | https://clinicaltrials.gov/study/NCT00395746 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | diabetes mellitus | LIRAGLUTIDE | targetBased | 3 | Completed | 01/10/2006 | https://clinicaltrials.gov/study/NCT00395746 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | diabetes mellitus | LIRAGLUTIDE | targetBased | 3 | Completed | 13/11/2012 | https://clinicaltrials.gov/study/NCT01541215 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | diabetes mellitus | LIRAGLUTIDE | targetBased | 3 | Completed | 13/11/2012 | https://clinicaltrials.gov/study/NCT01541215 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | diabetes mellitus | LIRAGLUTIDE | targetBased | 3 | Completed | 13/11/2012 | https://clinicaltrials.gov/study/NCT01541215 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | diabetes mellitus | LIRAGLUTIDE | targetBased | 3 | Completed | 01/09/2012 | https://clinicaltrials.gov/study/NCT01617434 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | diabetes mellitus | LIRAGLUTIDE | targetBased | 3 | Completed | 01/09/2012 | https://clinicaltrials.gov/study/NCT01617434 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | diabetes mellitus | LIRAGLUTIDE | targetBased | 3 | Completed | 01/09/2012 | https://clinicaltrials.gov/study/NCT01617434 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | diabetes mellitus | LIRAGLUTIDE | targetBased | 3 | Completed | 05/04/2012 | https://clinicaltrials.gov/study/NCT01572740 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | diabetes mellitus | LIRAGLUTIDE | targetBased | 3 | Completed | 05/04/2012 | https://clinicaltrials.gov/study/NCT01572740 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | diabetes mellitus | LIRAGLUTIDE | targetBased | 3 | Completed | 05/04/2012 | https://clinicaltrials.gov/study/NCT01572740 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | diabetes mellitus | LIRAGLUTIDE | targetBased | 3 | Completed | 21/07/2015 | https://clinicaltrials.gov/study/NCT02505334 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | diabetes mellitus | LIRAGLUTIDE | targetBased | 3 | Completed | 21/07/2015 | https://clinicaltrials.gov/study/NCT02505334 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | diabetes mellitus | LIRAGLUTIDE | targetBased | 3 | Completed | 21/07/2015 | https://clinicaltrials.gov/study/NCT02505334 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | diabetes mellitus | LIRAGLUTIDE | targetBased | 3 | Completed | 10/08/2016 | https://clinicaltrials.gov/study/NCT02863419 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | diabetes mellitus | LIRAGLUTIDE | targetBased | 3 | Completed | 10/08/2016 | https://clinicaltrials.gov/study/NCT02863419 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | diabetes mellitus | LIRAGLUTIDE | targetBased | 3 | Completed | 10/08/2016 | https://clinicaltrials.gov/study/NCT02863419 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | diabetes mellitus | LIRAGLUTIDE | targetBased | 3 | Completed | 01/04/2014 | https://clinicaltrials.gov/study/NCT02100475 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | diabetes mellitus | LIRAGLUTIDE | targetBased | 3 | Completed | 01/04/2014 | https://clinicaltrials.gov/study/NCT02100475 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | diabetes mellitus | LIRAGLUTIDE | targetBased | 3 | Completed | 01/04/2014 | https://clinicaltrials.gov/study/NCT02100475 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | diabetes mellitus | LIRAGLUTIDE | targetBased | 4 | Completed | 01/11/2014 | https://clinicaltrials.gov/study/NCT01966978 | 1 | GoF | protect | |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | diabetes mellitus | LIRAGLUTIDE | targetBased | 4 | Completed | 01/11/2014 | https://clinicaltrials.gov/study/NCT01966978 | 1 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | diabetes mellitus | LIRAGLUTIDE | targetBased | 4 | Completed | 01/11/2014 | https://clinicaltrials.gov/study/NCT01966978 | 1 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | diabetes mellitus | LIRAGLUTIDE | targetBased | 3 | Completed | 01/01/2008 | https://clinicaltrials.gov/study/NCT00614120 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | diabetes mellitus | LIRAGLUTIDE | targetBased | 3 | Completed | 01/01/2008 | https://clinicaltrials.gov/study/NCT00614120 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | diabetes mellitus | LIRAGLUTIDE | targetBased | 3 | Completed | 01/01/2008 | https://clinicaltrials.gov/study/NCT00614120 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | diabetes mellitus | LIRAGLUTIDE | targetBased | 3 | Completed | 03/03/2017 | https://clinicaltrials.gov/study/NCT02964247 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | diabetes mellitus | LIRAGLUTIDE | targetBased | 3 | Completed | 03/03/2017 | https://clinicaltrials.gov/study/NCT02964247 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | diabetes mellitus | LIRAGLUTIDE | targetBased | 3 | Completed | 03/03/2017 | https://clinicaltrials.gov/study/NCT02964247 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | diabetes mellitus | LIRAGLUTIDE | targetBased | 3 | Completed | 01/06/2008 | https://clinicaltrials.gov/study/NCT00700817 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | diabetes mellitus | LIRAGLUTIDE | targetBased | 3 | Completed | 01/06/2008 | https://clinicaltrials.gov/study/NCT00700817 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | diabetes mellitus | LIRAGLUTIDE | targetBased | 3 | Completed | 01/06/2008 | https://clinicaltrials.gov/study/NCT00700817 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | diabetes mellitus | LIRAGLUTIDE | targetBased | 3 | Completed | 01/09/2011 | https://clinicaltrials.gov/study/NCT01388361 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | diabetes mellitus | LIRAGLUTIDE | targetBased | 3 | Completed | 01/09/2011 | https://clinicaltrials.gov/study/NCT01388361 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | diabetes mellitus | LIRAGLUTIDE | targetBased | 3 | Completed | 01/09/2011 | https://clinicaltrials.gov/study/NCT01388361 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | diabetes mellitus | LIRAGLUTIDE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=35e613e3-7aae-4152-b827-99d1ee7841be | 1 | GoF | protect | |||
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | diabetes mellitus | LIRAGLUTIDE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=35e613e3-7aae-4152-b827-99d1ee7841be | 1 | GoF | protect | |||
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | diabetes mellitus | LIRAGLUTIDE | targetBased | 4 | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=35e613e3-7aae-4152-b827-99d1ee7841be | 1 | GoF | protect | |||
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | diabetes mellitus | LIRAGLUTIDE | targetBased | 3 | Completed | 01/10/2012 | https://clinicaltrials.gov/study/NCT01664247 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | diabetes mellitus | LIRAGLUTIDE | targetBased | 3 | Completed | 01/10/2012 | https://clinicaltrials.gov/study/NCT01664247 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | diabetes mellitus | LIRAGLUTIDE | targetBased | 3 | Completed | 01/10/2012 | https://clinicaltrials.gov/study/NCT01664247 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | diabetes mellitus | LIRAGLUTIDE | targetBased | 3 | Completed | 01/05/2014 | https://clinicaltrials.gov/study/NCT02098395 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | diabetes mellitus | LIRAGLUTIDE | targetBased | 3 | Completed | 01/05/2014 | https://clinicaltrials.gov/study/NCT02098395 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | diabetes mellitus | LIRAGLUTIDE | targetBased | 3 | Completed | 01/05/2014 | https://clinicaltrials.gov/study/NCT02098395 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | diabetes mellitus | LIRAGLUTIDE | targetBased | 3 | Completed | 31/01/2016 | https://clinicaltrials.gov/study/NCT02501161 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | diabetes mellitus | LIRAGLUTIDE | targetBased | 3 | Completed | 31/01/2016 | https://clinicaltrials.gov/study/NCT02501161 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | diabetes mellitus | LIRAGLUTIDE | targetBased | 3 | Completed | 31/01/2016 | https://clinicaltrials.gov/study/NCT02501161 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | diabetes mellitus | LIRAGLUTIDE | targetBased | 4 | Recruiting | 28/02/2019 | https://clinicaltrials.gov/study/NCT03883412 | 1 | GoF | protect | |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | diabetes mellitus | LIRAGLUTIDE | targetBased | 4 | Recruiting | 28/02/2019 | https://clinicaltrials.gov/study/NCT03883412 | 1 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | diabetes mellitus | LIRAGLUTIDE | targetBased | 4 | Recruiting | 28/02/2019 | https://clinicaltrials.gov/study/NCT03883412 | 1 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | diabetes mellitus | LIRAGLUTIDE | targetBased | 4 | https://www.whocc.no/atc_ddd_index/?code=A10BJ02 | 1 | GoF | protect | |||
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | diabetes mellitus | LIRAGLUTIDE | targetBased | 4 | https://www.whocc.no/atc_ddd_index/?code=A10BJ02 | 1 | GoF | protect | |||
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | diabetes mellitus | LIRAGLUTIDE | targetBased | 4 | https://www.whocc.no/atc_ddd_index/?code=A10BJ02 | 1 | GoF | protect | |||
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | diabetes mellitus | LIRAGLUTIDE | targetBased | 3 | Completed | 28/11/2011 | https://clinicaltrials.gov/study/NCT01392573 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | diabetes mellitus | LIRAGLUTIDE | targetBased | 3 | Completed | 28/11/2011 | https://clinicaltrials.gov/study/NCT01392573 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | diabetes mellitus | LIRAGLUTIDE | targetBased | 3 | Completed | 28/11/2011 | https://clinicaltrials.gov/study/NCT01392573 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | diabetes mellitus | LIRAGLUTIDE | targetBased | 3 | Completed | 01/08/2007 | https://clinicaltrials.gov/study/NCT00518882 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | diabetes mellitus | LIRAGLUTIDE | targetBased | 3 | Completed | 01/08/2007 | https://clinicaltrials.gov/study/NCT00518882 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | diabetes mellitus | LIRAGLUTIDE | targetBased | 3 | Completed | 01/08/2007 | https://clinicaltrials.gov/study/NCT00518882 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | diabetes mellitus | LIRAGLUTIDE | targetBased | 3 | Completed | 10/01/2012 | https://clinicaltrials.gov/study/NCT01512108 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | diabetes mellitus | LIRAGLUTIDE | targetBased | 3 | Completed | 10/01/2012 | https://clinicaltrials.gov/study/NCT01512108 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | diabetes mellitus | LIRAGLUTIDE | targetBased | 3 | Completed | 10/01/2012 | https://clinicaltrials.gov/study/NCT01512108 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | diabetes mellitus | LIRAGLUTIDE | targetBased | 3 | Completed | 01/02/2008 | https://clinicaltrials.gov/study/NCT00620282 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | diabetes mellitus | LIRAGLUTIDE | targetBased | 3 | Completed | 01/02/2008 | https://clinicaltrials.gov/study/NCT00620282 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | diabetes mellitus | LIRAGLUTIDE | targetBased | 3 | Completed | 01/02/2008 | https://clinicaltrials.gov/study/NCT00620282 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | diabetes mellitus | LIRAGLUTIDE | targetBased | 3 | Completed | 29/08/2012 | https://clinicaltrials.gov/study/NCT01676116 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | diabetes mellitus | LIRAGLUTIDE | targetBased | 3 | Completed | 29/08/2012 | https://clinicaltrials.gov/study/NCT01676116 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | diabetes mellitus | LIRAGLUTIDE | targetBased | 3 | Completed | 29/08/2012 | https://clinicaltrials.gov/study/NCT01676116 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | diabetes mellitus | LIRAGLUTIDE | targetBased | 3 | Completed | 20/09/2013 | https://clinicaltrials.gov/study/NCT01952145 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | diabetes mellitus | LIRAGLUTIDE | targetBased | 3 | Completed | 20/09/2013 | https://clinicaltrials.gov/study/NCT01952145 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | diabetes mellitus | LIRAGLUTIDE | targetBased | 3 | Completed | 20/09/2013 | https://clinicaltrials.gov/study/NCT01952145 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | diabetes mellitus | LIRAGLUTIDE | targetBased | 3 | Completed | 01/05/2006 | https://clinicaltrials.gov/study/NCT00331851 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | diabetes mellitus | LIRAGLUTIDE | targetBased | 3 | Completed | 01/05/2006 | https://clinicaltrials.gov/study/NCT00331851 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | diabetes mellitus | LIRAGLUTIDE | targetBased | 3 | Completed | 01/05/2006 | https://clinicaltrials.gov/study/NCT00331851 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | diabetes mellitus | LIRAGLUTIDE | targetBased | 3 | Completed | 01/03/2013 | https://clinicaltrials.gov/study/NCT02092896 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | diabetes mellitus | LIRAGLUTIDE | targetBased | 3 | Completed | 01/03/2013 | https://clinicaltrials.gov/study/NCT02092896 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | diabetes mellitus | LIRAGLUTIDE | targetBased | 3 | Completed | 01/03/2013 | https://clinicaltrials.gov/study/NCT02092896 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | non-alcoholic fatty liver disease | LIRAGLUTIDE | targetBased | 4 | Completed | 01/08/2014 | https://clinicaltrials.gov/study/NCT02147925 | 1 | GoF | protect | |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | non-alcoholic fatty liver disease | LIRAGLUTIDE | targetBased | 4 | Completed | 01/08/2014 | https://clinicaltrials.gov/study/NCT02147925 | 1 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | non-alcoholic fatty liver disease | LIRAGLUTIDE | targetBased | 4 | Completed | 01/08/2014 | https://clinicaltrials.gov/study/NCT02147925 | 1 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | morbid obesity | LIRAGLUTIDE | targetBased | 4 | Completed | 01/04/2014 | https://clinicaltrials.gov/study/NCT02616003 | 1 | GoF | protect | |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | morbid obesity | LIRAGLUTIDE | targetBased | 4 | Completed | 01/04/2014 | https://clinicaltrials.gov/study/NCT02616003 | 1 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | morbid obesity | LIRAGLUTIDE | targetBased | 4 | Completed | 01/04/2014 | https://clinicaltrials.gov/study/NCT02616003 | 1 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | nutritional disorder | LIRAGLUTIDE | targetBased | 3 | Completed | 06/02/2017 | https://clinicaltrials.gov/study/NCT02963935 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | nutritional disorder | LIRAGLUTIDE | targetBased | 3 | Completed | 06/02/2017 | https://clinicaltrials.gov/study/NCT02963935 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | nutritional disorder | LIRAGLUTIDE | targetBased | 3 | Completed | 06/02/2017 | https://clinicaltrials.gov/study/NCT02963935 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | nutritional disorder | LIRAGLUTIDE | targetBased | 3 | Completed | 06/02/2017 | https://clinicaltrials.gov/study/NCT02963922 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | nutritional disorder | LIRAGLUTIDE | targetBased | 3 | Completed | 06/02/2017 | https://clinicaltrials.gov/study/NCT02963922 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | nutritional disorder | LIRAGLUTIDE | targetBased | 3 | Completed | 06/02/2017 | https://clinicaltrials.gov/study/NCT02963922 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | nutritional disorder | LIRAGLUTIDE | targetBased | 3 | Completed | 09/11/2015 | https://clinicaltrials.gov/study/NCT02527200 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | nutritional disorder | LIRAGLUTIDE | targetBased | 3 | Completed | 09/11/2015 | https://clinicaltrials.gov/study/NCT02527200 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | nutritional disorder | LIRAGLUTIDE | targetBased | 3 | Completed | 09/11/2015 | https://clinicaltrials.gov/study/NCT02527200 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | diabetic nephropathy | LIRAGLUTIDE | targetBased | 3 | Completed | 01/04/2013 | https://clinicaltrials.gov/study/NCT01847313 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | diabetic nephropathy | LIRAGLUTIDE | targetBased | 3 | Completed | 01/04/2013 | https://clinicaltrials.gov/study/NCT01847313 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | diabetic nephropathy | LIRAGLUTIDE | targetBased | 3 | Completed | 01/04/2013 | https://clinicaltrials.gov/study/NCT01847313 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | diabetic nephropathy | LIRAGLUTIDE | targetBased | 4 | Completed | 01/04/2015 | https://clinicaltrials.gov/study/NCT02545738 | 1 | GoF | protect | |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | diabetic nephropathy | LIRAGLUTIDE | targetBased | 4 | Completed | 01/04/2015 | https://clinicaltrials.gov/study/NCT02545738 | 1 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | diabetic nephropathy | LIRAGLUTIDE | targetBased | 4 | Completed | 01/04/2015 | https://clinicaltrials.gov/study/NCT02545738 | 1 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | Hyperglycemia | LIRAGLUTIDE | targetBased | 3 | Unknown status | 01/01/2014 | https://clinicaltrials.gov/study/NCT02016846 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | Hyperglycemia | LIRAGLUTIDE | targetBased | 3 | Unknown status | 01/01/2014 | https://clinicaltrials.gov/study/NCT02016846 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | Hyperglycemia | LIRAGLUTIDE | targetBased | 3 | Unknown status | 01/01/2014 | https://clinicaltrials.gov/study/NCT02016846 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | insulin resistance | LIRAGLUTIDE | targetBased | 4 | Unknown status | 01/03/2013 | https://clinicaltrials.gov/study/NCT02403284 | 1 | GoF | protect | |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | insulin resistance | LIRAGLUTIDE | targetBased | 4 | Unknown status | 01/03/2013 | https://clinicaltrials.gov/study/NCT02403284 | 1 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | insulin resistance | LIRAGLUTIDE | targetBased | 4 | Unknown status | 01/03/2013 | https://clinicaltrials.gov/study/NCT02403284 | 1 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 1 diabetes mellitus | LIRAGLUTIDE | targetBased | 3 | Completed | 01/12/2012 | https://clinicaltrials.gov/study/NCT01753362 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 1 diabetes mellitus | LIRAGLUTIDE | targetBased | 3 | Completed | 01/12/2012 | https://clinicaltrials.gov/study/NCT01753362 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 1 diabetes mellitus | LIRAGLUTIDE | targetBased | 3 | Completed | 01/12/2012 | https://clinicaltrials.gov/study/NCT01753362 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 1 diabetes mellitus | LIRAGLUTIDE | targetBased | 3 | Completed | 01/08/2015 | https://clinicaltrials.gov/study/NCT02518945 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 1 diabetes mellitus | LIRAGLUTIDE | targetBased | 3 | Completed | 01/08/2015 | https://clinicaltrials.gov/study/NCT02518945 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 1 diabetes mellitus | LIRAGLUTIDE | targetBased | 3 | Completed | 01/08/2015 | https://clinicaltrials.gov/study/NCT02518945 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 1 diabetes mellitus | LIRAGLUTIDE | targetBased | 3 | Completed | 01/11/2012 | https://clinicaltrials.gov/study/NCT01722240 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 1 diabetes mellitus | LIRAGLUTIDE | targetBased | 3 | Completed | 01/11/2012 | https://clinicaltrials.gov/study/NCT01722240 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 1 diabetes mellitus | LIRAGLUTIDE | targetBased | 3 | Completed | 01/11/2012 | https://clinicaltrials.gov/study/NCT01722240 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 1 diabetes mellitus | LIRAGLUTIDE | targetBased | 3 | Completed | 01/07/2022 | https://clinicaltrials.gov/study/NCT05467514 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 1 diabetes mellitus | LIRAGLUTIDE | targetBased | 3 | Completed | 01/07/2022 | https://clinicaltrials.gov/study/NCT05467514 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 1 diabetes mellitus | LIRAGLUTIDE | targetBased | 3 | Completed | 01/07/2022 | https://clinicaltrials.gov/study/NCT05467514 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 1 diabetes mellitus | LIRAGLUTIDE | targetBased | 3 | Completed | 01/03/2016 | https://clinicaltrials.gov/study/NCT02777073 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 1 diabetes mellitus | LIRAGLUTIDE | targetBased | 3 | Completed | 01/03/2016 | https://clinicaltrials.gov/study/NCT02777073 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 1 diabetes mellitus | LIRAGLUTIDE | targetBased | 3 | Completed | 01/03/2016 | https://clinicaltrials.gov/study/NCT02777073 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 1 diabetes mellitus | LIRAGLUTIDE | targetBased | 4 | Unknown status | 01/01/2017 | https://clinicaltrials.gov/study/NCT03011008 | 1 | GoF | protect | |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 1 diabetes mellitus | LIRAGLUTIDE | targetBased | 4 | Unknown status | 01/01/2017 | https://clinicaltrials.gov/study/NCT03011008 | 1 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 1 diabetes mellitus | LIRAGLUTIDE | targetBased | 4 | Unknown status | 01/01/2017 | https://clinicaltrials.gov/study/NCT03011008 | 1 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 1 diabetes mellitus | LIRAGLUTIDE | targetBased | 3 | Active, not recruiting | 01/05/2012 | https://clinicaltrials.gov/study/NCT02516657 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 1 diabetes mellitus | LIRAGLUTIDE | targetBased | 3 | Active, not recruiting | 01/05/2012 | https://clinicaltrials.gov/study/NCT02516657 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 1 diabetes mellitus | LIRAGLUTIDE | targetBased | 3 | Active, not recruiting | 01/05/2012 | https://clinicaltrials.gov/study/NCT02516657 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 1 diabetes mellitus | LIRAGLUTIDE | targetBased | 3 | Completed | 01/03/2013 | https://clinicaltrials.gov/study/NCT02092896 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 1 diabetes mellitus | LIRAGLUTIDE | targetBased | 3 | Completed | 01/03/2013 | https://clinicaltrials.gov/study/NCT02092896 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 1 diabetes mellitus | LIRAGLUTIDE | targetBased | 3 | Completed | 01/03/2013 | https://clinicaltrials.gov/study/NCT02092896 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 1 diabetes mellitus | LIRAGLUTIDE | targetBased | 3 | Completed | 01/11/2013 | https://clinicaltrials.gov/study/NCT01836523 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 1 diabetes mellitus | LIRAGLUTIDE | targetBased | 3 | Completed | 01/11/2013 | https://clinicaltrials.gov/study/NCT01836523 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 1 diabetes mellitus | LIRAGLUTIDE | targetBased | 3 | Completed | 01/11/2013 | https://clinicaltrials.gov/study/NCT01836523 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 1 diabetes mellitus | LIRAGLUTIDE | targetBased | 3 | Withdrawn | 01/11/2012 | https://clinicaltrials.gov/study/NCT01722227 | 0.7 | GoF | protect | No Funding Received from ADA |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 1 diabetes mellitus | LIRAGLUTIDE | targetBased | 3 | Withdrawn | 01/11/2012 | https://clinicaltrials.gov/study/NCT01722227 | 0.7 | GoF | protect | No Funding Received from ADA |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 1 diabetes mellitus | LIRAGLUTIDE | targetBased | 3 | Withdrawn | 01/11/2012 | https://clinicaltrials.gov/study/NCT01722227 | 0.7 | GoF | protect | No Funding Received from ADA |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 1 diabetes mellitus | LIRAGLUTIDE | targetBased | 3 | Completed | 01/11/2012 | https://clinicaltrials.gov/study/NCT01722266 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 1 diabetes mellitus | LIRAGLUTIDE | targetBased | 3 | Completed | 01/11/2012 | https://clinicaltrials.gov/study/NCT01722266 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 1 diabetes mellitus | LIRAGLUTIDE | targetBased | 3 | Completed | 01/11/2012 | https://clinicaltrials.gov/study/NCT01722266 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 1 diabetes mellitus | LIRAGLUTIDE | targetBased | 3 | Completed | 01/05/2014 | https://clinicaltrials.gov/study/NCT02098395 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 1 diabetes mellitus | LIRAGLUTIDE | targetBased | 3 | Completed | 01/05/2014 | https://clinicaltrials.gov/study/NCT02098395 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 1 diabetes mellitus | LIRAGLUTIDE | targetBased | 3 | Completed | 01/05/2014 | https://clinicaltrials.gov/study/NCT02098395 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 1 diabetes mellitus | LIRAGLUTIDE | targetBased | 4 | Completed | 01/04/2013 | https://clinicaltrials.gov/study/NCT01787916 | 1 | GoF | protect | |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 1 diabetes mellitus | LIRAGLUTIDE | targetBased | 4 | Completed | 01/04/2013 | https://clinicaltrials.gov/study/NCT01787916 | 1 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 1 diabetes mellitus | LIRAGLUTIDE | targetBased | 4 | Completed | 01/04/2013 | https://clinicaltrials.gov/study/NCT01787916 | 1 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | gestational diabetes | LIRAGLUTIDE | targetBased | 4 | Completed | 01/07/2012 | https://clinicaltrials.gov/study/NCT01795248 | 1 | GoF | protect | |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | gestational diabetes | LIRAGLUTIDE | targetBased | 4 | Completed | 01/07/2012 | https://clinicaltrials.gov/study/NCT01795248 | 1 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | gestational diabetes | LIRAGLUTIDE | targetBased | 4 | Completed | 01/07/2012 | https://clinicaltrials.gov/study/NCT01795248 | 1 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | prediabetes syndrome | LIRAGLUTIDE | targetBased | 3 | Completed | 01/12/2009 | https://clinicaltrials.gov/study/NCT01784965 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | prediabetes syndrome | LIRAGLUTIDE | targetBased | 3 | Completed | 01/12/2009 | https://clinicaltrials.gov/study/NCT01784965 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | prediabetes syndrome | LIRAGLUTIDE | targetBased | 3 | Completed | 01/12/2009 | https://clinicaltrials.gov/study/NCT01784965 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | prediabetes syndrome | LIRAGLUTIDE | targetBased | 3 | Completed | 01/04/2013 | https://clinicaltrials.gov/study/NCT01779362 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | prediabetes syndrome | LIRAGLUTIDE | targetBased | 3 | Completed | 01/04/2013 | https://clinicaltrials.gov/study/NCT01779362 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | prediabetes syndrome | LIRAGLUTIDE | targetBased | 3 | Completed | 01/04/2013 | https://clinicaltrials.gov/study/NCT01779362 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | prediabetes syndrome | LIRAGLUTIDE | targetBased | 4 | Completed | 01/05/2016 | https://clinicaltrials.gov/study/NCT02488057 | 1 | GoF | protect | |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | prediabetes syndrome | LIRAGLUTIDE | targetBased | 4 | Completed | 01/05/2016 | https://clinicaltrials.gov/study/NCT02488057 | 1 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | prediabetes syndrome | LIRAGLUTIDE | targetBased | 4 | Completed | 01/05/2016 | https://clinicaltrials.gov/study/NCT02488057 | 1 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | obesity | LIRAGLUTIDE | targetBased | 4 | Recruiting | 08/09/2020 | https://clinicaltrials.gov/study/NCT04575194 | 1 | GoF | protect | |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | obesity | LIRAGLUTIDE | targetBased | 4 | Recruiting | 08/09/2020 | https://clinicaltrials.gov/study/NCT04575194 | 1 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | obesity | LIRAGLUTIDE | targetBased | 4 | Recruiting | 08/09/2020 | https://clinicaltrials.gov/study/NCT04575194 | 1 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | obesity | LIRAGLUTIDE | targetBased | 4 | Withdrawn | 01/09/2020 | https://clinicaltrials.gov/study/NCT02920190 | 1 | GoF | protect | Lack of funds to cover the costs of the study medications |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | obesity | LIRAGLUTIDE | targetBased | 4 | Withdrawn | 01/09/2020 | https://clinicaltrials.gov/study/NCT02920190 | 1 | GoF | protect | Lack of funds to cover the costs of the study medications |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | obesity | LIRAGLUTIDE | targetBased | 4 | Withdrawn | 01/09/2020 | https://clinicaltrials.gov/study/NCT02920190 | 1 | GoF | protect | Lack of funds to cover the costs of the study medications |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | obesity | LIRAGLUTIDE | targetBased | 3 | Recruiting | 24/05/2020 | https://clinicaltrials.gov/study/NCT04525300 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | obesity | LIRAGLUTIDE | targetBased | 3 | Recruiting | 24/05/2020 | https://clinicaltrials.gov/study/NCT04525300 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | obesity | LIRAGLUTIDE | targetBased | 3 | Recruiting | 24/05/2020 | https://clinicaltrials.gov/study/NCT04525300 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | obesity | LIRAGLUTIDE | targetBased | 3 | Recruiting | 01/12/2019 | https://clinicaltrials.gov/study/NCT03986008 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | obesity | LIRAGLUTIDE | targetBased | 3 | Recruiting | 01/12/2019 | https://clinicaltrials.gov/study/NCT03986008 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | obesity | LIRAGLUTIDE | targetBased | 3 | Recruiting | 01/12/2019 | https://clinicaltrials.gov/study/NCT03986008 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | obesity | LIRAGLUTIDE | targetBased | 3 | Active, not recruiting | 04/03/2021 | https://clinicaltrials.gov/study/NCT04775082 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | obesity | LIRAGLUTIDE | targetBased | 3 | Active, not recruiting | 04/03/2021 | https://clinicaltrials.gov/study/NCT04775082 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | obesity | LIRAGLUTIDE | targetBased | 3 | Active, not recruiting | 04/03/2021 | https://clinicaltrials.gov/study/NCT04775082 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | obesity | LIRAGLUTIDE | targetBased | 4 | Completed | 01/09/2016 | https://clinicaltrials.gov/study/NCT02911818 | 1 | GoF | protect | |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | obesity | LIRAGLUTIDE | targetBased | 4 | Completed | 01/09/2016 | https://clinicaltrials.gov/study/NCT02911818 | 1 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | obesity | LIRAGLUTIDE | targetBased | 4 | Completed | 01/09/2016 | https://clinicaltrials.gov/study/NCT02911818 | 1 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | obesity | LIRAGLUTIDE | targetBased | 3 | Completed | 09/11/2015 | https://clinicaltrials.gov/study/NCT02527200 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | obesity | LIRAGLUTIDE | targetBased | 3 | Completed | 09/11/2015 | https://clinicaltrials.gov/study/NCT02527200 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | obesity | LIRAGLUTIDE | targetBased | 3 | Completed | 09/11/2015 | https://clinicaltrials.gov/study/NCT02527200 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | obesity | LIRAGLUTIDE | targetBased | 3 | Completed | 18/08/2020 | https://clinicaltrials.gov/study/NCT04605861 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | obesity | LIRAGLUTIDE | targetBased | 3 | Completed | 18/08/2020 | https://clinicaltrials.gov/study/NCT04605861 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | obesity | LIRAGLUTIDE | targetBased | 3 | Completed | 18/08/2020 | https://clinicaltrials.gov/study/NCT04605861 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | obesity | LIRAGLUTIDE | targetBased | 4 | Active, not recruiting | 01/11/2016 | https://clinicaltrials.gov/study/NCT02944500 | 1 | GoF | protect | |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | obesity | LIRAGLUTIDE | targetBased | 4 | Active, not recruiting | 01/11/2016 | https://clinicaltrials.gov/study/NCT02944500 | 1 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | obesity | LIRAGLUTIDE | targetBased | 4 | Active, not recruiting | 01/11/2016 | https://clinicaltrials.gov/study/NCT02944500 | 1 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | obesity | LIRAGLUTIDE | targetBased | 3 | Completed | 11/09/2019 | https://clinicaltrials.gov/study/NCT04074161 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | obesity | LIRAGLUTIDE | targetBased | 3 | Completed | 11/09/2019 | https://clinicaltrials.gov/study/NCT04074161 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | obesity | LIRAGLUTIDE | targetBased | 3 | Completed | 11/09/2019 | https://clinicaltrials.gov/study/NCT04074161 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | obesity | LIRAGLUTIDE | targetBased | 4 | Active, not recruiting | 19/01/2023 | https://clinicaltrials.gov/study/NCT05579249 | 1 | GoF | protect | |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | obesity | LIRAGLUTIDE | targetBased | 4 | Active, not recruiting | 19/01/2023 | https://clinicaltrials.gov/study/NCT05579249 | 1 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | obesity | LIRAGLUTIDE | targetBased | 4 | Active, not recruiting | 19/01/2023 | https://clinicaltrials.gov/study/NCT05579249 | 1 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | obesity | LIRAGLUTIDE | targetBased | 4 | https://www.ema.europa.eu/en/medicines/human/EPAR/saxenda | 1 | GoF | protect | |||
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | obesity | LIRAGLUTIDE | targetBased | 4 | https://www.ema.europa.eu/en/medicines/human/EPAR/saxenda | 1 | GoF | protect | |||
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | obesity | LIRAGLUTIDE | targetBased | 4 | https://www.ema.europa.eu/en/medicines/human/EPAR/saxenda | 1 | GoF | protect | |||
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | obesity | LIRAGLUTIDE | targetBased | 4 | Active, not recruiting | 01/09/2016 | https://clinicaltrials.gov/study/NCT04122716 | 1 | GoF | protect | |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | obesity | LIRAGLUTIDE | targetBased | 4 | Active, not recruiting | 01/09/2016 | https://clinicaltrials.gov/study/NCT04122716 | 1 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | obesity | LIRAGLUTIDE | targetBased | 4 | Active, not recruiting | 01/09/2016 | https://clinicaltrials.gov/study/NCT04122716 | 1 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | obesity | LIRAGLUTIDE | targetBased | 4 | Completed | 22/05/2017 | https://clinicaltrials.gov/study/NCT03048578 | 1 | GoF | protect | |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | obesity | LIRAGLUTIDE | targetBased | 4 | Completed | 22/05/2017 | https://clinicaltrials.gov/study/NCT03048578 | 1 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | obesity | LIRAGLUTIDE | targetBased | 4 | Completed | 22/05/2017 | https://clinicaltrials.gov/study/NCT03048578 | 1 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | obesity | LIRAGLUTIDE | targetBased | 3 | Completed | 30/10/2008 | https://clinicaltrials.gov/study/NCT00781937 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | obesity | LIRAGLUTIDE | targetBased | 3 | Completed | 30/10/2008 | https://clinicaltrials.gov/study/NCT00781937 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | obesity | LIRAGLUTIDE | targetBased | 3 | Completed | 30/10/2008 | https://clinicaltrials.gov/study/NCT00781937 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | obesity | LIRAGLUTIDE | targetBased | 3 | Completed | 11/12/2017 | https://clinicaltrials.gov/study/NCT03374956 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | obesity | LIRAGLUTIDE | targetBased | 3 | Completed | 11/12/2017 | https://clinicaltrials.gov/study/NCT03374956 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | obesity | LIRAGLUTIDE | targetBased | 3 | Completed | 11/12/2017 | https://clinicaltrials.gov/study/NCT03374956 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | obesity | LIRAGLUTIDE | targetBased | 3 | Recruiting | 01/09/2018 | https://clinicaltrials.gov/study/NCT03671733 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | obesity | LIRAGLUTIDE | targetBased | 3 | Recruiting | 01/09/2018 | https://clinicaltrials.gov/study/NCT03671733 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | obesity | LIRAGLUTIDE | targetBased | 3 | Recruiting | 01/09/2018 | https://clinicaltrials.gov/study/NCT03671733 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | obesity | LIRAGLUTIDE | targetBased | 4 | Not yet recruiting | 01/04/2020 | https://clinicaltrials.gov/study/NCT04008290 | 1 | GoF | protect | |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | obesity | LIRAGLUTIDE | targetBased | 4 | Not yet recruiting | 01/04/2020 | https://clinicaltrials.gov/study/NCT04008290 | 1 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | obesity | LIRAGLUTIDE | targetBased | 4 | Not yet recruiting | 01/04/2020 | https://clinicaltrials.gov/study/NCT04008290 | 1 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | obesity | LIRAGLUTIDE | targetBased | 3 | Completed | 22/06/2017 | https://clinicaltrials.gov/study/NCT03115424 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | obesity | LIRAGLUTIDE | targetBased | 3 | Completed | 22/06/2017 | https://clinicaltrials.gov/study/NCT03115424 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | obesity | LIRAGLUTIDE | targetBased | 3 | Completed | 22/06/2017 | https://clinicaltrials.gov/study/NCT03115424 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | obesity | LIRAGLUTIDE | targetBased | 3 | Completed | 01/06/2011 | https://clinicaltrials.gov/study/NCT01272232 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | obesity | LIRAGLUTIDE | targetBased | 3 | Completed | 01/06/2011 | https://clinicaltrials.gov/study/NCT01272232 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | obesity | LIRAGLUTIDE | targetBased | 3 | Completed | 01/06/2011 | https://clinicaltrials.gov/study/NCT01272232 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | obesity | LIRAGLUTIDE | targetBased | 3 | Completed | 06/02/2017 | https://clinicaltrials.gov/study/NCT02963922 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | obesity | LIRAGLUTIDE | targetBased | 3 | Completed | 06/02/2017 | https://clinicaltrials.gov/study/NCT02963922 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | obesity | LIRAGLUTIDE | targetBased | 3 | Completed | 06/02/2017 | https://clinicaltrials.gov/study/NCT02963922 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | obesity | LIRAGLUTIDE | targetBased | 4 | Completed | 22/08/2018 | https://clinicaltrials.gov/study/NCT03341429 | 1 | GoF | protect | |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | obesity | LIRAGLUTIDE | targetBased | 4 | Completed | 22/08/2018 | https://clinicaltrials.gov/study/NCT03341429 | 1 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | obesity | LIRAGLUTIDE | targetBased | 4 | Completed | 22/08/2018 | https://clinicaltrials.gov/study/NCT03341429 | 1 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | obesity | LIRAGLUTIDE | targetBased | 3 | Completed | 01/06/2011 | https://clinicaltrials.gov/study/NCT01272219 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | obesity | LIRAGLUTIDE | targetBased | 3 | Completed | 01/06/2011 | https://clinicaltrials.gov/study/NCT01272219 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | obesity | LIRAGLUTIDE | targetBased | 3 | Completed | 01/06/2011 | https://clinicaltrials.gov/study/NCT01272219 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | obesity | LIRAGLUTIDE | targetBased | 3 | Completed | 06/02/2017 | https://clinicaltrials.gov/study/NCT02963935 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | obesity | LIRAGLUTIDE | targetBased | 3 | Completed | 06/02/2017 | https://clinicaltrials.gov/study/NCT02963935 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | obesity | LIRAGLUTIDE | targetBased | 3 | Completed | 06/02/2017 | https://clinicaltrials.gov/study/NCT02963935 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | obesity | LIRAGLUTIDE | targetBased | 3 | Completed | 29/09/2016 | https://clinicaltrials.gov/study/NCT02918279 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | obesity | LIRAGLUTIDE | targetBased | 3 | Completed | 29/09/2016 | https://clinicaltrials.gov/study/NCT02918279 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | obesity | LIRAGLUTIDE | targetBased | 3 | Completed | 29/09/2016 | https://clinicaltrials.gov/study/NCT02918279 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | obesity | LIRAGLUTIDE | targetBased | 3 | Recruiting | 09/05/2020 | https://clinicaltrials.gov/study/NCT04487743 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | obesity | LIRAGLUTIDE | targetBased | 3 | Recruiting | 09/05/2020 | https://clinicaltrials.gov/study/NCT04487743 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | obesity | LIRAGLUTIDE | targetBased | 3 | Recruiting | 09/05/2020 | https://clinicaltrials.gov/study/NCT04487743 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | obesity | LIRAGLUTIDE | targetBased | 3 | Terminated | 01/12/2011 | https://clinicaltrials.gov/study/NCT02417103 | 0.7 | GoF | protect | Recruiting failure |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | obesity | LIRAGLUTIDE | targetBased | 3 | Terminated | 01/12/2011 | https://clinicaltrials.gov/study/NCT02417103 | 0.7 | GoF | protect | Recruiting failure |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | obesity | LIRAGLUTIDE | targetBased | 3 | Terminated | 01/12/2011 | https://clinicaltrials.gov/study/NCT02417103 | 0.7 | GoF | protect | Recruiting failure |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | obesity | LIRAGLUTIDE | targetBased | 4 | Completed | 05/03/2018 | https://clinicaltrials.gov/study/NCT03347890 | 1 | GoF | protect | |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | obesity | LIRAGLUTIDE | targetBased | 4 | Completed | 05/03/2018 | https://clinicaltrials.gov/study/NCT03347890 | 1 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | obesity | LIRAGLUTIDE | targetBased | 4 | Completed | 05/03/2018 | https://clinicaltrials.gov/study/NCT03347890 | 1 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | metabolic syndrome | LIRAGLUTIDE | targetBased | 3 | Completed | 11/08/2011 | https://clinicaltrials.gov/study/NCT01234649 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | metabolic syndrome | LIRAGLUTIDE | targetBased | 3 | Completed | 11/08/2011 | https://clinicaltrials.gov/study/NCT01234649 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | metabolic syndrome | LIRAGLUTIDE | targetBased | 3 | Completed | 11/08/2011 | https://clinicaltrials.gov/study/NCT01234649 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | metabolic syndrome | LIRAGLUTIDE | targetBased | 4 | Recruiting | 01/11/2020 | https://clinicaltrials.gov/study/NCT04575844 | 1 | GoF | protect | |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | metabolic syndrome | LIRAGLUTIDE | targetBased | 4 | Recruiting | 01/11/2020 | https://clinicaltrials.gov/study/NCT04575844 | 1 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | metabolic syndrome | LIRAGLUTIDE | targetBased | 4 | Recruiting | 01/11/2020 | https://clinicaltrials.gov/study/NCT04575844 | 1 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | non-alcoholic steatohepatitis | LANIFIBRANOR | targetBased | 3 | Recruiting | 19/08/2021 | https://clinicaltrials.gov/study/NCT04849728 | 0.7 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | non-alcoholic steatohepatitis | LANIFIBRANOR | targetBased | 3 | Recruiting | 19/08/2021 | https://clinicaltrials.gov/study/NCT04849728 | 0.7 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | non-alcoholic steatohepatitis | LANIFIBRANOR | targetBased | 3 | Recruiting | 19/08/2021 | https://clinicaltrials.gov/study/NCT04849728 | 0.7 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | non-alcoholic steatohepatitis | LANIFIBRANOR | targetBased | 3 | Recruiting | 19/08/2021 | https://clinicaltrials.gov/study/NCT04849728 | 0.7 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | non-alcoholic steatohepatitis | LANIFIBRANOR | targetBased | 3 | Recruiting | 19/08/2021 | https://clinicaltrials.gov/study/NCT04849728 | 0.7 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | non-alcoholic steatohepatitis | LANIFIBRANOR | targetBased | 3 | Recruiting | 19/08/2021 | https://clinicaltrials.gov/study/NCT04849728 | 0.7 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | MK-0767 | targetBased | 3 | Terminated | 01/05/2003 | https://clinicaltrials.gov/study/NCT00543361 | 0.7 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | MK-0767 | targetBased | 3 | Terminated | 01/05/2003 | https://clinicaltrials.gov/study/NCT00543361 | 0.7 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | MK-0767 | targetBased | 3 | Terminated | 01/05/2003 | https://clinicaltrials.gov/study/NCT00543361 | 0.7 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | MK-0767 | targetBased | 3 | Terminated | 01/05/2003 | https://clinicaltrials.gov/study/NCT00543361 | 0.7 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | MK-0767 | targetBased | 3 | Terminated | 01/05/2003 | https://clinicaltrials.gov/study/NCT00543361 | 0.7 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | MK-0767 | targetBased | 3 | Terminated | 01/05/2003 | https://clinicaltrials.gov/study/NCT00543361 | 0.7 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | MK-0767 | targetBased | 3 | Terminated | 01/05/2003 | https://clinicaltrials.gov/study/NCT00543491 | 0.7 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | MK-0767 | targetBased | 3 | Terminated | 01/05/2003 | https://clinicaltrials.gov/study/NCT00543491 | 0.7 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | MK-0767 | targetBased | 3 | Terminated | 01/05/2003 | https://clinicaltrials.gov/study/NCT00543491 | 0.7 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | MK-0767 | targetBased | 3 | Terminated | 01/05/2003 | https://clinicaltrials.gov/study/NCT00543491 | 0.7 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | MK-0767 | targetBased | 3 | Terminated | 01/05/2003 | https://clinicaltrials.gov/study/NCT00543491 | 0.7 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | MK-0767 | targetBased | 3 | Terminated | 01/05/2003 | https://clinicaltrials.gov/study/NCT00543491 | 0.7 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | MK-0767 | targetBased | 3 | Terminated | 01/11/2002 | https://clinicaltrials.gov/study/NCT00543010 | 0.7 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | MK-0767 | targetBased | 3 | Terminated | 01/11/2002 | https://clinicaltrials.gov/study/NCT00543010 | 0.7 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | MK-0767 | targetBased | 3 | Terminated | 01/11/2002 | https://clinicaltrials.gov/study/NCT00543010 | 0.7 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | MK-0767 | targetBased | 3 | Terminated | 01/11/2002 | https://clinicaltrials.gov/study/NCT00543010 | 0.7 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | MK-0767 | targetBased | 3 | Terminated | 01/11/2002 | https://clinicaltrials.gov/study/NCT00543010 | 0.7 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | MK-0767 | targetBased | 3 | Terminated | 01/11/2002 | https://clinicaltrials.gov/study/NCT00543010 | 0.7 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | MK-0767 | targetBased | 3 | Terminated | 01/02/2003 | https://clinicaltrials.gov/study/NCT00543517 | 0.7 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | MK-0767 | targetBased | 3 | Terminated | 01/02/2003 | https://clinicaltrials.gov/study/NCT00543517 | 0.7 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | MK-0767 | targetBased | 3 | Terminated | 01/02/2003 | https://clinicaltrials.gov/study/NCT00543517 | 0.7 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | MK-0767 | targetBased | 3 | Terminated | 01/02/2003 | https://clinicaltrials.gov/study/NCT00543517 | 0.7 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | MK-0767 | targetBased | 3 | Terminated | 01/02/2003 | https://clinicaltrials.gov/study/NCT00543517 | 0.7 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | MK-0767 | targetBased | 3 | Terminated | 01/02/2003 | https://clinicaltrials.gov/study/NCT00543517 | 0.7 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | MK-0767 | targetBased | 3 | Terminated | 01/01/2003 | https://clinicaltrials.gov/study/NCT00543751 | 0.7 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | MK-0767 | targetBased | 3 | Terminated | 01/01/2003 | https://clinicaltrials.gov/study/NCT00543751 | 0.7 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | MK-0767 | targetBased | 3 | Terminated | 01/01/2003 | https://clinicaltrials.gov/study/NCT00543751 | 0.7 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | MK-0767 | targetBased | 3 | Terminated | 01/01/2003 | https://clinicaltrials.gov/study/NCT00543751 | 0.7 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | MK-0767 | targetBased | 3 | Terminated | 01/01/2003 | https://clinicaltrials.gov/study/NCT00543751 | 0.7 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | MK-0767 | targetBased | 3 | Terminated | 01/01/2003 | https://clinicaltrials.gov/study/NCT00543751 | 0.7 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | MK-0767 | targetBased | 3 | Terminated | 01/08/2003 | https://clinicaltrials.gov/study/NCT00543816 | 0.7 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | MK-0767 | targetBased | 3 | Terminated | 01/08/2003 | https://clinicaltrials.gov/study/NCT00543816 | 0.7 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | MK-0767 | targetBased | 3 | Terminated | 01/08/2003 | https://clinicaltrials.gov/study/NCT00543816 | 0.7 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | MK-0767 | targetBased | 3 | Terminated | 01/08/2003 | https://clinicaltrials.gov/study/NCT00543816 | 0.7 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | MK-0767 | targetBased | 3 | Terminated | 01/08/2003 | https://clinicaltrials.gov/study/NCT00543816 | 0.7 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | MK-0767 | targetBased | 3 | Terminated | 01/08/2003 | https://clinicaltrials.gov/study/NCT00543816 | 0.7 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | diabetes mellitus | MK-0767 | targetBased | 3 | Terminated | 01/06/2003 | https://clinicaltrials.gov/study/NCT00543738 | 0.7 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | diabetes mellitus | MK-0767 | targetBased | 3 | Terminated | 01/06/2003 | https://clinicaltrials.gov/study/NCT00543738 | 0.7 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | diabetes mellitus | MK-0767 | targetBased | 3 | Terminated | 01/06/2003 | https://clinicaltrials.gov/study/NCT00543738 | 0.7 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | diabetes mellitus | MK-0767 | targetBased | 3 | Terminated | 01/06/2003 | https://clinicaltrials.gov/study/NCT00543738 | 0.7 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | diabetes mellitus | MK-0767 | targetBased | 3 | Terminated | 01/06/2003 | https://clinicaltrials.gov/study/NCT00543738 | 0.7 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | diabetes mellitus | MK-0767 | targetBased | 3 | Terminated | 01/06/2003 | https://clinicaltrials.gov/study/NCT00543738 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | TIRZEPATIDE | targetBased | 3 | Completed | 30/08/2019 | https://clinicaltrials.gov/study/NCT04039503 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | TIRZEPATIDE | targetBased | 3 | Completed | 30/08/2019 | https://clinicaltrials.gov/study/NCT04039503 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | TIRZEPATIDE | targetBased | 3 | Completed | 30/08/2019 | https://clinicaltrials.gov/study/NCT04039503 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | TIRZEPATIDE | targetBased | 3 | Completed | 07/05/2019 | https://clinicaltrials.gov/study/NCT03861052 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | TIRZEPATIDE | targetBased | 3 | Completed | 07/05/2019 | https://clinicaltrials.gov/study/NCT03861052 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | TIRZEPATIDE | targetBased | 3 | Completed | 07/05/2019 | https://clinicaltrials.gov/study/NCT03861052 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | TIRZEPATIDE | targetBased | 3 | Completed | 20/11/2018 | https://clinicaltrials.gov/study/NCT03730662 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | TIRZEPATIDE | targetBased | 3 | Completed | 20/11/2018 | https://clinicaltrials.gov/study/NCT03730662 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | TIRZEPATIDE | targetBased | 3 | Completed | 20/11/2018 | https://clinicaltrials.gov/study/NCT03730662 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | TIRZEPATIDE | targetBased | 4 | Recruiting | 15/03/2022 | https://clinicaltrials.gov/study/NCT05553093 | 1 | GoF | protect | |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | TIRZEPATIDE | targetBased | 4 | Recruiting | 15/03/2022 | https://clinicaltrials.gov/study/NCT05553093 | 1 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | TIRZEPATIDE | targetBased | 4 | Recruiting | 15/03/2022 | https://clinicaltrials.gov/study/NCT05553093 | 1 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | TIRZEPATIDE | targetBased | 3 | Active, not recruiting | 29/05/2020 | https://clinicaltrials.gov/study/NCT04255433 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | TIRZEPATIDE | targetBased | 3 | Active, not recruiting | 29/05/2020 | https://clinicaltrials.gov/study/NCT04255433 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | TIRZEPATIDE | targetBased | 3 | Active, not recruiting | 29/05/2020 | https://clinicaltrials.gov/study/NCT04255433 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | TIRZEPATIDE | targetBased | 3 | Completed | 03/06/2019 | https://clinicaltrials.gov/study/NCT03954834 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | TIRZEPATIDE | targetBased | 3 | Completed | 03/06/2019 | https://clinicaltrials.gov/study/NCT03954834 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | TIRZEPATIDE | targetBased | 3 | Completed | 03/06/2019 | https://clinicaltrials.gov/study/NCT03954834 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | TIRZEPATIDE | targetBased | 4 | Active, not recruiting | 30/11/2022 | https://clinicaltrials.gov/study/NCT05564039 | 1 | GoF | protect | |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | TIRZEPATIDE | targetBased | 4 | Active, not recruiting | 30/11/2022 | https://clinicaltrials.gov/study/NCT05564039 | 1 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | TIRZEPATIDE | targetBased | 4 | Active, not recruiting | 30/11/2022 | https://clinicaltrials.gov/study/NCT05564039 | 1 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | TIRZEPATIDE | targetBased | 3 | Active, not recruiting | 13/04/2022 | https://clinicaltrials.gov/study/NCT05260021 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | TIRZEPATIDE | targetBased | 3 | Active, not recruiting | 13/04/2022 | https://clinicaltrials.gov/study/NCT05260021 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | TIRZEPATIDE | targetBased | 3 | Active, not recruiting | 13/04/2022 | https://clinicaltrials.gov/study/NCT05260021 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | TIRZEPATIDE | targetBased | 3 | Completed | 30/07/2019 | https://clinicaltrials.gov/study/NCT03987919 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | TIRZEPATIDE | targetBased | 3 | Completed | 30/07/2019 | https://clinicaltrials.gov/study/NCT03987919 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | TIRZEPATIDE | targetBased | 3 | Completed | 30/07/2019 | https://clinicaltrials.gov/study/NCT03987919 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | TIRZEPATIDE | targetBased | 4 | Active, not recruiting | 01/08/2022 | https://clinicaltrials.gov/study/NCT05433584 | 1 | GoF | protect | |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | TIRZEPATIDE | targetBased | 4 | Active, not recruiting | 01/08/2022 | https://clinicaltrials.gov/study/NCT05433584 | 1 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | TIRZEPATIDE | targetBased | 4 | Active, not recruiting | 01/08/2022 | https://clinicaltrials.gov/study/NCT05433584 | 1 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | TIRZEPATIDE | targetBased | 4 | Completed | 08/03/2023 | https://clinicaltrials.gov/study/NCT05706506 | 1 | GoF | protect | |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | TIRZEPATIDE | targetBased | 4 | Completed | 08/03/2023 | https://clinicaltrials.gov/study/NCT05706506 | 1 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | TIRZEPATIDE | targetBased | 4 | Completed | 08/03/2023 | https://clinicaltrials.gov/study/NCT05706506 | 1 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | TIRZEPATIDE | targetBased | 3 | Completed | 01/04/2019 | https://clinicaltrials.gov/study/NCT03882970 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | TIRZEPATIDE | targetBased | 3 | Completed | 01/04/2019 | https://clinicaltrials.gov/study/NCT03882970 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | TIRZEPATIDE | targetBased | 3 | Completed | 01/04/2019 | https://clinicaltrials.gov/study/NCT03882970 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | TIRZEPATIDE | targetBased | 3 | Active, not recruiting | 21/08/2023 | https://clinicaltrials.gov/study/NCT05963022 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | TIRZEPATIDE | targetBased | 3 | Active, not recruiting | 21/08/2023 | https://clinicaltrials.gov/study/NCT05963022 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | TIRZEPATIDE | targetBased | 3 | Active, not recruiting | 21/08/2023 | https://clinicaltrials.gov/study/NCT05963022 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | TIRZEPATIDE | targetBased | 4 | https://www.ema.europa.eu/en/medicines/human/EPAR/mounjaro | 1 | GoF | protect | |||
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | TIRZEPATIDE | targetBased | 4 | https://www.ema.europa.eu/en/medicines/human/EPAR/mounjaro | 1 | GoF | protect | |||
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | TIRZEPATIDE | targetBased | 4 | https://www.ema.europa.eu/en/medicines/human/EPAR/mounjaro | 1 | GoF | protect | |||
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | TIRZEPATIDE | targetBased | 3 | Completed | 09/12/2019 | https://clinicaltrials.gov/study/NCT04093752 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | TIRZEPATIDE | targetBased | 3 | Completed | 09/12/2019 | https://clinicaltrials.gov/study/NCT04093752 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | TIRZEPATIDE | targetBased | 3 | Completed | 09/12/2019 | https://clinicaltrials.gov/study/NCT04093752 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | TIRZEPATIDE | targetBased | 3 | Completed | 30/03/2019 | https://clinicaltrials.gov/study/NCT03861039 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | TIRZEPATIDE | targetBased | 3 | Completed | 30/03/2019 | https://clinicaltrials.gov/study/NCT03861039 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | TIRZEPATIDE | targetBased | 3 | Completed | 30/03/2019 | https://clinicaltrials.gov/study/NCT03861039 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | TIRZEPATIDE | targetBased | 4 | https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215866s000lbl.pdf | 1 | GoF | protect | |||
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | TIRZEPATIDE | targetBased | 4 | https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215866s000lbl.pdf | 1 | GoF | protect | |||
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | TIRZEPATIDE | targetBased | 4 | https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215866s000lbl.pdf | 1 | GoF | protect | |||
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | TIRZEPATIDE | targetBased | 3 | Not yet recruiting | 01/07/2024 | https://clinicaltrials.gov/study/NCT06246799 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | TIRZEPATIDE | targetBased | 3 | Not yet recruiting | 01/07/2024 | https://clinicaltrials.gov/study/NCT06246799 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | TIRZEPATIDE | targetBased | 3 | Not yet recruiting | 01/07/2024 | https://clinicaltrials.gov/study/NCT06246799 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | TIRZEPATIDE | targetBased | 3 | Completed | 19/10/2020 | https://clinicaltrials.gov/study/NCT04537923 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | TIRZEPATIDE | targetBased | 3 | Completed | 19/10/2020 | https://clinicaltrials.gov/study/NCT04537923 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | TIRZEPATIDE | targetBased | 3 | Completed | 19/10/2020 | https://clinicaltrials.gov/study/NCT04537923 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | TIRZEPATIDE | targetBased | 3 | Recruiting | 16/01/2024 | https://clinicaltrials.gov/study/NCT06221969 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | TIRZEPATIDE | targetBased | 3 | Recruiting | 16/01/2024 | https://clinicaltrials.gov/study/NCT06221969 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | TIRZEPATIDE | targetBased | 3 | Recruiting | 16/01/2024 | https://clinicaltrials.gov/study/NCT06221969 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | diabetes mellitus | TIRZEPATIDE | targetBased | 4 | https://www.whocc.no/atc_ddd_index/?code=A10BX16 | 1 | GoF | protect | |||
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | diabetes mellitus | TIRZEPATIDE | targetBased | 4 | https://www.whocc.no/atc_ddd_index/?code=A10BX16 | 1 | GoF | protect | |||
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | diabetes mellitus | TIRZEPATIDE | targetBased | 4 | https://www.whocc.no/atc_ddd_index/?code=A10BX16 | 1 | GoF | protect | |||
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | obesity | TIRZEPATIDE | targetBased | 4 | Recruiting | 13/09/2023 | https://clinicaltrials.gov/study/NCT06009653 | 1 | GoF | protect | |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | obesity | TIRZEPATIDE | targetBased | 4 | Recruiting | 13/09/2023 | https://clinicaltrials.gov/study/NCT06009653 | 1 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | obesity | TIRZEPATIDE | targetBased | 4 | Recruiting | 13/09/2023 | https://clinicaltrials.gov/study/NCT06009653 | 1 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | obesity | TIRZEPATIDE | targetBased | 3 | Completed | 10/05/2021 | https://clinicaltrials.gov/study/NCT04844918 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | obesity | TIRZEPATIDE | targetBased | 3 | Completed | 10/05/2021 | https://clinicaltrials.gov/study/NCT04844918 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | obesity | TIRZEPATIDE | targetBased | 3 | Completed | 10/05/2021 | https://clinicaltrials.gov/study/NCT04844918 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | obesity | TIRZEPATIDE | targetBased | 3 | Completed | 01/09/2021 | https://clinicaltrials.gov/study/NCT05024032 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | obesity | TIRZEPATIDE | targetBased | 3 | Completed | 01/09/2021 | https://clinicaltrials.gov/study/NCT05024032 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | obesity | TIRZEPATIDE | targetBased | 3 | Completed | 01/09/2021 | https://clinicaltrials.gov/study/NCT05024032 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | AVEXITIDE | targetBased | 3 | Completed | 15/04/2021 | https://clinicaltrials.gov/study/NCT04466618 | 0.7 | LoF | protect | |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | AVEXITIDE | targetBased | 3 | Completed | 15/04/2021 | https://clinicaltrials.gov/study/NCT04466618 | 0.7 | LoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | AVEXITIDE | targetBased | 3 | Completed | 15/04/2021 | https://clinicaltrials.gov/study/NCT04466618 | 0.7 | LoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | morbid obesity | AVEXITIDE | targetBased | 4 | Recruiting | 01/04/2014 | https://clinicaltrials.gov/study/NCT02336659 | 1 | LoF | protect | |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | morbid obesity | AVEXITIDE | targetBased | 4 | Recruiting | 01/04/2014 | https://clinicaltrials.gov/study/NCT02336659 | 1 | LoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | morbid obesity | AVEXITIDE | targetBased | 4 | Recruiting | 01/04/2014 | https://clinicaltrials.gov/study/NCT02336659 | 1 | LoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | obesity | AVEXITIDE | targetBased | 4 | Completed | 01/01/2013 | https://clinicaltrials.gov/study/NCT01701973 | 1 | LoF | protect | |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | obesity | AVEXITIDE | targetBased | 4 | Completed | 01/01/2013 | https://clinicaltrials.gov/study/NCT01701973 | 1 | LoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | obesity | AVEXITIDE | targetBased | 4 | Completed | 01/01/2013 | https://clinicaltrials.gov/study/NCT01701973 | 1 | LoF | protect | |
| Luminescence-based cell-based primary high throughput screening assay to identify biased ligands of the melanocortin 4 receptor (MC4R): agonists of MC4R | MC4R | MC4R | Melanocortin receptor 4 | obesity | SETMELANOTIDE ACETATE | targetBased | 4 | https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213793Orig1s000RPLlbl.pdf | 1 | GoF | protect | |||
| TRFRET-based cell-based primary high throughput screening assay to identify biased ligands of the melanocortin 4 receptor (MC4R): antagonists of MC4R | MC4R | MC4R | Melanocortin receptor 4 | obesity | SETMELANOTIDE ACETATE | targetBased | 4 | https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213793Orig1s000RPLlbl.pdf | 1 | GoF | protect | |||
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | CHIGLITAZAR | targetBased | 3 | Completed | 01/09/2014 | https://clinicaltrials.gov/study/NCT02173457 | 0.7 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | CHIGLITAZAR | targetBased | 3 | Completed | 01/09/2014 | https://clinicaltrials.gov/study/NCT02173457 | 0.7 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | CHIGLITAZAR | targetBased | 3 | Completed | 01/09/2014 | https://clinicaltrials.gov/study/NCT02173457 | 0.7 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | CHIGLITAZAR | targetBased | 3 | Completed | 01/09/2014 | https://clinicaltrials.gov/study/NCT02173457 | 0.7 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | CHIGLITAZAR | targetBased | 3 | Completed | 01/09/2014 | https://clinicaltrials.gov/study/NCT02173457 | 0.7 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | CHIGLITAZAR | targetBased | 3 | Completed | 01/09/2014 | https://clinicaltrials.gov/study/NCT02173457 | 0.7 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | CHIGLITAZAR | targetBased | 3 | Recruiting | 17/05/2021 | https://clinicaltrials.gov/study/NCT04807348 | 0.7 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | CHIGLITAZAR | targetBased | 3 | Recruiting | 17/05/2021 | https://clinicaltrials.gov/study/NCT04807348 | 0.7 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | CHIGLITAZAR | targetBased | 3 | Recruiting | 17/05/2021 | https://clinicaltrials.gov/study/NCT04807348 | 0.7 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | CHIGLITAZAR | targetBased | 3 | Recruiting | 17/05/2021 | https://clinicaltrials.gov/study/NCT04807348 | 0.7 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | CHIGLITAZAR | targetBased | 3 | Recruiting | 17/05/2021 | https://clinicaltrials.gov/study/NCT04807348 | 0.7 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | CHIGLITAZAR | targetBased | 3 | Recruiting | 17/05/2021 | https://clinicaltrials.gov/study/NCT04807348 | 0.7 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | CHIGLITAZAR | targetBased | 3 | Completed | 01/06/2014 | https://clinicaltrials.gov/study/NCT02121717 | 0.7 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | CHIGLITAZAR | targetBased | 3 | Completed | 01/06/2014 | https://clinicaltrials.gov/study/NCT02121717 | 0.7 | GoF | protect | |
| Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | CHIGLITAZAR | targetBased | 3 | Completed | 01/06/2014 | https://clinicaltrials.gov/study/NCT02121717 | 0.7 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | CHIGLITAZAR | targetBased | 3 | Completed | 01/06/2014 | https://clinicaltrials.gov/study/NCT02121717 | 0.7 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | CHIGLITAZAR | targetBased | 3 | Completed | 01/06/2014 | https://clinicaltrials.gov/study/NCT02121717 | 0.7 | GoF | protect | |
| Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma) | PPARG | PPARG | Peroxisome proliferator-activated receptor gamma | type 2 diabetes mellitus | CHIGLITAZAR | targetBased | 3 | Completed | 01/06/2014 | https://clinicaltrials.gov/study/NCT02121717 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | EFPEGLENATIDE | targetBased | 3 | Terminated | 26/09/2018 | https://clinicaltrials.gov/study/NCT03684642 | 0.7 | GoF | protect | Sponsor decision to cancel TRIAL, not related to safety concern. |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | EFPEGLENATIDE | targetBased | 3 | Terminated | 26/09/2018 | https://clinicaltrials.gov/study/NCT03684642 | 0.7 | GoF | protect | Sponsor decision to cancel TRIAL, not related to safety concern. |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | EFPEGLENATIDE | targetBased | 3 | Terminated | 26/09/2018 | https://clinicaltrials.gov/study/NCT03684642 | 0.7 | GoF | protect | Sponsor decision to cancel TRIAL, not related to safety concern. |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | EFPEGLENATIDE | targetBased | 3 | Terminated | 09/11/2018 | https://clinicaltrials.gov/study/NCT03713684 | 0.7 | GoF | protect | Sponsor decision to cancel TRIAL, not related to safety concern |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | EFPEGLENATIDE | targetBased | 3 | Terminated | 09/11/2018 | https://clinicaltrials.gov/study/NCT03713684 | 0.7 | GoF | protect | Sponsor decision to cancel TRIAL, not related to safety concern |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | EFPEGLENATIDE | targetBased | 3 | Terminated | 09/11/2018 | https://clinicaltrials.gov/study/NCT03713684 | 0.7 | GoF | protect | Sponsor decision to cancel TRIAL, not related to safety concern |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | EFPEGLENATIDE | targetBased | 3 | Terminated | 01/08/2019 | https://clinicaltrials.gov/study/NCT03770728 | 0.7 | GoF | protect | Sponsor decision to cancel TRIAL, not related to safety concern |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | EFPEGLENATIDE | targetBased | 3 | Terminated | 01/08/2019 | https://clinicaltrials.gov/study/NCT03770728 | 0.7 | GoF | protect | Sponsor decision to cancel TRIAL, not related to safety concern |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | EFPEGLENATIDE | targetBased | 3 | Terminated | 01/08/2019 | https://clinicaltrials.gov/study/NCT03770728 | 0.7 | GoF | protect | Sponsor decision to cancel TRIAL, not related to safety concern |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | EFPEGLENATIDE | targetBased | 3 | Completed | 05/12/2017 | https://clinicaltrials.gov/study/NCT03353350 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | EFPEGLENATIDE | targetBased | 3 | Completed | 05/12/2017 | https://clinicaltrials.gov/study/NCT03353350 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | EFPEGLENATIDE | targetBased | 3 | Completed | 05/12/2017 | https://clinicaltrials.gov/study/NCT03353350 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | EFPEGLENATIDE | targetBased | 3 | Terminated | 27/04/2018 | https://clinicaltrials.gov/study/NCT03496298 | 0.7 | GoF | protect | Sponsor decision to cancel TRIAL, not related to safety concern |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | EFPEGLENATIDE | targetBased | 3 | Terminated | 27/04/2018 | https://clinicaltrials.gov/study/NCT03496298 | 0.7 | GoF | protect | Sponsor decision to cancel TRIAL, not related to safety concern |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | type 2 diabetes mellitus | EFPEGLENATIDE | targetBased | 3 | Terminated | 27/04/2018 | https://clinicaltrials.gov/study/NCT03496298 | 0.7 | GoF | protect | Sponsor decision to cancel TRIAL, not related to safety concern |
| qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) | GLP1R | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | obesity | EFPEGLENATIDE | targetBased | 3 | Not yet recruiting | 19/12/2023 | https://clinicaltrials.gov/study/NCT06174779 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Agonists | GLP1R agonists | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | obesity | EFPEGLENATIDE | targetBased | 3 | Not yet recruiting | 19/12/2023 | https://clinicaltrials.gov/study/NCT06174779 | 0.7 | GoF | protect | |
| qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs) | GLP1R PAMs | GLP1R | Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor | obesity | EFPEGLENATIDE | targetBased | 3 | Not yet recruiting | 19/12/2023 | https://clinicaltrials.gov/study/NCT06174779 | 0.7 | GoF | protect |